UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF NEW YORK

MICHELE BAKER; CHARLES CARR; ANGELA CORBETT; PAMELA FORREST; MICHAEL HICKEY, individually and as parent and natural guardian of O.H., infant; KATHLEEN MAIN-LINGENER; KRISTIN MILLER, as parent and natural guardian of K.M., infant; JENNIFER PLOUFFE; SILVIA POTTER, individually and as parent and natural guardian of C.P, infant; and DANIEL SCHUTTIG, individually and on behalf of all others similarly situated,

Plaintiffs,

CIV. No. 1:16-CV-917 (LEK/DJS)

v.

SAINT-GOBAIN PERFORMANCE PLASTICS CORP., HONEYWELL INTERNATIONAL INC. f/k/a ALLIED-SIGNAL INC. and/or ALLIEDSIGNAL LAMINATE SYSTEMS, INC., E.I. DUPONT DE NEMOURS AND COMPANY and 3M CO.,

Defendants.

DECLARATION OF ALAN DUCATMAN, M.D.

I, Alan Ducatman, declare and state as follows:

- 1. I prepared the Expert Report attached as Exhibit A to this Declaration.
- Each of the opinions in the Expert Report is stated to a reasonable degree of medical and scientific certainty and was arrived at using reliable and generally accepted scientific methods.
- 3. If called as a witness, I will testify competently to the matters stated in this Expert Report.
- 4. I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 2 of 551

alon Jucatur

Dated: March 27, 2020

Alan Ducatman, M.D.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 3 of 551

EXHIBIT A

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 4 of 551

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF NEW YORK

IN RE HOOSICK FALLS PFOA CASES

Case No. 1:19-mc-00018-LEK-DJS

EXPERT REPORT OF Alan Ducatman, MD

BACKGROUND AND QUALIFICATIONS

I am board certified in Internal Medicine and Occupational Medicine, and have been licensed to practice medicine since 1982. I am a Professor Emeritus of Public Health at West Virginia University School of Public Health and was also a Professor of Medicine at West Virginia University School of Medicine. In the past, I was the Chair of the Department of Community Medicine in the West Virginia University School of Medicine for many years. I also have been a member of the American Board of Preventive Medicine, which determines credentials and qualifications for board certification, and Chair of the Residency Review Committee in Preventive Medicine, which accredits clinical residency training programs. I have participated on and chaired an external scientific advisory committee to the Agency for Toxic Substances and Disease Registry (ATSDR) and the National Center for Environmental Health (NEHC) of the US Centers for Disease Control and Prevention (CDC) and have a Director's Award for outstanding service to this federal agency. Before becoming a tenured professor at West Virginia University, I was Director of the Environmental Medical Service at Massachusetts Institute of Technology (1986-1992). Before that I was an active duty Lieutenant Commander in the U.S. Navy Medical Corps, responsible for national and international consultation concerning environmental exposures of active duty service personnel and employed civilians (1983-1986). A copy of my C.V. is attached as Exhibit A.

I have published numerous original papers, reviews, and book chapters and written extensively about the relationship of environmental chemicals to human disease, including, but not limited to, perfluoroalkyl substances (PFAS) such as perfluorooctanoic acid (PFOA). I also perform research and publish peer review articles concerning quality assurance in health care, notably in the setting of ordering and interpreting clinical testing, and increasing the value of clinical testing. I am the recipient of honors and recognitions in my field. I have been asked to

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 6 of 551

provide formal and informal health science advice to leaders of federal organizations such as the U.S. Centers for Disease Control and Prevention and the Environmental Protection Agency, state agencies with health and safety interests including the West Virginia Bureau for Public Health, nonprofit foundations, and industry. I have also been invited to provide summaries of the health effects of PFAS exposure in academic settings and for professional societies, for example at the 2019 PFAS meeting of the Society for Environmental Toxicology and Chemistry.

I have significant experience in evaluation and medical monitoring of humans exposed to PFOA. I am familiar with the C8 Health Project, which enrolled a large population and evaluated the health effects of PFOA and other PFAS among residents of PFOA-contaminated water districts in the mid-Ohio Valley. I advised the leaders of that Project and have published more than 25 peer-reviewed articles relating to the PFAS, including papers based upon analysis of the C8 Health Project data, and papers based on the national NHANES data set. This includes a summary article (published with members of the C8 Science Panel and with the leaders of the C8 Health Project design and the leaders of the enrollment effort), which describes the C8 Project's design, methods, and participants. (1) I led a team that analyzed data from the Project, and was responsible for a website that provided open access to summary data from the Project during its initial phase. I collaborate with scientists at many institutions regarding current PFAS knowledge. My work addresses the effects of PFOA and other PFAS on liver function and its biomarkers, thyroid function, kidney function, and on serum lipid levels (including total and LDL-cholesterol), among other subjects.

In my career, I have participated directly in the following medical monitoring projects in addition to the C8 Health Project mentioned above:

- the U.S. Navy Asbestos Medical Surveillance Program, which involved many thousands of Department of Defense employees, during my active duty as a Lieutenant Commander in the U.S. Navy Medical Corps from 1983-1986.
- Medical surveillance programs, including surveillance for lead poisoning, at the Massachusetts Institute of Technology, where I was Director of the Environmental Medical Service from 1986-1992.
- Multiple medical surveillance programs for workers at West Virginia University, from 1992-2018.
- And, I have advised the creation and direction of the state of West Virginia Lead Poisoning Prevention Program, and have been a consultant for decisions concerning the treatment of patients detected to have elevated blood lead concentrations.

My perspective is that of a clinician, with a career spanning more than three decades caring for patients and populations who have had exposures that can harm their health. I provide this report in support of plaintiffs' motion for class certification and specifically in support of class treatment for a medical monitoring program for individuals who meet the PFOA Invasion Injury Class definition. My rate for the expert work I perform in this case is \$450 per hour with an increase to \$600 per hour for deposition testimony and testimony in court. In the last four years, I have provided testimony in *Sullivan, et al. v. Saint-Gobain Performance Plastics, Co.*, Case No. 5:16-cv-00125.

FACTS AND DATA CONSIDERED; MATERIALS REVIEWED

To prepare this report, I reviewed certain data produced in this case pursuant to a subpoena by the New York State Department of Environmental Conservation (**Exhibit B**) and New York State Department of Health (**Exhibit C**), including PFOA blood testing results and data related to PFOA, testing of public and private wells and soils in and around the Village of Hoosick Falls and maps depicting these results produced by the agencies. I also reviewed the First Amended Master Consolidated Class Action Complaint in this action and the affidavits of the representative plaintiffs detailing their PFOA blood test results and the results of the PFOA

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 8 of 551

tests of their drinking water together with information about their water consumption. I reviewed the reports of Dr. David Savitz and Dr. Hyeong Moo Shin submitted in support of Plaintiffs' motion for class certification. I am familiar with the medical and scientific literature listed in **Exhibit D**, as well as the relevant papers listed in my CV, and am generally familiar with other medical and scientific literature concerning PFAS and their health effects, and concerning medical monitoring. The opinions that follow are based on my review of the specific case information listed above, my review of this literature and the report of Dr. Savitz, as well as on my decades of experience with medical monitoring programs, including the C8 Health Project, and are expressed to a reasonable degree of medical certainty.

CRITERIA FOR ASSESSING THE NEED FOR COMMUNITY MEDICAL MONITORING

The Agency for Toxic Substances and Disease Registry (ATSDR) is a lead agency in the Centers for Disease Control and Prevention tasked with conducting health surveillance assessments to evaluate exposure to hazardous agents in the environment and identify trends in adverse health outcomes resulting from chemical exposures. The ATSDR provides the following criteria for considering the establishment of medical monitoring programs in its Final Criteria for Determining the Appropriateness of a Medical Monitoring Program under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), published in the Federal Register, that have specific application to this case (quoted in part). (*See* **Exhibit E**)

ATSDR Background for Considering Medical Monitoring

• "Medical monitoring should be directed toward a target community identified as being at "significant increased risk for disease" on the basis of its exposure. Significant increased risk will vary for particular sites depending upon such factors as the underlying risk of the selected outcome, the risk attributable to the exposure, and the presence of sensitive subpopulations. These factors will be considered when evaluating the appropriateness of medical monitoring in a community."

ATSDR Exposure Criteria for Considering Medical Monitoring

- "There should be evidence of contaminant levels in environmental media that would suggest the high likelihood of environmental exposure to a hazardous substance and subsequent adverse health outcomes."
- "An exposure will be considered to be a sufficient level if there is documentation of an increased opportunity for exposure to a level that meets or exceeds *some* health-based comparison value such as Minimum Risk Levels (MRLs) or Reference Doses (RfDs) *or* that meets a level reported in the peer-reviewed literature to result in some adverse health effect. Documentation is considered sufficient if it is from an exposure assessment, environmental exposure modeling or sampling from the general area *Documentation of individual levels of exposure is not required.*" (emphasis added)

ATSDR Outcome Criteria for Considering Medical Monitoring

- "There should be documented human health research that demonstrates a scientific basis for a *reasonable association* between an exposure to a hazardous substance and a specific adverse health effect (such as an illness or *change in a biological marker or effect*)." (emphasis added)
- "The monitoring should be directed at detecting adverse health effects that are consistent with the existing body of knowledge and amenable to prevention or intervention measures."
- "In addition, the adverse health effects (disease process, illness, or biomarkers of effect) should be such that early detection and treatment or intervention interrupts the progress to symptomatic disease, improves the quality of life of the individual, or is amenable to primary prevention."

ATSDR System Criteria for Considering Medical Monitoring

• "The monitoring aspect of a health surveillance program consists of the periodic medical testing to screen individuals who are at increased risk of disease. Monitoring serves to identify those individuals with an unrecognized adverse health effect. This is consistent with the definition of screening as the presumptive identification of unrecognized disease or defect by the application of tests, examinations or other procedures which can be applied rapidly. Screening tests sort out apparently well persons who probably have a disease

from those who probably do not. A screening test is not intended to be diagnostic. Persons with positive or suspicious findings must be referred to their physicians for diagnosis and necessary treatment."

(See Exhibit E)

PFOA IS A HAZARDOUS SUBSTANCE THAT IS ASSOCIATED WITH ADVERSE HEALTH EFFECTS

PFOA is a man-made toxic substance, also known as a "toxicant." There is "documented human health research that demonstrates a scientific basis for a reasonable association between an exposure to [PFOA] and a specific adverse health effect (such as an illness or change in a biological marker of effect)." (See ATSDR Criteria, Exhibit E, p. 38841). Based on numerous peer-reviewed publications (See Exhibit D) reporting results from exposed communities in the United States and around the world (including, but not limited to the well-known C8 study of exposed communities in West Virginia and Ohio), and from governmental publications and assessments, we know to a reasonable degree of medical certainty that human exposure to PFOA leads to alterations in the biomarkers for and function of the liver, the thyroid, the immune system, and other organs. (1, 3, 13-19, 21-26, 28-35, 39-43, 45, 47-52, 54-55, 57-58, 63, 68, 89, 91-95, 114, 123, 125, 127)¹ PFOA exposure is associated with excess risks of adverse health effects, as compared to the background population, and we now have clinical population outcome data on these and a variety of health effects. (Id., 27, 36, 38, 44, 59-64, 69-75, 78-88, 90, 97-100, 113, 124, 127-134). The epidemiological literature on the health effects of PFOA exposure is also summarized in the report of Dr. Savitz that has been submitted in support of this motion. The number of known epidemiologic associations, experimentally verified toxicities in

¹ Parenthetical references are to articles listed in **Exhibit D**. These specific references are merely examples of voluminous published articles supporting an association between PFOA exposure and adverse health effects, many additional articles are listed in Exhibit D.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 11 of 551

vitro and in vivo, and accepted human health problems has increased over time as the scientific study of PFOA has advanced. The science is developing and the body of peer-reviewed literature finding new associations and providing further support of known associations continues to grow.

THE VILLAGE OF HOOSICK FALLS AND THE SURROUNDING AREA IS A TARGET COMMUNITY AT SIGNIFICANT INCREASED RISK FOR DISEASE BASED UPON EXPOSURES TO PFOA AT LEVELS THAT EXCEED HEALTH BASED COMPARISON LEVELS

PFOA is a manmade chemical that does not occur naturally in the environment and was identified by the United States Environmental Protection Agency (EPA) in 2009 as an emerging contaminant of concern. In 2013 the State of New Jersey established a preliminary health based guidance level of 40 ppt in drinking water. **See Exhibit F**. In May of 2016 EPA established drinking water health advisories of 70 ppt for the combined concentrations of PFOS and PFOA. (107) In March of 2017 the State of Vermont established a health advisory level for PFOA in water as 20 ppt. http://www.healthvermont.gov/health-environment/drinking-

<u>water/perfluorooctanoic-acid-pfoa</u>. In October of 2017 the New Jersey Drinking Water Quality Institute developed a Health-based Maximum Contaminant Level (MCL) of 14 ng/L (ppt). *See*

Exhibit F. This progressive lowering of the health-based MCL and health advisory contaminant levels for PFOA in drinking water by the federal government and the states has been driven by additional published research on PFOA and other PFAS health effects. New Jersey authors also note, correctly, as the EPA also recognized in its guidance, that PFOA exposure does not happen in a PFAS vacuum, and have made recommendations for total PFAS summed exposures, such as PFOA and PFOS. Nevertheless, experts affiliated with important research institutions have recommended in peer review settings that the New Jersey level is still too lenient, and have proposed that the PFOA health advisory level in drinking water should be reduced to 1 ppt. (108)

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 12 of 551

The State of New Jersey received publicly available communications from these scientists and from Environmental Groups pointing out that the 14 ppt standard could be lowered based on scientific evidence.² The New Jersey guidance is consistent with what could be accurately measured by commercial laboratories at that time, and the protective goal was achievable in contaminated systems with available technologies at that time. The conclusions found in numerous studies emphasize the need to consider fetal exposures (27, 36-37, 39, 53, 56-57, 62, 68-84, 86-87,97-98,100,105,115) and infant's exposure through breast milk (11, 65, 112, 116-117), when developing health-based toxicity values for exposure to PFOA and that current values may underestimate the potential risks for fetuses and nursing infants. (119, 122) This is an important consideration, it is based on excellent science, and targets a threshold effect that is deeply important to society.

An important factor in the human health hazard created by PFOA is that once ingested the chemical binds to proteins in blood serum and bioaccumulates in the body. While PFOA is typically detected in drinking water in units of ng/L (parts per trillion), it is typically measured in blood serum of those exposed to such PFOA-contaminated drinking water in ug/L (or ng/mL, parts per billion). As the New Jersey report states, the predicted ratio of PFOA drinking water: PFOA serum levels is ~ 114:1, meaning that an average level in the body is about 114 times higher than the level in the long-term ingested drinking water. (**Exhibit F**). An online serum PFOA calculator for adults consuming water at steady state, after starting or stopping consumption of PFOA-contaminated water, has recently been made publicly available by scientists from UC Irvine. (109).

When drinking water is contaminated with PFOA, we know from the contamination in the mid-Ohio Valley, as well as from other contaminated sites around the world, that the

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 13 of 551

contamination is long-lasting and that the drinking water is a primary source of exposure to PFOA for those who consume it. (Direct and indirect food contamination is most often the primary source when water is not contaminated.) The primacy of water contamination in populations exposed to PFOA-contaminated water has been shown by the work of Emmett, Holzer, Steenland, and others. (1, 2, 12, 104, 109, 110, 119) The population "half-life" of PFOA as measured in human serum has an arithmetic mean of about 3.8 years. (8, 9) We do not know the half-life of PFOA in other human organs, but we do know that PFOA is concentrated in the liver, lungs, bone, and in other organs (9-11). This means that those who drank PFOA-contaminated water in and around the Village of Hoosick Falls in the last 1-12 years likely have not excreted all of the PFOA that has bio-accumulated in their serum, with potentially longer time horizons for other organs in their bodies.

REDACTED PURSUANT TO PROTECTIVE ORDER (ECF NOs. 131 & 132)


				2 Now Vark's propos	ad
				. ² New York's propose	ea
MOL .	.1		1 1	1 22 4 1 1 1 1 41	1

MCL is among the most recent "health based comparison value" to be based on and thorough review of the most recent literature and established for PFOA health effects. (*See* ATSDR Criteria, **Exhibit E**, p.38841; **Exhibit F**).

² On March 13, 2019, the New Jersey Department of Environmental Protection established an interim specific ground water quality standard for PFOA of 10 ppt that became effective upon posting to the "Table of Interim Specific Ground Water Quality Criteria (ISGWQC), Interim PQLs (IPQLs), and Interim Specific Ground Water Quality Standards (ISGWQS) for Constituents in Class II-A Ground Water" on the NJDEP website at <u>https://www.nj.gov/dep/wms/bears/gwqs.htm</u>. See <u>https://www.nj.gov/dep/srp/emerging-contaminants/</u>.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 14 of 551

The geometric mean background blood serum level in the United States adult population for 2013-14 was 1.86 μ g/L.³ (114). **REDACTED PURSUANT TO PROTECTIVE ORDER (ECF NOS. 131 & 132)**



It appears that the Department of Health continues to offer blood testing. See

https://www.health.ny.gov/environmental/investigations/hoosick/ (last visited March 17, 2020). Accordingly, it is possible that some current and former residents of the Village of Hoosick Falls and the surrounding area who ingested significant quantities of PFOA in the contaminated drinking water at home and who have not yet had their blood tested will be shown to have serum concentrations well above US adult population geometric mean serum concentrations if tested. Many of the exposed individuals, including three representative plaintiffs, are children. Children are considered a sensitive subpopulation because they have smaller body mass, greater liquid

³ The geometric mean background level for 2015-2016 based on the US NHANES dataset is 1.56 μg/L. https://www.cdc.gov/exposurereport/pdf/FourthReport_Updated Tables Volume1 Jan2019-508.pdf (last visited April 10, 2019). This data was published in

January 2019 and reflects the geometric mean background level at the time the Hoosick Falls PFOA blood testing was conducted. Therefore, the threshold level for eligibility here (1.86 μ g/L) is a conservative number.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 15 of 551

ingestion per unit of body weight, and potentially greater adverse impact at equal concentration of PFOA in their bodies. Further, young children will start their lives with a body burden from their mother because PFOA is delivered to the developing human trans placentally. (77, 115) And, breast-feeding is highly recommended for maternal and child health, yet it too delivers PFOA directly to the infant. (112, 116, 117).

Among the representative plaintiffs for the medical monitoring class, the blood serum PFOA concentration measured for Plaintiff Michael Hickey was 24.6 μ g/L, for Plaintiff O.H. was 27.7 μ g/L, for plaintiff Kathleen Main-Lingener was 95.4 μ g/L, for another Plaintiff K.M. was108 μ g/L, for Plaintiff Silvia Potter was 120 μ g/L, and for Plaintiff C.P. was 28.6 μ g/L. These plaintiffs received their drinking water from the Village of Hoosick Falls three Municipal wells tested at ranges between 150 ppt to 662 ppt. *See*

https://www.villageofhoosickfalls.com/Water/testing.html (last visited March 17, 2020).

Plaintiff Charles Carr's serum tested at 186 μ g/L and this private well tested at 390 ppt. Plaintiff Angela Corbett's serum tested at 22.2 μ g/L and this private well tested at more than 500 ppt.

The U.S. Environmental Protection Agency (EPA) in late November of 2015 recommended residents, including the representative plaintiffs, stop drinking or cooking with their water and repeated this recommendation in mid-December 2015. *See*

https://www.villageofhoosickfalls.com/Media/PDF/EPA-PFOA-letter-112515.pdf (last visited March 17, 2020) and

<u>https://www.villageofhoosickfalls.com/Media/PDF/EPAStatementHoosickFallsWaterContamina</u> <u>tion.pdf</u> (last visited March 17, 2020). In mid-December, Saint-Gobain began providing bottled water to Village residents. In addition, the State began upon request testing private wells in area

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 16 of 551

in January 2016, and in late January 2016 the EPA advised individuals with private wells to use bottled water if there was more than 100 ppt of PFOA detected in their well. *See* <u>https://www.villageofhoosickfalls.com/Water/Documents/DOH-PrivateWells-Redacted-</u> <u>011916.PDF</u> (last visited March 17, 2020) and <u>https://www.villageofhoosickfalls.com/Water/Documents/EPAStatementPrivateWellsTownHoos</u> ick_012816.pdf (last visited March 17, 2020).

The PFAS that contaminate water, such as PFOA, can be encountered in straight ("n') or a mixed variety of branched isomeric forms ("m"). The precise biological half-life in humans also depends on the isomers encountered. (120) Recent data for drinking water contamination (from Ronneby, Sweden) indicates that average decline in PFOA following the specific case of cessation of contaminated drinking water exposure is about 27% annually, with a mean half-life of 2.7 years. (121) Many factors influence the isomeric content of drinking water contamination, so it is uncertain that the experience in Hoosick Falls will be similar; this is simply the best available evidence to use for "scoping" predictions. Using the child plaintiff K.M. as an example (PFOA level from blood serum drawn in March of 2016 of 108 µg/L), assuming a 2.7 years as the future half-life of PFOA in the blood serum and no further exposure, K.M. who was 7 years of age when his blood was drawn, will still have a PFOA level of approximately around 27 µg/L when he turns 13 in 2022. K.M. will generally be predicted to continue to have a PFOA level in his blood serum of substantially more than 10 times the 2013-14 geometric mean for the United States population generally when he turns 13 years of age about two years from now. Similarly, plaintiff Main-Lingener (PFOA level from blood serum drawn in February of 2016 of 95.4 μ g/L) is generally predicted to continue to have a PFOA serum level above the 2013-14 geometric mean serum concentration for the United States population for more than a decade

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 17 of 551

from now, with ongoing contamination of internal organs. Again, these data are presented to illustrate the scope of the problem, actual experience will be unique for both the population and the individuals within it. This acknowledged individual uniqueness is also why continued testing into the future is an important component of any medical monitoring plan that is implemented.

In Hoosick Falls there is not only "evidence of contaminant levels in environmental media that would suggest the high likelihood of environmental exposure to a hazardous substance" (See ATSDR Criteria, **Exhibit E,** p. 38841), but established exposure to PFOA via contaminated drinking water in both the public water system and more than 300 private wells above NY's proposed MCL. In addition, the PFOA in the blood serum of the exposed population above geometric mean US background levels were measured months after they stopped consuming the water. **REDACTED PURSUANT TO PROTECTIVE ORDER (ECF NOS. 131 & 132)**

This finding and other less dramatic exceedances in biological burdens show that these above-threshold exposures have been consequential in the exposure population. Thus, in Hoosick Falls, we know exposures to PFOA above health-based comparison levels *have occurred* and that the exposed population has PFOA in their blood at levels in excess of background, which will remain for years due to the long half-life of this chemical in serum, and its propensity to concentrate in vital organs such as bone, liver, kidneys, and testicles.

Based upon the above analysis, it is my opinion that the target community in Hoosick Falls has been exposed to PFOA above health based comparison values set by state and federal agencies and meets the criteria described by ATSDR for consideration of a medical monitoring program.

MONITORING FOR EVIDENCE OF CONTINUED EXPOSURE IS WARRANTED IN HOOSICK FALLS

As the ATSDR criteria states "[a]t sites with exposure in the community, the medical monitoring program might include biological markers of continuing exposure." (See Exhibit E, p. 38842). It is my opinion to a reasonable degree of medical certainty that ongoing testing for PFOA blood levels in the likely exposed population should continue into the future because(1) PFOA can be readily detected in blood serum; (2) PFOA is extremely persistent in the environment; (3) PFOA has a protracted half-life in the blood serum (and other organs) that varies from individual to individual; and (4) the presumed primary mechanism of transport of PFOA to the community was through air emissions that traveled significant distances before depositing in the soil (See Shin report, submitted herewith), and from air and soil into water .

MEDICAL TESTS AND SCREENING PROCEDURES ARE AVAILABLE TO DETECT ADVERSE HEALTH EFFECTS FROM PFOA

As the ATSDR criteria discuss, "[t]he monitoring aspect of a health surveillance program consists of the periodic medical testing to screen individuals who are at increased risk of disease". (See **Exhibit C**, p. 38842). Adverse instances of exposures and of health effects have been documented in multiple settings of PFOA-exposure community survey data, as well as from public health registries such as NHANES in the United States and from studies internationally. The report of David Savitz, Ph.D. submitted herewith, provides a summary of these health effects, although additional studies are being published weekly, and it is expected that additional adverse health effects may be identified. These increased risks of adverse health effects pertain to a wide variety of individuals, and, to a reasonable degree of medical certainty, require the

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 19 of 551

additional medical attention attained through medical monitoring for the relevant health condition and/or clinical biomarker measure. A medical monitoring program for the individuals in Hoosick Falls who have been exposed to PFOA through contaminated water should include monitoring for each of these health effects to the degree that useful testing exists.

A medical monitoring program for the population in Hoosick Falls exposed above background levels and at increased risk for developing one of the many conditions associated with PFOA ingestion should begin with a medical survey to be completed by each at-risk individual. Such a survey could be based on the C8 Health Survey but updated to include new scientific information, such as (but not limited to) diagnoses of gout and steatohepatitis (nonalcoholic fatty liver disease), as well as the birth weight and developmental weights/heights of children.⁴ (13-32, 40, 41, 43) It should include a review of systems that addresses the frequency of infectious diseases and respiratory diseases, especially in children. (33-39, 132-133)

The medical monitoring program for Hoosick Falls should also include periodic and serial clinical laboratory testing of biomarkers pertinent to PFOA exposure. As shown below, these tests are related primarily to PFOA serum concentrations, as well as early detection of specific cancers to the degree feasible, liver function, uric acid status, and disease such as ulcerative colitis, kidney function, endocrine function, lipid status, and participant concerns about pregnancy and transfer of toxins to infants and young children in utero or by breast feeding. (11,28-32,39,42,57,63-85,91-94,116-117) These tests are above and beyond those that are part of standard, recommended preventive health screening. For example, they target specific outcomes such as altered lipid metabolism in children that are not covered by standard screening. And, because the anticipated internal exposures are anticipated to diminish over time, there is the

⁴ This list of new information is meant to be illustrative, not exhaustive.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 20 of 551

potential to consider cessation of lipid lowering agents, a very important and unique topic area that is seldom addressed by routine visits. The information can be tied to unique opportunities for targeted consideration of the underlying metabolic defects specifically worsened by PFOA exposure, as clinicians can use the data in risk calculators and help participants to make lifestyle adjustments that can diminish, mitigate, and postpone disease processes. These empowering data do not dispel the inherent risk of PFOA exposure per se, they prepare the at risk population to deal with and diminish the risk. By way of another example, urinalysis, which is no longer part of routine annual examinations⁵, screens for renal disease and renal cancer in this population. It also provides important data that allows more comprehensive interpretation of the meaning of the serum PFOA concentration. Individuals with kidney disease and notably kidney disease with albuminuria are shown to have lower serum PFAS concentrations than the rest of the population.

Compilation of the tests to be performed and other elements of this medical monitoring program should benefit from collaborative review and comment work, with input from peer expert reviewers from different disciplines, as well as feedback from regional clinicians. Such interdisciplinary peer collaboration leads to better clinical biomonitoring programs and the advancement of science. (4-7) The development of specific additional monitoring tests and evaluations, aside from blood testing, as well as the methodology to implement these tests, will be set forth in a future report. The testing protocol that is ultimately recommended should be applied to all individuals who are at increased risk of developing future disease as a result of their exposure to PFOA. The monitoring program for this exposed population would include, for example, regular blood tests to monitor for thyroid, liver function abnormality, non-alcoholic fatty liver disease, hyperlipidemia, uric acid abnormalities, gout, and PFOA blood level; serum

⁵ <u>https://www.health.harvard.edu/diseases-and-conditions/urine-testing-no-longer-routine</u>

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 21 of 551

lipid screening; and urinalysis, with screens for renal disease and renal cancer. In addition, an appropriate monitoring program will also implement survey monitoring protocols consisting of diagnostic questions tailored to the human health conditions caused by exposure to PFOA.

Residents in and around Hoosick Falls, New York, who have been exposed to PFOA, primarily through consumption of contaminated drinking water, and have above-background levels of PFOA in their blood, have resulting increased risks of the developing the illnesses and adverse health conditions described at length in Dr. Savitz's report. To a reasonable degree of medical certainty, a medical monitoring program is clinically necessary for this population to detect known PFOA-related adverse health effects as early as possible in order to minimize disease and improve health outcomes. (5) The earlier these health conditions and precursors of adverse health conditions are detected, the more effectively they can be treated. Early diagnosis and treatment of virtually all cancers is beneficial, and this is certainly true of kidney cancer and testicular cancer that are associated with PFOA exposures. (59-61, 128) Similarly, thyroid disease can be treated effectively with medications and the sooner someone afflicted by this condition is treated the sooner the symptoms caused by this condition will diminish. Early detection of thyroid conditions is considered to be especially important in pregnancy. (111) High cholesterol and high uric acid levels can also be treated with medication once detected and risk can be lowered before conditions associated with these biomarkers can develop (e.g. higher uric acid is a risk factor for gout and cardiovascular disease; higher cholesterol levels mean that additional people will be recommended for lifestyle interventions and/or pharmacological treatment of elevated lipid levels to prevent coronary artery disease).

As is detailed in the report of Dr. Savitz, for all of the conditions associated with PFOA exposure, risk increases with exposure, although for some conditions, there appears to be a

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 22 of 551

plateau effect once PFOA blood levels reach a certain point. The presence of a dose plateau effect is not good news for the exposed population or for public health in general, since the implication is that the effects detected begin to operate at low serum concentrations. The epidemiological data does not provide a particular PFOA blood level in humans at which there is no increased risk of PFOA associated diseases other than zero. Because of this, it is my opinion that the proposed class definition for the medical monitoring program should include all of the exposed individuals in the Class Area whose blood serum was detected to contain PFOA at levels above the US (2013-4) geometric mean background level of 1.86 ug/L when the Hoosick Falls blood tests were done (circa 2016), months after these exposed residents stopped ingesting the contaminated water.

A MEDICAL MONITORING PROGRAM IS MOST PRACTICALLY AND EFFICIENTLY ADMINISTERED TO A COMMUNITY AND NOT ON AN INDIVIDUAL BASIS

I have been informed by the attorneys for the plaintiffs in this case that the Court on this motion must determine whether medical monitoring of an exposed population is best approached on a group or individual-by-individual basis. Based upon my background and experience, it is my opinion to a reasonable degree of medical certainty that establishing a program to provide appropriate medical surveillance for an entire exposed community is far superior in multiple ways compared to attempting to provide such surveillance on an individual basis. (3-7,110) The available criteria for medical monitoring programs (See **Exhibit E**) deal exclusively with programs administered on a community-wide basis. The reasons for this include simple feasibility to perform the needed tasks, lower cost due to economies of scale and centralized administration, increased capability to communicate with affected individuals and their treating clinicians, consistency of applying appropriate testing protocols and continuity into the future.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 23 of 551

Moreover, requiring each adversely affected individual to bring a separate lawsuit seeking medical monitoring damages would delay the implementation of such a program for some or most of these individuals for many years defeating the important purpose of beginning monitoring as soon as practicable so that illnesses can be detected and treated as early as possible.

Adequate medical monitoring proposed for this exposed population would have two temporal components. Medical screening (initial testing) focuses on protecting the health of an exposed population, generally emphasizes early detection and response to clinical outcomes of exposure. This would include screening for the health effects and risks listed in Dr. Savitz's accompanying report. Medical surveillance collects prospective data on the exposed population (providing a means to follow the exposed individuals over time). Ongoing monitoring adds the potential to detect the presence of additional and cumulative hazards (risks to be deterred) in individuals and populations. The goal is untoward health outcomes detected earlier, and negative consequences prevented or mitigated over time. Throughout the process, central data collection with ongoing assessment of what is being learned has the potential to inform about the ongoing exposure status and to add an element of protection. For industrial chemicals, the Department of Labor, Occupational Safety and Health Administration provides support to industry and explains the role of medical monitoring for employers of workers, recognizing that industrial chemicals in the workplace can be hazardous and that one aspect of a mitigation strategy is medical monitoring. https://www.osha.gov/SLTC/medicalsurveillance/ (last accessed March 17, 2020). These concepts translate to non-occupational settings when populations are exposed to industrial chemicals.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 24 of 551

A typical medical surveillance program collects survey questionnaire demographic information describing the participants, survey questionnaire health information directed at the population diseases, symptoms, and needs, as well as laboratory and/or radiographic/imaging information pertinent to detection of outcomes of known exposure risks. Depending on the nature of exposure, the targeted health information collected from the participants can also inform the data collected in follow up efforts and can seamlessly be turned into de-identified community summary data that portrays the community experience and protects individual privacy. Medical surveillance may also collect simple physical examination information such as height, weight, and blood pressure. Such programs feature a centralized data base so that meaningful reporting of summary data and key findings can occur. This step, providing community feedback concerning summary key findings, is important for fairness, participation/engagement, and quality assurance purposes. An example is reporting of sequential serum PFOA concentrations. Such feedback reporting is obviously impossible at the individual level, and the testing is more expensive per capita.

A medical surveillance program relies upon uniform data storage to collect information in a reliable way on behalf of participants as individuals and as members of the affected community. Other important benefits of uniform data storage include the ability to provide personal materials back to properly-identified participants who have lost their original data. (In the C8 Health Project, participants were provided their personal data, and there is a means for participants to identify themselves and obtain their data again). It is also very helpful to the members of the affected community to have an accessible health communications strategy that provides information about processes, procedures, and summary findings. This summary information is also generally available to anyone with internet access and interest in the

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 25 of 551

monitoring. The featured information is accessible to anyone, and the featured information deliberately has no means to identify individuals. The point about identification is important. In the C8 Health Study, focus group interviews of potential participants repeatedly mentioned loss of privacy as their largest fear. Any process which threatens loss of privacy is problematic. In that regard, the federal government provides guidance about the public reporting findings of rare diseases in small populations, with helpful guidance for protecting privacy.

The truism that individuals are unique is an argument for an appropriate community-wide medical monitoring program for the exposed population, rather than against, or a determinant of who should be included. In general, the uniqueness of individuals is understood in the medical and public health communities to illustrate the need to monitor more of the exposed population inclusively. That people have varying medical histories, including medical co-morbidities, is well understood by experts and by the general public. These unique individual characteristics include but are not limited to our individually inherited genetics, personal health habits, and varying historical environmental experiences. Our individual uniqueness means that we are aware of excess risks to the exposed population, but generally are unable to predict in advance who in the population with demonstrable excess risk will get which disease known or suspected to be associated with exposure, or when. In addition, we cannot predict the severity of the health effects for any particular individual. There are no known medical comorbidities that mitigate the risks from PFOA exposure (i.e. no trait or pre-existing condition has been identified that reliably protects an individual against the adverse health effects of PFOA). Rather, we must work to identify behaviors, characteristics, and comorbidities that may further increase these risks, and we work to identify the attendant disease processes as early as possible. Consider the half-life established for PFOA, by Olsen and colleagues from 3M. (8) This useful data represents a

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 26 of 551

population mean, and it is understood by readers that individuals will not all have this precise half-life, for a wide variety of reasons related to inherited genetics, environment, habits, absorption, excretion, and body habitus, among many variables that are different among all of us. The data are valuable estimates of mean tendencies despite the differences among those who were tested. (Id.) In health care, health professionals in many organizations collect data and become increasingly expert at predicting average tendencies, including factors that bring increased risk (e.g. the relationship between high cholesterol and heart disease), yet we remain persistently mediocre or worse at predicting who among the high risk community specifically will be the one(s) to suffer the outcome(s), and when the outcomes will occur. This necessitates monitoring all of an exposed population, and is why children are monitored for lead exposure in communities where that exposure is merely possible for all, but the extent of exposure is not determined in advance for any. In the Class Area, based on blood testing data from NYSDOH more than 2,000 individuals have tested above PFOA background, clearly demonstrating that the class requires attention. Individual medical records and histories are irrelevant to whether a medical monitoring program, as described above, is clinically necessary for exposed class members in a demonstrably contaminated geography. A need for pre-review of individual medical records is not mentioned in the ATSDR document addressing the rationale and implementation of medical monitoring for environmental risks. While individualized factors, such as age, sex, height, weight, prior medical conditions, and a host of other differences /between/among all people, can and do inform data collection, this information can be collected most efficiently and effectively though an appropriate survey, as part of a medical monitoring program administered to an entire group of exposed individuals.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 27 of 551

For example, we screen a small subset of adults for lead poisoning -- workers with potential lead exposure -- because we generally can target those as being most at risk. We screen many thousands of young children, including those who live in contiguous and potentially contaminated areas with different risks of lead poisoning, because the exposure is even more serious in children, and the specific behaviors and environmental and social circumstances that lead to childhood exposure are highly individualized. It is hard to predict the presence of safety in the absence of checking for the hazard. Further, we know that some conditions, such as inadequate diet, may increase the risk of childhood lead poisoning, but this does not dissuade us from monitoring, or limit those whom we monitor. In the case of Hoosick Falls, the existence of shared risk of exposure is certain. In all populations, the presence of some individuals with increased susceptibility due to age, co-morbidities or other factors, is also certain.

Similarly, the preventive health community does not limit monitoring based on more than one possible source of exposure of the offending toxin. We know that workers in a benzene monitoring program may have exposure from two (or more) sources, such as work and personal cigarette smoking, but that supports the need to include all workers, smoking and nonsmoking in the monitoring program, and to pair demographic data and environmental monitoring data collected in a worker survey, and to compare these to the laboratory results. We also know that some of the risks of asbestos exposure are potentiated by cigarette smoking (such as lung cancer and parenchymal asbestosis), whereas other diseases (such as malignant mesothelioma) are related to asbestos exposure and not potentiated by smoking. Smoking status is determined in surveys, but the status does not determine eligibility for monitoring in asbestos-affected workplaces and communities. It is also why demographic and independent risk data are collected

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 28 of 551

in the survey as part of the program which collects health and exposure data from the participants rather than trying to extract it from medical records.

In clinical care, if a risk is known to exist, we monitor and evaluate that risk to the degree possible and useful. In Hoosick Falls, multiple adverse health risks are present in the exposed population as a direct result of their exposure to PFOA, primarily in drinking water, and for this reason these risks and the population that has endured them should be monitored, irrespective of individual differences. The class is homogenous only in their a priori risk of exposure to PFOA. and therefore in their legitimate concern about health outcomes including increased risks of adverse health outcomes. These outcomes include ICD-codeable diseases, and markers for increased risks of diseases such as abnormal biomarkers of various body system functions. These risks determine the medical necessity of an appropriate medical monitoring program, as discussed by the ATSDR, just as exposure to asbestos or to lead determines the necessity of participation in an asbestos or lead medical monitoring program. Individualized predictions of outcomes are not possible, nor are they beneficial to the exposed population, and pretenses that we need to know outcomes before we search for evidence of disease turns the health care paradigm on its head. We can make assessments of increased risk in populations and in population subgroups, but we do not know enough to make such individualized assessments in order to determine outcomes before we find them. We know that every exposed person faces increased risks of related adverse health effects. The goal is early detection and mitigation of harm.

The literature establishes that drinking water that has been contaminated with PFOA is the primary source of exposure for those who consume it. Consistent with this literature, the data for the named representative plaintiffs supports that elevated PFOA in the drinking water leads to

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 29 of 551

elevated PFOA levels in the blood. (2, 12, 104, 119, 135) The consideration of an industrially contaminated residential population is also not unique to PFOA. (6,7) Possible subsidiary sources of PFOA - to the extent they exist - do not impact the clinical necessity of medical monitoring based on this primary exposure. Subsidiary sources are expected and documented in predecessor efforts for populations who have consumed contaminated water and do not negate the findings about primary sources in numerous studies including the population investigated in the C8 Health Study and other populations. (2, 10, 12, 104, 105-110, 119, 135) When drinking water is not contaminated, however, community exposures are from other sources, and, biological burdens are lower. (106, 119)

In my career, I have participated directly in multiple medical monitoring projects (see pages 3-4 above). In all of these projects and programs, admission to the program was based solely on exposure to the relevant toxic substance or hazard (PFOA, asbestos, lead, noise, etc.) and the risks resulting from that exposure, and was available to entire exposed and at-risk population. None of these projects and programs was based on individualized determinations of who among the exposed and at-risk population considered to be exposed should be excluded or participate. The programs were based on the opportunity for exposure that would place individuals at increased risk of developing illness. In this case, however, participation in the program would involve more than an opportunity for exposure because blood testing results are available and confirmatory. This testing has detected a population at risk and it can continue to demonstrate the ongoing quantity of PFOA in the blood of each participant. Existing PFOA serum testing provides a very high degree of capability to assess the degree to which the exposed population and its individuals did once and continue to carry a biological burden of exposure.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 30 of 551

From a medical perspective, another consideration favoring administering the medical monitoring program on a class-wide basis is the protection of the participants' privacy and confidential medical information. In the C8 Health Project, focus groups of the exposed population, and speakers in town meetings, repeatedly expressed the concern that their confidential information would be available to the company that was responsible for their exposure, and many would not have participated in the monitoring program absent strong protocols protecting their privacy and confidential medical information.

For all of these reasons, any suggestion that individual variability within the exposed population is an argument against using the class action vehicle to resolve claims for medical monitoring damages and to create a unified medical monitoring program for the exposed population in Hoosick Falls is contrary to the published medical literature, prior PFOA medical monitoring experience, accepted medical monitoring standards including federally published standards, and common sense. Individual histories or records are not relevant to determining the clinical appropriateness of medical monitoring, or who among the exposed population should be included in the program. Doctors routinely reject the idea that individual uniqueness is an argument against the usefulness of evaluation in a clinical setting.

Finally, that some of the testing that would be contemplated in a medical monitoring program for this population might be duplicative of testing some of these individuals would routinely receive during physicals with their primary care physician is also not a valid argument against a community-wide program. Consider serum lipid testing. Even if serum lipid levels (including total and LDL-cholesterol) are evaluated for some of the exposed population, the intervals at which they are checked is variable and would not replace a regimented program of testing designed specifically for the risks associated with PFOA exposure. Moreover, serum

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 31 of 551

lipid levels (including total and LDL-cholesterol) are infrequently or never checked in healthy children, adolescents and young adults. Individuals in the C8 Health study reported acting on such data by bringing the survey-determined information to their treating clinician. There may also be class members who have no insurance or who are underinsured. Thus, while some of the exposed population may receive some of the testing that would be included in a medical monitoring program for PFOA, this would not duplicate or replace the benefit of a specifically designed medical monitoring program to test for early adverse health effects associated with PFOA exposure.

In summary, it is my opinion to a reasonable degree of medical certainty, that establishing a medical monitoring program for the benefit of the entire class of individuals sufficiently exposed to PFOA to elevate their risk of developing diseases and conditions associated with PFOA exposure is supported by the published medical literature, standards published by ATSDR as well as the experience of the C8 Health Project and such an approach is far superior to attempting to provide medical monitoring on an individual basis.

alon Jucatur

Alan Ducatman, M.D.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 32 of 551

EXHIBIT A

December 12, 2018

CURRICULUM VITAE ALAN M. DUCATMAN, MD, MSc

Professor Emeritus, WVU School of Public Health Adjunct Professor, WVU School of Medicine

PERSONAL DATA

Citizenship: United States Family: Married, three children

ADDRESS

Alan Ducatman LLC 910 Westchester Way Birmingham, Mi 48009 Contact: 249 940-2950 Alan.ducatman@gmail.com

Academic Affiliation

Professor Emeritus WVU School of Public Health Once Medical Center Drive PO Box 9190 Morgantown, WV 26506-9190 aducatman@hsc.wvu.edu

Personal Statement: My current consultation work engages both environmental health and quality assurance. I have been a successful leader of occupational and environmental health enterprises in research, education, and clinical as well as consultation service. Previous settings for my work have included military service, compliance oversight in highly technical workplaces, and academic healthcare. I have been a successful consultant to government, industry, and labor entities. My work goal is simply to provide public health value to decision-making, whether the work is about clinical service, teaching, or research.

EDUCATION

- 1978 MD Medicine, Wayne State University, Detroit, MI
- 1974 MSc Environmental Health. City University of New York—Hunter College, and Mt. Sinai School of Medicine, New York, NY
- 1972 AB Analytical Biology. Columbia College, New York, NY

POSTGRADUATE TRAINING

- 1982 Fellowship in Occupational Medicine, Mayo Clinic, Rochester, MN
- 1981 Medical Residency. Mayo Clinic, Rochester, MN
- 1979 Medical Internship. Brown University, Providence, RI

ACADEMIC APPOINTMENTS

- June 2018- Professor Emeritus, West Virginia University
- 2012-2018 Professor of Public Health, and Professor of Medicine, West Virginia University

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 34 of 551

- 1992-2012 Professor of Medicine, West Virginia University School of Medicine
- 2012-2015 Professor, Department of Emergency Medicine, West Virginia University School of Medicine
- 2011-12 Professor and Interim Founding Dean, Professor of Public Health, West Virginia University School of Public Health
- 2002-present Adjunct Professor, Department of Animal and Nutritional Sciences, Davis College of Agriculture, Natural Resources, and Design, West Virginia University
- 1994-97 Adjunct Professor of Medicine. Medical University of South Carolina
- 1991-2004 Clinical Associate Professor of Preventive Medicine. University of Mississippi School of Medicine, Jackson, MS
- 1990-93 Adjunct Associate Professor of Public Health (Environmental Health). Boston University School of Medicine, Boston, MA
- 1990-93 Clinical Associate in Neurology, Massachusetts General Hospital, Boston, MA
- 1987-89 Lecturer on Medicine. Harvard Medical School, Boston, MA
- 1983-86 Assistant Professor of Community Medicine, Eastern Virginia Medical School, Norfolk, VA

PROFESSIONAL EXPERIENCE

- June 2018- Professor Emeritus, WVU School of Public Health
- 2012- 2018 Tenured faculty in the School of Public Health, co-appointment in the School of Medicine, Department of Medicine. Responsible for clinical care, graduate teaching (including forcredit as a member of the graduate faculty), funded research, and external consultation to industry, labor, government, and non-profit organizations. More recent duties also include for-credit teaching of true undergraduates.
- 2011-2012 Interim Founding Dean, West Virginia University School of Public Health. The School of Public Health enrolls over 170 master's and PhD graduate students in the MPH, the PhD in Public Health Sciences, and the MS in School Health Education.
- 1997-2011 Appointment as **Chair**, Department of Community Medicine, West Virginia University School of Medicine

The Department of Community Medicine has grown and evolved to become the WVU School of Public Health. This is the first fully new school at WVU in more than five decades. Faculty participate in and direct programs in a Prevention Research Center, an Injury Control Research Center, an Institute for Occupational and Environmental Health, a Health Services Research Center, and a Center on Aging, as well as the Mary Babb Randolph Cancer Center and other organ-based research centers. Faculty focus much of their research in population health, health services, community intervention, and community health in rural settings.

- 1996-97 **Interim Chair**, Department of Community Medicine, West Virginia University School of Medicine.
- 1992-97 **Director**, Institute of Occupational and Environmental Health (IOEH), West Virginia University School of Medicine

The IOEH sponsors NIOSH-supported occupational medicine residency training program and participates in multidisciplinary research and teaching activities. Service and research are provided for clinical care and outcomes, environmental health, toxic exposure assessment, health services research, ergonomics, and epidemiology. IOEH faculty provide clinical care, graduate and continuing medical education, grant-funded research with an emphasis on clinical outcomes, and workplace epidemiology consulting to government agencies, industry, and labor. A primary goal of the Institute is decreasing the frequency and severity of work-related injury in West Virginia.

- 1992 Faculty member, WVU Institute of Occupational and Environmental Health
- 1986-92 **Director**, Environmental Medical Service, Massachusetts Institute of Technology, Cambridge, MA

Responsible for Occupational/Environmental Health at Massachusetts Institute of Technology and affiliated institutions with over 20,000 employees, as well as students and official visitors. Supervised 50 professionals and support staff, with a budget in excess of \$3 million. Provided service to MIT in biohazards, industrial hygiene, radiation protection, nuclear reactor safety, occupational health, and toxicology. In addition, provided selective research and consultation to governments, industry, and workers.

1983-86 **Director**, Professional Occupational Health Branch, United States Navy Environmental Health Center, Norfolk, VA (LCDR, Medical Corps).

Responsible for worldwide consulting concerning occupational health problems of the Navy's 1.1 million employees. Reported to the Navy Inspector General concerning the status of occupational health care at Navy clinics. Provided quality assurance assessment for asbestos medical surveillance

1982-83 **Director**, Occupational Medical Services, Columbia Park and Brooklyn Park Medical Groups, Columbia Park and Brooklyn Park, MN. Founded a successful and rapidly expanding private occupational health practice within a multispecialty group.

PATIENT SERVICE

Outpatient Care Devise and conduct medical surveillance programs for industry, labor, and government in West Virginia and surroundings. Conduct clinical referral evaluations of patients with known or suspected environmental exposure.

Environmental Health Consulting: Evaluate and ameliorate environmental risks on behalf of government, industry, workers, and citizen groups.

CERTIFICATION AND LICENSURE

Certification: American Board of Preventive Medicine (Occupational Medicine) January 24, 1983 - Certificate Number 21816

> American Board of Internal Medicine September 16, 1981 - Certificate Number 79779

Licensure: West Virginia - July 13, 1992 - Perm. 16937

MilitaryLCDR, Medical Corps, USNR, 1983-86Service:CDR (inactive) USNR, 1986-91

UNDERGRADUATE AND MEDICAL STUDENT TEACHING

<u>Annual</u>

2016-17 PUBH 243 Global Occupational and Environmental Health (Required true undergraduate course in new public health program. Enrollment 2016, 29 students; 2017, 72 students)

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 36 of 551

- 2001-2005 MDS 124: Community Health and Disease (1 hour).
- 2000-2005 Pathology 751: Environmental Diseases (1 hour).
- 2000- CCMD 712 and CCMD 713: Public Health Topics in Disease Status and Disease Prevention.
- 1997-2001 Orientation 60 (undergraduate), 1 hour
- 1996-2001 **West Virginia School of Osteopathic Medicine**. MSI Lectures in Occupational and Environmental Health 6- 8 hours per year

Intermittent

- 1996 Physical diagnosis for medical students
- 1994 Medical University of South Carolina. Summer M2 Lectures, Environmental Health
- 1994-95 **Uniformed Service University of Health Sciences (Bethesda, MD)**, Occupational and Respiratory Disease (2 contact hours)
- 1993 Medical Aspects of Environmental Health, West Virginia University, 2.0 credits
- 1991-92 **Harvard University.** Principles of Occupational Health 4.0 credits, undergraduate faculty
- 1987-1991 **University of Mississippi**. Occupational Hazards of Rural Areas, Toxic Hazards in the Workplace, Environmental Dust Diseases. University of Mississippi School, of Medicine, Jackson, MS (Visiting Associate Professor, undergraduate medical education)
- 1990 **University of Mississippi**. Undergraduate Medical School Course (1 day) Occupational Medicine: An Environmental and Workplace Imperative (Mississippi Physicians and Nurses also attended)
- 1987 American Industrial Hygiene Association. Toxicology. American Industrial Hygiene Association. ABIH Certification Exam Review Class. Faculty
- 1973-74 Hunter/CUNY. Physiology Laboratory. Hunter/CUNY- 2.0 lab credits instructor

Graduate Teaching

1997-2015 West Virginia University Master of Public Health Program, Ph. D program. OEHS 601 (previously PUBH 601, 610, and 650): Environmental Health (Core Curriculum) - 3 credits. Principle Instructor and/or co-principal instructor. Course is now provided online, and in the classroom. Currently, Dr. Ducatman is the primary instructor for the online section (20-50 enrollees). 1999-2012 CMED 691A/PUBH 605: Introduction to International Public Health. Environmental influences on International Health (1 hour). 1997-2003 CMED 791C: Advanced Topics in Toxicology - 1 credit Special Projects and Independent Study - Variable Credit Plan of Study Committee - IOEH Residents 1997-present 1995 Critical Ethical and Legal Issues in Health Care, 3.0 credits

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 37 of 551

1987-92Harvard School of Public Health. Organic Solvents. Fundamentals of Industrial
Hygiene. (Twice annually; graduate visiting lecturer)

Doctoral Committees

.

2012-13	Member, PhD in Public Health Sciences Committee for Omayma Alshaarawy.
2011-12	Member, PhD in Public Health Sciences Committee for Sarah Geiger
2009-10	Member, PhD in Public Health Sciences Committee for Joseph Putila
2009-2011	Member, PhD in Public Health Sciences Committee for Loretta Cain

Clinical Teaching

2002-2017	Lectures to residents on selected topics
1993-2002	Residency Director, Occupational and Environmental Medicine, West Virginia University.
1992-	Medical student and resident rotations in Occupational Environmental Medicine, West Virginia University. Classroom teaching in environmental health; Clinic teaching in introduction to clinical medicine.
1987	Resident Training Advisor, Boston University School of Public Health . Residency rotations
1989	Resident Training Advisor, University of Kentucky , Department of Preventive Medicine and Environmental Health. Resident 3 weeks at MIT. 40 hours/week.

MEMBERSHIPS ON SUPERVISING COMMITTEES AND BOARDS OF TRUSTEES

West Virginia and Region

2016-2018	Advisory Committee to West Virginia DHHS, Bureau for Public Health. WV Childhood Lead Poisoning Prevention Council
2013-2018 2012	West Virginia Health Innovation Collaborative, member (for WV DHHR Cabinet Secretary) West Virginia Public Health Assessment Committee
2012	Governor's Advisory Council on Substance Abuse
2011-2014	External advisory member for health communications, Marietta (OH)/Mid-Ohio Valley (WV) US
2010	EPA Workgroup
2009-present	0
2006	Monongalia County All-Hazards Advisory Committee
2006	ATSDR State Environmental Waste Site Planning Committee
2005	West Virginia Leadership Council on Public Health Threat Preparedness
2003	West Virginia Heart Disease Program Advisory Council, WV Bureau for Public Health
2003	ATSDR Cooperative Programs Partner, WV DHHR
2003	Ad Hoc Potassium Iodide Policy Review Committee, WV Bureau for Public Health
2003	Monongalia County Health Department Threat Preparedness Advisory Committee
1999	Technical Assistance and Training Subcommittee, WV Bureau for Public Health
1999-2003	Lead Poisoning Prevention Committee, WV Bureau for Public Health
1999	Healthy People 2010 Cancer Work Group
1999	Healthy People 2010 Occupational Safety and Health Work Group
1998	Executive Council, WV Public Health Association
1998	Steering Committee, Tri-State (Southeast) Public Health Leadership Institute
1997-98	WV Bureau for Public Health Medical Waste Advisory Committee
1997-2000	Chair, WV Public Health Association Committee for Continuing Education

- 1997 Steering Committee, WV Bureau for Public Health Transitions Project
- 1995-1998 Lead Abatement Advisory Committee, WV Bureau for Public Health and
- WV Department of Environmental Health
- 1993-2009 WV Poison Control Center Advisory Board
- 1993-94 Grant Proposal Reviewer, WV University Injury Control Training and Demonstration Center.

National

- 2018 Science Advisory Board, PFAS "REACH" grant. Official title: Assessment of pediatric immunotoxicity, public education, and capacity-building in communities impacted by PFAScontaminated drinking water. Project period 09/07/2018 – 06/30/2023 Grant number: 1R01ES028311-01A1 PI: Laurel Schaider. Silent Spring Institute. CoPI Phil Brown, Northeastern University
- 2018 APC Program Steering Committee Annual Meeting Abstracts. Coronado, CA. July 15-19, 2018
- 2016 Ad hoc reviewer for Centers for Disease Control, Agency for Toxic Substances and Disease Agency for the work entitled "Health Consultation, Dimock Site." Published May 24, 2016
- 2014-2015 Member, Health Effects Institute Special Committee on Unconventional Oil and Gas Development
- 2008-present Accreditation Council for Graduate Medical Education (ACGME) Board of Appeals Panel member).
- 2007-2008 Member, Program Peer Review Subcommittee, Board of Scientific Counselors, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry.
- 2005-2008 Board of Scientific Counselors, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry. Appointed Committee Chair, August 2007; term ended October 2008.
- 2004-2009 Wayne State University, External Peer Review for Internal Research Grants Committee
- 2002-2004 Strategic Medical Intelligence Section, Department of Justice and University of Pittsburgh
- 2002-2003 American Board of Preventive Medicine. Core Examination Committee.
- 2002-2007 University of Kentucky Prevention Research Center, Markey Cancer Center; Community Advising Committee through 2003, Scientific Advisory Committee from 2003.
- 1999-2004 Residency Review Committee; Accreditation Council on Graduate Medical Education-Preventive Medicine, Appointed Vice Chair, 2002; Appointed Chair, 2004.
- 1998-2004 Board of Regents, American College of Preventive Medicine
- 1993-2002 American Board of Preventive Medicine, Trustee
 - Chair: Client and External Relations Committee, 1992-99
 - Chair: Combined Preventive Medicine/Internal Medicine Residency Training Committee
- 1993-95 International Union of Operating Engineers. National HAZMAT Program Board of Scientific Advisors
- 1988-92 Residency Advisory Committee, Boston University Medical Center Occupational Health Program
- 1988-95 American Board of Preventive Medicine/National Board of Medical Examiners. Occupational Medicine Examination Committee.
- 1985-2003 American College of Occupational and Environmental Medicine. Practice Committee.

International

2015-2016 International Agency for Research on Cancer (IARC). IARC Monographs Working Group for Volume 115 – "Some Industrial Chemicals."

<u>University</u>

- 2016-2018Elected Representative, School of Public Health Faculty Council2016-2018Search Committee, Departmental Chair, Occupational and Environmental Health Sciences2016-2018Curriculum Committee, School of Public Health2015-16Promotion and Tenure Committee Member, School of Public Health
- 2013 Search Committee Member, School of Dentistry

2012	WVU Energy Council
2011	Member, Internal Advisory Committee, Research Training in Behavioral and Biomedical Sciences T32 Grant
2011-	Member, Search Committee, Family Medicine Chair
2010-	Member of the MD/PhD Admissions Committee
2010-	Member of the MD/PhD Advisory Committee
2010-2011	Clinical Council of Chairs
2010 2009	Member of the Discovery and Innovation Input Group, WVU Strategic Planning Council Member of Search Committee for WVU Provost
2003	Steering Committee Member, WVU National Children's Center Project
2006-2008	Steering Committee Member, Center for Immunopathology and Microbial Pathogenesis
2005-2008	Steering Committee Member, Center for Respiratory Biology and Lung Disease
2005-present	Steering Committee Member, Injury Control Research Center
2004	Chair, United Way Campaign, School of Medicine
2003-2009	Scientific Advisory Board, School of Medicine
2003-2005	West Virginia Prepares: Virtual Medical Campus Continuing Education Partnership Advisory
	Board
2003	Search Committee Chair, Center for Rural Emergency Medicine Director
2002-2010	Executive Council (formerly known as Council of Chairs)
2001-2007	Mary Babb Randolph Cancer Center (MBRCC) Prevention, Education, and Outreach Advisory Committees
2001-2003	Prevention Research Center (PRC) Executive Planning Committee
2000-2001	Clinical Research Development Grant Study Section
1999	Ad hoc interdisciplinary committees
1999	Internal Reviewer, Grants and Contracts, West Virginia University School of Medicine
1997-2009	Basic Science Chairs Committee
1995-1997	External Advisory Committee, Department of Microbiology and Immunology
1992-1997	West Virginia University Safety Committee
1992-1999	School of Medicine Clinical Council
1992-2002	School of Medicine Executive Committee (Executive Faculty)

EXTERNAL PEER REVIEW

Peer Publications reviewed (by journal)

2018	BMJ Open, Chemosphere, Environment International, Environmental Health, Environmental
2017	Research (2), PLOS Biology (Ad hoc reviewer for all) Environmental Research, Nutrition and Metabolism, Occupational and Environmental
2017	Medicine, PLOS Biology, PLOS ONE, Preventive Medicine Reports (Ad hoc reviewer for all)
2016	Environmental Research (3), Environmental Toxicology and Pharmacology (2), PLoS ONE
2015	Environmental Health (2), Environmental Health Perspectives, Environmental Research (2),
	Military Medicine, Nutrition and Metabolism, PLoS ONE (Ad hoc reviewer for all)
2014	Environmental Health Perspectives (2), Environmental Research (3), Environment
	International, Occupational Medicine (2), Toxicology Letters (2). (Ad hoc reviewer)
	American Journal of Industrial Medicine (contributing editor)
2013	BMJ (Open), BMC Endocrine disorders, Diabetologia, Environmental Health Perspectives,
	Environment International, Nutrition and Metabolism, Public Health Reports (ad hoc reviewer)
2011	Archives of Environmental and Occupational Health (ad hoc reviewer)
2010	Public Health Reports (ad hoc reviewer)
2006-present	Journal of Occupational and Environmental Medicine (ad hoc reviewer)
2006-present	International Journal of Occupational and Environmental Health (ad hoc reviewer)
2005-present	Environmental Health Perspectives (ad hoc reviewer)
1990-	American Journal of Industrial Medicine (Contributing Editor)

- 2003 National Occupational Injury Research Symposium (abstract reviewer)
- 2003 USEPA reviewer: Human Health Research Implementation Plan for the National Health and Environmental Effects Research Laboratory
- 1996-2002 International Journal of Occupational Health (ad hoc reviewer)
- 1995 Southern Medical Journal (ad hoc reviewer)
- 1994 Cancer Prevention International (Topical Editor: Occupational and Environmental Health) 1994 American Journal of Public Health (ad hoc reviewer)
- 1993 Agency for Toxic Substances Disease Registry, Center for Disease Control, Case Studies Reviewer. Ionizing Radiation ATSDR 34; Oct. 1993.
- 1992-93Applied Radiology (Environmental Editor)
- 1991Journal of Occupational Medicine (ad hoc reviewer)
- 1990 Toxicology, Occupational Medicine and Environmental Series (TOMES), MICROMEDEX (Assistant Editor)
- 1990 Congress of United States, Office of Technology Assessment, OTA Reports (Reviewer)
- 1989-92 Van Nostrand Reinhold (new proposals reviewer)
- 1987-99 Occupational Environmental Medicine Report (Contributing Editor)

External Peer Review: Promotion and Tenure

- 2015 Mount Sinai School of Medicine
- 2012 School of Medicine, University of Virginia; School of Public Health, University of Illinois at Chicago
- 2011 College of Public Health, East Tennessee State University
- 2010 Department of Preventive Medicine, State University of New York At Stony Brook
- 2008 University of Virginia, University of Illinois at Chicago, University of Texas Health Science Center at Houston
- 2007 University of Illinois at Chicago, Tufts University, Yale University
- 2005 Uniformed University of the Health Sciences
- 2004 Dartmouth University School of Medicine, Uniformed Services University of the Health Sciences
- 2002 University of Pittsburgh
- 2001 Johns Hopkins University
- 2000 University of Pennsylvania
- 1999 Yale University, Univ. of Miami (Fla), UMDNJ-Robert Wood Johnson, Univ. of Utah, Boston University, Uniformed Services University of Health Sciences
- 1998 Texas A&M University
- 1997Jefferson Medical College, University of Maryland
- 1996 University of Miami (FL), Medical College of Wisconsin
- 1995 University of Texas, University of Iowa, University of Michigan, University of California, Los Angeles
- 1994 Tufts University, University of Mississippi

Other External Advising

- 2006 Asked by WV DHHR to review and assist with Childhood Lead Poisoning Prevention supplemental submission.
- 2005 Provided opinion to WV DHHR concerning the use of spit tobacco as a harm-reduction cessation therapy. Opinion cited (Ducatman, Meckstroth, Walker, and Swarm) by Governor Joe Manchin III in memorandum of November 1, 2005.
- 1999 Provided CDC-sponsored Health Officer Seminar in public health environmental issues, June 1999

Grant Peer Review (Study Section)

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 41 of 551

2018-9 PAR-15 Centers for Agricultural Health and Safety. Disease. Disability, and Injury Prevention and Control Special Emphasis Panel Meeting, Arlington, VA February 12-13, 2019

2016 PAR-15 353 Centers for Agricultural Health and Safety. Disease. Disability, and Injury Prevention and Control Special Emphasis Panel Meeting. Atlanta, GA, May 9-13, 2016

2004-2009 Wayne State University Institute for Population Studies, Health Assessment, Administration, Services and Economics (INPHAASE).

1995 National Cancer Institute RFA, CA-95-002. Occupational Exposure and Cancer Prevention Agency for Toxic Substances Disease Registry, Centers for Disease Control

Other National Peer Review or Service

Consultation to US EPA Region 3 and WVDHHR concerning environmental contamination in Minden, WV, 2017

Vaccine Injury Compensation Program (VICP), Medical Expert Panel, appointed 2015 (current).

Board of Appeals Panel Member. American Board of Preventive Medicine (Current)

Health Consultation: Dimock Groundwater Site, Released May 24, 2016 by USDHHS/Agency for Toxic Substances and Disease Registry, Division of Community Health Investigations (acknowledged external reviewer).

National Occupational Injury Research Symposium, National Institutes of Occupational Safety and Health, Pittsburgh, PA, October 28-30, 2003. Abstract and paper reviewer.

US Environmental Protection Agency: Human Health Research Implementation Plan for the National Health and Environmental Effects Research Laboratory (NHEERL), 2003. Ten-year plan reviewer.

RESEARCH and PUBLICATIONS

<u>Books</u>

Ducatman AM. Liberman DR (Eds). The Biotechnology Industry: "State of the Art Reviews - Occupational Medicine." Hanley and Belfus, Inc. Philadelphia 1991; 6:2, 326 pp.

Monographs

Hornberger GM, Cullen AC, Ducatman A, Jackson JK, Kappel WM, Krannich RS, Matthews V, Robinson AL, Sandler DP, Stout SL, Swackhammer DL, Zhang J. Strategic Research Agenda on the Potential Impacts of 21st Century Oil and Natural Gas Development in the Appalachian Region and Beyond. 2015, 240pp. Health Effects Institute, Boston MA. Available at www.healtheffects.org

Abdallah MA, Cattley RC, Ducatman A, Dunnick JK, et al., Some Industrial Chemicals/IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Vol 115 (2016: Lyon, France). ISBN 978-92-832-0181-6 ISSN 1017-1606 Distributed by WHO Press, Geneva, Switzerland.

Practice Guidelines

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 42 of 551

Sokas R, Fagan K, Ducatman A. The Association of Occupational and Environmental Clinics (AOEC) Practice Guidelines for Lead-Exposed Adults, Revised 04/24/2007. Available on-line at http://www.aoec.org/documents/positions/MMG_FINAL.pdf. Last accessed 4/9/18

Technical Reports

Gerber BJ, Ducatman A, Fischer M, Althouse R. The Potential for an Uncontrolled Mass Evacuation of the DC Metro Area Following a Terrorist Attach: A Report of Survey Findings. Dec 6, 2006. Research Supported by West Virginia Department of Military Affairs and Public Safety. DOI: 10.13140/RG.2.2.28585.39529 Affiliation: West Virginia University Available online at <u>http://www.hsp.wvu.edu/r/download/20487</u> Last Accessed 27 Dec 2016

Book Chapters

Jin CJ, Werntz C, Ducatman AM. Occupational Toxicology: Applying Toxicology to Individuals. In Ballantyne B, Marrs TC, Syberson T (Eds.). *General and Applied Toxicology* (3rd Ed). Wiley-Blackwell. Chichester, UK. ISBN 978-0-470-7327-4. 3755 pages, chapter pp. 2375-2399.

Ducatman, AM. Multiple Chemical Sensitivity. In Rom WN (Ed). Environmental and Occupational Medicine (4th Ed). Lippincott-Raven. Philadelphia, 2006.

Martin C, Ducatman AM. Nonionizing radiation. In Rosenstock L, Cullen M, Brodkin C, Redlich C (Eds). Textbook of Clinical Occupational and Environmental Medicine, 2nd Ed. Elsevier, Philadelphia, 2005. pp. 870-879.

Ducatman AM. Clinical environmental medicine. In McCunney R. (Ed). A Practical Approach to Occupational and Environmental Medicine. (3rd Ed). Lippincott Williams and Wilkins. Philadelphia, 2003. pp 737-745.

Ducatman, AM. Multiple Chemical Sensitivity. In Rom WN (Ed). Environmental and Occupational Medicine (3rd Ed). Lippincott-Raven. Philadelphia, 1998. pp 891-904.

Ducatman AM. Chemical exposures and causation. In Kaufman HH, Lewin JL (Eds). The Physician's Perspective on Medical Law. American Association of Neurologic Surgeons, Park Ridge, IL, 1997. pp 263-278.

Emmett MS, Emmett DC, Simoyi PM, Ducatman AM. The Changing Shape of Public Health Education. In Rowe and Joby (Eds). Advances in Health Care Research. Omni Press, Madison, WI, 1996.

Ducatman AM. Recombinant Biology. In Stave GM (Ed). Physical and Biological Hazards of the Workplace. Van Nostrand Reinhold, New York, 1994. pp. 479-482.

Ducatman AM. Vaccinia. In Stave GM (Ed). Physical and Biological Hazards of the workplace. Van Nostrand Reinhold, New York, 1994. pp. 312-315.

Ducatman AM. Hazardous environments and occupational physicians: Clinical cluster observations and etiologic causation. In Mehlman MA, Upton A (Eds). The Identification and Control of Environmental and Occupational Diseases. Princeton Scientific Publishing, Princeton, NJ, 1994. pp. 55-73.

Ducatman AM. Clinical Environmental Medicine. In McCunney RJ (Ed). A Practical Approach to Occupational and Environmental Medicine (2nd Ed). Little Brown, Boston, 1994, pp. 623-632.

Ducatman AM, Haes DL. Nonionizing radiation. In Cullen MR, Rosenstock L (Eds). Clinical Occupational Medicine. Saunders, Philadelphia, 1994, pp. 646-657.

Ducatman AM. Biotechnology, occupational health issues. In Corn M (Ed). Handbook of Hazardous Materials. Academic Press, San Diego, 1993, pp. 81-89.

Ducatman AM, Liberman DF. Biotechnology Companies. In Sullivan J, Krieger G (Eds). Hazardous Materials Toxicology. Williams Wilkins, Baltimore, 1991, pp. 556-562.

Ducatman AM, Coumbis J. Chemical hazards in the biotechnology industry. In Ducatman AM, Liberman DF (Eds). The Biotechnology Industry: "State of the Art Reviews - Occupational Medicine." Hanley and Blefus, Inc. Philadelphia 1991; 6:2, 193-208.

Liberman DF, Ducatman AM, Fink R. Biotechnology: Is there a role for medical surveillance? In Hyer WC (Ed). Bioprocessing Safety: Workers and Community Safety and Health Considerations. American Society for Testing and Materials, Philadelphia, 1990, pp. 101-110.

Ducatman AM. United States OSHA Laboratory Standard: "Regulation of toxic substances in laboratories." In Liberman DF, Gordon J (Eds). Biohazards Management Handbook. Marcel Dekker, New York, 1989 pp. 403-415.

Federal Reports

Chair (first author), Report Committee. Centers for Disease Control and Prevention, NCEH/ATSDR Peer Review. "Report on Peer Review and Clearance Policies and Functions in the National Center for Environmental Health and the Agency for Toxic Substances and Disease Registry." (Report is now in the Federal Register.)

State Reports

Ducatman A, Ziemkiewicz P, Quaranta J, Vandivort T, Mack B, Van Aken B. Coal Slurry Waste Underground Injection Assessment, Final Report: Phase II. West Virginia University Water Research Institute. July 30, 2010. 261 pp.

Papers Submitted

Yucel Tufekcioglu E, Koksal S, Ducatman A, Erdogan S. Burnout, depression and psychosocial risk factors among call center workers in three different regions.

Papers Published

Jain RB, Ducatman A. Dynamics of associations between perfluoroalkyl substances and uric acid across various stages of glomerular function. Environmental Science and Pollution Res. 2019 March 7 PMID 30847808 doi: <u>10.1007/s11356-019-04666-5</u>

Bassler J, Ducatman A, Elliott M, Wen S, Wahlang B, Barnett J, Cave MC. Environmental perfluoroalkyl acid exposures are associated with liver disease characterized by apoptosis and altered serum adipocytokines. Environmental Pollution. 2019; 247:1055-63 PMID: 30823334 doi: 10.1016/j.envpol.2019.01.064. Epub 2019 Jan 18

Jain RB, Ducatman A. Selective Associations of recent low concentrations of perfluoroalkyl substances with liver function biomarkers: NHANES 2011-2014 data on US adults aged ≥20 years. J Occup Environ Med 2018 .PMID 30589657 <u>https://doi.org/10.1097/JOM.00000000001532</u>

Jain RB, Ducatman A. Perfluoroalkyl substances follow inverted U-shaped distributions across various stages of glomerular function: implications for future research. Environmental Research 2019; 169:476-82 PMID: 30530087 https://doi.org/10.1016/j.envres.2018.11.033

Jain RB, Ducatman A. Roles of gender and obesity in defining correlations between perfluoroalkyl substances and lipid/lipoproteins. Science of the Total Environment 2019; 653: 74-81 https://doi.org/10.1016/j.scitotenv.2018.10.362

Jain RB, Ducatman A. Associations between lipid/lipoprotein levels and perfluoroalkyl substances among US children aged 6-11 years. Environ Pollut. 2018; 243 (Pt A):1-8 DOI: <u>10.1016/j.envpol.2018.08.060</u> PMID: 30170203 George C, Ducatman A, Conway BN. Increased risk of respiratory diseases in adults with type 1 and type 2 diabetes. Diabetes Research and Clinical Practice 2018 doi: https://doi.org/10.1016/j.diabres.2018.05.029

Jain RB, Ducatman A. Associations between smoking and lipid/lipoprotein concentrations among US adults aged ≥20 years. J Circulating Biomarkers 2018. 7:1-10 DOI: 10.1177/1849454418779310

Heibati B, Godri Pollitt KJ, Charati JY, Ducatman A, et al. Biomonitoring-based exposure assessment of benzene, toluene, ethylbenzene, and xylene among workers at petroleum distribution facilities. Exotoxicol Environ Saf 2018; 149: 19-25. doi: 10.1016/j.ecoenv.2017.10.070

Ducatman AM, Tacker DH, Ducatman BS, Long D, et al. Quality improvement intervention for reduction of redundant testing. Academic Pathology 2017; 4:1-10 DOI: 10.1177/2374289517707506

Heibati B, Godri Pollitt KJ, Karimi A, Charati JY, Ducatman A, Shokrzadeh M, Mohammadyan M. BTEX exposure and quantitative risk assessment among petroleum product distributors. Ecotoxicol Environmental Safety 2017;144: 445-49. doi: 10.1016/j.ecoenv.2017.06.055

Bruton TA, Blum A. Proposal for coordinated health research in PFAS-contaminated communities in the United States (Commentary. Co-signatory and contributing author). Environ Health 2017: 16: 120 doi: 10.1186/s12940-017-0321-6

Ducatman BS, Hashmi M, Darrow M, Flanagan MB, Courtney P, Ducatman AM. Use of pathology data to improve high-value treatment of cervical neoplasia. Academic Pathology 2016;3: doi:10.1177/2374289516679849

Alfaraj WA, McMillan B, Ducatman AM, Werntz CL. Tetryl exposure: forgotten hazards of antique munitions. Ann Occup Environ Med 2016 April 8; 28:20. doi: 10.1186/s40557-016-0102-7 PMID 27066259

Ducatman AM, Zhang J, Fan H. Response to prostate cancer and PFOA (letter). J Occup Environ Med 2015 Jun;57(6): e61. doi. 10.1097/JOM 00000000000470 PMID 26053372

Ducatman A, Zhang J, Fan H. Prostate-specific antigen and perfluoroalkyl acids in the C8 health study population. J Occup Environ Med 2015; 57 (1): 111-14 doi10.1097/JOM.00000000000319 PMID 25563548

Fan H, Ducatman A, Zhang J. Perfluorocarbons and Gilbert syndrome (phenotype) in the C8 health study population. Environ Res 2014: Published on line September 2014 DOI 10.1016/j.envres.2014.08.011 PMID 25262077

Van Aken B, Quaranta JD, Mack B, Yu H, Ducatman A, Ziemkiewicz P. Environmental Contaminants in coal slurry intended for underground injection in the state of West Virginia. J Environ Eng. 2015. E-Published Nov 2014 DOI 10:1061/(ASCE)EE.1943-7870.0000874

Quaranta JD, Mack B, Van Aken B, Ducatman A, Ziemkiewicz P. Practical application of dilution analysis for estimating groundwater effects due to coal slurry injection into underground mine voids. Mine Water Environment 2014; 33: 353-361. Published online April 8, 2014. DOI 10.1007/s10230-014-0274-8

Alshaarawy O, Zhu M, Ducatman AM, Conway B, Andrew ME. Urinary polycyclic aromatic hydrocarbon biomarkers and diabetes mellitus. Occup Environ Med 2014;71(6):437-41.

Innes KE, Wimsatt JH, Frisbee S, Ducatman AM. Inverse association of colorectal cancer prevalence to serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in a large Appalachian population. BMC Cancer 2014;14:45.

Geiger SD, Xiao J, Ducatman A, Frisbee S, Innes K, Shankar A. The association between PFOA, PFOS and serum lipid levels in adolescents. Chemosphere 2013. Epub Nov 13, 2013 doi: 10.1016/j.chemosphere.2013.10.005.

Alshaarawy O, Zhu M, Ducatman A, et al: Polycyclic aromatic hydrocarbon biomarkers and serum markers of

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 45 of 551

inflammation. A positive association that is more evident in men. Environ Res 2013;126:98-104,

Javins B, Hobbs G, Ducatman A, Pilkerton C, Tacker D, Knox S. Circulating maternal perfluoroalkyl substances during pregnancy in the C8 health study. *Environmental Science & Technology*. 2013 Jan8 [Epub ahead of print] PMID; 23272997.

Bhardwaj R, Ducatman A, Finkel MS, Petsonk E, Hunt J, Beto RJ. Chronic pulmonary dysfunction following acute inhalation of butyl acrylate. *West Virginia Medical Journal* 2012; 108:28-32.

Abraham RT, Walls RT, Fischer M, et al: Tabletop scenarios for realism in bioterrorism and threat preparedness. W V Med J 2012; 108:12-17

Luo J, Chen YJ, Narsavage GL, Ducatman A. Predictors of survival in patients with non-small cell lung cancer. *Oncol Nurs Forum* 2012; 39(6):609-16.

Shankar A, Xiao J, Ducatman A. Perfluorooctanoic acid and cardiovascular disease in US adults. Arch Intern Med 2012; 172: 1397-1403.

Hendryx M, Ducatman A, Zullig K, Ahern M, Crout R. Adult tooth loss for residents of us coal mining and Appalachian counties. Community Dent Oral Epidemiol 2012: 40: 488-97.]

Gallo V, Leonardi G, Genser B, Lopez-Espinosa MJ, Frisbee SJ, Karlsson L, Ducatman AM, Fletcher T. Serum perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) concentrations and liver function biomarkers in a population with elevated PFOA exposure. Environ Health Perspect 2012; 120:655-60.

Bhardwaj R, Dod H, Finkel MS, Dar I, Hobbs GR, Ducatman AM, Warden B, Gharib W, Beto RJ, Jain AC. Left atrial volume by echocardiography in patients with false positive myocardial perfusion scans. International Heart Journal 2012; 53:18-22.

Cain LR, Ducatman AM, Shankar A. The relationship between gamma-glutamyl transferase levels and chronic kidney disease among Appalachian adults. West Virginia Medical Journal 2012; 108(1):8-13.

Shankar A, Xiao J, Ducatman A. Perfluoroalkyl chemicals and elevated serum uric acid in US adults. Clinical Epidemiology 2011; 3:251-258.

Luo J, Hendryx M, Ducatman A. Association between six environmental chemicals and lung cancer incidence in the United States. J Environ Public Health 2011; 463701. Doi: 10.1155/2011/463701 Epub 2011 Jul 10.

Knox SS, Jackson T, Frisbee SJ, Javins B, Ducatman AM. Perfluorocarbon exposure, gender, and thyroid function in the C8 Health Project. Journal of Toxicological Sciences 2011; 36(4): 403-410.

Innes KE, Ducatman AM, Luster MI, Shankar A. Association of osteoarthritis to serum perfluorooctanoate and perfluorooctane sulfonate in a large Appalachian population. Am J Epidemiol 2011; 174(4):440-450.

Shankar A, Xiao J, Ducatman A. Perfluoroalkyl chemicals and chronic kidney disease in US adults. Am J Epidemiol 2011; 174(8):893-900.

Ahern, M.M., Hendryx M, Conley J, Fedorko E, Ducatman A, Zullig KJ. The association between mountaintop mining and birth defects among live births in central Appalachia, 1996–2003. Environ Res 2011; 111(6): 838-46.

Lopez-Espinosa, MJ, Fletcher T, Armstrong B, Genser B, Dhatariya K, Mondal D, Ducatman A, Leonardi G. Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with age of puberty among children living near a chemical plant. Environ Sci Technol 2011; 8160-6.

Shankar A, Jie X, Ducatman A. Perfluoroalkyl chemicals and chronic kidney disease in US adults. American Journal of Epidemiology 2011 10.1093/aje/kwr/171.

Knox SS, Jackson T, Javins B, Frisbee SJ, Shankar A, Ducatman AM. Implications of early menopause in

women exposed to perfluorocarbons. Journal of Clinical Endocrinology and Metabolism June 2011; 96(6): 1747-53.

Sivak-Callcott JA, Diaz SR, Ducatman AM, Rosen CL, Nimbarte AD, Sedgeman JA. A survey study of occupational pain and injury in ophthalmic plastic surgeons. Ophthal Plast Reconstr Surg 2011; 27(1): 28-32.

Jin C, Sun Y, Islam A, Ducatman A, Qian Y. Perfluoroalkyl acids including perfluorooctane sulfonate and perfluorohexane sulfonate in firefighters. J Occup Environ Med 2011; 53(3):324-28.

Rockett IR, Hobbs G. De Leo D, Stack S, Frost J, Ducatman AM, Kapusta ND, Walker RL. Suicide and unintentional poisoning mortality trends in the United States, 1987-2006: Two unrelated phenomena? BMC Public Health 2010; 10:705.

Blake KB, Shankar A, Madhavan SS, Ducatman A. Associations among cardiometabolic risk factor clustering, weight status and cardiovascular disease in an Appalachian population. Journal of Clinical Hypertension 2010; 12(12):964-972.

Frisbee SJ, Shankar A, Knox S, Steenland K, Savitz DA, Fletcher T, Ducatman AM. Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents. Archives of Pediatric and Adolescent Medicine 2010; 164(9):860-869.

Teppala S, Shankar A, Ducatman A. The association between acculturation and hypertension in a multiethnic sample of US adults. Journal of the American Society of Hypertension 2010; 4(5): 236-43.

Rockett IR, Wang S, Stack S, De Leo D, Frost JL, Ducatman AM, Walker RL, Kapusta ND. Race/ethnicity and potential suicide misclassification: window on a minority suicide paradox? BMC Psychiatry 2010; 10:35-42.

Steenland K, Tinker S, Shankar A, Ducatman A. Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA. Environ Health Perspect 2010; 118:229-33.

Qian Y, Ducatman A, Ward R, Leonard S, Bukowski V, Guo NL, Shi X, Vallyathan V, Castranova V. Perfluorooctane sulfonate (PFOS) induces reactive oxygen species (ROS) production in human microvascular endothelial cells: role in endothelial permeability. Journal of Toxicology & Environmental Health, Part A, 2010; 73:12, 819-836.

Teppala S, Shankar A, Li J, Wong T, Ducatman A. Association between serum gamma-glutamyl transferase and chronic kidney disease among US adults. Kidney and Blood Pressure Research 2010; 33:1-6.

Cain L, Shankar A, Ducatman AM, Steenland K. Association between serum uric acid and chronic kidney disease among Appalachian adults. Nephrology, Dialysis & Transplantation 2010; 25(11):3593-3599.

Steenland K, Tinker S, Frisbee S, Ducatman A, Vaccarino V. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. American Journal of Epidemiology 2009; 170:1268-1278.

MacNeil J, Steenland K, Shankar A, Ducatman A. A cross-sectional analysis of type II diabetes in a community with exposure to perfluorooctanoic acid (PFOA). Environ Res 2009; 109:997-1003.

Frisbee S, Brooks AP, Maher A, Flensborg P, Arnold S, Fletcher T, Steenland K, Shankar A, Knox S, Pollard C. Halverson J, Vieira V, Jin C, Leyden K, Ducatman A. The C8 Health Project: design, methods, and participants. Environ Health Perspect 2009; 117(12): 1873-1882.

Steenland K, Jin C, MacNeil J, Lally C, Ducatman A, Vieira V, Fletcher T. Predictors of PFOA levels in a community surrounding a chemical plant. Environ Health Perspect 2009; 117:1083-88.

Rockett IR, Lian Y, Stack S, Ducatman AM, Wang S. Discrepant comorbidity between minority and white suicides: a national multiple-cause-of-death analysis. BMC Psychiatry 2009; 9:10.

Charumathi S, Shankar A, Li J, Pollard C, Ducatman A. Serum gamma-glutamyl transferase level and

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 47 of 551

diabetes mellitus among US adults. Eur J Epidemiol 2009; 24:369-73.

Sun C, Jin C, Martin C, Gerbo R, Wang Y, Atkins J, Ducatman AM. Cost and outcome analyses on the timing of the first independent medical evaluation in patients with work-related lumbosacral sprain. J Occup Environ Med 2007; 49:1264-8.

Haut MW, Kuwabara H, Ducatman AM, et al. Corpus callosum volume in railroad workers with chronic exposure to solvents. J Occup Environ Med 2006; 48(6): 615-24.

Harber P, Ducatman AM. Training pathways for occupational medicine. J Occup Environ Med 2006; 48: 366-75.

Ducatman BS, Ducatman AM. Longitudinal case-based evaluation of diagnostic competency among pathology residents: a statistical approach. Arch Pathol Lab Med 2006; 130: 188-93.

Ducatman AM, Vanderploeg JM, Johnson M, et al. Residency training in preventive medicine: challenges and opportunities. Am J Prev Med 2005; 28: 403-412.

Ducatman BS, Ducatman AM. How expert are the experts? Implications for proficiency testing in cervicovaginal cytology (editorial). Arch Pathol Lab Med 2005; 129: 604-605.

Jin CH, Haut M, Ducatman AM. Industrial solvents and psychological effects. Clin Occup Environ Med 2004; 4: 597-620.

Martin CT, Werntz CL, Ducatman AM. The interpretation of zinc protoporphyrin changes in lead intoxication: a case report and review of the literature. Occupational Medicine 2004; 54 (7): 587-591.

Erdogan MS, Islam SS, Chaudhari A, Ducatman AM. Occupational carbon monoxide poisoning among West Virginia workers' compensation claims: diagnosis, treatment duration, and utilization. J Occup Environ Med 2004, 46(6) 577-83.

Ehrlich PF, McLellan WT, Ducatman AM, Helmkamp JC, Islam SS. Understanding work-related injuries in children: a perspective in West Virginia using the state-managed workers' compensation system. J Pediatric Surgery 2004; 39: 768-772.

Abdul-Razzaq WN, Lee V, Islam S, Ducatman AM. Quantification of lead in telephone cord: use of x-ray photoelectron spectroscopy technique. Appl Occup and Env Hygiene. 2003. 18: 553-557.

Islam SS, Edla S. Mujuru P, Doyle EJ, Ducatman AM. Risk factors for physical assault: state-managed workers' compensation experience. Am J Prev Med 2003; 25:31-37.

Li H, Wang M-L, Seixas N, Ducatman AM, Petsonk EL. Respiratory protection: associated factors and effectiveness of respirator use among underground coal miners. Am J Indus Med 2002; 42: 55-62.

Ducatman AM. ATDSR Case Studies in Environmental Medicine. Disease clusters: an overview. USDHHS/ATDSR. Course SS3096. August 2002. Document also available online at <u>www.atsdr.cdc.gov/HEC/CSEM</u>.

Ducatman AM. Educational module "Lead, it's everywhere." With the support of the American Occupational and Environmental Clinics (AEOC) and National Institute for Occupational Safety and Health (NIOSH), Cooperative Agreement U60/CCU317613-03, for a seminar/presentation at AEOC in 2002. Also available on CD-ROM, and via e-mail at <u>AOEC@aoec.org</u> and on-line at <u>www.aoec.org</u>

Islam SS, Biswas RS, Nambiar A, Syamlal G, Velilla AM, Doyle EJ, Ducatman AM. Incidence of work-related fracture injuries: experience of a state-managed workers' compensation system. J Occup Environ Med 2001; 43: 140-146.

Islam SS, Velilla AM, Doyle EJ, Ducatman AM. Gender differences in work-related injury/illness: analysis of workers' compensation claims. Am J Indus Med 2001; 38: 84-91.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 48 of 551

Hogan T, Lamm D, Ducatman AM. Smoking and renal cell carcinoma. WV Med J 2001; 97: 32-5.

Hogan T, Lamm D, Riggs D, Ducatman AM. Smoking and bladder cancer. WV Med J 2001; 97: 29-31.

Ducatman AM, McLellan R. American College of Occupational and Environmental Health Position Statement. Epidemiologic basis for an occupational and environmental policy on environmental tobacco smoke. J. Occup Environ Med 2000; 42: 575-581.

Franklin P, Goldenberg WS, Ducatman AM, Franklin E. Too Hot to Handle: An Unusual Exposure of HDI in Specialty Painters. Am J Indus Med 2000; 37: 431-437.

Islam SS, Doyle EJ, Velilla AM, Martin CJ, Ducatman AM. Epidemiology of compensable work-related ocular injuries and illnesses: incidence and risk factors. J Occup Environ Hlth 2000; 42: 575-581.

Islam SS, Nambiar AM, Doyle EJ, Velilla AM, Biswas RS, Ducatman AM. Epidemiology of work-related burn injuries: experience of a state-managed workers' compensation system. J Trauma 2000; 49: 1045-51.

Haut MW, Leach S, Kuwabara H, Whyte A, Ducatman AM, Lombardo LJ, Gupta N. Verbal working memory and solvent exposure: a position emission tomography study. Neuropsychology 2000; 14: 551-8.

Meyer JD, Becker PE, Stockdale T, Ducatman AM. The West Virginia Occupational Safety and Health Initiative: Practicum Training for a New Marketplace. Am J Prev Med 1999. 16(4): 347-350.

McClellan R, Becker CE, Borak J, Coplein C, Ducatman AM, et al. American College of Occupational & Environmental Medicine Position Statement. Multiple chemical sensitivities; idiopathic environmental intolerances. ACOEM Position Statement. J Occup Environ Med 1999; 41: 940-942.

Westra CS, Ducatman AM, Niewiadonska-Bugaj M, Hobbs GR. An estimate of prostate cancer prevalence for a demographically similar workforce population. WV Med J 1999; 95:116-122

Cohen A, Ducatman AM. Employing self-directed computer and printed resources to reform a medical school, epidemiology and biostatistics curriculum. Medical Education Outline (On-line) July 1998

Magnetti SM, Wyant W, Greenwood J, Roder N, Linton J, Ducatman AM. Injuries to volunteer firefighters in West Virginia. J Occup Environmental Med. 1999 Feb; 41 No. 2: 104-110.

Simoyi P, Islam S, Haque A, Meyer J, Doyle EJ, Ducatman AM. Evaluation of occupational injuries among young workers in West Virginia. Human Eval Risk Assess 1998; 4: 1405-15.

Bucklew NS, D'Alessandri R, Ducatman AM. The mentoring of the department chair: a new partnership model between the health sciences and business administration. Issues in the Cornerstone of Higher Education, 1998; 48:71-55 Vol. 48, pp. 71-75.

Meyer JD, Islam SS, Ducatman AM, McCunney RJ. Prevalence of small lung opacities in populations unexposed to dusts: a literature-analysis. Chest 1997; 111: 404-410.

Shy C, Anderson H, Ducatman A, Fleissner ML, et al. Summary report of the panel. Panel of the workshop on nasopharyngeal radium irradiation. Otolaryngol Head Neck Surg 1996: 115: 442-6. PMID 8903445

Ducatman AM. Disease clusters: paradoxes of perception and public health (editorial). Int J Occup Environ HIth 1995; 1:289-290.

Moore RS, Ducatman AM, Jozwiak JA. Home on the range: childhood lead exposure due to family occupation. Arch Pediatric Adolescent Med 1995; 149:1276-1277.

Boswell RT, DiBerardinis L, Ducatman AM. Descriptive epidemiology of indoor odor complaints at a large teaching institution. Appl Occup Environ Hyg 1994; 9:281-286.

Barbanel CS, Ducatman AM, Garston MJ, Fuller T. Laser hazards in research laboratories. J Occup Med 1993; 35:369-374.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 49 of 551

Ducatman AM. Occupational physicians and environmental medicine. J Occup Med. 1993; 35:251-259.

Ducatman AM. On "B-reading," radiology, the ILO system, and dust-related diseases. Applied Radiology 1993; 22: 72-73.

Fleming LE, Ducatman AM, Shalat SL. Disease clusters in occupational medicine: a protocol for their investigation in the workplace. Am J Indus Med 1992; 22: 33-47.

Perry GF, Hawes Clever L, Ducatman AM, et al. Scope of occupational and environmental health programs and practice. J Occup Med 1992; 34:436-440.

Fleming LE, Ducatman AM, Shalat SL. Disease clusters: a central and ongoing role in occupational medicine. J Occup Med 1991; 33:818-825.

Ducatman AM. Variability in interpretation of radiographs for asbestotic abnormalities: problems and solutions. Annals NY Acad Sci 1991; 643:108-120.

Stinson MC, Green BL, Marquardt CJ, Ducatman AM. Autoclave inactivation of infectious radioactive laboratory waste contained within a charcoal filtration system. Health Physics 1991; 61:137-142.

Ducatman AM, Forman SA, Teichman R, Gleason R. Occupational physician staffing in large U.S. corporations. J Occup Med 1991; 32:613-618.

Ducatman AM. Cost-shifting in workers' compensation: methods, money, and meaning (editorial). Am J Indus Med 1991; 19:279-282.

Ducatman AM, Chase KH, Farid I, et al. What is environmental medicine? (Editorial). J Occup Med 1990; 32:1130-1132.

Ducatman AM, Withers B, Yang WN. Smoking and roentgenographic opacities in U.S. Navy asbestos workers. Chest 1990; 97:810-813.

Stinson MC, Galanek MS, Ducatman AM, et al. Model for inactivation and disposal of infectious human immunodeficiency virus and radioactive waste in a P3 facility. Applied and Environmental Microbiology 1990; 56: 264-268.

Withers B, Ducatman AM, Yang WN. Roentgenographic evidence for predominant left-sided location of unilateral pleural plaques. Chest 1989; 95:1262-1264.

Ducatman AM. Career options of occupational physicians. J Occup Med 1988; 30:776-779.

Ducatman AM, Yang WN, Forman SA. "B-readers" and asbestos medical surveillance. J Occup Med 1988; 30:644-647.

Committee Report (Lewy R, Anstadt GW, Curtis EC, Ducatman AM, et al.) AIDS in the workplace: guidelines. J Occup Med 1988; 30:578-579.

Ducatman AM, Ducatman BS, Barnes JA. Lithium battery health hazard: old-fashioned planning implications of new technology. J Occup Med 1988; 30:309-311.

Ducatman AM, Bigby M. Systemic contact dermatitis after inhalation of 2-aminothiophenol. Contact Derm 1988; 18:57-58.

Ducatman AM, Crawl JR, Conwill CE. Cancer clusters, causation, and common sense. CHEMTECH (American Chemical Society) 1988; 18:204-210.

Garland FC, Gorham ED, Garland CF, Ducatman AM. Testicular cancer in U.S. Navy personnel. Am J Epidemiol 1988; 127:411-414.

Ducatman AM. Inevitable growth of workers' compensation. Best's Review Property/Casualty Insurance 1987; 88:50-53.

Ducatman AM. Workers' compensation cost-shifting: a unique concern of providers and purchasers of prepaid health care. J Occup Med 1986; 28:1174-1176.

Ducatman AM, Conwill DE, Crawl J. Germ cell tumors of the testicle among military aircraft repairmen. J Urol 1986; 136:834-836.

Ducatman AM, Moyer TP. Environmental exposure to common industrial solvents. Therapeutic Drug Monitoring, American Association for Clinical Chemistry, Washington, D.C., Vol 5, May 1984.

Ducatman AM, Moyer TP. The role of the clinical laboratory in the evaluation of the polyhalogenatedpolycyclic toxins: DDT, PBBs, dibenzodioxins and dibenzofurans, chlordecone (Kepone) and hexachlorophene. Therapeutic Drug Monitoring, American Association for Clinical Chemistry, Washington, D.C., Vol 4, Jan 1983.

Ducatman AM, Moyer TP. Clinical laboratory role in the evaluation of the patient exposed to acetylcholinesterase-inhibiting pesticides. Therapeutic Drug Monitoring, American Association for Clinical Chemistry, Washington, D.C., Vol 4, Jan. 1983.

Ducatman AM, Amundsen MA, Moyer TP. Case report: Evaluation of the role of organophosphate pesticides. Therapeutic Drug Monitoring, American Association for Clinical Chemistry, Washington, D.C., Vol 3, July 1982.

Ducatman AM, Hirschhorn K, Selikoff IJ. Vinyl chloride exposure and human chromosome aberrations. Mutation Research 1975; 31:163-168.

Web Communications

Ducatman A, Frisbee S, Stanley S, Shankar S, Knox S, Pollard C, Hobbs G, Firestone C, Mutambudzi M, Bunner E, Halverson J, Jin C, Leyden K, Tan J, Wang X, Wang Y. The C8 Health Project: WVU data-hosting website. Documents and summaries of results for the C8 Health Project. (Contained thousands of graphs and tables.) 2007 to 2013.Sonme parts of the information included from this effort are still housed at http://www.hsc.wvu.edu/resoff/research/c8/project/data-collection/

Letters and Other Documents

- Ducatman A. Ebola article highlights EHR usability problems. TechTarget. Nov 12, 2014. Available at <u>http://searchhealthit.techtarget.com/opinion/Ebola-article-highlights-EHR-usability-problems-saysdoc</u>
- Harber P, Ducatman AM. Training pathways for occupational medicine (response). J Occup Environ Med 2006; 48: 1115.
- Ducatman AM. Comparison of B readers' interpretations of chest radiographs for asbestos-related changes. Academic Radiology 2004; 11: 1398-99.
- Mitchell CS, Moline J, Avery AN, Blessman JE, et al. (Authors include Ducatman AM.) In response to the 2002, Vol 22, No. 4 article entitled: The rise and fall of occupational medicine in the US. Am J Prev Med 2002; 23:307-309.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 51 of 551

- Frumkin H, Ducatman AM, Kirkland K. Solvent exposure in the railroad industry. J Occup Environ Med 1997; 39: 926-30.
- Ducatman AM. Preventive pulmonary medical education (ltr). Chest. 1992; 102:326.
- Ducatman AM, Farber SA. Radium exposure in U.S. military personnel (ltr). NEJM. 1992; 326:71.
- Bakshi R, Ducatman AM, Hochberg FH. Glioblastomas in New England ophthalmologists (ltr). NEJM. 1991; 324:1440-1441.
- Masse FX, Coutu-Reilly J, Galanek M, Ducatman AM. The need for additional warning in x-ray diffraction equipment: a shutter failure incident (ltr). Health Physics. 1990; 58; 219.
- Ducatman BS, Wang HH, Jonasson JG, Ducatman AM. Cervical screening (ltr). Lancet 1989; 11: 628-629.
- Ducatman AM. Roentgenographic underestimation of early asbestosis (ltr). Chest 1989; 95:1165.
- Ducatman AM. Dimethylformamide, metal dyes, and testicular cancer (ltr). Lancet 1989; 1:911.
- Ducatman AM. Prader-Willi syndrome and paternal hydrocarbon exposure (ltr). Lancet 1988; 1:641.
- Ducatman AM. Industrial toxins and fulminant hepatitis (ltr). Mayo Clinic Proc 1985; 60:640.

Guidelines

Sokas R, Fagan K, Ducatman AM. Medical Management Guidelines for Lead-Exposed Adults. American Occupational and Environmental Clinics. <u>www.aoec.org/principles.htm</u>.

Abstracts

Misra R, Bhandari R, Sambamoorthi U, Khan R, Ducatman A. Association between liver enzymes and BMI Categories in the C8 Health Project. American Public Health Association Conference. Chronic Disease Epidemiology Poster Session Hepatoxicity and Drug Induced Injury. San Diego, CA Nov 9, 2018

Cave MC, Bassler J, Elliott M, Wen S, Wahlang B, Barnett J, Ducatman A. Environmental perfluoroalkyl substances are associated with the unusual combination of apoptotic liver disease and decreased serum proinflammatory cytokines: implications for nonalcoholic liver disease. Number 0724 American Association of Liver Disease Conference San Francisco, CA Nov 9-13, 2018

Misra R, Khan R, Bhandari R, Sambamoorthi U, Ducatman A. Gender differences in liver function biomarkers in the C8 Health Study. West Virginia Rural Health Association Conference, Pipestem, WV Oct 17, 2018

Ducatman A, Zhang J, Luster M, Fletcher T. Perfluoroalkyl substance excretion: effects of organic anioninhibiting and resin-binding drugs in a community setting. International Society of Environmental Epidemiology Conference, Exposures and Health Impacts of Perfluorinated Substances Session. Ottawa, Canada August 26-30, 2018

Ducatman BS, Hashmi M, Darrow M, Flanagan MB, Courtney P, Ducatman AM. Use of pathology data to improve high-value treatment of cervical neoplasia. Association of Pathology Chairs 51s Annual Meeting, Coronado, CA, July 16, 2018

Lee J, Ducatman A. Occupational lung disease clusters – does investigation of disease clusters continue to play a significant role in occupational health. American College of Occupational and Environmental Medicine Conference. New Orleans, LA April 29-May 2, 2018

Darrow MA, Ducatman BS, Hashmi M, Flanagan M, Long D, Ducatman AM. Look before you "LEEP." A retrospective quality assurance study. 103rd Annual Meeting of the United States and Canadian Academy of Pathology, San Diego, CA, March 7, 2014

Frisbee SJ, Frisbee JC, Ducatman AM. Abstract P380. Obesity and non-alcoholic fatty liver disease in children. Circulation 2012; 125: AP380. Available at: https://circ.ahajournals.org/cgi/content/meeting abstract/125/10 MeetingAbstracts/AP380

Geiger S, Shankar A, Ducatman A. Association between Serum PFOA Levels and Hyperuricemia in Children. Presented at the 3rd North American Congress of Epidemiology, June 21-24, 2011, in Montreal, Canada.

Frisbee SJ, Frisbee JC, Shankar A, Knox, SS, Ducatman AM. Associations between obesity and obesityrelated systemic inflammation and markers of immune function in children. Presented to the American Heart Association, March 23, 2011.

Frisbee SJ, Frisbee JC, Shankar A, Knox, SS, Ducatman AM. Contribution of Dyslipidemia vs. obesity to inflammation in children. Presented to the American Heart Association, March 23, 2011.

Frisbee SJ, Shankar A, Knox, SS, Ducatman AM. Associations between non-8-carbon-chain perfluoroalkyl acids and cholesterol in children. Presented to the American Heart Association, March 23, 2011.

Hendryx M, Crout R, Ducatman AM, Zullig K, Ahern M. Tooth loss among residents of Appalachian coalmining counties. Presented to the American Public Health Association annual meeting, November 2010.

Rockett, IRH, Hobbs G, De Leo D, Stack S, Ducatman AM, Frost J. Relationship of suicide and unintentional poisoning mortality trends in the United States, 1987-2006. Presented to the American Public Health Association annual meeting, November 2010.

Rockett IRH, Wang S, Stack S, De Leo D, Frost J, Ducatman AM, Walker R. Race/ethnicity and potential suicide misclassification: window on a minority suicide paradox? Presented to the American Public Health Association annual meeting, November 2010.

Qian Y, Ducatman A, Leonard S, Ward R, Vallyathan V, Castranova V. PFOA- and PFOS-induced oxidative stress response in human microvascular endothelial cells. Society of Toxicology Annual Meeting, Salt Lake City, UT, March 7-11, 2010.

Cain L, Ducatman A, Shankar A. The relationship between uric acid and chronic kidney disease. *Am J Epidemiol* 2009; 169(suppl): 397-S.

Rockett IRH, Lian Y, Stack S, Ducatman AM, Wang S. Discrepant comorbidity between minority and white suicides: a national multiple-cause-of-death analysis. Population Association of America Annual Meeting, Detroit, MI, May 1, 2009.

Blake K, Shankar A, Madhavan S, Ducatman AM. Prevalence of obesity and other cardiac risk factors in an Appalachian region. WVU Health Sciences Center Research Day and Van Liere Convocation, April 28-29, 2009. Also presented to the annual meeting of the American Public Health Association, November 7-11, 2008.

Teppala S, Sabanayagam S, Shankar A, Ducatman A. Association between sleep duration and cardiovascular disease among US adults. WVU Health Sciences Center Research Day and Van Liere Convocation, April 28-29, 2009. Also presented to the annual meeting of the American Public Health Association, November 7-11, 2008.

Peluso E, Haut M, Morrow L, Ducatman A, Kuwabara H. Hippocampal volume and functional brain abnormalities associated with chronic organic solvent exposure. Poster presented at the 2008 American Academy of Clinical Neuropsychology convention, Boston, MA, June 2008.

Gerber BJ, Scotti JR, Althouse R, Ducatman AM, Fischer M. Behavioral response of large populations to disaster and terrorism: where will they go? International Society for Traumatic Stress Studies, Baltimore, MD. ISTSS Conference Tracking ID 180248. Poster Session 3, November 17, 2007.

Haut M, Hatfield G, Kuwabara H, Morrow L, Parsons M, Ducatman AM. Solvent-related neuroimaging changes in railroad workers. International New Psychological Society Meeting, February 25, 2005. St. Louis, MO.

Islam S, Hassan M, Doyle E. Becker J, Weikle P, Ducatman A. Quantification of suspected addiction treatment of narcotic analgesics using prescription sequence analysis. Experience of a state-based workers' compensation system (abstr). International Society for Pharmacoeconomic and Outcome Research, Hamburg, Germany. October 25, 2004. Appeared in Value in Health 2004:7:727-8.

Goldberg RL, Vanderploeg J, Wald P, Ducatman AM. American Board of Preventive Medicine Certification Procedure. American Occupational Health Conference, April 29, 1999, New Orleans.

Ducatman AM, Lane DS, Johnson MB, Etzel RA. Preventive Medicine Certification and Recertification. Prevention '99, March 19, 1999, Arlington, VA.

Haut MW, Whyte S, Callahan TS, Ducatman, AM, et al. Verbal working memory in solvent exposure: a PET activation study. Intl neuropyschological society. Honolulu, HI, Feb 6, 1998.

Lombardo LJ, Meyer JD, Haut MW, Islam SS, Haque A, Ducatman AM. The health effects of solvent exposure in railroad workers. J Occup Environ Med 1997; 39:363.

Simoyi P, Islam S, Haque A, Ducatman AM. Evaluation of Occupational injuries among teenage workers in West Virginia. National Occupational Injury Research Symposium (NIOSH), Morgantown, WV, October 15, 1997.

Islam S, Hobbs G, Murray W, Suppa S, Ducatman, AM. Use of Narcotic and Non-Narcotic Analgesic Medications in occupational injuries: analysis of reimbursed prescriptions in a state run Workers' Compensation Database. National Occupational Injury Research Symposium (NIOSH). Morgantown, WV, October 15, 1997.

Islam S, Hobbs G, Haque A, Greenwood J, Bowers C, Ducatman AM. Differences in occupational injuries by gender in West Virginia: Analysis of Workers' Compensation Claims in Database. National Occupational Injury Research Symposium (NIOSH), Morgantown, WV, October 15, 1997.

Haut MW, Ducatman AM, Morrow L, Eckert RK. Neuropsychological functioning in railroad workers exposed to organic solvents. J Intl Neuropsych Soc 1996; 2: 63.

Ducatman AM, Simoyi RM, Emmett MS. Needs of prevention researchers West Virginia. CDC Prevention Center Meeting. Atlanta, GA. February 16-18, 1995.

Simoyi PM, Ducatman AM, et al. Protection and regulatory awareness of Appalachian workers. CDC Prevention Center Meeting. Atlanta, GA. February 16-18, 1995.

Martin KP, Ducatman AM. Actual vs. reported chance of encountering nonchrysotile asbestos types in O & M activities. Health Effects Institute-Asbestos Research, March 8-9, 1995.

Stinson M, Green B, Ducatman AM. Autoclave inactivation of infectious radioactive laboratory waste contained within a charcoal filtration system. 1990 ASM Annual Meeting. Anaheim, CA, May 13-17.

Ducatman AM, Ducatman BS, Barnes JA. Lithium battery health hazard. Aviation, Space and Environ Med 1986; 57:1216.

Ducatman AM. Clusters associated with chemical exposures, their significance and causation. Amer Chem Soc 193rd meeting abstracts. CHAS 46.

Liberman DF, Fink R, Ducatman AM. The evaluation of toxicity of chemicals and associated health risks for nontechnical workers in biotechnology facilities. International Symposium on Health and Environment in Developing Countries. Haikko, Finland, August 27-30, 1986.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 54 of 551

Garland FC, Gorham BA, Garland CF, Ducatman AM. Testicular cancer in U.S. Navy personnel. Am J Epidemiol 1986; 124: 531.

Book Reviews

- Ducatman A. Airborne Hazards Related to Deployment (Book Review). J Occup Environ Med 2016; 58(2): e60
- Coal River, by Michael Shnayerson, in the Journal of Occupational and Environmental Medicine 2008; 50:856-7.
- Environmental and Occupational Medicine, 2nd Ed in J Occup Med 1993; 35:1069-1070.
- Dermatotoxicology, 4th ed. in J Occup Medicine 1992; 34:1126-1127.

Occupational Medicine Forum: Published in the Journal of Occupational Medicine (major contributions listed).

Lerner AJ, Belleville B, Cassidy S, Hawes Clever L, Conage T, Ducatman AM, et al.

Can jet injector devices transmit pathogens?	1999; 41: 553-4
--	-----------------

Lerner PJ, Belleville B, Hawes Clever L, Ducatman, AM, et al.

Can heavy lifting cause epididymitis?	1997; 39:609-610
---------------------------------------	------------------

Whorton D, Weisenberger BI, Milroy WC, Hawes Clever L, Ducatman AM, et al.

Health effects of oxygenated fuels	1993; 35:980
X-ray technician with ulcerative colitis	1993; 35:650-652
Contact lenses in the chemical industry	1993; 35:650-652
Pros and cons of vaccinia immunization	1992; 34:757-758
Trichloroethane and connective tissue disorders	1992; 34:5-8
In-house medical officers	1991; 33:1206
In-house medical officers	1991; 33:1206
Hepatitis B Immunization	1991; 33:845
•	,

Perry GF, Brissendon R, Chase KH, Hawes Clever L, Ducatman AM, et al.

Benzene and Hodgkin's Lymphoma "Environmental Illness" Hepatitis B Vaccination	1990; 32:775 1990; 32:211 1990; 32:5
OSHA and the pharmaceutical and biomedical industries Risks of Xylene Substitute	1989; 31:955-956 1989; 31:202
Headaches in a bookbinding/ Screen-making company Reading asbestos exposure films	1989; 31:422-423 1989; 31:728-731

Anstadt GW, Baker EL, Bender JR, Chase KH, Hawes Clever L, Ducatman AM, et al.

Contamination from photocopiers	1988; 30:762-766
QMS - Lasergrafix RSI 8024 printer	1987; 29:692
Cutting, sanding, and heat welding polyvinyl chloride	1987; 29:693
Guidelines for use of respirators during pregnancy	1987; 29:782-786
Bacterial growth in eyewash stations	1987; 29:854

Anstadt GW, Chase KJ, Hawes Clever L, Ducatman AM, et al.

Chemical components of diesel fuel	1987; 29:13-14
Vanadium pentoxide exposure	1987; 29:14-17
Screening for hepatic damage	1987; 29:266-267

Research chemist with chronic lymphocytic leukemia The costs of defensive medicine

1987; 29:268-269 1986; 28:1132-1136

Federal Testimony

United States Senate, Subcommittee on Clean Air and Nuclear Regulation. Re: Nasopharyngeal Radiation of Military and Civilian Populations. Invited by Senator Joseph I. Lieberman, Sept. 27, 1994.

Court-Appointed Advisory Panel, United States District Court, Eastern and Southern Districts of New York. Re: Johns-Manville Corporation Personal Injury Settlement Trust and Populations of U.S. Asbestos Victims, 1991-1994.

Department of Labor 29CFR1910. Occupational Exposure to Hazardous Chemicals in Laboratories; Final Rule, January 31, 1990; 55 (21): 3314.

Areas of Research Interest

- 1. Clinical Quality Improvement, with an emphasis on laboratory orders and interdisciplinary teamwork for improvement
- 2. Occupational/Environmental epidemiology and toxicology, including:
- Perfluorocarbons
- Neurotoxicity
- Environmental health and endocrine disruption
- Use of administrative data in health services research, including workers' compensation
- · Training and evaluation in preventive medicine and public health
- Disease Clusters

Certificates

Certificate of Completion NIH Office of Human Studies Research computer-based training course on the Protection of Human Subjects, September 1, 2000, Serial: 967812471. Updated continuously as CITI training.

Annual HIPAA and compliance training.

RESEARCH SUPPORT

Submitted in 2016:

- Source: US Environmental Protection Agency
- Title: Investigating if Unconventional Oil and Gas Development in the Appalachian Region Impacts Environmental Health
- Role: Co-Investigator
- Outcome: Funding outcome anticipated May 2017

Source:USDHHS-NIH-NIEHSTitle:Cove Point Maryland Liquefied Natural Gas Facility Project

- Role: Co-investigator
- Outcome: Not funded

Source:CDC-ATSDRTitle:Brownfield-to-Trail RedevelopmentRole:Co-investigatorOutcome:Approved, not funded

Completed

National	
Source:	NIH/University of Pittsburgh (primary), WVU subrecipient of NIH grant
Title:	National Children's Health Study
Period:	9/28/08-9/29/09
Amount:	\$673,725
Role:	Co-investigator (10%)
Source:	NIH/University of Pittsburgh (primary), WVU subrecipient of NIH grant
Title:	National Children's Health Study
Period:	9/27/07-9/28/08
Amount:	\$455,467
Role:	Co-investigator (10%)
Source: Title: Period: Amount: Role:	NIOSH/Johns Hopkins University, WVU subrecipient of University of Maryland grant Occupational Injuries of Developmentally Disabled Sheltered-Workshop Workers in West Virginia 10/30/07-10/2/09 \$1,000 Co-investigator
Source: Title: Amount: Period: Role:	Office of Domestic Preparedness VMC Development Project for Online Training, Access, and Knowledge Resources for Weapons of Mass Destruction: IOC Phase \$1,360,959 9/1/03-3/31/05 Co-Investigator (6 percent)
Source:	USDHHS
Title:	West Virginia Prepares: CE Education Partnership
Amount:	\$2,242,659
Period:	9/30/02-9/29/05
Role:	Co-Investigator (10 percent)
Source:	CDC/NIOSH (contract 256809)
Title:	Review Database of Chemicals Used in Coal Preparation
Amount:	\$2400
Period:	2001-2002
Role:	Principal Investigator
Source:	CDC/NIOSH & University of Pittsburgh (RO1 OHO3646-01A2)
Title:	Solvent-Related Functional Brain Abnormalities
Amount:	\$227,822
Period:	2001-2004
Role:	Co-Investigator (5%)
Source: Title: Period: Amount: Role:	Department of Health and Human Services (DHHS 233-01-0064) Online Course and Knowledge Base for Improving Local-Level First and Emergency Responders' Coordination of Healthcare Response and Consequence Management for Weapons of Mass Destruction (Virtual Medical Campus) 10/1/02-3/31/04 \$258,372 Co-Investigator (10%)

Source:	CDC/UNC
Title:	SE Public Health Training Center Project
Period:	9/1/01-8/31/05
Amount:	\$47,000
Role:	Co-Investigator; WVU-PI Subrecipient agreement (5%)
Source:	CDC (H75/CCH322130)
Title:	Center for Healthy Communities
Period:	2002-2003
Amount:	\$1,997,974
Role:	Co-Investigator (5%)
Source:	CDC/NIOSH (T01/CCT/310455-09)
Title:	New Directions in Occupational Health
Period:	2001-2005
Amount:	\$292,000/yr (7/1/02-6/30/03)
Role:	Co-Investigator (10%)
Source:	NIOSH
Title:	New Directions in Occupational Health
Period:	1997-2001
Amount:	\$403,419/yr.
Role:	Principal Investigator
Source:	Centers for Disease Control and Prevention
Title:	Work Organization and Depression
Period:	1998-2000
Amount:	\$106,923
Role:	Co-Investigator and Subrecipient Agreement with University of Maryland
Source:	Environmental Protection Agency
Title:	Occupational Asthma: in and out of the workplace (national conference)
Period:	1998
Amount:	\$7,166
Role:	Principal Investigator
Source:	National Institute for Occupational Safety and Health
Title:	Workshop on Solvent Exposure among Railroad Workers
Period:	1996 (Nov 7-8)
Amount:	\$25,000
Role:	Co-Investigator (AOEC grant)
Source:	National Institute for Occupational Safety and Health - R13/CCR312621-01
Title:	Educational Conference on Occupational Safety and Health for Small Business
Period:	1995-1996
Amount:	\$12,000 (+ additional state matching funds)
Role:	Co-Principal Investigator
Source:	National Institute for Occupational Safety and Health
Title:	New Directions in Occupational Health Training - T01/CCT310455-01
Period:	Fiscal Year 1994-1997
Amount:	\$488,460/year
Role:	Principal Investigator, Director
Source:	Centers for Disease Control and Prevention
Title:	West Virginia University Prevention Center: Addressing the Risk Factors in Rural Appalachia

Period:	1994-1998
Amount:	\$100,000 of \$1,000,000 grant
Role:	Co-Investigator
Source:	National Institute for Occupational Safety and Health
Title:	National Environmental Education and Training Center
Period:	1994-1995
Amount:	\$13,500 of \$86,500
Role:	Co-Investigator
Source:	Department of Energy, National Research Center for Coal & Energy
Title:	Winfield, WV, Risk Communication
Period:	1994-1995
Amount:	\$10,000
Source:	EPA Hazardous Substance Research Center
Title:	Integrating Safety and Waste Management Practices in Laboratory Organizations
Period:	January 1991 - January 1992
Amount:	\$42,664
Role:	Principal Investigator
Source:	DOE/Oak Ridge Associated Universities
Title:	IND for DTPA
Period:	1990-1992
Role:	Co Investigator
Source:	EPA Hazardous Substance Research Center
Title:	Hazardous Substance Management Program; Laboratory Safety Training Program - R-815734-01
Period:	3/89 - 3/90
Amount:	\$20,000
Role:	Principal Investigator
<u>State</u>	
Source:	West Virginia Department of Health and Human Resources
Title:	GEO-22: Coal Slurry ATSDR Assessment
Period:	4/1/09-3/31/10
Amount:	\$221,519
Role:	Principal Investigator
Source:	West Virginia Insurance Commission
Title:	WVU Data Analysis Project
Period:	4/1/07-2/29/08
Amount:	\$242,627
Role:	Principal Investigator
Source:	West Virginia Insurance Commission
Title:	WVU Data Analysis Project
Period:	1/1/07-12/31/07
Amount:	\$242,627
Role:	Principal Investigator, 10% support
Source:	West Virginia Higher Education Policy Commission
Title:	Health Study of Hardy County
Period:	7/1/05-6/30/07
Amount:	\$250,000/yr
Role:	Principal Investigator, 10% support

Source:	WV Workers' Compensation Division
Title:	Workers' Compensation Data Analysis
Period:	1/1/06-12/31/06
Amount:	\$454,277
Role:	Principal Investigator, 10% support
Source:	West Virginia Insurance Commission
Title:	Insurance Commission-WVU Data Analysis Project
Period:	3/1/06-12/31/06
Amount:	\$165,683
Role:	Principal Investigator, 10% support
Source:	WV Workers' Compensation Division
Title:	Medical Support Project
Period:	7/1/05-12/31/05
Amount:	\$353,104
Role:	Clinician, 10% support
Source:	WV Bureau of Employment Programs
Title:	Workers' Compensation Data Analysis Project
Amount:	\$203,000
Period:	7/1/05-12/31/05
Role:	Principal Investigator (10 percent support)
Source:	WV Workers' Compensation Division
Title:	Medical Support Project
Amount:	\$706,209
Period:	7/1/04-6/30/05
Role:	Clinician (10 percent)
Source:	WV Bureau of Employment Programs
Title:	Workers' Compensation Data Analysis Project
Amount:	\$234,855
Period:	7/1/04-6/30/05
Role:	Principal Investigator (10 percent, 8% FY 2005)
Source:	WV Higher Education Policy Commission/WV Economic Development Office
Title:	WVU Health Study of Hardy County
Amount:	\$250,000
Period:	7/1/03-6/30/05
Role:	Principal Investigator (10%)
Source:	WV Bureau of Employment Programs
Title:	Workers' Compensation Data Analysis Project
Amount:	\$230,666
Period:	7/1/03-6/30/04
Role:	Principal Investigator (10 percent)
Source:	WV Bureau of Employment Programs
Title:	WVU Transitional Medical Support Project
Amount:	\$500,019
Period:	7/1/03-6/30/04
Role:	Co-Investigator (10 percent)
Source:	WV Department of Health & Human Resources

Title: Period: Amount: Role:	Childhood Lead Poisoning Prevention project 7/1/02-6/30/03 \$10,000/yr (contract) Principal Investigator (5%)
Source: Title: Period: Amount: Role:	WV Workers' Compensation Division WVU-Office of Medical Services Support 1/1/99-6/30/02 \$1,382,333/yr. Principal Investigator
Source: Title: Period: Amount: Role:	WV Department of Health & Human Services Childhood Lead Poisoning Prevention Project 7/01- 6/02 \$8,071 Principal Investigator
Source: Title: Period:	WV Bureau for Employment Programs Enhanced Approach to Health Care Cost Data Systems and Analysis 7/1/02-6/30/03 - \$348,416 1/01-12/01 - \$139,945 1/99-12/01 - \$378,850
Role:	Co-Investigator through 2001; PI in 2002 (15%)
Source: Title: Period: Amount: Role:	WV Workers' Compensation Division Medical Support and Medical Services Contract 1/1/03-6/30/03 \$813,355 Co-Investigator (15%)
Source: Title: Period: Role:	WV Bureau of Employment Programs WVU-Office of Medical Services Support 1/01-6/30/03 - \$1,382,333 1/01-12/01 - \$1,291,726 1/99-12/01 - \$3,473,939 Co-Investigator through 2001, Principal Investigator in 2002 (10%)
Source: Title: Period:	WV Bureau of Employment Programs Enhanced Approach to Health Care Cost Data Systems and Analysis 1/01-12/01 - \$139,945 1/99-12/01 - \$ 378,850
Role:	Co-Investigator (5%)
Source: Title: Period: Role:	WV Bureau of Employment Programs Assisting Policy (Targeted Analysis Project) 7/02-12/02 - \$220,614/yr 7/01-6/02 - \$200,149 Co-Investigator (5%)
Source: Title: Period: Amount: Role:	WV Workers' Compensation Division, Bureau of Employment Programs, RIA/WC Research Health Care Cost Data Systemization & Analysis Project 1999-2002 \$812,039 Principal Investigator
Source:	WV Workers' Compensation Division

Title:	Small Business Safety Outreach
Period:	1999-2002
Amount:	\$214,968/yr.
Role:	Co-Investigator
Source: Title: Period: Amount: Role:	WV Workers' Compensation Division Targeted Analysis of Outcomes and Effectiveness of Workers' Health Care Services and Interventions 1999-2002 \$163,977/yr Co-Investigator
Source:	West Virginia Bureau of Employment & Education
Title:	Evaluation of Managed Care Occupational Health Service
Period:	1996-99
Amount:	\$88,201
Role:	Co-Investigator
Source:	West Virginia Department of Health and Human Services, Bureau for Public Health, CDC grant
Title:	Lead Poisoning Prevention
Period:	1998-2001
Amount:	\$10,000/yr
Role:	Consultant
Source:	West Virginia Department of Labor, Workers' Compensation Division
Title:	Health Care Advisory Panel
Period:	7/92-7/98
Amount:	\$10,000/yr
Role:	Occupational Medical Illness Protocol
Source:	West Virginia Bureau of Employment
Title:	Trend and Cluster Analysis
Period:	1996-98
Amount:	\$55,265
Role:	Co-Investigator
Source:	West Virginia Bureau of Employment
Title:	Point of Sale Drug Utilization Review
Period:	1996-98
Amount:	\$55,815
Role:	Co-Investigator
Source:	West Virginia Bureau of Employment
Title:	Vertically Integrated Intervention Access
Period:	1996-97
Amount:	\$284,492
Role:	Principal Investigator

Corporate and Foundation

Source:	Claude Worthington Benedum Foundation
Title:	Interprofessional Education: Translating Research into Improved Practice in Rural Hospitals
Period:	December 15, 2014 – Dec 15, 2015
Amount:	\$10,000
Role:	Subrecipient co-principle investigator

Source:	Health Effects Institute (Professional Services Agreement with WVU)
Title:	Special scientific committee on unconventional oil and gas development
Period:	August 2014-August 2015
Amount:	\$10,500 and related expenses
Role:	Participant, document writer, concerning regional and national research needs
Source:	Claude Worthington Benedum Foundation
Title:	Project Hope
Period:	1/1/2014-12/31/2014
Amount:	\$150,000 for entire grant, \$50,000 for specific project
Role:	Author and project leader for the Quality Clinical Health Care Analytics aim (Suresh Madhavan, PI
for entire g	grant).
Source:	Claude Worthington Benedum Foundation
Title:	WVU School of Public Health Project (20110033 – 2W537)
Period:	4/1/11-9/30/12
Amount:	\$185,000
Role:	Principal Investigator
Source:	Brookmar, Inc.
Title:	C8 Health Project Supplement
Period:	7/1/08-8/31/08
Amount:	\$8,000
Role:	Principal Investigator
Source:	Brookmar, Inc.
Title:	Data Hosting for the C8 Health Project
Period:	7/1/06-6/30/08
Amount:	\$315,044
Role:	Principal Investigator
Source:	Brookmar, Inc.
Title:	Data Hosting for the C8 Health Project
Period:	6/1/06-6/30/08
Amount:	\$54,463
Role:	Principal Investigator
Source:	Brookmar, Inc.
Title:	Quality Assurance for the C8 Health Project
Period:	7/1/06-6/30/08
Amount:	\$37,397
Role:	Principal Investigator
Source:	BrickStreet Mutual Insurance Company
Title:	WVU Data Analysis Project
Period:	1/1/08-12/31/08
Amount:	\$448,668
Role:	Principal Investigator
Source:	BrickStreet Mutual Insurance Company
Title:	BrickStreet Mutual-WVU Data Analysis Project
Period:	1/1/07-12/31/07
Amount:	\$417,385
Role:	Principal Investigator, 8% support

Source:	Brookmar, Inc.
Title:	C8 Health Projects (several)
Period:	7/25/06-8/31/08
Amount:	\$373,510
Role:	Principal Investigator (effort varies by subproposal)
Source:	Brookmar, Inc.
Title:	Hourly Consulting for C8 Health Project
Period:	7/1/05-present
Amount:	service contracted to UHA
Role:	Consultant
Source: Title: Period: Amount: Role:	
Source:	MIT Licensure Agreement with COSTAR
Title:	Mixed Waste Disposal OSP #74329
Period:	1989-91
Role:	Laboratory Director

<u>University</u>

Source:	West Virginia University
Title:	Summer Research Project for M1 Student: On Line Interactive Resources for Epidemiology
Period:	Summer, 1997
Amount:	\$1,000
Role:	Principal Investigator
Source:	Medical University of South Carolina
Title:	Environmental Consultant to Major DOE grantee
Period:	1994-96
Amount:	\$10,000/year
Role:	Consultant
Source: Title: Period: Amount: Role:	Office of the Dean of Graduate Studies Summer Research Project for M1 Student: State Policy for Controversial Compensable Diagnosis Summer, 1996 \$2,000 Principal Investigator

PROFESSIONAL AFFILIATIONS

Current Professional and Scientific Organizations and Societies

- **Fellow**, American College of Occupational Medicine **Fellow**, American College of Physicians American Teachers of Preventive Medicine ٠
- •
- •

Offices in Professional and Accreditation Organizations

2012-2014	Member, West Virginia State Public Health Assessment Advisory Group
1999-2004	Chair, Residency Review Committee, Preventive Medicine. Accreditation Council on Graduate
	Medical Education
1999-2001	Steering Committee, SE Public Health Leadership Institute (NC, SC, TN, VA & WV)
1988-92	Council on Scientific Affairs, American College of Occupational Medicine
1988-93	Chair, Occupational & Clinical Toxicology Committee, American College of Occupational
	Medicine
1993-2002	Trustee, American Board of Preventive Medicine
1986-2003	Occupational Medicine Practice Committee, American College of Occupational Medicine

National/International Committees of Professional Organizations or Foundations

- International Agency for Research on Cancer (IARC). IARC Monographs Working Group for Volume 115
 – "Some Industrial Chemicals." Lyon, France. March 2016
- Health Effects Institute. Unconventional Special Committee on unconventional oil and gas development. 2014-2015
- American College of Occupational and Environmental Medicine. Environmental Medicine Committee. 1992-2002
- American National Standards Institute (ANSI). Medical Surveillance Subcommittee Z136, Safe use of lasers. 1989-1992.
- American College of Occupational and Environmental Medicine, Practice Committee, 1985-94
- Office of Science and Technology Policy. Study on Risk Assessment, 1985-1986.

HONORS AND AWARDS

- First author publication cited among "Compilation of Best Papers, 1979-1991." J Occup Environ Med 2016: 58(2); 111-13
- Appointed, Best Doctors in America, November 2015
- Inducted as faculty to WVU chapter of Delta Omega, the national honor society in public health, May 2014
- Appointed to the Governor's Advisory Council on Substance Abuse, August 2011.
- Appointed Guest Researcher, National Institute of Occupational Safety and Health (NIOSH), September 2010.
- NCEH/ATSDR (National Center for Environmental Health and Agency for Toxic Substances and Disease Registry, CDC) Director's Award for Outstanding Service, October 2008.
- The Department of Community Medicine was selected as the "Health Care Heroes" for the state of West Virginia, August 2008.
- Invited attendee, NIOSH Digital Imaging Workshop, March 11-13, 2008, Rockville, MD.
- Appointed Chair, Board of Scientific Counselors, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry, 2007.
- Selected as one of the Best Doctors in America, by Best Doctors, Inc., Aiken, SC (2007-2010).
- Nominated to the US Task Force on Community Prevention Services, CDC, 2006.
- Appointed by the US Secretary for Health and Human Services to the Board of Scientific Counselors, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry, 2006.
- Appointed Clinical Professor, West Virginia School of Osteopathic Medicine, 2004.
- Department of Community Medicine: Dean's Award for Excellence in Research, 2002.
- Certificate of Appreciation for Service to the West Virginia Public Health Association, 2000.
- On behalf of Department of Community Medicine, State Health Education Award for Outstanding Organizational Leadership to SHEC and Health Promotion in West Virginia, 1999.
- Certificate of Appreciation, Service to the Executive Council, West Virginia Public Health Association, 1999.
- Robert A. Kehoe Award of Merit, American College of Occupational and Environmental Medicine, 1998.
- Harriet Hardy Award for the physician who exemplifies the highest ideals of occupational and environmental medicine. New England College of Occupational and Environmental Medicine, 1997.

- Adolph H. Kammer Merit in Authorship Award, American College of Occupational and Environmental Medicine, 1994.
- Top Ten Percent Award, Teachers of Introduction to Clinical Medicine, West Virginia University, 1994.
- Robert J. Hilker Lectureship Award, American College of Occupational and Environmental Medicine, 1993.
- Navy Achievement Medal, 1984
- Navy Letters of Commendation (several)
- Finalist, Leo Friend Award for Best Professional Paper, 1988
- Fellow, American College of Occupational Medicine
- Fellow, American College of Physicians

Postgraduate Presentations and Teaching

Invited CDC/ATSDR presentation. PFAS: Findings, Gaps, Opportunities. Atlanta, GA May 17, 2018

Grand Rounds WVU Department of Medicine. 25 Years of Toxic Exposures in WV. Morgantown WV, April 13, 2018

Association of Pathology Chairs 2017 Annual Meeting. (Podium Presentation): Use of laboratory data to improve high value care in the diagnosis of myocardial infarction. Washington, DC, July 26, 2017.

Highly Fluorinated Compounds – Social and Scientific Discovery. (Podium Presentation): State of the Science on PFAS. Boston, MA, June 14, 2015.

American College of Nutrition (Podium Presentation): Personal poisons: the role of nutrition. San Diego, CA. November 10, 2016

Inter-professional Education Speaker Series: Across professions and institutions, what does it take to improve care? August 26, 2016, at West Virginia University

WV Data for Improving Clinical Orders. Panel address to WV Choosing Wisely Quality Improvement meeting. Charleston, WV. Sponsored by CAMC Institute and West Virginians for Affordable Health Care, May 6, 2015

Toxicologic Challenges: Population and Occupational Health Risks. Keynote address to the 28th Annual meeting of the Allegheny-Erie Society of Toxicology Regional Chapter. May16, 2014

West Virginia's Public Health: What Can We Achieve? Keynote address to the West Virginia Public Health Association Annual Conference, September 19, 2012.

Coal Slurry Waste Underground Injection Study. Presented to the Joint Committee on Water Resources of the WV Legislature, August 9 and 10, 2010 (two presentations).

Air Pollution and Climate Change. Presented to PUBH 605: Introduction to International Public Health, June 16, 2010.

Environmental Issues in West Virginia. Presented to the Occupational Medicine Grand Rounds, December 1, 2009.

Secondhand Smoke, Primary Prevention. Presented to the Department of Medicine Grand Rounds, October 20, 2009.

Environmental Questions and Community Concerns: The Role of Public Health Research. Presented to PUBH 706: Current Research Issues, August 27, 2009.

Air Pollution and Climate Change. Presented to PUBH 605: Introduction to International Public Health, June 10, 2009.

Environmental Issues in West Virginia. Presented to the Occupational Medicine Grand Rounds, May 12, 2009.

From the Mountains to the Valleys: Recent Environmental Issues in West Virginia. Presented to the Department of Medicine Grand Rounds, February 20, 2009.

Low Back Pain. Presented to the Occupational Medicine Grand Rounds, November 11, 2008.

Environmental Health Issues in West Virginia. Presented to the Annual Conference of the West Virginia Public Health Association, September 17, 2008.

Lead and Health. Presented to the Occupational Medicine Grand Rounds, August 26, 2008.

Air Pollution and Climate Change. Presented to PUBH 605: Introduction to International Public Health, June 11, 2008.

Pandemic Influenza. Presented to CCMD 712: Epidemiology and Biostatistics (for medical students), November 1, 2007.

Air Quality. (Television presentation, seen in Clarksburg/Morgantown – WBOY, Huntington/Charleston – WOWK, Wheeling/Steubenville – WTRF, Beckley/Bluefield/Lewisburg – WVNS), June 11, 2007.

Asbestos in Buildings and Health Effects. Public Health Grand Rounds. November 30, 2006. Simulcast, web-archived, and used for training at WVU. Used by permission at other universities.

Influenza: Preparing to Prevent a Pandemic Disaster – Pandemic and Other Public Health Concerns. The Tuberculosis Association of Ohio County (WV), November 14, 2006.

Toxic Industrial Symposium (ATSDR and WV Poison Center, Charleston, WV). Toxic Industrial Chemicals. September 11, 2006.

State Health Education Council of West Virginia. Trails to a Healthy West Virginia: Pandemic Flu and Mass Migration. May 3, 2006.

Southeast Public Health Leadership Center. Disease Clusters, Causation, and Common Sense. Teleconference, February 16, 2005.

Wheeling-Charleston Diocese, Appalachian Institute. Health: A Comprehensive Checkup for Rural West Virginia. Being Well in Rural West Virginia Conference. Bishop Hodges Pastoral Center, Huttonsville, WV. April 22, 2005.

US National Conservation Training Center. Emerging Contaminants and Water Supply Workshop. Environmental questions and Community Concerns: The Role of Public Health Research. September 19, 2005.

Biology Department Invited Seminar. Hardy County Research Findings and Plans. October 17, 2005.

Parkersburg Academy of Medicine. Pandemics. November 8, 2005.

Public Health Grand Rounds. Influenza: Preparing to Prevent a Pandemic Disaster. December 8, 2005.

Hardy County (West Virginia) Health Care Professionals. Cancer and Other Health Outcomes in Hardy County. Moorefield, WV. November 15, 2004. (Grant funded, 30 attendees).

West Virginia Public Health Association. Epidemiology of Disease Clusters. Huntington, WV. September 23, 2004.

American Association of Legal Nurse Consultants Fifteenth National Educational Conference. Disease clusters, causation, and common sense. Chicago, IL, April 1, 2004.

Respiratory Risk Factors in a Rural State. West Virginia Lung Association, Morgantown, WV. March 27, 2004.

Media Science Forum: Making Prevention Research News. Research America! And the West Virginia Prevention Research Center (panelist).

Molds. Pediatrics Grand Rounds. December 17, 2003.

Gatekeepers' Response to a Bioterrorism Attack. Eighth Annual Mountain Retreat, Snowshoe, WV. September 18, 2004.

Healthy West Virginia Summit 2003. Preventing chronic illness: closing the gap between research and prevention. August 4, 2003, Stonewall Resort, Lewis County, WV.

West Virginia Bar Association. Understanding disease clusters and causation in environmental medicine. Greenbrier Hotel, White Sulphur Springs, WV, July 12, 2003.

WAJR, Morgantown, WV. ("Talk Radio"). Mold. April 3, 2003.

National Institute of Occupational Safety and Health. Best Practices in Workplace Surveillance Conference. Identification and tracking of workplace injury. Illness, exposure, and hazards. A system for rapid analysis of transactional insurance data to identify trends in costs of work-related injuries. Cincinnati, OH, November 2001.

American Occupational Health Conference on behalf of ACOEM Millennium Series: Occupational Disease. San Francisco, CA, April 2001.

Massachusetts Medical Society. Environmental Issues in Clinical Practice. Cluster Analysis in Environmental Medicine. Boston, MA. Earth Day, April 22, 2001.

Governor's Occupational Safety and Health Conference (PA). "What's new in workers' health?" Hershey, PA, October 29, 2001

Fifth Annual Cost-Effectiveness Evaluation and Management of Low Back Pain Conference. The epidemiology of low back injuries. Morgantown, WV, November 5, 1999.

75th West Virginia Public Health Association Meeting. Health Effects of Air Pollution, Canaan Valley, WV, September 23, 1999

Sentinel Events in the Clinic. Cleveland Clinic Foundation, Cleveland, OH, June 4, 1998.

Lead Poisoning, Issues and Treatment. Northern Panhandle Childhood Lead Poisoning Prevention Project, Wheeling, WV, May 14, 1998.

Occupational Asthma: in and out of the workplace. **NIOSH-West Virginia University Conf**. Session Co-Chair Overview and Clinical Session, Morgantown, WV, April 30, 1998.

Core Curriculum in Environmental Medicine. **American College of Occupational and Environmental Medicine**, Nashville, TN, October 30-31, 1998.

Coping in the Trenches. **New England College of Occupational and Environmental Medicine**, Boston, MA. December 5, 1997.

Inhalation and Toxicity Injuries. **West Virginia University School of Medicine**. Emergency Medicine Grand Rounds, October 2, 1997.

Multiple Chemical Sensitivity. AASCIF Claims/Rehab. Seminar, Charleston, WV, September 18, 1997.

Occupational and Environmental Cluster Management. American College of Occupational and Environmental Medicine. Orlando, FL, May 13, 1997.

Occupational Asthma. Tri-State Medical Association. Lakeview, WV, September 27, 1996.

Laser eye injuries in academic research settings. **NIOSH Division of Safety Research**. Morgantown, WV, August 15, 1996.

Pesticides: Health-related issues. Assoc. Southern Feed, Fertilizer, and Pesticide Control Officials. Lakeview Conference Center, Morgantown, WV, June 18, 1996.

Low-dose risks, reproductive hazards, and risk assessment. **Medical University of South Carolina**, **Department of Family Medicine.** Spoleto Festival. Charleston, SC, May 25, 1996.

Epidemiology and cluster assessment. **American College of Occupational and Environmental Medicine.** Core Curriculum in Environmental Medicine. Alexis Park Resort, Las Vegas, May 6-7, 1995 and San Antonio, TX, April 27-28, 1996.

"Twitchy airways in the 21st century." **Industrial Health Foundation Conference**. Occupational Health Issues of the Next Decade. Orlando, FL, March 28, 1996.

The wherefore of risk assessment and discussion. **Medical University of South Carolina Environmental Hazards Assessment Program**. Charleston, SC, October 26, 1995.

Risk in the practice of medicine and risk assessment as it extends to the community. **Medical University of South Carolina Environmental Hazards Assessment Program**. Charleston, SC, October 26, 1995.

Air Pollution (outdoor). **American College of Occupational and Environmental Medicine**. Environmental exposures and susceptibility: a clinical and policy focus. Las Vegas, May 4, 1995.

Three mini-epidemics: goodwill and regulation. **US Dept of Labor**, Occupational Safety and Health Administration, Washington, DC, April 24, 1995.

Public Health in the Clinic: Three West Virginia Mini-epidemics. Internal Medicine Grand Rounds. **West Virginia University**, Morgantown, WV, March 31, 1995.

Disease clusters & causation. Michigan Occupational and Environmental Medicine Association. Lansing, MI, June 3, 1994.

Keynote address: Health care reform, you, and me. Mixed chemical exposures. **Midwest Center for Occupational Health and Safety**. Minneapolis, MN, March 15-16, 1994.

Occupational physician in environmental health. **Southern Medical Association**. 87th Annual Scientific Assembly, New Orleans, October 19, 1993.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 69 of 551

Introduction to environmental medicine (ATSDR-sponsored course). **American College of Occupational/Environmental Medicine**. State of the Art Conference. Dallas, TX, October 27, 1993.

Between "B"-ing and nothingness (The ILO system). **CDC-NIOSH,** invited speaker. Morgantown, WV, July 14, 1993.

Occupational Health and Environmental Medicine: comparisons, not contrasts. **CSOMA Robert J. Hilker, MD, Award Lecture.** Chicago, March 19, 1993.

Occupational Epidemiology. Thirty-fourth Navy Occupational Health and Preventive Medicine Workshop. Norfolk, VA, February 27, 1993.

Occupational health and the primary care physician. **Philadelphia County Medical Society.** October 19, 1992.

Environmental Medicine: What it is and isn't. **American Occupational Health Conference.** Washington, DC, May 6, 1992.

Workplace cancer clusters: causation and the limits of technical common sense. **Semiconductor Safety Association,** 14th Annual Meeting, Phoenix, AZ. April 6, 1992.

Disease clusters: environmental causation and common sense. **MIT-Lincoln Laboratory Distinguished Lecture Series.** Lexington, MA, March 18, 1992.

Grand Rounds. Baystate Medical Center, Springfield, MA, March 11, 1992.

Keynote Address: Occupational Environmental Medicine: Comparisons and Contrasts. **American College of Occupational Medicine State of the Art Conference.** St. Louis, MO, October 30, 1991.

Introduction. Conference on Laboratory Waste Management. **Massachusetts Institute of Technology**, Cambridge, MA, October 24, 1991.

Solvents in the workplace. Hazard Control in Semiconductor Manufacturing. **Semiconductor Industry Association.** Westborough, MA, October 17, 1991.

Biotechnology Industry Issues: Genetic Engineering and Worker Health. **American College of Occupational Medicine.** San Francisco, CA. May 2, 1991.

Epidemiology of Toxic Clusters. Neurology in the 1990's, **Harvard Medical School.** Boston, MA, March 23, 1991.

OSHA Laboratory Standard: Regulation of Toxic Substances in Laboratories and Waste Management in Laboratories. U.S. Dept of Commerce, **National Institute of Standards and Technology.** Gaithersburg, MD, Sept. 26, 1990.

Variability in interpretation of radiographs of x-rays for asbestos abnormalities: problems and solutions. **Collegium Ramazzini.** The Third Wave of Asbestos Disease. New York. June 7, 1990.

Workplace Medical Surveillance: Goals, Principles, and Breaking the Rules. **American Chemical Society**, Division of Chemical Health and Safety. Boston, MA, April 24, 1990.

Occupational Health Aspects of Biotechnology. **Society for Occupational and Environmental Health**. Washington, DC, April 24, 1990.

Approaching a Cancer Cluster. Thirty-Second Environmental Health Center Conference. **United States Navy**, Virginia Beach, VA. March 23, 1990.

Cancer Clusters. The Charles A. Dana Seminar Series in Environmental Epidemiology. New York, **Mt. Sinai** Medical School, February 16, 1990.

Conference on Laboratory Waste Management (conference organizer, supported by EPA #R-815734-01.) **Massachusetts Institute of Technology,** Cambridge, MA, January 31, 1990.

Protecting research laboratory workers. **American College of Occupational Medicine Conference**. Boston, MA, May 5, 1989.

Postgraduate seminar: Medical Surveillance Programs. **American College of Occupational Medicine** Conference. Boston, MA, May 1, 1989.

Biotechnology and Occupational Health. **American Public Health Association.** Annual Meeting, Boston, MA, November 14, 1988.

Eighth International Pneumoconiosis Conference. Pittsburgh, PA, August 23-26, 1988.

- 1. "B-Readers" and asbestos medical surveillance
- 2. Smoking and radiologic opacities in U.S. Navy asbestos workers
- 3. Asbestos medical surveillance population: predominant left-sided location of unilateral plaques

Asbestos medical surveillance: clinical and radiographic basis. **American Occupational Medical Association Conference**. New Orleans, LA, April 29, 1988.

Clusters, environmental causation, and common sense. **American Occupational Medical Association Conference.** New Orleans, LA, April 27, 1988.

Grand Rounds: Disease Clusters. Mount Auburn Hospital. Cambridge, MA, July 14, 1988.

Government regulation and occupational exposures of biotechnology researchers and production staff. Biotechnology, Regulation, and Human Health Symposium. **Massachusetts Institute of Technology,** August 7, 1987.

Risks from lithium batteries. The New Technologies Health and Safety Institute. **Worcester Polytechnic Institute.** Worcester, MA, May 28, 1987.

Occupational Health Issues in Biotechnology. **American Occupational Medical Association Conference.** Philadelphia, PA, April 1987.

An occupational physician looks at low back pain. Environmental Health Center Annual conference. **United States Navy.** Virginia Beach, VA, April 1984.

Potential health hazards of lithium manganese oxide and lithium carbon monofluoride batteries. **Power Sources Symposium**. Cherry Hill, NJ, June 1984.

Recognition of disease caused by chemical exposure: taking the history. Risk Management of Toxic Substances: Recognition, Prevention, Potential Liability. The **Hampton Institute** Center for Marine and Coastal Studies. Hampton, VA, July 1984.

Potential health hazards of lithium thionyl chloride batteries. Lithium Battery Tri-Service Working Group. San Diego, CA, February 1984.

Worker fitness and health responsibilities. **American Public Works Association.** Minneapolis, MN, May 1983.

Neurotoxicity of industrial solvents. Current Concepts for Cardiopulmonary and Occupational Medicine, **Midwest Center for Occupational Health,** St. Paul, MN, March 1983.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 71 of 551

PCB's, PBB's, Dibenzodioxins, and resources for assistance. Medical and Legal Management of Workplace Health Concerns. **Midwest Center for Occupational Health.** Minneapolis, MN, November 1982.

OTHER ACTIVITIES

Community Activities:

- . Provided public comments to State of NJ Drinking Water Quality Institute available on line at <u>http://www.nj.gov/dep/watersupply/g_boards_dwgi.html</u>
- Southwest Pennsylvania Environmental Health Project (<u>www.environmentalhealthproject.org</u>). Scientific Advisory Committee Member, 2016-December, 2018)
- Public Comments Submitted: Health-Based Maximum Contaminant Level Support Document: Perfluorooctanoic acid (PFOA) (See Response to Public Comments available at: <u>http://www.nj.gov/dep/watersupply/pdf/pfoa-appendixd.pdf</u>)
- Pathology and Population Health Steering Committee for the Association of Pathology Chairs, 2016-17.
- United Way Volunteer Leader, WVU School of Medicine Faculty, 2004
- Troop 62 Committee, Boy Scouts of America, Morgantown, WV, 1996-97
- Emergency Planning Boards, Cities of Cambridge and Lexington, MA, 1989-1992
- Environmental Hazards of Fires (lecture series) City of Cambridge, MA, Fire Department, 1990, 1992
- Health Right Free Clinic, Morgantown, WV Environmental Consultant, 1992-1994
- Numerous lectures to community groups, religious organizations, senior citizen groups, rotary clubs, PTAs, boards of education, etc., concerning environmental health and safety.
- Community Health Advocacy and Transformation Team. Monongalia County Health Department, 1997-98.

EXHIBIT B TO DECLARATION OF ALAN DUCATMAN, M.D. IN SUPPORT OF PLAINTIFFS' MOTION FOR CLASS CERTIFICATION

NYDEC Private Well Sampling Results (18 pages)

EXHIBIT SUBJECT TO PENDING MOTION TO SEAL FILED ON APRIL 6, 2020

EXHIBIT C TO DECLARATION OF ALAN DUCATMAN, M.D. IN SUPPORT OF PLAINTIFFS' MOTION FOR CLASS <u>CERTIFICATION</u>

NYSDOH Blood Testing Results

(72 pages)

EXHIBIT SUBJECT TO PENDING MOTION TO SEAL FILED ON APRIL 6, 2020

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 74 of 551

EXHIBIT D

EXHIBIT D

REFERENCE LIST

1. Frisbee SJ, Brooks AP, Jr., Maher A, et al. The C8 health project: design, methods, and participants. Environ Health Perspect. 2009;117(12):1873-1882.

2. Emmett EA, Shofer FS, Zhang H, Freeman D, Desai C, Shaw LM. Community exposure to perfluorooctanoate: relationships between serum concentrations and exposure sources. J Occup Environ Med. 2006;48(8):759-770.

3. Winquist A, Lally C, Shin HM, Steenland K. Design, methods, and population for a study of PFOA health effects among highly exposed mid-Ohio valley community residents and workers. Environ Health Perspect. 2013;121(8):893-899.

4. Raymond J, Brown MJ. Childhood blood lead levels in children aged <5 years -United States, 2009-2014. MMWR Surveill Summ. 2017;66(3):1-10.

5. Wones R, Pinney SM, Buckholz JM, Deck-Tebbe C, Freyberg R, Pesce A. Medical monitoring: a beneficial remedy for residents living near an environmental hazard site. J Occup Environ Med. 2009;51(12):1374-1383.

6. Signorini S, Gerthoux PM, Dassi C, et al. Environmental exposure to dioxin: the Seveso experience. Andrologia. 2000;32(4-5):263-270.

7. Noonan CW, Conway K, Landguth EL, et al. Multiple pathway asbestos exposure assessment for a Superfund community. J Expo Sci Environ Epidemiol. 2015;25(1):18-25.

8. Olsen GW, Burris JM, Ehresman DJ, et al. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect. 2007;115(9):1298-1305.

9. Fabrega F, Kumar V, Schuhmacher M, Domingo JL, Nadal M. PBPK modeling for PFOSand PFOA: Validation with human experimental data. Toxicol Lett. 2014.

10. Perez F, Nadal M, Navarro-Ortega A, et al. Accumulation of perfluoroalkyl substances in human tissues. Environ Int. 2013;59:354-362.

11. Karrman A, Domingo JL, Llebaria X, et al. Biomonitoring perfluorinated compounds in Catalonia, Spain: concentrations and trends in human liver and milk samples. Environ Sci Pollut Res Int. 2010;17(3):750-758.

12. Steenland K, Jin C, MacNeil J, et al. Predictors of PFOA levels in a community surrounding a chemical plant. Environ Health Perspect. 2009;117(7):1083-1088.

13. Steenland K, Tinker S, Frisbee S, Ducatman A, Vaccarino V. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am J Epidemiol. 2009;170(10):1268-1278.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 76 of 551

14. Nelson JW, Hatch EE, Webster TF. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environ Health Perspect. 2010;118(2):197-202.

15. Frisbee SJ, Shankar A, Knox SS, et al. Perfluorooctanoic acid, perfluorooctanesulfonate and serum lipids in children and adolescents: results from the C8 Health Project. Arch Pediatr Adolesc Med. 2010;164(9):860-869.

16. Geiger SD, Xiao J, Ducatman A, Frisbee S, Innes K, Shankar A. The association between PFOA, PFOS and serum lipid levels in adolescents. Chemosphere. 2013.

17. Eriksen KT, Raaschou-Nielsen O, McLaughlin JK, et al. Association between plasma PFOA and PFOS levels and total cholesterol in a middle-aged Danish population. PLoS One. 2013;8(2):e56969.

18. Lopez-Espinosa MJ, Fitz-Simon N, Bloom MS, Calafat AM, Fletcher T. Comparison between free serum thyroxine levels, measured by analog and dialysis methods, in the presence of perfluorooctane sulfonate and perfluorooctanoate. Reprod Toxicol. 2012;33(4):552-555.

19. Fletcher T, Galloway TS, Melzer D, et al. Associations between PFOA, PFOS and changes in the expression of genes involved in cholesterol metabolism in humans. Environ Int. 2013;57-58:2-10.

20. Jain RB. Contribution of diet and other factors to the levels of selected polyfluorinated compounds: Data from NHANES 2003–2008. International Journal of Hygiene and Environmental Health. 2014;217(1):52-61.

21. Starling AP, Engel SM, Whitworth KW, et al. Perfluoroalkyl substances and lipid concentrations in plasma during pregnancy among women in the Norwegian Mother and Child Cohort Study. Environ Int. 2013;62C:104-112.

22. Fu Y, Wang T, Fu Q, Wang P, Lu Y. Associations between serum concentrations of perfluoroalkyl acids and serum lipid levels in a Chinese population. Ecotoxicol Environ Saf. 2014;106:246-252.

23. Winquist A, Steenland K. Modeled PFOA exposure and coronary artery disease, hypertension, and high cholesterol in community and worker cohorts. Environ Health Perspect. 2014;122(12):1299-1305.

24. Zeng XW, Qian Z, Emo B, et al. Association of polyfluoroalkyl chemical exposure with serum lipids in children. Sci Total Environ. 2015;512-513:364-370.

25. Skuladottir M, Ramel A, Rytter D, et al. Examining confounding by diet in the association between perfluoroalkyl acids and serum cholesterol in pregnancy. Environ Res. 2015;143(Pt A):33-38.

26. Maisonet M, Nayha S, Lawlor DA, Marcus M. Prenatal exposures to perfluoroalkyl acids and serum lipids at ages 7 and 15 in females. Environ Int. 2015;82:49-60.

27. Kishi R, Nakajima T, Goudarzi H, et al. The association of prenatal exposure to perfluorinated chemicals with maternal essential and long-chain polyunsaturated fatty acids during pregnancy and the birth weight of their offspring: The Hokkaido Study. Environ Health Perspect. 2015;123(10):1038-1045.

28. Sakr CJ, Kreckmann KH, Green JW, Gillies PJ, Reynolds JL, Leonard RC. Crosssectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers. J Occup Environ Med. 2007;49(10):1086-1096.

29. Lin CY, Lin LY, Chiang CK, et al. Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults. Am J Gastroenterol. 2010;105(6):1354-1363.

30. Gallo V, Leonardi G, Genser B, et al. Serum perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) concentrations and liver function biomarkers in a population with elevated PFOA exposure. Environ Health Perspect. 2012;120(5):655-660.

31. Gleason JA, Post GB, Fagliano JA. Associations of perfluorinated chemical serum concentrations and biomarkers of liver function and uric acid in the US population (NHANES), 2007-2010. Environ Res. 2014;136c:8-14. 3

32. Yamaguchi M, Arisawa K, Uemura H, et al. Consumption of seafood, serum liver enzymes, and blood levels of PFOS and PFOA in the Japanese population. J Occup Health. 2013;55(3):184-194.

33. Grandjean P, Andersen EW, Budtz-Jorgensen E, et al. Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. JAMA. 2012;307(4):391-397.

34. Looker C, Luster MI, Calafat AM, et al. Influenza vaccine response in adults exposed to perfluorooctanoate and perfluorooctanesulfonate. Toxicol Sci. 2014;138(1):76-88.

35. Grandjean P, Heilmann C, Weihe P, Nielsen F, Mogensen UB, Budtz-Jorgensen E. Serum vaccine antibody concentrations in adolescents exposed to perfluorinated compounds. Environ Health Perspect. 2017.125(7): 077018

36. Dalsager L, Christensen N, Husby S, et al. Association between prenatal exposure to perfluorinated compounds and symptoms of infections at age 1-4 years among 359 children in the Odense Child Cohort. Environ Int. 2016;96:58-64.

37. Goudarzi H, Miyashita C, Okada E, et al. Prenatal exposure to perfluoroalkyl acids and prevalence of infectious diseases up to 4years of age. Environ Int. 2017.

38. Timmermann CA, Budtz-Jorgensen E, Jensen TK, et al. Association between perfluoroalkyl substance exposure and asthma and allergic disease in children as modified by MMR vaccination. J Immunotoxicol. 2017;14(1):39-49.

39. Granum B, Haug LS, Namork E, et al. Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood. J Immunotoxicol. 2013;10(4):373-379.

40. Steenland K, Tinker S, Shankar A, Ducatman A. Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA. Environ Health Perspect. 2010;118(2):229-233.

41. Geiger SD, Xiao J, Shankar A. Positive association between perfluoroalkyl chemicals and hyperuricemia in children. Am J Epidemiol. 2013;177(11):1255-1262.

42. Kataria A, Trachtman H, Malaga-Dieguez L, Trasande L. Association between perfluoroalkyl acids and kidney function in a cross-sectional study of adolescents. Environ Health. 2015;14:89.

43. Qin XD, Qian Z, Vaughn MG, et al. Positive associations of serum perfluoroalkyl substances with uric acid and hyperuricemia in children from Taiwan. Environ Pollut. 2016;212:519-524.

44. Melzer D, Rice N, Depledge MH, Henley WE, Galloway TS. Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey. Environ Health Perspect. 2010;118(5):686-692.

45. Knox SS, Jackson T, Frisbee SJ, Javins B, Ducatman AM. Perfluorocarbon exposure, gender and thyroid function in the C8 Health Project. J Toxicol Sci. 2011;36(4):403-410.

46. Pirali B, Negri S, Chytiris S, et al. Perfluorooctane sulfonate and perfluorooctanoic acid in surgical thyroid specimens of patients with thyroid diseases. Thyroid. 2009;19(12):1407-1412.

47. Lopez-Espinosa MJ, Mondal D, Armstrong B, Bloom MS, Fletcher T. Thyroid function and perfluoroalkyl acids in children living near a chemical plant. Environ Health Perspect. 2012;120(7):1036-1041.

48. Wen LL, Lin LY, Su TC, Chen PC, Lin CY. Association between serum perfluorinated chemicals and thyroid function in U.S. adults: the National Health and Nutrition Examination Survey 2007-2010. J Clin Endocrinol Metab. 2013;98(9):E1456-1464. 4

49. Jain RB. Association between thyroid profile and perfluoroalkyl acids: data from NHNAES 2007-2008. Environ Res. 2013;126:51-59.

50. Winquist A, Steenland K. Perfluorooctanoic acid exposure and thyroid disease in community and worker cohorts. Epidemiology. 2014;25(2):255-264.

51. Webster GM, Rauch SA, Marie NS, Mattman A, Lanphear BP, Venners SA. Cross-Sectional Associations of Serum Perfluoroalkyl Acids and Thyroid Hormones in U.S. Adults: Variation According to TPOAb and Iodine Status (NHANES 2007-2008). Environ Health Perspect. 2016;124(7):935-942.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 79 of 551

52. Coperchini F, Awwad O, Rotondi M, Santini F, Imbriani M, Chiovato L. Thyroid disruption by perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA). J Endocrinol Invest. 2017;40(2):105-121.

53. Kim S, Choi K, Ji K, et al. Trans-placental transfer of thirteen perfluorinated compounds and relations with fetal thyroid hormones. Environ Sci Technol. 2011;45(17):7465-7472.

54. Webster GM, Venners SA, Mattman A, Martin JW. Associations between Perfluoroalkyl acids (PFASs) and maternal thyroid hormones in early pregnancy: a population-based cohort study. Environ Res. 2014;133:338-347.

55. Yang L, Li J, Lai J, et al. Placental transfer of perfluoroalkyl substances and associations with thyroid Hormones: Beijing prenatal exposure study. Sci Rep. 2016;6:21699.

56. Kim DH, Kim UJ, Kim HY, Choi SD, Oh JE. Perfluoroalkyl substances in serum from South Korean infants with congenital hypothyroidism and healthy infants--Its relationship with thyroid hormones. Environ Res. 2016;147:399-404.

57. de Cock M, de Boer MR, Lamoree M, Legler J, van de Bor M. Prenatal exposure to endocrine disrupting chemicals in relation to thyroid hormone levels in infants - a Dutch prospective cohort study. Environ Health. 2014;13:106.

58. Shrestha S, Bloom MS, Yucel R, et al. Perfluoroalkyl substances and thyroid function in older adults. Environ Int. 2015;75:206-214.

59. Vieira VM, Hoffman K, Shin HM, Weinberg JM, Webster TF, Fletcher T. Perfluorooctanoic acid exposure and cancer outcomes in a contaminated community: a geographic analysis. Environ Health Perspect. 2013;121(3):318-323.

60. Steenland K, Woskie S. Cohort mortality study of workers exposed to perfluorooctanoic acid. Am J Epidemiol. 2012;176(10):909-917.

61. Barry V, Winquist A, Steenland K. Perfluorooctanoic acid (PFOA) exposures and incident cancers among adults living near a chemical plant. Environ Health Perspect. 2013;121(11-12):1313-1318.

62. Wang IJ, Hsieh WS, Chen CY, et al. The effect of prenatal perfluorinated chemicals exposures on pediatric atopy. Environ Res. 2011;111(6):785-791.

63. Dong GH, Tung KY, Tsai CH, et al. Serum polyfluoroalkyl concentrations, asthma outcomes, and immunological markers in a case-control study of Taiwanese children. Environ Health Perspect. 2013;121(4):507-513, 513e501-508.

64. Qin XD, Qian ZM, Dharmage SC, et al. Association of perfluoroalkyl substances exposure with impaired lung function in children. Environ Res. 2017;155:15-21.

65. Romano ME, Xu Y, Calafat AM, et al. Maternal serum perfluoroalkyl substances during pregnancy and duration of breastfeeding. Environ Res. 2016;149:239-246.

66. Sheng N, Li J, Liu H, Zhang A, Dai J. Interaction of perfluoroalkyl acids with human liver fatty acid-binding protein. Arch Toxicol. 2016;90(1):217-227.

67. Beggs KM, McGreal SR, McCarthy A, et al. The role of hepatocyte nuclear factor 4alpha in perfluorooctanoic acid- and perfluorooctanesulfonic acid-induced hepatocellular dysfunction. Toxicol Appl Pharmacol. 2016;304:18-29.

68. Goudarzi H, Araki A, Itoh S, et al. The association of prenatal exposure to perfluorinated chemicals with glucocorticoid and androgenic hormones in cord blood samples: The Hokkaido Study. Environ Health Perspect. 2017;125(1):111-118.

69. Apelberg BJ, Witter FR, Herbstman JB, et al. Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. Environ Health Perspect. 2007;115(11):1670-1676.

70. Fei C, McLaughlin JK, Tarone RE, Olsen J. Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. Environ Health Perspect. 2007;115(11):1677-1682.

71. Washino N, Saijo Y, Sasaki S, et al. Correlations between prenatal exposure to perfluorinated chemicals and reduced fetal growth. Environ Health Perspect. 2009;117(4):660-667.

72. Stein CR, Savitz DA, Dougan M. Serum levels of perfluorooctanoic acid and perfluorooctane sulfonate and pregnancy outcome. Am J Epidemiol. 2009;170(7):837-846.

73. Andersen CS, Fei C, Gamborg M, Nohr EA, Sorensen TI, Olsen J. Prenatal exposures to perfluorinated chemicals and anthropometric measures in infancy. Am J Epidemiol. 2010;172(11):1230-1237.

74. Chen MH, Ha EH, Wen TW, et al. Perfluorinated compounds in umbilical cord blood and adverse birth outcomes. PLoS One. 2012;7(8):e42474.

75. Maisonet M, Terrell ML, McGeehin MA, et al. Maternal concentrations of polyfluoroalkyl compounds during pregnancy and fetal and postnatal growth in British girls. Environ Health Perspect. 2012;120(10):1432-1437.

76. Wu K, Xu X, Peng L, Liu J, Guo Y, Huo X. Association between maternal exposure to perfluorooctanoic acid (PFOA) from electronic waste recycling and neonatal health outcomes. Environ Int. 2012;48:1-8.

77. Lee YJ, Kim MK, Bae J, Yang JH. Concentrations of perfluoroalkyl compounds in maternal and umbilical cord sera and birth outcomes in Korea. Chemosphere. 2013;90(5):1603-1609.

78. Darrow LA, Stein CR, Steenland K. Serum perfluorooctanoic acid and perfluorooctane sulfonate concentrations in relation to birth outcomes in the Mid-Ohio Valley, 2005-2010. Environ Health Perspect. 2013;121(10):1207-1213.

79. Johnson PI, Sutton P, Atchley DS, et al. The Navigation Guide - evidence-based medicine meets environmental health: systematic review of human evidence for PFOA effects on fetal growth. Environ Health Perspect. 2014;122(10):1028-1039.

80. Alkhalawi E, Kasper-Sonnenberg M, Wilhelm M, Volkel W, Wittsiepe J. Perfluoroalkyl acids (PFAAs) and anthropometric measures in the first year of life: Results from the Duisburg Birth Cohort. J Toxicol Environ Health A. 2016;79(22-23):1041-1049.

81. Minatoya M, Itoh S, Miyashita C, et al. Association of prenatal exposure to perfluoroalkyl substances with cord blood adipokines and birth size: The Hokkaido Study on environment and children's health. Environ Res. 2017;156:175-182.

82. Ashley-Martin J, Dodds L, Arbuckle TE, et al. Maternal and neonatal levels of perfluoroalkyl substances in relation to gestational weight gain. Int J Environ Res Public Health. 2016;13(1): 146

83. Lenters V, Portengen L, Rignell-Hydbom A, et al. Prenatal phthalate, perfluoroalkyl acid, and organochlorine exposures and term birth weight in three birth cohorts: Multi-pollutant models based on elastic net regression. Environ Health Perspect. 2016;124(3):365-372.

84. Verner MA, Loccisano AE, Morken NH, et al. Associations of perfluoroalkyl substances(PFAS) with lower birth weight: An evaluation of potential confounding by glomerular filtration rate using a physiologically based pharmacokinetic model (PBPK). Environ Health Perspect. 2015;123(12):1317-1324.

85. Steenland K, Zhao L, Winquist A, Parks C. Ulcerative colitis and perfluorooctanoic acid(PFOA) in a highly exposed population of community residents and workers in the mid-Ohio valley. Environ Health Perspect. 2013;121(8):900-905.

86. Savitz DA, Stein CR, Elston B, et al. Relationship of perfluorooctanoic acid exposure to pregnancy outcome based on birth records in the mid-Ohio Valley. Environ Health Perspect. 2012;120(8):1201-1207.

87. Avanasi R, Shin HM, Vieira VM, Savitz DA, Bartell SM. Impact of exposure uncertainty on the association between perfluorooctanoate and preeclampsia in the C8 Health Project population. Environ Health Perspect. 2016;124(1):126-132.

88. Uhl SA, James-Todd T, Bell ML. Association of Osteoarthritis with Perfluorooctanoate and Perfluorooctane Sulfonate in NHANES 2003-2008. Environ Health Perspect. 2013;121(4):447-452, 452e441-443.

89. Galloway TS, Fletcher T, Thomas OJ, Lee BP, Pilling LC, Harries LW. PFOA and PFOS are associated with reduced expression of the parathyroid hormone 2 receptor (PTH2R) gene in women. Chemosphere. 2015;120:555-562.

90. Innes KE, Ducatman AM, Luster MI, Shankar A. Association of osteoarthritis with serum levels of the environmental contaminants perfluorooctanoate and perfluorooctane sulfonate in a large Appalachian population. Am J Epidemiol. 2011;174(4):440-450.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 82 of 551

91. Raymer JH, Michael LC, Studabaker WB, et al. Concentrations of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) and their associations with human semen quality measurements. Reprod Toxicol. 2012;33(4):419-427.

92. Joensen UN, Bossi R, Leffers H, Jensen AA, Skakkebaek NE, Jorgensen N. Do perfluoroalkyl compounds impair human semen quality? Environ Health Perspect. 2009;117(6):923-927.

93. Toft G, Jonsson BA, Lindh CH, et al. Exposure to perfluorinated compounds and human semen quality in Arctic and European populations. Hum Reprod. 2012;27(8):2532-2540.

94. Vested A, Ramlau-Hansen CH, Olsen SF, et al. Associations of in utero exposure to perfluorinated alkyl acids with human semen quality and reproductive hormones in adult men. Environ Health Perspect. 2013;121(4):453-458, 458e451-455.

95. Louis GM, Chen Z, Schisterman EF, et al. Perfluorochemicals and human semen quality: the LIFE study. Environ Health Perspect. 2015;123(1):57-63.

96. Hu Q, Franklin JN, Bryan I, Morris E, Wood A, DeWitt JC. Does developmental exposure to perfluorooctanoic acid (PFOA) induce immunopathologies commonly observed in neurodevelopmental disorders? Neurotoxicology. 2012;33(6):1491-1498.

97. Strom M, Hansen S, Olsen SF, et al. Persistent organic pollutants measured in maternal serum and offspring neurodevelopmental outcomes--a prospective study with long-term follow-up. Environ Int. 2014;68:41-48.7

98. Goudarzi H, Nakajima S, Ikeno T, et al. Prenatal exposure to perfluorinated chemicals and neurodevelopment in early infancy: The Hokkaido Study. Sci Total Environ. 2016;541:1002-1010.

99. Hoffman K, Webster TF, Weisskopf MG, Weinberg J, Vieira VM. Exposure to polyfluoroalkyl chemicals and attention deficit/hyperactivity disorder in U.S. children 12-15 years of age. Environ Health Perspect. 2010;118(12):1762-1767.

100. Lien GW, Huang CC, Shiu JS, et al. Perfluoroalkyl substances in cord blood and attention deficit/hyperactivity disorder symptoms in seven-year-old children. Chemosphere. 2016;156:118-127.

101. Ducatman AM, Withers BF, Yang WN. Smoking and roentgenographic opacities in US Navy asbestos workers. Chest. 1990;97(4):810-813.

102. Ducatman AM, Yang WN, Forman SA. 'B-readers' and asbestos medical surveillance. J Occup Med. 1988;30(8):644-647.

103. Ducatman AM, Zhang J, Fan H. Prostate-specific antigen and perfluoroalkyl acids in the C8 health study population. J Occup Environ Med. 2015;57(1):111-114.

104. Post GB, Cohn PD, Cooper KR. Perfluorooctanoic acid (PFOA), and emerging drinking water contaminant: a critical review of recent literature. Environ Res 2012 Jul; 116:93-117 doi: 10.1016/j.envres.2012.03.007.

105. Wilhelm M, Wittsiepe J, Volkel W, Fromme H, et al. Perfluoroalkyl acids in children and their mothers: Association with drinking water and time trends of inner exposures – Results of the Duisburg birth cohort and Bochum cohort studies. Int J Hyg Environ Health 2015 Oct; 218(7); 645-55 doi: 10.1016/j.ijheh.2015.07.001

106. Domingo JL, Ericson-Jogsten I, Perello G, Nadal M, et al. Human exposure to perfluorinated compounds in Catalonia, Spain: contribution of drinking water and fish and shellfish. J Agric Food Chem 2012 May 2;60(17)4408-15 doi: 10.1021/jf300355c.

107. US EPA Technical Fact Sheet – Perfluorooctane Sulfonate (PFOS) and Perfluorooctanoic Acid (PFOA) November, 2017.

108. Grandjean P, Clapp R. Perfluorinated alkyl substances: Emerging insights Into health risks. New Solut. 2015;25(2):147-163.

109. Bartell SM. Online serum PFOA calculator for adults. Environ Health Perspect. 2017;125(10):104502.

110. Holzer J, Midasch O, Rauchfuss K, et al. Biomonitoring of perfluorinated compounds in children and adults exposed to perfluorooctanoate-contaminated drinking water. Environ Health Perspect. 2008;116(5):651-657.

111. Hernandez M, Lopez C, Soldevila B, et al., Impact of TSH during the first trimester of pregnancy and foetal complications: Usefulness of 2.5mIU/L cut-off value. Clin Endocrinol (Oxford). 2018; 88: 728-734.

112. Papadopoulou E, Sabaredzovic A, Namork E, et al., Exposure of Norwegian toddlers to perfluoroalkyl substances (PFAS): The association with breastfeeding and maternal PFAS concentrations. Environment International. 2016; 94: 687-94

113. Khalil N, Ebert JR, Honda M, et al. Perfluoroalkyl substances, bone density, and cardiometabolic risk factors in obese 8-12 year old children: A pilot study. Environ Res. 2017;160:314-321.

114. Liu HS, Wen LL, Chu PL, Lin CY. Association among total serum isomers of perfluorinated chemicals, glucose homeostasis, lipid profiles, serum protein and metabolic syndrome in adults: NHANES, 2013-2014. Environ Pollut. 2018;232:73-79.

115. Kato K, Wong LY, Chen A, et al. Changes in serum concentrations of maternal poly- and perfluoroalkyl substances over the course of pregnancy and predictors of exposure in a multiethnic cohort of Cincinnati, Ohio pregnant women during 2003-2006. Environ Sci Technol. 2014;48(16):9600-9608.

9

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 84 of 551

116. Mondal D, Weldon RH, Armstrong BG, et al. Breastfeeding: a potential excretion route for mothers and implications for infant exposure to perfluoroalkyl acids. Environ Health Perspect. 2014;122(2):187-192.

117. Kang H, Choi K, Lee HS, et al. Elevated levels of short carbon-chain PFCAs in breast milk among Korean women: Current status and potential challenges. Environ Res. 2016;148:351-359.

118. Newton S, McMahen R, Stoeckel JA, Chislock M, Lindstrom A, Strynar M. Novel polyfluorinated compounds identified using high resolution mass spectrometry downstream of manufacturing facilities near Decatur, Alabama. Environ Sci Technol. 2017;51(3):1544-1552.

119. Post GB, Gleason JA, Cooper KR. Key scientific issues in developing drinking water guidelines for perfluoroalkyl acids: Contaminants of emerging concern. PLoS Biol. 2017;15(12):e2002855.

120. Zhang Y, Beesoon S, Zhu L, Martin JW. Biomonitoring of perfluoroalkyl acids in human urine and estimates of biological half-life. *Environ Sci Technol.* 2013;47(18):10619-10627.

121. Li Y, Fletcher T, Mucs D, et al. Half-lives of PFOS, PFHxS and PFOA after end of exposure to contaminated drinking water. *Occup Environ Med.* 2018;75(1):46-51.

122. Kieskamp KK, Worley RR, McLanahan ED, Verner MA. Incorporation of fetal and child PFOA dosimetry in the derivation of health-based toxicity values. *Environ Int.* 2017. 111:260-267

123. Ballesteros V, Costa O, Iñiguez C, Fletcher T, Ballester F, Lopez-Espinosa M-J. Exposure to perfluoroalkyl substances and thyroid function in pregnant women and children: A systematic review of epidemiologic studies. Environ Int 2017 Feb; 99:15-28.

124. Andersson EM, Scott K, Xu YY, Li Y, Olsson DS, Fletcher T, Jakobsson K. High exposure to perfluorinated compounds in drinking water and thyroid disease. A cohort study from Ronneby, Sweden. Environ Res 2019;176:108540.

125. Fitz-Simon N, Fletcher T, Luster MI, Steenland K, Calafat AM, Kato K, Armstrong B. Reductions in serum lipids with a 4-year decline in serum perfluorooctanoic acid and perfluorooctanesulfonic acid. Epidemiology. 2013 Jul;24(4):569-76.

126. Rappazzo KM, Coffman E,Hines EP. Exposure to perfluorinated alkyl substances and health outcomes in children: A systematic review of the epidemiologic literature. Int J Environ Res Public Health 2017;201; 14(7).

127. Xu Y, Li Y, Scott K, Lindh C, Jakobsson K, Tony Fletcher T, Ohlsson B, Andersson E. Inflammatory bowel disease and biomarkers of gut inflammation and permeability in a

community with high exposure to perfluoroalkyl substances through drinking water. 2020; 181: 108923.

128. Raleigh KK, Alexander BH, Olsen GW, Ramachandran G, Morey SZ, Church TR, Logan PW, Scott LL, Allen EM. Mortality and cancer incidence in ammonium perfluorooctanoate production workers. Occup Environ Med. 2014;71(7):500-6.

129. Huang R, Chen Q, Zhang L, Luo K, Chen L, Zhao S, Feng L, Zhang J. Prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and the risk of hypertensive disorders of pregnancy. Environ Health. 2019;18(1):5.

130. Wikström S, Lindh CH, Shu H, Bornehag CG. Early pregnancy serum levels of perfluoroalkyl substances and risk of preeclampsia in Swedish women. Sci Rep. 2019 Jun 24;9(1):9179.

131. Liew, Z, Goudarzi H, Oulhote Y. Developmental Exposures to Perfluoroalkyl Substances (PFASs): An Update of Associated Health Outcomes. Curr Environ Health Rep 2018;5(1): 1-19.

132. Impinen A., Longnecker MP, Nygaard UC, London SJ, Ferguson KK, LHaug LS, Granum B. Maternal levels of perfluoroalkyl substances (PFASs) during pregnancy and childhood allergy and asthma related outcomes and infections in the Norwegian Mother and Child (MoBa) cohort. Environ Int 2019; 124: 462-472.

133. Impinen A, Nygaard UC, Lodrup Carlsen KC, Mowinckel P, Carlsen KH, Haug LS, Granum B. Prenatal exposure to perfluoralkyl substances (PFASs) associated with respiratory tract infections but not allergy- and asthma-related health outcomes in childhood. Environ Res 2018;160: 518-523.

134. Steenland K, Zhao L, Winquist A. A cohort incidence study of workers exposed to perfluorooctanoic acid (PFOA). Occup Environ Med. 2015;72(5):373-80.

135. Shin HM, Vieira VM, Ryan PB, Steenland K, Bartell SM. Retrospective exposure estimation and predicted versus observed serum perfluorooctanoic acid concentrations for participants in the C8 Health Project. Environ Health Perpect. 2011 Dec; 119(12):1760-5.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 86 of 551

EXHIBIT E

credit accident and health insurance directly related to extensions of credit, pursuant to § 225.25(b)(8)(i) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, July 24, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–18569 Filed 7–27–95; 8:45 am] BILLING CODE 6210–01–F

South Banking Company; Formation of, Acquisition by, or Merger of Bank Holding Companies

The company listed in this notice has applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that application or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Comments regarding this application must be received not later than August 11, 1995.

A. Federal Reserve Bank of Atlanta (Zane R. Kelley, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303:

1. South Banking Company, Alma, Georgia; to acquire 100 percent of the voting shares of Pineland State Bank, Metter, Georgia.

Board of Governors of the Federal Reserve System, July 24, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–18568 Filed 7–27–95; 8:45 am] BILLING CODE 6210–01–F

FEDERAL TRADE COMMISSION

Regulations under the Comprehensive Smokeless Tobacco Health Education Act of 1986; Information Collection Requirement

AGENCY: Federal Trade Commission. **ACTION:** Notice of application to OMB under the Paperwork Reduction Act (44 U.S.C. 3501 *et seq.*) for clearance of information collection requirements contained in the Regulations under the Comprehensive Smokeless Tobacco Health Education Act of 1986.

SUMMARY: This publication provides notice that the Federal Trade Commission is seeking renewed approval for three years from OMB for the information collection requirements contained in the Regulations under the Comprehensive Smokeless Tobacco Health Education Act of 1986. The present OMB approval for the information collection requirements is scheduled to expire on August 31, 1995.

The Smokeless Tobacco Act requires, among other things, that manufacturers, packagers, and importers of smokeless tobacco products include health warnings on packages and in advertisements. The Act also requires each manufacturer, packager, and importer of a smokeless tobacco product to submit a plan to the Commission that specifies the methods used to rotate, display, and distribute the warning statements required to appear in advertising and labeling. Section 3(d) directs the Commission to approve plans that provide for rotation, display, and distribution of the warning statements in accordance with the regulations. All the affected companies have previously filed plans, but the plan submission requirement continues to apply to a company that amends its plans, or to a new company that enters the market.

Estimate of Information Collection Burden

In 1986, staff estimates that as many as ten domestic and four foreign smokeless tobacco companies would submit plans specifying the method used to rotate, display, and distribute health warnings in their labeling and advertising. This prediction was accurate. Fourteen plans were received.

When the regulations were first proposed, representatives of the Smokeless Tobacco Council, Inc., indicated that six companies that it represented would require a total of 700 to 800 hours (or about 133 hours apiece, on average) to prepare the required plans. We also assumed that the other companies, whose plans were prepared by other representatives, would require more time, on average, and used 150 hours per plan to account for the remainder of the expected submissions. Based on these assumptions staff estimated that no more than 2,000 hours would be spent to prepare and submit compliance plans. (Six companies total=800 hours, plus eight companies at 150 hours=1,200 hours.) The Commission provided a burden estimate to OMB of 2,000 hours for the reporting requirements.

In 1992, the Commission proposed amendments to the rotation of health warnings on point-of-sale and nonpoint-of-sale promotional materials. Pursuant to the proposed amendment, affected firms will have to submit new plans for Commission approval. The amendment of previously submitted plans to incorporate plans for promotional materials should require less time than was devoted to the original submissions. As in 1992, there is no substantial basis for calculating the proportion of the original burden estimate that will be attributable to the amendment process and accordingly, the Commission proposes to retain the existing burden estimate for purposes of seeking this extension.

DATES: Comments on this application must be submitted on or before August 28, 1995.

ADDRESSES: Send comments both to the Office of Information and Regulatory Affairs, Office of Management and Budget, New Executive Office Building, Room 3228, Washington, D.C. 20503, ATN: Desk Officer for the Federal Trade Commission, and the Office of the Secretary, Room 159, Federal Trade Commission, Washington, D.C. 20580. Copies of the application may be obtained from the Public Reference Section, Room 130, Federal Trade Commission, Washington, D.C. 20580.

FOR FURTHER INFORMATION CONTACT:

Phillip S. Priesman, Attorney, Federal Trade Commission, Washington, D.C. 20580 (202) 326–2484. Stephen Calkins, *General Counsel.* [FR Doc. 95–18595 Filed 7–27–95; 8:45 am] BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

[ATSDR-96]

ATSDR's Final Criteria for Determining the Appropriateness of a Medical Monitoring Program Under CERCLA

AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR), Public Health Service (PHS), Department of Health and Human Services (HHS). **ACTION:** Notice.

SUMMARY: This notice announces the criteria for determining the appropriateness of a medical monitoring program under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Draft criteria were published for public comment on September 9, 1994 (59 FR 46648). The public comment period ended October 24, 1994. Comments were received from 15 individuals representing States, industry, activist groups, and environmental medicine clinics. This document reflects those comments received on the draft criteria.

ADDRESSES: Division of Health Studies, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road, NE., Mailstop E–31, Atlanta, Georgia 30333, telephone (404) 639–6200.

FOR FURTHER INFORMATION CONTACT: Dr. Wendy E. Kaye, Chief, Epidemiology and Surveillance Branch, Division of Health Studies, ATSDR, telephone (404) 639–6203.

SUPPLEMENTARY INFORMATION: Section 104(i)(9) of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), as amended [42 U.S.C. 9604(i)(9)], provides for the Administrator of the Agency for Toxic Substances and Disease Registry (ATSDR) to initiate a health surveillance program for populations at significantly increased risk of adverse health effects as a result of exposure to hazardous substances released from a facility. A program included under health surveillance is referred to as "Medical Monitoring or Screening" by ATSDR and is defined in the legislation as "the periodic medical testing to screen people at significant increased risk for disease." ATSDR has established criteria to determine when medical monitoring is an appropriate health activity and the requirements for establishing a medical monitoring program at a site. The legislation also

states that a mechanism to refer people for treatment should be included in the program. Statutory language only allows ATSDR to provide medical care or treatment in cases of public health emergencies as declared by the President.

Background

ATSDR is responsible for the public health-related activities of CERCLA. ATSDR's primary initial response at a hazardous waste site is the public health assessment, which is required for every site on the National Priorities List (NPL). A public health assessment can also be conducted in response to a petition from the public. Other important components of ATSDR's initial response at sites include health consultations and public health advisories. During the process of developing the public health assessments and health advisories, ATSDR invites the participation of communities through a variety of avenues such as public meetings, public availability sessions, and Community Assistance Panels (CAPs). The documents produced by ATSDR during the process are placed in a public repository to allow the public access to the documents. The public health assessments, health consultations, and public health advisories undergo review by ATSDR to determine if follow-up health-related activities are needed for populations at risk in the affected community.

The types of follow-up health activities recommended for a site will depend on the amount of information on the possible exposures and their suspected pathways. In any case in which an association has not been established between an exposure and a specific adverse health outcome, several research and health education activities may be considered. Those activities could include health outcome studies, an exposure assessment at the site, epidemiologic studies, or professional education.

ATSDR's Division of Health Assessment and Consultation has established a program for the investigation of exposures in communities which enables a more timely response to questions on whether individuals in a community are being exposed. The program incorporates a variety of industrial hygiene techniques for measuring chemicals in the environment, as well as selected biological markers of exposure.

The Division of Health Education provides a wide variety of services to educate health care professionals and communities on the effects of exposures to hazardous substances. Activities in a community around a hazardous waste site may include conducting grand rounds for health care providers on the effects of a specific chemical, providing fact sheets on chemicals, conducting workshops on clues to environmental disease, and producing case studies in environmental medicine.

The Division of Health Studies is responsible for conducting epidemiologic research, including several types of studies (cluster investigations, disease and symptom prevalence studies, analytic epidemiologic studies), surveillance programs, and exposure registries. Cluster investigations and disease and symptom prevalence studies investigate the occurrence of disease in populations. Analytic epidemiology studies are conducted to evaluate the causal nature of associations between exposure to hazardous substances and disease outcomes. The surveillance program focuses on exposures to substances at hazardous waste sites and includes systems that follow populations exposed to hazardous wastes because of where they live or their occupation. It also includes surveillance of emergency events in which hazardous substances are released into the environment. The National Exposure Registry maintains a listing of people exposed to hazardous substances. The Registry is composed of chemical specific subregistries. The chemicals are selected from the ATSDR/ EPA priority list of hazardous substances.

Medical monitoring is considered one of several follow-up health activity options under the site-specific work conducted by ATSDR. A medical monitoring program for the community around a site will be considered with other health follow-up activities when the information from ATSDR's initial response at the site is reviewed. In cases in which there is no known association between the exposure and specific adverse health effects (which could include health outcomes, illnesses, or markers of effect), medical monitoring is not an appropriate public health activity. In cases in which there is limited information on a specific health effect's relationship to an exposure, then options such as epidemiologic surveillance, a disease and symptom prevalence study, or an epidemiologic study are more appropriate. When adequate information exists that links exposure to a chemical with a specific adverse health effect, further consideration will be given to the appropriateness of medical monitoring in that population.

Medical monitoring should be directed toward a target community identified as being at "significant increased risk for disease" on the basis of its exposure. Significant increased risk will vary for particular sites depending upon such factors as the underlying risk of the selected outcome, the risk attributable to the exposure, and the presence of sensitive subpopulations. These factors will be considered when evaluating the appropriateness of medical monitoring in a community. The CERCLA legislation also provides for a mechanism for referral for treatment of those who are screened positive for the selected health outcomes; therefore, a mechanism to refer people for diagnosis, interventions, or treatment should be in place prior to the initiation of a medical monitoring program.

The primary purpose of a medical monitoring program is not considered to be a research activity that further investigates the cause-effect relationship between exposure and outcome. The purpose of a medical monitoring program is case-finding in order to refer individuals for further evaluation and, as appropriate, treatment. Within this framework, medical monitoring includes both testing for early biological effect and an assessment of exposure using biological specimens (for example, blood or urine), when appropriate. This is provided as a service to individuals in communities where there is believed to be an increased risk of disease from exposure to hazardous substances released into the environment.

Criteria for Considering Medical Monitoring

The criteria outlined below will be used to determine the appropriateness of conducting medical monitoring in a community and will be applied in a phased approach. Phase I, conducted by ATSDR, consists of an evaluation of the exposure and outcome criteria. Phase II consists of an evaluation of the system criteria. Phase II will be conducted with the input of a panel consisting of community, State and local health officials, and ATSDR. At the end of Phase II, a detailed medical monitoring plan will be written at sites where a monitoring program is established. All of the criteria must be met at a site in order for a medical monitoring program to be established at that site. In addition, resources must be available to initiate and sustain the program.

Phase I

Exposure Criteria

A. There should be evidence of contaminant levels in environmental media that would suggest the high likelihood of environmental exposure to a hazardous substance and subsequent adverse health outcomes.

The National Research Council (NRC) defines exposure as "an event that occurs when there is contact at a boundary between a human and the environment at a specific contaminant concentration for a specified period of time; the units to express exposure are concentration multiplied by time" (NRC, 1991). The specific contaminant concentration and period of time will vary for different chemicals and different media. The exposure must be to a hazardous substance as defined under CERCLA, and the result of a release from a CERCLA-covered facility. A release from a CERCLA-covered facility includes those events that establish an open pathway of exposure (i.e., an unfenced area with high soil contamination could be considered a "release") or allows contaminants to go off-site via air, surface water, ground water, or other pathway. The primary criteria for medical monitoring should be documented evidence of exposure of a population to a hazardous substance in the environment. An exposure will be considered to be at a sufficient level if there is documentation of an increased opportunity for exposure to a level that meets or exceeds some health-based comparison value (such as Minimum Risk Levels (MRLs) or Reference Doses (RfDs)) or that meets or exceeds a level reported in the peer-reviewed literature to result in some adverse health effect. Documentation is considered sufficient if it is from an exposure assessment, environmental exposure modeling, or sampling from a general area (for example, water samples from an aquifer or a town water supply). Documentation of individual levels of exposure is not required. In cases in which exposures are unknown or undocumented, environmental monitoring is a more appropriate initial activity.

B. There should be a well-defined, identifiable target population of concern in which exposure to a hazardous substance at a sufficient level has occurred.

Initially, the target population of concern will be defined geographically on the basis of exposure. In addition, all populations considered will be assessed for the presence of any sub-population at increased risk of the adverse health effects associated with the exposures. An example of a subpopulation at increased risk would be preschool children in an area with known lead exposures. The size of the target population of concern is not a factor in the decision for monitoring. In areas where biological markers of exposure have not been collected, environmental sampling can be used to estimate exposure levels. The target population of concern is the population in which there is documented exposure at a sufficient level to place the individuals in that population at significant increased risk for developing some specific adverse health effect.

Outcome Criteria

A. There should be documented human health research that demonstrates a scientific basis for a reasonable association between an exposure to a hazardous substance and a specific adverse health effect (such as an illness or change in a biological marker of effect).

Previous studies on human populations must demonstrate a reasonable association between a particular exposure and an adverse health effect. In order to make that inference, consideration should be given to the strength, specificity, and consistency of the association among the identified studies. The period of exposure (including the timing and duration of the exposure) and its relationship to the latency period for the disease or illness should also be examined if information is available. Consideration should be given to whether the association has demonstrated a dose-response relationship and whether the association is consistent with the existing body of knowledge. This information could include a variety of occupational, epidemiological, or other studies involving human populations.

B. The monitoring should be directed at detecting adverse health effects that are consistent with the existing body of knowledge and amenable to prevention or intervention measures.

The monitoring should be established for specific adverse health effects. The specific adverse health effect being monitored should be a result of the possible exposure consistent with the existing body of knowledge. An adverse health effect is consistent with the existing body of knowledge if it has been described in the literature as caused by that agent or by similar agents, taking into account structureactivity relations.

In addition, the adverse health effects (disease process, illness, or biomarkers of effect) should be such that early detection and treatment or intervention Federal Register / Vol. 60, No. 145 / Friday, July 28, 1995 / Notices

interrupts the progress to symptomatic disease, improves the prognosis of the disease, improves the quality of life of the individual, or is amenable to primary prevention. If the adverse health effects that are of concern in an individual or in a community are not easily detectable and not medically treatable, then medical monitoring would not be beneficial and would not be an appropriate public health activity. An easily detectable effect is one that can be found on clinical examination, or through the use of simple, diagnostic tests in an outpatient setting. Also, the test procedures must be acceptable to the patient and the community. The diagnostic tests must be nonexperimental, relatively noninvasive (such as the drawing of a tube of blood for laboratory tests), and simple to administer.

Monitoring for Evidence of Continuing Exposure

At sites with exposure in the community, the monitoring program might include biological markers of continuing exposure. For example, the Bunker Hill Superfund site has had lead screening of children for many years. Those sites would be ones in which the exposure is known to have a variety of adverse health effects, but for which no tests are available to detect those effects at a time when intervention could affect the course of the disease process. In those instances, the primary intervention is to remove the individual from the exposure. This allows the medical monitoring system to recommend referral for intervention prior to the onset of detectable adverse health effects. A monitoring system that includes biomarkers of continuing exposure is similar to medical surveillance of hazardous waste workers where changes indicative of increasing or continued exposures occur sufficiently early that the exposure can be curtailed and the risk for disease reduced (Gochfeld 1990).

Phase II

General Information

Phase II of the program is carried out by ATSDR with assistance from the community. When ATSDR has determined that exposure from a site has met the exposure and outcome criteria, a site panel will be formed based on recommendations from the community and the State and/or local health departments to review the system criteria and to assist in the development of a site-specific medical monitoring plan. The site panel will include representatives from ATSDR, the

community, State or local health departments, local medical societies, and subject experts as necessary. The site panel will function in much the same manner as the Community Assistance Panels (CAPs) that are established at some sites during the public health assessment process. The site panel will follow the established procedures for those CAPs. The site panel will be responsible for assessing the available community health resources and determining the feasibility and extent of the screening program for the community. If the panel determines that a screening program is feasible in the community and ATSDR concurs with that decision, ATSDR will develop a site-specific monitoring plan. That plan will be presented to the site panel for review and concurrence. After the plan has been developed and has undergone peer review, it will be presented to the community at large for their input prior to establishing the program.

System Criteria

A. The general requirements for a medical screening program should be satisfied.

The monitoring aspect of a health surveillance program consists of the periodic medical testing to screen individuals who are at increased risk of disease. Monitoring serves to identify those individuals with an unrecognized adverse health effect. This is consistent with the definition of screening as "the presumptive identification of unrecognized disease or defect by the application of tests, examinations, or other procedures which can be applied rapidly. Screening tests sort out apparently well persons who probably have a disease from those who probably do not. A screening test is not intended to be diagnostic. Persons with positive or suspicious findings must be referred to their physicians for diagnosis and necessary treatment." (Commission on Chronic Illness, 1957) In general, the ability to predict the presence or absence of disease from test results depends on the sensitivity and specificity of the test and the prevalence of the disease in the population being tested. The higher the prevalence, the more likely a positive test indicates disease (Mausner & Kramer, 1985). In order for a screening program to be of public health benefit, the population being screened should be at a significantly high risk for the undiagnosed disease (i.e., the disease should have a sufficiently high prevalence in the population).

Given that definition, there are certain requirements for screening programs

that should be considered when evaluating a possible medical monitoring program for a site (adopted from Mausner & Kramer, 1985). Those requirements are:

★ The natural history of the disease process should be understood sufficiently for screening.

★ The early detection through screening should be known to have an impact on the natural history of that disease process. For example, the detection of breast cancer while it is localized has been shown to increase the ten-year survival rate. For that reason, several groups have made recommendations for the early detection of breast cancer in asymptomatic women. Those recommendations include breast self-examination, breast physical examination, and mammography (Mettlin & Dodd, 1991; Kelsey & Gammon, 1991).

★ There should be an accepted screening test that meets the requirements for validity, reliability, estimates of yield, sensitivity, specificity, and acceptable cost. The purpose of ATSDR-sponsored medical monitoring is not to develop new screening tests. The medical monitoring program will use tests that have been recommended and used for screening in other settings.

The U.S. Preventive Services Task Force has established criteria for determining the effectiveness of preventive strategies including screening tests. The criteria for effectiveness of a screening test include the efficacy of the screening test and the effectiveness of early detection. The Task Force used efficacy to mean accuracy and reliability. The accuracy is measured using four indices: sensitivity, specificity, positive predictive value, and negative predictive value (see table below for definitions). A test with poor sensitivity will result in a large proportion of persons with disease being told they are free of disease (falsenegatives). A test with poor specificity will result in healthy persons being told they have the disease (false-positives). There may be serious consequences in the use of screening tests with poor sensitivity and/or specificity. Persons with false negative results may have delays in diagnosis and treatment. False positive results can result in follow-up testing that is uncomfortable, expensive and potentially harmful. The evaluation and selection of a screening test must include a determination of the likelihood of producing false positive results (the positive predictive value (PPV)). The PPV changes in accordance with the prevalence of the condition in the screened population. PPV is unlike

Federal Register / Vol. 60, No. 145 / Friday, July 28, 1995 / Notices

sensitivity and specificity in that it is not a constant characteristic of a screening test. If the condition is sufficiently rare in the screened population, even tests with excellent sensitivity and specificity can have low PPV, having more false positive results than true positive results. Another important aspect in determining the efficacy of a screening test is the reliability of the test. The reliability (reproducibility) is the ability of the test to give the same result when it is repeated. An accurate test with poor reliability can produce results that vary widely from the correct value, even though the average of the results approximates the true value. Poor reliability may be due to either interobserver variation or intraobserver variation (U.S. Preventive Services Task Force, 1989).

DEFINITION OF TERMS

Term	Definition	Formula*
Sensitivity	Proportion of persons with the condition who	a
	test positive.	a + c
Specificity	Proportion of persons without the condition who test negative.	d b + d
Positive Predictive Value	Proportion of persons with positive test who	a
	have condition.	a + b
Negative Predictive Value	Proportion of persons with negative test who	d
	do not have the condition.	c + d
*Explanation of Symbols		
	Condition absent	Condition present
Positive Test	a	b
Negative Test	с	d

Legend: a=true +; b=false +; c=false -; d=true -.

★ The screening program should be one that is feasible and acceptable to individuals and the community. Therefore, plans and possible screening tests for a medical monitoring program will be presented to the community for input prior to the initiation of any recommended program.

B. An accepted treatment, intervention, or both, for the condition (outcome or marker of exposure) must exist and a referral system should be in place prior to the initiation of a medical monitoring program.

There should be established criteria for determining who should receive referral for intervention or treatment. These criteria will be based on the selected effect being screened for and the screening test being used. Results will be evaluated by ATSDR longitudinally and cross-sectionally to identify changes in the system or screening tools that require follow-up (Gochfeld 1990). A referral mechanism should exist so that those who are eligible for the intervention can be referred to a qualified health care provider for further diagnosis, treatment, or intervention. The referral must be for treatment or intervention that is standard practice and not experimental in nature. The medical monitoring (screening) program is not responsible for the cost of the referral, the intervention, or the treatment of individuals participating in the program.

C. The logistics of the system must be resolved before the program can be initiated.

After medical monitoring has been determined to be appropriate for a site, the specifics of the monitoring system will be detailed in a site-specific medical monitoring plan. The site panel consisting of the community members, appropriate health officials, and subject experts as necessary will work with ATSDR to develop and review the sitespecific medical monitoring plan. The specifics of the medical monitoring system recommended can vary for each site. The monitoring plan is the protocol for the specific program to be proposed in a community. The plan will outline the target community, the types of outcomes to be screened for, the participants in the referral system, and the program reports. The plan will include a review of the latency period for the outcomes being monitored and the duration of the exposure to define the period of time that the program will operate in a specific site population. The target population; the completeness with which the exposed population can be identified, contacted, and followed; the screening tests; and the selected health outcomes will all influence the specifics of the system. Existing medical facilities and personnel will be used when possible.

The monitoring plan will be submitted for peer review prior to its implementation at a site. The plan for a site might require additional review by an expert panel (ethicists, NRC) to evaluate the screening tests recommended. ATSDR's Division of Health Studies will work closely with the Division of Health Education to provide professional health education when needed to enhance the medical monitoring program.

Medical monitoring is one of ATSDR's service activities and is not considered to be a research tool. The monitoring activity at each site will be routinely evaluated for the effectiveness of the screening tests in place and the types of effects being detected. Due to confidentiality issues in dealing with small groups of people, the reporting from the system will consist of annual reports noting the number of individuals screened, the number of referrals made, and the number of conditions diagnosed in the referral system. ATSDR will develop a list that includes information on the types of exposures seen in the communities and the types of screening tests that were included in the monitoring. ATSDR can provide this information as available to the site panels to assist them in deciding on the types of screening tools based on what has been used in other areas.

The referral system will consist of the review of the screening results and the referral to appropriate health care providers or referral physicians. The specific mechanisms for determining who needs referral and for selecting the health care providers in the referral pool must be in place prior to the initiation of the medical monitoring. Once the participant has been referred to the Federal Register / Vol. 60, No. 145 / Friday, July 28, 1995 / Notices

referral providers, those providers will be responsible for any subsequent diagnosis, treatment, or intervention.

Summary of Medical Monitoring

Medical monitoring will be considered along with the other health follow-up activities to be recommended for populations around specific sites. The Division of Health Studies will make a determination on whether a site meets the exposure and outcome criteria for medical monitoring. If a site meets the previously discussed criteria and is selected for further consideration of a medical monitoring program, ATSDR will work with the community and other appropriate entities in designing the specific monitoring and referral system for that site's target population. ATSDR will notify, and where appropriate, work with the state health department to establish the program. The Division of Health Studies will monitor the program and be responsible for the oversight on the annual reports.

References

- Commission on Chronic Illness. Chronic Illness in the United States, Vol. 1. Commonwealth Fund, Harvard University Press, Cambridge, 1957, page 45.
- Gochfeld M. Medical surveillance of hazardous waste workers. In Principles and Problems in Occupational Medicine State of the Art Reviews: Hazardous Waste Workers. Gochfeld M and EA Favata, editors. Philadelphia: Hanley & Belfus, Inc., 1990; 5(1):1–8.
- Kelsey JL and MD Gammon. The epidemiology of breast cancer. CA–A Cancer Journal for Clinicians 1991; 41(3):146–165.
- Mausner JS and S Kramer. Epidemiology—an introductory text. Philadelphia: W.B. Saunders, 1985, pages 220–230.
- Mettlin C and GD Dodd. The American Cancer Society guidelines for the cancerrelated checkup: An update. CA–A Cancer Journal for Clinicians 1991; 41(5):279–282.
- NRC (National Research Council). Human Exposure Assessment for Airborne Pollutants: Advances and Opportunities. Washington, D.C.: National Academy Press, 1991, pages 17–37.
- U.S. Preventive Services Task Force. Guide to Clinical Preventive Services: An Assessment of the Effectiveness of 169 Interventions. Baltimore: Williams & Wilkins, 1989, pages xxix–xxxvii. Dated: July 24, 1995.

Claire V. Broome,

Deputy Administrator, Agency for Toxic Substances and Disease Registry.

[FR Doc. 95–18578 Filed 7–27–95; 8:45 am]

BILLING CODE 4163-70-P

Centers for Disease Control and Prevention

[Announcement 562]

Analytic Studies to Elaborate the Impact of Race, Ethnicity, and Socioeconomic Status Upon the Health of Minority Populations

Introduction

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 1995 funds for cooperative agreements to conduct analytic studies to elaborate the impact of race, ethnicity, and socioeconomic status (SES) upon the health of minority populations in the United States. Research sponsored by this announcement will focus on the performance of special studies and analyses of existing data to:

1. Identify the critical features of SES which determine health, delineate the mechanisms and processes whereby social stratification produces disease, and specify the psychological and interpersonal processes that can intensify or mitigate the effects of social structure on health behaviors, access to care, and health outcomes;

2. Explore the need for more accurate descriptions of racial and ethnic status to monitor the differential impact of health policy changes and system reform on minority subpopulations; and,

3. Increase understanding of the impact of ethnicity on health by identifying the ways in which SES, cultural factors, and racial/ethnic variables and discrimination impact on health behaviors, access to health care, and health outcomes.

The "Disadvantaged Minority Health Improvement Act of 1990" (Pub.L. 101– 527) which established the Minority Health Statistics Grants Program and subsequent reauthorizing legislation contained in the "Preventive Health Amendments of 1993" (Pub.L. 103– 183), recognized the need for improved and refined data to monitor and focus on the differences in health status between and among minority populations.

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity to reduce morbidity and mortality and improve the quality of life. This announcement is related to the priority area of Surveillance and Data Systems. (For ordering a copy of "Healthy People 2000," see the section "Where to Obtain Additional Information.")

Authority

This program is authorized under section 306(m) of the Public Health Service Act [42 U.S.C. 242k(m)] as amended.

Smoke-Free Workplace

The PHS strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products, and Public Law 103–227, the Pro-Children Act of 1994, prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, and early childhood development services are provided to children.

Eligible Applicants

Applications may be submitted by nonprofit organizations and institutions, and governments and their agencies. Thus, universities, colleges, research institutions, hospitals, other public and private nonprofit organizations, State and local governments or their bona fide agents, federally recognized Indian tribal governments, Indian tribes or Indian tribal organizations, are eligible to apply.

Availability of Funds

Approximately \$500,000 will be available in FY 1995 to fund approximately 3 to 7 awards ranging from \$50,000 to \$200,000. It is expected that the average award will be \$150,000. It is expected that the awards will begin on or about September 30, 1995, and will be made for a 12-month budget period within a project period of up to 3 years. Funding estimates may vary and are subject to change. Applications requesting funds greater than an upper limit of \$250,000 total costs for any 12month budget period will be returned to the applicant without review. Continuation awards within the project period will be made on the basis of satisfactory progress and the availability of funds.

Purpose

The purpose of this program announcement is to support special studies and analyses that will elucidate the impact of race/ethnicity and SES upon the health of minority populations in the United States.

Research priorities for race/ethnicity and SES have been divided into several categories. Genetics is an important variable; however, it diverts attention from the more influential social and environmental differences which have erroneously been attributed as race differences. Implicit in these priorities are a number of methodological and analytical issues, such as finding and Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 93 of 551

EXHIBIT F

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 94 of 551

APPENDIX A

HEALTH-BASED MAXIMUM CONTAMINANT LEVEL SUPPORT DOCUMENT: PERFLUOROOCTANOIC ACID (PFOA)

New Jersey Drinking Water Quality Institute Health Effects Subcommittee February 15, 2017

Subcommittee Members: Jessie A. Gleason, M.S.P.H., Chair Keith R. Cooper, Ph.D. Judith B. Klotz, M.S., Dr.P.H. Gloria B. Post, Ph.D., DABT George Van Orden, Ph.D. Page intentionally left blank

Acknowledgements

The Health Effects Subcommittee would like to recognize former Subcommittee members -Daniel Caldwell, Perry Cohn, Leslie McGeorge, and David Pringle - for their contributions to the Subcommittee's earlier evaluation of PFOA in 2009-10.

The Subcommittee also thanks Alan Stern of the NJDEP Division of Science, Research and Environmental Health (DSREH) for assistance with Benchmark Dose modeling, Sandra Goodrow of DSREH for assistance with analysis of New Jersey PFOA drinking water occurrence data, and Gwen Haile and Theresa Tucker of DSREH for technical and editorial assistance.

Finally, this work would not have been possible without the ongoing support of the librarians of the NJDEP Environmental Research Library - Dorothy Alibrando, Mary Kearns-Kaplan (former), and Tonia Wu.

Page intentionally left blank

TABLE OF CONTENTS

ABSTRACT	1
EXECUTIVE SUMMARY	2
INTRODUCTION	
BACKGROUND INFORMATION	
GUIDANCE AND STANDARDS DEVELOPED BY NEW JERSEY, OTHER SAND USEPA	· · · · · · · · · · · · · · · · · · ·
ENVIRONMENTAL FATE, TRANSPORT, AND OCCURRENCE	
HUMAN BIOMONITORING	
SOURCES OF HUMAN EXPOSURE	
TOXICOKINETICS	
HEALTH EFFECTS - HUMAN STUDIES	60
HEALTH EFFECTS - ANIMAL TOXICOLOGY	104
MODE OF ACTION	180
DEVELOPMENT OF RECOMMENDED HEALTH-BASED MCL	204
DISCUSSION OF UNCERTAINTIES	
CITATIONS	221

Appendices

APPENDIX 1. Literature Search Criteria and Documentation - PFOA	.3
APPENDIX 2: Comparison of USEPA Office of Water Health Advisory and DWQI	
recommended Health-based MCL for PFOA	.5
APPENDIX 3: Risk Assessment Considerations for Butenhoff et al. (2002) Subchronic	
Cynomolgus Monkey Study	18
APPENDIX 4. Individual tables for epidemiology studies	21
APPENDIX 5: Individual Tables for Toxicology Studies	78
APPENDIX 6: Outputs of Benchmark Dose Modeling for Mammary Gland Developmen	t
Endpoints1	12
APPENDIX 7: Benchmark dose analysis of relative liver weight in response to PFOA	
(linear/branched) using BMR of 10% increase relative to controls1	62
APPENDIX 8: Benchmark dose analysis of testicular tumor data in response to	
PFOA using 5%BMR of tumor incidence1	76

TABLE OF TABLES

Table 1. PFOA concentrations in raw or finished water from PWS included in NJDEP database	33
Table 2. New Jersey versus national UCMR3 PFC occurrence data as of January 2016	34
Table 3. Serum PFOA concentration from NHANES (ng/ml)	36
Table 4: Serum/plasma elimination half-lives of PFOA	46
Table 5. Increase in serum PFOA concentrations predicted from various concentrations of PFOA in drinking water	59
Table 6A. Summary of findings from epidemiologic studies of PFOA and serum lipids	93
Table 6B. Summary of findings from epidemiologic studies of PFOA and liver enzymes/bilirubin	97
Table 6C. Summary of findings from epidemiologic studies of PFOA and thyroid hormones and diseases	99
Table 6D. Summary of findings from epidemiologic studies of PFOA and uric acid	102
Table 6E. Summary of findings from epidemiologic studies of PFOA and antibody concentrations (following vaccination)	103
Table 7. Relative Liver Weight (compared to controls) in 90 Day Rhesus Monkey Study (Goldenthal, 1978)	106
Table 8. Liver enzymes (relative to control) in serum of mice exposed to PFOA in drinking water for 21 days (Son et al., 2008)	116
Table 9. Developmental events in human and rodent mammary tissue (Fenton, 2006)	129
Table 10. Summary of Increased Relative Liver Weight Data from Rodents Studies Using Doses < 1 mg/kg/day, and 90 Day N	
Table 11. Summary of toxicological studies of effects of oral exposure to PFOA on the immune system	155
Table 12: Summary of studies of effects of gestational/lactational exposure to PFOA in mice (most sensitive effect(s) in each study are shown in <i>red italics</i>)*	160
Table 13. Identification of most sensitive endpoints in mouse developmental studies of PFOA*	170
Table 14A. Summary of publications/studies evaluating effects of PFOA on mammary gland (MG) development in mice – Includes studies with exposure during pregnancy, gestation, and/or lactation (6 publications/10 studies).	174
Table 14B. Summary of publications/studies evaluating effects of PFOA on mammary gland (MG) development in mice – Stud with peripubertal exposure (3 publications).	
Table 15. Mammary gland development parameters selected for dose-response modeling from PND 21 female offspring after exposure on GD 10-17	207
Table 16. Benchmark Dose modeling of serum PFOA data (PND1) for mammary gland developmental effects (PND 21) in CD mouse pups	
Table 17: Serum PFOA and relative liver weight in Male CD-1 mice dosed with branched/linear PFOA for 14 days	212
Table 18. Benchmark Dose analysis for a 10% increase in relative liver weight from linear/branched PFOA in male mice (Loveless et al., 2006) ^a	213
Table 19. BMD modeling (0.05 BMR; 5% response) of rat testicular tumor data (Butenhoff et al., 2012) ^a	218

TABLE OF FIGURES

Figure E-1. Increases in serum PFOA concentrations predicted from mean and upper percentile consumption of drinking water with various concentrations of PFOA, as compared to U.S median and 95 th percentile serum PFOA levels (NHANES, 2011-12)6
Figure E-2. From Verner et al. (2016a). Modeling simulation of the ratio of PFOA in blood plasma in breast fed infants/children to plasma concentration in mother
Figure 1. Increases in serum PFOA concentrations predicted from consumption of drinking water with various concentrations of PFOA
Figure 2. Major transport pathways of PFCs to the Arctic (and other remote locations), by Annika Jahnke (Butt et al., 2010)
Figure 3. APFO (PFOA) transport near discharge source (Davis et al., 2007)
Figure 4. Structure of diPAPs 8:2
Figure 5. PFOA concentration in cord blood and blood collected in infants around six and nineteen months after birth
Figure 6. Serum PFOA concentrations over time in 12 infants from Mogensen et al. (2015)
Figure 7. Monte Carlo simulations ($n = 10\ 000$) of child/mother ratios of plasma PFOA levels (ng/ml ; right side of figure) and doses ($ng/kg/day$; left side of figure) for a breastfeeding period of 30 months
Figure 8. Increases in serum PFOA concentrations predicted from mean and upper percentile consumption of drinking water with various concentrations of PFOA, as compared to U.S median and 95th percentile serum PFOA levels (NHANES, 2011-12)60
Figure 9. Adjusted-predicted total cholesterol change with increasing group median deciles. (A). Adults, Steenland et al., 2009 (B). Adolescents,
Figure 10. Timeline of critical periods of mammary gland development and potential effects of endocrine disrupting compounds on mammary gland development (Fenton, 2006)
Figure 11. White et al. (2011b) study design and experimental timeline
Figure 13. Relative liver weight and relative PCO activity (compared to controls) versus serum PFOA concentrations in male mice dosed with linear/branched, linear, or branched PFOA for 14 days (Loveless et al., 2006)
Figure 14. Relative liver weight and relative PCO activity (compared to controls) versus serum PFOA concentrations in male rats dosed with linear/branched, linear, or branched PFOA for 14 days (Loveless et al., 2006)
Figure 15. Relative liver weight and relative PCO activity (compared to controls) versus serum PFOA concentrations in male rats and mice dosed with PFOA for 4, 7, or 13 weeks (Perkins et al., 2004)
Figure 16. Changes in PFOA levels in breast-fed infants from birth to later timepoints (Fromme et al., 2010; Mogensen et al., 2015)
Figure 17. Monte Carlo simulations of child/mother ratios of plasma PFOA levels (ng/ml) a breastfeeding period of 30 months. Black line - 50th percentile; blue line - 5th percentile; red line - 95th percentile; dotted lines - minimum and maximum values216

ABBREVIATIONS

ALP — alkaline phosphatase ALT /SGPT - alanine aminotransferase APFO — ammonium perfluorooctanoate, the ammonium salt of PFOA AST /SGOT — aspartate aminotransferase BMD — Benchmark Dose BMDL — lower 95% confidence limit on the Benchmark Dose BMR — Benchmark Response CAR — constitutive androstane receptor C8 — a synonym for PFOA DWQI - New Jersey Drinking Water Quality Institute FTOH — fluorotelomer alcohol GD — gestational day GFR — glomerular filtration rate GGT — gamma-glutamyl transferase GM — geometric mean H & E — hematoxylin and eosin HDL — high-density lipid cholesterol IARC — International Agency for Cancer Research IRIS - USEPA Integrated Risk Information System LDL — low-density lipid cholesterol LOAEL — Lowest Observed Adverse Effect Level MCL — Maximum Contaminant Level NHANES — National Health and Nutrition Examination Survey NJDEP — New Jersey Department of Environmental Protection NJDOH - New Jersey Department of Health NOAEL - No Observed Adverse Effect Level NTP — National Toxicology Program OR — odds ratio PAPs ---polyfluoroalky phosphoric acid diesters PCO — palmitoyl CoA oxidase PFC — perfluorinated compound PFOA — perfluorooctanoic acid PFOS — perfluorooctane sulfonate PFNA — perfluorononanoic acid PND — postnatal day POD — Point of Departure PPAR — peroxisome proliferator activated receptor PTFE – polytetrafluoroethylene PWS – public water supplies PXR — pregnane X receptor RfD — Reference Dose RL — Reporting Level RSC — Relative Source Contribution SAB - Science Advisory Board SDWA — Safe Drinking Water Act

- SMR standardized mortality ratio
- TSH thyroid stimulating hormone
- TT3 total triiodothyronine
- TT4 total thyroxine
- UCMR3 Unregulated Contaminant Monitoring Rule 3
- UF uncertainty factor
- VLDL very low-density lipid cholesterol
- USEPA United States Environmental Protection Agency
- WY Wyeth 14,643 (4-Chloro-6-[2,3-xylidino]-2-pyrimidinylthio)acetic acid), a model PPAR-alpha activating compound

ABSTRACT

A Health-based Maximum Contaminant Level (Health-based MCL) for perfluorooctanoic acid (PFOA, C8) was developed using a risk assessment approach intended to protect for chronic (lifetime) drinking water exposure. A public health-protective approach in developing a Health-based MCL based on animal toxicology data is supported by associations of PFOA with a number of health effects in the general population and communities with drinking water exposure, as well as PFOA's biological persistence and bioaccumulation from drinking water in humans. PFOA was described as "likely to be carcinogenic to humans" by the USEPA Science Advisory Board, "possibly carcinogenic to humans" by the International Agency for Research on Cancer (IARC), and as having "suggestive evidence of carcinogenic potential" by the USEPA Office of Water. Both non-carcinogenic and carcinogenic effects were evaluated for Health-based MCL development. Delayed mammary gland development and increased liver weight were the most sensitive non-carcinogenic endpoints with data needed for dose-response modeling. For each of these endpoints, benchmark dose modeling of serum PFOA levels from mouse studies was performed and appropriate uncertainty factors were applied to develop a Target Human Serum Level (analogous to a Reference Dose but on a serum level basis). A clearance factor (1.4×10^{-4}) L/kg/day) which relates serum PFOA concentrations to human PFOA doses was applied to the Target Human Serum Levels to develop Reference Doses. For delayed mammary gland development, the Target Human Serum Level is 0.8 ng/ml, which is below the median serum PFOA level in the U.S. general population. The Reference Dose for this endpoint is 0.11 ng/kg/day. Because the use of delayed mammary gland development as the basis for quantitative risk assessment is a currently developing topic, a Health-based MCL using this endpoint as its primary basis was not recommended. However, it was concluded that an uncertainty factor for sensitive endpoints is needed to protect for this and other effects that occur at similarly low doses. A Health-Based MCL protective for increased relative liver weight was derived based on a study in which male mice were exposed to PFOA for 14 days. For increased relative liver weight, the Target Human Serum Level is 14.5 ng/ml and the Reference Dose is 2 ng/kg/day. This Target Human Serum Level and Reference Dose incorporate uncertainty factors to protect sensitive human subpopulations, to account for toxicodynamic differences between human and experimental animals, and to protect for more sensitive endpoints that occur from developmental exposures (delayed mammary gland development, persistent hepatic toxicity, and others). Default values for drinking water exposure assumptions (2 L/day water consumption; 70 kg body weight) and Relative Source Contribution factor (20%) were used to develop a Health-based MCL of 14 ng/L was based on the Reference Dose for increased relative liver weight. A cancer slope factor of 0.021 (mg/kg/day)⁻¹ was developed based on increased incidence of testicular tumors in a chronic rat study. This slope factor was used to develop a Health-based MCL protective for cancer effects at the 1×10^{-6} (one in one million) lifetime cancer risk level of 14 ng/L, identical to the Health-based MCL based on non-cancer endpoints. The recommended Health-based MCL is therefore 14 ng/L (0.014 μ g/L).

EXECUTIVE SUMMARY

Perfluorooctanoic acid (PFOA, C8) is a member of the group of substances called perfluorinated compounds (PFCs), chemicals that contain a totally fluorinated carbon chain which varies in length and a functional group such as carboxylic or sulfonic acid. PFCs are part of a larger group of chemicals called poly- and perfluoroalkyl substances (PFAS).

The New Jersey Drinking Water Quality Institute (DWQI) voted to pursue development of a Maximum Contaminant Level (MCL) recommendation for PFOA on January 27, 2009 based on its potential health effects and its occurrence in New Jersey public water supplies (PWS). The Health Effects Subcommittee began its evaluation of PFOA during 2009-2010, but a Health-based MCL recommendation was not finalized at that time. A review of PFOA as an emerging drinking water contaminant was subsequently published by several current and former Subcommittee members in 2012 (Post et al., 2012). On March 21, 2014, New Jersey DEP Commissioner Bob Martin requested that the DWQI recommend an MCL for PFOA and two other perfluorinated compounds, perfluorononanoic acid (PFNA, C9) and perfluoroctane sulfonic acid (PFOS). The Subcommittee's evaluation and recommended Health-based MCL for PFOA are presented in this document.

As is the case for Health-based MCLs recommended by the DWQI in general, the recommended Health-based MCL for PFOA is based on the goals specified in the 1984 Amendments to the New Jersey Safe Drinking Water Act (SDWA) at N.J.S.A. 58:12A-20. This statute specifies a one in one million (10⁻⁶) risk of cancer from lifetime exposure to carcinogens, and that no "adverse physiological effects" are expected to result from lifetime ingestion for non-carcinogenic effects. Human health risk assessment approaches used by the DWQI to develop Health-based MCLs generally follow USEPA risk assessment guidance.

Manufacturing and Use

Because carbon-fluorine bonds are among the strongest found in organic chemistry, PFOA and other PFCs are extremely stable and resistant to chemical reactions. PFOA has been produced for use in commercial products and industrial processes for over 60 years. Its unique surfactant properties and resistance to chemical and thermal degradation make it useful in many applications including water-, soil-, and stain-resistant coatings, fire-fighting foams, and industrial uses. Large amounts of PFOA were used industrially as a processing aid (emulsifier) in the production of fluoropolymers and fluoroelastomers for use as non-stick coatings.

Because of concerns about its ubiquitous presence in environmental media (including wildlife) and human blood serum worldwide, its persistent and bioaccumulative nature, and its potential health effects, the eight major U.S. producers of PFOA entered into a voluntary agreement with USEPA in 2006 to reduce emissions and product content of PFOA and its precursors by 95% by 2010 and to work towards eliminating them by 2015. However, other manufacturers and users of PFOA that are not participants in the voluntary agreement with USEPA continue to emit large

amounts of PFOA to the environment, particularly overseas. Although the production and use of PFOA and its precursors has been phased out by major U.S. manufacturers, environmental contamination and resulting human exposure to PFOA are anticipated to continue for the foreseeable future due to its persistence, formation from precursor compounds, and continued production by other manufacturers.

Environmental Fate and Transport

Because of the extreme stability of their carbon–fluorine bonds, PFOA and other PFCs are extremely resistant to degradation in the environment and thus persist indefinitely. PFOA and other PFCs are found in many environmental media and in wildlife worldwide including in remote polar regions. PFOA is much less bioaccumulative in fish than PFOS or perfluorinated carboxylates with more than eight carbons, and PFOA concentrations in wildlife are generally lower than for these other PFCs. PFOA and other PFCs can be taken up into plants from contaminated soil or irrigation water. In general, PFOA and other longer chain PFCs are preferentially taken up into the root and shoot parts of the plant.

PFOA and some other PFCs are distinctive from other persistent and bioaccumulative organic compounds because of their importance as drinking water contaminants. PFOA does not bind well to soil, migrates readily from soil to ground water, and is highly water-soluble. These properties of PFOA differ from those of other well-known persistent and bioaccumulative organic pollutants such as polychlorinated dioxins and polychlorinated biphenyls (PCBs) that have a high affinity for soil and sediments but low water solubility.

PFOA that is released into the environment can contaminate surface water and groundwater used as drinking water sources. Environmental sources include industrial discharge to soil, air, and water; release of aqueous firefighting foams; disposal in landfills; wastewater treatment plant discharge; street and storm water runoff; and land application of biosolids, industrial solid waste, and wastewater. PFOA also enters the environment through the breakdown of precursor compounds such as the fluorotelomer alcohol 8:2 FTOH and larger molecules that can release 8:2 FTOH. These precursor compounds are used industrially and in consumer products. They are converted to PFOA by microbes in soil, sludge, and wastewater and through atmospheric chemical reactions.

As is the case for other ground water contaminants, PFOA can reach drinking water wells via migration of a ground water plume. Unlike many other environmental contaminants, PFOA emitted to air from industrial facilities can also contaminate distant groundwater wells through air transport, followed by deposition from air onto soil, and migration through the soil to groundwater.

Occurrence in Drinking Water

PFOA and other PFCs are not effectively removed from drinking water by standard treatment processes but can be removed from drinking water by granular activated carbon (GAC) or reverse osmosis. Therefore, unless specific treatment for removal of PFCs is in place, concentrations of PFOA detected in raw drinking water can be considered to be representative of concentrations in finished drinking water.

The occurrence of PFOA and other PFCs in public water supplies (PWS) has been evaluated more extensively in New Jersey than in most or all other states. More than 1,000 samples from 80 NJ PWS were analyzed with relatively low Reporting Levels (RLs; generally \leq 5 ng/L) in 2006-2016. PFOA was the most frequently detected PFC and was found in samples from approximately 60% of the 80 NJ PWS tested. In the 2013-2015 USEPA Unregulated Contaminant Monitoring Rule 3 (UCMR3) survey of all large (>10,000 users) and a subset of smaller PWS in the U.S., PFOA was detected more than five times more frequently in New Jersey PWS (10.5%) than nationally (1.9%). The RL in UCMR3 was 20 ng/L, much higher than the RLs for most other NJ PWS monitoring. PFOA has also been detected in NJ private wells near sources of industrial discharge.

Human Biomonitoring

PFOA and other PFCs are found ubiquitously in the blood serum of the general population in the U.S. and worldwide. The most recent (2011-2012) National Health and Nutrition Examination Survey (NHANES), a representative sample survey of the U.S. general population conducted by the U.S. Centers for Disease Control and Prevention (CDC), determined the geometric mean and 95th percentile serum PFOA concentrations as 2.08 and 5.68 ng/ml, respectively. Serum PFOA levels in the U.S. general population have declined since the first NHANES monitoring in 1999-2000 when the geometric mean and 95th percentile values were 5.21 and 11.9 ng/ml. In communities exposed through contaminated drinking water, serum PFOA levels are elevated compared to the general population. Exposures to industrially-exposed workers or others with occupational exposure are much higher than in the general population. Serum PFOA concentrations of greater than 100,000 ng/ml (100 ppm) have been reported in industrially exposed workers, although levels in most workers were lower.

Sources of Exposure

Sources of exposure to PFOA and/or its precursors include drinking water, food and food packaging, treated fabrics, protective sprays and waxes, cosmetics and personal care products, house dust, and inhalation of indoor and outdoor air. Most studies predict that food and food packaging are the predominant exposure sources, and several studies suggest that PFOA and its precursors in indoor air and/or house dust can be a major exposure source. It should be noted that migration of PFOA from polytetrafluoroethylene (PTFE)-coated non-stick cookware into food is not considered to be a significant source of exposure. The contribution of ingested drinking water to total exposure from all sources (e.g. diet, consumer products, etc.) is dependent

on the concentration of PFOA in the drinking water, and relatively low concentrations in water substantially increase human body burden. Inhalation from showering, bathing, laundry, and dishwashing, and dermal absorption during showering, bathing, or swimming, are not expected to be significant sources of exposure from contaminated drinking water.

Exposures to PFOA may be higher in young children than in older individuals because of agespecific behaviors such as greater drinking water and food consumption on a body weight basis, hand-to-mouth behavior resulting in greater ingestion of house dust, and more time spent on floors where treated carpets are found.

Toxicokinetics

PFOA is well absorbed orally, and it was also absorbed dermally and by inhalation in toxicological studies. It is water soluble and distributes primarily to the liver and serum, and, to a lesser degree, to the kidney. Unlike most other bioaccumulative organic compounds, it does not distribute to fat. In the serum, PFOA is almost totally bound to albumin and other proteins. Since it is chemically non-reactive, it is not metabolized. The rate of excretion is largely dependent on the extent of secretion and reabsorption by organic anion transporters in the kidney. The excretion rate varies widely among species, and in some cases between males and females of the same species.

PFOA's half-life in humans is several years and is similar in males and females. Because of its long half-life, it remains in the human body for many years after exposures cease. PFOA is persistent in both male and female mice and in male rats, with half-lives of days to weeks. However, PFOA is rapidly excreted in female rats (half-life of 2-4 hours); thus, this species is not an ideal model for studying potential human developmental effects. Because of the large variation in half-lives, the internal dose resulting from a given administered dose varies widely among species and, in some cases, genders of the same species. For this reason, interspecies (e.g. animal-to-human) comparisons are made on the basis of internal dose, as indicated by serum level, rather than administered dose.

Relationship between drinking water exposure and human serum levels

Data from communities with contaminated drinking water indicate that ongoing human exposure to PFOA in drinking water increases serum levels, on average, by at least 100 times the drinking water concentration. A human clearance factor for PFOA of 1.4×10^{-4} L/kg/day was developed by USEPA researchers (Lorber and Egeghy, 2011) to relate serum PFOA concentration to administered dose. Assuming an average U.S. daily water consumption rate, the clearance factor predicts a serum:drinking water ratio of 114:1, consistent with the ratios that have been observed in exposed communities.

Continued exposure to even low drinking water concentrations results in substantially increased serum PFOA levels. Based on the clearance factor, each 10 ng/L in drinking water is predicted

to increase serum PFOA by 1.1 ng/ml with an average water consumption rate, and 2.0 ng/ml with an upper percentile water consumption rate. These increases in serum PFOA from drinking water can be compared to the most recent NHANES geometric mean, 2.08 ng/ml, and 95th percentile, 5.68 ng/ml, serum PFOA concentrations. Increases in serum PFOA levels predicted from average and upper percentile drinking water consumption at various drinking water PFOA concentrations are shown in Figure E-1.




Figure E-1. Increases in serum PFOA concentrations predicted from mean and upper percentile consumption of drinking water with various concentrations of PFOA, as compared to U.S median and 95th percentile serum PFOA levels (NHANES, 2011-12).

Exposures to infants

In humans, PFOA has been measured in amniotic fluid, maternal serum, umbilical cord blood, and breast milk. Serum PFOA concentrations in infants at birth are similar to those in maternal serum. Both breast-fed infants whose mothers ingest contaminated drinking water and infants fed with formula prepared with contaminated drinking water receive much greater exposures to PFOA than older individuals who consume drinking water with the same PFOA concentration. PFOA exposure in breast-fed infants is greatest during the first few months of life because both PFOA concentrations in breast milk and the rate of fluid consumption are highest then. As a result, serum PFOA concentrations in breast-fed infants increase several fold from levels at birth within the first few months of life (Figure E-2). Exposures to infants who consume formula prepared with contaminated water are also highest during this time period. While serum PFOA levels peak during the first year of life, they remain elevated for several years. These elevated

exposures during infancy and early childhood are of particular concern because early life effects are sensitive endpoints for the toxicity of PFOA.




Figure E-2. From Verner et al. (2016a). Modeling simulation of the ratio of PFOA in blood plasma in breast fed infants/children to plasma concentration in mother.

Black line - 50th percentile. Blue line - 5th percentile. Red line - 95th percentile. Dotted lines - minimum and maximum values.

Health Effects

Because the scientific database related to health effects of PFOA is very large, the Subcommittee focused its evaluation on specific endpoints from human and animal studies. Relevant studies were identified through literature searches of the PubMed database, from earlier evaluations of PFOA by the Health Effects Subcommittee, and through backwards searching.

Epidemiology

The choice of endpoints selected for comprehensive review from epidemiology studies was largely based on knowledge gained from previous evaluations by the Subcommittee. Health endpoints evaluated comprehensively were serum cholesterol/lipids, liver enzymes/bilirubin and liver disease, uric acid, thyroid function and thyroid disease, and antibody concentrations following vaccination. In total, 54 epidemiological studies were evaluated in depth, including studies from the general population, communities with drinking water exposures including most notably the C8 Health Study - a large study of about 70,000 Ohio and West Virginia residents exposed to a wide range of PFOA concentrations (>50 ng/L to over 3000 ng/L) in drinking water, and occupationally exposed workers. Recent comprehensive reviews by other authoritative scientific groups were evaluated for two additional critical endpoints, fetal growth following developmental exposure and cancer.

Of the endpoints that were evaluated comprehensively, the evidence for associations with PFOA was strongest for increases in serum levels of cholesterol, the liver enzyme ALT, and uric acid.

PFOA was associated with clinically defined hypercholesterolemia in a community exposed through drinking water. The epidemiological evidence supports multiple criteria for a causal relationship between PFOA and both serum cholesterol and ALT. Notably, the steepest dose-response for associations with these endpoints was within the range of serum PFOA concentrations found in the general population and communities with drinking water exposures, with a much flatter curve at higher serum concentrations.

For some other endpoints that were comprehensively reviewed, limited evidence of an association with PFOA was found. Although there is consistent evidence of decreased antibody concentrations following vaccination, most of the vaccine types were evaluated in only one or two studies. Other endpoints with limited evidence of an association include LDL, the liver enzymes GGT and AST, bilirubin, liver disease, and thyroid disease. There was limited or no evidence of association of PFOA with TSH and thyroid hormones, and no evidence for association with HDL or the liver enzyme ALP.

A systematic review using the Navigation Guide methodology concluded that there is "sufficient" human evidence, the strongest descriptor for strength of evidence, that developmental exposure to PFOA reduces fetal growth (e.g. birth weight) in humans (Johnson et al., 2015). The Health Effects Subcommittee found that the basis for this conclusion is reasonable and supportable. Maternal glomerular filtration rate (GFR) was evaluated as a potential confounding factor for this effect, and it was concluded that decreased GFR does not account for the major portion of the decrease in fetal growth associated with PFOA.

PFOA was associated with increased incidence of testicular and kidney cancer in communities with drinking water exposure. These studies accounted for smoking history and other relevant factors. The USEPA SAB (2006) described PFOA as "likely to be carcinogenic to humans." based on the criteria provided in USEPA (2005b) cancer risk assessment guidance. More recently, IARC (2015) concluded that PFOA is possibly carcinogenic to humans, and the USEPA Office of Water (2016a) described it as having suggestive evidence of carcinogenic potential.

Although the magnitude of change for some of the parameters associated with PFOA was relatively small, they are of public health concern because population-level changes of this magnitude will result in a shift in the overall distribution of values such that the number of individuals with clinically abnormal values is increased. Additionally, small changes in a clinical biomarker may be an indicator of other effects that were not evaluated. For example, relatively small decreases in birth weight may be an indication of changes in other more subtle developmental parameters which were not assessed.

In summary, associations of PFOA with numerous health endpoints have been found in human populations with evidence supporting criteria for causality for some endpoints. These health endpoints include non-carcinogenic effects in the general population, and both non-carcinogenic

effects and cancer in communities with drinking water exposure. The epidemiologic data for PFOA are notable because of the consistency between results among human epidemiologic studies in different populations, the concordance with toxicological findings from experimental animals, the use of serum concentrations as a measure of internal exposure, the potential clinical importance of the endpoints for which associations are observed, and the observation of associations within the exposure range of the general population. These features of the epidemiologic data distinguish PFOA from most other organic drinking water contaminants and justify concerns about exposures to PFOA through drinking water. Although there is evidence to support causality for some epidemiological endpoints, the human data have limitations and therefore are not used as the quantitative basis for the Health-based MCL. Instead, the potential Health-based MCLs developed below are based on sensitive and well established animal toxicology endpoints that are considered relevant to humans based on mode of action data.

Toxicology

The toxicological database for PFOA includes evaluation of numerous effects in non-human primates and rodents. The Health Effects Subcommittee's review focused on endpoints that were identified as sensitive and potentially appropriate for use in risk assessment. The effects selected for detailed review were hepatic toxicity, developmental effects, immune system toxicity, and carcinogenicity. As discussed above, effects relevant to these endpoints have been associated with PFOA in human epidemiological studies. Additionally, information is presented on general toxicity in non-human primates, as well as thyroid, neurobehavioral, and male reproductive effects.

The non-human primate studies have limitations that preclude their consideration as the basis for risk assessment. These include very small numbers of animals, severe toxicity at the lowest dose, loss of animals during the study due to toxicity and/or mortality, and lack of dose-response for key endpoints (e.g. increased liver weight).

Increased liver weight is a sensitive toxicological endpoint for PFOA which has been observed in many studies in both non-human primates and rodents. Increased liver weight can co-occur with and/or progress to more severe hepatic effects including hepatocellular necrosis, fatty liver, increased serum liver enzymes, and hyperplastic nodules. Recent studies show that developmental exposure to low doses of PFOA in mice causes cellular changes indicative of liver toxicity that persist until adulthood.

Reproductive or developmental effects of PFOA have not been studied in non-human primates. The mouse is an appropriate species for evaluating effects on reproduction and development since the female mouse excretes PFOA slowly, as do humans. In contrast, rats and rabbits are not ideal models for studying these effects because they excrete PFOA very quickly, with a halflife of a few hours. Effects from developmental exposures in mice include full litter resorptions, decreased postnatal survival and growth, delayed development, accelerated sexual maturation in males, persistent liver toxicity (noted above), and delayed mammary gland development. PFOA also causes reproductive toxicity in male mice.

Delayed mammary gland development and persistent liver toxicity after perinatal (prenatal and/or neonatal) exposure are sensitive endpoints which occur in mice at lower doses of PFOA than other developmental effects. Delayed mammary gland development has been reported in nine separate studies presented in five publications, while only one study which has several general problematic issues did not find this effect. Gestational and/or lactational exposures to PFOA caused delayed mammary gland development in pregnant dams and/or female offspring in two strains of mice. Histological changes in the mammary gland of exposed offspring occurred in a dose-related fashion, persisted until adulthood, and were considered permanent. However, available toxicological information is not sufficient to make conclusions about the effects of PFOA on lactational function. Maternal PFOA exposure was associated with shorter breastfeeding in the three human studies that evaluated this effect, and there is no information indicating that the histological changes observed in mice are not relevant to humans.

Additional studies evaluated effects of peripubertal (around the time of puberty) exposure on mammary gland development in mice. These studies cannot be directly compared to studies of perinatal exposure because effects on mammary gland development differ depending on the lifestage when exposure occurs. Additionally, interpretation of the peripubertal studies is problematic because each PFOA dose level was used in only one study in each of the strains of mice evaluated, such that dose-response interpretations can only be made by combining data from different studies.

PFOA suppressed the immune system in studies of rhesus monkeys and mice. Decreased bone marrow cellularity and lymphoid atrophy occurred in monkeys, while effects in mice included decreased spleen and thymus weights, decreased thymocyte and splenocyte counts, decreased immunoglobulin response, and changes in total numbers and/or specific populations of lymphocytes. Immune system effects were not observed in two rat studies which included doses higher than those which generally caused these effects in mice.

Review of the toxicological data indicates that increased liver weight is an endpoint that is as sensitive or more sensitive than immune system toxicity or reproductive/developmental effects, with the exception of delayed mammary gland development.

PFOA caused tumors of the liver, pancreatic acinar cells, and testicular Leydig cells in male rats. Since PFOA is rapidly excreted by female rats, chronic studies in another species in which PFOA is persistent in both sexes, such as the mouse, would provide important information specific to females. A recent study suggests that prenatal exposure to PFOA in mice caused an increased incidence of liver tumors. However, this study was not designed as a carcinogenicity bioassay and does not provide definitive information on this issue. Additional research on carcinogenicity later in life after developmental exposures to PFOA is needed.

Mode of Action

The mode(s) of action of PFOA have not been fully characterized. Based on the information reviewed by the Health Effects Subcommittee, the toxicological effects of PFOA are generally considered relevant to humans for the purposes of risk assessment.

PFOA is not chemically reactive. Thus, it is not metabolized to reactive intermediates and does not covalently bind to nucleic acids and proteins. Consistent with these properties, available data indicate that it is not genotoxic.

Activation of nuclear receptors and role of PPAR-alpha

Effects of PFOA occur through multiple modes of action including activation of receptors that control the expression of genes involved in many biological pathways. Much attention has been focused on the potential human relevance of effects that occur through activation of the nuclear receptor, peroxisome proliferator-activated receptor-alpha (PPAR-alpha). This question arises because many PPAR-alpha activating compounds cause rodent liver tumors; the human relevance of these tumors is subject to debate due to lower levels and/or differences in intrinsic activity of PPAR-alpha in human liver. However, the uncertainty about human relevance does not necessarily apply to PPAR-alpha mediated effects other than liver tumors. Both human and mouse PPAR-alpha are activated by PFOA *in vitro*, and the results do not clearly indicate that human PPAR-alpha is less sensitive than rodent PPAR-alpha in these *in vitro* systems.

Hepatic effects

Studies of non-human primates, standard strains of rats and mice, PPAR-alpha null mice, and humanized PPAR-alpha mice support the conclusion that hepatic effects of PFOA are relevant to humans for the purposes of risk assessment. As noted above, PFOA is associated with increased liver enzymes in human epidemiological studies.

In a subchronic study of cynomolgus monkeys, a species in which human relevance of hepatic effects is not in question, PFOA caused increased liver weight and peroxisomal proliferating activity similar in magnitude to that seen in rats, demonstrating that hepatic PPAR-alpha activity in response to PFOA is not limited to rodents. In this study, several animals exhibited notably increased liver weight, highly elevated serum liver enzymes, and/or severe hepatic toxicity.

Observations in standard strains of laboratory rodents indicate that PFOA causes PPAR-alpha independent hepatic effects in rodents with normal PPAR-alpha function. In these strains,

increased relative liver weight caused by PFOA did not directly correspond with hepatic peroxisome proliferating activity. Additionally, PFOA caused fatty liver in these standard strains, although PPAR-alpha activation decreases hepatic lipids. Finally, developmental exposure to PFOA caused abnormal mitochondria in livers of a standard mouse strain, with no evidence of peroxisome proliferation.

PFOA caused decreased serum lipids, typically associated with PPAR-alpha activation, in rodents, while increased serum lipids are associated with PFOA exposure in humans. Recent studies suggest that these differences may be related to the low fat diet generally used in laboratory rodent studies versus the higher fat content of a typical Westernized human diet, rather than solely to interspecies differences.

Studies comparing wild type (with normal PPAR-alpha) and PPAR-alpha null (lacking PPARalpha) mice provide further evidence that hepatic effects occur through both PPAR-alpha dependent and independent pathways. PFOA caused similar increases in liver weight in wild type and PPAR-alpha null strains. Increased liver enzymes and histopathological changes, particularly damage to the bile duct, also occurred in PFOA-treated PPAR-alpha null mice. Additionally, developmental exposures to PPAR-alpha null mice caused persistent histopathological changes in the liver.

Studies of strains of mice which express human PPAR-alpha in the liver (humanized PPARalpha mice) indicate that PFOA causes hepatic effects through activation of human PPAR-alpha. In humanized PPAR-alpha mice, PFOA caused increased liver weight similar to that in wild type mice, activation of hepatic genes associated with PPAR-alpha, and histopathological changes in the liver. Fetal liver weight was increased similarly in wild type and humanized PPAR-alpha mice after *in utero* exposure, and expression of genes associated with PPAR-alpha in fetal liver was increased to a greater degree in humanized PPAR-alpha mice than in wild type mice.

Immune system effects

PFOA suppresses the immune system in both non-human primates and mice. As noted above, decreased response to vaccinations has been associated with PFOA in human epidemiological studies. Data from mouse studies indicate that these effects on the immune system occur through both PPAR-alpha dependent and independent modes of action. Both PPAR-alpha dependent and independent effects on the immune system are considered relevant to humans for the purposes of risk assessment.

Developmental and reproductive effects

As noted above, decreased fetal growth is associated with PFOA in human epidemiological studies. Developmental effects of PFOA in rodents appear to occur primarily through PPAR-alpha dependent mechanisms, while some reproductive effects such as full litter resorptions

appear to be PPAR-alpha independent. PPAR-alpha and other PPARs are present in human fetal tissues and are expected to have important roles in reproduction and development. Therefore, PPAR-alpha mediated effects of PFOA on development are considered relevant to humans for the purposes of risk assessment. Toxicity to the placenta may play a role in PFOA's developmental effects such as fetal growth retardation; more research is needed on this question.

Delayed mammary gland development after developmental exposure is a sensitive endpoint for PFOA toxicity in mice. The rodent is considered a good model for human mammary gland development, and there is no mode of action evidence suggesting that the effects of PFOA on this endpoint are not relevant to humans.

PFOA also causes male reproductive toxicity in mice, and there is no mode of action information to suggest that these effects are not relevant to humans.

Carcinogenicity

As noted above, PFOA has been associated with increased incidence of kidney and testicular cancer in communities exposed through drinking water after adjustment for smoking and other relevant factors. The USEPA Science Advisory Board (2006) concluded that the liver tumors caused by PFOA in rats are potentially relevant to humans, based on similarities in hepatic effects of PFOA in monkeys and rodents and the limited evidence available at the time on hepatic effects of PFOA in PPAR-alpha null mice. Subsequent studies in PPAR-alpha null mice have provided substantial additional relevant data. Importantly, hepatic cell proliferation, a causal event for tumor formation, is increased similarly by PFOA in wild type and PPAR-alpha null mice. Although a carcinogenicity bioassay of PFOA has not been conducted in PPAR-alpha null mice, a recent study suggests that developmental exposures to PFOA may cause hepatic tumors in adulthood in this strain. Finally, studies in rainbow trout, a species used as a model for human liver cancer because it lacks PPAR-alpha, suggest that PFOA causes liver tumors through an estrogenic mode of action.

The mode of action for the testicular and pancreatic tumors caused by PFOA in rats has not been established. Therefore, they are considered relevant to humans for the purposes of risk assessment.

Additional modes of action

A number of other modes of action for PFOA have been suggested including effects on intercellular gap junction communication, effects on mitochondria, changes in expression of microRNAs (miRNAs), and effects related to transporter proteins such as organic anion transporters (OATs) and multidrug resistance-associated proteins (MRPs).

Development of Recommended Health-based MCL

Health-based MCLs developed by the DWQI are intended to be protective for chronic (lifetime) exposure through drinking water. The 1984 Amendments to the New Jersey Safe Drinking Water Act (N.J.S.A. 58:12A-20) stipulate that Health-based MCLs be based on a one in one million lifetime cancer risk level for carcinogens and no adverse effects from lifetime ingestion for non-carcinogens. PFOA was described as "likely to be carcinogenic to humans" by the USEPA Science Advisory Board and "possibly carcinogenic to humans" by the International Agency for Research on Cancer (IARC), and as having "suggestive evidence of carcinogenic potential" by the USEPA Office of Water. As such, the Health Effects Subcommittee evaluated both non-carcinogenic and carcinogenic effects using approaches consistent with USEPA risk assessments guidance and previous risk assessments developed by NJDEP and the DWQI.

Both the human epidemiology data and the animal toxicology data were considered as part of the overall weight of evidence for the potential human health effects of PFOA. As discussed above, PFOA is associated with non-carcinogenic effects in the general population, and with both non-carcinogenic effects and cancer in communities with drinking water exposure. Although the data for some endpoints support multiple criteria for causality, the human epidemiology data have limitations and are therefore not used as the quantitative basis for the Health-based MCL. As such, the recommended Health-based MCL is based on sensitive and well established animal toxicology endpoints that are considered relevant to humans. Notwithstanding, the human data suggest that continued human exposure to even relatively low concentrations of PFOA in drinking water results in elevated body burdens that increase the risk of health effects, indicating a need for caution about exposures from drinking water. Therefore, the human epidemiological data support the use of a public health-protective approach in developing a Health-based MCL recommendation based on animal toxicology data.

Health-based MCL based on non-carcinogenic effects

Delayed mammary gland development and increased relative liver weight were identified as the most sensitive non-carcinogenic endpoints with data appropriate for dose-response modeling, and it was concluded that these endpoints are relevant to humans for the purposes of risk assessment. Benchmark dose (BMD) modeling of serum PFOA data from toxicological studies was performed to determine the BMDLs (lower 95% confidence limit on the doses corresponding to a minimal response) for the serum concentrations that are used as the points of departure (PODs) for these endpoints. Only studies that provide serum PFOA data were considered for dose-response modeling for these effects, since measured serum levels are associated with less uncertainty than serum level estimates from pharmacokinetic modeling or interspecies extrapolations based on half-life differences.

Effects on mammary gland development

Delayed mammary gland development is the most sensitive systemic endpoint with data appropriate for dose-response modeling, and a Reference Dose (RfD) was developed for this endpoint. To the knowledge of the Health Effects Subcommittee, this endpoint has not previously been used as the primary basis for health-based drinking water concentrations or other human health criteria. Because the use of delayed mammary gland development as the basis for quantitative risk assessment is a currently developing topic, a Health-based MCL with this RfD as its primary basis was not recommended. However, it was concluded that an additional uncertainty factor (UF) should be incorporated into the RfD based on increased liver weight (the endpoint used as the basis for the recommended Health-based MCL - see below) to protect for mammary gland effects, persistent liver toxicity, and other effects from developmental exposures at doses far below those that cause increased relative liver weight.

A study of exposure to pregnant mice on days 10-17 of gestation (Macon et al., 2011) is the only developmental exposure study of mammary gland development that provides serum PFOA data appropriate for dose-response modeling. Of the multiple time points assessed in this study, delays in mammary gland development were most evident on postnatal day (PND 21). Of the several endpoints related to mammary gland development that were evaluated, decreases in mammary gland developmental score and number of terminal end buds were selected for dose-response modeling because they showed a statistically significant dose-related decrease at PND 21. BMD modeling was based on serum levels at PND 1, since they were higher at this time than at later time points. The serum concentration BMDLs for a 10% change in decreased developmental score and decreased number of terminal end buds were 24.9 and 22.9 ng/ml, respectively.

A total UF of 30, including UFs of 10 for intra-human variability and 3 for animal-to-human toxicodynamic differences, was applied to the serum level BMDL for decreased number of terminal end buds, 22.9 ng/ml, to derive a Target Human Serum Level of 0.8 ng/ml. The typical UF of 3 for toxicokinetic variability between species is not included because the risk assessment is based on comparison of internal dose (serum levels) rather than administered dose. The Target Human Serum Level is analogous to a RfD in terms of internal, rather than administered, dose. This Target Human Serum Level for delayed mammary gland development of 0.8 ng/ml is below the median serum PFOA level in the U.S. general population (2.1 ng/ml). The clearance factor mentioned above, $1.4 \times 10^{-4} L/kg/day$, was applied to the Target Human Serum Level, 0.8 ng/ml, to calculate an RfD of 0.11 ng/kg/day.

Hepatic effects

Increased relative liver weight is a well-established effect of PFOA which is more sensitive than most other toxicological effects such as immune system toxicity and most

reproductive/developmental effects (Table 12 of Animal Toxicology section). The recommended Health-based MCL for non-carcinogenic effects is based on this endpoint.

A study of male mice exposed to branched/linear PFOA for 14 days (Loveless et al., 2006) that showed a dose-related increase in relative liver weight was selected for dose-response modeling. This isomeric mixture is relevant to environmental contamination and human exposure, and it was used in almost all toxicological studies of PFOA. Because review of studies of increased relative liver weight indicated that the magnitude of this effect does not increase with exposure durations longer than 14 days, this study was considered to be of sufficient duration for use as the basis for a Health-based MCL. BMD modeling of the serum PFOA data from the study determined a serum level BMDL for a 10% increase in relative liver weight of 4350 ng/ml.

A total UF of 300 was applied to the serum level BMDL of 4350 ng/ml to derive a Target Human Serum Level of 14.5 ng/ml. This UF includes UFs of 10 for intra-human variability, 3 for animal-to-human toxicodynamic differences, and 10 to protect more sensitive toxicological effects. These more sensitive effects, including delayed mammary gland development and hepatic toxicity after developmental exposures, occurred at doses 100-fold lower than the Lowest Observed Adverse Effect Level (LOAEL) for increased liver weight. Although the study duration was only 14 days and the Health-based MCL is intended to protect for chronic exposure, a UF for less-than-chronic duration of exposure was not applied because increased liver weight does not appear to increase in magnitude when exposures continue beyond two weeks. The clearance factor mentioned above, $1.4 \times 10^{-4} L/kg/day$, was applied to the Target Human Serum Level, 14.5 ng/ml, to calculate an RfD of 2 ng/kg/day.

Relative Source Contribution factor

A Relative Source Contribution (RSC) factor that accounts for non-drinking water sources including food, soil, air, water, and consumer products is used by USEPA, NJDEP, and the DWQI in the development of health-based drinking water concentrations based on non-carcinogenic effects. The default value for the RSC is 20%, meaning that 20% of total exposure is assumed to come from drinking water and 80% from non-drinking water sources. If supported by available data, a higher chemical-specific value (up to 80%) can be used (i.e. the percent exposure from non-drinking water sources is lower than the default assumption of 80%). The Health Effects Subcommittee concluded that there are insufficient data to develop a chemical-specific RSC for PFOA. USEPA UCMR3 monitoring shows that PFOA occurs (at concentrations greater than 20 ng/L) more frequently in PWS located throughout New Jersey (10.5%) than nationwide (1.9%).

There are no New Jersey-specific biomonitoring data for PFOA, and the more frequent occurrence in NJ PWS suggests that New Jersey residents may also have higher exposures from non-drinking sources, such as contaminated soils, house dust, or other environmental media,

than the U.S. general population. Additionally, the default RSC of 20%, while not explicitly intended for this purpose, also partially accounts for the greater exposures to infants who are breast-fed or consume formula prepared with contaminated drinking water, as compared to older individuals. These higher exposures during infancy must be considered because short term exposures to infants are relevant to the effects of concern (delayed mammary gland development and increased relative liver weight). Therefore, the default RSC of 20% was used to develop the Health-based MCL.

Health-based MCL based on non-carcinognic effects

The Health-based MCL protective for increased liver weight, based on the RfD of 2 ng/kg/day, standard drinking water exposure assumptions (2 L/day water consumption; 70 kg body weight), and a 20% RSC is 14 ng/L (0.014 μ g/L).

Health-based MCL based on carcinogenic effects

Testicular tumor data from the chronic dietary exposure rat study (Butenhoff et al., 2012) are the only tumor data appropriate for dose-response modeling and were used to develop a cancer potency factor. The BMDL for 5% tumor incidence is 2.36 mg/kg/day, and the corresponding cancer potency factor is 0.021 (mg/kg/day)⁻¹. The dose in rats corresponding to a 1 x 10⁻⁶ risk level, 4.8 x 10⁻⁵ mg/kg/day, was converted to the human equivalent dose of 4 x 10⁻⁷ mg/kg/day (0.4 ng/kg/day) using a pharmacokinetic adjustment based on the ratio of half-lives in the two species. Using default drinking water assumptions (2 L/day water consumption; 70 kg body weight), the Health-based MCL at the 1 x 10⁻⁶ lifetime cancer risk level is 14 ng/L. This value is identical to the Health-based MCL based on non-cancer endpoints developed above.

Potential for additive toxicity with other PFCs

The Health Effects Subcommittee notes that available information indicates that the target organs and modes of action are generally similar for PFOA and some other PFCs, such as PFNA. Therefore, the toxicity of PFOA and other PFCs may be additive. Although PFOA and other PFCs, including PFNA, are known to co-occur in some NJ public water supplies, the potential for additive toxicity of PFOA and other PFCs was not considered in development of the Health-based MCL.

The recommended Health-based MCL is 14 ng/L (0.014 µg/L).

INTRODUCTION

Development of Health-based MCLs by New Jersey Drinking Water Quality Institute

The New Jersey Drinking Water Quality Institute (DWQI) was established by the 1984 amendments to the New Jersey Safe Drinking Water Act (SDWA) at N.J.S.A. 58:12A- 20. It is charged with developing standards (Maximum Contaminant Levels; MCLs) for hazardous contaminants in drinking water and for recommending those standards to the New Jersey Department of Environmental Protection (NJDEP). The Health Effects Subcommittee (formerly "Lists and Levels Subcommittee") of the DWQI is responsible for developing health-based drinking water levels (Health-based MCLs) as part of the development of MCL recommendations (for example: DWQI, 1987; 1994; 2009a).

Health-based MCLs are based on the goals specified in the 1984 Amendments to the NJ SDWA. For carcinogens, it is generally assumed that any level of exposure results in some level of cancer risk, and a one in one million (10⁻⁶) risk level from lifetime exposure is specified in the statute. Health-based MCLs for carcinogens are thus set at levels that are not expected to result in cancer in more than one in one million persons ingesting the contaminant for a lifetime. For non-carcinogenic effects, it is generally assumed that exposure below a threshold level will not result in adverse effects. As specified in the statue, Health-based MCLs are set at levels which are not expected to result in "any adverse physiological effects from ingestion" for a lifetime. The risk assessment approach used to develop Health-based MCLs is generally consistent with USEPA risk assessment guidance.

Other factors such as analytical quantitation limits and availability of treatment removal technology are also considered in the final MCL recommendation. For carcinogens, the 1984 Amendments to the NJ SDWA require that MCLs are set as close to the one in one million lifetime risk goal as possible "within the limits of medical, scientific and technological feasibility." For non-carcinogens, MCLs are set as close to the goal of no adverse effects as possible "within the limits of practicability and feasibility."

To support the development of an MCL recommendation by the DWQI, the Health Effects Subcommittee has developed a draft Health-based Maximum Contaminant Level for PFOA. As specified in the 1984 Amendments to the NJ SDWA, this Health-based MCL is intended to be protective for chronic (lifetime) drinking water exposure.

Timeline of Health Effects Subcommittee's evaluation of PFOA

On January 27, 2009, the DWQI voted unanimously to add PFOA to its work plan for development of an MCL recommendation (DWQI, 2009b). On September 10, 2010, the Health Effects Subcommittee reported to the DWQI Testing and Treatment Subcommittees that it had made progress in its evaluation PFOA. Although no decision on a Health-based MCL recommendation had been made, the Subcommittee provided a memo stating that it was

considering potential values for a PFOA Health-based MCLs within the range of 10 ng/L to 40 ng/L, or as low as reasonably achievable (DWQI, 2010).

In 2012, several current and former members of the Health Effects Subcommittee published a comprehensive review of PFOA as an emerging drinking water contaminant in a peer-reviewed journal (Post et al., 2012). This publication was based in part on the literature review and evaluation conducted by the Health Effects Subcommittee in 2009-2010.

On March 21, 2014, New Jersey DEP Commissioner Bob Martin requested that the DWQI recommend MCLs for three perfluorinated compounds: perfluorononanoic acid (PFNA, C9), PFOA, and perfluorooctane sulfonic acid (PFOS). The Health Effects Subcommittee commenced its evaluation of PFOA after completing its work on PFNA, for which the DWQI recommended an MCL on July 1, 2015 (DWQI, 2015a).

Document development process

The Subcommittee began its current evaluation of PFOA by formulating an approach for the review of relevant information and document development. Because the scientific database related to health effects of PFOA is very large, the Subcommittee chose to focus on specific endpoints from human and animal studies for hazard identification and/or dose-response. Criteria for selection of the human and animal endpoints that were reviewed in depth are discussed in the Epidemiology and Toxicology sections.

The Health Effects Subcommittee conducted a literature search of the PubMed database through April 2015 using relevant search terms which are provided in Appendix 1. The U.S. National Library of Medicine's Toxline database was searched using similar keywords as the PubMed search strings. The Toxline search yielded a significant number of non-peer reviewed documents including articles, policy papers, and grant proposals, and ultimately Toxline did not identify additional peer-reviewed literature for inclusion in the Subcommittee's review. Studies evaluated by the Subcommittee also included relevant citations from the earlier Subcommittee evaluations of PFOA mentioned above, as well as backward searching. PubMed is searched on a monthly basis by the NJDEP Environmental Research Library, and an ongoing title review of these searches was conducted to identify any additional studies for inclusion.

The original PubMed search identified 2,016 references. All of these references were screened by title, abstract, and/or full text. Title and abstract review was used to sort studies into inclusion categories for consideration for detailed evaluation related to hazard identification and/or dose-response evaluation using EndNote (Appendix 1). Studies were excluded if they were "Unrelated" (did not assess PFOA, proposals, or reviews), or "Non-health"" (studies of a analytical methods, environmental occurrence, sources of human or wildlife exposure, and other topics not directly related to health effects). Some studies categorized as "Non-health" are cited

in relevant sections of the document, when appropriate. Remaining studies were identified as either "*in vitro*", "Experimental Animal", or "Human". Further categorization of included studies is described in more detail in the <u>Epidemiology</u> and <u>Toxicology</u> sections. The number of records retrieved and number of studies sorted into inclusion/exclusion categories are also provided in Appendix 1. Following identification of studies to be reviewed in depth, data were extracted from included studies into individual study tables and/or summary tables, as described in the <u>Epidemiology</u> and <u>Toxicology</u> sections. Individual study tables for the <u>Epidemiology</u> section are provided in Appendix 4 and for the <u>Toxicology</u> section in Appendix 5.

Some sections of the document that provide background information but do not directly impact development of the Health-based MCL (e.g. <u>Environmental Sources, Fate, and Occurrence</u>) are based on updates of the Subcommittee's previous evaluations of PFOA.

In 2014, the DWQI posted a request for public input regarding data or technical information about the toxicology, epidemiology, toxicokinetics, or other health effects topics related to PFOA that should be considered in developing an MCL. The DWQI received one submission on PFOA, and relevant comments from this submission were considered by the Health Effects Subcommittee.

A draft of the Health-based MCL Support Document was completed on June 27, 2016. Public comments on the draft document were accepted from September 22 to November 21, 2016. Minor revisions were made to the draft document based on consideration of the comments, to add relevant recent information, and to update a few citations. The conclusions presented herein in the final document do not differ from those presented in the draft document.


BACKGROUND INFORMATION

PFOA is a member of a class of anthropogenic chemicals called perfluorinated chemicals (PFCs) with structures consisting of a totally fluorinated carbon chain of varying length and a charged functional group, such as carboxylate or sulfonate (Lindstrom et al., 2011a). PFCs are members of a larger class of compounds, poly- and perfluoroalkyl substances (PFAS) which also includes fluorinated compounds with structures that differ from PFCs (Buck et al., 2011). The eight-carbon PFCs, PFOA and PFOS, were the most intensively investigated compounds in earlier studies, while current research focuses on a wider range of PFAS.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 123 of 551

Physical and Chemical Properties (PubChem, 2016)

Chemical Name:	Perfluorooctanoic acid
Synonyms:	PFOA, C8
CAS #:	335-67-1
Chemical Formula	$C_8HF_{15}O_2$
Chemical Structur	e: $CF_3(CF_2)_6COOH$



Molecular Weight:	414.07
Physical State:	Solid
Melting Point:	54.3 °C
Boiling Point:	189 – 192.4 °C
Vapor Pressure:	0.017 mm Hg at 20 °C
Density:	1.8 g/cm ³ at 20 °C
Water Solubility:	9.5 g/L at 25 °C
Log octanol/water	
partition coefficient:	Not applicable (see below).
Taste Threshold (water):	No data
Odor Threshold (water):	No data
Odor Threshold (air):	No data

PFOA is a fully fluorinated carboxylic acid. Because carbon-fluorine bonds are among the strongest found in organic chemistry due to fluorine's electronegativity, PFOA and other PFCs are extremely stable and resistant to chemical reactions. PFOA is resistant to biodegradation, direct photolysis, atmospheric photooxidation, and hydrolysis, and is not known to degrade in the environment (Vaalgamaa et al., 2011).

PFOA contains a long perfluorocarbon tail that is both hydrophobic and oleophobic (repels both water and oil) and a charged end (the carboxylate group) that is hydrophilic. Because it forms a separate layer when mixed with hydrocarbons and water, measurement of the octanol:water partition coefficient is not practical (Prevedouros et al., 2006).

PFOA has been manufactured as salts such as ammonium perfluorooctanoate (APFO) or sodium perfluorooctanoate (NaPFOA) which dissociate in water. The PK_a of PFOA is 2.8. At the pH range found in drinking water (6.5-8.5) and within the body, PFOA is present almost totally in the non-volatile anionic form, the perfluorooctanoate anion (Goss, 2008; Rayne and Forest, 2010).

Production and Use

PFOA and other PFCs have been produced for use in commercial products and in industrial processes for over 60 years. Because of their unique surfactant properties and their resistance to chemical and thermal degradation, they have been used in many applications including water-, soil-, and stain-resistant coating for fabrics used in clothing, upholstery, and carpets, oil-resistant coatings for food contact paper, aviation hydraulic fluids, fire-fighting foams, paints, adhesives, waxes, and polishes, and other products. They are used industrially as surfactants, emulsifiers, wetting agents, additives, and coatings. PFOA is used as a processing aid (emulsifier) in the production of fluoropolymers such as polytetrafluoroethylene (PTFE) and fluoroelastomers used as non-stick coatings on cookware, membranes for waterproof/breathable clothing, electrical wire casing, fire and chemical resistant tubing, and plumbing thread seal tape (Lau et al., 2007; Buck et al., 2011; Lindstrom et al., 2011a; Post et al., 2012).

PFOA has been produced by two different manufacturing methods, electrochemical fluorination (ECF) and telomerization. The ECF process was primarily used from 1947 to 2002. In this process, 1-heptanecarbonyl fluoride is dissolved in anhydrous hydrogen fluoride, and an electrical current is passed through the solution causing all hydrogen atoms on the carbon backbone to be replaced with fluorine atoms. This process produces a mixture of isomeric forms including branched, linear, and cyclic isomers of various chain lengths (Prevedouros et al., 2006; Buck et al, 2011; Lindstrom et al., 2011a).

The second process, telomerization, has been primarily used since 2002. This process involves reacting pentafluoroiodoethane with tetrafluoroethane in the molar ratio that gives the desired chain length. The product of this reaction is then oxidized to form the carboxylic acid. This process produces straight chain (linear) PFOA (Prevedouros et al., 2006; Buck et al, 2011; Lindstrom et al., 2011a).

Historically, PFOA and PFOS were the two PFCs produced in the greatest amounts. PFOS was principally manufactured by the 3M Company, which completed its phase-out of production of this chemical in 2002. In 2006, the eight major U.S. producers of PFOA voluntarily agreed to reduce emissions and product content of PFOA and related substances, including precursors of PFOA, on a global basis by 95% by 2010 and to work towards elimination of these substances by 2015 (USEPA, 2016b). According to USEPA, reports submitted by the participating companies in 2013 and 2014 indicated that they were on track to achieve the goal of phasing out these chemicals by the end of 2015. However, other manufacturers and users of PFOA that are not participants in the voluntary agreement with USEPA continue to emit large amounts of PFOA to the environment, particularly in nations overseas including China, India, Russia, and Poland (USEPA, 2009; Lindstrom et al., 2011; OECD, 2015).

In 2009, the USEPA Office of Pollution Prevention and Toxics (OPPT) developed action plans for several groups of chemicals of concern including PFCs (USEPA, 2009a). According to the USEPA Action Plan, concerns about PFOA and other PFCs include their worldwide presence in the environment, wildlife, and humans; their persistence in the environment and bioaccumulative potential in humans and wildlife; and the significant adverse effects observed in wildlife and laboratory animals. USEPA stated that "given the long half-life of these chemicals in humans (years), it can reasonably be anticipated that continued exposure could increase body burdens to levels that would result in adverse outcomes."

USEPA (2009a) stated that PFOA and other long-chain PFCs are of concern for children's health, based on studies in laboratory animals that have demonstrated developmental toxicity, including neonatal mortality. They stated that: "Children's exposures are greater than adults due to increased intakes of food, water, and air per pound of body weight, as well as child-specific exposure pathways such as breast milk consumption, mouthing and ingestion of non-food items, and increased contact with the floor. Biomonitoring studies have found PFCs in cord blood and breast milk, and have reported that children have higher levels of some PFCs compared to adults. Thus, given the pervasive exposure to PFCs, the persistence of PFCs in the environment, and studies finding deleterious health effects, USEPA will examine the potential risks to fetuses and children."

USEPA (2009a) stated that it intended to propose actions to address the potential risks from long-chain PFCs in 2012 under the Toxic Substances Control Act (TSCA). USEPA stated that potential actions could include banning or restricting their manufacture (including import), processing, and use, depending on the findings of more detailed analysis of information on these compounds.

In 2013, the European Chemical Agency (ECHA) Member State Committee unanimously agreed that PFOA should be classified as a Substance of Very High Concern (SVHC) because it has potential to cause reproductive toxicity and is persistent, bioaccumulative, and toxic (ECHA, 2013. ECHA (2015) is currently considering restrictions on the manufacture, marketing and use of PFOA, its salts and PFOA-related substances, as well as of articles and mixtures containing these substances.

GUIDANCE AND STANDARDS DEVELOPED BY NEW JERSEY, OTHER STATES, AND USEPA

New Jersey Health-based Drinking Water Guidance

New Jersey DEP developed chronic (lifetime) drinking water guidance for PFOA in drinking water of 40 ng/L in 2007 (NJDEP, 2007). The basis for the NJDEP guidance was subsequently published in a peer-reviewed journal (Post et al., 2009a).

The New Jersey guidance is based on the NOAELs (No Observed Adverse Effects Levels) and LOAELs from toxicology studies identified in the draft USEPA (2005a) PFOA risk assessment and considered the conclusions of the USEPA Science Advisory Board (2006) review of this draft risk assessment. The draft USEPA (2005a) risk assessment compared PFOA exposures prevalent within the U.S. general population with NOAELs and LOAELs for various life stages identified in toxicology studies. As such, the USEPA (2005a) draft risk assessment did not develop a Reference Dose or a cancer slope factor for PFOA, and it did not address the relationship between drinking water concentration and human body burden, as measured by serum level.

Because the half-life of PFOA is much longer in humans (several years) than in the animal species used in the toxicological studies (several hours to 30 days), a given external dose (mg/kg/day) results in a much greater internal dose (as indicated by serum level) in humans than in animals. Therefore, comparisons between effect levels in animal studies and human exposures were made on the basis of serum levels rather than external dose. This approach was recommended by USEPA (2005a) and the USEPA Science Advisory Board (2006).

Target Human Serum Levels (analogous to RfDs, but on a serum level basis) were derived by applying UFs to the measured or modeled serum levels at the NOAELs or LOAELs identified by USEPA (2005a). The default RSC of 20% was applied to the Target Human Serum Levels to account for contributions to serum PFOA from non-drinking water exposures. The default RSC value is used when the relative contributions of drinking water versus non-drinking water sources are not fully characterized, as is the case for PFOA.

USEPA (2005a) classified PFOA as having "suggestive evidence of carcinogenic potential", whereas the USEPA Science Advisory Board (2006) disagreed and recommended a classification of "likely to be carcinogenic to humans". For the cancer end point, the serum level resulting in a one in one million (10^{-6}) risk level was estimated by linear extrapolation from the modeled serum level in animals at a dose resulting in an approximate 10% tumor incidence.

The mean ratio of approximately 100:1 between serum PFOA levels and drinking PFOA water concentrations in exposed communities was used to determine the drinking water concentrations that are expected to result in a given increase in serum PFOA level (Post et al., 2009a). Data supporting a ratio of 100:1 or greater is discussed in the <u>Toxicokinetics</u> section below. Because this approach is based on the observed relationship between serum and drinking water concentrations, assumptions for body weight, volume of water ingested daily, or half-life of PFOA in humans or experimental animals were not explicitly used in the calculation of the health-based drinking water concentrations.

The range of health-based drinking water concentrations for the seven endpoints assessed was $0.04-0.26 \ \mu g/L$, and several of the concentrations fell within a similar range (0.04, 0.05, 0.06, 0.07, and 0.08 $\mu g/L$). The most sensitive endpoints, resulting in a drinking water concentration of 40 ng/L, were decreased body weight and hematological effects in the adult female rat in a chronic dietary study (Sibinski, 1987). This value was determined to be protective for carcinogenic effects, as the drinking water concentration at the 10⁻⁶ cancer risk level was estimated as 60 ng/L.

It should be noted that a large body of health effects information, including toxicology studies reporting sensitive developmental effects in mice and epidemiology studies reporting associations of PFOA with numerous health effects, has become available subsequent to the USEPA (2005a) risk assessment that served as the basis for the New Jersey guidance. These data were therefore not considered in the development of the NJDEP (2007) guidance, and they are considered in the development of the recommended Health-based MCL presented in this document.

USEPA Drinking Water Health Advisory

In May 2016, the USEPA Office of Water finalized a drinking water Health Advisory for PFOA of 70 ng/L (USEPA, 2016a). This Health Advisory is intended to apply to both lifetime exposure and short term exposure. It replaces the earlier the USEPA Office of Water (2009b) Provisional Health Advisory for PFOA of 400 ng/L, developed in 2009, which was stated to be intended to protect for "short-term exposure" (defined by the USEPA Integrated Risk Information System (IRIS) as up to 30 days; USEPA, 2011a).

USEPA (2016c) also finalized a Health Advisory for PFOS of 70 ng/L, and USEPA (2016d) states that the total concentration of PFOA and PFOS in drinking water should not exceed 70 ng/L.

A detailed discussion of the basis for the USEPA (2016a) Health Advisory for PFOA and a comparison with the recommended DWQI Health-based MCL are provided in Appendix 2. In summary, the USEPA Health Advisory is based on a Reference Dose (RfD) of 20 ng/kg/day. The RfD is based on delayed ossification and accelerated puberty in male offspring in a mouse developmental toxicology study (Lau et al., 2006). The default Relative Source Contribution factor of 20% was used to account for non-drinking water exposures. The USEPA Health Advisory uses a drinking water consumption rate of 0.054 L/kg/day, based on the 90th percentile for lactating women, which is higher than the default consumption rate of based on adult exposure factors.

Figure 1 shows the predicted increases in serum PFOA levels from ongoing exposure in drinking water at the USEPA Health Advisory (70 ng/L), the NJDEP (2007) guidance (40 ng/L), and the

Health-based MCL (14 ng/L) recommended in this document. Predictions based on both average (0.016 L/kg/day) and upper percentile (0.029 L/kg/day) drinking water ingestion rates are shown. A clearance factor developed by USEPA scientists (Lorber and Egeghy, 2011) to relate human PFOA exposures to human serum PFOA levels was used to predict the increases in serum PFOA from exposures to these level in drinking water. With average water consumption, ongoing exposure to 70 ng/L (the USEPA Health Advisory) is predicted to increase serum PFOA by 8.0 ng/ml, a 4.8-fold increase from the U.S. general population (NHANES) median of 2.1 ng/ml (CDC, 2015). With upper percentile water consumption, the increase in serum PFOA level from 70 ng/L is predicted as 14 ng/ml, a 7.7-fold increase from the general population (NHANES) median.




Figure 1. Increases in serum PFOA concentrations predicted from consumption of drinking water with various concentrations of PFOA (14 ng/L – Recommended Health-based MCL; 40 ng/L – NJDEP guidance (2007); 70 ng/L – USEPA Lifetime Health Advisory).

Guidance and standards of other states

Several other states (e.g. Minnesota, Maine, and North Carolina) developed standards or guidance for PFOA in drinking water or groundwater prior to 2016. Because many states have stated that their earlier PFOA values will be updated or are under review in light of the finalization of the USEPA (2016a) Health Advisory, the basis for these earlier values is not presented here. New Hampshire recently adopted 70 ng/L for the total of PFOA and PFOS as a groundwater standard that is also applicable to public water systems (NH, 2017; NH DES, 2017).

In 2016, Vermont developed a drinking water health advisory (VT DOH, 2016) that was used for a basis for a Ground Water Enforcement Standard (VT DEC, 2016a) which is also applied as a drinking water standard (VT DEC, 2016b) for PFOA, PFOS, and the total of the two compounds of 20 ng/L. These Vermont values are based on the Reference Dose (RfD) of 2 x 10⁻⁵ mg/kg/day from the draft USEPA (2014) PFOA Health Advisory (which is the same as the RfD in the final USEPA [2016a] PFOA Health Advisory), drinking water exposure assumptions for a child less than 1 year of age (instead of default adult exposure assumptions), and the default Relative Source Contribution (RSC) factor of 20%.

ENVIRONMENTAL FATE, TRANSPORT, AND OCCURRENCE

Environmental Fate and Transport

Because of the extreme stability of their carbon-fluorine bonds, PFOA and other PFCs are extremely resistant to degradation in the environment and thus persist indefinitely (Buck et al., 2011; Lindstrom et al., 2011a). As discussed above, the production and use of PFOA and its precursors has been phased out by major U.S. manufacturers. However, environmental contamination and resulting human exposure to PFOA are anticipated to continue for the foreseeable future due to its environmental persistence, formation from precursor compounds, and continued production by other manufacturers.

PFOA and other PFCs are found in many environmental media (e.g. drinking water, surface water, groundwater, air, sludge, soils, sediments, outdoor and indoor dust, and ice caps) in locations around the world including remote polar regions (Lau et al., 2007). PFCs are also found in wildlife (fish, birds, mammals) including in remote polar regions. However, the bioconcentration factor for PFOA is lower than for PFOS or longer chain perfluorocarboxylates such as PFNA (Martin et al., 2003; Conder et al., 2008), and concentrations of PFOA in wildlife in remote locations are generally lower than for these other compounds (Butt et al., 2010).

Two major pathways have been proposed for long-range transport of PFOA and other PFCs to remote locations worldwide, including the Arctic (Figure 2; Lau et al., 2007, 2013; Butt et al., 2010). The relative contributions of each of these pathways are not known. The first pathway involves the atmospheric transport of volatile precursors such as 8:2 fluorotelomer alcohol (8:2 FTOH), followed by oxidation of the precursors to PFOA and other PFCs which are then deposited onto the land or the water. The second pathway involves long-range aqueous transport of emitted perfluorinated carboxylates such as PFOA in their anionic forms to remote locations by currents on the ocean's surface.




Figure 2. Major transport pathways of PFCs to the Arctic (and other remote locations), by Annika Jahnke (Butt et al., 2010)

Fate and Transport Relevant to Drinking Water Contamination

PFOA and some other PFCs are distinct from other persistent and bioaccumulative organic compounds because of their importance as drinking water contaminants. PFOA exists predominantly as an anion under environmental conditions, does not bind well to soil, migrates readily from soil to groundwater, and is highly water-soluble (Davis et al., 2007). These properties of PFOA differ from those of other persistent and bioaccumulative organic pollutants such as polychlorinated dioxins and furans, PCBs, and pesticides like chlordane and DDT. These other compounds are generally not significant as drinking water contaminants because they have high octanol/water partition coefficients. Thus, they have a high affinity for soil and sediments but low water solubility (Post et al., 2011).

PFOA that is released to the environment can contaminate surface water and groundwater used as sources of drinking water. Sources of PFOA in the environment include discharge to air and water from industrial facilities where it is made or used (Davis et al., 2007); release of aqueous firefighting foams, particularly at military sites, airports, and fire fighter training facilities (Moody et al., 2003; Backe et al., 2013); disposal in landfills (Eggen et al., 2010); discharge from wastewater treatment plants treating domestic and/or industrial waste (Sinclair and Kannan, 2006); street runoff (Murakami et al., 2009); storm water runoff (Kim and Kannan, 2007); land application of biosolids (sludge) from wastewater treatment plants treating industrial waste (Clarke and Smith, 2011; Lindstrom et al., 2011b; Sepulvado et al., 2011); land application of wastewater from industrial sources (Konwick et al., 2008); and use of contaminated industrial waste as a soil amendment (Skutlarek et al., 2006; Hölzer et al., 2008).

Environmental transport pathways that can result in surface water and groundwater contamination by PFOA after release from an industrial source are shown in Figure 3 (Davis et al., 2007) and were reviewed by Lau et al. (2007) and Butt et al. (2010).

As is the case for other groundwater contaminants, PFOA can reach drinking water wells via the well-established pathway of migration of a groundwater plume that has been contaminated either directly from surface spills or by contaminated surface water mixing with groundwater drawn in by pumping wells. Unlike many other environmental contaminants, PFOA can also reach groundwater from air emissions from nearby industrial facilities, followed by deposition from air onto soil, and migration through the soil to groundwater (Davis et al., 2007).

In West Virginia and Ohio, drinking water wells as far as 20 miles away were contaminated with PFOA by releases from an industrial facility where it was used as a processing aid in fluoropolymer production. Groundwater contamination occurred via soil deposition of PFOA that had been emitted into the air followed by migration to groundwater, and, to some extent, recharge of the groundwater aquifer with contaminated surface water from the Ohio River (Steenland et al., 2009a; Shin et al., 2011). PFOA was detected in public water supply wells in this vicinity at levels up to > 4000 ng/L (DuPont and URS Diamond Corporate Remediation Group, 2008) and in private wells at up to >13,000 ng/L (Hoffman et al., 2011). In New Jersey, PFOA was detected at up to 190 ng/L in shallow unconfined wells of a public water supply located near an industrial source (Post et al., 2009a), and at > 40 ng/L, with a maximum above 400 ng/L, in 59 of 104 private wells within a radius of slightly more than 2 miles of this facility (DuPont, 2009); contamination of the distant wells was likely due to air deposition (Post et al., 2012).




Figure 3. APFO (PFOA) transport near discharge source (Davis et al., 2007)

Formation from precursor compounds

An additional source of PFOA in the environment is the breakdown of precursor compounds such as the fluorotelomer alcohol, 8:2 FTOH [$F_3(CF_2)_7CH_2CH_2OH$], used industrially and in consumer products (Butt et al., 2010; Buck et al., 2010; Butt et al., 2014).

8:2 FTOH [CF₃(CF₂)₇CH₂ CH₂OH] \rightarrow PFOA [CF₃(CF₂)₆COOH]

Larger molecules such as polyfluoroalkyl phosphoric acid diesters (diPAPs) (e.g. diPAPs 8:2; Figure 4) are found in greaseproof food contact papers, wastewater treatment plant sludge, and paper fibers from paper mills (D'eon et al., 2009). These larger molecules release 8:2 FTOH that can degrade to PFOA.




Figure 4. Structure of diPAPs 8:2

PFOA is formed from these precursor compounds through biodegradation in soil, sludge, and wastewater (Sinclair and Kannan, 2006; Lee et al., 2010) as well as through chemical reactions in the atmosphere (Figure 2). PFOA and other PFCs have been found at higher concentrations in effluent than influent at wastewater treatment plants. This increase is believed to result from the biodegradation of telomer alcohols and other precursors from domestic and industrial sources within the wastewater treatment plant (Sinclair and Kannan, 2006; Lee and Mabury, 2011). Fluoroacrylate polymers, used in commercial products, may also degrade in soil to release FTOH which can degrade to PFCs such as PFOA (Russell et al., 2008; Washington et al., 2009). Since PFOA, once formed, does not degrade appreciably, environmental PFOA levels are increased by conversion of even a small fraction of the precursors to the terminal breakdown product, PFOA.

Occurrence in drinking water

PFOA and other PFCs occur in raw and finished drinking water from both groundwater and surface water sources in New Jersey, other parts of the United States, and nations around the world (reviewed by Mak et al., 2009; Post et al., 2012; Post et al., 2013). PFOA and other PFCs are found in drinking water impacted by discharges from industrial facilities, release of aqueous firefighting foam, and other known sources of contamination, as well as where the source is unknown (Post et al., 2012).

PFOA has been detected at high frequency in some river basins that are important sources of drinking water. For example, it was detected (>1 ng/L) in 82.3% of samples from 80 locations throughout the Cape Fear River (North Carolina) drainage basin, population 1.7 million, at a median of 12.6 ng/L and a maximum of 287 ng/L (Nakayama et al., 2007). In the Upper Mississippi River drainage basin in the Midwestern U.S., population 30 million, it was detected (>1 ng/L) in 73% of 88 locations with a median of 2.07 ng/L and a maximum of 125 ng/L. Elevated levels at certain sites were attributed to point sources in this study (Nakayama et al., 2010). In the Tennessee River in Alabama, PFOA levels were 395±128 ng/L in samples from the 35 river miles downstream of the site of discharge from a fluorochemical manufacturing

facility, with the highest levels (521-598 ng/L) in the 6 river miles furthest downstream (Hansen et al., 2002). In Germany, PFOA and other PFCs in organic material applied to agricultural land contaminated the Moehne and Ruhr Rivers, important sources of drinking water. PFOA was detected at up to 33,900 ng/L in a creek near the site of contamination upstream of these rivers, and at up to 519 ng/L in drinking water from the Moehne River (Skutlarek et al., 2006).

PFOA and other PFCs are not effectively removed from drinking water by standard treatment processes such as coagulation/flocculation, sand filtration, sedimentation, medium-pressure ozonation, chloramination, and chlorination. However, PFOA can be removed from drinking water by granular activated carbon (GAC) or reverse osmosis (Rumsby et al., 2009, Bartell et al., 2010a, Tagaki et al., 2011; Eschauzier et al., 2012; Appleman et al., 2014; DWQI, 2015b). Therefore, unless specific treatment for removal of PFCs is in place, concentrations of PFOA and other PFCs detected in raw drinking water can be considered to be representative of concentrations in finished drinking water (Post et al., 2013).

Occurrence in New Jersey drinking water

Considerable information is available on the occurrence of PFOA and other PFCs in New Jersey public water systems (PWS). This includes data from 53 PWS from two NJDEP occurrence studies of PFCs, substantial additional data submitted to NJDEP by PWS and other parties, and data from the nationwide USEPA Unregulated Contaminant Monitoring Rule 3 (UCMR3) survey. For the two NJDEP occurrence studies and most of the additional data submitted to NJDEP, analysis of samples was performed by certified laboratories with Reporting Levels (RLs) that were generally 4-5 ng/L or lower. To the knowledge of the Health Effects Subcommittee, statewide drinking water studies of PFOA with sensitive RLs such as these have not been conducted in states other than New Jersey. In contrast, the RL for PFOA in USEPA UCMR3 is much higher (20 ng/L) than the RLs in the other NJ PWS monitoring data.

NJDEP studies of occurrence in New Jersey public water systems

Following detection of PFOA in a New Jersey PWS at up to 190 ng/L in a groundwater source and up to 64 ng/L in tap water, two statewide studies of the occurrence of PFOA and other PFCs in drinking water were conducted by NJDEP. The 2006 study tested 23 PWS for PFOA and PFOS, and the 2009-10 study tested 33 additional PWS for PFOA, PFOS, and eight other PFCs (NJDEP, 2007b; NJDEP, 2014; Post et al., 2009a; Post et al., 2013).

The 2006 NJDEP study included 29 samples of raw and/or finished water from 23 NJ PWS including 14 with groundwater sources, 8 with surface water sources, and one using both groundwater and surface water. In the 4 PWS where both raw and finished water were analyzed, PFOA concentrations were similar in both samples. Of the PWS in this study, PFOA was detected in 15 of 23 systems (65%) at or above the RL (4 ng/L), and in 3 of 23 systems below the RL. PFOA was detected above the RL (9 of 13) at up to 33 ng/L, or below the RL (1 of 13), in

10 of 13 groundwater samples (77%) from unconfined or semiconfined aquifers, but was not detected in the two groundwater samples from confined aquifers. Additionally, PFOA was detected above the RL (7 of 9; 78%) at up to 39 ng/L, or below the RL (2 of 9; 22%), in samples from all 9 PWS using surface water sources. In this study, PFOS was detected (>4 ng/L) in 30% of the PWS, less frequently than PFOA (NJDEP, 2007; Post et al., 2009a).

The 2009-2010 NJDEP study tested raw water from 30 PWS for PFOA, PFOS, and 8 other PFCs. The sites for this study were chosen for geographic diversity, representing 19 of NJ's 21 counties. The study included 18 PWS with groundwater sources (17 unconfined, one confined) and 12 PWS with surface water sources. One or more PFC was detected (>5 ng/L) at 21 sites (70%), with the number of individual compounds detected varying from one (in 8 samples) to a maximum of 8 in one sample. PFOA was the most commonly detected PFC (17 of 30 samples; 57%), including 6 of 18 of groundwater samples (33%) and 11 of 12 of surface water samples (92%). When PFOA was detected, other PFCs were often but not always found in the same sample. PFOA was found at the highest maximum concentration of any of the PFCs analyzed in the study, 100 ng/L. This highest detection was in a PWS intake from a river, and the likely source was subsequently identified as discharge from an upstream facility that made and used products containing PFOA and other PFCs (Post et al., 2013; NJDEP, 2014).

NJDEP database of PFCs in New Jersey Public Water Systems

The NJDEP Division of Science, Research, and Environmental Health maintains an internal database of PFC results from NJ PWS including the two NJDEP occurrence studies, additional raw and finished water data submitted to NJDEP by PWS and other parties, and detections from UCMR3 data. As of January 2016, the database included 1035 samples (423 raw water, 549 finished water, and 63 distribution system) from 282 sampling locations in 80 PWS (including 72 PWS with data from NJDEP studies and/or submitted to NJDEP, and 8 additional PWS with PFC detections in UCMR3). Of these samples, 374 were analyzed for only PFOA and PFOS, and 661 were analyzed for a broader suite of PFCs.

PFOA was the most frequently detected PFC in NJ PWS. It was detected at some level in 65% of 72 PWS included in the NJDEP database (excluding UCMR3 data; Table 1). The highest detection in finished water was 100 ng/L, and concentrations exceeding 40 ng/L were reported in at least one finished water sample from 12 of 72 PWS (17%). It was also detected at >20 ng/L in UCMR3 monitoring in finished water from six additional PWS that are not otherwise included in the database, including two PWS that had levels above 40 ng/L.

Table 1. PFOA concentrations in raw or finished water from PWS included in NJDEP database*						
PFOA Concentration (ng/L) Number of PWS % of PWS						
ND**	25	35%				
RL - <10**	15	21%				
10 - <20**	10	14%				
20 - <40	10	14%				
>40	12	17%				

*Data shown are highest concentration found in raw or finished water from the PWS. Levels in finished water from some water supplies included may be lower because several raw water sources are blended in the treatment plant.

**Reporting levels (RLs) vary among samples and range from 2.5 - 20 ng/L. Therefore, the percentage of PWS with RL-<10, and 10 - <20, may actually be higher than shown.

Comparison of NJ occurrence to nationwide UCMR3 data and studies from other nations

Data on PFOA in PWS in New Jersey and nationwide is available through the USEPA UCMR3. Under UCMR3, nationwide monitoring of finished water for 30 unregulated contaminants, including PFOA and 5 other PFCs, was conducted in 2013–2015 by all U.S. large PWS (serving more than 10,000 people) and 800 representative smaller PWS (serving less than 10,000 people) (USEPA, 2012b). UCMR3 data therefore provide useful information on occurrence of PFCs in NJ in comparison to the rest of the United States. However, comparison of the UCMR3 PFC data with other New Jersey PFC occurrence data is complicated by the fact that the UCMR3 RLs for PFOA (20 ng/L) and other PFCs are much higher than the RLs for other PFC data in the NJDEP database (generally \leq 5 ng/L).

UCMR3 monitoring in New Jersey includes all 165 large community PWS, 13 of about 435 small community PWS, and 8 of about 700 non-transient non-community water systems. A comparison of national versus New Jersey PFC data from UCMR3 reported through January 2016 is shown in Table 2 (data obtained from USEPA, 2016f). PFOA was detected (≥ 20 ng/L) in PWS at locations throughout the state, and was detected more than five times more frequently in New Jersey PWS (10.53%) than nationally (1.93%). PFNA was also detected only in the vicinity of a likely industrial source located in Gloucester County (DWQI, 2015c) but not in other parts of New Jersey. The occurrence of the other PFCs included in UCMR3 (PFHpA, PFOS, PFHxS, PFBS) was similar or slightly higher in New Jersey compared to nationally.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 136 of 551

Table 2. New Jersey versus national UCMR3 PFC occurrence data as of January 2016							
	Reporting	New Jersey		United States (other than NJ)			
Compound*	Level (RL) (ng/L)	Number of PWS	Number above RL	Percent above RL	Number of PWS	Number above RL	Percent above RL
PFOA	20	171	18	10.53 %	4617	89	1.93 %
PFNA	20	171	4	2.34 %	4617	10	0.22 %
PFHpA	10	171	5	2.92 %	4617	77	1.67 %
PFOS	40	171	5	2.92 %	4617	88	1.91 %
PFHxS	30	171	2	1.17 %	4617	52	1.13 %
PFBS	90	171	0	0 %	4617	6	0.13 %

*PFHpA – perfluoroheptanoic acid (C7); PFBS – perfluorobutane sulfonate; PFHxS – perfluorohexane sulfonate.

The occurrence of PFCs in NJ PWS in the 2009-10 NJDEP study was also compared to similar occurrence studies in other nations by Post et al. (2013). PFOA was detected more frequently and at a higher maximum concentration in the 2009-10 New Jersey PWS study than in comparable drinking water studies in France, Spain, and China which had RLs similar to the RL in the NJ study.

Occurrence in NJ private wells

A statewide study of PFOA or other PFCs in New Jersey private wells has not been conducted. PFOA was detected at >40 ng/L, with a maximum above 400 ng/L, in 59 of 104 private wells within a radius of slightly more than 2 miles of a New Jersey industrial source (DuPont, 2009); contamination of the distant wells was likely due to air deposition. More recently, PFOA has been detected in private wells near another facility which used and discharged a mixture of PFCs that consisted primarily of PFNA and also contained PFOA (DWQI, 2015c).

HUMAN BIOMONITORING

Human biomonitoring studies show that exposure to PFOA and/or its precursors is ubiquitous in the U.S. and throughout the world. PFOA has a human half-life of several years and remains in the body for a long period of time after exposure occurs. Data on blood serum concentrations from the general population, communities with contaminated drinking water, and workers with occupational exposure are summarized below. Consumption of contaminated drinking water results in increased blood serum concentrations, while the highest blood serum concentrations have been found in occupationally exposed workers. PFOA is detected in human breast milk, amniotic fluid, and umbilical cord blood, demonstrating that exposure occurs during prenatal and postnatal development, and it has also been detected in human seminal fluid.

Blood Serum

General population

PFOA and other PFCs are present in the serum of the general population in the United States and in countries worldwide. This topic was recently comprehensively reviewed by Kato et al. (2015).

Data from archived serum samples from the United States and Norway indicate that human exposure to PFOA has been ongoing for decades, and that exposure increased greatly in the 1980s in these two locations. Analysis of serum samples collected up to 56 years ago found that the median level in serum from pregnant California women sampled in 1960-63 (n=40) was 0.27 ng/ml, approximately 10-fold lower than the median in serum from California women sampled in 1981-86 (n=30) and 2009 (n=35), which were 2.71 and 2.08 ng/ml, respectively (Wang et al., 2011a). In pooled serum samples from Norwegian men (age 40-50) collected over a 29 year period (1977-2006), PFOA levels gradually increased from 0.58 ng/ml in 1976 to 4.9 ng/ml in 2001, an 8-fold increase, followed by a yearly decline to 2.7 ng/ml in 2006. A similar temporal pattern was seen in serum samples collected from Norwegian children and male and female adults of other age groups between 1976 and 2007 (Haug et al., 2009).

The largest studies of the U.S. general population are from the National Health and Nutrition Examination Survey (NHANES) conducted by the U.S. Centers for Disease Control and Prevention (CDC) (Kato et al., 2011; CDC, 2015) and American Red Cross blood donors (Olsen et al., 2012). PFOA is one of four PFCs (PFOA, PFOS, PFNA, and perfluorohexane sulfonate [PFHxS]) that have been detected in the serum of greater than 99% of a representative sample of the U.S. population, age 12 or older, in NHANES (Kato et al., 2011). PFOA and these other PFCs are biologically persistent, with human half-lives of several years, as discussed in the <u>Toxicokinetics</u> section below.

Data from six cycles of NHANES monitoring between 1999-2000 and 2011-12 show that serum PFOA levels have decreased in the U.S. general population during this time period (Table 3). In the first NHANES (1999-2000), the geometric mean serum concentration was 5.21 ng/ml and the 95th percentile was 11.9 ng/ml, while the most recent NHANES (2011-12) found a geometric mean and 95th percentile of 2.08 and 5.68 ng/ml, respectively. In the NHANES surveys, PFOA concentrations were lower in those 12-19 years of age than in older individuals, and were somewhat higher in males than females. In data from the three ethnic groups that were analyzed over time, levels were consistently lowest in Mexican Americans, intermediate in non-Hispanic blacks, and highest in non-Hispanic whites (CDC, 2015).

Table 3. Seru (ng/ml)	um PFOA cor	ncentra	tion fro	om NHA	ANES	
	Geometric	Percentile				
Year	Mean	50th	75th	90th	95th	n
2011-12	2.08	2.08	3.03	4.35	5.68	1904
2009-10	3.07	3.20	4.60	6.00	7.50	2233
2007-08	4.12	4.30	5.90	7.90	9.60	2100
2005-06	3.92	4.20	6.20	9.00	11.3	2120
2003-04	3.95	4.10	5.80	7.80	9.80	2094
1999-2000	5.21	5.20	6.90	9.40	11.9	1562
CDC, 2015		1	1	1	•	1

A similar pattern of decreasing serum PFOA concentrations over time was seen in three studies of American Red Cross blood donors in 2000-2001, 2006, and 2010 (Olsen et al., 2012). Each study included samples from 600-645 subjects from six locations throughout the U.S., with an approximately equal number in each of five 10-year age categories (20-29 through 60-69 years of age) from each location. Geometric means and 95th percentile concentrations, respectively, were 4.7 and 12.0 ng/ml in 200-01, 3.44 and 7.9 ng/ml in 2006, and 2.44 and 6.6 ng/ml in 2010. As in the NHANES studies, serum concentrations were generally higher in males than females.

Serum PFOA levels are generally comparable to those found in the U.S in developed countries throughout the world, including Europe, Asia, and Australia (Post et al., 2012; Kato et al., 2015). In contrast to industrialized nations where serum PFOA is almost universally detected, PFOA was detected at > 0.5 ng/ml in only 12 of 55 serum samples from Afghan children and adults, with a maximum of 1.5 ng/ml; relatively low serum levels have also been reported in other developing countries where exposure to PFOA and other PFCs may be lower than in industrialized nations (Hemat et al., 2010).

PFOA concentrations in pooled serum samples from children (age 3-11) in 2001-2002 NHANES ranged from about 6-8 ng/ml, significantly higher than in pooled serum samples from adults in this study (Kato et al., 2009). Median and maximum serum PFOA levels in 300 Texas children, age <1 to 12 years, were 2.85 ng/ml and 13.50 ng/ml; adults were not included in this study. In the Texas study, the median level did not differ between genders, and was lower in those less than 3 years of age than in the older age groups (Schecter et al., 2011). Exposures to infants and young children are discussed in detail in the section on developmental exposures below.

Communities with drinking water exposures

Continued exposure to even relatively low concentrations of PFOA in drinking water concentrations results in substantial increases in serum levels. The quantitative relationship between drinking water exposure and human serum PFOA levels is discussed below.

A recent study (Hurley et al., 2016) found substantially increased serum PFOA levels in individuals served by PWSs reporting detection of PFOA in UCMR3 monitoring. PFOA detections were relatively low, ranging from 20 ng/L (the UCMR3 RL) to 53 ng/L, with a mean of 28 ng/L. The study group consisted of middle aged and older California women (n=1,333; 70% between 60 and 79 years of age). Of this group, 4.5% resided in a zipcode where a PWS reporting detection of PFOA in UCMR3 monitoring is located. The distribution of serum concentrations differed significantly (p<0.0001) in those served by a PWS where PFOA was detected ("exposed") as compared to those served by a PWS without a detection ("unexposed"). The median serum PFOA concentrations in the "exposed" group was 38% higher (3.46 ng/ml) than in the "unexposed" group (2.51 ng/ml). The authors note that the contribution of drinking water to serum PFOA is likely actually greater than observed in the study since some of those classified as "exposed" may have received their drinking water from another point of entry (e.g. treatment plant) within the PWS that detect PFOA. Additionally, the serum PFOA levels of some participants classified as "not exposed" may have been increased by PFOA in drinking water at concentrations below the UCMR3 RL of 20 ng/L.

Public water supply wells and private wells in several Ohio and West Virginia communities were contaminated by PFOA emissions from an industrial facility. In Little Hocking, Ohio, the concentration in drinking water was 3550 ng/L in 2002-2005, and the median serum PFOA concentration in 282 individuals tested in 2004-2006, with occupationally exposed individuals excluded, was 371 μ g/L (Emmett et al., 2006a). The C8 Health Study (described in more detail below) is a much larger study of Little Hocking and several other communities in this vicinity with drinking water PFOA concentrations ranging from >50 ng/L to over 3000 ng/L (Post et al., 2009a). In approximately 69,000 C8 Health Study participants, including some with occupational exposures, the median serum PFOA concentration in 2005-2006 was 28.2 ng/ml, as compared to the median of 4 ng/ml in the 2003-2004 NHANES study (Steenland et al., 2009a). The upper 25% of C8 Health Study participants had serum PFOA levels greater than 71 ng/ml, only slightly below the highest concentration found in 2003-2004 NHANES, 77.1 ng/ml. As in the NHANES and Red Cross blood donor studies of the general population discussed above, the median serum concentrations in males (33.7 ng/ml) were higher than females (23.7 ng/ml) in this large study of an exposed population.

Emmett et al. (2006a) observed higher serum levels in children ages 2-5 than in older children and adults in their study of Little Hocking, Ohio residents with exposure to PFOA in drinking water. Adults over 60 years of age also had higher levels than other age groups. In the larger C8 Health Study population, serum concentrations were also higher in children and older adults, with the lowest levels in those age 20-29 (Steenland et al., 2009a). More recently, Shin et al. (2011) estimated a median one-year old child:maternal serum ratio of 1.27:1 from data on 40 child-mother pairs in the C8 Health Study. In a much larger study of almost 5000 mother-child

pairs from the C8 Health Study, serum levels in children up to age 12 were higher than in their mothers in this population; in the youngest age category (≤ 5 years), mean levels were 44% higher than maternal levels (Mondal et al., 2012).

Serum PFOA levels were also higher than in the general population in several other communities with exposure from drinking water. These include communities in Germany whose surface water source of drinking water was contaminated by runoff from industrial waste used as a soil amendment (Hölzer et al., 2008); in Alabama where a river used as a public water supply source was contaminated by industrial discharge, and PFOA from contaminated biosolids applied to agricultural land reached drinking water wells (ATSDR, 2013); in Minnesota communities where private wells and public water supply wells were contaminated by disposal of industrial waste (Landsteiner et al., 2014); in Pease, NH where public water supply wells were contaminated by military use of aqueous firefighting foam (NHDHHS, 2015); and in Hoosick Falls, NY, where drinking water was contaminated by releases from an industrial facility (NYS DOH, 2016)

Occupationally exposed workers

Serum PFOA levels in workers at facilities where PFOA is made or used in fluoropolymer production are much higher than in the general population. Biomonitoring data from workers at such facilities were reviewed by Olsen (2015). Mean or median serum concentrations of several 1000 ng/ml (several ppm) were reported for some job categories at some facilities, with maximum serum concentrations of over 100,000 ng/ml (100 ppm), although levels in most workers were lower. In the C8 Health Study participants, the median serum level among those currently working at the Washington Works plant where PFOA was used in fluoropolymer production (n=1,171) was 148 ng/ml, as compared to 24 ng/ml in those who did not work there at or prior to the time of sampling (Steenland et al., 2009a).

Serum concentrations of PFOA and other PFCs are also elevated in professional ski waxing technicians due to exposures to fluorinated ski waxes that contain both the compounds themselves and their precursors (reviewed by Olsen, 2015).

Other human biological matrices

Seminal plasma

PFOA and other PFCs were found in human seminal plasma in a study of Sri Lankans. The mean and median concentrations were 6.38 and 4.02 ng/ml, respectively, and PFOA concentrations were significantly correlated with serum PFOA concentrations (Guruge et al., 2005).

Amniotic fluid

PFOA was detected in amniotic fluid in a study in the United States (Stein et al., 2012). The median blood serum:amniotic fluid concentration ratio was about 13:1.

Umbilical cord blood serum

PFOA and other PFCs were detected in numerous studies of umbilical cord blood from the general population worldwide in studies reviewed by Post et al. (2012). Locations of these studies included Baltimore, Maryland (Abelberg et al, 2007), Ontario, Canada (Monroy et al, 2008), Denmark (Fei et al., 2007), Germany (Midasch et al., 2007), Norway (Gützkow et al., 2011), the Faroe Islands (Needham et al., 2011), Australia (Toms et al., 2009), South Africa (Hannsen et al., 2010), Korea (Kim et al., 2011), and Taiwan (Lien et al., 2011). Mean serum (or plasma) levels in these studies ranged from 1.1 ng/ml in Korea (Kim et al., 2011) to 4.4 ng/ml in Taiwan (Lien et al., 2011). No geographic pattern was apparent from this dataset, as the levels reported from Africa, Australia, Europe, and North America fell in between the levels in the two Asian studies. More recent additional data are reviewed by Kato et al. (2015).

Breast milk

PFOA was detected in human breast milk in studies from locations worldwide (reviewed by Liu et al., 2010; White et al., 2011a; Post et al., 2012) including Massachusetts (Tao et al, 2008a), Japan (Tao et al., 2008b), China (So et al., 2006; Liu et al., 2010), Korea (Kim et al., 2011), Belgium (Roosens et al., 2010), Spain (Llorca et al., 2010), Norway (Haug et al., 2011; Thomsen et al., 2010), and Sweden (Sunstrom et al., 2011). Concentrations in breast milk were generally similar in studies from different parts of the world. In studies using sensitive analytical methods enabling detection of lower concentrations, median PFOA levels were 36 ng/L (Massachusetts; Tao et al., 2008a), 67 ng/ml (Japan; Tao et al., 2008b), and 46 ng/L (China; Liu et al., 2010), while PFOA was not detected or was infrequently found in breast milk in some other studies with higher detection limits (Fromme et al., 2010; von Ehrenstein et al., 2009). In the studies cited above, PFOA was frequently found in breast milk at concentrations higher than 40 ng/L, with some detections exceeding 100 ng/L (for example, in Belgium; Roosens et al., 2010).

Notably, breast milk concentrations were much higher in both rural and urban samples from Shanghai province (urban mean, 616 ng/L; rural mean, 814 ng/L) than in 12 other Chinese provinces (mean, 46 ng/L). Maternal exposures were likely higher in Shanghai than in the other areas sampled because PFOA levels are higher in Shanghai drinking water and surface water, likely because many fluorochemical manufacturing plants are located there (Liu et al., 2010).

SOURCES OF HUMAN EXPOSURE

The human body burden of PFOA results from exposure to both PFOA itself and to precursor compounds that can be metablized to PFOA, such as FTOH and diPAPs (D'eon and Mabury, 2011a; Lee and Mabury, 2011). Sources of exposure to PFOA and/or its precursors include drinking water, food, migration from food packaging into food, treated fabrics (carpets, upholstery, and clothing), protective sprays, ski waxes, cosmetics and personal care products, house dust, and inhalation of indoor and outdoor air (Trudel et al., 2008; Guo et al., 2009;

Gewurtz et al., 2009; Freberg et al, 2010; Nilsson et al., 2010; Fraser et al., 2012; Knobeloch et al., 2012; Fujii et al., 2013; Fraser et al., 2013; Kotthoff et al., 2015). Migration into food from non-stick (PTFE-coated) cookware is not considered to be a significant exposure source (Trudel et al., 2008).

The relative contributions from direct exposure to PFOA and exposure to its precursors, used in products including food contact paper and stain resistant carpet and textile coatings, is uncertain and varies among individuals (D'eon and Mabury, 2011b; Gebbink et al., 2015a). Other classes of precursor molecules, some of which are known or suspected to be metabolically converted to PFOA in humans, have also been detected in human serum (Lee and Mabury, 2011). Some of these precursor compounds are known to be present in consumer products at much higher levels than PFOA itself (Lee and Mabury, 2011).

Efforts have been made to model the relative contributions of consumer products, indoor and outdoor air, house dust, diet, and/or other sources to exposures of PFOA and other PFCs in the general population. Some of these studies estimated the contributions of precursors (Fromme et al., 2008; Vestergren and Cousins, 2009: Gebbink et al., 2015b) while others did not (Washburn et al., 2005; Tittlemeier et al., 2007; Trudel et al., 2008; Cornelius et al., 2012); a high level of uncertainty is associated with the precursor estimates.

Most of these studies predict that diet is the predominant exposure source. Typical adult total exposures of about 2-3 ng/kg/day in Europe or North American were estimated in several studies (Fromme et al., 2009; Trudel et al., 2008; Vestergren and Cousins, 2009), while some more recent studies give higher dietary estimates (6.1 ng/kg/day in Flanders, Belgium; Cornelis et al., 2012) or lower dietary estimates (0.6 ng/kg/day in Norway, Haug et al., 2010a; 0.2 ng/kg/day in The Netherlands, Noorlander et al., 2011; 0.16 ng/kg/day (location not specified), Gebbink et al., 2015b). Such dietary exposure estimates, in general, are highly uncertain because there are relatively few data on PFOA levels in food, analytical methods for food lack sufficient sensitivity, detection limits vary greatly among food types, and PFOA levels differ greatly in samples of the same foods obtained from different sources and/or locations.

PFOA has been detected in at least some samples of several types of foods including milk, butter, meats, fish, vegetables (including potatoes), bread, and microwave popcorn, but was not detected in most food samples tested (reviewed by D'Hollander et al., 2010; Domingo et al., 2012).

Commercially available infant formula products do not appear to be a major source of exposure to PFOA or other PFCs in the U.S. Tao et al. (2008a) evaluated PFCs in 21 samples of five brands of infant formula representing >99% of the U.S. market. Products tested included milk-, organic-and soy-based formula, packed in cans, glass, or plastic, in liquid, powdered, and concentrated

liquid forms. PFOA was not detected (<0.048 ng/L) in any sample. Other PFCs (for which detection levels varied) were also not detected or were infrequently found (PFOS – one detection at 11.3 ng/L; perfluorohexane sulfonate (PFHxS)-two detections at up to 3.59 ng/L). In this study, PFCs were also analyzed in 12 samples of 11 brands of dairy milk purchased in Albany, NY in 2008, an there was only one detection of PFHxS at 3.83 ng/L. However, it should be noted that exposure to infants occurs when powdered or concentrated formula is prepared with drinking water contaminated with PFOA.

Llorca et al. (2010) analyzed two brands of dry infant cereal and three brands of powdered milkbased infant formula purchased in Spain. PFOA concentrations in the cereals were 166 and 438 ng/kg, and in the formulas, 374, 488, and 723 ng/kg. The concentrations in these products when prepared for consumption were not given.

PFOA and other PFCs can be taken up into plants grown on contaminated soil (e.g. from application of PFOA-contaminated biosolids) or irrigated with contaminated water, including into the parts of some vegetables and grains that are consumed by humans and by grazing livestock (Stahl et al., 2009; Lechner and Knapp, 2011; Yoo et al., 2011). The potential for human exposure to PFOA through this route generally depends on the part of the plant that is consumed. In general, shorter chain PFCs are preferentially taken up into the fruit of the plant, while longer chain PFCs such as PFOA are preferentially taken up into the root and shoot parts of the plant (Blaine et al., 2013a, b, 2014; Felizeter et al., 2012, 2014). In the C8 Health Study population, consumption of locally grown or home grown vegetables was associated with higher serum PFOA levels (Emmett et al., 2006a; Steenland et al., 2009a; Hoffman et al., 2011).

PFOA is much less bioaccumulative in fish than other PFCs that have a longer fluorinated carbon chain, including PFOS (Conder et al., 2008). Thus, consumption of fish from waterways contaminated with PFOA does not result in the high exposures typical of other persistent organic contaminants, including PFOS, which are bioaccumulative in fish (Hölzer et al., 2011). However, PFOA has been detected in edible fish and other seafood, and consumption of aquatic organisms may represent a significant portion of total dietary exposure in some populations (Haug et al., 2010 b; Zhang et al., 2011).

Several studies suggest that PFOA and its precursors in indoor air and/or house dust may be a major exposure source for some individuals (Haug et al., 2011; Shoeib et al., 2011; Schlummer et al., 2013; Gebbink et al., 2015a). Fraser et al. (2013) reported that the concentration of the PFOA precursor 8:2 FTOH in indoor air in offices is a predictor of serum PFOA concentration. Levels of this compound were greatly elevated in offices with new carpets compared to other offices.

Greater exposures to PFOA may occur in young children than in older individuals because of age-specific behaviors such as greater drinking water and food consumption on a body weight basis, hand-to-mouth behavior resulting in greater ingestion of house dust, and more time spent on floors where treated carpets are found (Section 5.1; Trudel et al., 2008; Shoeib et al., 2011).

Occupational exposure to PFOA is believed to occur primarily through inhalation (Vestergren and Cousins, 2009).

Exposures from drinking water

It is well established that serum PFOA concentrations are greatly elevated in communities with highly contaminated drinking water resulting from environmental discharges (discussed in <u>Biomonitoring</u>, above). As discussed in <u>Biomonitoring</u> (above) and <u>Toxicokinetics</u> (below), continued exposure to even relatively lower drinking water concentrations which are more widespread (Section 3 above) can also substantially increase total human exposure, as indicated by serum PFOA levels.

The total exposure studies discussed above provide varying conclusions about the relative importance of drinking water to total exposure; these conclusions are highly dependent on the concentration of PFOA in drinking water assumed in the analyses. For example, Fromme et al. (2008) and Cornelis et al. (2012) concluded that drinking water contributed <1% to total exposure, assuming drinking water levels of 1 ng/L and 2 ng/L, respectively, while Noorlander et al. (2011) estimated that 55% of exposure comes from drinking water, assuming 9 ng/L. Vestergren and Cousins (2009) and Thompson et al. (2011) demonstrated that the contribution of drinking water to total exposure depends on the concentration of PFOA, and Thompson et al. (2011) predicted that a drinking water level of 9.66 ng/L contributed 24% to total exposure.

PFOA exists in drinking water in its non-volatile anionic form, and the formation of inhalable water droplets during showering or bathing is minimal. Therefore, inhalation exposure is not expected to be significant from non-ingestion uses of drinking water such as showering, bathing, laundry, and dishwashing (Trudel et al., 2008; USEPA, 2016e). In contrast, these are important exposure routes for volatile drinking water contaminants. Similarly, dermal absorption of PFOA during showering, bathing, or swimming is not expected to be significant compared to exposure through ingestion, based on analysis by NJDOH (2014) using skin permeability data from Franko et al. (2012).

TOXICOKINETICS

Absorption, Distribution, Metabolism, and Excretion

<u>Summary</u>

PFOA is well absorbed orally, and can also be absorbed dermally and by inhalation. The ammonium (APFO) or sodium (NaPFO) salts dissociate to PFOA (the anionic form) in the body.

PFOA is water soluble and distributes primarily to the liver and serum, and, to a lesser degree, to the kidney. Unlike most other bioaccumulative organic compounds, it does not distribute to fat. In the serum, PFOA is almost totally bound to albumin and other proteins. Since it is chemically non-reactive, it is not metabolized. The rate of excretion of PFOA varies widely among species, and in some cases between males and females of the same species. The excretion rate is largely dependent on the extent of secretion and reabsorption by organic anion transporters in the kidney. In humans, the half-life is several years, and half-lives in male and female mice and male rats are days to weeks, so that PFOA reaches steady-state in these species/genders after continued dosing. However, PFOA is rapidly excreted in female rats (half-life of 2-4 hours) and does not reach steady-state after continued once-daily dosing. For this reason, the rat is not an ideal model for studying developmental effects of PFOA. Because of the large variations in half-lives, the internal dose resulting from a given administered dose varies widely among species and, in some cases, genders of the same species. For this reason, interspecies (e.g. animal-to-human) comparisons are made on the basis of internal dose, as indicated by serum level, rather than administered dose.

Absorption

PFOA is well absorbed by the oral route (Lau et al., 2007). More than 95% of a single dose of 0.1 to 25 mg/kg APFO (the ammonium salt of PFOA) was absorbed in male and female rats (Kemper, 2003). It was also well absorbed in mice, rats, hamsters, and rabbits in studies by Hundley et al. (2006). About 98.7% of an oral dose given to pregnant rats on gestation day (GD) 8 or 9 was excreted in the urine within 24 hours (Gibson and Johnson, 1983). Additionally, a recent study in mice (Fujii et al., 2015) estimated the oral absorption of PFOA as 98.7% in males and 99.8% in females. The extent of oral absorption was determined by comparing fecal excretion after intravenous dosing (representing biliary excretion of PFOA into the gastrointestinal tract) and oral dosing (representing both unabsorbed PFOA and biliary excretion). PFOA is well absorbed by humans exposed orally, as demonstrated by elevated serum concentrations in residents of communities with contaminated drinking water (discussed above).

PFOA penetrated rat and human skin in an *in vitro* system (Fasano et al., 2005), and dermal exposure caused liver toxicity in rats (Kennedy, 1985) and immune effects in mice (Fairley et al., 2007). The dermal permeability coefficient of PFOA (14,000 ng/L [14 μ g/L] in water, pH 5.01) was estimated as 8.8 x 10⁻⁵ cm/hr (Fasano et al., 2005). As above, dermal absorption is not expected to be a significant source of exposure from contaminated drinking water (NJDOH, 2014).

Inhalation exposure to APFO in rats caused hepatic effects (Kennedy et al., 1986). Elevated serum levels of PFOA in workers in facilities making or using PFOA are likely to result primarily from inhalation exposure (Olsen, 2015). As above, PFOA does not volatilize from

water, and inhalation is not expected to be a significant source of exposure from contaminated drinking water (Trudel et al., 2008; USEPA, 2016e).

Distribution

After oral administration, the highest concentrations of PFOA are found in the liver and serum, followed by the kidney, with lower concentrations in other organs (Vanden Heuvel et al., 1991; Kemper, 2003; Hundley et al., 2006; Fujii et al., 2015). After *in utero* exposure to mice, PFOA persisted in bone until adulthood (Koskela et al., 2016). In the serum, PFOA is almost totally bound to albumin and other proteins (SRI, 2003: Han, 2003). Unlike many other persistent bioaccumulative compounds, PFOA does not distribute to fat, and the concentrations of PFOA in the fat after dosing are very low (Vanden Heuvel et al., 1991; Hundley et al., 2006; Fujii et al., 2015).

The fraction of the dose found in the liver is dose-dependent and varies between male and female animals. For example, in male rats two hours after a single intravenous dose, 52% of a low dose (0.041 mg/kg) and 27% of a higher dose (16.56 mg/kg) were found in liver (Kudo et al., 2007). Serum concentrations were similar in male and female CD-1 mice after a single oral gavage dose of 1 or 10 mg/kg PFOA (Lou et al., 2009). However, the concentration in the liver was higher in males than in females.

In another study in which rats were given a single dose of 25 mg/kg, the absolute concentrations in the livers of males were higher than in females, as expected based on the slower excretion by male rats (see below), and the percentage of PFOA in the cytosolic fraction of the liver was higher in females (49%) than in males (26%) (Han et al., 2005).

The subcellular distribution within the liver of male rats was also found to be dose-dependent (Kudo et al., 2007). Over 40% of a low dose (0.041 mg/kg) distributed to the 8000xg pellet (nuclei, mitochondria, and cellular debris), followed by lysosomes and peroxisomes, microsomes, with the least amount found in cytosol (less than 5%), while over 43% of a higher dose (16.56 mg/kg) distributed to cytosol, followed by the 8000xg pellet, lysosomes and peroxisomes, and microsomes. In another part of this study using a range of doses, there was a dose-dependent increase in the percentage found in cytosol.

<u>Metabolism</u>

PFOA is chemically unreactive due to its carbon-fluorine bonds, one of the strongest found in organic chemistry (Vaalgamaa et al., 2011. Therefore, it is not metabolized by biological systems.

Excretion

PFOA is excreted in the urine and the feces, and the proportion in the urine versus the feces varies among species (Hundley et al., 2006; Cui et al., 2010). It is believed that PFOA undergoes enterohepatic circulation (Kudo and Kawashima, 2003) since oral administration of cholestyramine (an anion exchange resin which is not absorbed from the gastrointestinal tract) increased the fecal elimination of PFOA in male rats by 10-fold (Johnson et al., 1984).

Data from several studies indicate that blood loss (e.g. through menstruation, blood donation, or venesection) is an additional excretion route for PFCs (Harada and Koizumi, 2009; MDH, 2013; Taylor et al., 2014; Lorber et al., 2015)

The half-life of PFOA varies among species, and it also differs between males and females in some species, most notably rats and hamsters (Table 4; Hundley et al., 2006, Lau et al., 2007). PFOA is excreted much more quickly in female rats ($t_{1/2} = 2-4$ hours) than in male rats ($t_{1/2} = 4-6$ days), while the excretion rate in hamsters is much more rapid in males than in females. The half-life in both sexes of mice is similar (17 days in females and 19 days in males), while excretion is rapid in both sexes of rabbits with half-lives of 5.5 hours in males and 7 hours in females.

The differences in excretion rates between species and between male and female rats are thought to be due to variations in renal clearance rates. These rates are controlled by specific organic anion transporters that are responsible for the active transport (secretion or reabsorption) of many organic anions, including endogenous substances and xenobiotics, across membranes in several organs including the kidney (Weaver et al., 2010; Han et al., 2012). The specific transporters believed to be responsible for renal reabsorption of PFOA have been identified in male rats as Oatp1a1 and in humans as OAT4 and URAT1 (Han et al., 2012).

Table 4: Serum	n/plasma elimination h	half-lives of PFOA						
Species	Females	Males	References					
Rat	2–4 hours	4–6 days	Johnson et al. (1979);					
			Kemper and Jepson					
			(2003)					
Mouse	17 days	19 days	Lau et al. (2005)					
Rabbit	7 hours	5.5 hours	Hundley et al. (2006)					
Dog	8–13 days	20–30 days	Hanhijarvi et al. (1988)					
Cynomolgus	30 days	21 days	Butenhoff et al.					
Monkey			(2004a)					
Human	3.8 y	Olsen et al. (2007)						
(males and	2.3 years (adults after	Bartell et al. (2010a)						
females	contaminated drinking							
combined)	3.3 years (average of	Brede et al. (2010)						
	of exposure from co							
	Adults and children	Seals et al. (2011)						
	contaminated drinking water.							
	Highly exposed grou	p: 2.9 years (initial 4 years post-						
	exposure); 10.1 year							
	Less exposed group:							
	exposure); no appare							
	exposure).							

Adapted from Lau, 2012

Renal excretion of PFOA appears to be under hormonal control (Ylinen et al., 1989; Kudo et al., 2002). Kudo et al. (2002) found that the clearance of PFOA in female rats (15 ml/min/kg) is greater than the glomerular filtration rate (10 ml/min/kg), suggesting that PFOA is actively excreted through renal tubular secretion, while the renal clearance was much lower in male rats, 0.6 ml/min/kg (Kudo et al., 2002). Castration of male rats increased the clearance to a rate similar to that in females, and this increase was reversed by administration of testosterone to the castrated rats (Ylinen et al., 1989; Kudo et al., 2002). Administration of testosterone to female rats increased the renal excretion of PFOA, and administration of testosterone to female rats reduced the clearance to a rate similar to that of male controls (Ylinen et al., 1989; Kudo et al., 2002). Probenecid, an inhibitor of renal tubular secretion of organic anions, greatly reduced the clearance of PFOA in female and castrated male rats, but had little effect on the excretion rate in control male rats (Hanhijarvi et al., 1982; Kudo et al., 2002).

The gender-dependent differences in excretion rate in rats appear to develop between 3 and 5 weeks of age (Hinderliter et al., 2006). At 4 weeks of age, serum concentrations 24 hours after a single oral dose of 10 mg/kg PFOA were similar (within 3-fold) in male and female rats, while at 5 weeks and older, serum levels were at least 30-fold higher in males than in females receiving the same dose. This greater difference in older rats resulted from age-dependent changes in both males and female. At 5 weeks of age or older, serum levels in males at this dose were about 5-fold higher than serum levels at 4 weeks, while serum levels in females 5 weeks or older are 2-3 fold lower than at 4 weeks of age.

Human half-life

The half-life of PFOA in humans is several years and does not appear to differ significantly between males and females. Inter-individual differences in half-life may be due to differences in renal transport by OATs. A mean half-life of 3.8 years was estimated from data from 26 retired workers with occupational exposure, with no difference found between men and women (Olsen et al., 2007). Bartell et al (2010a) estimated a half-life of 2.3 years in a more heterogeneous study population consisting of 200 adults exposed to PFOA in drinking water. This estimate was based on average decreases in serum level of 26% and 24% for a one-year period after treatment to remove PFOA was initiated in two water districts contaminated by PFOA emissions from a West Virginia manufacturing facility. There was no evidence of age- or gender-dependence in elimination rates in this study. During the second year of follow-up of the same individuals, serum PFOA levels decreased more slowly (9% and 15% in the two water districts), suggesting either ongoing exposures from sources other than residential drinking water or that kinetics do not follow first-order elimination (Bartell et al., 2010b).

Seals et al. (2011) studied the rate of decline of serum PFOA levels in former residents of Little Hocking (n = 602) and Lubeck (n = 971), the two water districts with the highest drinking water PFOA levels of the six districts included in the C8 Health Study. Median serum levels in current and former residents of Little Hocking (current residents, 241.0 ng/ml; former residents regardless of years elapsed, 60.6 ng/ml) were much higher than in Lubeck (current residents, 69.4 ng/ml; former residents regardless of years elapsed, 31.0 ng/ml), due to the much higher drinking water PFOA concentrations in Little Hocking than Lubeck. The number of years elapsed since the former residents moved and thus stopped consuming contaminated water ranged from less than one year to almost 25 years. The data on the relationship between years elapsed since moving and serum PFOA levels suggest that PFOA elimination is biphasic and dependent on serum concentration. In former residents of Little Hocking, the half-life was 2.9 years for the first 4 elapsed years, and about 8.5 years for the first 9 elapsed years, with no apparent decline in serum levels after 9 elapsed years.

PFOA levels in serum of exposed individuals were also studied in Arnsberg, Germany, where the Moehne River which is used a drinking water source was contaminated by runoff from PFOA-contaminated industrial waste applied to agricultural land (Brede et al., 2010). In a two-year study of 138 individuals before and after drinking water treatment removal was initiated, the geometric mean PFOA plasma levels declined by 39% in children and mothers, and by 26% in men; the geometric mean half-life was estimated as 3.26 years.

Isomer-specific kinetics

PFOA exists as a mixture of linear and branched isomers, and the isomer profile varies depending on the manufacturing process used. PFOA made by the telomerization process is primarily linear, while PFOA produced by electrochemical fluorination consists of a mixture of linear and branched isomers. Differences in the rates of elimination of the isomers have been investigated (Loveless et al., 2006; DeSilva et al., 2009). Loveless et al. (2006) reported that, after equivalent doses, serum levels of branched PFOA were lower than for linear PFOA in rats and mice. Similarly, after subchronic administration to rats, most branched isomers were eliminated more quickly than linear PFOA, with the exception of two minor unidentified branched isomers which had half-lives about twice that of linear PFOA (DeSilva et al., 2009). In humans, branched isomers were also more rapidly eliminated than linear isomers (Zhang et al., 2013; Gao et al., 2015). PFOA isomer profiles differed in maternal and cord serum within human infant-mother pairs, indicating that most branched isomers cross the placenta more efficiently than the linear forms (Beesoon et al., 2011). It has recently been reported that linear PFOA has a higher binding affinity than branched PFOA for human serum albumin and serum proteins in general, providing a potential explanation for the more rapid excretion of branched isomers of PFOA (Beesoon and Martin, 2015).

Toxicokinetics Relevant to Developmental Exposures

<u>Summary</u>

It is important to consider toxicokinetics relevant to developmental exposures of PFOA in detail. Developmental effects are the most sensitive known endpoints for PFOA toxicity in experimental animals, and prenatal exposure is associated with decreased fetal growth in humans (see <u>Toxicology</u> and <u>Epidemiology</u> sections, below).

The toxicokinetics of PFOA during gestation and lactation have been studied in rats and mice but have not been evaluated in non-human primates. In rodents, PFOA is present in fetuses of dosed dams, as well as in the placenta and amniotic fluid. PFOA is also present in the breast milk of gestationally exposed dams.

Because it is excreted very quickly in female rats but very slowly in humans, the rat is not an ideal model for study of developmental effects of PFOA. In contrast, the mouse is a preferable

model for evaluation of developmental effects because PFOA is excreted slowly in female mice. For this reason, many recent developmental studies have been conducted in mice.

In humans, PFOA has been measured in amniotic fluid, maternal serum, umbilical cord blood, and breast milk. PFOA concentrations are similar in maternal serum and umbilical cord blood serum, which is reflective of serum levels in the newborn. PFOA exposure in breast-fed infants is greatest during the first few months of life because both PFOA concentrations in breast milk and the rate of fluid consumption are highest during this time period. As a result, serum PFOA concentrations in breast-fed infants increase several fold from levels at birth within the first few months of life. Exposures to infants who consume formula prepared with contaminated water are also highest during this time period. These greatly elevated exposures during the first months of life are of special concern because the neonatal period is a sensitive time period for the toxicological effects of PFOA.

Rats

As discussed above, PFOA is excreted very rapidly by female rats (half-life of 2-4 hours). Because of its rapid excretion, PFOA is not continuously present in female rats dosed once daily, and the fetuses are thus not exposed continuously to PFOA from such a dosing regimen. Because PFOA is highly persistent in humans, the rat is not an ideal model for evaluation of developmental effects of PFOA.

In female rats given a single oral dose of PFOA, the maximum plasma concentration occurred about 1.25 hours after dosing (Kemper and Jepson, 2003). About 98.7% of an oral dose given to pregnant rats on gestation day (GD) 8 or 9 was excreted in the urine within 24 hours (Gibson and Johnson, 1983).

Kinetics of PFOA were studied in pregnant rats (strain not stated) dosed once daily by gavage with 3, 10, or 30 mg/kg/day on GD 4 to postnatal day (PND) 21, and their pups (Hinderliter et al., 2005). Because the gender difference in kinetics in rats develops at about 5 weeks of age (Hinderliter et al., 2006), plasma levels were similar in male and female pups until PND 21, the time period evaluated in this study. Plasma was taken from the dams 2 hours after dosing to allow maximum detection of PFOA, since virtually all PFOA is excreted within 24 hours after dosing of female rats. Mean PFOA concentrations in maternal plasma approximately 2 hours after doses of 3, 10, or 30 mg/kg were 11,000, 27,000, and 67,000 ng/ml, respectively. On GD 21, levels in fetal plasma were about half of those in the dams. Concentrations in milk were fairly constant on PND 3 through PND 21, and were about 10-fold lower than maternal serum levels. Pup plasma levels were about 4-fold lower than maternal plasma levels on PND 3, and about 10-fold lower at later time points. PFOA was also detected in the placenta and amniotic fluid. Interpretation of these data is complicated by the fact that maternal plasma levels varied

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 152 of 551

widely during the course of the day between the daily doses, and milk and fetal/pup levels are compared to maternal plasma levels in samples taken near their daily peaks.

Mice

In contrast to female rats, PFOA is slowly excreted in female mice with a half-life of several weeks (discussed above). Therefore, the fetus is continuously exposed when pregnant mice are dosed once daily. Because PFOA is persistent in humans, the mouse is a preferable model for evaluation of PFOA's developmental effects than the rat, and many recent developmental studies have been conducted in mice.

Fenton et al. (2009) studied the disposition of PFOA in pregnant CD-1 mice and their pups after a single oral gavage dose of 0.1, 1, or 5 mg/kg on GD 17. On GD 18 prior to delivery, the PFOA concentration in the amniotic fluid was about half of the concentration in maternal serum. PFOA concentrations in the whole pup on GD 18 were similar to those in maternal serum. On PND 1 (the earliest time at which serum was measured in pups), pup serum PFOA concentrations were about 1.5 times the concentrations in maternal serum. The exposure of pups at this stage was thought by the authors to result primarily from *in utero* exposure rather than through lactation.

PFOA concentrations in maternal serum and in aspirated milk followed a U-shaped curve over time between PND 1 (serum) or PND 2 (milk) and PND 18, with decreases between the earliest time point (PND 1 or 2) and mid-lactation (PND 8, pups, and PND 11, milk), and increases from mid-lactation to PND 18. This increase between PND 8 and 18 was thought to result from decreased dilution of maternal serum and milk at PND 18. PFOA concentrations in pup serum and in whole pups decreased over time from postnatal day 1 to 18 on a ng/ml or ng/g basis, while the total PFOA pup body burden increased from GD 18 to PND 8, and decreased between PND 8 and 18, presumably because the intake of milk has decreased during this period. Milk concentrations were lower than maternal serum concentrations at all doses and time points, ranging from 11% to 56% of the serum concentration, with the higher percentages at early and late lactation time points.

Serum PFOA concentrations in lactating CD-1 mouse dams and their pups were also measured in a cross-fostering study of mammary gland developmental effects (White at al., 2009) in which dams were treated by gavage with 5 mg/kg/day from GD 8-17. After birth, litters of similar ages and exposures were mixed and fostered, resulting in four treatment groups: untreated dam with unexposed pup, treated dam with unexposed pup, untreated dam with pup exposed during gestation, and treated dam with pups exposed during gestation. Consistent with the single dose study (Fenton et al., 2009), serum PFOA levels on PND 1 in pups exposed *in utero* were about 50% higher than in treated dams. On PND 1, PFOA in the pups is primarily attributable to *in utero* exposure, rather than lactational exposure during the first postnatal day, since serum PFOA concentrations in pups not exposed *in utero* but nursing on treated dams were only about 3% of

the concentrations in pups exposed *in utero*. Serum levels in treated dams and pups decreased between PND 1 and PND 10, with a greater decrease in pups exposed *in utero* that nursed from untreated dams than in pups exposed in *utero* that nursed from treated dams. Serum levels from pups not exposed *in utero* that nursed from treated dams rose over time, and by PND 10 serum levels in these pups were similar to levels in the treated dams they nursed from. Interestingly, serum levels in untreated dams that nursed pups exposed *in utero* increased between PND 1 and PND 10, presumably due to maternal behavior (grooming, and ingestion of urine and feces) resulting in ingestion of PFOA from the pups.

In a more recent study of effects on mammary gland development from lower doses of PFOA (Macon et al., 2011), pregnant CD-1 mice were dosed by gavage on GD 10 to 17 with 0, 0.01, 0.1, or 1 mg/kg/day. At PND 1, serum levels in the pups were 24, 285, 2304, and 16,306 ng/ml in the untreated, 0.01, 0.1, and 1 mg/kg groups, respectively. The pup serum levels decreased over time to 3, 17, 132, and 2683 ng/ml at PND 21. Maternal serum levels were not measured by Macon et al. (2011). However, in other studies in which serum data are available for dams and pups within the same study (e.g. Fenton et al., 2009), serum levels on PND 1 were higher in pups than dams.

White et al. (2011) provide data on serum PFOA concentrations in CD-1 dams and female pups exposed to 5000 ng/L (5 μ g/L) PFOA in drinking water over multiple generations. Results of this study are discussed in the section on <u>Developmental Effects</u>. Exposure began in P0 dams on GD 7 and continued throughout the F1 and F2 generations (except during F1 breeding and early gestation, to avoid exposing control males). Serum concentrations were 74.8 ng/ml in the P0 dams and 86.09 ng/ml in the F1 dams at weaning on PND 22, as compared to 4 and 2 ng/ml, respectively, in the corresponding control groups of dams. At this time point, the P0 dams had been exposed for about 32 days and the F1 dams had been exposed throughout their lifetimes beginning *in utero*, except during breeding and early gestation. As discussed below, serum concentrations in humans with ongoing exposure PFOA in drinking water are, on average, more than 100-fold higher than the concentration in drinking water. Thus, the serum PFOA concentrations in the mice exposed to 5000 ng/ml (5 μ g/L) in drinking water are much lower than the average serum concentrations.

Serum PFOA concentrations were similar in F1 and F2 pups, and concentrations in the pups were lower than in the dams at weaning. The serum concentrations in the F1 and F2 pups at PND 22 were 21.3 and 26.6 ng/ml, respectively; at PND 42, they were 48.9 and 57.4 ng/ml; and at PND 63, they were 66.2 and 68.4 ng.ml.

<u>Humans</u>

Relationship between maternal and fetal/neonatal exposures

PFOA has been detected in umbilical cord blood serum in studies of the general population worldwide. In seven studies reviewed by Post et al. (2012) in which both maternal and cord blood were analyzed, the mean cord blood serum:maternal serum (or plasma) ratio ranged from 0.68:1 to 1.26:1, with a mean ratio of less than 1:1 in all but one study. However, cord:maternal serum (or plasma) ratios for some individual neonate-maternal pairs within these studies were greater than 1:1. Since umbilical cord serum (or plasma) is reflective of neonatal serum (or plasma), these data indicate that serum (or plasma) levels are generally similar in the neonate and the mother. A more recent review by Kato et al. (2015) that evaluated 12 studies in total also concluded that the maternal:cord serum ratios for PFOA is approximately 1:1.

Exposure to infants through breast milk and infant formula

PFOA is detected in human breast milk worldwide (reviewed by Liu et al., 2010; White et al., 2011a; Post et al., 2012). Factors which may potentially affect the concentration of PFOA in breast milk include whether the mother has previously nursed other infants and how soon after birth the sample is taken (Tao et al., 2008a; Haug et al., 2011; Thomsen et al., 2010). Thomsen et al. (2010) found that average breast milk concentrations were highest initially and decreased by about 7.7% per month, or about 94% during the first year of breast feeding, presumably due to decreased maternal body burden resulting from excretion into breast milk.

Breast milk PFOA concentrations were reported to be about 1% of mean general population serum levels by Tao et al. (2008a), and to be 2.5% and 9% of median maternal serum levels by Kim et al. (2011) and Liu et al. (2011), respectively. These data suggest a breast milk:maternal serum ratio of about 1:100 to 1:11. Based on a breast milk:maternal serum ratio of greater than or equal to 1:100 (Tao et al., 2008a; Kim et al., 2011; Liu et al, 2011) and a serum:drinking water ratio of greater than or equal to 100:1 (discussed below), the initial PFOA concentration in breast milk is expected to be greater than or equal to the concentration in the maternal drinking water source (Post et al., 2012).

Exposures to infants to PFOA from breast milk or formula are higher than in older individuals exposed to the same concentration of PFOA in drinking water. Mean breast milk consumption is 150 ml/kg/day during the first post-partum month when PFOA levels in breast milk are highest (Thomsen et al., 2010), and it is 83 ml/kg/day from 6-12 months of age (USEPA, 2008a). Similarly, the mean drinking water intakes in infants who consume drinking water (e.g. in formula prepared with water) are 137 ml/kg/day from birth to 1 month of age, and 53 ml/kg/day at 6-12 months of age (USEPA, 2011b). These fluid intakes are much higher than the mean drinking water consumption rates in lactating women, 26 ml/kg/day (USEPA, 2011b), and the general population (11 years of age or older), 13 ml/kg/day (USEPA, 2008a). Although breast milk or

formula consumption on a body weight basis decreases as the infant gets older, it remains much higher than adult water consumption throughout infancy.

As noted above, serum PFOA levels are similar in newborns and in their mothers. Several studies, summarized below, have consistently demonstrated that serum PFOA concentrations in breast-fed infants increase by several fold during the first few months of life, presumably because both breast milk PFOA concentrations and intake of breast milk on a body weight basis are highest during this time period. Infants fed with formula prepared with contaminated drinking water also receive the greatest exposures during the first few months of life because the rate of fluid intake is highest then.

Serum PFOA levels were measured in umbilical cord blood at delivery and at 6 month and 19 months of age in infants from the German general population (Fromme et al., 2010). Average body burdens, as indicated by serum levels, were increased, typically by several-fold, from birth to 6 months by exposure through breast milk. Levels declined between 6 months and 19 months, a time point at which breast feeding had stopped or was decreased, but remained higher at 19 months than at birth (Figure 5).




Figure 5. PFOA concentration in cord blood and blood collected in infants around six and nineteen months after birth (Fromme et al., 2010)

Duration of breastfeeding was also associated with higher serum PFOA concentrations in infants (n=49) from a community with PFOA-contaminated drinking water (the C8 Health Study). The increases were estimated as 6% per month of breastfeeding and 96% for one year of breastfeeding (Mondal et al., 2014). The authors noted that these values may underestimate the actual increases from exposure through breastfeeding, because they are based on comparisons to non-breastfed infants from the same communities who may also have had increased serum PFOA concentrations from exposures via formula prepared with contaminated drinking water.

Similarly, a study of Faroese infants (n= 80) with serum PFOA data at birth and 11, 18, and 60 months estimated an increase in serum PFOA concentrations of about 28% per month during the period of exclusive breast feeding (median of 4.5 months in the study group) and about 4% per month during the period of partial breast feeding (median of 4 additional months) (Mogensen et al., 2015). Serum PFOA concentration did not increase in non-breastfed (e.g. formula-fed) infants; presumably, the drinking water in this location was not contaminated with PFOA. Data for 12 infants from the study are shown in Figure 6.




Figure 6. Serum PFOA concentrations over time in 12 infants from Mogensen et al. (2015).

Finally, Verner et al. (2016a,b) developed a pharmacokinetic model that predicts PFOA doses and plasma levels in breastfed infants and children, and their mothers. Monte Carlo simulations were used to predict the distribution of child:mother ratios for doses and plasma levels starting at birth (Figure 7). Doses (ng/kg/day) to infants were much higher than in their mothers during the first year of life. The infant:mother dose ratio peaked right after birth, with a median ratio of about 75:1 and a maximum of 231:1, and declined thereafter (Figure 7, right side). The infant:mother plasma level ratio peaked during the first year of life, with predicted ratios of 4.5-fold (median), 7.8-fold (95th percentile), and 15.3-fold (maximum) higher plasma PFOA concentrations in infants than in their mothers during the period of greatest infant exposure (Figure 7, left side).




Figure 7. Monte Carlo simulations (n = 10 000) of child/mother ratios of plasma PFOA levels (ng/ml; right side of figure) and doses (ng/kg/day; left side of figure) for a breastfeeding period of 30 months. The black line represents the 50th percentile, the blue line represents the 5th percentile, the red line represents the 95th percentile, and the dotted lines represent minimum and maximum values (Verner et al., 2016a,b).

While peak serum PFOA concentrations occur during the first year of life, levels remain elevated for at least several additional years. Serum PFOA levels in children up to age 5 (or older) were higher than in adults in communities exposed through contaminated drinking water (Emmett et al., 2006a; Steenland et al., 2009a; Mondal et al., 2012, discussed above). In the study of Faroese children (Mogensen et al., 2015), serum PFOA levels declined after their peak in infancy but remained elevated above initial levels at birth until at least age 5 years, the last time point assessed. Similarly, the model developed by Verner et al. (2016a) predicts that plasma PFOA concentrations will remain several fold higher than at birth until at least age 3 years, the last time point modeled.

In summary, both breast-fed and formula-fed infants receive much greater exposures to PFOA from contaminated drinking water (directly or indirectly) than older individuals. Serum PFOA levels peak during the first year of life and remain elevated for several years. These elevated exposures during early life are of special concern because effects from neonatal exposure are sensitive endpoints for the toxicity of PFOA.

Relationship between administered dose and internal dose

Repeated Dose Animal Studies

Information on kinetics in repeated dose animal studies was reviewed by Post et al. (2012). At higher doses, the kinetics of PFOA in rodents and primates (Griffith and Long, 1980; Ylinen et al., 1990; Mylchreest, 2003; Butenhoff et al., 2004a; Perkins et al., 2004; Loveless et al., 2006; Lau et al., 2006; Das et al., 2010) are not consistent with one-compartment or simple first-order models (Anderson et al., 2006; Clewell, 2009). Serum levels did not increase proportionally with increasing dose, except at lower doses in some studies. Additionally, steady-state was reached more rapidly at high doses than predicted by classical kinetics (4 to 5 half-lives).

However, at lower doses closer to those relevant to human environmental exposures, kinetics are consistent with first order processes, and serum levels are proportional to administered dose (Clewell, 2009; Lou et al., 2009; Loveless et al., 2006; Das et al., 2010). Available data indicate that serum levels in mice from doses below the administered range can be estimated by linear extrapolation from data on doses of 1 mg/kg/day or lower. The kinetics are consistent with the saturation of OATs responsible for renal reabsorption at high doses, resulting in a higher excretion rate at high doses than at low doses (Anderson et al., 2006; Clewell, 2009).

Human studies

Relationship between drinking water and serum concentrations in exposed communities

In communities with drinking water contaminated by PFOA, mean and median serum PFOA levels higher than in the general population. Variations in serum PFOA concentrations among individuals using the same source of drinking water arise from inter-individual differences in daily water consumption rates (L/kg/day) and/or toxicokinetic factors. The relationship between drinking water concentration and serum concentration has been extensively evaluated for PFOA. It is well established that ongoing human exposure to PFOA in drinking water increases serum levels, on average, by at least 100 times the drinking water concentration. This conclusion is based on data from several studies of populations whose public water supplies or private wells were contaminated with a wide range of PFOA concentrations (60 ng/L to 13,300 ng/L).

In 282 residents of Little Hocking, Ohio at least six years of age exposed for two years or more, with occupationally exposed individuals excluded, the median ratio between the PFOA concentration in serum (371 ng/ml) and drinking water (3,550 ng/L) was 105:1 (25th-75th percentile range, 62:1-162:1), with a higher median ratio in young children (Emmett et al., 2006a).

This approximate 100:1 central tendency value for the serum:drinking water ratio was confirmed in communities with lower drinking water PFOA concentrations (Post et al., 2009a) based on data from approximately 70,000 residents of Little Hocking and five other Ohio and West Virginia water districts, when background serum levels found in the general population from non-water sources of exposure were taken into account. Drinking water levels in four of these districts were in the range of about 60 ng/L to 400 ng/L, while levels in a fifth district and Little Hocking were higher (Anderson-Mahoney et al., 2008).

Additionally, Hoffman et al. (2011) studied the relationship between drinking water concentrations and serum levels in the same region of Ohio and West Virginia in a study of 108 individuals using 62 private wells, with 1 to 4 participants using each well. Since the PFOA concentrations differed in each private well, this study included a greater range of drinking water

concentrations than studies of the six affected public water districts in this vicinity. The median and mean PFOA levels in the wells were 200 ng/L and 800 ng/L, respectively, and the maximum concentration was 13,300 ng/L. An adjusted robust regression model of the serum and drinking water data provided an estimated serum:drinking water ratio of 141:1 (95% CI: 135:1 – 148:1), while a one-compartment pharmacokinetic model based on assumed water intake of 1.41 L/day and half-life of 2.3 years provided an estimated ratio of 114:1.

An approximate ratio of 100:1 or greater between serum and drinking water concentrations is also consistent with observations in 98 Minnesota residents tested 34 months after exposure to contaminated drinking water ended (MDH, 2009), when the expected post-exposure decline in serum levels is considered.

A lower serum:drinking water PFOA ratio of approximately 50:1 was observed in a German community whose drinking water source was contaminated with PFOA and other PFCs (Hölzer et al., 2008). Possible reasons for this difference are the use of bottled water by some participants who were aware of the contamination for up to 6 months before their blood was sampled, uncertainty about the duration and time course of the water contamination, or differences in drinking water consumption patterns between German and U.S. residents.

Pharmacokinetic modeling of the relationship between dose and serum concentration

Biologically based pharmacokinetic modeling predicts a linear relationship in humans between external dose and internal dose, as measured by serum PFOA level, at doses relevant to environmental exposures such as from contaminated drinking water (Clewell, 2009). Increased serum levels that are linearly proportional to exposure levels have been observed in communities using contaminated drinking water (discussed above). However, non-linear kinetics such as observed in animals at higher doses, may occur at higher (occupational) human exposures (Clewell, 2009).

Lorber and Egeghy (2011) developed a simple single-compartment pharmacokinetic model that predicts the relationship in humans between PFOA dose (ng/kg/day) and serum concentration (ng/ml) based on volume of distribution and elimination rate, as follows:

Serum concentration (ng/ml) =	Dose (ng/kg/day)		
	Volume of distribution (ml/kg) x Elimination rate (day ⁻¹)		

This model uses a volume of distribution of 170 ml/kg (0.17 L/kg), based on a model calibrated with data from an Australian population exposed to PFOA through drinking water (Thompson et al., 2010), and an elimination rate of 0.0008 day⁻¹, based on the human half-life of 2.3 years observed in the C8 Health Study population (Bartell et al., 2010a). The product of these two values provides a clearance factor that relates serum concentration (ng/ml) to dose (ng/kg/day) of

0.14 ml/kg/day (or 0.00014 L/kg/day). It is noted that the half-life of 2.3 years (Bartell et al., 2010a) is the shortest value reported in the literature (Table 4) and is based on data from a community whose exposure to PFOA in drinking water had ended. Use of the other values reported in the literature (shown in Table 4) would result in a clearance factor that predicts a higher serum level from a given dose of PFOA.

The USEPA Office of Water (2016a) used the same values for volume of distribution and human half-life (elimination rate) selected by Lorber and Egeghy (2011) to derive the same clearance factor, 0.00014 L/kg/day. This value is very close to the clearance factor of 0.127 ml/kg/day (0.000127 L/kg/day) from the earlier unpublished model developed by Clewell (2006) that is discussed in Post et al. (2012).

USEPA (2016f) presents the following equation, which is equivalent to the equation presented by Lorber and Egeghy (2011) above:

Serum Concentration (μ g/L) x Clearance (1.4 x 10⁻⁴ L/kg/day) = Human Dose (μ g/kg/day)

The relationship between the concentration of PFOA in drinking water and serum predicted by the clearance factor of 0.00014 L/kg/day (Lorber and Egeghy, 2011; USEPA, 2016a) was compared with the empirically observed average ratio of > 100:1 in communities with drinking water exposure to PFOA (discussed above) as follows:

The daily dose from a given concentration of PFOA in drinking water is:

Human Dose ($\mu g/kg/day$) = Drinking Water Concentration ($\mu g/L$) x 0.016 L/kg/day

Where: 0.016 L/kg/day is the mean daily water ingestion rate in the U.S. (USEPA, 2011b).

Therefore:

Drinking Water Conc. (μ g/L) x 0.016 L/kg/day = Serum Conc. (μ g/L) x Clearance (1.4 x 10⁻⁴ L/kg/day)

And:

$$\frac{\text{Serum Concentration (µg/L)}}{\text{Drinking Water Concentration (µg/L)}} = \frac{0.016 \text{ L/kg/day}}{1.4 \text{ x } 10^{-4} \text{ L/kg/day}} = 114:1$$

The serum:drinking water ratio of 114:1 based on the clearance factor and average daily water consumption is consistent with the observed ratios in communities exposed to contaminated drinking water. This calculation verifies that the clearance factor accurately predicts the relationship between human dose and human serum level. The clearance factor can therefore be

used in the development of a Reference Dose (RfD) for PFOA from the Target Human Serum Level (RfD in terms of serum level).

Increases in serum levels associated with PFOA in drinking water

The increase in serum PFOA level, on average, expected from ongoing consumption of a given concentration of PFOA in drinking water can be predicted using the clearance factor, 0.00014 L/kg/day, and an assumed drinking water ingestion rate (L/kg/day). As above, the half-life of 2.3 years used in the clearance factor is shorter than other human half-life values reported in the literature (Table 4). Use of a longer half-life value would result in a higher predicted serum PFOA level from a given daily dose or drinking water concentration.

The mean daily water ingestion rate in the U.S. is 0.016 L/kg/day (from above), and the daily water ingestion rate based on the upper percentile factors (2 L/day water consumption; 70 kg body weight) used to derive Health-based MCLs is 0.029 L/kg/day. For each 10 ng/L in drinking water, on average, ongoing exposure at the mean ingestion and upper percentile ingestion rates are predicted to increase serum PFOA by 1.2 ng/ml and 2.0 ng/ml, respectively. Increases in serum levels from various concentrations of PFOA in drinking water, and the percent increases from the most recent median serum level, 2.1 ng/ml, from NHANES (2011-12; CDC, 2015) are shown in Table 5 and Figure 8.

PFOA in drinking water									
Drinking	Mean Water Ingestion Rate			Upper Percentile Water Ingestion Rate					
Water	(0.016 L/kg/day)			(0.029 L/kg/day)					
Conc.	Increase	Total	% increase from	Increase	Total	% increase from			
(ng/L)	in serum	serum*	drinking water*	in serum	serum*	drinking water*			
	(ng/ml)	(ng/ml)		(ng/ml)	(ng/ml)				
1	0.1	2.2	5%	0.2	2.3	10%			
10	1.1	3.2	52%	2.0	4.1	95%			
20	2.3	4.4	110%	4.0	6.1	190%			
40	4.6	6.7	219%	8.0	10.1	381%			
100	11.4	13.5	543%	20.0	22.1	952%			
400	45.6	47.7	2171%	80.0	82.1	3810%			

 Table 5. Increase in serum PFOA concentrations predicted from various concentrations of PFOA in drinking water

*Total serum concentrations and % increases from drinking water are based on assumption of 2.1 ng/ml in serum (U.S. median value from NHANES, 2011-12; CDC, 2015) from non-drinking water exposures.




Figure 8. Increases in serum PFOA concentrations predicted from mean and upper percentile consumption of drinking water with various concentrations of PFOA, as compared to U.S median and 95th percentile serum PFOA levels (NHANES, 2011-12).

It is evident from Table 5 and Figure 8 that relatively low concentrations of PFOA in drinking water are associated with substantial increases in serum PFOA concentrations; this has recently been observed in a study of serum PFOA levels in individuals served by PWS with PFOA detections in UCMR3 (median UCMR3 detection – 28 ng/L; Hurley et al., 2016). For example, ongoing exposure to 20 ng/L at the upper percentile ingestion rate is predicted to result in a serum concentration of 6.1 ng/ml, which is above the 95th percentile in the U.S population of 5.7 ng/ml (NHANES, 2011-12; CDC, 2015). With an average (mean) water ingestion rate, exposure to 40 ng/L is expected to result in an elevation in serum level to 6.7 ng/ml, also above the 95th percentile from NHANES. Additionally, it should be kept in mind that (as discussed above), the increases in serum levels in infants are expected to be several fold higher than those shown in Table 5 and Figure 8.

HEALTH EFFECTS - HUMAN STUDIES

Overview

The epidemiological database for PFOA is much larger than for most other drinking water contaminants, including those previously evaluated by the DWQI. Considering the large body of epidemiologic studies assessing associations with PFOA, the Health Effects Subcommittee chose

to narrow and focus the human health effects section of this report. Studies of selected health endpoints were comprehensively reviewed, while information on other endpoints is summarized in the text. Conclusions of reviews of selected additional key health endpoints performed by other groups were also evaluated by the Subcommittee and are cited. This method allowed the Subcommittee to focus its resources while maintaining a high level of scientific review.

The basis for selection of endpoints for comprehensive review was largely supported by a previous detailed evaluation of the scientific literature on PFOA by the Health Effects Subcommittee in 2009-2010, and a subsequent comprehensive review of PFOA as an emerging drinking water contaminant (Post et al., 2012). These efforts represent a large amount of work that had already been completed in reviewing information relevant to the development of a Health-based MCL recommendation for PFOA and served as a starting point for the evaluation presented in this document.

Health endpoints evaluated comprehensively include: serum cholesterol/lipids, liver enzymes/bilirubin and liver disease, uric acid, thyroid function and thyroid disease, and antibody concentrations following vaccination. Some of the factors considered in selection of these endpoints were the extent and consistency of the data, whether the effect has been observed at exposures relevant to potential drinking water exposures, and evidence for reverse causality. Comprehensive evaluation involved the review of peer-reviewed studies identified through an *a priori* literature search and screening criteria. An individual study table summarizing the study design, location, study population characteristics, outcome and exposure assessment, study population exposure, statistical methods, results, major limitations which addresses risk of bias, and funding source for each reviewed study can be found in Appendix 4, and tables summarizing all studies of each endpoint are found below. Two other critical endpoints, fetal growth following developmental exposure and cancer, were recently comprehensively reviewed by other authoritative scientific groups. Review reports by these groups are evaluated and summarized in this document.

In total, 54 epidemiological studies assessing associations with serum cholesterol/lipids, liver enzymes/bilirubin, uric acid, thyroid function and thyroid disease, and/or antibody concentrations following vaccination were evaluated in depth. The studies were conducted on populations in the U.S., Canada, and several European and Asian countries. The studies evaluated the general population, communities with drinking water contaminated with PFOA, and occupationally-exposed workers, thereby assessing health effects over a wide range of PFOA exposures and serum concentrations.

In human environmental health effect studies in general, confounding by co-exposure to contaminants other than the one being evaluated may be particularly important since it may bias results. In some instances, PFOA has been shown to be strongly correlated with other co-

occurring PFCs which may not have been controlled for, and the same may be true for other environmental contaminants. This confounding bias could impact studies in any type of population, but may play a more important role in occupational populations which may be more likely than the general population to be exposed to co-occurring contaminants at meaningful levels. In general, co-exposure to other chemicals could also be more likely in communities where there are high levels of environmental contamination. However, this is not likely the case in the C8 Health Project, a large community study of populations with drinking water exposure to PFOA (discussed in more detailed below), since PFOA is the only contaminant that was reported to be present at elevated levels in drinking water or other environmental media.

As is the case for epidemiologic studies of environmental contaminants in general, the nature of these observational epidemiology studies, in contrast to experimental studies, limits our ability to definitively conclude that PFOA causes health effects. However, the findings from observational epidemiology studies are useful in assessing consistency, strength of association, exposure-response, temporality, specificity, and biologic plausibility - criteria which are useful in assessing causation.

Studies of Exposure Levels Found in the General Population

For the endpoints that were comprehensively reviewed, the majority of studies evaluated the general population and/or study populations with general population-level exposures to PFOA. Twenty nine (29) studies with general population, low-level exposures were identified. The serum PFOA concentrations (based on a measure of central tendency, which was presented as median, mean, or geometric mean) in these studies range from 0.9 to 7.1 ng/ml. A strength of the general population studies is their use of serum PFOA levels as the basis for exposure assessment. Because of the long human half-life of PFOA, serum levels do not rapidly fluctuate with short term variations in exposure, and serum levels taken at a single time therefore reflect long-term exposures. Serum levels thus provide an accurate measure of internal exposure for each study participant, an advantage over studies based on external exposure metrics such as drinking water concentrations. Among these studies, the large majority are cross-sectional (23 studies, plus one which includes a cross-sectional component).

A general limitation of cross-sectional studies is that they evaluate information on both exposure and outcome at the same point in time, limiting their ability to establish temporality.

Studies in Exposed Communities

For the endpoints selected for comprehensive evaluation, 15 studies evaluated highly-exposed individuals residing in communities with known PFOA drinking water contamination or in close proximity to a factory utilizing or producing PFOA. A large majority of these studies (14) occurred among communities in the Mid-Ohio Valley near the DuPont Washington Works plant in Parkersburg, WV. This industrial facility used large amounts of PFOA in the manufacturing of

a fluoropolymer, polytetrafluoroethylene (PTFE), and discharged PFOA to the environment resulting in widespread drinking water contamination. Many of the studies in this population are the result of the settlement of a class-action lawsuit by residents exposed to PFOA-contaminated drinking water which mandated that DuPont fund a health study called the C8 Health Project. Additional epidemiologic studies of associations with PFOA and health endpoints in this population have also been published by other researchers.

The C8 Health Project is a community health study of approximately 70,000 Ohio and West Virginia residents of all ages (infants to very elderly) with at least one year of exposure to drinking water contaminated with PFOA at >50 ng/L to over 3000 ng/L (Frisbee et al, 2009; C8 Science Panel, 2014). The C8 Health Project was conducted by the C8 Science Panel, which consisted of three epidemiologists chosen jointly by the parties involved in the legal settlement. This study is notable because of its large size, the wide range of exposure levels, and the large number of parameters evaluated. Data collected included serum levels of PFOA and other PFCs, clinical laboratory values, and health histories. The median serum PFOA concentration in this population was 28 ng/ml (ppb), and serum concentrations in the lowest two deciles were within the U.S. general population range at the time (<10 ng/ml).

The C8 Science Panel was charged with determining if "probable links" exist between diseases and PFOA exposure in the C8 study population, based on the results of their studies and other information from the scientific literature. Probable links were defined as ".... given the scientific evidence available, it is more likely than not that a connection exists between C8 exposure and a particular human disease among class members...". Probable links were established with PFOA exposure and six health endpoints (clinically defined high cholesterol, kidney and testicular cancer, ulcerative colitis, thyroid disease, and pregnancy-induced hypertension). For a number of other endpoints, no probable link with PFOA exposure was reported. Associations were also found with additional health endpoints for which no probable link evaluation was conducted because they were not considered to be clinically defined diseases. These endpoints include increased serum levels of liver enzymes, uric acid, C-reactive protein, and others. C8 Science Panel reports and citations for peer-reviewed publications presenting the results of these studies are found at the C8 Science Panel website (C8 Science Panel, undated, b).

Occupational Studies

There are 14 peer-reviewed occupational studies of the endpoints chosen for detailed evaluation, three of which also studied exposed community populations (Wang et al., 2012, Winquist and Steenland, 2014a, and Winquist and Steenland, 2014b). Eight of the 14 occupational studies are cross-sectional. Locations include industrial facilities in the U.S., Italy, Belgium, and China. Occupational studies are often considered useful for evaluating effects of environmental contaminants because exposure levels are generally higher than in general population or in communities exposed through site-specific environmental contamination. Mean or median serum

PFOA levels in occupational studies reviewed in this report were generally over 1,000 ng/ml (ppb), several orders of magnitude higher than the median concentrations in the general population or in communities with drinking water exposure.

Associations of PFOA with some clinical parameters, including cholesterol, liver enzymes, and uric acid, exhibit a steep dose-response curve in the lower exposure range found in the general population, with a much flatter slope (approaching a plateau) at higher exposure such as those found occupationally (discussed in more detail below). For dose-response curves of this type, the associations found in populations with lower exposures may not be observed in workers because even the least exposed workers used as the comparison/reference group in occupational studies may have exposure levels that are high enough to fall on the much flatter upper portion of the dose-response curve.

Occupational studies may also have a selection bias from a "healthy worker effect" whereby workers usually have lower overall mortality and morbidity than individuals of the same age as a whole, since severely ill and disabled persons are typically not included in the workforce, especially in industrial settings (Shah, 2009). Longer duration of employment may also increase the effects of this bias, since sick people will be more likely to leave or change to safer work. Therefore, data based on duration of employment may not accurately reflect higher prevalence or larger magnitude of effects that are associated with longer exposures to the contaminant being evaluated.

Another issue with occupational studies of PFOA is the small number of exposed female employees which limits the ability of the occupational epidemiology to adequately address specific effects among women.

An additional issue is the possibility of effect modification due to exposure to other chemicals. Exposure to other PFCs, including PFOS at the 3M Decatur plant, may have played a role in the observed associations. Differences in exposures to other chemicals among manufacturing facilities may result in differences in degree of association with various effects.

Comprehensively Reviewed Endpoints

Serum lipids

Associations of serum lipids and PFOA were evaluated in 24 studies, each of which included one or more of the following endpoints: total cholesterol, high density lipid cholesterol (HDL), non-HDL, ratio of total cholesterol to HDL, low-density lipid cholesterol (LDL), very low-density lipid cholesterol (VLDL), ratio of HDL to LDL, and triglycerides. There is also one additional study which only evaluated expression of genes related to cholesterol transport in humans (Fletcher et al., 2013). Study details are provided in the tables for individual studies (Appendix 4) and the summary table for serum lipids (Table 6A).

In total, 20 studies evaluated serum total cholesterol and two evaluated self-reported clinically defined high cholesterol (Steenland et al., 2015 and Winquist and Steenland, 2014). Among the 20 serum total cholesterol studies, 15 were cross-sectional (Emmett et al., 2006b; Eriksen et al., 2013; Fisher et al., 2013; Frisbee et al., 2010; Fu et al., 2014; Geiger et al., 2014; Gilliland et al., 1996; Nelson et al., 2010; Olsen et al., 2000; Olsen and Zobel 2007; Sakr et al., 2007a; Starling et al., 2014; Steenland et al., 2009; Wang et al., 2012; and Zeng et al., 2015) and two studies included cross-sectional and other analyses (Costa et al., 2009; and Olsen et al., 2003). The cross-sectional studies include seven studies of the general population or individuals with lowlevel exposures (Eriksen et al., 2013; Fisher et al., 2013; Fu et al., 2014; Geiger et al., 2014; Nelson et al., 2010; Starling et al., 2014; and Zeng et al., 2015); four studies of residents of highly exposed communities (Emmett et al., 2006b; Frisbee et al., 2010; Steenland et al., 2009; Wang et al., 2012); and five studies of occupationally exposed individuals (Gilliland et al., 1996; Olsen et al., 2000; Olsen and Zobel 2007; Sakr et al., 2007a; and Wang et al., 2012). Five remaining studies evaluating serum total cholesterol and PFOA include an occupational casecontrol study (Costa et al., 2009), and four cohort studies including one study of residents of a highly-exposed community (Fitz-Simon et al., 2013) and three studies of occupationally exposed individuals (Olsen et al., 2003; Olsen et al., 2012; and Sakr et al., 2007b).

Six of seven cross-sectional studies of the general population or populations with low-level exposures found evidence of statistically significant positive associations with serum cholesterol and PFOA. These studies of general population level exposures include a study nested in a larger cohort in Denmark of adults, aged 50 to 65 years, with mean serum PFOA concentration of 7.1 ng/ml (Eriksen et al., 2012); a general population study in Canada with a PFOA geometric mean of 2.5 ng/ml (Fisher et al., 2013); a small study of individuals randomly selected from attendees at a health check-up clinic with a median serum PFOA concentration of 1.4 ng/ml (Fu et al., 2014); a study of children in the U.S. general population with a serum PFOA mean concentration of 4.3 ng/ml (Geiger et al., 2014); a study of the general U.S. population aged 12 years older with a median PFOA concentration of 3.8 ng/ml (Nelson et al., 2010); and a study of subjects recruited from the control group of another study in Taiwan with median PFOA exposures of 1.1 ng/ml in boys and 0.9 ng/ml in girls (Zeng et al., 2015). A study of pregnant women recruited from a larger cohort in Norway, with a median serum PFOA concentration of 2.3 ng/ml, did not find a statistically significant positive association with PFOA and serum cholesterol; however, results showed a positive and increasing association of cholesterol with increasing quartiles of PFOA (Starling et al., 2014).

Two large cross-sectional studies evaluated individuals residing in communities located in the mid-Ohio Valley with drinking water contaminated with PFOA. One study included 12,476 children aged 1 to 17.9 years with a mean serum PFOA concentration of 69.2 ng/ml (Frisbee et al., 2010) and the other included 46,294 individuals aged 18 years or older with a median serum

PFOA concentration of 27 ng/ml (Steenland et al., 2009). Both studies found a positive, statistically significant association of serum PFOA and cholesterol. A third smaller (n=371) cross-sectional study from the water district in the mid-Ohio Valley with the highest PFOA levels in its drinking water, with a much higher median serum PFOA concentration, 354 ng/ml, did not find a statistically significant association (Emmett et al., 2006)b. A fourth study from China, which in addition to a study of 132 residents located near a plant utilizing PFOA with a median PFOA concentration of 284 ng/ml also included a worker study, did not find an association with serum cholesterol in either group (Wang et al., 2012).

Of the five occupational cross-sectional studies, only one U. S. occupational study (n=840) with a median serum PFOA concentration of 189 ng/ml found a positive statistically significant association with serum cholesterol (Sakr et al., 2007a). The remaining four occupational cross-sectional studies which did not find evidence of an association include two U.S. male only worker studies, one with a mean serum PFOA concentration of 3,300 ng/ml and a sample size of 115 (Gilliland et al., 1996), and one with a mean serum PFOA concentration of 1,190 ng/ml with a sample size of 265 (Olsen et al., 2000). The third study took place in both the U.S. and Belgium with a median PFOA concentration of 2210 ng/ml and a sample size of 506 (Olsen and Zobel 2007) and the fourth cross-sectional study included 55 workers in China with a median PFOA concentration of 1,636 ng/ml (Wang et al., 2012).

Five of the 20 studies had study designs other than cross-sectional. A longitudinal analysis of workers from Belgium and U.S. with a range of PFOA means of 1,220 to 1,900 ng/ml (Olsen et al., 2003), and another longitudinal worker cohort analysis from the U.S. with a range of PFOA exposure from 1,010 to 1,160 ng/ml (Sakr et al., 2007b), both found evidence of an association with PFOA and serum cholesterol. A third occupational cohort study utilizing matched-pair analysis of 98 to 179 workers (highly exposed of 881 ng/ml PFOA mean v. lower exposed of 28.9 ng/ml PFOA mean) did not find a statistically significant association (Olsen et al., 2012). None of these studies found evidence of a statistically significant inverse association with serum cholesterol and PFOA. An Italian male occupational case-control study with PFOA median concentration 4,400 among formerly exposed workers and a median of 5,700 ng/ml among currently exposed workers, with cross-sectional analysis, found evidence of a positive association (Costa et al., 2009). Among the cohort studies, a longitudinal study of individuals in highly-exposed mid-Ohio Valley communities, with geometric mean PFOA concentrations of 74.8 ng/ml at baseline and 30.8 ng/ml at follow-up, found evidence of a positive association (Fitz-Simon et al., 2013).

Although 15 of the 20 studies evaluating associations of PFOA and serum cholesterol were cross-sectional, thereby limiting the interpretation of temporality since exposures and outcomes are measured at the same point in time, four studies included longitudinal analyses (Fitz-Simon et al., 2013; Sakr et al., 2007b; Costa et al., 2009; Olsen et al., 2003). Each of these studies had

multiple measurement data, and all four found a significant correlation over time between cholesterol and PFOA levels (Fitz-Simon et al., 2013; Steenland et al., 2010b). In summary, the epidemiologic data provide evidence of consistency, strength and dose-response, including some evidence of temporality, of PFOA and serum cholesterol.

Several of the studies mentioned above showed statistically significant trends for increased serum cholesterol with increasing serum PFOA. A decile analysis of PFOA with total cholesterol among a large study of residents of a highly exposed community showed an increasing effect of PFOA on cholesterol and additionally the odds of clinically defined hypercholesterolemia (\geq 240 mg/dL) increased 40-50% from the lowest to the highest quartile of PFOA (Steenland et al., 2009). A statistically significant trend of increasing serum cholesterol with increasing PFOA was also reported in at least five other studies (Frisbee et al., 2010, Fu et al., 2014, Geiger et al., 2014; and Zeng et al., 2015).

In summary, general population level exposure studies (seven), found consistent evidence of a positive association between PFOA and serum cholesterol. Additionally, three very large studies (two cross-sectional and a cohort study) of highly exposed community populations found evidence of a positive association between PFOA and serum cholesterol. Two longitudinal occupational studies also found a positive association, along with one case-control occupational study. In contrast, results from two much smaller cross-sectional studies of highly exposed community populations (with higher median population exposures than the three larger studies) and a matched-pairs occupational study did not find an association. Although findings from the occupational cross-sectional studies in general (four out of five) found no evidence of an association, they may be biased toward the null by a healthy worker effect. This is suggested by a similar pattern of inconsistency among these study's findings as compared to the findings from the corresponding database were also noted for other serum lipid endpoints (HDL and LDL – discussed below).

In general, studies of the general population, as well as large, mid-exposure range community studies and occupational studies with longitudinal designs, found consistent evidence of an association, while a few smaller, higher exposure range community and occupational studies found no evidence. None of the 20 studies evaluated found evidence of an inverse association.

A review by Steenland et al. (2010a) summarized and evaluated the epidemiologic literature on PFOA and cholesterol available at that time. The authors noted that the lower the range of PFOA that was studied, the greater the change in cholesterol per unit change in PFOA. They suggest that, as discussed in <u>Occupational Studies</u> (above), an exposure-response relationship that is steep at low PFOA concentrations and then flattens out (i.e. approaches a plateau) at higher serum PFOA concentrations is a possible explanation for the observed differences in effect magnitudes. Therefore, studies of populations with high serum PFOA concentrations may not detect an association of PFOA with serum cholesterol if there is a steep dose-response curve for

the association in the lower exposure ranges. For dose-response curves of this type, associations may not be evident in populations with higher exposures since even the least exposed individuals in the comparison group may have exposures that fall on the much flatter (approaching a plateau) portion of the exposure/response curve.

Associations of PFOA and high density lipid cholesterol (HDL), non-HDL, ratio of total cholesterol to HDL, low-density lipid cholesterol (LDL), very low-density lipid cholesterol (VLDL), ratio of HDL to LDL, and/or triglycerides were evaluated in 20 studies. All but two of these 20 studies also evaluated serum cholesterol.

HDL and PFOA were evaluated in 19 studies. It should be noted that an increase in HDL is considered to be beneficial, as compared to increases in total cholesterol, LDL, and non-HDL, which are considered to be undesirable. None of these studies found an association with increased HDL, while four of the 19 studies found evidence of statistically significant decreased association with HDL (Gilliland et al., 1996; Olsen et al., 2000; Olsen and Zobel 2007; and Wang et al., 2012). Interestingly, these four studies are all occupational cross-sectional studies which also did not find evidence of an association with PFOA and increased serum cholesterol (described above), whereas the only other additional occupational cross-sectional study found no evidence of an association with HDL but did find a statistically significant positive association between PFOA and cholesterol (Sakr et al., 2007a). These differences in findings suggest that these occupational cross-sectional studies may be biased from a healthy worker effect. There was no evidence of statistically significant associations with HDL in any of the other 15 studies (Costa et al., 2009; Fisher et al., 2013; Fitz-Simon et al., 2013; Frisbee et al., 2010; Fu et al., 2014; Geiger et al., 2014; Lin et al., 2011; Nelson et al., 2010; Olsen et al., 2003; Olsen et al., 2012; Sakr et al., 2007a; Sakr et al., 2007b; Starling et al., 2014; Steenland et al., 2009; Wang et al., 2012 [resident study]; and Zeng et al., 2015).

Non-HDL was evaluated in four studies: two general population cross-sectional studies (Fisher et al., 2013; and Nelson et al., 2010), a U.S. occupational longitudinal study (Olsen et al., 2012), and a large cross-sectional study of residents in highly exposed communities (Steenland et al., 2009). Three of the studies found statistically significant positive associations with non-HDL and PFOA (Fisher et al., 2013; Nelson et al., 2010; and Olsen et al., 2012), while the occupational longitudinal study had a negative association with non-HDL which was not statistically significant (Olsen et al., 2012).

The ratio of total cholesterol to HDL was evaluated in three studies with inconsistent findings. A general population study in Canada did not find evidence of a statistically significant association (Fisher et al., 2013), U.S. occupational longitudinal study found a statistically significant negative association (Olsen et al., 2012), and a large study of residents from a highly exposed community found a statistically significant positive association (Steenland et al., 2009).

Associations of LDL and PFOA were evaluated in 16 studies. Fourteen of the studies are crosssectional, which includes seven low level exposure populations (Fisher et al., 2013; Fu et al., 2014; Geiger et al., 2014; Lin et al., 2013; Nelson et al., 2010; Starling et al., 2014; and Zeng et al., 2015), three studies of residents from a highly exposed community (Frisbee et al., 2010; Steenland et al., 2009; Wang et al., 2012), and five studies of occupationally exposed individuals (Gilliland et al., 1996; Olsen et al., 2000; Olsen and Zobel 2007; Sakr et al.; 2007a ; and Wang et al., 2012). The other two studies of LDL and PFOA include an occupational longitudinal study (Sakr et al., 2007b) and a cohort study of residents from the highly exposed community, mid-Ohio Valley (Fitz-Simon et al., 2013).

Among the cross-sectional studies of populations with low level exposure, three found evidence of statistically significant positive associations with LDL (Fu et al., 2014; Geiger et al., 2014; and Zeng et al., 2015) and four found no statistically significant evidence of an association (Fisher et al., 2013; Lin et al., 2013; Nelson et al., 2013; and Starling et al., 2014). Of the three cross-sectional studies of residents from a highly exposed community; the two large studies in the mid-Ohio Valley, one which included children and the other of adults, found evidence of statistically significant positive association (Frisbee et al., 2010, and Steenland et al., 2009); while the third smaller study of 132 residents in China found no evidence of an association (Wang et al., 2012). Four of the five occupational cross-sectional studies found no association (Gilliland et al., 2996; Olsen et al., 2000; Olsen and Zobel, 2007; and Wang et al., 2012) while only one of the studies found evidence of a statistically significant association with both LDL and VLDL (Sakr et al., 2007a). Additionally, an occupational longitudinal study found a positive, non-statistically significant association with LDL (Sakr et al., 2007b) while a cohort study of residents from a highly exposed community found a statistically significant positive association (Fitz-Simon et al., 2013). Finally, the ratio of HDL to LDL was evaluated in a crosssectional study which assessed both occupational and highly exposed residential populations and found a negative association with the worker population and no evidence of a statistically significant association with the residential population (Wang et al., 2012).

In summary, positive associations with PFOA and LDL were inconsistent among low level exposure populations, and largely unassociated in occupational studies, but there is consistent evidence of an association with PFOA and LDL among larger studies of the highly exposed mid-Ohio Valley communities: two cross-sectional studies one among children and another among adults, and a longitudinal study.

Sixteen studies evaluated triglycerides with inconsistent findings. Four of the studies found evidence of positive statistically significant association (Frisbee et al., 2010; Olsen et al., 2003; Olsen and Zobel, 2007; and Zeng et al., 2015), one found evidence of a negative statistically significant association (Lin et al., 2013), and 11 studies found no evidence of a statistically

significant association (Costa et al., 2009; Fisher et al., 2013; Fitz-Simon et al., 2013; Fu et al., 2014; Geiger et al., 2014; Lin et al., 2011; Olsen et al., 2000; Sakr et al., 2007a; Sakr et al., 2007b; Starling et al., 2014; and Wang et al., 2012).

Selection bias may be an issue in Fu et al. (2014) since the study included only individuals attending a health clinic check-up such that individuals concerned with existing health issues may be more likely to be included. Selection bias may also be an issue in Lin et al. (2013), which included individuals with an abnormal urinalysis from a population-based screening program in which the final study population was made up of 246 (37%) individuals with elevated blood pressure. Information bias is unlikely to have an impact in the general population studies which relied on serum concentrations and clinical biomarkers. In contrast, some occupational studies relied on medical record abstraction of clinical parameters. Other limitations of occupational studies include small sample size that may limit power to detect associations, possibility of healthy worker effect, inclusion of few or no women, and the possibility that exposure in the least exposed groups may be well above the population exposure range in occupationally exposed individuals.

The biological plausibility of the association of PFOA and serum cholesterol was investigated in a study of associations of serum PFOA and changes in expression of genes involved in cholesterol metabolism. In this cross-sectional study, expression of 13 genes involved in cholesterol metabolism (cholesterol biogenesis, peroxisome proliferation, cholesterol transport, downstream transcriptional activation of PPAR-alpha, and mobilization of cholesterol) was evaluated in whole blood from 290 subjects from a highly exposed community (geometric mean serum PFOA, 32.2 ng/ml). Statistically significant associations between genes involved in cholesterol transport and mobilization and PFOA were found, and the affected genes differed in men and women. The authors state that these change in gene expression "appear consistent with PFOA promoting a hypercholesterolemic environment" (Fletcher et al., 2013).

Effects of PFOA on serum lipids in laboratory animals are considered in evaluating the biological plausibility of the associations of PFOA and cholesterol found in humans. Serum cholesterol was not affected by PFOA in a 6-month study of cynomolgus monkeys (Butenhoff et al., 2002), while triglycerides were significantly increased compared to controls at several time points in the monkeys in the mid- and high dose groups (10 and 20/30 mg/kg/day). As discussed above, the dose-response curve for increased cholesterol in humans appears steepest at serum PFOA levels below about 40 ng/ml, with a much flatter dose-response at higher serum levels. In the monkey study, the mean serum PFOA level in the control group was 134 ng/ml. If the dose-response curve is similar in monkeys such that effects on serum cholesterol are steepest at lower serum PFOA levels, effects may not be observable because the control exposure levels could be high enough to fall on the much flatter portion of the dose-response curve.

Although PFOA is consistently associated with increased serum cholesterol in humans, serum cholesterol and triglycerides are generally decreased by PFOA in rodents. This effect in rodents is attributed to PPAR-alpha activation (Lau, 2013). As discussed in detail in the <u>Mode of Action</u> section below, PPAR-alpha activators typically reduce serum lipids in both rodents and humans, and this is the basis for the use of fibrates as hypolipidemic drugs in humans. It is well established that the effects of PFOA in rodents differ from those of other PPAR-alpha activators, and that PFOA affects rodents through both PPAR-alpha independent and PPAR-alpha dependent pathways. It is possible that the dissimilar effects of PFOA on serum lipids in humans and rodents could arise from a different balance of PPAR-alpha dependent and independent processes with opposite effects on this endpoint.

Two recent studies, discussed in detail in the Mode of Action section, suggest the important possibility that the contrasting effects on serum cholesterol observed in humans and animals may result from differences in dietary fat content, rather than intrinsic interspecies biochemical or physiological differences (Tan et al., 2013; Rebholz et al., 2016). In these studies, mice were fed a diet with a high fat content, similar to that of a typical U.S. diet, instead of standard lower fat laboratory chow. Serum cholesterol was either increased or unaffected in mice fed the high fat diets. In contrast, serum cholesterol was decreased, as is typically seen in mice fed the regular diet in Tan et al. (2013), while Rebholz et al. (2016) did not include a regular diet group. These results suggest that effects of PFOA on cholesterol may be similar in rodents and humans consuming the same dietary fat content, and they provide evidence for biological plausibility for PFOA's effects on serum cholesterol in humans.

In summary, the epidemiologic database for serum cholesterol and PFOA, which included twenty studies, provides evidence of consistency, strength and dose-response, including some evidence of temporality. Associations with clinically defined hypercholesterolemia were reported in some studies. These findings provide evidence supporting a causal relationship between PFOA and serum cholesterol. Overall, the epidemiologic evidence suggests no evidence of an association with HDL and PFOA. There were a limited number of epidemiologic studies evaluating an association with non-HDL or the ratio of total cholesterol to HDL and PFOA. The epidemiologic database for PFOA and LDL appears inconsistent. Although there is some evidence of an association with LDL, it remains limited due to the interpretation of other studies which found no evidence of an association. There is limited epidemiologic evidence evaluating associations of VLDL, the ratio of HDL to LDL, and triglycerides with PFOA.

Liver enzymes/bilirubin

A total of 16 studies evaluated associations between PFOA and clinical biomarkers used in the diagnosis and/or evaluation of treatment of liver function or metabolic disease. These biomarkers include the following liver enzymes: alanine aminotransferase (ALT /SGPT), gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST /SGOT), and alkaline phosphatase (ALP), as well as total bilirubin or unspecified bilirubin (TB) and direct bilirubin (DB). Additionally,

two studies assessed PFOA and liver disease (LD). Study details are provided in the tables for individual studies (Appendix 4) and the summary table for liver enzymes/bilirubin (Table 6B).

Two larger cross-sectional general population studies utilizing different survey cycles of the U.S. National Health and Nutrition Examination Survey (NHANES) both found evidence of statistically significant positive associations with PFOA and the liver enzyme ALT (Gleason et al., 2015 and Lin et al., 2010). Two other cross-sectional studies of a population with low-level exposure cross-sectional studies have also evaluated this association. A study that was based on a population recruited from a larger cohort in Taiwan (n=608) found a positive statistically significant correlation (Yamaguchi et al., 2013), while a small study (n=141) of pregnant women in China did not find a significant correlation between PFOA and ALT (Jiang et al., 2014). Of the three cross-sectional studies of mid-Ohio Valley residents, the smaller study (n=371) with a higher median and narrower range of PFOA exposure found no evidence of an association (Emmett et al., 2006b), while the two larger studies (n=47,092) with a wider range of exposures found a consistent positive statistically significant association with ALT and PFOA (Gallo et al., 2012; and Gallo et al., 2016). Nine additional occupational studies investigated associations of ALT and PFOA with inconsistent findings. Among these studies only one cross-sectional study found evidence of a positive association (Olsen et al., 2007), one found evidence of a negative association (Gilliland et al., 1996) and four cross-sectional studies found no consistent evidence of an association (Olsen et al., 2000; Olsen et al., 2003; Sakr et al., 2007a; and Wang et al., 2012). An occupational case-control study, with cross-sectional components, found some evidence of a positive association (Costa et al., 2009); one longitudinal occupational study found evidence of a negative association (Olsen et al., 2012), and a second longitudinal occupational study found no evidence of an association (Sakr et al., 2007b).

Although results of occupational studies were inconsistent, both cross-sectional general population studies found evidence of an increasing trend (Gleason et al., 2015 and Lin et al., 2010). The much larger studies of a highly-exposed community also found increasing levels of ALT with increasing serum concentrations of PFOA (Darrow et al., 2016; Gallo et al., 2012). Further, the associations noted by Gallo et al. (2012) were consistent both between water districts and among individuals within the same district, which also increased the strength of evidence. Additionally, the modeled serum PFOA exposure assessment used by Darrow et al. (2016) complements evidence from previous studies because these estimates are not affected by reverse causation.

Thirteen studies evaluated associations of PFOA and GGT: six studies found evidence of a positive statistically significant association (Costa et al., 2009; Gallo et al., 2012; Gleason et al., 2015; Lin et al., 2010; Olsen and Zobel, 2007; and Sakr et al., 2007a) and the remaining seven studies found no statistically significant evidence of an association (Darrow et al., 2016; Emmett et al., 2006b; Gilliland et al., 1996; Olsen et al., 2000; Olsen et al., 2003; Sakr et al., 2007b; and

Yamaguchi et al., 2013). Twelve studies also evaluated the association of PFOA and AST; three found evidence of a positive statistically significant negative association (Gleason et al., 2015; Sakr et al., 2007b; Yamaguchi et al., 2013); two studies found some evidence of a negative association (Gilliland et al., 1996 and Wang et al., 2012) and seven other studies found no evidence (Emmett et al., 2006; Jiang et al., 2014; Olsen et al., 2000; Olsen et al., 2003; Olsen and Zobel 2007; Olsen et al., 2012; and Sakr et al., 2007a).

Eight studies evaluated the association of PFOA and the liver enzyme ALP. Only one found some limited evidence of a positive statistically significant association (Costa et al., 2009), while the other seven studies found no evidence of an association (Emmett et al., 2006b; Gleason et al., 2015; Olsen et al., 2000; Olsen et al., 2003; Olsen and Zobel, 2007; Olsen et al., 2012; and Sakr et al., 2007b).

Thirteen studies evaluated the association of PFOA and either total or direct bilirubin. A component of total bilirubin is direct bilirubin, a product of hemoglobin metabolism for which increased serum concentrations reflect increases in liver and bile duct disease. Therefore, total bilirubin serves only as an inferential measure of liver function. Among studies of total bilirubin, three studies found evidence of a statistically significant association (Costa et al., 2009; Olsen and Zobel, 2007; and Sakr et al., 2007b); one study found a positive statistically significant association (Gleason et al., 2015); and seven found no association with total bilirubin (Emmett et al., 2006b; Jiang et al., 2014; Lin et al., 2010; Olsen et al., 2000; Olsen et al., 2003; Olsen et al., 2012; and Sakr et al., 2007a). Two additional studies found no association with direct bilirubin (Gallo et al., 2012; and Darrow et al., 2016), and Olsen et al. (2000) also found no association with total or direct bilirubin.

Three studies investigated association with PFOA and clinical liver disease. Melzer et al., 2011 found no statistically significant association of PFOA and current liver disease in a cross-sectional study of the U.S. general population (NHANES). Also Darrow et al. (2016) found no evidence of an association with modeled serum PFOA and medically-validated liver disease when categorized as either any liver disease or restricted to enlarged liver, fatty liver, or cirrhosis among the highly exposed C8 Health Study community. A retrospective cohort of a U.S. occupational population also found no association with self-reported liver disease and estimated serum PFOA concentration (Steenland and Zhao et al., 2015).

As previously described, cross-sectional studies limit interpretation of temporality. Information bias is unlikely to have an impact in the general population studies which relied on serum concentrations and clinical biomarkers. Small sample sizes in some studies may have limited their power to detect associations (Emmett et al., 2006b; Jiang et al., 2014; Wang et al., 2012; and Yamaguchi et al., 2013). In addition to small sample size, some occupational studies relied on abstraction of clinical parameters from medical records. Other limitations of occupational

studies include the possibility of healthy worker effect, inclusion of few or no women, and the possibility that exposure in the least exposed groups may be well above the population exposure range in occupationally exposed individuals.

Toxicological and mode of action data support the biological plausibility of hepatic effects of PFOA in humans. As discussed in detail in the <u>Toxicology</u> and <u>Mode of Action</u> sections below, it is well established that hepatic toxicity is a sensitive effect of PFOA in experimental animals. Based on studies in non-human primates, standard strains of rodents, and rodents lacking a functional PPAR-alpha receptor, hepatic effects of PFOA are considered relevant to humans.

In summary, the evaluation of epidemiologic studies provides evidence of some inconsistencies among the group of studies evaluated. However, there was consistency among the larger non-occupational studies, as well as evidence of specificity, exposure-response, strength, and biologic plausibility for PFOA and ALT. These findings provide evidence supporting a causal relationship between PFOA and ALT. The epidemiologic evidence of an association with PFOA and GGT, AST, and bilirubin is inconsistent, while there was no evidence of an association with PFOA and ALP. There is also limited epidemiologic evidence of a causative relationship with PFOA and liver disease, and the available studies did not find an association.

Thyroid hormones, TSH, and thyroid disease

Twenty studies were identified as evaluating thyroid hormones, TSH, hypo-and hyperthyroidism, thyroid disease in general, and/or other thyroid conditions. Study details are provided in the tables for individual studies (Appendix 4) and the summary table for thyroid effects (Table 6C).

Thyroid stimulating hormone (TSH) was the most commonly evaluated thyroid endpoint, and there was limited evidence of a positive statistically significant relationship with PFOA. Three general population studies which include a cross-sectional U.S. population study (Jain, 2013), a South Korean prospective birth cohort (Kim et al., 2011), and a prospective cohort study in Canada (Webster et al., 2014) found some evidence of a positive statistically significant association of elevated TSH and PFOA. The remaining 12 studies found limited or no evidence of a positive association. These 12 studies are all cross-sectional study design, which include six general population studies (Bloom et al., 2010; Ji et al., 2012; Lin et al., 2013; Shrestha et al., 2015; Wang et al., 2014; and Wen et al., 2013), three studies of residents in a highly exposed community (Emmett et al., 2006b; Knox et al., 2011; Lopez-Espinosa et al., 2012), and three occupational studies (Olsen et al., 1998; Olsen et al., 2003; Olsen and Zobel 2007). Three of the 12 studies also included components of other study designs in addition to the cross-sectional design: birth cohort (Lopez-Espinosa et al., 2012), longitudinal (Olsen et al., 1998), and prospective birth cohort (Wang et al., 2014)

Additionally, total thyroxine (TT4) has been extensively evaluated with little evidence of a positive statistically significant association. Only two studies found some evidence of statistically significant positive association (de Cock et al., 2014, and Knox et al., 2011), while 11 others found no evidence of a statistically significant association (Jain 2013; Ji et al., 2012; Kim et al., 2011; Lin et al., 2013; Lopez-Espinosa et al., 2012; Olsen et al., 2003; Olsen and Zobel 2007; Shrestha et al., 2015; Wang et al., 2014; Webster et al., 2014; and Wen et al., 2013). A case-control study of hypothyroxemic pregnancy matched with non-hypothyroxemic pregnant women in Canada evaluated the association of PFOA and maternal hypothyroxemia, a common condition in pregnant women characterized by low maternal free thyroid hormone (fT4) and normal TSH levels, and found no evidence of a statistically significant association (Chan et al., 2011).

Eight studies evaluated PFOA and associations with total triiodothyronine (TT3). Four of these studies found some evidence of a statistically significant positive association, including two larger (n=1,540 and 1,180) cross-sectional studies of the U.S. general population (Jain 2013 and Wen et al., 2013, respectively) as well as both of the occupational studies (Olsen et al., 2003; Olsen and Zobel 2007). Three studies did not find any statistically significant evidence of an association (Kim et al., 2011; Shrestha et al., 2015; and Wang et al., 2014), while a large (n=50,113) cross-sectional study of the mid-Ohio Valley which found some evidence of an inverse association (Knox et al., 2011). Two of these studies also evaluated free triiodothyronine (FT3) and neither found evidence of a statistically significant association (Jain, 2013; and Wen et al., 2013). These same two studies also evaluated associations of PFOA and thyroglobulin and found no evidence of a statistically significant association (Jain, 2013).

Three studies evaluated the association of PFOA and hypo- and hyperthyroidism, with mixed results. Hypothyroidism is a condition in which the thyroid gland is under-active and is characterized by elevated TSH serum levels combined with low serum FT4. Hyperthyroidism is a condition involving an over-active thyroid gland and is characterized by very low TSH hormone and raised FT4. Lopez-Espinosa et al. (2012) found a borderline statistically significant positive association with measured PFOA concentrations and self-reported subclinical hypothyroidism, but found non-statistically significant results for modeled PFOA, including modeled in utero exposure to PFOA, and subclinical measures of hypothyroidism. Odds ratio for PFOA and hyperthyroidism were mixed and not statistically significant. A study by Wen et al. (2013) of the U.S. adult general population found a statistically significant positive association of hypothyroidism among women but not men, and a statistically significant negative association of hyperthyroidism among men and not women. Winquist and Steenland (2014b) found increasing hazards with increasing PFOA exposure for hypothyroidism, although the trend was not statistically significant, while retrospective and prospective analyses were statistically significantly positively associated among men. A statistically significant trend of hyperthyroidism and increasing PFOA exposure was found overall and for women.

Five studies evaluated thyroid disease in general, which may also include hypo- and hyperthyroidism. Three studies found some evidence of a statistically significant positive association with PFOA and thyroid disease. A large study of highly exposed children in the mid-Ohio Valley found a positive statistically significant association among measured PFOA concentrations, median of 29 ng/ml, and parent-reported thyroid disease, but this association was not statistically significant with modeled PFOA (Lopez-Espinosa et al., 2012). A cross-sectional study of the U.S. general population found increasing odds ratio of self-reported thyroid disease, both ever and current, with increasing guartiles of PFOA among women but not men (Melzer et al., 2011). A large retrospective cohort study with prospective analyses found evidence of a positive association with thyroid disease and increasing quintiles of PFOA which was strongest among women for retrospective analyses, but prospective analyses found no clear associations with PFOA and thyroid disease (Winquist and Steenland, 2014b). The remaining two studies, a small study in a highly exposed community wiht median serum PFOA concentration of 354 ng/ml and a relatively narrow range of exposures (Emmett et al., 2006b), and a retrospective occupational cohort with a median PFOA exposure of 113 ng/ml (Steenland et al., 2015), found no evidence of a statistically significant association with thyroid disease and PFOA.

As discussed above, the C8 Science Panel concluded there was a probable link with PFOA and thyroid disease. The C8 Science Panel summarized the epidemiologic evidence of an association with PFOA and thyroid function or disease and, although the evidence was deemed inconsistent, concluded that "...the presence of some independent pieces of evidence indicative of an association was not easily dismissed, despite a lack of coherence among them." The C8 Science Panel determined the strongest evidence for an association was increased occurrence of medically validated thyroid disease (hyperthyroidism in women, hypothyroidism in men) with increasing measured PFOA exposure (2005-2006) in the prospective analyses (2005-2010). Therefore, despite inconsistencies in the evidence, the Panel concluded that there was evidence of a probable link between C8 and thyroid disease (C8 Science Panel, 2012).

Selection bias may be an issue in Lin et al. (2013b) which included individuals with an abnormal urinalysis from a population-based screening program. Information bias is unlikely to have had an impact in these studies, as they relied mostly on serum concentrations of exposure and outcomes. Although serum thyroid function measures are collected at a single time point in many studies, these thyroid function measures are maintained over time in the body. Also, reliance on recall for studies assessing thyroid disease, hypo-, and hyperthyroidism may bias results (Lopez-Espinosa et al., 2012). Small sample sizes in some studies may have limited their power to detect associations (Bloom et al., 2010; Kim et al., 2011b; Mundt et al., 2007; and Webster et al., 2014).

Although thyroid endpoints were not evaluated in most toxicology studies of PFOA, data from a limited number of studies, reviewed in the <u>Toxicology</u> section below, support the biological plausibility of effects of PFOA on human thyroid function. Although no effects on thyroid hormones were seen in a very small 29-day study of cynomolgus monkeys, changes in TSH, T3, and T4 occurred at multiple time points in a 6-month study in this species. Thyroid hormones were significantly decreased in rats in a short duration exposure study using a high dose of PFOA. Thyroid endpoints have not been evaluated in longer duration, lower dose, or rodent studies.

Overall, studies evaluating thyroid hormones, TSH, and thyroid disease provide inconsistent evidence of any associations with PFOA. The C8 Science Panel concluded that, despite the inconsistencies of findings among studies, compelling evidence for associations with thyroid disease could not be dismissed, and a probable link with PFOA and thyroid disease was determined.

Uric acid

Uric acid is a product of purine metabolism with both oxidant and antioxidant properties, and elevated levels are a marker of kidney disease. Additionally, some studies have shown that elevated uric acid is associated with cardiovascular disease and may trigger hypertension (Klein et al., 1973; Fang et al., 2000; and Freedman et al., 1995). Seven studies evaluated the association of uric acid and serum PFOA concentrations; three of these also assessed clinically defined hyperuricemia. Study details are provided in the tables for individual studies (Appendix 4) and the summary table for uric acid (Table 6D).

These studies include six cross-sectional studies and one occupational study which was a casecontrol study with cross-sectional components. All of these studies found strong, positively statistically significant associations of uric acid and PFOA (Costa et al. 2009; Geiger et al., 2013; Gleason et al., 2015; Sakr et al., 2007a; Shankar et al., 2011; and Steenland et al., 2010) with the exception of Lin et al., 2013 which did not find a statistically significant association. Additionally, all three studies which evaluated clinically defined hyperuricemia found strong evidence of a positive statistically significant association (Geiger et al., 2013; Shankar et al., 2011; and Steenland et al., 2010b).

Although the six studies with evidence of statistically significant association are mainly crosssectional, they represent the general population, residents from a highly exposed community, and an occupationally exposed population. These studies therefore evaluated a wide range of serum PFOA concentrations - about 4 ng/ml in the general population studies (Geiger et al., 2013; Gleason et al., 2015; Shankar et al., 2011), a median of about 28 ng/ml in a highly exposed community population (Steenland et al., 2010b), and a median serum PFOA concentration range from 428 ng/ml (Sakr et al., 2007a) to 4,400 -5,700 ng/ml (Costa et al., 2009) among occupationally exposure populations. Also, importantly, these studies evaluated a wide range of age groups as well, including children less than 19 years of age (Geiger et al., 2013), adolescents and adults greater than 11 years of age (Gleason et al., 2015), and adult populations 20 years or older (Costa et al., 2009, Shankar et al., 2011; and Steenland et al., 2010b).

The general population studies which evaluated associations of uric acid with increasing serum concentrations of PFOA found strong exposure-response relationships (Geiger et al., 2013; Gleason et al., 2015; and Shankar et al., 2011). Additionally, Steenland et al. (2010b) found a significant trend and some evidence of increased changes in uric acid with high level of serum PFOA concentrations among residents from a highly exposed community. Lin et al. (2013) did not find evidence of a statistically significant trend in mean uric acid across categories of PFOA exposure but there does appear to be a small, non–significant increase in uric acid level as serum PFOA concentrations increase.

Information bias is unlikely to have an impact in the general population studies which relied on serum concentrations and clinical biomarkers. Selection bias may have impacted findings in Lin et al. (2013), which included individuals with an abnormal urinalysis from a population-based screening program in which the final study population was made up of 246 (37%) individuals with elevated blood pressure.

Reverse causality is a potential explanation for increased uric acid with increasing PFOA. It has been proposed that PFOA could be higher in individuals with reduced excretion due to reduced kidney function, and that this would also result in increased uric acid (Kataria et al., 2015). Also, Kataria et al., (2015) reviewed toxicology evidence and suggests that PFOA and other PFCs can adversely impact renal function. Unfortunately, a hypothesis of reverse causality cannot be assessed because the six studies which evaluated uric acid and PFOA are limited by their cross-sectional design in which exposures and outcomes are measured at the same point in time.

Epidemiologic evidence provides evidence of consistency among findings, strength of findings with clinically defined outcomes, and exposure-response with PFOA and uric acid. These findings provide evidence supporting a causal relationship between PFOA and uric acid. However, there are limitations in use of the epidemiologic evidence to draw conclusions regarding temporality and there remain some questions of biologic plausibility due to possible reverse causality explanation.

Antibody concentrations following vaccination

Five studies evaluated associations of serum PFOA concentrations and antibody concentrations following six types of vaccines. Study details are provided in the tables for individual studies (Appendix 4) and the summary table for this effect (Table 6E). Only one type of vaccine (tetanus) was evaluated in three of the five studies, each of four vaccine types were evaluated in two studies each, and one (mumps) was evaluated in only one study. These five studies include a prospective cohort following 656 singleton births recruited from birth and followed to seven years of age (n=587) in the Faroe Islands (Grandjean et al., 2012). In this group of children with a median serum PFOA concentration at 5 years of age of 4.1 ng/ml, researchers found strong statistically significant evidence of a decrease in antibody concentrations following a tetanus or diphtheria vaccination at age 5 and 7 years. Another prospective birth cohort study in Norway collected blood samples at delivery from 99 pregnant women with a subsequent follow-up sample of 56 children at 3 years of age (Granum et al. 2013). The median PFOA maternal serum concentration was 1.1 ng/ml. Investigators found strong evidence of decreased rubella-induced antibodies with increasing PFOA maternal serum concentrations, but associations with PFOA and responses to tetanus, measles, and influenza vaccines were not statistically significant. A prospective cohort of 12 adults recruited from hospital staff in Denmark with median serum PFOA concentration of 1.7 ng/ml found no statistically significant associations with antibody response to tetanus or diphtheria vaccines (Kielsen et al., 2015). A larger prospective cohort of 411 adults from the mid-Ohio valley with a high median serum PFOA concentration of 31.5 ng/ml found evidence of decreasing antibody concentrations following Influenza A H3N2 vaccination; however no statistically significant associations were found with responses to vaccines for Influenza Type B or Influenza Type A H1N1 (Looker et al., 2014). The largest of the studies includes a sample size of 1,191 adolescents aged 12 to 19 years of age from the U.S. general population with a geometric mean serum PFOA concentration of 4.1 ng/ml. This crosssectional study found some evidence of a statistically significant decrease of rubella- and mumps vaccine induced antibody concentration, but a decreased antibody response to measles vaccine was not statistically significant (Stein et al., 2016).

Associations between decreased antibody concentration and increasing PFOA concentration may be related to a threshold such that limited evidence of associations was found among the two studies with median serum PFOA concentrations below 2 ng/ml (Granum et al, 2013 and Kielsen et al., 2015). Both of these studies also had small sample sizes which may have restricted the power of the study to detect a statistically significant decrease.

Specificity of the observed association may also be difficult to interpret since responses to many different vaccines were evaluated, with each type of vaccine included only in a few (and often in only one or two) studies. Unlike many of the other outcomes evaluated in studies of the human health effects of PFOA, four of the studies that assessed associations with antibody concentrations following vaccination had a prospective study design, allowing temporality

assessment. Since the exposures and outcomes were followed over time, it can be concluded that exposures preceded the outcome.

Data from other human studies and toxicology studies provide support for biological plausibility of decreased immune system response to vaccines in humans. As discussed in the <u>Toxicology</u> and <u>Mode of Action</u> sections, PFOA suppressed the immune system in studies of both non-human primates and rodents. Fletcher et al. (2009) reported several statistically significant associations between several markers of immune function (decreased IgA; decreased IgE in females only; increased anti-nuclear antibody; decreased C-reactive protein) and serum PFOA levels in communities with drinking water exposure to PFOA in a C8 Science Panel status report (Fletcher et al., 2009). As yet, only the information on C-reactive protein has been published (Genser et al., 2015). Genser et al. (2015) found consistent and significant associations of serum PFOA with this effect, both within each of the six water districts included in the study and on an aggregated basis. They concluded that these within- and between-district associations strengthen the evidence of causality for this effect.

Review of epidemiologic studies provides evidence of consistent findings among studies of decreased antibody concentrations following vaccination and PFOA. There is epidemiologic evidence of temporality. However, there are a limited number of comparisons across the same vaccination types, making consistency/specificity difficult to evaluate.

Additionally, the National Toxicology Program (NTP) recently completed a draft systematic review of immunotoxicity of PFOA, based on consideration of human and animal studies, along with mechanistic data (NTP, 2016). The draft NTP assessment concluded that PFOA is <u>presumed to be an immune hazard to humans</u> based on (1) a high level of evidence from animal studies and a moderate level of evidence from human studies that PFOA suppresses antibody response, and (2) a high level of evidence from animal studies and a low level of evidence from human studies that PFOA increases hypersensitivity-related outcomes. NTP also considered additional, although weaker, evidence primarily from epidemiological studies that PFOA reduced infectious disease resistance and increased autoimmune disease. NTP states that the evidence for effects on multiple aspects of the immune system supports the overall conclusion that PFOA alters immune function in humans.

Endpoints Evaluated by Other Researchers:

Fetal growth

A collaborative team of scientists developed a methodology for the systematic review of environmental health data titled the "Navigation Guide." The Navigation Guide is intended as a "systematic and rigorous approach to research synthesis" that will "reduce bias and maximize transparency in the evaluation of environmental health information" (Woodruff and Sutton, 2014). The Navigation Guide methodology utilizes a three-step process in which a study question is specified, evidence is selected, and the quality and strength of the evidence is evaluated. Developmental exposure to PFOA and fetal growth was selected by the research group as a proof-of-concept of the methodology. This effort included evaluation of human epidemiologic data (Johnson et al., 2014), animal toxicology data (Koustas et al., 2014), and a synthesis of both types of data to develop overall conclusions (Lam et al., 2014).

The application of the Navigation Guide methodology to human studies required that each identified study was evaluated for risk of bias, and that the quality and strength of the evidence across all studies was rated. The authors reviewed 19 datasets available from 18 studies which met the inclusion criteria. Additionally, a meta-analysis of 10 studies with combinable study attributes was performed. Investigators concluded there was a low risk of bias across the studies. The meta-analyses of birth weight resulted in an overall continuous regression estimate per ng/ml serum PFOA of -18.9 g (95% CI -29.8, -7.9), an estimate of -0.06 cm (95% CI -0.1, -0.02) in birth length, a -0.01 (95% CI 0.03, 0.01) reduction in ponderal index (birth weight/length³ x 100), and a -0.03 cm (95% CI -0.08, 0.01) reduction in head circumference. The quality of the human evidence was rated as "moderate". By evaluating the quality of studies, direction of effect estimate, confidence of effect, and other possible compelling attributes, it was concluded that there is "sufficient" human evidence, the strongest descriptor for strength of evidence, that developmental exposure to PFOA reduces fetal growth in humans (Johnson et al., 2014).

The conclusions of another recent meta-analysis of human data (Verner et al., 2015) were generally consistent with Johnson et al. (2014). Verner et al. (2015) estimated a decrease in birth weight per ng/ml PFOA in maternal or cord blood serum of -14.7 g (95% CI -21.7, -7.8). They note that their analysis was less formal than the one conducted by Johnson et al. (2014) and that it did not include two studies included in the analysis of Johnson et al. (2014).

The animal evidence was also reviewed by the Navigation Guide research group, and it was concluded that there is "sufficient" evidence that exposure to PFOA adversely affects fetal growth in animals (Koustas et al., 2014). The human and non-human evidence was integrated to develop an overall conclusion on whether developmental exposure to PFOA affects fetal growth in humans. The human and non-human mammalian evidence were both rated as being of "moderate" quality and "sufficient" strength. The authors concluded that there is "sufficient" evidence that developmental exposure to PFOA adversely affects human health based on decreased fetal growth in both human and non-humans (Lam et al., 2014).

Although previous research in the C8 Health Study population did not find an association with clinically defined birth weight and PFOA (Stein et al., 2009, C8 Science Panel, 2011), a subsequent study in this population found associations with low birth weight evaluated as a continuous variable (Savitz et al., 2012). Thus, findings from the C8 Health Study do not contradict conclusions reached by the Navigation Guide.

Evidence supporting biological plausibility for decreased fetal growth from PFOA is provided by studies (discussed in the <u>Toxicology</u> section) showing that PFOA adversely effects prenatal and postnatal growth and development. As discussed in the Mode of Action section, cellular receptors that play a role in the developmental toxicity of PFOA are found in human tissues, and developmental effects observed in laboratory animals are believed to be relevant to humans.

<u>Potential impact of glomerular filtration rate on association of PFOA and fetal growth</u> Glomerular filtration rate (GFR) is the flow rate of fluids being filtered through the kidneys. GRF increases during the first half of pregnancy and declines slightly during the second half (Gibson 1973). Decreased GFR has been associated with lower infant birth weight in some studies (reviewed by Lam et al., 2014; Morken et al., 2014). Because decreased GFR might also result in higher serum PFOA levels due to slower excretion, it has been hypothesized that lower GFR could be a confounding factor for the association of PFOA and decreased fetal growth.

Lam et al. (2014) considered the evidence for reverse causality related to decreased GFR for the association of PFOA with decreased fetal growth. They concluded that the available data did not justify revision of their conclusion of sufficient human evidence for association of PFOA and decreased fetal growth. Vesterinen et al. (2015) subsequently adapted and applied the Navigation Guide methodology, described above, to assess the evidence of an association between fetal growth and GFR. The authors identified 35 relevant studies (31 human observational, two nonhuman observational, and two non-human experimental), all of which were rated as either "low" quality or "very low" quality. All three of these evidence streams were classified as "inadequate," indicating that the association between GFR and fetal growth was "not classifiable." Based on their review, Vesterinen et al. (2015) concluded that the current evidence is insufficient to support the plausibility of a reverse causality hypothesis for the associations between environmental chemicals during pregnancy and fetal growth. In an additional recent study not included in the review of Vesterinen et al. (2015), Morken et al. (2014) analyzed data from 953 pregnant Norwegian women (470 with pre-eclampsia and 483 without pre-eclampsia) and estimated GFR in the second trimester based on plasma creatinine. The association of estimated GFR and infant birth weight was not significant at p<0.05 when women with preeclampsia, which is associated with decreased kidney function, were excluded from the analysis. When these women with pre-eclampsia were included, the association was significant.

Verner et al. (2015) used data from three studies that provide data on maternal GFR and birth weight on an individual basis to modify a physiologically based pharmacokinetic (PBPK) model for PFOA during pregnancy (previously developed by Loccisano et al., 2013) to include the relationship between GFR and birth weight. A Monte Carlo simulation using the modified model was used to estimate the population distribution of PFOA levels in maternal and cord blood plasma during pregnancy and at delivery. Based on an assumed PFOA half-life of 3.8 years, the

model simulation predicted a decrease in birth weight per ng/ml PFOA of -7.9 g (CI -9.4, -6.4) based on maternal plasma at term and -7.1 g (95% CI -8.5, -5.8) based on cord plasma at delivery. When a shorter half-life of 2.3 years (which is likely more appropriate, discussed in <u>Toxicokinetics</u> section) was assumed, greater effects on birth weight per ng/ml PFOA were predicted: -9.6 g (95% CI -11.0, -8.2) based on maternal plasma at delivery and -8.1 g (95% CI - 9.4, -6.8) based on cord plasma at delivery. The data from the simulation were compared to the results of a meta-analysis of the effect of maternal or cord plasma PFOA on birth weight (-14.7 g per ng/ml, 95% CI -21.7, -7.8) to estimate the effect of GFR on this association. Results of this study suggests that GFR may confound a portion (less than 50%) of the association between PFOA and decreased birth weight, and that it would be desirable to control for GFR in studies of PFOA and birth weight to account for potential confounding by GFR.

Based on review of the relevant information, the Health Effects Subcommittee concludes that confounding by GFR does not account for the major portion of the decrease in fetal growth that is associated with PFOA.

Cancer

The USEPA Science Advisory Board (USEPA, 2006) described PFOA as "likely to be carcinogenic to humans" according to the criteria provided in the USEPA Guidelines for Carcinogen Risk Assessment (2005b). This determination was made prior to the publication of the epidemiology studies summarized below and was based on the toxicology and mode of action data available at that time.

The International Agency for Research on Cancer (IARC) is the specialized cancer agency of the World Health Organization (WHO). One of IARC's major activities is the evaluation of the evidence of human carcinogenicity of specific exposures, including environmental contaminants, by international expert working groups which it convenes. IARC considers human, animal, and mechanistic data in making its determinations of evidence for cancer risk to humans. It has classified PFOA as "possibly carcinogenic to humans" (Group 2B) based on "limited evidence that PFOA causes testicular and renal cancer, and limited evidence in experimental animals" (IARC, 2016). The human data considered by IARC (2016) in making this determination included increases in kidney cancer among workers in the DuPont Washington Work plant in Parkersburg, WV (Steenland and Woskie, 2012) and in kidney and testicular cancer among highly exposed members of the C8 Health Project study population (Barry et al., 2013) and Vieira et al., 2013). IARC (2016) also notes that a second occupational study (Raleigh et al., 2014) from another location did not find evidence for increased incidence of kidney cancer. The epidemiological studies cited by IARC (2016) as the basis for its conclusion are presented in more detail below.

More recently, the USEPA Office of Water (2016a) concluded that PFOA has suggestive evidence of carcinogenic potential for PFOA based on the human studies mentioned above that found an association of serum PFOA with kidney and testicular tumors in communities with drinking water exposure and increased incidence of tumors in one more organs in two chronic rat bioassays.

It is also noted that an evaluation by Health Council of the Netherlands published in 2013 concludes that the available data are insufficient to evaluate PFOA's carcinogenic properties. However, the document states that this group primarily relies on IARC evaluations, when available. The more recent IARC (2016) review, which concluded that PFOA is possibly carcinogenic to humans, was not available when the Health Council of the Netherlands (2013) conducted its evaluation. Additionally, the criteria used by the Health Council of the Netherlands to determine carcinogenicity classifications are different from those used by USEPA, NJDEP, and the DWQI.

Steenland and Woskie (2012) studied the mortality of 5,791 workers at the DuPont chemical plant in Parkersburg, West Virginia from 1952-2008. Exposure to PFOA in workers was estimated using a job exposure matrix developed from serum data available for a smaller set of workers. Standardized Mortality Ratios (SMRs) were calculated using other DuPont workers in the region and the U.S. population as referent groups. PFOA exposure was categorized into quartiles. The SMR for kidney disease increased with increasing quartiles of exposure (Quartile 1: SMR=1.07, 95% CI 0.02, 3.62 (based on 1 death); Quartile 2: SMR=1.37, 95% CI 0.28, 3.99 (based on 3 deaths); Quartile 3: SMR=0.00, 95% CI 0.00, 1.42 (based on 0 deaths); Quartile 4: SMR=2.66, 95% CI 1.15, 5.24 (based on 8 deaths). Mesothelioma and chronic renal disease (malignant and non-malignant) also both had exposure-response relationships with PFOA. When investigators lagged models by 10-years and 20-years, kidney cancer and chronic renal disease remained most elevated in the highest quartile of exposure compared to the lower quartiles. An important potential confounder in this occupational cohort could be tetrafluoroethylene (TFE) which was also used in the manufacture fluoropolymers at the Parkersburg, WV facility and has been identified as a rodent kidney carcinogen (NTP, 1997). However, the authors believe that appreciable exposures would have been unlikely, since TFE exposure would have been well controlled due to its explosive and volatile nature.

Raleigh et al. (2014) studied the mortality and cancer incidence among 9,027 employees of two 3M facilities in Minnesota. The exposed population came from an ammonium perfluorooctanoate (AFPO), the ammonium salt of PFOA, production company and the non-exposed referent population from a non-AFPO facility. Among the AFPO exposed employees, 4,668 were from a previous study of this population (Gilliland et al., 1993; Lundin et al., 2009) and an additional 675 employees were recruited. Cancer outcomes of interest included cancers

of the liver, pancreas, testes, kidney, prostate and breast. There were too few incidence testicular cancer cases to include in analyses. Incidence cancers were identified through the Minnesota and Wisconsin cancer registries and a vital status assessment was used to determine vital status and case of death. Occupational exposure to AFPO was characterized from work history records, industrial hygiene monitoring data, information from current and former workers and industrial hygiene professionals, and average annual APFO production levels. Exposure among AFPO workers was classified into quartiles, and employees of the non-AFPO production facility served as the referent population. There were no statistically significant SMRs by exposure quartile for any of the outcomes, with the state of Minnesota serving as the comparison group. The workers had modestly elevated risk of death from prostate cancer (Q4: HR=1.32, 95% CI 0.61 to 2.84), pancreatic cancer (Q4: HR=1.2, 95% CI 0.50, 3.00), bladder cancer (Q3-4: HR=1.96, 95% CI 0.63 to 6.15), and chronic renal disease (O4: HR=1.37, 95% CI 0.38 to 4.95), but the effects were not statistically significant. There was no evidence of elevated risk for kidney cancer. There was little evidence that APFO increased the risk of prostate cancer (Q4: HR=1.11, 95% CI 0.82 to 1.49), pancreatic cancer (Q3-Q4: HR=1.36, 95% CI 0.59 to 3.11) and bladder cancer (Q4: HR=1.66, 95% CI 0.86 to 3.18) but these also were not statistically significant. There was no evidence of increased risk for kidney cancer. Investigators noted that unlike the PFOA-exposed occupational cohort in Parkerburg, WV this population was not exposed to the potential confounder TFE, which could account for absence of an association with kidney cancer.

Vieira et al. (2013) performed an ecological study in 13 counties which encompass six PFOAcontaminated water districts in Ohio and West Virginia located near the DuPont chemical plant in Parkersburg, West Virginia. Cases of 18 types of cancer were obtained from the Ohio and West Virginia cancer registries, in which the final data set included 7,869 Ohio cases and 17,328 West Virginia cases. To calculate adjusted odds ratios (OR) with logistic regression, controls were selected from the state cancer registries as all other cases of cancers (excluding cases of kidney, pancreatic, testicular, and liver cancers, the types which have been associated with PFOA in animal or human studies). Exposure estimates were based on estimated 1995 median serum PFOA concentrations in the six water districts. The analysis was adusted for age, sex, diagnosis year, smoking status, and insurance provider. The first of two analyses, using water district of residence as the exposure of interest and including both Ohio and West Virginia cases, found the odds of testicular cancer was statistically significantly increased (OR=5.1, 95% CI 1.6-15.6) and the odds of kidney, non-Hodgkin lymphoma, and prostate cancer were also increased, in the highest exposed water district of Little Hocking, although not statistically significant. Kidney cancer was also elevated in the third highest exposed water district of Tuppers Plain (OR=2.0, 95% CI 1.3-3.1). Lung cancer was statistically significantly associated with PFOA in the total exposed group and in two of the water districts. For the second analysis, serum PFOA levels were estimated at a finer geographic scale and restricted to Ohio-only cases. Kidney cancer was elevated in both the very highly exposed category (serum concentration of 110-665

ng/ml; OR=2.0, 95% CI 1.0, 3.9) and the highly exposed category (serum concentration of 30.8-109 ng/ml; OR=2.0, 95% CI 1.3, 3.2) groups.

Barry et al. (2013) evaluated cancer incidence among individuals exposed to PFOA through contaminated drinking water in the mid-Ohio Valley, as well as subjects who worked at the local chemical plant where PFOA was used (n=32,254). Associations between self-reported cancers and cumulative (based on retrospective yearly estimates for each individual) serum PFOA concentrations were evaluated using a proportional hazards model. The model was adjusted for time-varying smoking, time-varying alcohol consumption, sex, education, and 5-year birth year period. Analyses were restricted to the 21 types of reported primary cancers validated through medical records and state cancer registries (n=2,507, 70% validated). Among the cancer types, only testicular cancer was statistically significantly associated with cumulative serum PFOA concentration (OR=1.34, 95% CI 1.00, 1.79), and the effect was stronger when restricted to community members only (OR=1.73 95% CI 1.24,2.40). Thyroid cancer was statistically significantly associated with cumulative serum PFOA concentrations among occupational workers (OR=1.93, 95% CI 1.00, 3.71) but not among the community study population. Results for cumulative serum PFOA concentrations by quartiles show that estimated risk ratios for kidney cancer (p-value=0.10) and testicular cancer (p-value=0.05) generally increased across quartiles. This pattern was less consistent for thyroid cancer (p-value=0.20), except when restricted to the occupational study population (p-value=0.04). Since this is largely a survivor cohort, differences in cancer survival rates could cause cancer types with shorter than 5-year survival to be likely to be captured by the study. Additionally, if individuals with cancers caused by high exposure were more likely to die before being captured in the cohort, results could be biased towards the null (less likely to find an association). Therefore, results about these cancer types should be interpreted with caution.

A comprehensive review of PFOA as an emerging drinking water contaminant (Post et al., 2012) found evidence that occupational studies showed some consistency of increased cancer mortality and/or incidence for bladder, kidney, and prostate cancer. Post et al. (2012) also reviewed studies showing that white blood cell neoplasms (Leonard, 2003; Leonard et al., 2008), thyroid cancer (Leonard et al., 2008), and carcinoid tumors (Morel-Symons et al., 2007) were also increased at one industrial facility.

A recent review of PFOA's carcinogenic potential focusing on human epidemiological studies (Chang et al., 2014) concludes that the "existing epidemiological evidence does not support the hypothesis of a causal association between PFOA exposure and cancer in humans. However, further research on this topic is warranted." Specificially, Chang et al. (2014) suggest that quantitative exposure assessment at industrial facilities in Asia that continue to produce or use PFOA (now phased out in the U.S.) could be used as the basis for future cohort studies with sufficient follow up time. Additionally, continued follow-up of existing cohorts with use of

cancer incidence data from cancer registries could provide further information about human cancer risk of PFOA.

Information on human breast cancer and PFOA is of interest because toxicological findings provide some evidence suggesting biological plausibility, although the available toxicological data do not support firm conclusions on this topic. Developmental exposures to PFOA cause delayed mammary gland development in mice. Several researchers have stated that, in general, such disruptions of mammary gland development may result in adverse effects later in life resulting in increased cancer risk, although no information specific to PFOA is available on this question (Fenton 2006; Rudel and Fenton, 2009; IOM, 2011; Rudel et al., 2011; Fenton et al., 2012). Developmental exposures to PFOA in mice also caused increased numbers of darkly stained foci (described in detail in the <u>Toxicology</u> section) that persisted into adulthood and are considered permanent (White et al., 2009). Gore et al. (2015) notes that abnormalities of this type can be associated with increased breast cancer risk. However, chronic carcinogenicity studies have not been conducted in mice.

Epidemiological studies of associations of PFOA with breast cancer did not evaluate early life exposures. Studies of workers with occupational exposures to PFOA include very few women and are thus not informative about disease incidence in females. The incidence of breast cancer was not increased in a study of many types of cancer in the C8 Health Study population in Ohio and West Virginia communities with drinking water exposure to PFOA that included about 17,000 women (Barry et al., 2013). A small study (31 cases and 98 controls) in the Inuit population in Greenland found significantly increased risk of breast cancer associated with PFOA, perfluorooctane sulfonic acid (PFOS), total perfluorinated carboxylates, and total perfluorinated sulfonates (Bonefeld-Jorgensen et al., 2011). A subsequent study of this small group of cases and controls found a greatly elevated odds ratio for breast cancer in women with both high PFC levels and specific polymorphisms of xenobiotic metabolizing enzymes that affect levels of hormones such as estrogens, suggesting that inter-individual variations in these polymorphisms may affect sensitivity to the effects of PFCs on breast cancer risk (Ghisari et al., 2014). Because this was the only such study and it is of small size, these data are considered preliminary and suggest the need for further research on this topic.

In regard to biological plausibility for human carcinogenicity, PFOA caused hepatic, testicular Leydig cell, and pancreatic acinar cell tumors in two chronic studies in male rats (discussed in <u>Toxicology</u> section). Potential human relevance of these tumors is discussed in the <u>Mode of Action</u> section. Although liver tumors in rodents caused by compounds that activate PPAR-alpha are generally not considered relevant to humans, activation of this receptor may not be the sole mode of action for liver tumors caused by PFOA. Additionally, a PPAR-alpha mode of action may be involved in hepatic effects in the fetus, infants, and children. Therefore, the potential for

human relevance of the tumors observed in rodents cannot be dismissed. The mode of action for the testicular and pancreatic tumors has not been established.

Additional endpoints

In addition to the epidemiologic endpoints reviewed above, there remain a large number of peerreviewed studies that have evaluated other endpoints. Associations with PFOA have been found in some of these studies and not in others. Although these endpoints are not evaluated in this document, other organizations and publications may provide a more comprehensive review

Additional endpoints evaluated in studies but not reviewed in this report include biomarkers of kidney function or damage such as blood urea nitrogen, serum creatinine, renal glomerular filtration rate (eGFR) and chronic kidney disease; heart disease and hypertension; cerebrovascular disease including stroke, diabetes, immune function (with the exception of immune response following vaccination which was reviewed above) including asthma and other allergies, autoimmune disease including osteoarthritis, lupus, juvenile diabetes, rheumatoid arthritis, multiple sclerosis, and Crohn's disease; osteoporosis and bone mineral density; neurological and neurodegenerative disorders including self-reported memory impairment and Parkinson's disease; cognitive and behavioral developmental milestones; performance testing, and attention deficit hyperactivity disorder (ADHD) in children; reproductive and developmental outcomes (with the exception of lower birth weight and birth size of neonates), including decreased sperm count, longer time to pregnancy, birth defects, miscarriage and stillbirth, and overweight and obesity measured by BMI and waist circumference in offspring. It is noted that the C8 Science Panel concluded that there are "probable links" with PFOA exposure in the C8 Health Study population for two adverse health conditions, pregnancy-induced hypertension and ulcerative colitis, that were not reviewed above.

Health effects that occur later in life from prenatal and early life exposures to environmental contaminants are a current focus of research in toxicology and epidemiology (Barouki et al., 2012; Heindel and Vandenberg, 2015). Exposures of developing tissues to toxic substances during sensitive time periods can result in increased risk or severity of later disease or dysfunction (Heindel and Vandenberg, 2015). Recent studies have found that developmental exposures to PFOA cause toxicological effects that persist into adulthood and/or become evident later in life, including hepatic toxicity, delayed mammary gland development, and bone morphology and mineral denisty (Macon et al., 2011; White et al., 2009; Filgo et al., 2015; Quist et al., 2015; Koskela et al., 2016). However, the effects of developmental exposures to PFOA on these endpoints have not been evaluated in humans.

Summary of conclusions for epidemiologic information

Of the endpoints that were evaluated comprehensively by the Health Effects Subcommittee, the evidence for association with PFOA is strongest for serum cholesterol which demonstrates

consistency, strength, dose-response and some evidence of temporality. PFOA was associated with clinically defined hypercholesterolemia in a community exposed through drinking water. There was also consistency among the larger non-occupational studies, as well as evidence of specificity, exposure-response and strength for associations between PFOA and both serum cholesterol and the liver enzyme ALT. These findings provide evidence supporting a causal relationship between PFOA and both cholesterol and ALT. There is evidence of consistency, strength, and exposure-response with PFOA and uric acid as well, but interpretation for temporality is limited.

In general, the human data for PFOA are notable because of the consistency between results among human epidemiologic studies in different populations for some endpoints, the concordance with toxicological findings from experimental animals, the use of serum concentrations as a measure of internal exposure, the potential clinical importance of the endpoints for which associations are observed, and the observations of associations within the exposure range of the general population.

As mentioned above, the epidemiologic databases for cholesterol, the liver enzyme ALT, and other endpoints are sufficient to support one or more of the criteria for causality. The sufficiency of the database to support these criteria is particularly evident when compared to the human epidemiologic databases for numerous other environmental contaminants for which quantitative risk assessment is based on animal toxicological studies in the absence of substantial support from human epidemiologic data (for example, 1,2,3-trichloropropane and methyl tertiary butyl ether [MTBE]).

For some endpoints, studies of populations from varied locations including the U.S., Canada, and several European and Asian countries, with study populations including children, young adults, adults, the elderly, and pregnant women, demonstrate a congruence of consistent findings. Although the human epidemiologic database is largely driven by cross-sectional studies, consistency is supported from studies with stronger study designs such as cohort and/or case-control, especially in studies of the general populations and populations exposed to drinking water contaminated with PFOA.

A particular strength of epidemiologic studies of PFOA and other PFCs is the availability of serum concentrations, a direct and accurate measure of internal dose in individuals. In contrast, human studies of most other environmental contaminants usually rely on estimates of external exposure. Exposure assessment tends to be susceptible to misclassification that may lead to biased findings. However, information bias is unlikely to have an impact in most general population studies of PFOA because of their reliance on serum concentrations and clinical biomarkers

Application of the Navigation Guide systematic review methodology to epidemiologic data resulted in the conclusion that there is sufficient evidence that developmental exposure to PFOA adversely affects fetal growth. The methodology developed and utilized to assess the relationship of PFOA and fetal growth was substantive and robust such that conclusions reached through application of the Navigation Guide are reasonable and supportable.

Reviews by several authoritative groups concluded that there is evidence of carcinogenic potential in humans for PFOA. The USEPA SAB (2006) described PFOA as "likely to be carcinogenic to humans" based on the criteria provided in USEPA (2005b) cancer risk assessment guidance. More recently, IARC (2015) concluded that, based on its evaluation criteria, PFOA is possibly carcinogenic to humans. Finally, the USEPA Office of Water (2016a) concluded that there is suggestive evidence of human carcinogenicity for PFOA.

For some other endpoints, limited evidence of an association with PFOA was found. There is consistent evidence of decreased antibody concentrations following vaccination, with evidence of temporality. However, most of the vaccine types were evaluated in only one or two studies, limiting the ability to determine specificity. The epidemiologic database for PFOA and LDL appears inconsistent, although there is some evidence of an association. Epidemiologic evidence for other serum lipid endpoints is limited. The epidemiologic evidence of a casual association with PFOA and GGT, AST, and bilirubin lacks consistency, and there is a limited evidence of associations with PFOA and liver disease. Evidence of thyroid disease remains limited.

There was no evidence of an association with PFOA and the liver enzyme ALP. Overall the epidemiologic evidence suggests no evidence of an association with HDL and PFOA. Overall studies evaluating thyroid hormones and TSH provide limited or no evidence of any associations with PFOA.

Although the magnitude of change for the parameters associated with PFOA is generally relatively small, they are of public health concern because population-level changes of this magnitude in parameters such as serum cholesterol or liver enzymes will result in a shift in the overall distribution of values such that the numbers of individuals with clinically abnormal values is increased. Additionally, small changes in a clinical biomarker may be an indicator of other effects which were not assessed. For example, birth weight represents a gross measure of development, and relatively small decreases in birth weight may be an indication of changes in other subtler developmental parameters which were not assessed.

The steepest dose-response for associations of some health endpoints with PFOA has been observed within the lower range of serum PFOA concentrations. Epidemiologic studies of smaller numbers of highly exposed participants may not be inclusive of these low level exposure ranges and thus may not detect associations. Therefore, an important limitation of studies of

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 193 of 551

participants with extremely high serum PFOA concentrations may be that there are an insufficient number of study participants with low(er) level exposures who can serve as a comparison.

To illustrate this point, Figures 9A and 9B show changes in total serum cholesterol across deciles of serum PFOA concentrations in adults (Steenland et al., 2009) and children (Frisbee et al., 2010) from the mid-Ohio Valley. In both children and adults, associations increased steeply at low ranges of serum PFOA concentrations, with a much flatter dose-response at higher levels. In the absence of data from the lower range of serum PFOA concentrations, modeling techniques might not be able to detect statistically significant changes of this effect with increasing serum PFOA concentrations.




Figure 9. Adjusted-predicted total cholesterol change with increasing group median deciles. (A). Adults, Steenland et al., 2009 (B). Adolescents, Frisbee et al., 2009

For instance, in Emmett et al. (2006b), almost all participants had highly elevated serum PFOA levels (25th percentile value was 184 ng/ml), and comparisons were made only within the study population. Most or all of the lowest exposed individuals in this study may have had serum levels that fall on the flatter portion of the dose-response curve for serum cholesterol, limiting the ability to detect an association. Additionally, Olsen and Zobel (2007) provide data on serum cholesterol and other lipids in workers with PFOA exposure which indicate that the median serum PFOA level in the lowest exposed group, 60 ng/ml, lies on the flatter portion of the dose-response curve in Figure 9A and 9B above.

In summary, the consistency between results in different populations, the concordance with toxicological findings from experimental animals, the potential clinical importance of the endpoints for which associations are observed, and the observation of associations within the exposure range of the general population justify concerns about exposures to PFOA through drinking water. Although there is evidence to support causality for some epidemiological

endpoints, the epidemiological data have limitations and therefore are not used as the quantitative basis for the Health-based MCL. Instead, the human data are considered as part of the weight of evidence for the health effects of PFOA and are used to support a public health-protective approach in development of a recommended Health-based MCL based on animal toxicology data.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 195 of 551

Citation	Study Population	Study Details	ТС	HDL	Non-	TC/	LDL	VLDL	HDL/	TG	Genes
					HDL	HDL			LDL		
1. Costa et al., 2009	Italy., Occupational: Cases – Male workers engaged in the PFOA production department; Controls – Male workers never exposed to PFOA	* <i>Study Design:</i> Exposure case-control & Cross- sectional * <i>Study Size</i> : n=160 * <i>Study Population Age</i> : 20-63 years * <i>Exposure Range (Median)</i> : 4400 – 5700 ng/ml	Ţ								
2. Emmett et al., 2006b	U.S., Highly exposed community	*Study Design: Cross-sectional *Study Size: n=371 *Study Population Age: 2.5-89 years *Exposure Range (Median): 354 ng/ml									
3. Eriksen et al., 2013	Demark, nested in a larger cohort, General population	*Study Design: Cross-sectional *Study Size: n=753 *Study Population Age: 50-65 years *Exposure Range (Mean): 7.1 ng/ml	↑								
4. Fisher et al., 2013	Canada, General population	*Study Design: Cross-sectional *Study Size: n=5,604 *Study Population Age: 6-79 years *Exposure Range (Geo Mean): 2.46 ng/ml	↑-		^-						
5. Fitz- Simon et al., 2013	U.S., Highly exposed community	*Study Design: Cohort *Study Size: n=560 *Study Population Age: 20-60 years *Exposure Range (Geo Mean): 30.8 – 74.8 ng/ml	↑-				Ţ				
6. Fletcher et al., 2013	U.S., Highly exposed community	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> n=290 * <i>Study Population Age:</i> 20-60 years * <i>Exposure Range (Median):</i> 30.1 ng/ml									¹ ↑-
7. Frisbee et al., 2010	U.S., Highly exposed community	* <i>Study Design:</i> Cross-sectional * <i>Study Size</i> : n=12,476 * <i>Study Population Age</i> : 1-17.9 years * <i>Exposure Range (Mean)</i> : 69.2 ng/ml	Ţ				Ť			↑-	
8. Fu et al., 2014	China, random selection of attendees to health check-up clinic (General population)	* <i>Study Design:</i> Cross-sectional * <i>Study Size</i> : n=133 * <i>Study Population Age</i> : 0-88 years * <i>Exposure Range (Median)</i> : 1.43 ng/ml	↑ (Ţ			_	
Citation	Study Population	Study Details	ТС	HDL	Non- HDL	TC/ HDL	LDL	VLDL	HDL/ LDL	TG	Genes

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 196 of 551

		se 1:16-cv-00917-LEK-DJS Document				age 190	01001	1			ı
9. Geiger et al., 2014	U.S., General population	* <i>Study Design:</i> Cross-sectional * <i>Study Size</i> : n=815									
al., 2014		*Study Population Age: ≤ 18 years	^-	—			1			—	
		* <i>Exposure Range (Mean</i>): 4.3 ng/ml									
10.	U.S., Occupational - men	*Study Design: Cross-sectional									
Gilliland et	, 1	* <i>Study Size</i> : n=115									
al., 1996		*Study Population Age: Mean 39.2 years		↓-							
		*Exposure Range (Mean): 3300 ng/ml									
11. Lin et	Taiwan, Recruited from	*Study Design: Cross-sectional									
al., 2011	hypertension cohort	* <i>Study Size</i> : n=287									
	(General population)	*Study Population Age: 12-30 years									
		*Exposure Range (Median): 2.39 ng/ml									
12. Lin et	Taiwan, Individuals with	*Study Design: Cross-sectional									
al., 2013	abnormal urinalysis results	* <i>Study Size</i> : 664 (246 w/ elevated blood pressure									
	from population-based	and 398 w/ normal blood pressure)								\downarrow	
	screening program in	*Study Population Age: 12-30 years									
12 Malaan	Taiwan	* <i>Exposure (Median</i>): 3.49 ng/ml									
13. Nelson et al., 2010	U.S., General population	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> n=416 to n=860									
et al., 2010		*Study Population Age: 12-80 years	↑-	—	↑		—				
		* <i>Exposure Range (median)</i> : 3.8 ng/ml									
14. Olsen et	U.S., Occupational – male	*Study Design: Cross-sectional									
al., 2000	workers	* <i>Study Size</i> : n=265									
,		*Study Population Age: Adults		↓-							
		*Exposure Range (Median): 1190 ng/ml									
15. Olsen et	Belgium & U.S.,	*Study Design: Cross-sectional & Longitudinal									
al., 2003	Occupational	* <i>Study Size</i> : n=421 & 174	↑							↑	
		*Study Population Age: Adults	I							I	
		*Exposure Range (Mean): 1220-1990 ng/ml									
16. Olsen	Belgium & U.S.,	*Study Design: Cross-sectional									
and Zobel	Occupational - male	* <i>Study Size</i> : n=506									
2007		*Study Population Age (Mean): 37-41									
		*Exposure Range (Median): 2210 ng/ml									
				↓-			—			1-	
Citation	Study Population	Study Details	ТС	HDL	Non-	TC/	LDL	VLDL	HDL/	TG	Genes
					HDL	HDL			LDL		
			1		I		1	1	1		1

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 197 of 551

		se 1:16-cv-00917-LEK-DJS Document 1		<u>eu 04/00</u>	J/20 Pa	age 197	01 221	1	1		
17. Olsen et al., 2012	U.S., Occupational, direct employed and contract workers	* <i>Study Design:</i> Longitudinal * <i>Study Size</i> : n=179 * <i>Study Population Age</i> : Adults * <i>Exposure Range (Mean)</i> : Baseline/mean change - direct employed (881/-218.3 ng/ml), contract (28.9/32.1 ng/ml)				Ļ					
18. Sakr et al., 2007a	U.S., Occupational	*Study Design: Cross-sectional *Study Size: n=840 *Study Population Age: Adults *Exposure Range (Median):189 ng/ml	Ţ				Ţ	Ţ			
19. Sakr et al., 2007b	U.S., Occupational	*Study Design: Longitudinal *Study Size: n=454 *Study Population Age: Adults *Exposure Range (Median): 1040/1160 ng/ml	↑ (
20. Starling et al., 2014	Norway, Pregnant women recruited from larger cohort	*Study Design: Cross-sectional *Study Size: n=891 *Study Population Age: not stated - Adults *Exposure Range (Median): 2.25 ng/ml	_	—			_				
21. Steenland et al., 2009	U.S., Highly exposed community	*Study Design: Cross-sectional *Study Size: n=46,294 *Study Population Age: ≥ 18 years *Exposure Range (Median): 27 ng/ml	↑		1	Ţ	↑				
22. Steenland et al., 2015	U.S., Occupational	* <i>Study Design:</i> Retrospective cohort * <i>Study Size:</i> n=3,713 * <i>Study Population Age:</i> Adult (mean year of birth 1951) * <i>Exposure Range (Median):</i> 113 ng/ml	2								
23. Wang et al., 2012	China, Occupational (male) and Highly exposed community	*Study Design: Cross-sectional *Study Size: Workers: n=55 / Residents: n=132 *Study Population Age: Adult *Exposure Range (Median): 1636 / 284 ng/ml	/	<u>↓/</u>			/		<u>↓/</u>	/	
24. Winquist and Steenland, 2014a	U.S., Occupational (male) and Highly exposed community	* <i>Study Design:</i> Retrospective cohort (prospective analyses) * <i>Study Size:</i> Workers: n=3,713/ Residents: n=28,541 * <i>Study Population Age:</i> Adult * <i>Exposure Range (Median):</i> 112/ 24 ng/ml	2↑								
Citation	Study Population	Study Details	ТС	HDL	Non- HDL	TC/ HDL	LDL	VLDL	HDL/ LDL	TG	Genes
25. Zeng et al., 2015	Taiwan, recruited from control group of another study	* <i>Study Design:</i> Cross-sectional * <i>Study Size</i> : n=255 * <i>Study Population Age</i> : 12-15 years * <i>Exposure Range (Median)</i> : Boys=1.1, Girls=0.9 ng/ml	Ţ				¢			Î	

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 198 of 551

 \uparrow = statistically significant increased association, \downarrow = statistically significant decreased association, \uparrow - = inconsistent positively associated finding (findings from different models resulted in both statistically and non-statistically significant associations), \downarrow - = inconsistent negatively associated finding, — = not statistically significant, [statistical significant determined at α =0.05]

TC= total cholesterol, HDL= high density lipoprotein cholesterol, LDL=low density lipoprotein cholesterol, TG=triglycerides

1. Changes in the expression of genes 2. Self-reported high cholesterol

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 199 of 551

Table 6B. S	Fable 6B. Summary of findings from epidemiologic studies of PFOA and liver enzymes/bilirubin								
Citation	Study Population	Study Details	ALT	GGT	AST	ALP	TB	DB	LD
1. Costa et	Italy, Occupational (male)	*Study Design: Exposure case-control & Cross-sectional							
al., 2009		*Study Size: n=160	*	*		*			
		*Study Population Age: 20-63 years	↑-			1-	↓-		
		*Exposure Range (Median): 4400 – 5700 ng/ml							
2. Darrow	U.S., Highly exposed	*Study Design: Cross-sectional							
et al., 2016	community	*Study Size: up to n=32,254 including 3,713 workers	↑						
		*Study Population Age: >20 years of age						¥	1
		*Exposure Range (Median): 16.5 ng/ml							
3. Emmett	U.S., Highly exposed	*Study Design: Cross-sectional							
et al.,	community	* <i>Study Size</i> : n=371							
2006b		*Study Population Age: 2.5-89 years			_				
		*Exposure Range (Median): 354 ng/ml							
4. Gallo et	U.S., Highly exposed	*Study Design: Cross-sectional							
al., 2012	community	* <i>Study Size</i> : n=47,092	*	*					
		* <i>Study Population Age</i> : \geq 18 years							
		*Exposure Range (Median): 23.1 ng/ml							
5. Gilliland	U.S., Occupational (male)	*Study Design: Cross-sectional							
et al., 1996		* <i>Study Size</i> : n=115							
		*Study Population Age: Mean 39.2 years	↓-		↓-				
		*Exposure Range (Mean): 3300 ng/ml							
6. Gleason	U.S., General population	*Study Design: Cross-sectional							
et al., 2015		* <i>Study Size</i> : n=4,333	*	*	*		^		
		* <i>Study Population Age</i> : \geq 12 years	I				I		
		*Exposure Range (Median): 3.7 ng/ml							
7. Jiang et	China, pregnancy women	*Study Design: Cross-sectional							
al., 2014		*Study Size: 141							
		*Study Population Age: Not stated - adults							
		*Exposure Range (Median): 4.2 ng/ml							
8. Lin et	U.S., General population	*Study Design: Cross-sectional							
al., 2010		* <i>Study Size</i> : n=2,216	↑	↑					
		*Study Population Age: \geq 18 years	I	I					
		*Exposure Range (Mean): 4.5 ng/ml							
9. Melzer	U.S., General population	*Study Design: Cross-sectional							—
et al., 2011		*Study Size: n=3,974							
		*Study Population Age: ≥ 20 years							
		* <i>Exposure Range (Geo Mean)</i> : Men=4.9, Women=3.8 ng/ml							
Citatier	Study Domail - 4	Study Dataila	ATT	ССТ	ACT	AID	тр	DD	
Citation	Study Population	Study Details	ALT	GGT	AST	ALP	TB	DB	LD

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 200 of 551

10. Olsen et al., 2000U.S., Occupational – (male)*Study Design: Cross-sectional *Study Size: n=265 *Study Population Age: Adults *Exposure Range (Median): 1190 ng/ml	
*Study Population Age: Adults *Exposure Range (Median): 1190 ng/ml 11. Olsen Belgium & U.S., *Study Design: Cross-sectional & Longitudinal et al., 2003 Occupational *Study Size: n=421 & 174	
11. Olsen et al., 2003 Belgium & U.S., Occupational *Study Design: Cross-sectional & Longitudinal *Study Size: n=421 & 174 *Study Size: n=421 & 174	
11. Olsen et al., 2003 Belgium & U.S., Occupational *Study Design: Cross-sectional & Longitudinal *Study Size: n=421 & 174 *Study Size: n=421 & 174	
11. Olsen et al., 2003 Belgium & U.S., Occupational *Study Design: Cross-sectional & Longitudinal *Study Size: n=421 & 174	
et al., 2003 Occupational * <i>Study Size</i> : n=421 & 174	
*Exposure Range (Mean): 1220-1990 ng/ml	
12. Olsen Belgium & U.S., *Study Design: Cross-sectional	
and Zobel Occupational *Study Size: n=506	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
*Exposure Range (Median): 2210 ng/ml	
13. Olsen U.S., Occupational *Study Design: Longitudinal	
et al., 2012 Study Size: n=98-179	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
* <i>Exposure Range (Mean</i>): Baseline/mean change -direct employed	
(881/-218.3ng/ml), contract (28.9/32.1ng/ml)	
14. Sakr et U.S., Occupational *Study Design: Cross-sectional	
al., 2007a study Size: n=840	
al., 2007a Study 512e. It 640 *Study Population Age: Adults	
* <i>Exposure Range (Median</i>):189 ng/ml	
15. Sakr U.S., Occupational *Study Design: Longitudinal	
et al., *Study Size: n=454	
$\begin{bmatrix} ct al., \\ 2007b \end{bmatrix} = \begin{bmatrix} -1434 \\ *Study Population Age: Adults \end{bmatrix} = \begin{bmatrix} -1 \\ -1 \end{bmatrix} \downarrow$	
*Study Population Age. Adults *Exposure Range (Median): 1040/1160 ng/ml	
16. U.S., Occupational *Study Design: Retrospective cohort	
Steenland Study Size: n=3,713	
	_
*Exposure Range (Median): 113 ng/ml	
17. Wang, China, Occupational *Study Design: Cross-sectional (mala) and Highly 45. (mala) 45. (mala	
et al., 2012 (male) and Highly *Study Size: Workers: n=55 / Residents: n=132 —//	
exposed community *Study Population Age: Adults $-$	
*Exposure Range (Median): 1636 / 284 ng/ml	
18. Taiwan, recruited from *Study Design: Cross-sectional	
Yamaguchi larger cohort <i>*Study Size</i> : n=608	
et al., 2013 *Study Population Age: 16-76 years	
*Exposure Range (Median): 2.1 ng/ml	

 \uparrow = statistically significant increased association, \downarrow = statistically significant decreased association, \uparrow = inconsistent positively associated finding (findings from different models resulted in both statistically and non-statistically significant association), \downarrow = inconsistent negatively associated finding, — = not statistically significant, [statistical significant determined at α =0.05], — findings from some analyses are negative, positive, and non-significant

ALT (SGPT)=alanine aminotransferase, GGT=gamma-glutamyl transferase, AST (SGOT)=aspartate aminotransferase, ALP=alkaline phosphatase, TB=total bilirubin, DB=direct bilirubin, LD=liver disease

¹Includes findings from both any liver disease and second category of liver disease which includes enlarged liver, fatty liver, and cirrhosis

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 201 of 551

Table 6C.	Cable 6C. Summary of findings from epidemiologic studies of PFOA and thyroid hormones and diseases Citation Study Reputation Study Reputation Study Details											
Citation	Study Population	Study Details	TSH	TT4	FT4	TT3	FT3	TG	TD	Нуро	Hyper	OC
1. Bloom	U.S., Subgroup of	*Study Design: Cross-sectional										
et al.,	sportfish anglers	* <i>Study Size</i> : n=31-38										
2010		*Study Population Age: 31-45 years										
		*Exposure Range (Geo Mean): 1.3 ng/ml										
2. Chan	CAN, Cases -	*Study Design: Matched case-control										
et al.,	hypothyroxemic	* <i>Study Size</i> : n=271										
2011	pregnant women;	*Study Population Age: Adults										<u>a</u>
	Controls –	*Exposure Range (Median): Cases -3.9,										
	nonhypothyroxemic	Controls – 3.6 ng/ml										
	pregnant women											
3. de	The Netherlands,	*Study Design: Cross-sectional										
Cock et	Mother-child pairs	* <i>Study Size</i> : n=83 pairs		¹ ↑-								
al., 2014		*Study Population Age: Newborns		I								
		*Exposure Range (Median): 0.9 ng/ml										
4.	U.S., Highly	*Study Design: Cross-sectional										
Emmett	exposed community	* <i>Study Size</i> : n=371										
et al.,		*Study Population Age: 2.5-89 years										
2006b		*Exposure Range (Median): 354 ng/ml										
5. Jain	U.S., General	*Study Design: Cross-sectional										
2013	population	* <i>Study Size</i> : n=1,540	↑			↑						
		* <i>Study Population Age</i> : > 12 years	I			I						
		*Exposure Range (Median): 4.1 ng/ml										
6. Ji et	South Korea,	*Study Design: Cross-sectional										
al., 2012	Recruited from	* <i>Study Size</i> : n=633										
	cohort study	* <i>Study Population Age</i> : > 12 years										
		*Exposure Range (Median): 2.7 ng/ml										
7. Kim et	South Korea,	*Study Design: Prospective birth cohort										
al., 2011	Mother-Infant pairs	* <i>Study Size</i> : Mothers – n=44, Pairs - n=26										
		* <i>Study Population Age</i> : > 25 years	³ ↑-									
		*Exposure Range (Median): Maternal										
		prepartum blood– 1.5, Cord Blood- 1.2										
0.17		ng/ml		-								
8. Knox	U.S., Highly	* <i>Study Design:</i> Cross-sectional										
et al.,	exposed community	* <i>Study Size</i> : n=50,113										
2011		*Study Population Age: >20 years										
		* <i>Exposure Range (Mean)</i> : 86.6 ng/ml		↑-		↓-						
						-						
Citation	Study Population	Study Details	TSH	TT4	FT4	TT3	FT3	TG	TD	Нуро	Hyper	OC
9. Lin et	Individuals with	*Study Design: Cross-sectional										
al., 2013	abnormal urinalysis			_								
	results from									1		

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 202 of 551

16.	U.S., Occupational	* <i>Study Design:</i> Retrospective cohort * <i>Study Size</i> : n=3,713										
Citation	Study Population	Study Details	TSH	TT4	FT4	TT3	FT3	TG	TD	Нуро	Hyper	OC
15. Shrestha, et al., 2015	U.S., Community- based	*Study Design: Cross-sectional *Study Size: n=87 *Study Population Age: 55-74 years *Exposure Range (Median): 9.3 ng/ml										0.2
14. Olsen and Zobel 2007	Belgium & U.S., Occupational - male	*Study Design: Cross-sectional *Study Size: n=506 *Study Population Age (Mean): 37-41 *Exposure Range (Median): 2210 ng/ml	_		↓-	^-						
13. Olsen et al., 2003	Belgium & U.S., Occupational	*Study Design: Cross-sectional & Longitudinal *Study Size: n=421 & 174 *Study Population Age: Adults *Exposure Range (Mean): 1220-1990 ng/ml	_	_	_	Î						
12 Olsen et al., 1998	U.S., Male, Occupational	*Study Design: Cross-sectional *Study Size: 111 (1993) and 80 (1995) *Study Population Age: Not presented *Exposure Range (Range) 0 to 80,000 (1993) and 0 to 115,000 (1995) ng/ml	_									
11. Melzer et al., 2011	U.S., General population	*Study Design: Cross-sectional *Study Size: n=3,974 *Study Population Age: ≥ 20 years *Exposure Range (Geo Mean): Men=4.9 and Women=3.8 ng/ml							¹ ↑-			
10. Lopez- Espinosa et al., 2012	U.S., Highly exposed community	*Study Design: Cross-sectional and birth cohort *Study Size: n=10,725 *Study Population Age: 1-17 years *Exposure Range (Median): 29 ng/ml	_	_					↑-	↑-		
	population-based screening program in Taiwan	* <i>Study Size</i> : 664 (246 w/ elevated blood pressure and 398 w/ normal blood pressure) * <i>Study Population Age</i> : 12-30 years * <i>Exposure (GM)</i> : 2.7 ng/ml						3 202 0				

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 203 of 551

	C C	ase 1.10-CV-00917-LEK-DJS D00	Jumeni		FIIEU U4	+/00/20	гаус	5 203 (л <u>ээт</u>			
Steenland		*Study Population Age: Adult (mean year										
et al.,		of birth 1951)										
2015		*Exposure Range (Median): 113 ng/ml										
17.	Taiwan, pregnant	*Study Design: Cross-sectional and										
Wang et	women recruited	prospective birth cohort										
al., 2014	from cohort	* <i>Study Size</i> : n=285 women and n=116										
		neonates										
		*Study Population Age: Adult and										
		newborns										
		* <i>Exposure Range (Median)</i> : maternal=2.4										
		ng/ml										
18.	Canada, Euthyroid	*Study Design: Prospective cohort study										
Webster	pregnant women	* <i>Study Size</i> : n=152										
et al.,	recruited from study	*Study Population Age: >18 years	⁴ ↑-		—							
2014		* <i>Exposure Range (Median</i>): 1.7 ng/ml										
19.	U.S., General	*Study Design: Cross-sectional										
Wen et	population	* <i>Study Size</i> : n=1,180				¹ ↑-				¹ ↑-	² ↓-	
al., 2013	1 1	*Study Population Age: > 20 years				-1-				-11-	~↓-	
-		*Exposure Range (Geo Mean): 4.2ng/ml										
20.	U.S., Highly	*Study Design: Retrospective cohort,										
Winquist	exposed community	prospective analyses										
and	and Occupational	*Study Size: Resident, n=28,541; Worker,							¹ ↑-	² ↑-	↑-	
Steenland		n=3,713							-	-	-	
, 2014b		* <i>Study Population Age</i> : > 20 years										
* <i>Exposure Range (Median)</i> : 26.1 ng/ml												
\uparrow = statistically significant increased association, \downarrow = statistically significant decreased association, \uparrow = inconsistent positively associated finding (findings from different												
models resulted in both statistically and non-statistically significant associations), \downarrow - = inconsistent negatively associated finding, — = not statistically significant, [statistical												
significant determined at $\alpha = 0.05$]												
TSH=thyroid stimulating hormone, TT4=total thyroxine, FT4=free thyroxine, TT3=total triiodothyronine, FT3= free triiodothyronine, TG=thyroglobulin, TD=thyroid												
disease, Hy	disease, Hypo=hypothyroidism, Hyper=hyperthyroidism, OC=other thyroid conditions (a. Maternal hypothyroxemia)											

1. In girls/women only. 2. Men only 3. Outcome is fetal thyroid concentrations. 4. Sensitivity analysis indicates association in High TPOAb (marker of autoimmune hypothyroidism) only

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 204 of 551

Table 6D. Summary of findings from epidemiologic studies of PFOA and uric acid								
Citation	Study Population	Study Details	Uric Acid	Hyper				
1. Costa et al., 2009	Italy, Occupational: Cases – Male workers engaged in the PFOA production department; Controls – Male workers never exposed to PFOA	* <i>Study Design:</i> Exposure case-control & Cross-sectional * <i>Study Size:</i> n=160 * <i>Study Population Age:</i> 20-63 years * <i>Exposure Range (Median):</i> 4400 – 5700 ng/ml	î					
2. Geiger et al., 2013	U.S., General population	*Study Design: Cross-sectional *Study Size: n=1,772 *Study Population Age: ≤ 18 years *Exposure Range (Median): 4.3 ng/ml	î	ſ				
3. Gleason et al., 2015	U.S., General population	*Study Design: Cross-sectional *Study Size: n=4,333 *Study Population Age: ≥ 12 years *Exposure Range (Median): 3.7 ng/ml	î					
4. Lin et al., 2013	Taiwan, Individuals with abnormal urinalysis results from population-based screening program in Taiwan	* <i>Study Design:</i> Cross-sectional * <i>Study Size</i> : 664 (246 w/ elevated blood pressure and 398 w/ normal blood pressure) * <i>Study Population Age</i> : 12-30 years * <i>Exposure (Median)</i> : 3.5 ng/ml	_					
5. Sakr et al., 2007a	U.S., Occupational	*Study Design: Cross-sectional *Study Size: n=840 *Study Population Age: Adults *Exposure Range (Median):189 ng/ml	î					
6. Shankar et al., 2011	U.S., General population	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> n=3,883 * <i>Study Population Age:</i> > 20 years * <i>Exposure (Median):</i> Women, 3.5; Men 4.6 ng/ml	î	Ţ				
7. Steenland et al., 2010b	U.S., Highly exposed community	*Study Design: Cross-sectional *Study Size: n=54,591 *Study Population Age: > 20 years *Exposure (Median): 27.9 ng/ml	ſ	ſ				
positively a	associated finding (findings from different s), \downarrow - = inconsistent negatively asso at α =0.05]	on, \downarrow = statistically significant decreased associat fferent models resulted in both statistically and n ociated finding, — = not statistically significant,	on-statistically	significant				

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 205 of 551

Citation	Study Population	Study Details	Tetanus	Diphtheria	Rubella	Measles	Mumps	Influenza
1. Grandjean et	Faroe Islands, singleton	*Study Design: Prospective birth cohort					-	
al., 2012	births following through	*Study Size: n=656 \rightarrow 587						
	age 7 years	*Study Population Age: Birth to 7 years	\downarrow	\downarrow				
		* <i>Exposure Range (Median)</i> : Children (age 5)						
		4.1 ng/ml						
2. Granum et	Norway, Sub-cohort	*Study Design: Prospective birth cohort						
al., 2013	recruited from cohort	*Study Size: $n=99 \rightarrow 56$						1
		*Study Population Age: Birth to 3 years	_		\downarrow			·
		*Exposure Range (Median):1.1 ng/ml						
3. Kielsen et	Denmark, recruited from	*Study Design: Prospective cohort						
al., 2015	hospital staff	* <i>Study Size</i> : n=12						
	-	*Study Population Age: 23-66 years						
		*Exposure Range (Median): 1.7 ng/ml						
4. Looker et al.,	U.S., Highly exposed	*Study Design: Prospective cohort						
2014	community	* <i>Study Size</i> : n=411						2 -
		*Study Population Age: Adult						-↑-
		*Exposure Range (Median): 31.5 ng/ml						
5. Stein et al.,	U.S., General population	*Study Design: Cross-sectional						
2016		* <i>Study Size</i> : n=1,191			1			
		*Study Population Age: 12-19 years			↓-		↓-	
		*Exposure Range (Geo Mean): 4.1 ng/ml						

determined at α =0.05]

Tetanus=tetanus antibody concentrations; diphtheria=diphtheria antibody concentrations; Rubella = rubella antibody concentrations; Measles = measles antibody concentrations; Influenza = Influenza antibody titer

1. Haemophilus influenza type B (HiB) antibody concentrations 2. Influenza A H3N2 virus and an increased risk of not attaining the antibody threshold considered to offer long-term protection, other virus studied included Influenza Type B and Influenza Type A H1N1.

HEALTH EFFECTS - ANIMAL TOXICOLOGY

Overview

The toxicological database for PFOA includes studies of numerous effects in non-human primates and rodents. As discussed in the <u>Introduction</u>, a literature search was performed to identify publications relevant to health effects of PFOA including toxicological studies. The Health Effects Subcommittee's review focused on toxicological endpoints identified as sensitive and potentially relevant for use in risk assessment. The effects selected for detailed review were hepatic toxicity, developmental effects, immune system toxicity, and carcinogenicity. As discussed in the <u>Epidemiology</u> section, effects relevant to these endpoints have been associated with PFOA in humans. Studies related to these endpoints were summarized in summary tables and/or individual study tables, as described in the sections on each endpoint below. Additionally, information is presented on general toxicity in non-human primates, as well as thyroid, neurobehavioral, and male reproductive effects.

General issues

In reviewing the toxicology data, it should be kept in mind that female rats excrete PFOA much more quickly than males. Therefore, assuming that both genders are equally sensitive based on internal dose, effects are expected from lower administered doses of PFOA in male rats than female rats.

Another general issue for some of the animal toxicology studies is that, using sensitive analytical methods, measurable levels of PFOA were detected in the serum of animals in the untreated control groups. This exposure was likely due to a combination of two factors. First, there is likely some level of unavoidable background exposure to PFOA in laboratory animals, just as in the general human population, due to the ubiquitous presence of PFOA at low levels in the environment. Second, in some studies, the controls may have experienced some level of inadvertent exposure to the PFOA used to dose the treated animals. Serum levels of PFOA in control groups from the some of the studies discussed below were: Butenhoff et al. (2004a) cynomolgus monkey – 134 ng/ml; Loveless et al. (2006) rat and mouse – 100-400 ng/ml; DeWitt et al. (2008) mouse – 25-600 ng/ml; Abbott et al. (2007) mouse developmental: adults – 28-131 ng/ml, pups – 17-29 ng/ml; Macon et al. (2011) low dose mouse developmental: pups – 4-23 ng/ml.

Such low level exposure in laboratory control groups from sources such as diet and bedding also occurs for many other chemicals that are ubiquitous environmental contaminants. However, this issue is of particular relevance to PFOA because, unlike most other environmental contaminants, the dose-response curves for several of the associations seen in human epidemiology studies appear to be steepest at serum levels below about 40 ng/ml (discussed in <u>Human Studies</u>, above). Quantitation levels for serum PFOA in animal toxicology studies (e.g. 5 ng/ml, Reiner et al., 2009) are higher than in studies of human populations (e.g. 0.1 ng/ml in NHANES; CDC, 2015),

and serum levels in the control groups in some animal studies are within or above the range in which associations are found in the general population. Thus, the shape of the dose-response curve within the lower range of serum levels (at which associations were observed in some epidemiology studies) cannot be determined in these animal studies.

Finally, it should be noted that ammonium perfluorooctanoate (APFO, the ammonium salt of PFOA) was administered in some studies. Because APFO dissociates to PFOA in the body, results of studies of APFO are applicable to the evaluation of PFOA's toxicity.

Acute Toxicity

Oral LD₅₀ values of 680 mg/kg (95% CI 399-1157 mg/kg) and 430 mg/kg (95% CI 295-626 mg/kg) were reported for male and female albino rats, respectively, after a single gavage doses of APFO and observation for 14 days (Griffith and Long 1980). In this study, five rats per sex per dose group were administered 100, 215, 464, 1000, or 2150 mg/kg. One or more deaths occurred in all groups except the 215 mg/kg group, and all animals in the 2150 mg/kg group died on day 1. Ptosis, piloerection, hypoactivity, decreased limb tone, ataxia, and corneal opacity were reported. These signs were intermittent, and there was no apparent dose-response relationship for them. Changes in the lungs (congestion, pitting, red foci) and the stomach (distension, hyperemic and thickened mucosa) were commonly seen in animals that died during the study, and many survivors had mottled kidneys and stomach changes similar to those in the animals that died. Other oral acute toxicity studies, as well as dermal and inhalation studies, are summarized by Kennedy et al. (2004).

Subchronic Studies in Non-Human Primates

90-day rhesus monkey study (Goldenthal, 1978)

Goldenthal (1978) dosed rhesus monkeys (2/sex/group) with 0, 3, 10, 30 or 100 mg/kg/day APFO by gavage for 90 days (13 weeks). All 3 and 10 mg/kg/day animals survived the study. Soft stools, diarrhea, and frothy emesis were seen in the 3 mg/kg/day group, and one monkey in the 10 mg/kg/day group was anorexic during week 4, had a pale and swollen face in week 7, and had black stools for several days in week 12. In the 3 and 10 mg/kg-day groups, body weight gains were similar to controls, and no treatment related hematology or clinical chemistry changes were reported. Serum PFOA data are not provided in this study.

Mortality occurred in the two higher dose groups. In the 30 mg/kg/day group, 3 of 4 monkeys died during the study, one male during week 7 and the two females during weeks 12 and 13. All 30 mg/kg/day animals showed decreased activity, beginning in week 4. One monkey in this group had emesis and ataxia, swollen face, eyes, and vulva, as well as pallor of the face and gums. Beginning in week 6, two monkeys in this group had black stools, and one monkey had slight to moderate dehydration and ptosis of the eyelids.

All monkeys in the 100 mg/kg/day group died by week 5, with the first death occurring during week 2. These animals showed signs and symptoms that first appeared during week 1 including

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 208 of 551

anorexia, frothy emesis, pale face and gums, swollen face and eyes, decreased activity, prostration and trembling. Weight loss occurred in the two higher dose groups after week 1.

No treatment related gross pathological lesions were reported. Histopathological examination revealed effects on the adrenal gland, bone marrow, spleen, and lymph nodes in the two higher dose groups. Notably, all animals that died during the study had marked diffuse lipid depletion in the adrenal glands. All animals (including the one 30 mg/kg/day survivor) in the two higher dose groups had slight to moderate hypocellularity of the bone marrow and moderate atrophy of lymphoid follicles in the spleen, and one 30 mg/kg/day female and all 100 mg/kg/day animals had moderate atrophy of the lymphoid follicles in th

Statistically significant changes in absolute or relative organ weights at either 3 or 10 mg/kg/day in either males or females (but not both) were reported for heart, brain, and pituitary. The biological significance of these changes was stated to be unknown.

Relative liver weight data are of interest because this endpoint was affected by PFOA in cynomolgus monkeys and rodents (see below). Since each dose group consisted of only two animals, a large change would be needed to reach statistical significance for this effect. Although there were no statistically significant effects on this endpoint, the data presented in Table 7 suggests that PFOA caused increased relative liver weight at 30 and 100 mg/kg/day.

	Table 7. Relative Liver Weight (compared to controls) in 90							
Day Rhesus Monkey Study (Goldenthal, 1978)								
	Relative Liver Weight							
Dose	Dose Males (2 per Females							
(mg/kg/day)	group)							
0	1	1						
3	1.1	1						
10	1.1	1						
30	1.4 (1.5)	(1.9)						
100	(1.6)	(1.4)						

(Numbers in parentheses include dead animals)

The LOAEL for this study was 3 mg/kg/day based on the toxicity described above in this group, and no NOAEL was identified.

Because serum PFOA levels were not measured in this study, it is not possible to compare the internal dose at which effects occurred in the rhesus monkeys with the results from cynomolgus monkeys and rodents (detailed below).

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 209 of 551

4 week cynomolgus monkey study (Thomford, 2001a)

In a range finding study, the toxicity of APFO was studied in male cynomolgus monkeys (young adult to adult) dosed daily by capsule for 4 weeks (Thomford, 2001a). Dose levels were 0 (n=2), 2 mg/kg/day (n=3), and 20 mg/kg/day (n=3). Parameters evaluated in blood (prior to treatment and on Day 30) included serum PFOA (although data were not reported in Thomford et al., 2001a), hematology, clinical chemistry (also evaluated on Day 2, about 24 hours after first dose), and hormones (estradiol, estrone, estriol, thyroid stimulating hormone, total and free triiodothyronine, and total and free thyroxin). Of the parameters measured in blood, estrone was notably lower in both treated groups

All animals survived until the end of the study, no clinical signs of toxicity were observed in the treated groups, and body weight was not affected by treatment. Low or no food consumption occurred in one animal dosed with 20 mg/kg-day. Microscopic evaluation of the adrenals, liver, pancreas, spleen, and testes found minimal mineralization in the adrenals of one animal given 2 mg/kg/day and immature testes in one animal in each of the two dosed groups (2 of 6 dosed animals). The authors stated that these findings were not related to PFOA treatment. There was no evidence of peroxisome proliferation (assessed by palmitoyl CoA oxidase activity; PCO) in the liver, or increased cell proliferation (assessed by the proliferatingn cell nuclear antigen; PCNA) in the liver, testes, and pancreas of treated monkeys. The authors concluded that NOAEL was 20 mg/kg, and no LOAEL was established.

<u>6 month (26 week) cynomolgus monkey study (Thomford, 2001b; Butenhoff et al., 2002)</u> The toxicity of APFO was studied in male cynomolgus monkeys dosed daily by capsule for 6 months (Thomford, 2001b; Butenhoff et al., 2002). This study is described in detail because it has been used as the partial or entire basis for several earlier final and draft PFOA risk assessments (USEPA, 2005a; MDH, 2008; Post et al., 2009a; Tardiff et al., 2009; NC SAB, 2010; ATSDR, 2015), and because it is considered in evaluating the human relevance of hepatic effects of PFOA (See <u>Mode of Action</u> section, below). Concerns related to use of this study as the basis for risk assessment and the reasons why the data do not support Benchmark Dose modeling based upon it (Butenhoff et al., 2004a) are discussed in detail in Appendix 3 of this document. A table summarizing this study, with a focus on hepatic effects, is included in Appendix 5. Data for increased liver weight from this study are included in Table 10.

In this study as originally designed, male monkeys, age 3 to 9 years, were to be administered doses of 0, 3, 10, or 30 mg/kg/day by capsule, 7 days per week for 26 weeks. Six animals were dosed per group, except for the 3 mg/kg/day group which had four animals. However, as detailed below, the high dose (30 mg/kg/day) was reduced to 20 mg/kg/day due to overt toxicity. Additionally, only three of the four low dose (3 mg/kg/day) and two of the six high dose (30 mg/kg/day) monkeys tolerated the administered dose well enough to complete the study, while all six animals in the mid-dose group (10 mg/kg/day) completed the study. Two animals from the control and 10 mg/kg/day groups were observed for delayed effects for 13 weeks following the 6 months of dosing.

One low dose (3 mg/kg/day) monkey was sacrificed on day 137 (week 19) after loss of about 10% of its weight in one week accompanied by low food consumption, few feces, hind-limb paralysis, ataxia, and lack of response to pain. No specific organ pathology or clinical chemistry changes explaining the morbidity were found, and the study authors stated that it was unclear whether or not these effects resulted from exposure to PFOA. It is notable that the liver-to-body weight ratio in this animal, 2.44, was much higher than for other animals in this group and was comparable to the ratios in the high dose group. Also, the liver-to-brain weight ratio in this animal, 1.66, was the highest of any animal in the study. However, the serum and liver PFOA levels in this animal were not higher than for other animals in the same treatment group. These findings suggest that this animal may have been particularly susceptible to the hepatic effects of PFOA.

Dosing of the high dose (30 mg/kg/day) group was stopped on day 12 due to toxicity in the first week, including low food consumption, weight loss, and few or no feces. The dosing of this group was restarted at 20 mg/kg/day on day 22, after a 10-day break to allow for recovery from the toxicity in first week.

One high dose monkey was sacrificed on day 29 due to decreased body weight, lack of eating, hypoactivity, and coldness to touch. The liver of this animal had lesions including mid-zonal and centrilobular hepatocellular degeneration and necrosis, diffuse hepatocellular vacuolation, and centrilobular hepatocyte basophilia indicative of liver regeneration. Other effects observed in this monkey included necrosis, erosions, and ulcerations of the esophagus and stomach, and involution of the thymus. This animal had increased serum enzymes indicative of substantial liver and muscle injury, and a marked decrease in serum cholesterol to about 10% of control levels. The study authors state that the liver lesions were likely related to treatment.

Dosing of three high dose (30/20 mg/kg/day) monkeys was stopped on days 43, 66, and 81 due to low or no food consumption, dramatic weight loss (18-23% of body weight), and few or no feces. These three monkeys were monitored without dosing for the rest of the study, and their body weights increased to above pre-dosing levels by the end of the study.

In the study, serum PFOA levels were analyzed every 2 weeks, including in animals for which dosing was stopped. Steady state was reported to have been reached after 4-6 weeks. The complete set of serum data was reported in a separate publication (Butenhoff et al., 2004a). Means and standard deviations for serum levels in the control, 3, 10, and 30/20 mg/kg/day groups, excluding animals for which dosing was stopped, were reported as $134\pm113 \text{ ng/ml}$, $80,000\pm40,000 \text{ ng/ml}$, $99,000\pm49,000 \text{ ng/ml}$, and $155,000\pm103,000 \text{ ng/ml}$. It is evident from the data that there was a wide variation in serum levels within the same treatment group, and that serum levels did not increase proportionally with dose. The ratios between mean serum levels at steady-state in the 3, 10, and 30/20 mg/kg/day groups were approximately 1:1:2 (i.e. serum

levels were similar in the 3 and 10 mg/kg/day groups), and the mean serum levels at 3 mg/kg/day and 10 mg/kg/day did not differ significantly at the p<0.05 level (Butenhoff et al., 2002).

Hepatic PFOA concentrations at sacrifice did not differ between the 3 and 10 mg/kg/day groups $(15,000\pm3600 \text{ ng/g} \text{ and } 14,000\pm7600 \text{ ng/g}, \text{ respectively})$ and were very disparate in the two high dose (20/30 mg/kg/day) animals that completed the study (16,000 and 83,000 ng/g). It is notable that the highest liver concentration by far (154,000 ng/g) was found in the high dose animal sacrificed due to treatment-related morbidity at week 5.

Average body weight gains during the dosing period in the 0, 3, and 10 mg/kg/day groups were 19, 20, and 20%, while the weight changes in the two 30 mg/kg/day animals that completed the study were -8% and 18%.

Serum cholesterol was not affected by PFOA treatment in this study, while triglycerides were significantly increased compared to controls at several time points in the mid- and high dose group. These observations are notable, since decreases in serum cholesterol have been observed in rodent studies with PFOA, consistent with the effects of other PPAR-alpha activators, and since human PFOA exposure has been associated with increases in cholesterol (see <u>Epidemiology</u> section, above). As discussed above, the dose-response curves for increased cholesterol in humans appears steepest at serum PFOA levels below about 40 ng/ml, with a much flatter dose-response between about 40 and 350 ng/ml PFOA in serum (Nelson et al., 2010; Steenland et al., 2009b). Since the mean serum PFOA level in the control monkeys was 134 ng/ml, the shape of the dose response curve for cholesterol at serum levels relevant to effects observed in humans is not known.

In the high dose group, including the three monkeys in which treatment was stopped, total neutrophils, total serum protein, and albumin were decreased. In the two monkeys in this group that were dosed until the end of the study, the changes were not significant but were consistent over time. In one of the monkeys whose dosing was stopped, serum liver enzyme levels and elevated serum bile acids were greatly increased three days prior to the stopping of the dosing. Additionally, the high dose monkey that was sacrificed in moribund condition on Day 29 had markedly elevated liver enzymes and markedly low cholesterol.

Changes in thyroid hormone levels occurred in treated groups; these are described in detail in the section on thyroid effects below. Although estradiol levels in the high dose group appeared to decrease with treatment, the authors did not attribute these findings to treatment.

Absolute liver weight and liver-to-body weight ratios were increased in all treated groups (Butenhoff et al., 2002). The increase in absolute liver weight was statistically significant (p<0.01) in all groups, but was only significant for relative liver weight in the high dose group. However, this analysis does not include the animals that were sacrificed in moribund condition during the study. The absolute and relative liver weight of the sacrificed low dose monkey was

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 212 of 551

far higher than the others in its group, and inclusion of data for this animal increases the mean value for these parameters (Table 10). Liver-to-brain weight ratio is considered to be a reliable measure of effects on liver weight, because brain weight tends to remain stable when body weight changes. This ratio was increased in all treated groups compared to controls, but did not increase with administered dose or serum level (Butenhoff et al., 2004c). In the control, 3, 10, and 30/20 mg/kg/day groups, the liver-to-brain weight ratios were 0.934, 1.34, 1.30, and 1.22, respectively.

No gross or microscopic pathological changes were seen in the organs examined from animals that completed the study. However, as mentioned above, multiple pathological changes were found in the high dose monkey sacrificed in moribund condition on Day 29. These included edema and inflammation of the esophagus and stomach (attributed to dosing injury); liver lesions including mid-zonal and centrilobular hepatocellular degeneration and necrosis, diffuse hepatocellular vacuolation, and hepatocyte basophilia in centrilobular areas indicative of liver regeneration; involution of the thymus (noted as a common stress response); and degeneration and necrosis of the heart (noted as likely an agonal change).

Two monkeys from the control group and two from the 10 mg/kg/day group were observed for 13 weeks following the 6-month treatment period. Weight gain during the recovery period was lower in the 10 mg/kg/day animals than in the controls. During the recovery period, the control group monkeys gained 10 and 11% of their body weight, while one treated monkey gained 5% and the other lost 3%.

Studies of hepatic biochemical markers in this study are discussed in the <u>Mode of Action</u> section, below.

The LOAEL in this study is 3 mg/kg/day based on mortality possibly related to treatment (25%) and increased liver weight, and the NOAEL is unknown. Mean serum levels at this dose were reported by Butenhoff et al. (2004a) as $80,600 \pm 40,000$ ng/ml. It is important to note that 6 months represents less than 2% of the lifespan of about 30 years in this species of monkey. It is not known whether additional or more severe effects would have occurred with continued dosing of the monkeys that tolerated dosing for the full 6 months of the study. Additionally, this study did not include female monkeys and, because exposure was initiated at age 3 to 9 years, effects specific to exposures during development or at younger ages would not be evident.

Comparison of the results of this study with chronic rat studies discussed below suggests that cynomolgus monkeys are more sensitive to the overt toxicological effects of PFOA than are rodents. As discussed above, four of the six high dose monkeys exhibited severe toxicity that necessitated removal from the study. The serum PFOA level in the high dose monkey that was sacrificed on Day 29 with severe multi-organ toxicity was 822,000 ng/ml. The serum levels of the other three high dose monkeys removed from the study on days 43, 66, and 81 due to overt toxicity (low or no food consumption, dramatic weight loss of 18-23%, and few or no feces)

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 213 of 551

were 102,000 ng/ml, 467,000 ng/ml, and 235,000 ng/ml, respectively, at the times when dosing was stopped. These severe toxic effects occurred after dosing for about 0.3-0.7% of the monkeys' lifespans. In contrast, survival was unaffected or increased compared to controls, and no overt toxicity was observed, in male rats with lifetime (2 year) exposure to PFOA doses that were estimated to result in serum PFOA levels of almost 600,000 ng/ml (Sibinski 1987; Biegel et al., 2001; USEPA, 2005a). Thus, severe toxicity resulted from relatively short exposures to PFOA in primates at serum levels below those that were well tolerated chronically by rats.

Hepatic Effects in Rodents and Non-Human Primates

PFOA causes liver toxicity in experimental animals, including rodents and non-human primates (reviewed by Kennedy et al., 2004; Lau, 2012). As discussed in the <u>Epidemiology</u> section, increased liver enzymes are associated with exposure to PFOA in humans.

Increased liver weight is a sensitive toxicological endpoint for PFOA that has been observed in many toxicological studies. Although studies of PFOA that report increased liver weight do not always include evaluation of other hepatic endpoints, numerous studies of PFOA have demonstrated that increased liver weight co-occurs with and/or progresses to more severe hepatic effects including increased serum liver enzymes, hepatocellular necrosis, fatty liver, and/or hyperplastic nodules. Additionally, recent studies show that cellular damage indicative of liver toxicity persists until adulthood following developmental exposure to PFOA.

This section first reviews data indicative of liver damage from toxicological studies of PFOA. This is followed by a presentation of data on increased relative liver weight from PFOA. Numerous toxicological studies of PFOA have evaluated liver weight, and a separate discussion of each of these is beyond the scope of this document. Because studies of increased liver weight that include relatively low doses of PFOA are most relevant to quantitative risk assessment, they are reviewed in detail and are summarized in Table 10.

Chronic exposure to PFOA also caused hepatic adenomas in rats (See <u>Chronic Studies</u>, below). The mode of action for hepatic effects, particularly as related to human relevance, is discussed in detail in the <u>Mode of Action</u> section.

Histopathological changes in the liver

Hepatocellular hypertrophy is a consistently reported histopathological finding for PFOA that accompanies increased absolute and relative liver weight. A number of studies in both non-human primates and rodents also report other histopathological changes that are indicative of liver injury and/or lipid accumulation in the liver. These effects occurred at doses similar to those causing increased liver weight. Notably, prenatal exposure to a very low dose (0.01 mg/kg/day) of PFOA caused liver toxicity that persisted until adulthood at doses below those which caused increased liver weight (Quist et al., 2015).

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 214 of 551

International harmonization of diagnostic criteria and terminology for histopathologic lesions has recently been developed to provide consistency and to reflect current knowledge of the biochemical and cellular processes involved in changes in the liver and other organs (Mann et al., 2012). The terminology and current definitions that are recommended by the international harmonization group to describe hepatic damage were applied where appropriate to describe the histopathological findings discussed below.

Information from some studies that reported histopathological effects indicative of liver damage is summarized below. It should be noted that this summary does not represent a complete compilation of all studies such effects. The significance of these effects as related to the mode of action of PFOA is discussed in the <u>Mode of Action</u> section.

As discussed above, the high dose (30/20 mg/kg/day) male cynomolgus monkey sacrificed in moribund condition on Day 29 of the 90-day study had liver lesions including mid-zonal and centrilobular hepatocellular degeneration and necrosis, diffuse hepatocellular vacuolation, and centrilobular hepatocyte basophilia indicative of liver regeneration (Butenhoff et al., 2002).

In a 28-day study of male and female Chr-CD albino rats with dietary exposure to 30-1000 ppm APFO, degeneration and/or necrosis of hepatocytes and focal bile duct proliferation occurred in all treated groups (Kennedy et al., 2004). The dose from 30 ppm in the diet was estimated as 1.5 mg/kg/day. Similar changes were seen in livers of rats dosed with 3 to 1000 ppm in the diet for 90 days, and were stated to be more frequent in males, and most pronounced at the highest dose (Griffith and Long, 1980).

Individual cell and focal necrosis, increased hepatocellular mitotic figures, fatty changes, and bile duct hyperplasia were observed in male CD-1 mice dosed by gavage with linear APFO for 29 days (Loveless et al., 2008). The LOAEL for individual cell and focal necrosis was reported by the authors as 1 mg/kg/day, and the NOAEL as 0.3 mg/kg/day. Focal necrosis occurred in one of ten mice at 0.3 mg/kg/day but was stated by the authors to not be related to PFOA treatment. Increased mitotic figures, fatty changes, and bile duct hyperplasia occurred at ≥ 10 mg/kg/day.

Multiple histopathological changes were observed in the livers of three strains (wild type, PPARalpha null, and humanized PPAR-alpha) of male Sv/129 mice dosed with 1 or 5 mg/kg/day PFOA for 6 weeks (Nakagawa et al., 2011). PFOA caused a dose-dependent increase in macrovesicular steatosis in the PPAR-alpha null mice, while this effect was not seen in the wild type mice. Additionally, microvesicular steatosis occurred at both doses in the PPAR-alpha null and humanized PPAR-alpha mice. Lobular inflammation was observed only in the PPAR-alpha null mice treated with PFOA. Single cell necrosis occurred in all three strains of PFOA treated mice and appeared to be most severe in the wild type mice. Hydropic degeneration of hepatocytes was seen in the PPAR-alpha null and humanized PPAR-alpha strains treated with PFOA, but not the wild type strain. Adverse histological changes including deranged liver architecture, severe edema, vacuolar degeneration, focal necrosis, and obvious inflammatory infiltration were observed in livers of male Kunming (KM) mice dosed by gavage with 2.5 to 10 mg/kg/day PFOA for 14 days (Yang et al., 2014). These changes were more severe with increasing dose and were not seen in the control mice.

Bile duct injury, which was much more severe in PPAR-alpha null mice than in wild type mice (male 129S4 strain), occurred after 4 weeks of gavage dosing with 4.4, 10.8, or 21.6 mg/kg/day APFO (Minata et al., 2010). Microvesicular steatosis was also more prominent in treated PPAR-alpha null than similarly treated wild type mice, and focal necrosis occurred at the highest dose in the null mice.

Focal and multi-focal hepatic necrosis was observed at sacrifice on PND 109-120 in F1 male offspring in the 3, 10, and 30 mg/kg/day dose groups (but not at 1 mg/kg/day) in a two-generation rat reproductive developmental study that is discussed in detail below (Butenhoff et al., 2004b).

Histopathological changes occurred in the livers of male Sprague-Dawley rats sacrificed one day after the end of dietary exposure to 300 ppm APFO for 1, 7, or 28 days (Elcombe et al., 2010). This study was conducted twice, and the daily doses were estimated as 19 mg/kg/day and 23 mg/kg/day in the two studies. In both studies, PFOA caused periportal glycogen depletion after 1, 7, and 28 days of exposure to PFOA, hepatocellular hypertrophy after 7 and 28 days, and hepatocellular hyperplasia in all treated rats after 28 days.

In a chronic rat study discussed in detail below (Sibinski, 1987; Butenhoff et al., 2012), focal hepatocellular necrosis occurred in 6/15 high dose (14.2 mg/kg/day) males but not in any of the 15 controls at the one-year sacrifice. (The low dose group was not evaluated at one year). At the two-year sacrifice, the incidence of focal hepatocellular necrosis was similar in control and treated groups, but the incidence of hepatic hyperplastic nodules was increased in the high dose males compared to the control and low dose groups. Butenhoff et al. (2012) concluded that the increased incidence of focal necrosis and vacuolation at one year, but not at later time points, may have been due to the higher background incidence of these changes in older rats.

Additionally, PFOA caused hepatocellular adenomas in chronically exposed male rats in one of the two chronic rat studies that have been conducted (Biegel et al. 2001). Although these tumors were not increased in the other chronic rat study (Sibinski et al., 1987), the EPA Science Advisory Board (2006) concluded that the increased in hepatic hyperplastic nodules in Sibinski et al. (1987) may have been part of the continuum of proliferative lesions in the hepatic carcinogenic process. More recently, Butenhoff et al. (2012) suggested that the observations at one year and two years in Sibinski et al. (1987) suggest a progression of lesions "from hepatocellular hypertrophy to fatty degeneration to necrosis followed by regenerative

hyperplasia." Butenhoff et al. (2012) also note that the diagnostic criteria for these nodules, which indicate a regenerative process, have changed since the study was evaluated in 1986.

PFOA caused hepatic triglyceride accumulation (fatty liver) in male Wistar rats after 7 days of dietary exposure (Kawashima et al., 1995). Hepatic triglyceride levels were significantly increased at the lowest dose (25 ppm) and were 3.5 times control levels in the 100 ppm dose group.

Several studies have evaluated hepatic effects of PFOA in mice that were fed diets containing specific types of lipids or higher general fat content. Kudo and Kawashima (1997) studied the effect of PFOA (2.5 - 10 mg/kg/day by intraperitoneal injection for 7 days) on hepatic triglyceride accumulation in male mice that had been fed diets containing soy bean oil, perilla oil, or fish oil for 4 weeks. Fish oil, but not the other two types of oil, was known to generally decrease hepatic triglycerides. PFOA caused a dose-dependent increase in hepatic triglycerides in mice exposed to perilla oil and soybean oil, but had no effect in mice exposed to fish oil.

Additionally, necrotic cell death, lipid droplet accumulation, and inflammatory cell infiltration were found in male C57BL/6N mice dosed with 5 mg/kg/day PFOA in a liquid diet for 3 weeks (Tan et al., 2013). These effects of PFOA were more severe in mice receiving a high fat diet than a regular diet. PFOA caused increased hepatic triglyceride levels in mice receiving regular diets or high fat diets, and relative white adipose tissue weight was decreased by PFOA treatment.

Finally, PFOA (5, 10, or 20 mg/kg/day by gavage for 14 days) caused lipid accumulation in the livers of male Balb/C mice fed either a regular diet or a high fat diet (Wang et al., 2013). Consistent with Tan et al. (2013), PFOA caused decreased relative weight of adipose tissue in mice receiving either diet. The authors concluded that lipids were both being released from the adipose tissue and accumulating in the liver. Evaluation of hepatic ultrastructural changes showed that PFOA caused a dose-dependent increase in the accumulation of lipid droplets in the nucleus of hepatic cells; the dose-response for this effect was similar in the regular and high fat diet groups. In the regular diet mice dosed with 10 and 20 mg/kg/day, dilation of the endoplasmic reticular was observed. More severe changes were seen in high fat diet mice at these doses including mitochondrial swelling, irregular nuclei, and condensed chromatin suggesting apoptosis.

Two recent studies found persistent hepatic damage in female mouse offspring after maternal gestational exposure to low doses of PFOA. Quist et al. (2015) evaluated hepatic effects in female CD-1 mouse offspring from dams dosed with 0.01 to 1 mg/kg/day PFOA on GD 1-17. Livers from offspring were evaluated on PND 21 (weaning) and PND 91. On PND 21, relative liver weight was significantly increased at 0.3 and 1 mg/kg/day, with no effect at 0.01 or 0.1 mg/kg/day, and PFOA treatment did not cause hepatocellular hypertrophy at any dose at this time point. In contrast, hepatocellular hypertrophy was significantly increased (p<0.01) at PND 91 in all dosed groups (0.01 mg/kg/day; NOAEL not identified), although the increased relative

liver weight observed at higher doses on PND 21 had been resolved. Additionally, dose-related hepatic periportal inflammation occurred in treated offspring on PND 21 and 91, and was more severe on PND 21 than on PND 91. On PND 21, the severity score for this effect was significantly (p<0.05) increased at all doses ($\geq 0.01 \text{ mg/kg/day}$) in a dose-related fashion, with no NOAEL identified. In this study, periportal inflammation was a more sensitive indicator of toxicity from prenatal exposure to PFOA than increased liver weight in female CD-1 mice.

Quist et al. (2015) also evaluated ultrastructural hepatic changes in control and highest dose (1 mg/kg/day) mice using transmission electron microscopy. Mitochondrial proliferation and abnormal mitochondrial morphology occurred in PFOA-treated mice at both PND 21 and PND 91 and was more severe at the later time point. Peroxisomes were present only in a single liver section from one treated animal and were closely associated with areas of mitochondrial proliferation.

In summary, hepatocellular hypertrophy was observed by Quist et al. (2015) at low doses (\geq 0.01) on PND 91, a time point when PFOA had almost completely been eliminated from the body and the transient increased relative liver weight observed at the higher PFOA doses on PND 21 had resolved. Although hepatocellular hypertrophy from PFOA in adult rodents has typically been associated with proliferation of peroxisomes or smooth endoplasmic reticulum, these changes were not seen in adult (PND 91) female mice after prenatal exposure to PFOA (1 mg/kg/day). Instead, hepatocellular hypertrophy was associated with mitochondrial proliferation and abnormal mitochondria. The significance of these observations is further discussed in the Mode of Action section.

Filgo et al. (2015) evaluated histopathological effects in the liver at age 18 months in female offspring of dams dosed during gestation. The study evaluated three strains of mice: CD-1, 129/Sv wild type, and 129/Sv PPAR-alpha null. CD-1 dams were dosed with PFOA at 0, 0.01, 0.1, 0.3, 1, and 5 mg/kg/day, and 129/Sv wild type and PPAR-alpha null dams were dosed with 0, 0.1, 0.3, 1, and 3 mg/kg/day. Findings related to non-neoplastic hepatic changes in CD-1 mice included significant dose-related trends for increased incidence of centrilobular hepatocyte hypertrophy, Ito cell hypertrophy, and oval cell hyperplasia, and for increased severity of chronic active inflammation. In the 129/Sv strains, non-neoplastic hepatic changes caused by PFOA were primarily observed in the PPAR-alpha null mice. These included increased incidence of bile duct hyperplasia, hyaline droplet accumulation in the bile duct, hematopoietic cell proliferation, and centrilobular hepatocyte hypertrophy. In the wild type 129/Sv mice, only severity of centrilobular hepatocyte hypertrophy was increased by PFOA treatment.

The incidence of liver tumors was also evaluated by Filgo et al. (2015) because of the unexpected finding of hepatic tumors in some animals that died before the scheduled end of the study. However, the authors emphasize that the study was not designed or intended to be a carcinogenicity bioassay. In CD-1 mice, single or multiple hepatocellular adenomas were found in one or more animals in each of the treated groups (n=21 to 37 per group) except for at the

lowest dose (0.01 mg/kg/day), but were not found in controls (n=29). In total, adenomas occurred in 4.9% (7 of 144) treated CD-1 mice, compared to a historic control incidence of 0.4% in untreated female CD- mice. Hepatocellular carcinomas occurred in two treated CD-1 mice (0.3 and 5 mg/kg/day) but not in controls. In 129/Sv wild type mice, hepatocellular adenomas did not occur in control or treated groups (n=6 to 10 per group). In PPAR-alpha null mice of this strain, in contrast, there were no adenomas in the controls (n=6), one adenoma in the 0.1, 0.3, and 1 mg/kg/day groups (n=9 or 10), and two adenomas at 3 mg/kg/day (n=9). These tumors occurred in 13.2% of all treated PPAR-alpha null mice. The significance of these findings is further discussed in the <u>Mode of Action</u> section below.

Serum liver enzymes and bile acids

Most toxicology studies of PFOA's effects on liver weight and histopathology did not assess serum levels of hepatic enzymes or bile acids. However, several studies in rodents have reported that these parameters were increased by PFOA, and these data are summarized below. As above, this summary does not represent a complete compilation of all data on these endpoints. These endpoints are of interest because they are indicative of hepatic damage, and because increased serum liver enzymes are associated with PFOA in human studies of the general population, communities with drinking water exposure, and workers (see Epidemiology section, above).

In the 90 day cynomolgus monkey study, ALT and AST were greatly elevated (about 10 to 50 times control levels) in two of the high dose animals that experienced toxicity from PFOA prior to the end of the scheduled dosing period (Butenhoff et al., 2002).

The liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were increased in all dose groups ($\geq 0.49 \text{ mg/kg/day}$) in a study of mice dosed with PFOA in drinking water for 21 days (Table 8). These increases were statistically significant (p<0.05) at \geq 2.64 mg/kg/day for AST and \geq 17.62 mg/kg/day for ALT (Son et al., 2008).

Table 8. Liver enzymes (relative to control) in serum of mice exposed to PFOA in drinking water for 21 days (Son et al., 2008)			
Dose (mg/kg/day)	ALT	AST	
0	1	1	
0.49	1.5	2.0	
2.64	2.9*	1.5	
17.62	4.2*	3.3*	
47.21	5.2*	4.0*	

* $p \le 0.05$.

Numerical data for liver enzymes (mean \pm SD) are presented in Son et al. (2008).

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 219 of 551

PFOA caused dose-related increases in serum levels of four liver enzymes (ALT, AST, alkaline phosphatase, and lactic dehydrogenase [LDH]), as well as total bile acids, in male mice (Yang et al., 2014). The LOAEL for increased ALT was 2.5 mg/kg/day (the lowest dose in the study), while the LOAEL for increases in the other liver enzymes and total bile acids was 5 mg/kg/day. All parameters were increased to several-fold above control levels at 5 and/or 10 mg/kg/day.

Dose-related increases in ALT, AST, total bilirubin, and total bile acids occurred in both wild type and PPAR-alpha null mice treated with PFOA (Minata et al., 2010). For all of these parameters, the maximum increase at the highest dose was much greater in the PPAR-alpha null mice than in the wild type mice.

Nakagawa et al. (2011) also reported small but statistically significant increases in ALT in all three strains of mice (wild type, PPAR-alpha knockout, humanized PPAR-alpha) studied. The greatest increase was 2.3-fold in wild type mice given 5 mg/kg/day PFOA, with smaller increases in the PPAR-alpha null and humanized PPAR-alpha strains.

Liver enzymes (AST, ALT, GGT, and LDH) were significantly elevated on GD 18 in pregnant ICR mice dosed with 10 mg/kg/day PFOA on GD 1-17. AST and ALT were elevated at 5 mg/kg/day, but this effect was not significant, while no changes were observed at 1 mg/kg/day. (Yahia et al., 2010).

In a chronic rat study discussed below, ALT, AST, and alkaline phosphatase were increased in males in both low (1.3 mg/kg/day) and high dose (14.2 mg/kg/day) groups between 2 and 18 months of dosing, and in the high dose group after 24 months of dosing (Sibinski, 1987; Butenhoff et al., 2012). Butenhoff et al. (2012) conclude that these increases may result from the hepatic hypertrophy and/or "borderline chronic liver toxicity" caused by PFOA.

Detailed review of selected data for increased relative liver weight

Numerous studies have consistently reported that PFOA causes increased absolute and relative liver weight in laboratory animals. Increased relative liver weight is a sensitive endpoint for PFOA that co-occurs and/or can progress to more severe manifestations of hepatic toxicity. Data on increased relative liver weight from rodent studies that used relatively low doses (1 mg/kg/day or less), as well as the 90 day cynomolgus monkey study (Butenhoff et al., 2002), are summarized in Table 10. This group of studies includes five studies that provide data on serum PFOA levels at the end of the dosing period period (Butenhoff et al., 2002; Lau et al., 2006; Loveless et al., 2006; Perkins et al., 2004; Macon et al., 2011) and six additional studies that do not include such serum data. Studies providing serum PFOA data at the end of the dosing period are most appropriate for dose-response evaluation in risk assessment, because serum levels are highest at this time point and thus represent the maximum internal doses that could have caused the observed effect. Detailed individual study tables are found in Appendix 5 for the five studies that provide relevant serum PFOA levels.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 220 of 551

Rodent data on increased relative liver weight

Three studies (Perkins et al., 2004; Loveless et al., 2006; Loveless et al., 2008) evaluated effects in male rats exposed to APFO. Perkins et al. (2004) and Loveless et al. (2006) provide serum PFOA data useful for dose-response modeling, while Loveless et al. (2008) does not include serum PFOA levels. Individual study tables for the two rat studies that include serum data (Perkins et al., 2004 and Loveless et al., 2006) are found in Appendix 5.

APFO formulations containing differing isomeric compositions (linear/branched, linear, or branched) were used in the three male rat studies (Perkins et al., 2004; Loveless et al., 2006; Loveless et al., 2008). Both linear/branched and linear PFOA were produced industrially, while information on effects of the branched form, which was not produced industrially, contributes to the understanding of the toxicology and mode of action of PFOA. Perkins et al. (2004) evaluated effects of linear/branched PFOA for 4, 7, and 13 weeks, while Loveless et al. (2006) studied the effects of 2 weeks of exposure to the linear isomer, branched isomers, or a mixture of linear/branched isomers. Both of these studies evaluated absolute and relative liver weight, hepatic palmitoyl CoA oxidase activity (PCO; a marker of peroxisome proliferation), and serum PFOA levels at sacrifice. The third male rat study, Loveless et al. (2008) evaluated the linear isomer of PFOA and reported relative liver weight data after exposure for 29 days, but did not report serum PFOA levels or PCO activity. (Both Loveless et al., 2006, and Loveless et al., 2008, also evaluated male mice, discussed below.)

In Perkins et al. (2004), serum PFOA levels in rats reached steady state by 4 weeks. The doseresponse curves for increased liver weight relative to body weight were almost identical at all three time points (4, 7, and 13 weeks), indicating that relative liver weight did not continue to increase over time with exposures longer than 4 weeks.

In the study evaluating the three PFOA formulations with differing isomer content (Loveless et al., 2006), serum PFOA levels from branched PFOA were lower than from the same doses of linear/branched or linear PFOA. This difference is likely to result from the more rapid excretion of the branched isomers (Benskin et al., 2009; DeSilva et al., 2009). The serum level LOAELs for male rats after 2 weeks of exposure to linear/branched PFOA reported by Loveless et al. (2006) are consistent with those from the longer exposure periods in Perkins et al (2004). The serum level dose response curves for increased relative liver weight from linear/branched PFOA in these two male rat studies with differing exposure durations are also consistent at the lower serum PFOA levels (less than 75,000 ng/ml) and are generally similar at the higher serum PFOA levels. Additionally, the dose-response curves for male rats based on administered doses of linear PFOA in the 2-week study (Loveless et al., 2006) and the 29-day study (Loveless et al., 2008) are generally consistent; serum PFOA data are not provided in the 29-day study.

Effects in male mice from exposure for 2 weeks to the three isomeric formulations of PFOA were also studied by Loveless et al. (2006). The same parameters that were evaluated in rats were studied in the mice, including absolute and relative liver weight, hepatic PCO activity, and

serum PFOA levels at sacrifice. The dose-response curves for male mice based on administered doses of linear PFOA in the the 2-week study (Loveless et al., 2006) and the 29-day study (Loveless et al., 2008) were generally similar. However, as above, serum PFOA data are not provided in the 29-day study.

The LOAEL for increased in liver weight in male mice was 0.3 mg/kg/day (the lowest dose in the study) for the linear form and the branched form. The serum levels at this dose were 13,000 ng/ml for the linear form and 14,000 ng/ml for the branched form. These are the lowest serum level LOAELs that were identified for increased relative liver weight. The relative liver weight at this dose was 1.17 for the linear form and 1.19 for the branched form, compared to the controls. For linear/branched PFOA, the serum level at 0.3 mg/kg/day was 10,000 ng/ml, and relative liver weight was 1.19 compared to the controls (similar to the increase at 0.3 mg/kg/day for the other isomeric forms). However, this change was not reported to be statistically significant, and the authors reported 0.3 mg/kg/day as the NOAEL and 1 mg/kg/day as the LOAEL for the linear/branched mixture.

PFOA increased hepatic peroxisome proliferation (as indicated by PCO activity) in rats in Perkins et al. (2004) and in rats and mice in Loveless et al. (2006). Evaluation of these PCO data reveals that, in the standard strains of rodents used in these experiments, increased liver weight did not correlate well with this biochemical marker of hepatic peroxisome proliferation, particularly in mice. Additionally (as mentioned above), PFOA caused increased hepatic peroxisome proliferation (as indicated by PCO activity) in primates as well as rodents. These PCO data are informative in evaluating the role of PPAR-alpha activation in the increased liver weight caused by PFOA and are discussed in detail in the <u>Mode of Action</u> section below.

In another study that includes serum PFOA data from the end of the dosing period, pregnant mice were dosed on GD 1-17 with 1, 3, 5, 10, 20, or 40 mg/kg/day PFOA (Lau et al, 2006; Table 10; Appendix 5A). At sacrifice on GD 18, the serum level LOAEL for increased liver weight was 22,000 ng/ml (from an administered dose of 1 mg/kg/day) and a NOAEL was not identified (Lau et al., 2006). (Numerical data are not shown in publication and were provided by the investigator.)

A second study of pregnant mice evaluated liver weight and serum PFOA levels on PND 21 in wild type and PPAR-alpha null mice dosed throughout gestation (Abbott et al., 2007). The NOAELs and LOAELs for increased liver weight based on serum PFOA from this study are not comparable to those from the other studies because serum PFOA was evaluated 3 weeks after dosing ended.

Two additional studies in male (Son et al., 2008) or female (DeWitt et al., 2008) adult mice exposed to PFOA in drinking water for 15 or 21 days that did not report serum PFOA data are also included in Table 10. As shown in the table, LOAELs based on administered dose from

these studies are generally consistent with the other mouse studies discussed above. NOAELs were not identified in these studies.

Three studies included in Table 10 evaluated increased liver weight in mouse pups after developmental exposures to PFOA. One of these studies (Macon et al., 2011) evaluated liver weight in offspring on PND 1, 4, 7, 14, and 21 after maternal exposure on GD 10-17 (late gestation). This study provides serum PFOA data from PND 1, one day after gestational exposure ended. As shown in the detailed table for this study in Appendix 5B and in Table 12, delayed mammary gland development (LOAEL – 0.01 mg/kg/day) was a much more sensitive endpoint than increased liver weight (LOAEL – 1 mg/kg/day) in this study. In an additional component of this study with full gestational exposure (GD 1-17) to PFOA, serum PFOA levels were not measured. The LOAEL for increased liver weight on PND 7 was lower with the longer exposure period (GD 1-17) than for the late gestational (GD 10-17) exposure discussed above, consistent with the greater total dose from longer exposure.

Another study (Tucker et al., 2015) assessed relative liver weight on PND 21 and later time points in CD-1 and C57/Bl mouse pups after maternal exposure to 0.01 - 1 mg/kg/day PFOA on GD 1-17. As in Macon et al. (2011), delayed mammary gland development was a more sensitive endpoint than increased liver weight in this study.

Finally, Abbott et al. (2007) evaluated relative liver weight in wild type and PPAR-alpha null offspring, as well as maternal relative liver weight (above), on PND 21. In this study, the LOAEL for increased relative liver weight in wild type pups (0.1 mg/kg/day) was 10-fold lower than the maternal LOAEL (1 mg/kg/day), while the LOAEL for this effect in PPAR-alpha null mice was the same in pups and dams (3 mg/kg/day).

Cynomolgus monkey data on increased relative liver weight

Liver weight (absolute and relative to body weight) was increased in all treated groups in the 90day study of cynomolgus monkeys (Appendix 5; Butenhoff et al., 2002). The increase in absolute liver weight was statistically significant (p<0.01) in all groups, but relative liver weight was significantly increased only in the high dose group. However, this analysis did not include the animals sacrificed during the study due to overt toxicity. The absolute and relative liver weight in the sacrificed low dose monkey was far higher than the others in its group, and inclusion of data for this animal increases the mean value for these parameters in the low dose group. Liver-to-brain weight ratio is considered to be a reliable measure of effects on liver weight, because brain weight tends to remain stable when body weight changes. This ratio was increased in all treated groups compared to controls, with statistical significance at the two lower dose levels, but there was no dose-response based on either administered dose or serum level. As discussed above, serum PFOA levels did not differ significantly between the low and mid dose groups (Butenhoff et al., 2004c). The data from Butenhoff et al. (2002) are not informative as to the dose-response curve or the NOAEL for PFOA's effects on increased liver weight in this species of monkey, because this effect did not increase with either administered or internal dose. Additionally, mortality of one of four animals at the lowest dose was possibly treatment-related, and four of the six high dose monkeys did not complete the study because of overt toxicity or mortality.

Comparison of the relative liver weight and serum PFOA level data from the 90 day cynomolgus monkey study and the rat studies (Perkins et al., 2004; Loveless et al., 2006) reveals similar increases in liver weight at comparable serum levels in both species. Additionally, comparable increases in PCO activity occurred at similar serum PFOA levels in monkeys and rats (discussed further in <u>Mode of Action</u> section). These data suggest that cynomolgus monkeys and rats have similar sensitivity to the hepatic effects of PFOA.

Immune system effects in rodents and non-human primates

PFOA causes suppression of the immune response in experimental animals. As discussed in the <u>Epidemiology</u> section, decreased response to vaccinations has been associated with PFOA in humans. Toxicological studies that evaluated effects of oral exposure to PFOA on the immune system in rodents are summarized in Table 13. Sixteen publications of such studies were identified. Of these, 14 publications report only studies of mice, one publication reports only studies in rats, and one publication includes studies in both species. Both of the rat studies, and 11 of the 15 mouse studies, were conducted in males, while two of the mouse studies evaluated adult females, and two of the mouse studies evaluated effects of developmental exposures on offspring. Additionally, effects on the immune system were reported in the 90-day oral study of rhesus monkeys (Goldenthal, 1978). Studies of effects on the immune system from dermal exposure to PFOA are not reviewed in this document. Toxicological effects on the immune system are of particular interest because PFOA and other PFCs have been associated with decreased vaccine response in humans (see Epidemiology section).

Non-human primates

In the 90-day rhesus monkey study (Goldenthal, 1978), histopathological changes related to the immune system occurred in all animals in the two higher dose groups (30 and 100 mg/kg/day). All animals in these two dose groups had slight to moderate hypocellularity of the bone marrow and moderate atrophy of lymphoid follicles in the spleen, and one 30 mg/kg/day female and all 100 mg/kg/day animals had moderate atrophy of the lymphoid follicles in the lymph nodes. These changes were not seen in the lower dose groups (3 and 10 mg/kg/day). Because serum PFOA levels are not provided in this study, it cannot be used for dose-response in risk assessment.

Rodents

PFOA consistently suppressed the immune system in studies of mice (Table 13). Effects in mice include decreased absolute and relative spleen and thymus weights, decreased thymocyte and splenocyte counts, decreased immunoglobulin response, and changes in total numbers and/or

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 224 of 551

specific populations of lymphocytes in the spleen, thymus, peripheral blood, and bone marrow. The available data indicates that rats are less sensitive than mice to immunotoxic effects of PFOA, since immune system effects were not observed in the two studies that have been conducted in rats. These rat studies included doses higher than those which generally caused immune effects in mice.

Relative liver weight was evaluated along with immune parameters in nine of the 13 studies of adult mice. In all of these nine studies, the LOAEL for increased relative liver weight was the same or lower than the LOAEL for immune system effects. As shown in Table 13, the lowest dose at which immune effects were clearly demonstrated in mice is 0.49 mg/kg/day in a 21-day drinking water study, with no NOAEL reported (Son et al., 2009). Increased liver weight also occurred at this dose in this study, as reported in the accompanying paper (Son et al., 2008). Therefore, the data available at this time suggest that increased relative liver weight is an endpoint that is as sensitive as or more sensitive than immune system effects in rats and mice. For this reason, immune system effects from toxicology studies were not used as the basis for the dose-response in this risk assessment, and individual study tables are not provided for these studies.

Reproductive and Developmental Effects

Overview

As discussed in the <u>Pharmacokinetics</u> section (above), PFOA exposures in the developing human fetus are similar to those experienced by the mother, and neonatal exposure from breast-feeding or consuming formula prepared with contaminated drinking water is much higher than in the mother or other older individuals using the same drinking water source. As discussed in the <u>Epidemiology</u> section, prenatal exposure to PFOA is associated with decreased birth weight in human epidemiology studies (Johnson et al., 2014).

Reproductive or developmental effects of PFOA have not been studied in non-human primates. Prior to 2006, the reproductive and developmental effects of PFOA had been studied only in rats and rabbits. These species are not the most appropriate models for evaluation of the potential for human reproductive and developmental effects of PFOA because the half-life of PFOA in female rats and female (as well as male) rabbits is only a few hours (see Table 4 in Toxicokinetics section). Because of this rapid elimination, serum levels from a given dose of PFOA in females of these species are much lower than in other species with long half-lives, such as mice and humans, and PFOA does not reach steady state in females of these species with daily dosing by gavage.

Beginning in 2006, the reproductive and developmental toxicity of PFOA has been studied in mice. The mouse is a more appropriate species for evaluating the potential human effects of PFOA on reproduction and development, since the female mouse excretes PFOA slowly and steady state is achieved with continued dosing. As discussed in detail below, effects observed in mice include full litter resorptions, decreased postnatal survival and growth, delayed development, and accelerated sexual maturation in males. More recent studies have found that

delayed mammary gland development is caused by developmental exposure to doses as low as 0.01 mg/kg/day.

In this section, the mouse studies of developmental and reproductive effects from gestational dosing with PFOA are presented in Table 12 and discussed in the text. This is followed by a detailed discussion of effects of developmental exposures to PFOA on mammary gland development, the most sensitive developmental endpoint with serum data appropriate for dose-response modeling. Summaries of additional studies of effects of pre-pubertal exposure to PFOA on reproductive organs in female mice, and of reproductive effect in male mice, are then presented. Finally, the studies of developmental and reproductive effects in rats and rabbits that were conducted prior to the mouse studies are summarized.

Mouse developmental studies

Summary of study designs

Table 12 summarizes data on reproductive and developmental effects from gestational and/or lactational exposure to PFOA in mice. Sixteen publications reporting such studies are included in the table. Several of these publications include multiple studies with different exposure protocols, in one case, different aspects of the same study are described in two publications (Wolf et al., 2007; White et al., 2009). In total, 18 separate studies, three of which used multiple strains of mice, are reported. Most but not all of the studies assessed both maternal/reproductive endpoints and developmental endpoints in the offspring. The table includes the six publications that evaluated developmental effects of PFOA on mammary gland development in the dam and/or the female offspring, as well as other endpoints. Effects on mammary gland development are further discussed in detail in a separate section below.

Several additional studies of effects of gestational dosing with PFOA are not included in the Table 12 because they did not evaluate standard reproductive or developmental endpoints and/or because they used non-standard exposure protocols. These papers are discussed elsewhere in this document. These include two studies of histopathological changes in the livers of mice in adulthood after low dose developmental exposures (Filgo et al., 2015; Quist et al., 2015), a study of intestinal tumorigenesis in wild type and genetically susceptible strains of mice (Ngo et al., 2014), and three studies of neurobehavioral effects at age 5-8 weeks in offspring of dams dosed during gestation (Johansson et al., 2008; Onishchenko et al., 2011; Sobolewski et al., 2014).

Most (11 of 16) of the studies in Table 12 used CD-1 mice, three used C57Bl/6 mice, one study (Tucker et al., 2015) used both strains, and one study used ICR mice (Yahia et al., 2010). Two studies included strains of mice with differingnt PPAR-alpha status (wild type, null, and/or humanized) and are discussed in more detail in the <u>Mode of Action</u> section.

In most of the studies (13), dosing was by oral gavage, while one study used drinking water exposure (Hu et al., 2010), one study used drinking water exposure with or without additional

gavage exposure in some, but not all, dose groups (White et al., 2011b), and one study used dietary exposure (van Esterik et al., 2016).

In most of the studies (10), the dams were dosed with PFOA throughout gestation, and postnatal development of the offspring was assessed. However, other protocols were used in some studies. In two studies (Hu et al., 2012; van Esterik et al., 2016), maternal dosing began before mating and continued until weaning. In other studies, the dosing period was shorter than the full period of gestation. Fenton et al. (2009) was primarily a pharmacokinetic study of a single dose of PFOA administered on GD 17 and is included because offspring body weight was assessed. In several other studies, PFOA was administered for only a portion of gestation (Hu et al., 2010, GD 6-17; Macon et al., 2011 "late gestation study", GD 10-17; Suh et al., 2011, GD 11-16; White et al., 2007 "restricted exposure study", GD 1-17, 8-17, and 12-17; Wolf et al., 2007, "restricted exposure study", GD 7-17, 10-17, 13-17, and 15-17). Two studies, one with exposure on GD 8-17 (White et al., 2009) and one with exposure on GD 1-17 (Wolf et al., 2007; White et al., 2009) used a cross-fostering protocol in which offspring were exposed during gestation and/or lactation. In these studies, treated dams were dosed during gestation. The dams that were not dosed but fostered pups from dosed dams were exposed to PFOA via grooming of the pups and ingestion of excreted pup urine and feces. One study (White et al.; 2011b) was a multigeneration study in which effects on three generations were evaluated (P0, F1, and F2). Effects on P0 dams and F1 offspring are shown in Table 12; complete information on the study is presented in the section on mammary gland development (below).

Most of the studies (15) assessed both maternal/reproductive endpoints and endpoints of postnatal developmental in the offspring, although the specific endpoints that were evaluated differed among studies. Only two of the studies evaluated malformations at birth. These were Lau et al. (2006), which also evaluated postnatal development, and Yahia et al. (2010). Two studies (Macon et al., 2011, and Tucker et al., 2015) assessed effects in the offspring, but not maternal or reproductive effects. Several studies focused on specific effects in addition to standard developmental endpoints or mammary gland development. Hines et al. (2009) evaluated effects in female offspring of developmental exposures on body weight and hormones (insulin and leptin) in adulthood. Hu et al. (2010) and Hu et al. (2012) assessed effects of developmental exposures on immune endpoints at age 7 to 9 weeks and are also included in the summary table of immune effects (Table 13). Finally, Suh et al. (2011) focused on placental toxicity and other reproductive endpoints, and did not evaluate the offspring.

Two additional studies assessed the effects of pre-pubertal exposure to PFOA on the reproductive system in female mouse pups (Dixon et al., 2012; Yao et al., 2014). These are not included in the table and are discussed in the text later in this section.

Maternal and reproductive effects

PFOA caused reproductive effects in mice including increases in full litter resorptions (Abbott et al., 2007), increased litter loss, prenatal loss per live litter, or fetal resorptions/dead fetus (Abbott

et al., 2007; Lau et al., 2006; Suh et al., 2011; White et al., 2007; White et al., 2011b), and decreased number of live fetuses per litter or decreased litter size (Lau et al., 2006; Suh et al., 2010; van Esterik et al., 2016; Wolf et al., 2007; White et al., 2011b). In all of these studies, one or more of these reproductive effects occurred at doses below those which caused decreased maternal weight gain, an indicator of general maternal toxicity.

PFOA caused toxicity to the placenta, including decreased placental weight, decreased fetal/placental weight ratio, and decreased expression of genes for prolactin family hormones (hormones that support fetal growth and nutrition), after treatment on GD 11-16 at the lowest dose tested, 2 mg/kg/day (Suh et al., 2011). Higher doses caused placental necrosis and reduced numbers of placental trophoblast cells. These results suggest that placental toxicity may contribute to the increased number of dead fetuses/decreased number of live fetuses and decreased fetal growth observed in this and other developmental studies of PFOA.

Effects on maternal relative liver weight and maternal mammary gland development are discussed below.

Effects in Offspring: Fetal through Weaning

Fetal teratology

Two studies evaluated fetal teratology. In CD-1 mice, gestational exposure to PFOA caused reduced ossification of phalanges, limb and tail defects, and microcardia at doses below those which affected maternal weight gain (Lau et al., 2006). Reduced ossification of proximal phalanges of both the forelimb and the hindlimb was significantly increased at the lowest dose used (1 mg/kg/day) but was not significantly increased in some higher dosed groups. This effect represents a delay in timing of development rather than a permanent structural change, since the phalanges developed normally in mice treated with PFOA that were not sacrificed prior to delivery in this study (personal communication with C. Lau). Ossification at other sites (caudal vertebrae, metacarpals, and metatarsals) was delayed only at a much higher dose (20 mg/kg/day) which also caused maternal and reproductive toxicity.

In ICR mice, gestational exposure to PFOA caused increased incidence of cleft sternum, delayed ossification of phalanges, and delayed incisor eruption. The LOAEL and NOAEL for increased incidence of cleft sternum, delayed ossification of phalanges, delayed incisor eruption were 10 mg/kg/day and 5 mg/kg/day, respectively (Yahia et al., 2010). In this study, maternal weight gain, fetal weight, and pup survival until PND 4, were significantly decreased at dose(s) below the LOAEL for increased cleft sternum, delayed ossification, and delayed incisor eruption. No pups survived until PND 4 at 10 mg/kg/day, the LOAEL for delayed ossification.

Birth weight, and growth and postnatal development until weaning

PFOA caused decreased body weight at birth, postnatal mortality, reduced postnatal growth until weaning, and delayed development (as indicated by day of eye opening) in mice. As shown in Table 12, one or more of these effects was reported by Abbott et al. (2007), Hines et al. (2009),

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 228 of 551

Hu et al. (2010), Hu et al. (2012), Lau et al. (2006), Tucker et al. (2015), van Esterik et al. (2016), White et al. (2007), White et al. (2007), White et al. (2011b), and Yahia et al. (2010). Exposure during only the latter part of gestation (GD 15-17) was sufficient to cause decreased body weight at birth, increased postnatal mortality, and decreased postnatal growth (Wolf et al., 2007). Furthermore, decreased postnatal growth resulted from either gestational or lactational exposure, as shown by the results of the cross-fostering study by White et al. (2009).

Effects on relative liver weight and mammary gland development during the period from birth until weaning are discussed below.

Effects in Offspring: Post-Weaning

In studies which continued to assess offspring during the post-weaning period, effects at these later time points were observed in some studies (summarized below) but not in others (e.g. no effect on body weight in Abbott et al., 2007, or on immune parameters in Hu et al., 2012).

In the restricted exposure component of Wolf et al. (2007), developmental exposure to 5 mg/kg/day PFOA beginning on GD 10 caused decreased body weight in male offspring until age 10-11 weeks. In the cross fostering study component of the same publication, body weight remained decreased until PND 36 in male offspring after *in utero* and lactational exposure to 5 mg/kg/day PFOA, and until PND 85 in females exposed to the same dose *in utero* even without postnatal exposure from breastmilk.

Markers of sexual maturation (vaginal opening and first estrus) were delayed in female CD-1 mouse offspring with gestational exposure to PFOA. However, sexual maturation (preputial separation) in male offspring was accelerated by PFOA exposure, despite the fact that PFOA caused decreased body weight at 6.5 weeks of age (Lau et al., 2006). Notably, acceleration puberty in males did not follow a typical dose-response curve. The greatest acceleration occurred at the lowest dose (1 mg/kg/day) with a smaller effect at each increasing dose. At the highest dose (20 mg/kg/day), puberty was delayed rather than accelerated.

Body weight and hormone (insulin and leptin) levels were increased in early adulthood (20-29 weeks) in CD-1 mice with gestational exposure to low doses (0.01 to 0.1 mg/kg/day for obesity; 0.01 to 0.3 mg/kg/day for hormones) but not at higher doses. In this study, body weight at birth or early in life was not affected by the low doses that caused increased body weight later in life (Hines et al., 2009). In contrast, Ngo et al. (2014) found no effect on body weight at age 12-20 weeks in male or female wild type or Min/+ (a strain susceptible to intestinal tumorigenesis) C57Bl/6 mice offspring of dams dosed with 0.01, 0.1, and 3 mg/kg/day PFOA during gestation. These studies are of interest because several epidemiology studies evaluated associations of prenatal and/or early life PFOA exposure with parameters associated with increased body weight in childhood or adulthood. Three studies found associations of maternal serum PFOA levels during pregnancy with increased risk of overweight/obesity and changes in metabolic hormones

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 229 of 551

in young women (Halldorsson et al., 2012), more rapid weight gain in girls (Maisonet et al., 2012), or greater adiposity and more rapid increase in BMI in childhood (Braun et al., 2016), while two studies did not find such an association with prenatal or early childhood exposure to PFOA (Andersen et al., 2013; Barry et al., 2014).

Splenic T cells were decreased at age 6 weeks in C57Bl/6 mice exposed gestationally to 2 mg/kg/day PFOA, with no effect at 0.2 mg/kg/day (Hu et al., 2012). The NOAEL and LOAEL for this effect were the same as for decreased body weight gain on PND 1-21, suggesting that the immune system effect from developmental exposure was not a more sensitive endpoint than other developmental effects in this study.

Effects on relative liver weight and mammary gland development during the post-weaning period are discussed below.

Relative liver weight

Increased relative liver weight is a sensitive toxicological endpoint for PFOA. This effect was evaluated in dams and/or offspring in 12 of the 18 mouse developmental studies summarized in Table 12. Maternal relative liver weight was assessed at delivery in three studies, between delivery and weaning in two studies, and at weaning in five studies. In offspring, relative liver weight was evaluated at birth in two studies, between birth and weaning in three studies, at weaning in five studies, and post-weaning in five studies.

The NOAELs and LOAELs for increased relative liver weight in dams and/or offspring and for other reproductive and developmental effects are presented in Table 12. (*Note*: Fenton et al., 2009, is not included in this table because no effects were seen at the single dose used.) In all studies except one (Hu et al., 2010), the LOAEL and/or NOAEL for increased relative liver weight in the dam and/or the offspring is the same or lower than the LOAEL and/or NOAEL for reproductive developmental effects (other than delayed mammary gland development). In Hu et al. (2010), offspring liver weight was evaluated on PND 48 and PND 63; these are post-weaning time points at which PFOA was almost totally eliminated from the body. These data indicate that increased relative liver weight (maternal and/or offspring) is an endpoint for PFOA toxicity in mice that is as sensitive or more sensitive than most of the other reproductive and developmental effects that were evaluated, with the exception of delayed mammary gland development which is discussed below.

Mammary gland development

Background information on mammary gland development as a toxicological endpoint

Because the developmental patterns of the mammary gland are similar in humans and rodents, rodents provide a good model for studying the effects of environmental contaminant on human mammary gland development (Rudel and Fenton, 2009; Fenton et al. 2012; Rudel et al., 2011; Fenton and Birnbaum, 2015; Osborne et al., 2015). The development of the mammary gland in

these species involves a complex series of events that is regulated by a balance of hormones, growth factors and stromal factors (Osborne et al., 2015; Gore et al., 2015). Agents that affect any of these steps can interfere with the normal process of mammary gland development, and this process is particularly sensitive to effects of endocrine disrupting chemicals, including environmental contaminants such as bisphenol A, atrazine, and dioxin (Gore et al., 2015; Fenton and Birnbaum, 2015; Fenton et al., 2012; IOM 2011; Rudel et al., 2011). As reviewed in detail below, adverse effects on mammary gland development are sensitive toxicological endpoints for PFOA, and a NOAEL for these effects has not been identified.

The mammary gland is most sensitive to the effects of toxic substances during critical periods when development occurs including fetal, neonatal, puberty, and pregnancy (Gore et al., 2015; Osborne et al., 2015), while the mammary glands of non-pregnant adult females may not be affected by the same exposures. Adverse effects on the mammary gland from early life exposures can include accelerated or delayed development (Macon and Fenton, 2013; Osborne et al., 2015), and effects of the same chemical on mammary gland development may vary depending on the life stage when exposure occurs (Osborne et al., 2015). These disruptions of mammary gland development may result in adverse effects later in life including impaired lactation and increased cancer risk (Fenton 2006; IOM, 2011; Rudel et al., 2011; Fenton et al., 2012).

The mammary gland is distinct from other tissues in that it undergoes a significant portion of its development postnatally; in addition to the fetal/neonatal period, puberty and pregnancy are critical periods of mammary gland development (Osborne et al., 2015). The mammary gland grows and differentiates slowly during embryonic and juvenile life and does not mature until after puberty. Mammary gland development in rodents has been reviewed by Sakakura (1987) and Daniel and Silberstein (1987) and in humans by Russo and Russo (1987) and Howard and Gusterson (2000).

The mammary gland is an organ that is unique to the class *Mammalia*, and its embryonic, postnatal, and adult development is highly conserved between species. Mammary gland development in humans and rodents takes place at a similar biological pace, although the absolute timeframes differ (Table 12 and Figure 10, both from Fenton, 2006). The description of mammary gland development below is taken from concise summaries provided by Osborne et al. (2015) and Fenton et al. (2012).

In rodents and humans, mammary gland development begins with the formation of the mammary, or milk line, during embryonic development. This structure separates into individual placodes (areas of thickening of the ectodermal layer), each of which develops into a ductal tree that embeds in a fat pad to form the mammary bud. Although there are slight timing differences in mammary gland development among species, ductal branching begins during the prenatal period in both rodents and humans. Subsequent to the fetal/neonatal period, there is little epithelial growth until puberty. During puberty, exponential growth of the female mammary

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 231 of 551

gland occurs for several weeks in rodents and several years in humans. During puberty, the fat pad rapidly fills with epithelial cells to become the adult form of the gland. The epithelium develops bundles of ducts, which then form club-like structures, called terminal end buds (TEB) in humans. Each TEB cleaves into alveolar buds and sprouts into ductules, forming a structure called the terminal ductal lobular unit. In rodents, TEBs are the sites of future ductal branching and disappear as the gland differentiates, and they are the structures considered to be most functionally equivalent to the terminal ductal lobular unit in humans. TEBs are particularly susceptible to the effects of carcinogens, and it has been suggested that "factors that lengthen the period when TEBs are present lengthen the period during which the mammary gland remains in a resting state until pregnancy occurs. During pregnancy, the gland undergoes another period of rapid differentiation, involving branching and the development of lobulo-alveoli to prepare for lactation.

Table 9. Developmental events in human and rodent mammary tissue (Fenton, 2006)			
Developmental Event	Human	Rodent	
Milk Streak Evident	EW4-6	GD10-11 (mice)	
Mammary Epithelial Bud Forms	EW10-13	GD12-14 (mice), GD14-16 (rat)	
Female Nipple and Areola Form	EW12-16	GD18 (mice), GD20 (rat)	
Branching and Canalization of	EW20-32	GD16 to birth (mice, GD18 to	
Epithelium		birth (rat)	
Secretion is Possible	EW32-40 (ability lost	At birth, with hormonal stimuli	
	Postnatally)		
Isometric Development of Ducts	Birth to Puberty	Birth to Puberty	
TEBs Present (Peripubertal)	8 to 13 yr old girls	23-60 d old (rat)	
Formation of Lobular Units	EW32-40, or within 1-2 yr of	Puberty and into Adulthood	
	first menstrual cycle		

EW - embryonic week; GD - gestation day




Figure 10. Timeline of critical periods of mammary gland development and potential effects of endocrine disrupting compounds on mammary gland development (Fenton, 2006).

Effects on mammary gland development in rodents are commonly assessed by evaluation of "whole mounts". In this approach, the entire fourth and/or fifth abdominal mammary gland fat pad is mounted flat on a slide, fixed, stained, defatted, and permanently affixed to the slide.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 232 of 551

Whole mounts are assessed microscopically for parameters such as numbers of mammary terminal ductal structures (i.e., TEBs, terminal ducts, alveolar buds, and lobules), extension of the epithelial cells through the fat pad, and branching patterns and density at different times during development branching (Rudel et al., 2011). Whole mounts were evaluated in the nine studies of the effects of PFOA on mammary gland development in mice described below, and tissue sections stained with hematoxylin and eosin (H&E) were also examined in some of these studies. Effects on mammary gland development are reported as overall age-adjusted developmental scores based on a number of parameters and/or as quantitative values for specific parameters.

Effects of PFOA on mammary gland development in mice

Delayed mammary gland development in mice is a sensitive toxicological endpoint that is considered relevant to humans because developmental patterns are similar in both species. Nine publications have reported the effects of PFOA on mammary gland development in mice, and some of these publications include multiple studies. These studies are summarized in Table 16, and details of each study are provided in an individual study table for each publication in Appendix 5. Information related to the mode of action of PFOA's effects on mammary gland development is reviewed in the <u>Mode of Action</u> section, below.

Studies of effects of maternal and fetal/neonatal exposure to PFOA

Six publications evaluated effects of PFOA exposure during gestation and/or lactation on mammary gland development. Studies presented in these publications are summarized in Table 16A, and details for each study are provided in Appendix 5. Some of these publications include multiple studies, and, in total, ten separate studies were reported. Nine of these studies reported delayed mammary gland development, and one reported no effect on mammary gland development. Five of these publications report studies in CD-1 mice (White et al., 2007, three studies; White et al., 2009, two studies; Macon et al., 2011, two studies; White et al., 2011b; Tucker et al., 2015), and one of these also includes C57Bl/6 mice (Tucker et al., 2015). The sixth publication evaluated wild type, PPAR-alpha null, and PPAR-alpha humanized mice of the Sv/129 genetic background (Albrecht et al., 2007; White et al., 2009; White et al., 2011b) evaluated pregnant and/or lactating dams.

Effects on structure of the mammary gland development

PFOA exposure during critical developmental periods (fetal, neonatal, pregnancy, and lactation) caused delayed mammary gland development in both lactating dams (White et al., 2007; White et al., 2009; White et al., 2011b) and pups (White et al., 2007; White et al., 2009; Macon et al., 2011; White et al., 2011b; Tucker et al., 2015), while even a high dose (5 mg/kg/day) did not affect mammary gland development in non-pregnant adult female mice (White et al., 2007).

As shown in the comparison of LOAELs and NOAELs for mammary gland development and other endpoints in Table 12, mammary gland development was a more sensitive endpoint for PFOA than other effects found in dams and pups in mouse developmental studies including

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 233 of 551

reproductive endpoints (number of fetuses per litter, prenatal loss, prenatal survival), pubertal markers (day of vaginal opening or day of first estrus; Tucker et al., 2015), estrogen or progesterone levels (Tucker et al., 2015), body weight, or liver weight (Macon et al., 2011; Tucker et al., 2015).

Lactating dams

Delayed mammary gland development occurred in lactating dams after dosing with PFOA during gestation (White et al., 2007; 2009; 2011b) or from exposure via treated pups (White et al., 2009). At the end of pregnancy just prior to initiation of nursing (GD 18; White et al., 2007) and on PND 1 after one day of nursing (White et al., 2009), mammary glands of treated dams were not saturated with milk filled alveoli, as is normally seen, but rather exhibited stunted, immature development. On PND 10, normally the peak of lactation, mammary glands from treated mice were delayed in development and resembled those normally seen earlier in lactation (White et al., 2007; 2009). On PND 20-22, mammary glands from treated dams had milk-filled alveoli and resembled normal mammary glands at the peak of lactation on PND 10, instead of the normal involution that occurs at weaning, indicating delayed development of up to 10 days (White et al., 2007; 2011b).

Female offspring

Delayed mammary gland development occurred in female pups in both CD-1 and C57Bl/6 strains (Tucker et al., 2015). In CD-1 mice, the mammary gland developmental score was significantly decreased compared to controls at all doses including the lowest dose (0.01 mg/kg/day). In C57Bl/6 mice, the developmental score was decreased compared to controls at all doses at both timepoints assessed (PND 21 and PND 61). However, this difference was not statistically significant at the two lowest doses (0.01 and 0.1 mg/kd/day), but was significant at 0.3 and 1 mg/kg/day. Serum PFOA levels in C57Bl6 pups were lower than in CD-1 pups at the same administered dose. Lack of statistical significance in C57Bl/6 offspring at the two lowest doses may be due to the lower serum PFOA levels and/or small number of animals in the two lower dose group), rather than differences in intrinsic sensitivity to effects of PFOA on mammary gland development in the two strains mice (Tucker et al., 2015). It should be noted that the LOAELs in female offspring for other well-established developmental effects of PFOA (decreased body weight and increased relative liver weight, both on PND 21) were also higher in C57Bl/6 mice than in CD-1 mice in this study, possibly due to the factors mentioned above.

PFOA is found in breast milk after maternal exposure in both rodents and humans, resulting in lactational exposure to offspring (reviewed in Post et al., 2012; also Mogensen et al., 2015). Cross-fostering studies in which pups with no prenatal exposure were exposed via breast milk from exposed dams, and pups with prenatal exposure were fostered by untreated dams, show that delayed mammary gland development results from exposure during gestation, lactation, or both. Significant delays in mammary gland development occurred as early as PND 1 in non-gestationally exposed pups nursing from treated dams for only 12-24 hours, and as early as PND

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 234 of 551

3 in non-gestationally exposed dams nursing treated pups. The exposure in these dams was only through maternal behavior such as ingestion of treated pups' waste and grooming of treated pups (White et al., 2009).

In White et al. (2009), effects on the mammary gland persisted in exposed offspring until 18 months of age, long after PFOA had been eliminated from the body; these effects are considered to be permanent. Although the study was not designed to quantitatively evaluate mammary gland development in older animals, epithelial density appeared to be reduced in the mammary glands of exposed animals at 18 months. An increase in the number of unusual darkly staining foci per gland of approximately 5-fold was also seen at 18 months in the mammary glands of exposed mice. According to the authors, these foci appeared to result from hyperplasia of ductal epithelium, infiltration of inflammatory cells into ductal regions, increased stromal density surrounding the ducts, and/or inappropriate differentiation of the ductal epithelium. Gore et al. (2015) notes that abnormalities of this type can be associated with increased breast cancer risk.

Mammary gland development, as assessed on PND 21 by overall developmental score, number of terminal end buds, and other measures of mammary gland development, was delayed in a dose-related fashion in CD-1 mouse pups after late gestational exposure (GD 10-17) to doses lower than those used in earlier studies (Macon et al., 2011). The LOAEL was 0.01 mg/kg/day, with no NOAEL identified. These effects occurred at serum PFOA levels of 285 ng/ml or below, lower than the mean serum level (371 ng/ml) in a community exposed to highly contaminated drinking water (Emmett et al., 2006a).

In a multi-generation study of CD-1 mice exposed to 5000 ng/L (5 μ g/L) PFOA in drinking water, mammary gland development was delayed in both F1 dams (PND 22) and F1 female pups (PND 22, 42, and 63) at serum levels relevant to human environmental exposures (White et al., 2011b). Pups were significantly affected at serum levels as low as 21.3 ng/ml on PND 22 (compared 0.6 ng/ml in controls at this time point). This serum level is below the mean serum level of 28 ng/ml in the six Ohio and West Virginia communities with contaminated drinking water that comprise the C8 Health Study population, and is within about 10-fold of the mean and 4-fold of the 95th percentile serum levels in the U.S. general population (CDC, 2015). This serum level would be expected in humans with ongoing exposure to drinking water ratios discussed above.

In contrast to the delays in mammary gland development observed in CD-1 and C57Bl/6 mice in the five studies discussed above, no significant effects on mammary gland development were found in wild type, PPAR-alpha null, or humanized PPAR-alpha Sv/129 mouse pups exposed gestationally to 3 mg/kg/day PFOA (Albrecht et al., 2013). This is the only study of mammary gland development in these strains. Albrecht et al. (2013) report that postnatal lethality occurred in the wild type mice, but not in the PPAR-alpha null or humanized PPAR-alpha mice. They conclude that the study confirms the PPAR-alpha dependent postnatal lethality of PFOA

previously reported by Abbott et al. (2007). However, several problematic issues with this study limit the consideration of its results:

- Although postnatal lethality in wild type mice treated with 3 mg/kg/day (the only dose used in the study) on PND 20 was reported as statistically significant (p<0.05), this conclusion appears to be based on an inappropriate statistical comparison. In evaluating postnatal lethality, the number of pups per litter on PND 20 in the control and PFOA-treated groups of wild type mice were compared. However, this comparison does not appear to be valid because the control and PFOA treated litters initially had different numbers of pups on PND 0. The appropriate evaluation of this parameter is a comparison of the number of pups within the same litter on PND 0 and PND 20 (i.e. percent mortality within the litter between PND 0 and PND 20). In wild type pups, 96% of controls and 70% of PFOA-treated survived from PND 0 to PND 20. From the analysis presented, it is unclear whether postnatal lethality is actually significantly increased by PFOA in wild type pups. For this reason, the basis for the conclusion that wild type, but not humanized PPAR-alpha, mice are sensitive to developmental effects of PFOA is uncertain.
- An important concern is that Albrecht et al. (2013) state that elevated PFOA levels (up to > 1000 ng/ml) were found in liver and serum from some control fetuses, pups, and dams. However, no further information such as which groups of animals these samples came from, how many samples had elevated PFOA concentrations, or statistical data for serum levels in the control samples is provided. Importantly, data from control animals with elevated PFOA exposures do not appear to have been excluded in the comparisons of endpoints of toxicity in control and treated groups. Inclusion of these data from the control animals could have affected the results of these comparisons, especially since serum levels in some of the treated groups were only a few fold higher than those in some of the controls.
- Developmental effects observed in the same strain of mice (SV/129) in another study (Abbott et al., 2007) at lower doses (0.6 and 1 mg/kg/day) were not observed at the higher dose (3 mg/kg/day) used by Albrecht et al. (2013). Abbott et al. (2007) observed significantly increased postnatal lethality in wild type pups exposed gestationally to 0.6 and 1 mg/kg/day PFOA. Additionally, eye opening was significantly delayed in the 0.6 and 1 mg/kg/day wild type pups in Abbott et al. (2007), but not at 3 mg/kg/day in Albrecht et al. (2013).
- Although both studies used SV/129 mice, Albrecht et al. (2013) obtained them from NIH and Abbott et al. (2007) obtained them from Jackson Laboratories. Albrecht et al. (2013) suggest that pharmacokinetic differences in the wild type mice from the two different sources may explain the differences in effects of PFOA in these mice in the two studies. However, a close review of the data from the two studies (Table 3 of Abbott et al., 2007; Figure 10 of Albrecht et al., 2013) indicates that the serum levels in wild type pups in Albrecht et al. (2013) at which no developmental effects occurred were higher than the

serum levels in wild type pups at which delayed eye opening and postnatal mortality were reported by Abbott et al. (2007). Furthermore, the serum PFOA data for wild type dams on PND 20 appear to be inconsistent within the publication. Maternal serum levels in wild type dams on PND 20 are stated to range from 2066 - 6812 ng/ml, and no statistical parameters (e.g. median, mean, S.D.) are provided. However, the estimated serum level from the bar graph of maternal serum levels is 6700 ± 3600 in the wild type dams (higher than what would be expected from the range provided in the text).

In summary, no effect of PFOA on mammary gland development was reported in pups from the three strains on PND 20; this is the only study that evaluated PFOA's effect on this endpoint in these strains. It is possible that these strains are less sensitive to this effect than are the other strains in which effects were reported. However, the general issues with this study create uncertainty about its conclusions related to mammary gland development. As discussed above, the inclusion of data from controls with elevated PFOA exposures may have affected the ability to observe effects in treated groups. Pertinent data on serum levels is not presented or appears to be presented inconsistently. The differences in developmental effects in wild type pups in Albrecht et al. (2013) versus Abbott et al. (2007) cannot be explained on the basis of pharmacokinetic differences in the two studies, since effects occurred at pup serum levels in Abbott et al. (2007) that are lower than the pup serum levels in Albrecht et al. (2013).

Effects on milk quality and quantity

In dams exposed to PFOA during pregnancy, the morphological delays observed in mammary glands during lactation suggest that milk production and/or composition may be impacted. Potentially relevant to this issue, maternal PFOA exposure was associated with shorter duration of breast feeding in all three human studies that evaluated this effect (Fei et al., 2010; Romano et al., 2016; Timmermann et al., 2016). However, the available toxicological information is not sufficient to make conclusions about the effects of developmental exposure to PFOA on lactational function, as only one study (White et al., 2007) evaluated effects on the composition of milk, and only one study (White et al., 2011b) evaluated the amount of milk produced. Evaluation of effects on growth of offspring is complicated by the fact that PFOA itself can cause decreased postnatal growth in mouse pups from only *in utero* exposure in a cross-fostering study (Wolf et al., 2007). Therefore, effects on postnatal growth could result from the intrinsic toxicity of PFOA and/or from decreased lactational function.

In the only toxicological study of effects on milk composition, expression of genes for four milk proteins (beta-casein, EGF, alpha-Lac, and LactoF) in mammary gland tissue were altered in dams exposed to 5 mg/kg/day PFOA during gestation. For example, peaks in LactoF expression normally seen early and late in lactation were delayed, consistent with the observed structural delays in mammary gland development at these time points (White et al., 2007).

The only toxicological data on effects of prenatal and early life exposure to PFOA on milk production in adulthood comes from the two-generation study in CD-1 mice (White et al.,

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 237 of 551

2011b). The design of this study is shown in Figure 11. As part of this study, a lactational challenge experiment was conducted in F1 dams and their F2 litters on PND 10, the time point at which lactation is at its peak. Except for the dose group receiving 5000 ng/L (5 μ g/L) PFOA in drinking water throughout the experiment, the F1 dams that were evaluated for lactational function were exposed prenatally and in neonatal life until weaning through breast milk, but not after weaning or while pregnant and lactating. Milk production was evaluated by weighing a litter of 10 F2 pups before and after a nursing period of 30 minutes. There were no statistically significant effects on milk production, as measured by weight gain in the litter, or on time to initiate nursing behavior. However, high variability, the small number of animals assessed, and the lack of sensitivity of this assay may have limited the ability to detect effects on lactational function. Additionally, postnatal survival and body weight were not affected in the F2 pups, indicating that the ability of the F1 dams to provide nutritional support was not decreased. The authors note that it is not known whether deficits in lactational function were present, but were compensated for by increased frequency or longer duration of nursing events, since these parameters were not assessed.

Possibly relevant to this issue, the three available human studies all suggest that maternal exposure to PFOA may be related to shorter duration of breastfeeding. A study of 1400 Danish women from the general population found that serum PFOA concentration during early pregnancy was associated with shorter duration of breastfeeding among multiparous, but not nulliparous, women (Fei et al., 2010). Because women who breastfed previously were more likely to so again, and because longer duration of lactation would result in decreased serum PFOA due to excretion via breast milk, reverse causality could not be ruled out. A second study evaluated 336 U.S. women from a community with median serum PFOA levels about twice those in the U.S. general population, possibly due to past exposure to contaminated drinking water (Romano et al., 2016). Finally, Timmermann et al. (2016) found an association of serum PFOA (median - 2.40 ng/ml) and duration of breastfeeding in Faroese women (n=1092). In contrast to Fei et al. (2010), both Romano et al. (2016) and Timmermann et al. (2016) controlled for prior breast feeding history. Notably, serum PFOA levels during pregnancy were associated with shorter duration of breast feeding even after adjustment for previous breast feeding in these two studies.




Figure 11. White et al. (2011b) study design and experimental timeline. Bar color denotes dose – green, 0 mg PFOA/kg body weight/day; yellow, 1 mg PFOA/kg body weight/day; red, 5 mg PFOA/kg body weight /day; blue, 5 ppb PFOA in drinking water – and bar thickness denotes timing of treatment – thick bars denote on-going direct treatment, thin bars denote only group identity subsequent to treatment.

Studies of effects of peripubertal exposure to PFOA

Three studies reported effects of peripubertal (during periods between 3 and 7 weeks of age) exposure to PFOA on mammary gland development in female mice. Studies presented in these publications are summarized in Table 16B, and details for each study are provided in Appendix 5. Two studies used C57Bl/6 and Balb/C mice (Yang et al., 2009a; Zhao et al, 2012). One of these studies (Zhao et al., 2012) and an additional study (Zhao et al., 2010) evaluated C57Bl/6 PPAR-alpha null mice. Data on serum PFOA levels from all three of these studies are presented in Zhao et al. (2012). Interpretation of the combined results of these three studies is problematic because each PFOA dose level was used in each strain in only one of the three studies, and any dose-response interpretations must be made based on combining data from different studies. Because conditions (e.g. animals, housing conditions, time) may vary during different studies, dose-response curves based on combining data from different studies are difficult to interpret and conclusions based on such dose-response curves are highly uncertain.

Yang et al. (2009a) reported stimulation of mammary gland development in C57Bl/6 mice at 1 and 5 mg/kg/day PFOA, but complete inhibition at 10 mg/kg/day. In contrast, mammary gland development was inhibited at these three doses in a dose-related manner in Balb/c mice in this same study (Yang et al., 2009a).

A subsequent study (Zhao et al. 2012) attempted to further elucidate the dose response for mammary gland effects in these two strains by using a single dose in between those used in the first study in each strain (2.5 mg/kg/day in Balb/c; 7.5 mg/kg/day in C57Bl/6). Mammary gland development was inhibited at these doses in both strains. However, the doses used in the Yang et al. (2009) were not repeated in Zhao et al. (2012), and, importantly, the stimulatory effects

reported at 1 and 5 mg/kg/day in C57Bl/6 mice by Yang et al. (2009a) were not replicated in Zhao et al. (2012).

It is important to note that the stimulation of mammary gland development in C57Bl/6 mice exposed to 5 mg/kg/day by Yang et al. (2009a) was not replicated in a second study. Additionally, this observation does not contradict the findings of delayed mammary development in this strain after gestational exposure (Tucker et al., 2015), since effects on mammary gland development may differ depending on life stage of exposure.

In C57Bl/6 PPAR-alpha null mice, mammary gland development was not affected by 7.5 mg/kg/day PFOA (Zhao et al., 2012), and was reported to be stimulated at 5 mg/kg/day, although quantitative data are not shown by Zhao et al. (2010). As was the case for the studies of C57Bl/6 wild type mice and Balb/C mice discussed above, each dose was used in PPAR-alpha null mice in only one of the studies (Zhao et al., 2010; Zhao et al., 2012). The effects on mammary gland development in the PPAR-alpha null mice therefore were similar to those in wild type mice of the same strain at 5 mg/kg/day and differed at 7.5 mg/kg/day. As above, interpretation of these data is problematic because only one dose was used in each study.

Effects of pre-pubertal PFOA exposure on reproductive organs in female mice

Two studies evaluated effects of pre-pubertal exposure to PFOA on reproductive organs in female mice. Groups of female CD-1 mouse pups (8 per group) to 0.01, 0.1, or 1 mg/kg/day were exposed to PFOA by gavage for three days starting on PND 18 (Dixon et al., 2012) and sacrificed one day after the last dose. Uterine weight (absolute and relative) was significantly increased (about 1.5-fold) only at 0.01 mg/kg/day, the lowest dose, while body weight was not affected by any dose of PFOA. As expected in this model, administration of 17-beta-estradiol greatly increased uterine weight by about 10-fold, and PFOA had no effect on uterine weight in the estradiol treated animals. In mice treated with PFOA alone, histopathological changes in the uteri in some, but not all, sections included minimal to mild endometrial and myometrial edema, and hyperplasia of the mucosal and endometrial glandular epithelia and smooth muscle layers. There was also focal minimal stromal edema of the cervix and focal areas of mucification of the vagina in some, but not all, sections from PFOA treated mice. The severity scores for these changes were statistically significant (p<0.05) only in the low dose (0.01 mg/kg/day) and may have contributed to the increased uterine weight in this dose group, indicating a non-monotonic dose response curve for this effect. In reproductive organs from mice treated with estradiol, histological changes that are known to result from estradiol were observed and these changes were more severe than those seen in PFOA treated mice. The authors note that PFOA did not appear to have anti-estrogenic effects in this study, since it did not decrease the uterine weight gain induced by estradiol, and that more research is needed regarding the mechanism for the observed histopathologic effects of PFOA.

In a second study of similar design, groups of 15 female CD-1 mouse pups were dosed with 0.005, 0.01, 0.02, 0.05, 0.1, or 1 mg/kg/day PFOA for 3 days beginning on GD-18 (Yao et al.,

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 240 of 551

2014). Another group of 15 female mouse pups was dosed with 17-beta-estradiol (0.5 mg/kg/day) for the same 3-day time period. Mice were sacrificed one day after the last dose. In this study, PFOA did not affect relative uterine weight at any dose, while estradiol caused the expected increase in relative uterine weight. Body weight was not affected by PFOA or estradiol treatment. In histological examination of the uterus, cervix, and vagina from 5 mice from each treatment group, there were no differences in types or severity of observations between controls and PFOA treated groups, while estradiol treatment produced the expected histopathological changes. In uterine tissue from the other 10 mice per treatment group, expression of estrogen receptor target genes in the uterus was not changed in PFOA-treated mice. Additionally, the human estrogen receptor was not activated by PFOA *in vitro* studies. Based on these results, the authors concluded that PFOA does not activate the mouse or human estrogen receptor.

Reproductive effects in male mice

Adverse reproductive effects were observed in four studies of male mice.

Li et al. (2011) studied the effects of 6 weeks of oral exposure to 0, 1, and 5 mg/kg/day APFO in wild type, PPAR-null, and humanized PPAR-alpha 129/sv mice. Serum testosterone was significantly decreased and the percentage of abnormal sperm was significantly increased in a dose-dependent manner in wild type and humanized PPAR-alpha mice, but not in PPAR-alpha null mice. Histopathological examination of the testis found increased vacuolated cells in the seminiferous tubules of wild type and humanized PPAR-alpha at both doses, while no obvious effects occurred in the PPAR-alpha null mice.

Male Balb/C mice (10 per group) were dosed with PFOA by gavage for 28 days with 0, 0.31, 1.25, 5, and 20 mg/kg/day (Zhang et al., 2014). Sperm parameters were evaluated in five mice from the control and 5 mg/kg/day groups, histopathological studies were performed on testes from three mice from each dose group, and testes from the remaining animals were used in mode of action studies not described here. Relative testes weight was not affected by PFOA treatment, and absolute testes weight was decreased only at the highest dose (20 mg/kg/day). Sperm numbers, sperm motility, and sperm progression were significantly decreased, and percent teratosperm was markedly and significantly increased, by treatment with 5 mg/kg/day PFOA. Histopathological examination found no differences in testes in the two lower dose groups (0.31 and 1.25 mg/kg/day) as compared to controls, while the seminiferous tubules in the testes of the two higher dose groups (5 and 20 mg/kg/day) were severely damaged.

In a second study from this research group, fertility of male Balb/C mice (6-8 weeks old) was significantly reduced after 28 days of gavage dosing with 5 mg/kg/day PFOA (Lu et al., 2015). The number of mated females and the number of pregnant females per male mouse were significantly decreased by treatment of the males with PFOA. Further studies found that the blood-testis barrier was disrupted after 28 days of exposure to 1.25 or 5 mg/kg/day.

Finally, Liu et al. (2015), reported testicular toxicity in Kunming mice dosed with 2.5, 5, or 10 mg/kg/day PFOA for 14 days. Testicular damage including atrophy of seminiferous tubules, disrupted arrangement of spermatogenic cells, depletion of spermatagonial cells, detachment of germ cells from seminiferous epithelium, and decreased sperm production occurred in all treated groups, with severity increasing with dose. Epididymal sperm count was decreased in a dose-related fashion, with no NOAEL identified. Other parameters evaluated in this study are discussed in the <u>Mode of Action</u> section.

These adverse reproductive effects in male mice are in contrast to the results of the two generation study in rats (Butenhoff et al., 2004b, see below). In this study, mating, fertility, and sperm parameters in F0 and F1 male rats were unaffected by PFOA at up to 30 mg/kg/day. Additionally, Cui et al. (2009) did not observe distinct histopathological changes in the testes of male Sprague-Dawley rats treated with 5 or 20 mg/kg/day of PFOA for 28 days and found that testes weight relative to body weight was significantly increased at both doses. As discussed below, PFOA increased the incidence of testicular Leydig cell tumors in two chronic studies of male rats (Biegel et al., 2001; Butenhoff et al., 2012). In the chronic study of male rats dosed with 13.6 mg/kg/day PFOA in the diet for 24 months (Biegel et al., 2001), absolute testes weight was significantly increased by PFOA at 21 months or earlier time points.

Reproductive and developmental studies in rats and rabbits

As discussed above, the rat and the rabbit are not the most appropriate animal models for human reproductive and developmental effects of PFOA because of their rapid excretion of this chemical in female rats and both male and female rabbits. Studies of reproductive and developmental effects in these species are summarized below.

Rabbit developmental study

Gortner (1982, cited in USEPA, 2005a) studied developmental effects in New Zealand white rabbits (18/dose group) given 0, 1.5, 5, or 50 mg/kg/day PFOA on gestation days 6-18. Maternal body weight was decreased in treated groups on GD 6-9 but returned to control levels on GD 12-29. Parameters such as number of resorptions and implantations, and fetal viability, sex ratio, and weight, were not affected by treatment. A dose related increase in incidence of the skeletal variation, extra ribs or 13th rib, was observed, with incidence of 16, 20, 30, and 38% in the 0, 1.5, 5, and 50 mg/kg/groups. This increase was statistically significant in the highest dose group.

Rat studies

Rat developmental study

Gortner (1981, cited in USEPA, 2005a) gave Sprague-Dawley rats (22/dose group) 0, 0.05, 1.5, 5, and 150 mg/kg/day APFO on gestation days 6-15. The maternal NOAEL was 5 mg/kg/day and the LOAEL was 150 mg/kg/day, based on decreased body weight, ataxia, and mortality seen only in the high dose group. Parameters including number of resorptions and implantations, or fetal viability, sex ratio of offspring, and pup weight, were not affected by treatment. A significantly increased incidence of missing sternebrae occurred in the high dose group. Since

this effect was also seen in the control and lower dose groups at lower frequency, the study authors did not believe that it was treatment related.

Two-generation rat reproductive study

A two-generation reproductive study in Sprague-Dawley rats using gavage doses of 0, 1, 3, 10, and 30 mg/kg/day APFO was conducted by York (2002) and was also reported by Butenhoff et al. (2004b). Various parameters related to reproduction and development, as well as general toxicology endpoints, were evaluated in each generation (F0, F1, F2). Because of the design of the study, some observed effects may have been due to developmental/reproductive toxicity and others due to adult toxicity (USEPA, 2005a).

The parental (F0) generation (30 per sex per group) were dosed for at least 70 days prior to cohabitation beginning at age 6 weeks and until after mating in males and through pregnancy and lactation until weaning of pups for females. Males of the F0 generation were sacrificed after mating, and females were sacrificed at weaning of offspring on PND 22.

Mean serum levels on the day of sacrifice in the F0 males in the control, 10, and 30 mg/kg/day groups were 34 ng/ml, 51,500 ng/ml and 45,300 ng/ml, with no increase in serum levels with increasing dose. In females, serum levels were much lower, < 5 ng/ml, 370 ng/ml, and 1020 ng/ml in the control, 10 and 30 mg/kg/day groups. Serum levels were not measured in the 1 and 3 mg/kg/day groups.

In the F0 males, there were no effects on mating, fertility, or sperm parameters. There were dose-related statistically significant decreases in body weight and body weight gain at 3, 10, and 30 mg/kg/day of 6, 11, and 25%, respectively, although relative food consumption was increased in these groups. Liver weights (absolute, relative to body weight, and relative to brain weight) were increased significantly in all dose groups (1 mg/kg/day and above). Kidney weights were also increased relative to brain and liver weights in all dose groups. Livers and kidneys were not examined histologically. Reproductive and endocrine organs were examined histologically, and hypertrophy and/or vacuolation of the zona glomerulosa of the adrenal glands were seen in 20% of the 10 mg/kg/day group and 70% of the 30 mg/kg/day group.

In F0 females, there were no effects on estrous cyclicity, mating, fertility, pup sex ratio, pup viability, pup birth weight, or other related parameters. Relative kidney weights were reduced at 30 mg/kg/day, and relative liver weight was reduced at 3 and 10 mg/kg/day. This decrease in relative liver weight is in contrast to findings in many other studies in which increased liver weight increases occurred. Histological examination was not performed on the kidneys or livers. Lau et al. (2006) concluded that the profile of maternal effects in the rat study differed from those seen in similar studies in mice because of the more rapid excretion in the adult female rat compared to the adult female mouse.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 243 of 551

Dosing of F1 offspring with the same dose levels that their parents had received began at weaning (PND 22). Most of the F1 animals were sacrificed after sexual maturation (about 5 weeks in females and 7 weeks in males). From the F1 generation, 30 pairs per dose group were selected to be bred to produce the F2 generation. These F1 males were sacrificed at about 133 days of age, after 113 days of treatment, and F1 females were sacrificed at weaning of the pups, at 13 to 15 weeks of age.

The weight of the F1 pups (males and females combined) was reduced compared to controls through lactation on a per litter basis in the 30 mg/kg/day group. During the post-weaning period, signs of toxicity in the F1 males included increased incidence of annular constriction of the tail at all doses (significant at 1, 10, and 30 mg/kg/day), significant increases in the number of emaciated pups at 10 and 30 mg/kg/day, and significantly increased urine-stained fur, decreased motor activity, and abdominal distention at 30 mg/kg/day. Deaths were significantly increased in the 30 mg/kg/day males during the post-weaning period. Sexual maturation, as indicated by day of preputial separation, was significantly delayed in the high dose group (52.2 days) compared to controls (48.5 days).

No effects were observed on mating, fertility, or sperm parameters in the F1 males. There was a significant dose-related reduction in body weight gain at all doses (1 mg/kg/day and above) during the post-weaning period, although relative food consumption was significantly increased. At sacrifice (day 113 of dosing), body weights were reduced by 6, 6, 11, and 22% in the 1, 3, 10, and 30 mg/kg/day groups compared to controls. Absolute and relative liver weights were increased at all doses, and hepatocellular hypertrophy and necrosis were seen in livers of some animals in the 3, 10, and 30 mg/kg/day groups. Kidney weight relative to body and brain weight was increased in all treated groups, but histopathological examination was not performed. Hypertrophy and vacuolation of the adrenal cortex was seen in 70% of high dose animals, but not in other groups.

In F1 females, there was a significant increase (6/60) in mortality in the high dose group 2-8 days post-weaning. Sexual maturation, as indicated by day of vaginal opening, was significantly delayed in the 30 mg/kg/day group, from 34.9 days in controls to 36.6 days in treated females. Significant reductions in body weight were seen at several time points during post-weaning, gestation, and lactation, although relative food intake was not decreased and body weight was not decreased at terminal sacrifice. No effects were seen in F1 females on mating or fertility parameters, or number of implantations, number of stillborn pups, or length of gestation.

The F2 pups were followed until weaning at PND 22. In the F2 generation, no treatment-related effects were seen on pup viability until weaning, percentage of male pups, litter size, average pup body weight on days 1, 5, 8, 15, or 22, or anogenital distance. Because these pups were sacrificed at weaning, post-weaning effects were not assessed.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 244 of 551

Several LOAELs and NOAELs were identified in this study for males and females at different life stages, and the serum PFOA levels at these NOAELs and LOAELs were modeled (USEPA, 2005a). The LOAEL for adult males in this study was 1 mg/kg/day (modeled serum concentration – 42,000 ng/ml) with no NOAEL identified, based on increased liver weight in the F0 and F1 generations and decreased body weight in the F1 generation. For pregnant females, the LOAEL was 10 mg/kg/day, based on decreased body weight in F1 pups during post-weaning, and the NOAEL was 3 mg/kg/day (modeled serum concentration – 3500 ng/ml). For the male rat pups during post-weaning, the LOAEL was 10 mg/kg/day and the NOAEL was 3 mg/kg/day (modeled serum concentration – 3500 ng/ml). For the male rat pups during post-weaning, the LOAEL was 10 mg/kg/day and the NOAEL was 3 mg/kg/day (modeled serum concentration - 3500 ng/ml). For the male rat pups during post-weaning, the LOAEL was 10 mg/kg/day and the NOAEL was 3 mg/kg/day (modeled serum concentration - 3500 ng/ml) at week 7, based on decreased body weight in the F1 generation. For the female rat pups during post-weaning, the LOAEL was 30 mg/kg/day and the NOAEL was 10 mg/kg/day (modeled serum concentration - 13,000 ng/ml) at week 7, based on decreased body weight in the F1 generation.

Thyroid effects

Effects of PFOA on the thyroid in animal toxicology studies are of interest because there have been many human epidemiological studies of PFOA and thyroid hormones and/or thyroid disease. However, only a few toxicology studies have evaluated effects of PFOA on thyroid function.

In the 4-week study of male cynomolgus monkeys (Thomford et al., 2001a), there were no effects on thyroid hormones (thyroid stimulating hormone, TSH; total and free triiodothyronine, T3; total and free thyroxin, T4) after 29 days of exposure to 0, 2, or 20 mg/kg/day APFO. It should be noted that the number of animals per dose group in this study was very small (controls, n=2; treated, n=3).

Changes in thyroid hormones were observed in PFOA-treated male cynomolgus monkeys in the 6-month study (Butenhoff et al., 2002). This study is described in detail above. At the beginning of the study, there were 6 monkeys in the control and high dose group, and 4 in the other two groups. Some animals in the treated groups did not complete the study because of mortality or overt toxicity (3 mg/kg/day, n=3; 30/20 mg/kg/day, n=2 at end of study.) Thyroid hormones (total and free triiodothyronine, T3; total and free thyroxin, T4) and TSH (thyroid stimulating hormone) were measured before dosing, and after 5, 10, 14, and 27 weeks of dosing with 0, 3, 10, 30/20 mg/kg/day APFO. Interpretation of the data is complicated by the fact that comparisons for these parameters are made both to the pretreatment values for the same animals and to the control animals at the concurrent time point. Statistically significant changes were reported for all hormones at one or more time points in one or more dosed groups.

TSH was significantly increased at week 35 compared to pretreatment values at 3 and 10 mg/kg/day. Total T4 was significantly decreased compared to concurrent controls in all dosed groups (3, 10, and 30/20 mg/kg/day) at week 35, at all time points during treatment (weeks 5 to 35) at 10 mg/kg/day, and at week 10 and week 35 at 30/20 mg/kg/day. Free T4 was significantly lower than in concurrent controls at 10 mg/kg/day at weeks 5, 10, and 27, and at 30/20

mg/kg/day at weeks 5 and 27. Total T3 was significantly increased compared to pretreatment values at two time points (weeks 10 and 14) at 3 mg/kg/day, and was decreased compared to concurrent controls in all dosed groups at 30/20 mg/kg/day; this change was not significant at 10 weeks. Finally, free T3 was significantly decreased compared to concurrent controls in the 30/20 mg/kg/day group at weeks 5, 10, and 35.

The authors reported that all thyroid hormone values were within normal range, and that no relevant histological observations were observed. They also state that there were no relevant changes in TSH or T4, despite the changes in levels of these hormones noted above. It is stated, in the 3 high dose monkeys that were removed from the study due to toxicity, the decreased T3 observed during treatment trended upward after treatment ceased. The authors state that the observed changes in thyroid hormone levels were likely due to stress or normal variation rather than a direct effect of APFO (PFOA).

Thyroid hormones (total T4, free T4, and total T3) were measured in male Sprague-Dawley rats one day after dosing for 1, 3, or 5 days with a high dose (20 mg/kg/day) of PFOA (Martin et al., 2007). Levels of free and total T4 in PFOA treated animals were significantly reduced to several fold below control levels at all three time points. Total T3 was also significantly decreased at all three time points, although the magnitude of the decreases was smaller than for T4. The effects were similar or greater than those caused by PFOS at 10 mg/kg/day in the same study. Unfortunately, thyroid hormones have not been evaluated in longer term, lower dose rodent studies of PFOA.

Neurobehavioral and Central Nervous System Effects

Several studies have found neurobehavioral effects, particularly increased activity, in rodents exposed to low doses of PFOA during development. Although human studies on these effects are not reviewed in this document, toxicological studies of neurobehavioral effects are of interest because some human studies have reported associations of PFOA and other PFCs with behavioral effects, particularly attention deficit hyperactivity disorder, in children (Hoffman et al., 2010; Ode et al., 2014).

Johannson et al. (2008) found significant behavioral effects in adult male NMRI mice given a single gavage dose of 0.58 or 8.7 mg/kg PFOA at 10 days of age. Behavioral tests were conducted at 2 and 4 months of age. These behavioral tests included spontaneous behavior (locomotion, rearing, total activity) over three consecutive 20-minute time periods (an indicator of habituation over time), nicotine-induced motor activity (locomotion, rearing, total activity), and behavior in an elevated plus-maze (a measure of anxiety). These single doses of PFOA did not affect weight gain or cause any overt signs of toxicity. At 2 and 4 months, some or all measures of spontaneous behavior were affected in both the low and high dose groups, with greater effects in the high dose group (8.7 mg/kg) and at the later time point (4 months). Habituation was greatly decreased at both 2 and 4 months in the high dose group compared to

controls. This effect increased with age of the treated mice. Lack of effect in the elevated plusmaze test indicated that these effects were not likely to be caused by anxiety.

Responses over three 20 minute periods following an injection of 80 μ g/kg nicotine, a measure of the susceptibility of the cholinergic system, was also significantly altered in high and low dose mice at 4 months. Control mice showed an increase in activity from the nicotine, followed by a decrease to baseline behavior. Low dose mice also showed increased activity after receiving nicotine, but less so than controls, and this increased activity was followed by greater activity than in controls during the last 20-minute time period. In contrast, high dose mice showed decreased activity during the first 20 minutes after receiving nicotine but were hyperactive during the later time period. The authors concluded that neonatal PFOA exposure caused deranged spontaneous behavior such as lack of habituation and hyperactivity that worsened with age in adult mice, and that PFOA exposure also affected the cholinergic system.

Significant effects were seen at both doses in this study. Therefore, the LOAEL was 0.58 mg/kg, and no NOAEL was identified. Serum levels were not measured in this study and have not been measured in neonatal mice administered a single dose of PFOA. A single oral dose of 1 or 10 mg/kg to adult CD-1 mice resulted in maximum serum concentrations of about 10,000 and 100,000 ng/ml (Lou et al., 2009). From these data, the serum concentrations from 0.58 and 8.7 mg/kg can be estimated as 5800 and 87,000 ng/ml, assuming that kinetics in these neonatal mice are similar to in adult mice.

The authors stated that the effects caused by PFOA in this study are similar to those seen with PCBs and PBDEs, known developmental neurotoxicants, and that PFOA should be classified as a developmental neurotoxicant along with these other persistent chemicals. It is noted that studies from this laboratory using the same dosing protocol (a single dose given to 10 day old mice) and the same behavioral tests are the basis for the chronic USEPA IRIS Reference Doses developed in 2008 for two PBDEs, 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) and 2,2',4,4',5-pentabromodiphenyl ether (BDE-99) (USEPA 2008b,c). Because the effects persisted into adulthood and were permanent, these effects were regarded by USEPA IRIS as chronic, not acute, even though only a single dose was given.

A second study in this laboratory (Johansson et al., 2009) examined the effects of a single gavage dose of 8.7 mg/kg PFOA to 10 day old mice on proteins important for neuronal growth and synaptogenesis in the developing brain. The mice were sacrificed 24 hours after dosing. Rapid brain development, the "brain growth spurt," occurs in mice during this time period. Levels of two proteins known to be involved with neuronal survival, growth, synaptogenesis, and other aspects of neuronal development were significantly increased in the hippocampus but not the cerebral cortex of treated mice, and two other proteins were increased in both areas of the brain. PBDEs, which are known to affect behavior after developmental exposures, had previously been found by these researchers to cause similar effects. The authors conclude that these changes may relate to some of the observations in their earlier behavioral study.

Onishchenko et al. (2010) found sex-related behavioral changes in offspring of C57Bl/6 mice exposed to 0.3 mg/kg/day PFOA throughout gestation. Liver weights were significantly increased in treated pups that were sacrificed at birth. PFOA exposure did not affect locomotor behavior in 5-8 week old mice tested individually, but significant sex-related effects were seen on circadian activity when these mice were housed in social groups. Initially, PFOA treated males were more active than controls, while treated females were less active than controls. After habituation, activity in both light and dark phases was increased during the remainder of the first 24 hours in exposed males, while no effects were seen in exposed females. During the second 24-hour period when the mice were more adapted to the test environment, the number of inactive periods during the light phase was decreased in both male and female PFOA-treated mice, and also in the dark phase in PFOA-treated males. No effects of PFOA were seen in other tests, including the elevated plus-maze test for anxiety-like behavior, the forced swimming test for depression-like behavior, or muscle strength in the hanging wire test. Serum PFOA levels in this study were not measured, but they are not expected to be below the serum levels at the LOAELs and NOAELs in some other studies which evaluated other effects. The NOAEL for these effects is not known.

Finally, Sobolewski et al. (2014) studied behavioral effects of developmental exposures to PFOA in C57Bl/6 mice. Three other unrelated environmental contaminants and a mixture of all four chemicals were also evaluated; only results for PFOA alone are reported here. PFOA (0.1 mg/kg/day) was administered to dams in puffed wheat cereal on GD7 through weaning. Behavioral effects were evaluated in male and female offspring (one or two per sex per litter) beginning at age 60 days.

PFOA treatment caused behavioral effects, which differed between males and females. Locomotor behavior was increased in males treated with PFOA, while no effect was seen in females. Horizontal movement and ambulatory movements were increased and resting time was decreased during one or more of three test sessions, while vertical activity was unaffected in males. Behaviors related to novel object exploration and recognition were altered in both PFOAtreated males and females to a highly significant degree, although the specific parameters affected differed between sexes. Fixed interval reinforcement schedule-controlled behavior was not affected by PFOA treatment in males or females.

Chronic toxicity and carcinogenicity

As discussed in the <u>Epidemiology</u> section, PFOA has been associated with increased incidence of kidney and testicular cancer in humans exposed through drinking water, after adjustment for smoking and other relevant factors. The chronic toxicity and carcinogenicity of PFOA has been evaluated in two dietary studies in rats. One study (Sibinski et al., 1987; Butenhoff et al., 2012) included male and female rats, while Biegel et al. (2001) studied only males. As such, chronic toxicity and carcinogencity have been studied only in the rat, a species in which PFOA is rapidly excreted by females. Chronic studies in another species in which PFOA is persistent in both

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 248 of 551

sexes, such as the mouse, would provide important information specific to females. Furthermore, the chronic studies did not assess effects including carcinogenicity which might result from exposures during the critical developmental stages now known to be sensitive periods for PFOA toxicity.

Two year chronic/carcinogenicity study in male and female rats

Sprague-Dawley rats (30 per sex per group) were dosed with APFO through diets containing 0, 30, or 300 ppm APFO for two years (Sibinski, 1987; Butenhoff et al., 2012). Additional animals (15 per sex) were included in the control and high dose groups for evaluation at sacrifice after one year. From food consumption data, mean APFO doses were determined to be 1.3 and 14.2 mg/kg/day in males, and 1.6 and 16.1 mg/kg/day in females, for the 30 and 300 ppm groups, respectively.

Body weight gains were decreased in both sexes in the high dose group, with maximum differences between the high dose group and controls of 21% in males at 6 weeks and 11% in females at 92 weeks. Smaller decreases were seen in low dose males, and decreases were not consistently seen in low dose females. Decreases in weight gain were treatment-related, since food consumption on a body weight basis was increased in treated males, by about 13% in the high dose group. Mortality was not increased by APFO treatment, and 2-year survival rates were 70%, 72% and 88% in males and 50%, 48% and 58% in females in the 0, 30 ppm, and 300 ppm groups, respectively.

The incidence of ataxia was increased in female rats treated with PFOA and occurred most frequently in moribund animals. Ataxia occurred in 3%, 18% and 23% of rats in the control, low-and high-dose groups (including animals sacrificed at one year), respectively.

Clinical chemistry changes occurred in high and low dose males, but not in females. The liver enzymes alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase were increased in both low dose and high dose males between 2 and 18 months, but only in the high dose group at 24 months. Albumin was significantly increased in the male low dose group at 3 and 6 months, and until 24 months in the high dose group. Butenhoff et al. (2012) concluded that the elevations in liver enzymes in both high and low dose males may represent "borderline chronic liver toxicity".

Hematological parameters including red blood cell counts, hemoglobin concentrations and hematocrit were significantly decreased in high and low dose males and females at different time points. In high dose males, these erythrocyte-related hematological parameters were decreased from 3 to 18 months. Additionally, leukocytes were increased in both dose groups of males during the first year. Statistically significant changes included increases in lymphocytes and neutrophils at 3 and 12 months in both dose groups, and in lymphocytes and 6 and 18 months in the low dose group.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 249 of 551

In females, hematological parameters were significantly changed with equal frequency in the high and low dose groups. At 3 months, red blood cells were decreased in the low dose group and hematocrit was decreased in the high dose group. At 6 months, erythrocytes, hemoglobin, and hematocrit were decreased only in the low dose group, while at 12 months, these three parameters were decreased only in the high dose group.

At the one-year interim sacrifice, statistically significant changes in organ weights in high dose males included increased liver weight and decreased pituitary weight (absolute and relative to body or brain weight), increased kidney weight (only relative to body weight), decreased adrenal and heart weight (absolute and relative to brain weight). No organ weight changes were observed in high dose females sacrificed at one year.

At the one-year interim sacrifice, histopathological changes in the livers of high dose males included diffuse hepatocellular hypertrophy in 12/15 (compared to 0/15 controls); portal mononuclear cell infiltration in 13/15 (compared to 7/15 controls); and focal hepatocellular necrosis in 6/15 (compared to 0/15 controls). In high dose females, hepatocellular vacuolation occurred in 11/15 (compared to 5/15 controls). Testicular tubular atrophy and marked aspermatogenesis was found in 2/15 high dose males but in none of the controls.

At the two-year sacrifice, slight non-significant increases in liver weight occurred in all treated groups of males and females. Relative kidney weight was slightly increased in male and female high dose rats, and this change was significant in females.

Several non-neoplastic liver lesions were also increased in treated animals at two years. Hepatocellular hypertrophy did not occur in controls but was found in 12% and 80% of the males, and 2% and 16% of the females, in the low and high dose groups, respectively. Hepatic cystoid degeneration occurred in 8%, 14% and 56% of the control, low, and high-dose males. However, hepatocellular necrosis or hepatocellular vacuolation was not increased in treated animals compared to controls, although an increase of focal hepatocellular necrosis in high dose males and hepatocellular vacuolation in high dose females was observed at the one-year sacrifice.

Hepatocellular carcinomas were found in the control (6%), low dose (10%), and high dose (2%) males, and occurred in females only in the high dose group (2%). The incidence of hepatic hyperplastic nodules was 6% in high-dose males, and they were not found in the other groups of males. In females, these nodules were found in 2% of the control and high dose animals, but not in the low dose group. Butenhoff et al. (2012) state that diagnostic criteria for these nodules, which represent a regenerative process, have changed since the histopathological evaluation for this study was performed. The USEPA SAB (2006) concluded that these nodules may have been part of the continuum of proliferative lesions in the liver carcinogenic process. Butenhoff et al. (2012) further conclude that the increased incidence of focal necrosis and vacuolation in treated animals, which was observed at the one year sacrifice but not at the two year sacrifice (because of the higher background incidence of these changes in older rats), suggests a progression of lesions

"from hepatocellular hypertrophy to fatty degeneration to necrosis followed by regenerative hyperplasia."

The incidence of neoplastic lesions of the testes differed significantly between control and treated rats. Leydig cell adenomas of the testes were found in 0, 4, and 14% of the control, low, and high dose males, respectively, with a significantly increased incidence in the high dose group. Additionally, vascular mineralization of the testes occurred in 0, 6, and 18% of control, low, and high dose males, respectively, and reached statistical significance in the high-dose group.

The incidence of mammary gland fibroadenomas was 22%, 42%, and 48% in the control, low dose, and high dose females, and the increase in the high dose group was significant. Mammary gland adenocarcinomas were present in 15, 31, and 11% of the control, low, and high dose females, respectively. A subsequent Pathology Working Group reevaluation of the mammary gland slides concluded that the incidence of mammary gland proliferative lesions was not increased by PFOA in this study (Hardisty et al., 2010).

A statistically significant, dose-related increase in the incidence of ovarian tubular hyperplasia was found in female rats at the two-year sacrifice, with incidence of 0%, 14%, and 32% in the control, low, and high dose groups. The authors of the study report stated that the biological significance of this effect was unknown, as there was no evidence of progression to tumors. Slides of the ovaries were later re-evaluated (Mann and Frame, 2004) using more recent pathology criteria. In the reevaluations, no statistically significant increases in hyperplasia (total number), adenomas, or hyperplasia/adenoma combined were seen in treated groups compared to controls. Although the size of stromal lesions was increased in the high dose group, the incidence of ovarian adenomas was higher in the controls than in the treated groups.

USEPA (2005a) concluded that "based on these toxic effects, the high dose selected in this study appears to have reached the Maximum Tolerated Dose. Based on a decrease in body weight gain, increase in liver and kidney weights and toxicity in the hematological and hepatic systems, the LOAEL for male rats is 300 ppm and the NOAEL is 30 ppm. The LOAEL for female rats is 300 ppm based on a decrease in body weight gain and hematologic effects and the NOAEL is 30 ppm."

However, as noted above, a significant increase in the incidence of ataxia, as well as hematological effects equivalent to those in the high dose group, occurred in low dose females in this study. Also, in males in this study, there were significant changes in several clinical chemistry parameters at multiple time points in the low dose group. Thus, statistically significant effects occurred at multiple time points in the low dose males and female in this study. It should be noted that the study authors concluded that the elevation of the three liver enzymes, alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase, in both dosed groups of males, in conjunction with liver weight changes and histopathology observations, suggested that PFOA affected hepatocytes in both the low dose and the high dose groups of male rats. The serum level in the low dose (1.6 mg/kg/day) females, considered to be the NOAEL by USEPA (2005a), was estimated at 1800 ng/ml, based on average AUC (USEPA, 2005a; Post et al., 2009a). The serum levels in the low dose (1.3 mg/kg/day) males were much higher, and can be estimated at 55,000 ng/ml from the kinetic data presented by USEPA (2005a).

Chronic mechanistic study in male rats

The second chronic study (Biegel et al., 2001) was designed to investigate the mode of action for testicular tumors observed in male rats in the first chronic study (Sibinski et al.,1987; Butenhoff et al., 2012). Male Sprague-Dawley rats were given 300 ppm PFOA in the diet (mean dose of 13.6 mg/kg/day) for up to two years. Serum levels at this dose were estimated as 572,000 ng/ml (USEPA, 2005a). Two controls groups were used, an *ad libitum* fed (AL) group and a pair-fed (PF) group in which the food intake was controlled to match the food intake of the PFOA exposed group. Another group of rats was treated with Wyeth 14,643 (WY), a model peroxisome proliferator. There were 156 rats in each of the control and dosed groups.

At interim time points of 1, 3, 6, 9, 12, 15, 18, and 21 months, the liver and testes from six rats per treatment group were weighed and evaluated for cell proliferation. At each time point, peroxisome proliferation (PCO) was evaluated in 6 additional rats per group, and serum hormone levels (estradiol, testosterone, LH, FSH, and prolactin) were measured in 10 rats from each group.

Liver-to-body weight ratios were increased in PFOA treated animals at all time points compared to controls. This increase was greatest at the earliest time point (1 month) and decreased over time. At 24 months, there was only a slight difference in liver-to-body weight ratio between the treated and control animals. Similarly, the increase in peroxisomal beta-oxidation (PCO), a measure of peroxisome proliferation, in the liver was greatest at 1 month, and the magnitude of the increase over controls decreased with time. WY also increased liver weight and peroxisomal beta-oxidation (PCO). Liver cell proliferation was increased by WY but not by PFOA.

In contrast to the liver, relative organ weight, PCO activity, and cell proliferation in testes were not affected in PFOA or WY treated rats except for increased relative testicular weight at 18 and 24 months in PFOA treated animals and at 24 months in WY treated animals. In the pancreas, PFOA increased acinar cell proliferation at 12, 16, 18, and 21 months, while WY did not have this effect.

Estradiol levels were significantly increased by PFOA at the 1, 3, 6, 9, and 12-month time points. WY also increased serum estradiol. Testosterone, prolactin, LH, and FSH were not changed compared to pair-fed controls.

In this study, there was a significant increase of three types of tumors (Leydig cell adenomas, hepatic adenomas, and pancreatic acinar cell adenomas) in the PFOA treated group at the 24-month sacrifice. The incidence of these tumors in the ad libitum control (AL), pair fed control

(PF), and treated groups was: Leydig cell adenomas (AL – 0/80; PF – 2/78, treated – 8/76), hepatic adenomas (AL – 2/80, PF – 1/79, treated –10/76), and pancreatic acinar cell adenomas (AL – 0/80, PF- 1/79, treated – 7/76). These same three types of tumors also occurred at a higher rate in the WY treated animals. As discussed above, the incidence of testicular Leydig cell adenomas was also increased by PFOA in a dose-related fashion in the first chronic study (Sibinski et al., 1987; Butenhoff et al., 2012).

Information relevant to carcinogenicity from developmental exposure

Carcinogenicity studies using prenatal or perinatal exposure protocols have not been reported for PFOA. Very limited information is available that is relevant to carcinogenicity after developmental exposure to PFOA.

As discussed in the section on hepatic effects above, Filgo et al. (2015) evaluated hepatic histopathological effects, including tumor incidence, at age 18 months in female offspring of dams dosed on GD 1-17. The study evaluated three strains of mice - CD-1, 129/Sv wild type, and 129/Sv PPAR-alpha knockout. CD-1 dams were dosed with 0, 0.01, 0.1, 0.3, 1, and 5 mg/kg/day, and 129/Sv wild type and PPAR-alpha null dams dosed with 0, 0.1, 0.3, 1, and 3 mg/kg/day.

The authors emphasize that the study was not designed or intended to be a carcinogenicity bioassay. Rather, the incidence of liver tumors was evaluated by Filgo et al. (2015) because of the unexpected finding of liver tumors in some treated animals that died before the scheduled end of the study. In CD-1 mice in this study, single or multiple hepatocellular adenomas were found in one or more animals in each of the treated groups (n=21 to 37 per group) except for at the lowest dose (0.01 mg/kg/day), but not in controls (n=29). In total, adenomas occurred in 4.9% (7 of 144) treated animals, compared to a historic control incidence of 0.4% in untreated female CD-mice. Hepatocellular carcinomas occurred in two treated mice (0.3 and 5 mg/kg/day) but not in controls.

In 129/Sv mice, hepatocellular adenomas did not occur in control or treated groups (n=6 to 10 per group). In PPAR-alpha null mice of this strain, in contrast, there were no adenomas in the controls (n=6), one adenoma in the 0.1, 0.3, and 1 mg/kg/day groups (n=9 or 10), and two adenomas at 3 mg/kg/day (n=9). These tumors occurred in 13.2% of all treated PPAR-alpha null mice.

Possibly because of the small numbers of animals per dose-group, tumor incidences were not significantly increased in PFOA-treated groups compared to control in this study, with the exception of the CD-1 mice dosed with 0.3 mg/kg/day in which adenomas were found in 4 of 26 animals. The results of this study are suggestive of the potential for developmental exposures to PFOA to cause tumors in mice later in life, and also suggest that these tumors may occur through a PPAR-alpha independent pathway. An additional study with larger numbers of animals and designed to detect increased tumor incidence is needed to further evaluate these questions.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 253 of 551

Ngo et al. (2014) evaluated the incidence of intestinal tumors and other endpoints in wild type and Min/+ C57Bl/6 mice offspring of dams dosed with 0.01, 0.1, and 3 mg/kg/day PFOA during gestation. The Min/+ strain has a mutation of a tumor suppressor related to intestinal adenomatous polyps and is a sensitive model for chemical-induced intestinal tumorigenesis. PFOA did not cause increased intestinal tumorigenesis at sacrifice at age 11 weeks in either wild type or Min/+ mice.

Discussion

Leydig cell testicular tumors were the only tumor type that were increased by PFOA in the chronic study of Butenhoff et al. (2012), and the incidence of these tumors was also increased by PFOA in Biegel et al. (2001). In Biegel et al. (2010), the incidence of hepatic and pancreatic tumors was also increased to a similar degree as testicular tumors in male rats treated with PFOA.

Although hepatic tumors were not significantly increased in treated animals in Butenhoff et al. (2012), both the USEPA SAB (2006) and Butenhoff et al. (2012) point out that the incidence of hepatic hyperplastic nodules was increased in the high dose males in comparison to the control and low dose groups in this study. Butenhoff et al. (2012) state that diagnostic criteria for these nodules, which represent a regenerative process, have changed since the histopathological evaluation for this study was performed. The EPA SAB (2006) concluded that these nodules may have been part of the continuum of proliferative lesions in the liver carcinogenic process, and Butenhoff et al. (2012) further conclude that the increased incidence of focal necrosis and vacuolation found at the one year sacrifice but not at the two year sacrifice (because of the higher background incidence of these changes in older rats) suggests a progression of lesions "from hepatocellular hypertrophy to fatty degeneration to necrosis followed by regenerative hyperplasia."

In regard to pancreatic tumors, Frame and McConnell (2003) reevaluated the slides of the pancreas from both studies and found that different diagnostic criteria and nomenclature were used by the pathologists in Sibinski et al. (1987) and Biegel et al. (2001). Frame and McConnell (2003) concluded that the incidence of pancreatic focal acinar lesions, which can progress to adenomas, was increased by 300 ppm PFOA in the diet in both studies and that these lesions were larger, more frequent, and had a greater tendency to progress to adenomas in Biegel et al. (2001).

PFOA has been shown to promote liver carcinogenesis in rats initiated with diethylnitrosamine as well as with a more complex initiating protocol (Abdellatif et al.,1991; Nilsson et al., 1991). PFOA also promoted hepatocarcinogenicity in rainbow trout, a model species for human liver cancer (discussed in <u>Mode of Action</u> section, below).

An increased incidence of liver tumors from prenatal exposure to PFOA in CD-1 and PPAR-alpha null mice is suggested by the results of Filgo et al. (2015). However, this study is not definitive, and additional research on carcinogenicity later in life after developmental exposures to PFOA is needed.

Information related to the mode of action for carcinogenicity is discussed in the <u>Mode of Action</u> section below.

Summary of Conclusions of Toxicology Studies

The Subcommittee's review of the toxicology data identified increased relative liver weight and delayed mammary gland development from developmental (perinatal) exposure as the most sensitive systemic toxicological endpoints with data appropriate for dose-response modeling. Delayed mammary gland development in mice is the most sensitive systemic endpoint with data appropriate for dose-response modeling. Increased liver weight is a more sensitive endpoint than most other systemic effects, and it co-occurs with and/or progresses to more severe hepatic effects including increased serum liver enzymes, hepatocellular necrosis, fatty liver, and/or hyperplastic nodules. PFOA also causes other types of toxicity including reproductive effects in both males and females, delayed growth and development, immune system toxicity, and neurobehavioral effects. PFOA caused tumors in two chronic rat studies, and one of these toxicological effects are considered relevant to humans for the purposes of risk assessment, as discussed in the <u>Mode of Action</u> section.

			T	ABLE 1	0A: STUDIE	S PROVI	DING SEF	RUM PF	OA DATA AT END OF DOSING PERIOD*
Citation	Species	Life- stage	Doses (mg/kg/day)	Dura- tion	NOAEL (mg/kg/day)	Serum NOAEL (ng/ml)	LOAEL (mg/kg/day)	Serum LOAEL (ng/ml)	Comments
Lau et al. (2006)	Female mouse	Preg- nant GD 18	0, 1,3, 5, 10, 20, 40	GD 1- 18			1	22,00	 Data for absolute liver weight are presented in bar graph in publication. Numerical data were obtained from the investigator. Data on relative liver weight are based on comparisons with body weight after gravid uterus was removed. These data are not shown in the publication and were obtained from the investigator.
Loveless et al. (2006)	Male rat	Adult	0, 0.3, 1, 3, 10, 30	2 weeks	Linear/ Branched 0.3 Linear 0.3 Branched 0.3	19,000 20,000 16,000	1	51,000 65,000 48,000	 Three formulations of PFOA of differing isomer compositions were tested. This study also provides data on peroxisomal beta-oxidation. In mice, increased relative liver weight does not correlate with increased peroxisomal beta oxidation among formulations with differing isomer compositions, indicating PPAR-alpha independent effects on liver weight.
	Male mouse	Adult	0, 0.3, 1, 3, 10, 30	2 weeks	Linear/ Branched 0.3 Linear Branched	10,000 	1 0.3 0.3	27,000 13,000 14,000	
Macon et al. (2011)	Female mouse	Female pup PND 1	0, 0.01, 0.1, 1	GD 10-17	0.1	2300	1	16,000	 LOAEL for increased relative liver weight is 100 fold higher than LOAEL for delayed mammary gland development. PFOA serum levels were measured on PND 1. With longer GD 1-17 exposure, LOAEL for increased relative liver weight was 0.3 mg/kg/day in maland female pups on PND 7. PFOA serum levels were not measured in this component of the study.
Perkins et al. (2004)	Male rat	Adult	0, 1,10, 30, 100 ppm in diet	4, 7, 13 weeks	0.07 (1 ppm) at 4 weeks	6500	0.71 (10 ppm) at 4 weeks	55,000	Steady-state serum levels were reached by 4 weeks. Dose-related increases in relative liver weight were similar at 4, 7, and 13 wks (see individual study table in Appendix 5).
Thomford et al. (2001); Butenhoff et al. (2002)	Male cynomol- gus monkey	Adult	0, 3, 10, 20/30	26 weeks			3	72,000	 PFOA serum levels did not significantly differ at 3 and 10 mg/kg/day. NOAEL was not identified.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 256 of 551

Citation	Species	Life- stage	Doses (mg/kg/day)	Duration	NO (mg/i	AEL Kg/day)	Serum NOAE L (µg/L)	LOAEL (mg/kg/day)	Serum NOAEL (µg/L)	DATA AT END OF DOSING PERIOD* Comments			
Abbott et al. (2007)	Mouse (PND 21)	WT** dam WT pup PPAR-α null dam PPAR-α null pup	0, 0.1, 0.3, 0.6, 1.0 0, 0.1, 0.3, 1.0, 3.0	GD 1-17	0.3 1 1	۲ 	NA	1 0.1 3 3	NA	 Serum data are not presented in this table because they are from PND 21 and do not reflect maximum exposure at end of dosing period. Liver weight was assessed in offspring on PND 21 and later time points. No data are available from earlier time points closer to the end of dosing. 			
DeWitt et al. (2008)	Female mouse	Adult	0, 0.94, 1.88, 3.75, 7.5	15 days		Ν	NA	0.94	NA	Serum PFOA data are not available for the two lowest doses in this study.			
Loveless et al. (2008)	Male mouse Male rat	Adult Adult	0, 0.3, 1, 10, 30	29 days	0.3	Ν	NA	1	NA NA	 Linear PFOA was used in this study. Relative liver weight increased in a dose-related manner at all doses below the LOAELs, but changes were not statistically significant. 			
Quist et al. (2015)	Female mouse (PND 21)	Pup	0, 0.01, 0.1, 0.3, 1 (On control or high fat diet from PND 35- 77)	GD 1-17	0.1 (Note: N NOAEL identifier other hej effects in chronic a inflamm PND 21 hepatoce hypertro PND 91	lo was d for patic ncluding active ation on and ellular phy on	NA	0.3 (Note: LOAEL was 0.01 mg/kg/day for chronic active inflammation on PND 21 and hepatocellular hypertrophy on PND 91)	NA	 Relative liver weight was increased on PND 21, but not on PND 91. Frequency and severity of hepatocellular hypertrophy increased on PND 91 in all dosed groups, in the absence of increased liver weight. Statistical analysis was not presented. Increased severity of chronic active hepatic periportal inflammation on PND 21 was significantly increased in all dosed groups. This effect occurred at doses below those that caused increased liver weight on PND 21. Increased severity of periportal inflammation also occurred on PND 91, but was less severe than on PND 21. Hepatic mitochondrial abnormalities occurred at 1 mg/kg/day on PND 21 and PND 91; they were more severe on PND 91. This effect was not evaluated at other doses. Hepatic peroxisome proliferation was not observed at 1 mg/kg/day on PND 91; other doses were not evaluated. 			
Son et al. (2008)	Male mouse	Adult	0. 0.49, 2.64, 17.63, 47.21	4 weeks		N	NA	0.49	NA	 PFOA serum data are not available from this study. Significantly increased levels of one or both liver enzymes, ALT and AST, occurred at all doses (data shown in Table 8). 			
Tucker et al. (2015)	Female mouse	Pup PND 21	0, 0.01, 0.1, 0.3, 1	GD 1-17	CD-1 C57/Bl		NA NA	1	NA NA	 Serum data are not presented here because they are from PND 21 and do not reflect maximum exposure at end of dosing period. Liver weight was assessed in offspring on PND 21 and later time points. No data are 			
		WT pup PPAR-α null dam PPAR-α null pup	0, 0.1, 0.3, 1.0, 3.0		 1 1	·		0.1 3 3	-	 Elver weight was assessed in onspiring on TND 21 and later time points. No data are available from earlier time points closer to the end of dosing. Increased liver weight w not observed at time points later than PND 21. At these time points, PFOA body burd would be lower than on PND 21. Delayed mammary gland development occurred at lower doses than liver effects in bo strains. 			

*LOAELs are based on statistical significance at p<0.05. Effects that were not statistically significant occurred at doses below the NOAELs in some studies. **WT – Wild Type

Citation	Species & Strain	Lifestage for Dosing	Dose(s) (mg/kg/day)	Dosing Duration	Endpoint(s)*	NOAEL** (mg/kg/day)	LOAEL** (mg/kg/day)	PFOA Serum Concentration (ng/ml)	Comments
Botelho et al. (2015)	Male C57BL/6 (H-2) ^b mice	Adult	0, 20, 50, 100, and 200 ppm in diet (20 ppm estimated as 3 mg/kg/day from Qazi et al., 2013)	10 days	↓ complement activation (various parameters) at end of dosing period.	100 ppm (estimated as 15 mg/kg/day based on data for lower dose in Quazi et al., 2013)	200 ppm (estimated as 30 mg/kg/day based on data for lower dose in Quazi et al., 2013)	Estimated serum level at 200 ppm (LOAEL): 152,000 ng/ml (Qazi et al., 2009b)	Effects associated with PPAR- alpha occurred at doses below the LOAEL for ↓ complement activation; authors concluded that ↓ complement activation is PPAR- alpha independent. LOAEL for ↑ liver weight was lower than for immune effect.
DeWitt et al. (2008)	Female C57/BL6N mice	Adult	0, 3.75, 7.5, 15, and 30 mg/kg/day in drinking water. 0, 0.94, 1.88, 3.75, and 7.5 mg/kg/day in drinking water.	15 days	 ↓ IgM, ↑ IgG after immunization with sheep red blood cells ↓ IgM, ↑ IgG after immunization with sheep red blood cells ↓ relative spleen weight 	1.88 mg/kg/day	3.75 mg/kg/day 3.75 mg/kg/day	74,913 ng/ml at 3.75 mg/kg/day (LOAEL), one day post-dosing	NOAEL and LOAEL for ↓ relative spleen and thymus weight were higher than for other effects. NOAEL and LOAEL for ↓ relative thymus weight were higher than for other effects. LOAEL for ↑ liver weight was lower than for immune effect.
DeWitt et al. (2009a)	Female C57/BL6N mice	Adult	0, 3.75, 7.5, and 15 mg/kg/day in drinking water	10 days	↓ IgM	7.5 mg/kg/day (sham operated)3.75 mg/kg/day (adrenalectomized)	15 mg/kg/day (sham operated) 3.75 mg/kg/day (adrenalectomized)	Not assessed	Authors conclude that effects on immune system are not due to increased serum corticosterone.
Hu et al. (2010)	Female C57/BL6N mice	Pregnant	0, 0.5, and 1 mg/kg/day Gavage	GD 6-17	IgM (PND 49), IgG (PND 63) after immunization with sheep red blood cells. Absolute and relative spleen and thymus weight (PND 49 and 63) in offspring	1 mg/kg/day		Not assessed at end of dosing	

Citation	Species & Strain	Lifestage for Dosing	Dose(s) (mg/kg/day)	Dosing Duration	Endpoint(s)*	NOAEL** (mg/kg/day)	LOAEL** (mg/kg/day)	PFOA Serum Concentration (ng/ml)	Comments
Hu et al. (2012)	Female C57/BL6N mice	Pregnant and lactating	0, 0.02, 0.2, and 2 mg/kg/day Gavage	Pre- pregnancy (10.1-15.7 days) through weaning	↓ percentage of splenic T regulatory cells in offspring (age - at least 6 weeks old)	0.2 mg/kg/day/ (see Comments)	2 mg/kg/day/0.02 mg/kg/day (see Comments)	Not assessed	$Ex vivo$ IL-10 production by splenic CD4+ T cells was \downarrow at \geq 0.02 mg/kg/day in male offspring; it was \uparrow at 0.02 mg/kg/day but not other doses in females.No effect on two serum autoantibodies. For 3rd serum autoantibodies (anti-ssDNA), \downarrow at 0.02 and 2, but not 0.2 mg/kg/day, in females only. Significance of changes at 0.02 mg/kg/day are not clear.
Iwai and Yamashita (2006)	Male Crj:CD (SD)IGS rats	Adult	0, 0.5, 5, and 50 mg/kg/day Gavage	14 days	Percent lymphocytes in peripheral blood Percent or number of lymphocytes subsets in peripheral blood Absolute or relative spleen weight	50 mg/kg/day		Not assessed	Relative liver weight ↑ at NOAEL for immune effects (50 mg/kg/day).
Loveless et al. (2008)	Male Crj:CD (SD)IGS rats	Adult	0, 0.3, 1, 10, 30 mg/kg/day	28 days Gavage	Several immune parameters	30 mg/kg/day		Not assessed	Other immune effects in mice occurred at doses above LOAEL for decreased relative spleen weight.
	Male Crj:CD (SD)IGS mice				↓ relative spleen weight	0.3 mg/kg/day	1 mg/kg/day		LOAEL in mice was also 1 mg/kg/day for ↑ relative weight and necrosis in liver. Although authors concluded immune effects are secondary to ↑ corticosterone, corticosterone was not ↑ at LOAEL for ↓ relative spleen weight.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 258 of 551

Citation	Species & Strain	Lifestage for Dosing	Dose(s) (mg/kg/day)	Dosing Duration	Endpoint(s)*	NOAEL** (mg/kg/day)	LOAEL** (mg/kg/day)	PFOA Serum Concentration (ng/ml)	Comments
Qazi et al. (2009a)	Male C57BL/6 (H-2) ^b mice	Adult	10 or 200 ppm in diet	10 days	Numerous parameters related to immune function	10 ppm (data not shown) Estimated as 1.5 mg/kg/day from Qazi et al. (2013).	200 ppm Estimated as <30 mg/kg/day from Qazi et al. (2013)	Estimated serum level at 200 ppm (LOAEL) was 152,000 ng/ml (Qazi et al., 2009b)	
Qazi et al. (2009b)	Male C57BL/6 (H-2) ^b mice	Adult	200 ppm in diet	10 days	 ↓ relative spleen and thymus weight. ↓ spleen and thymus cellularity. ↓ splenocyte and thymocyte cell populations. Histopathological changes in thymus. 		200 ppm Estimated as <30 mg/kg/day from Qazi et al. (2013)	152,000 μg/L	Relative liver weight also ↑ at LOAEL.
Qazi et al. (2010)	Male C57BL/6 (H-2) ^b mice	Adult	20 ppm in diet	10 days	Several parameters of hepatic immune status		20 ppm Estimated as 3 mg/kg/day from Qazi et al. (2013).	87,600 ng/ml	↑ liver weight and histopathological changes in the liver also occurred at this dose.
Qazi et al. (2012)	Male C57BL/6 (H-2) ^b mice	Adult	10, 20, or 200 ppm in diet	10 days	↓ numbers of beta- lymphoid cells and beta-lymphoid cell subpopulations in bone marrow.	10 ppm Estimated as 1.5 mg/kg/day from Qazi et al. (2013).	20 ppm Estimated as 3 mg/kg/day from Qazi et al. (2013).	Estimated serum level at 20 ppm (LOAEL) was 87,600 ng/ml (Qazi et al., 2010)	Effects at 200 ppm may be secondary to decreased food consumption. Food consumption not decreased at LOAEL of 20 ppm. ↑ relative liver weight at NOAEL for immune effects of 10 ppm.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 259 of 551

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 260 of 551

Citation	Species & Strain	Lifestage for Dosing	Dose(s) (mg/kg/day)	Dosing Duration	Endpoint(s)*	NOAEL** (mg/kg/day)	LOAEL** (mg/kg/day)	PFOA Serum Concentration (ng/ml)	Comments
Qazi et al. (2013)	Male C57BL/6 (H-2) ^b mice	Adult	0.5 or 20 ppm in diet 0.07 or 3 mg/kg/day	10 days (high dose) 28 days (low dose)	 ↑ Concavalin A- induced liver damage. Changes in cytokine levels (both with and without response to Con A). 	0.07 mg/kg/day (0.5 ppm) for 28 days	3 mg/kg/day (20 ppm) for 10 days	Estimated serum level at 20 ppm (LOAEL) was 87,600 ng/ml (Qazi et al., 2010)	
Son et al. (2009)	Male ICR mice	Adult	0.49, 2.64, 17.63, 47.21 mg/kg/day	21 days	↓ numbers of splenic T cell subpopulations (CD4-CD8+, CD4+CD8+).		0.49 mg/kg/day		These T cell subpopulations were not evaluated in other studies of PFOA. ↑ liver weight at LOAEL for immune effects in this study, as reported in accompanying paper (Son et al., 2008)
Yang et al. (2000)	Male C57BL/6 mice	Adult	200 ppm in diet	Up to 10 days	 ↓ absolute and relative thymus and spleen weight beginning at 5 days. ↓ thymocyte and splenocyte numbers, selective ↓ in immature thymocyte subpopulations, ↓ T and B cells in spleen, ↓ numbers of splenic T cell subpopulations (CD4 +, D4+CD8+), inhibition of thymocyte proliferation at 7 days (other time points not evaluated). 		200 ppm in diet Estimated as <30 mg/kg/day from Qazi et al. (2013	Estimated serum level at 200 ppm (LOAEL) was 152,000 ng/ml (Qazi et al., 2009b)	Relative liver weight also ↑ at LOAEL.

Citation	Species & Strain	Lifestage for Dosing	Dose(s) (mg/kg/day)	Dosing Duration	Endpoint(s)*	NOAEL** (mg/kg/day)	LOAEL** (mg/kg/day)	PFOA Serum Concentration (ng/ml)	Comments
Yang et al. (2002a)	Male C57BL/6 mice	Adult	200 ppm in diet	10 or 16 days	↓ IgM and IgG response to horse red blood cell (HRBC) immunization.		200 ppm in diet Estimated as <30 mg/kg/day from Qazi et al. (2013)	Estimated serum level at 200 ppm (LOAEL) was 152,000 ng/ml (Qazi et al., 2009b)	
Yang et al. (2002b)	Male C57BL/6 mice (wild type) Male Sv/129 PPAR- alpha null mice	Adult	200 ppm in diet	7 days	$C57BL/6$ wild type: \downarrow spleen and thymusweight. \downarrow # of splenocytes andthymocytes. \downarrow CD4+CD8+thymocytes. \downarrow T and B cells inspleen. \downarrow % of proliferatingthymocytes. \downarrow proliferation ofsplenocytes ex vivo inresponse toproliferativestimulation. $Sv/129$ PPAR-alphanull: \downarrow thymus weight andnumber of thymocytes(attenuated). \downarrow CD4+CD8+thymocytes(attenuated). \downarrow % of proliferatingthymocytes(attenuated).		200 ppm in diet Estimated as <30 mg/kg/day from Qazi et al. (2013)		Comparison of wild type versus PPAR-alpha null mice was between two different strains. Strain differences unrelated to PPAR-alpha status may have affected the results. Similar increase in relative liver weight occurred in both wild type C57BL/6 and Sv/129 PPAR-alpha null mice. Peroxisome proliferation only increased in wild type mice. Effects of PFOA on thymus occurred in PPAR-alpha null mice, to a lesser degree than in wild type mice. WY also caused these effects in PPAR-alpha null mice. Effects of PFOA on spleen seen in wild type mice did not occur in PPAR-alpha null mice.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 261 of 551

	Citation and	Study Design		Maternal/ Reproductive Effects			Effects in Offsp Fetal through We			Effects in Off Post-wear		g:	Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
Abbott et al. (2007)	129S1/SvlmJ wild type	0, 0.1, 0.3, 0.6, 1, 5, 10, or 20 Gavage	GD 1-17	 Maternal weight gain % FLR Implants/litter % litter loss (includes FLR) Pups/litter (live + dead; excludes FLR) ↑ relative liver weight on PND 22. 	10 1 20 0.3 1 0.6	 5 0.6 	 Body weight at birth Eye opening delay Postnatal mortality Neonatal growth ↑ relative liver weight on PND 22. 	1 0.6 0.3 0.6 	 1 0.6 1 0.1	• Body weight at week 28 (M) & week 52 (F)	1		 No wild type live pups at ≥ 5 mg/kg/day. FLR is PPAR-alpha independent. ↑ pup liver weight is most sensitive endpoint i both strains.
	129S1/SvlmJ PPAR-α null	0, 0.1, 0.3, 1, 3, 5, 10, or 20 Gavage	GD 1-17	 Maternal weight gain % FLR Implants/litter % litter loss (includes FLR) Pups/litter (live + dead; excludes FLR) ↑ relative liver weight on PND 22. 	20 3 20 3 1	 5 3	 Body weight at birth Eye opening Postnatal mortality Neonatal growth ↑ relative liver weight on PND 22. 	20 3 3 1		• Body weight at week 28 (M) & week 52 (F)	3		

	Citation	and Study Desig	n	Maternal/Reproductive Effe	ects		Effects in Offspring: Fetal through Weaning (includi body weight and malformati		tal	Effects in Post-	ı Offsp weanii		Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
Albrecht	Sv/129	0 or 3	GD 1-17	Maternal weight gain	3		• Body weight and crown-to-rump	3		NA	NA	NA	Issues related to this study are
et al.	wild-			Day of parturition	3		length on GD 18						discussed in text and individual
(2013)	type	Gavage		• Implants/litter	3		Postnatal mortality	3					study table in Appendix 5.
				• % litter loss	3		Postnatal growth	3					 No significant effect for any
				• Live fetuses/litter	3		• Eye opening	3					developmental endpoint in any
				Male/female ratio	3		 ↑ relative liver weight on GD 		3				strain. Not consistent with effects
				 ↑ relative liver weight on GD 18 		3	18						reported in Abbott et al. (2007).
				 ↑ relative liver weight on PND 		3	 ↑ relative liver weight on PND 		3				• ↑ maternal and pup liver weight
				20			20						is the most sensitive endpoint in all
							• MG on PND 20	3					strains.
	Sv/129			 Maternal weight gain 	3		• Body weight & crown-to-rump	3		NA	NA	NA	
	PPAR-			• Day of parturition	3		length on GD 18						
	alpha			• Implants/litter	3		Postnatal mortality	3					
	null			• % litter loss	3		Postnatal growth	3					
				• Live fetuses/litter	3		• Eye opening delay	3					
				Male/female ratio	3		 ↑ relative liver weight on GD 	3					
				 ↑ relative liver weight on GD 18 		3	18						
				• ↑ relative liver weight on PND	3		• ↑ relative liver weight on PND	3					
				20			20 • MG on PND 20	3					
	Sv/129	-		Maternal weight gain	3		• Body weight & crown-to-rump	3		NA	NA	NA	
	Human-			Day of parturition	3		length on GD 18	5		1 17 1	1 1 1 1	1 12 1	
	ized			• Implants/litter	3		Postnatal mortality	3					
	PPAR-			• % litter loss	3		Postnatal growth	3					
	alpha			• Live fetuses/litter	3		• Eye opening	3					
	··· ·r ····			Male/female ratio		3	J r0	-	1				
				• ↑ relative liver weight on GD 18		3	• ↑ relative liver weight on GD		3				
							18		1				
				• ↑ relative liver weight on PND	3		• ↑ relative liver weight on PND	3					
				20			20		1				
							• MG on PND 20	3					

MG - delayed mammary gland development.

		d Study Design		Maternal/Reprod Effects	Effects in Offs Fetal through V (including fetal bo and malforms	Veani ody we	ng eight	Effects in Offsp Post-weanin		Comments			
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
Fenton et al. (2009)	CD-1	0, 0.1, 1, or 5 Gavage	GD 17 Single dose	 Body weight on GD 17 and 18, and PND 1 -18 ↑ relative liver weight on GD 18, PND 1,4, 8, 18 	5 5		Offspring body weight on GD 18 and PND 1-18	5		NA	NA	NA	• This was primarily a pharmacokinetic study and used a single dose.
Hines et al. (2009)	CD-1	0, 0.01, 0.1, 0.3, 1, 3 or 5	GD 1-17	• Live pups/litter	NA 5	NA 	↓ Body weight at PND 1 •↓ Body weight at PND 22	1 0.3	5	 ↑ Body weight at 20- 29 wks*** ↓ Body weight at 20- 29 wks ↑ insulin & leptin at 21-33 wks*** (Only females evaluated) 	1	0.01 5 0.01	 Effects at 20-29 weeks on body weight (0.01-0.3 mg/kg/day) and hormones (0.01-0.1 mg/kg/day) occurred at low doses but not higher doses. Mortality occurred in all groups including controls after 36 weeks. Effects at 18 months are not in this table.
Hu et al. (2010)	C57BL/6N	0, 0.5, 1 Drinking water	GD 6-17	 Maternal body weight M/F ratio 	1		 ↓ Body weight at PND 2 ↓ Body weight at PND 7 & 14 ↑ relative liver weight on GD 18 	 0.5 1	0.5 1 	 IgM on PND 48 IgG on PND 63 Spleen, adrenal, thymus weight, PND 48 & 63 ↑ relative liver weight on PND 48 & 63 	1 1 1	 	See also summary table of studies of immune effects (Table 11).
Hu et al. (2012)	C57BL/6N	0.02, 0.2 or 2 Gavage	Pre-mating – PND 21; (mean 12.9 days pre- pregnancy)	 Maternal body weight (through weaning) Pups/litter M/F ratio 	2 2 2	 	•↓Body weight at PND 1 - 21	0.2	2	 Body weight at 6 weeks. ↓ T cells in spleen at ~ 6 wks (Only females evaluated). 	2 0.2	2	• <i>Ex vivo</i> and inconsistent <i>in vivo</i> immune effects observed at 0.02 mg/kg/day; see summary table for immune effects (Table 11).

•

	Citation	and Study Desig	1	Mater Reprodu Effec	ictive		Effects in Offspring Weaning (including weight)			Effects in Offs Post-weani			Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
Lau et al. (2006)	CD-1	0, 1, 3, 5, 10, 20, or 40 Gavage	GD 1-17 (sacrificed GD 18) GD 1-18 (allowed to deliver)	 ↓ Maternal weight gain FLR # of implants Live fetuses/litter Prenatal loss/live litter ↑ relative liver weight on GD 18 	10 3 10 10 	20 5 40 20 20 1	 ↓ fetal body weight ↑ reduced ossification (several sites) ↑ Limb & tail defects ↑ Micro-cardia ↑Postnatal mortality ↓ Postnatal growth Delayed eye opening 	10 3 10 3 1 3	20 1 ^{<i>a</i>} 5 ^{<i>a</i>} 10 5 3 5	 ↓ body weight in males at 6.5 weeks (p<0.05 for treatment effect) Delay in vaginal opening. Delay in first estrus. Accelerated preputial separation. 	Not sta- ted 20 3 	Not sta- ted 10 5 <i>1^a</i>	 Reduced ossification and increased limb defects did not increase as dose increased. These effects were not significant at one or more doses above the LOAEL. Accelerated preputial separation was not observed at 20 mg/kg/day. Body weight in treated animals tended to be higher than in controls as animals aged (until age 60 wks). Maternal serum levels on GD 18 shown graphically. This study is also summarized in liver weight tables (Table 10).
Macon et al. (2011)	CD-1	0, 0.3, 1, or 3 Gavage 0, 0.01, 0.1, or 1 Gavage	GD 1-17 GD 10-17	NA	NA	NA	 Body weight PND 7-21 ↑ relative liver weight on PND 7 MG at PND 14 & 21^a Body weight at birth (females) Body weight on PND 1-21 ↑ relative liver 	3 1 1 0.1	 0.3ª 0.3	Body weight on PND 42-84 MG at PND 42 & 84 ^a NA	3 NA	 <i>0.3</i> NA	 LOAELs for ↑ pup liver weight were higher at later pre-weaning and post-weaning time points. LOAEL for MG was higher at PND 7. MG was not significant at 3 mg/kg/day on PND 63 and 84, possibly due to small n (n=2) Pup serum levels measured on PND 1 (end of dosing). Increased relative liver weight not significant on PND 1 and 21. Delayed mammary gland
							 Tretative river weight on PND 4, 7, 14^a MG at PND 21 	0.1	ı 0.01				• Delayed mammary gland development more sensitive endpoint than increased relative liver weight in offspring.

		l Study Design		Maternal/Repro Effects			Offspr W (inclue) body	ffects i ring th Veanin uding weight ormati	rough g fetal t and	Effects in Offspring: Post-weaning			Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
Suh et al. (2011)	CD-1	0, 2, 10 or 25 Gavage	GD 11- 16	 ↓ Maternal body weight on GD 13- 16 <i>Endpoints assessed on GD 16.</i> ↓ placenta weight Necrotic changes in placenta^a ↓ levels of gene expression for three placental lactogens (PRL family) and two pituitary-specific positive transcription factor 1 isoforms. ↓ # of placental trophoblast cells ↓ fetal weight ↓ fetal/ placental weight ratio # of implantations ↑ # of resorptions/dead fetus ↓ # of live fetus 	10 ^a 2 10 2 25 2	25 ^a 2 10 2 2 10 2 2 10 2 10	NA	NA	NA	NA	NA	NA	 Doses at which maternal body weight ↓ are not stated, although significance for trend is shown on various GDs. NOAEL & LOAEL in this table is based on graph of data. Effects on placenta and production of placental factors may contribute to decreased fetal growth. Fetal/placental ratio indicates efficiency of placenta. Levels of placental lactogens significantly correlate with fetal weight on individual basis. Statistical evaluation for necrotic changes in placenta is not provided; doses where this effect occurred are discussed in text. NOAELs for potentially important placental effects not identified.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 267 of 551

	Citation and	d Study Design		Repr	ternal/ oducti [.] ffects		Effects in Offspring through Wea (including fetal body weight an malformations)			Effects in Offspring: Post-weaning			Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
Tucker et al. (2015)	CD-1	0, 0.01, 0.1, 0.3, 1 Gavage	GD 1-17	NA	NA	NA	 ↓ body weight on PND 21 ↓ body weight minus liver weight on PND 21 Estrogen & progesterone, PND 21 ↑ relative liver weight, PND 21 • MG at PND 21 	1 0.3 1 0.3 0.01	 1 1 0.1	 Body weight & body weight minus liver weight on PND 35 & 56 Day of vaginal opening Day of first estrus Estrogen & progesterone on PND 35 & 56 ↑ relative liver weight, PND 35 & 56 MG at PND 35 & 56 	1 1 1 1 1	 0.01	PFOA serum data provided from PND 21 and later time points. Higher serum levels at same PFOA dose in CD-1 mice than C57Bl/6 mice may contribute to the
	C57Bl/6	_					 ↓ body weight on PND 21 ↓ body weight minus liver weight on PND 21 Estrogen & progesterone on PND 21 ↑ relative liver weight, PND 21 MG at PND 21 	1 1 1 1 0.1	 0.3	 Body weight & body weight minus liver weight on PND 61 Day of vaginal opening Day of first estrus Estrogen & progesterone, PND 61 ↑ relative liver weight on PND 61 MG at PND 61 	1 1 1 1 1 0.1	 0.3	greater sensitivity of CD-1.

	Citation and	l Study Design		Materna Reproduct Effects			Effects in Offspring t (including fetal bo malforma	dy weigl		Effects in Off Post-wean			Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect ^a	NOAEL	LOAEL	
van Esterik et al. (2016)	C57Bl/6J	0, 003, 0,01, 0.1, 0.3, 1, or 3 mg/kg/day Dietary	2 weeks before mating through weaning	 Maternal weight gain ↓ litter size Male/female ratio 	3 ^a 0.3 ^a 3 ^a	 1ª 	 ↓ Body weight on PND 4 Neonatal survival 	 3ª	0.003 ^a				 Exposure regimen differed from other studies. Exposure began before mating and continued through lactation. Data presented as BMD and BMDL for each endpoint. NOAELs and LOAELs in table are based on interpretation of graphs and/or discussion in text; statistical significance is not presented. Personal communication with authors indicates that study was not intended to identify LOAELs and NOAELs. Data for some endpoints (e.g. relative liver weight) not presented in usable form. The LOAEL for decreased neonatal body weight appears to be much lower than in other studies. As above, personal communication with authors indicates that study was not intended to identify LOAELs and NOAELs. Text states that body weight decrements persisted through lactation and until wk. 21. Doses at which this occurred not stated. Later in life studies relate to mode of action and effects with high fat versus control diet.

	Citation	and Study Desig	1	Repr	ternal/ oductive ffects		Effects in Offsprin fetal body w	ng through Wean eight and malfor			s in Offspring: st-weaning		Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
White et al. (2007)	CD-1	0 or 5 Gavage	GD 1-17, GD 8-17, GD 12-17 Restricted exposure study****	 ↓ Maternal weight gain, GD 18 # of implants Live fetuses/litter % prenatal loss/live litter 	GD 1-17 GD 1-17 GD 1-17 GD 8-17	 GD 1- 17	 ↓ Body weight on PND 1, 5, 10, 20 • MG on PND 21 		GD 12-17 GD 12-17	NA	NA	NA	
White et al. (2009)	CD-1	0 or 5 Gavage	GD 8-17 Cross- foster study*****	 ↑ Maternal weight gain (GD 8-17) Litter size ↑ relative liver weight, PND 1, 3, 5, 10 	 5 0 dam, 5U pups	5 5 dam, control pups	 ↓ Body weight on PND 1, 3 ↓ Body weight on PND 10, 20 ↑ relative liver weight, PND 1, 3 ↑ relative liver weight, PND 5, 10 MG, PND 1, 3, 5, 10 	5L, 5U 5L 	5U+L 5L, 5U 5U 5L, 5U 5L, 5U	NA	NA	NA	
White et al. (2009); Wolf et al. (2007)	CD-1	0, 3, or 5 Gavage	GD 1-17 Cross- foster study*****	↑ Maternal wt. gain, GD 17 • FLR • # of implants • Live fetuses/litter • Prenatal loss/live litter • ↑ relative liver wt., PND 22 • MG at PND 22	 3 5 5 5 5 5 5 3L	3 5 3 3U	 ↓ Body weight at birth ↓ Body weight on PND 22 (males) ↓ Body weight on PND 22 (females) Delayed eye opening ↓ survival to PND 22 ↑ relative liver weight, PND 22 MG at PND 22 	3 3U, 5L 3U, 3L 3U, 5L 3U+L, 5U, 5L 3L	5 3U+L, 5U 3U+L, 5U, 5L 3U+L, 5U 5U+L 3L, 3U 3U	 ↓ Body weight until PND 36 (M) ↓ Body weight until PND 85 (F) • MG at PND 42, 63 	3U+L, 5U, 5L 3U+L, 5L 	5U+L 5U 3L, 3U	Body weight of male 3U group was increased from PND 85 (week 12) to week 35.

U = exposure in utero only; L = exposure through lactation only; U + L = exposure both in utero and through lactation.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 270 of 551

	Citation	and Study Design	1	Rep	aternal/ roductive Effects		Fetal through Weaning (in	n Offspring: ncluding fetal body prmations)	y weight and		in Offsprir -weaning	ıg:	Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
Wolf et al. (2007) (See White et al., 2009 for additional study from this public- ation)	CD-1	0 5; GD 15-17, 13-17, 10-17, or 7-17. 20; GD 15-17 (Post-natal endpoints were not assessed at this dose due to decreased post- natal survival.) Gavage	GD 15-17, GD 13-17, GD 10-17, GD 7-17 <i>Restricted</i> <i>exposure</i> <i>study****</i>	 ↑ Maternal weight gain # of implants • Pups/ litter • % prenatal loss 	5, GD 10-17 5, GD 7-17 5, GD 7-17 5, GD 7-17	5, GD 13-17 	 ↓ Body weight at birth (males) ↓ Body weight at birth (females) ↓ survival until PND 22 Delayed eye opening ↓ Body weight at PND 22 	5, GD 13-17 20,GD 15-17; 5, GD 7-17 5, GD 7-17 5, GD 13-17 	20, GD 15-17; 5, GD 10-17 20,GD 15-17 5, GD 10-17 5, GD 15-17	•↓ Body weight until age 10-11 weeks (males)	5, GD 13-17	5, GD 10 -17	Body weight of 5 mg/kg/day females exposed on GD 13-17 was increased above controls after PND 161 (week 23).
White, et al. (2011b)	CD-1	0, 1 or 5 (gavage) 0 or 1 (gavage) plus 5 ppb (5000 ng/L) in drinking water	GD 1-17 (P0) for gavage exposures. GD 1 (P0) – PND 63 (F2) for drinking water exposures <i>Multi-</i> <i>generation</i> <i>study.</i> (See <i>comments.</i>)	 ↓ Maternal weight gain Implants/ litter Live fetus/litter Prenatal loss 	5 5 1 1	5 5 5	 ↓ Body weight at PND 22 ↓ Survival until PND 22 ↑ relative liver weight, PND 22 • MG at PND 22 	5	 5 1 (not significant at 1 + 5 ppb in drinking water) 5 ppb in drinking water; 1 mg/kg/day	 ↓ Body weight at PND 42 ↓ Body weight at PND 63 ↑ relative liver weight, PND 42 • MG at PND 42, 63 	1 5 1 	5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Only effects for P0 dams and F1 offspring presented here. See Table 14 and individual study table in Appendix 5 for additional information on this study.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 271 of 551

		Citation and Stu	dy Design	Matern: Reproduc Effect:	tive		Effects in Offspring: Fetal through Weaning (including fet and malformations)	al body	weight	Effects in Post-	ı Offspi weaning		Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
Yahia et al. (2010)	ICR	0, 1, 5, 10 Gavage	GD 0-17 (assessed on GD 18) GD 0-18 (postnatal assessment)	 ↓ Maternal weight gain ↑ Relative kidney weight ↓ absolute brain weight ↑ serum liver enzymes. ↓ serum lipids ↑ relative liver weight, PND 22. 	1 	5 1 10 10 10 1	 ↓ fetal GD 18 body weight & birth weight ↓ survival until PND 4 ↑ cleft sternum, delayed ossification of phalanges, delayed incisor eruption 	1 1 5	5 5 5 10	NA	NA	NA	NOAEL for delayed ossification is higher than LOAEL (1 mg/kg/day) for this effect in Lau et al. (2006). All pups died by PND 4 at LOAEL for delayed ossification (10 mg/kg/day).

* General notes:

NOAEL is defined as the highest dose that did not produce a statistically significant effect ($p \le 0.05$) compared to control. LOAEL is defined as the lowest dose with statistically significant effects observed ($p \le 0.05$) compared to control. For some studies, there were dose-related trends that included non-statistically significant changes at lower doses.

- In some studies, not all dose groups were evaluated for some endpoints. For some studies, not all endpoints evaluated are listed.
- Several studies that focused on other specific endpoints also evaluated reproductive and/or developmental endpoints but did not present data for these endpoints in usable form, or did not provide statistical significance. These studies are mentioned in the text but are not included in this table.
- Serum data are useful for dose-response modeling only when measured at end of dosing period. Serum data in many studies were from later time points; these data provide useful pharmacokinetic information but are not appropriate for dose-response modeling.

** See Table 14 and individual study tables in Appendix 5 for more details on studies in which mammary gland development was evaluated.

*** Effect occurred at low, but not high, doses.

**** In **restricted exposure studies**, gestational exposure was to the same dose for varying periods of time. In determining LOAELs and NOAELs, shorter time periods of dosing were considered to have been lower exposures than longer time periods of dosing.

***** In cross foster studies, pups were exposed *in utero* (U), through lactation (L), or both (U+L). In determining LOAELs and NOAELs, all groups to exposed lower doses (L, U, or U+L) were considered to have had lower exposure than those with higher doses. Within the same dosage level (mg/kg/day), L and U groups were considered to have had lower exposure than U+L groups.

FLR - full litter resorptions. MG - Delayed mammary gland development. NA - not assessed.

Table 13. I	Identification	of most sens	sitive endpoin	ts in mouse	developmental	studies of PFOA*
-------------	----------------	--------------	----------------	-------------	---------------	------------------

	Citation and	Study Design		Most Sensitive Reproductive/Developmental		
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Endpoint(s) (other than increased relative liver weight or delayed mammary gland development)	Delayed Mammary Gland Development	Increased Relative Liver Weight
Abbott et al. (2007)	129S1/SvlmJ wildtype	0, 0.1, 0.3, 0.6, 1, 5, 10, or 20	GD 1-17	% litter loss (includes full litter resorption); postnatal mortality NOAEL – 0.3	NA	Pup, PND 22 NOAEL-ND
		Gavage		LOAEL – 0.6		LOAEL-0.1
	129S1/SvlmJ PPAR-alpha null	0, 0.1, 0.3, 1, 3, 5, 10, or 20	GD 1-17	% full litter resorptions; % litter loss (includes full litter resorption)	NA	Maternal and pup, PND 22
		Gavage		NOAEL – 3		NOAEL - 1
				LOAEL – 5		LOAEL - 3
Albrecht et al. (2013)	Sv/129 wild-type	0 or 3 Gavage	GD 1-17	All effects:		Maternal and offspring, GD 18 and PND 20
				NOAEL – 3	NOAEL – 3	NOAEL – ND
				LOAEL - ND	LOAEL - ND	LOAEL - 3
	Sv/129 PPAR-alpha null			All effects		Maternal, GD18, offspring GD 18 and PND 20
				NOAEL – 3	NOAEL – 3	NOAEL – ND
				LOAEL - ND	LOAEL - ND	LOAEL - 3
	Sv/129 humanized PPAR-alpha			Male/female offspring ratio	NOAEL – 3 LOAEL - ND	Maternal andoffspring, GD 18
				NOAEL – ND		NOAEL – ND
				LOAEL - 3		LOAEL - 3
Hines et al. (2009)	CD-1	0, 0.01, 0.1, 0.3, 1, 3 or 5	GD 1-17	Increased body weight, insulin & leptin in female offspring at weeks 20-29	NA	NA
		Gavage		NOAEL – ND		
				LOAEL - 0.01		
				(No effects at some higher doses)		
Hu et al. (2010)	C57BL/6N	0, 0.5, 1 Drinking	GD 6-17	Decreased offspring body weight at PND 2	NA	Offspring, PND 48 and 63
		water		NOAEL – ND		NOAEL – 1
				<i>LOAEL</i> – 0.5		LOAEL – ND (not evaluated at earlier times)
Hu et al. (2012)	C57BL/6N	0.02, 0.2 or 2 Gavage	Pre-mating – PND 21	↓ Body weight at PND $1 - 21$; ↓ T cells in spleen at ~ 6 wks	NA	NA
				<i>NOAEL – 0.2</i>		
				LOAEL – 2		

	Citation a	nd Study Design		Most Sensitive		
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Reproductive/Developmental Endpoint(s) (other than increased relative liver weight or delayed mammary gland development)	Delayed Mammary Gland Development	Increased Relative Liver Weight
Lau et al. (2006)	CD-1	0, 1, 3, 5, 10, 20, or 40 Gavage	GD 1-17 or GD 1-18	Reduced ossification (not significant at some doses >LOAEL); accelerated preputial separation (did not occur at 20 mg/kg/day)	NA	Maternal, GD 18
				NOAEL – ND LOAEL – 1		NOAEL – ND LOAEL – 1
Macon et al. (2011)	CD-1	0, 0.3, 1, or 3	GD 1-17	Offspring body weight, PND 7- 84		Offspring, PND 7
		Gavage		NOAEL – 3 LOAEL - ND	NOAEL – ND LOAEL – 0.3	NOAEL – ND LOAEL – 0.3
		0, 0.01, 0.1, or 1	GD 10-17	Body weight, birth – PND 21	Offspring, PND 21	Offspring, PND 4,7, 14
		Gavage		NOAEL – 1 LOAEL – ND	NOAEL – ND LOAEL – 0.01	NOAEL – 0.1 LOAEL – 1
Suh et al. (2011)	CD-1	0, 2, 10 or 25 Gavage	GD 11-16	Decreased placenta weight; decreased gene expression for placental factors; decreased fetal/ placental weight ratio; increased number of resorptions/dead fetuses	NA	NA
				NOAEL – ND LOAEL – 2		
Tucker et al. (2015)	CD-1	0, 0.01, 0.1, 0.3, 1	GD 1-17	Decreased body weight minus liver weight, PND 21	Offspring, PND 35 and 56	Offspring, PND 21
		Gavage		NOAEL – 0.3 LOAEL – 1	NOAEL – ND LOAEL – 0.01	NOAEL – 0.3 LOAEL – 1
	C57Bl/6			All effects evaluated:	Offspring, PND 61	Offspring, PND 21 and 61
				NOAEL – 1 LOAEL – ND	NOAEL - 0.1 LOAEL - 0.3	NOAEL – 1 LOAEL – ND
van Esterik et al. (2016)	C57Bl/6 J	0, 003, 0,01, 0.1, 0.3, 1, or 3 mg/kg/day	2 weeks before mating through weaning	Decreased body weight on PND 4 NOAEL – ND	NA	NA
		Dietary	wearing	LOAEL - 0.003		
White et al. (2007)	CD-1	0 or 5 Gavage	GD 1-17, GD 8-17, or GD 12- 17 Restricted exposure study**	% prenatal loss per live litter NOAEL – 5 mg/kg, GD 8-17 LOAEL – 5 mg/kg, GD 1 – 17	Offspring, PND 10, 20 <i>NOAEL – ND</i> <i>LOAEL -</i> <i>5 mg/kg</i> , <i>GD 12-17</i>	NA

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 274 of 551

	Citation a	nd Study Design		Most Sensitive Reproductive/Developmental		
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Endpoint(s) (other than increased relative liver weight or delayed mammary gland development)	Delayed Mammary Gland Development	Increased Relative Liver Weight
White et al. (2009)	CD-1	0 or 5	GD 8-17	Decreased body weight on PND 10, 20	Offspring, PND 1-10	Offspring, PND 5-10
		Gavage	Cross- foster Study***	NOAEL – ND LOAEL – 5L, 5U	NOAEL – ND LOAEL – 5L, 5U	NOAEL – ND LOAEL – 5L, 5U
White et al. (2009); Wolf	CD-1	0, 3, or 5	GD 1-17	Decreased body weight on PND 22	Offspring, PND 42, 63	Offspring, PND 22
et al. (2007)		Gavage	Cross- foster Study***	NOAEL – 3U, 3L LOAEL – 3 U+L, 5L, 5U	NOAEL – ND LOAEL – 3L, 3U	NOAEL – ND LOAEL – 3L, 3U
White, et al. (2011b) Multi- generation study – onlyP0 dam and F1 offspring data shown here	CD-1	0, 1 or 5 (Gavage) 0 or 1 (gavage) with 5 ppb in drinking water	GD 1-17 (P0) for gavage exposures. GD 1 (P0) – PND 63 (F2) for drinking water exposures	Increased prenatal loss; decreased live fetus/litter; decreased body weight on PND 42 NOAEL – 1 LOAEL - 5	NA	Offspring, PND 22 <i>NOAEL-ND</i> <i>LOAEL-1</i> (Not significant at 1 mg/kg/day plus 5 ppb in drinking water)
Wolf et al. (2007) (See White et al., 2009 for other study from this publication)	CD-1	0 5; GD 15-17, 13-17, 10-17, or 7-17. 20; GD 15-17 Gavage	GD 15-17, GD 13-17, GD 10-17, or GD 7-17 <i>Restricted</i> <i>exposure</i> <i>study**</i>	Increased maternal weight gain NOAEL – 5 mg/kg, GD 13-17 LOAEL – 5 mg/kg, GD 15–17	Offspring, PND 10,20 NOAEL – ND LOAEL – GD 15-17	NA
Yahia et al. (2010)	ICR	0, 1, 5, 10 Gavage	GD 0-17 or GD 0-18	Increased maternal relative kidney weight, GD 18	NA	Increased maternal relative liver weight, GD 18
				NOAEL – ND LOAEL - 1		NOAEL – ND LOAEL - 1

* General notes:

- NOAEL is defined as the highest dose that did not produce a statistically significant effect ($p \le 0.05$) compared to control. LOAEL is defined as the lowest dose with statistically significant effects observed ($p \le 0.05$) compared to control. For some studies, there were dose-related trends that included non-statistically significant changes at lower doses.
- In some studies, not all dose groups were evaluated for some endpoints. For some studies, not all endpoints evaluated are listed.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 275 of 551

• Several studies that focused on other specific endpoints also evaluated reproductive and/or developmental endpoints but did not present data for these endpoints in usable form, or did not provide statistical significance. These studies are mentioned in the text but are not included in this table.

** In **restricted exposure studies**, gestational exposure is to the same dose for varying periods of time. In determining LOAELs and NOAELs, shorter time periods of dosing were considered to have been lower exposures than longer time periods of dosing.

*** In **cross foster studies**, pups were exposed *in utero* (U), through lactation (L), or both (U+L). In determining LOAELs and NOAELs, both all groups to exposed lower doses (L, U, U+L) were considered to have had lower exposure than those with higher doses. Within the same dosage level (mg/kg/day), L and U groups were considered to have had lower exposure than U+L groups.

FLR – full litter resorptions

NA - not assessed

ND - not determined

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 276 of 551

Citation	Strain	Lifestage(s) for Dosing	Dose(s) (mg/kg/day)	Dosing Duration	Lifestage for MG Assessment	Timepoint for MG Assessment	Endpoint(s) Assessed	Effect	NOAEL* (mg/kg/day)	LOAEL* (mg/kg/day)	Comments/Other Mammary Gland Effects
Albrecht et al. (2013)	Sv/129 Wild Type (KO), PPAR- alpha null (KO), and humanize d PPAR- alpha (H)	Gestation	0, 3	GD 1-17	Female pups	PND 20	MG whole mounts. # terminal end buds/gland; ductal length	No effect	3		 -This is the only study of MG gland development in this strain. -Other developmental effects seen at similar serum PFOA levels in this strain by Abbott et al. (2007) were not observed in this study. Some control animals had elevated PFOA levels in serum and liver. These issues create uncertainty about the conclusion that PFOA did not affect MG development in this study.
Macon et al. (2011)	CD-1	Gestation	0, 0.3, 1, 3	GD 1-17 "Late Gestation"	Female pups	PND 7, 14, 21, 28, 42, 63, 84	MG whole mounts, scored 1-4.	Delayed development		0.3	 Delays occurred in absence of effects on body weight. Delays persisted until end of study on PND 84 (12 weeks of age)
Macon et al. (2011)	CD-1	Gestation	0, 0.01, 0.1, 1	GD 10-17 "Full Gestation"	Female pups	PND 14, 21	MG whole mounts. PND 14- longitudinal growth, change in long. Growth PND 22 – Score 1-4, longitudinal and later growth, lateral growth, change in long. and lateral growth, # terminal endbuds and terminal ends.	Delayed development		0.01 (Developmental Score, p<0.05)	 Serum levels in offspring on PND 1 are provided and can be used for dose-response modeling. Serum levels are highest on PND 1 (end of dosing period) and decline thereafter. The serum level at the LOAEL (0.01 mg/kg/day) in PND offspring was 285 ng/ml. Liver weight and body weight in the pups were not affected at 0.01 mg/kg/day and higher doses, indicating that MG development is a more sensitive endpoint than decreased body weight or increased liver weight

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 277 of 551

Citation	Strain	Lifestage(s) for Dosing	Dose(s) (mg/kg/day)	Dosing Duration	Lifestage for MG Assessment	Timepoint for MG Assessment	Endpoint(s) Assessed	Effect	NOAEL* (mg/kg/day)	LOAEL* (mg/kg/day)	Comments/Other Mammary Gland Effects
Tucker et al. (2015)	CD-1 C57Bl/6	Gestation	0, 0.01, 0.1, 0.3, 1	GD 1-17	Female pups	CD-1: PND 21, 35, 56 C57BI/6: PND 21, 61	MG whole mounts. Scored 1-4.	Delayed development	(CD-1) 0.1 (C57Bl/6)	0.01 (CD-1) 0.3 (C57Bl/6)	 Delayed MG development occurred in the absence of effects on body wt, liver wt, day of vaginal opening, day of first estrus, or serum estradiol and progesterone in both strains. Serum PFOA levels were first measured on PND 21 (3 weeks after dosing ended) and therefore cannot be used for dose-response modeling. Higher serum levels from same dose in CD-1 mice than C57Bl/6 mice may contribute to the greater sensitivity of CD-1 to effects on MG development.
White et al. (2007)	CD-1	Gestation	0, 5	GD 1-17	Dams	GD 18	MG whole mounts, scored 1-4	Delayed development		5, GD 1-17	
White et al. (2007)	CD-1	Gestation	0, 5	GD 1-17, 8- 17, or 12-17 "Restricted Exposure"	Dams	PND 10 and 20	MG whole mounts, scored 1-4; H&E slides also evaluated.	Delayed development	5 GD 8-17 exposure (PND 10)	5 GD 12-17 exposure (PND 10). All treated groups on PND 20.	 No effect in non-pregnant adult females dosed for 17 days. Expression of milk proteins changed on PND 10 and 20, consistent with delays on PND 20.
					Female Pups		MG whole mounts, scored 1-4	Delayed development		5, GD 8-17 exposure	

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 278 of 551

Citation	Strain	Lifestage(s) for Dosing	Dose(s) (mg/kg/day)	Dosing Duration	Lifestage for MG Assessment	Timepoint for MG Assessment	Endpoint(s) Assessed	Effect	NOAEL* (mg/kg/day)	LOAEL* (mg/kg/day)	Comments/Other Mammary Gland Effects
White et al. (2009)	CD-1	Gestation	0, 5	GD 8-17 (Cross- fostering: exposure during gestation, lactation, or both)	Dams	PND 1,3,5, 10	MG whole mounts, numerical data not shown.	Delayed development		5 In both treated dams nursing treated or untreated pups beginning on PND 1, and untreated dams nursing treated pups beginning on PND 3.	
					Female pups		MG whole mounts, scored 1-4	Delayed development		5 All treated groups beginning on PND 1, including lacation only exposure (serum level ~2000 ng/ml).	
White et al. (2009)	CD-1	Gestation	0, 3, 5	GD 1-17 (Cross- fostering: exposure during gestation and/or lactation)	Female pups	PND 22, 42, 63, and 18 months	MG whole mounts, scored 1-4	Delayed development		3 All treated groups including gestation or lactation only exposure beginning PND 22 and persisting to PND 63.	At 18 months, changes in MG persisted in treated groups (whole mounts and H&E slides) including increased number of darkly staining foci per gland and reduced epithelial density. These effects could not be scored using the criteria that were used at earlier time points.
White et al. (2009)	CD-1	Gestation	0, 5	GD 15-17, 13-17, 10-17, 7-17 "Restricted Exposure"	Female pups	PND 29, 32 and 18 months	MG whole mounts, scored 1-4	Delayed development		5, GD 15-17 exposure.	At 18 months, changes in MG persisted in treated groups (whole mounts and H&E slides) including increased numbers of darkly staining foci per gland in all treated groups. These effects could not be scored

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 279 of 551

Citation	Strain	Lifestage(s) for Dosing	Dose(s) (mg/kg/day)	Dosing Duration	Lifestage for MG Assessment	Timepoint for MG Assessment	Endpoint(s) Assessed	Effect	NOAEL* (mg/kg/day)	LOAEL* (mg/kg/day)	Comments/Other Mammary Gland Effects
											using the criteria used at earlier time points
White et al. (2011b)	CD-1	Gestation and/or postnatal (multi- generation study)	GD 1-17 (0, 1, 5 mg/kg/day) and/or 5 ppb in drinking water (through PND 22 in P0 and F1 dams; through PND 63 in F1 and F2 pups)		P0 Dams	PND 22	MG whole mounts, scored 1-4. H&E slides for some groups.	Delayed development	 (P0 dams)	(exposure P0 GD 1-17) or 5 ppb in drinking water (exposure P0 GDdams and F2 litters on I volume was decreased initiate was increased in groups. However, thes	In lactational challenge test in F1 dams and F2 litters on PND 10, milk volume was decreased and time to initiate was increased in all treated groups. However, these changes were not statistically significant. High
				· ·	F1 Dams	PND 10, 22			 (F1 dams on PND 10).	On PND 10: 1 variability limited power to	variability limited power to detect statistically significant differences.
					F1 Female pups	PND 22,42, 63			 (F1 pups)	1 mg/kg/day (exposure P0 GD 1-17) or 5 ppb in drinking water (exposure P0 GD 7- F1 PND 63). Serum PFOA level in 5 ppb group was 21.3 ng/ml	
					F2 Female pups	PND 10, 22, 42, 63			doses and tim	it effects at most	
									(F2 pups)		

Citation	Strain	Lifestage(s) for Dosing	Dose(s) (mg/kg/day)	Dosing Duration	Lifestage for MG Assessment	Timepoint for MG Assessment	Endpoint(s) Assessed	Effect	NOAEL (mg/kg/da		Comments/Other Mammary Gland Effects
Yang et al. (2009a)	Balb/C C57Bl/6	Peripubertal	0,1,5,10	4 weeks, starting at 3 wks of age.	Peripubertal females	7 weeks of age	MG whole mounts. Ductal length, # terminal end buds, # terminal ducts	Balb/C - Delayed development C57Bl/6 - Stimulated development & totally inhibited development	Balb/C - 1 <i>C57Bl/</i> 6 - 1	Balb/C – 5 C57Bl/6 - Stimulation at 5 Total inhibition at 10	MG cell proliferation measured by BrDu incorporation: - In Balb/C, proliferation of MG cells was inhibited at 1 and 5 mg/kg/day. - In C57BI/6, proliferation of MG cells was stimulated at 1 and 5 mg/kg/day, and totally stopped at 10 mg/kg/day Serum PFOA data provided in Zhao et al. (2012)
Zhao et al. (2010)	C57BI/6 Wild Type Ovariecto - mized (OVX)	Peripubertal. OVX at 3 weeks (before PFOA treatment)	0, 5	4 weeks starting at 4 weeks of age	Peripubertal OVX females	8 weeks of age	MG whole mounts scored based on longitudinal growth, # of terminal end buds, stimulated/ enlarged	Total inhibition of development in both control and PFOA- treated OVX mice	NA	NA	Groups of non-OVX mice were not included in these studies.
	C57Bl/6 PPAR- alpha null (KO)	Peripubertal. OVX at 7 weeks (after PFOA treatment)		4 weeks starting at 3 weeks of age	Peripubertal OVX Females, treated with saline, or progesterone and/or estradiol after OVX	9 weeks of age	terminal ducts. Numerical data not shown.	In mice treated with hormones, stimulation of development by PFOA compared to controls (no PFOA).	NA	NA	
		Peripubertal		4 weeks, starting at 3 wks of age.	Peripubertal females	7 weeks of age		Stimulated development		5	C57BI/6 WT were not included in this study. Serum PFOA data provided in Zhao e al. (2012)

Citation	Strain	Lifestage(s) for Dosing	Dose(s) (mg/kg/day)	Dosing Duration	Lifestage for MG Assessment	Timepoint for MG Assessment	Endpoint(s) Assessed	Effect	NOAEL (mg/kg/da		Comments/Other Mammary Gland Effects
Zhao et al. (2012)	Balb/C C57Bl/6 (WT) C57Bl/6 PPAR- alpha null (KO)	Peripubertal	Balb/C: 0, 2.5 C57Bl/6 WT and KO: 0, 7.5	4 weeks, starting at 3 wks of age.	Peripubertal females	7 weeks of age	MG whole mounts. Ductal length, # terminal end buds, # terminal ducts	Balb/C – Delayed development C57Bl/6 WT – Delayed development KO – no effect	Balb/C & C57Bl/6 WT – C57Bl/6 KO - 7.5	Balb/C – 2.5 C57BI/6 WT – 7.5 C57BI/6 KO – 	 PFOA doses in all 3 strains of mice in this study are different than those used in earlier studies of these strains (Yang et al., 2009a; Zhao et al., 2010) Doses from the earlier study in each strain were not repeated in this study. Data from different studies may not be directly comparable. Lack of inhibition of MG developmen in KO mice may be due to lower serum PFOA levels rather than PPAR status. Serum PFOA levels for this study and the 2 earlier studies are presented in this study.

MODE OF ACTION

Overview

The mode(s) of action of PFOA are not fully characterized. PFOA structurally resembles a free fatty acid, and it thus may act similarly to a free fatty acid in activating nuclear receptors, binding to transporters and carrier proteins, and interacting with membranes (Butenhoff, 2009). However, it is non-reactive and therefore is not a substrate for biochemical reactions involving fatty acids. It also has been shown to have estrogenic activity and to act through other mechanisms. The mode of action for some of the effects of PFOA is unknown. A summary of information on PFOA's mode of action, with emphasis on potential human relevance, is presented below.

Genotoxicity

Since PFOA is not chemically reactive, it is not metabolized to reactive intermediates and does not covalently bind to nucleic acids and proteins. Therefore, it is considered unlikely to be genotoxic. Information on the genotoxicity of PFOA was reviewed by Butenhoff et al., (2014). PFOA was not mutagenic or genotoxic in most of a series of *in vitro* assays in bacterial and mammalian cells, with or without metabolic activation. It did not cause chromosomal aberrations in Chinese hamster ovary cells at non-cytotoxic concentrations, although some positive results were reported at cytotoxic concentrations. It did not cause chromosomal aberrations in human lymphocytes in whole blood with or without metabolic activation, and it did not transform cells in culture. Although PFOA caused DNA strand breaks and increased the incidence of micronuclei in cultured human hepatoma cells in a dose-related manner (Yao and Zhong, 2005), high doses of PFOA did not induce micronuclei in mice *in vivo*. In male rats, PFOA increased the levels of

8-hydroxydeoxyguanosine in liver DNA, but not in kidney DNA (Takagi et al., 1991). These effects were accompanied by a significant increase in reactive oxygen species, which the investigators suggested caused the DNA damage. In contrast, PFOA increased the formation of reactive oxygen species but was not genotoxic in *in vitro* studies by other investigators.

PPAR-alpha and Other Nuclear Receptors

PFOA activates the nuclear receptor, peroxisome proliferator-activated receptor-alpha (PPAR- alpha) as well as other nuclear receptors including PPAR-gamma, CAR (constitutive activated receptor), PXR (pregnane X receptor) and estrogen receptor-alpha (reviewed by Peters and Gonzalez, 2011). When activated, nuclear receptors bind to DNA and alter the expression of genes that control many biological processes involved in development, homeostasis, and metabolism. PPAR-alpha and other nuclear receptors are found at varying levels in many tissues in rodents, humans, and other species. PPARs affect many biological processes beyond stimulation of peroxisome proliferation in rodents, the effect for which they were originally named. Levels of PPARs may vary during different stages of development, and their role in development is discussed further below.

Much attention has been focused on the role of PPAR-alpha activation in the toxicity of PFOA and on the potential human relevance of effects that occur through activation of this receptor. The major role of PPAR-alpha is regulation of energy homeostasis. Levels of PPAR-alpha are highest in tissues with high rates of catabolism of fatty acids and peroxisomal activity, including liver, brown adipose tissue, heart, kidney, and intestine. Hepatic effects of PPAR-alpha include increased fatty acid oxidation, increased degradation of

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 283 of 551

cholesterol, increased gluconeogenesis, synthesis of ketone bodies, and control of lipoprotein assembly. By increasing oxidation of fatty acids, activation of PPAR-alpha decreases serum triglycerides and serum cholesterol and prevents the accumulation of fat in the liver (Michalik et al., 2006). Consistent with PPAR-alpha's inhibition of hepatic lipid accumulation, PPAR-alpha null mice developed fatty livers, which were more severe with a high fat diet, while fatty liver did not occur in wild type mice on either a regular or high fat diet (Abdelmegeed et al., 2011). In addition to its effects on metabolism, activation of PPAR-alpha also decreases inflammatory response. PPAR-alpha activators such as fibrate drugs are used in humans to decrease serum lipids. The anti-inflammatory effects of these drugs may contribute to their actions in preventing atherosclerosis and reducing the incidence of cardiovascular events (Michalik et al., 2006).

In vitro activation of human and rodent PPAR-alpha by PFOA has been evaluated in several studies of cultured cells transfected with plasmids containing PPAR-alpha from these species. As noted by Vanden Heuvel et al. (2006), these *in vitro* assays measure only the first step in the series of complex steps involved in regulation of gene expression by PPAR-alpha. Therefore, interspecies comparisons based solely on these *in vitro* data may not necessarily be valid.

Relative sensitivities of human and rodent PPAR-alpha to PFOA differed among these studies, and the results do not clearly indicate that human PPAR-alpha is less sensitive than rodent PPAR-alpha in *in vitro* systems. Maloney and Waxman (1999) reported that somewhat higher concentrations of PFOA were needed to cause maximal activation of human PPAR-alpha as compared to mouse PPAR-alpha. In contrast, Vanden Heuvel et al. (2006) found that mouse and human PPAR-alpha were similarly responsive to PFOA, while rat PPAR-alpha was less responsive than mouse or human PPAR-alpha. Two studies from the same laboratory reported differing results on the responsiveness of mouse and human PPAR-alpha to PFOA. In the first study (Wolf et al., 2008), human PPAR-alpha was somewhat less responsive to PFOA than mouse PPAR-alpha. In the second study (Wolf et al., 2012), the dose-response curves for activation by PFOA were identical for mouse and human PPAR-alpha.

Many PPAR-alpha activators (e.g. phthalates, trichloroethylene, and perchloroethylene) cause liver tumors in rodents. The human relevance of these tumors is subject to debate because of the lower levels and/or differences in intrinsic activity of hepatic PPAR-alpha in humans as compared to rodents (NRC, 2006; Corton, 2010). However, the uncertainty about human relevance does not necessarily apply to PPAR-alpha mediated effects other than liver tumors, as illustrated by the use of fibrate drugs to decrease cholesterol and lipids in humans by activation of PPAR-alpha.

Furthermore, as discussed in detail below, effects of PFOA clearly occur through both PPAR-alpha independent and PPAR-alpha dependent processes. Therefore, conclusions from studies with pure PPAR-alpha activators such as Wyeth 14,643 (WY) cannot necessarily be extrapolated to PFOA.

Hepatic Toxicity

As discussed in the <u>Epidemiology</u> section, PFOA is associated with increased serum liver enzymes in human. The studies in non-human primates, standard strains of rats and mice, PPAR-alpha null mice, and humanized PPAR-alpha mice that are summarized below support the conclusion that hepatic effects of PFOA in experimental animals are relevant to humans for the purposes of risk assessment.

Data from non-human primates

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 284 of 551

In the 13-week study in male cynomolgus monkeys (Butenhoff et al., 2002), PFOA increased relative liver weight in a dose-related fashion. Several monkeys that did not complete the study due to overt toxicity exhibited notable increases in liver weight, highly elevated serum liver enzymes, and/or severe hepatic toxicity.

Subcellular biochemical markers were evaluated in the livers of the monkeys that completed the study; animals that had been removed due to toxicity were not included. Hepatic DNA content was decreased by PFOA (statistically significant at highest dose); a marker of peroxisome proliferation (palmitoyl CoA oxidation; PCO) was increased in a dose-related manner (2.6-fold and statistically significant at highest dose; Figure 12); and the mitochondrial enzyme, succinate dehydrogenase, was increased although not in a dose related manner (statistically significant at highest dose). Hepatic alkaline phosphatase (a lysosomal marker) and glucose-6-dehyrogenase (a marker for endoplasmic reticulum) were not affected by PFOA treatment.

Although no histopathological changes were reported in the livers of the treated monkeys that completed the study, the authors state that the dose-related decrease in hepatic DNA content is indicative of hepatocellular hypertrophy. The dose-related increase in peroxisome proliferating activity (PCO) was similar in magnitude to the increases reported in PFOA treated rats (below), demonstrating that substantial hepatic PPAR-alpha activity occurs in response to PFOA in non-human primates. The authors also state that the increased succinate dehydrogenase activity suggests mitochondrial proliferation, although this possibility was not evaluated by microscopic studies.

As discussed below, data from rats (Perkins et al., 2004) indicate that the increase in PCO activity in response to PFOA becomes smaller in magnitude with longer exposure duration, while the increase in relative liver weight remains stable over time. Since PCO data are available only from a single time point (13 weeks) in the monkeys, it is unknown whether they represent the maximum PCO activity in response to PFOA. The USEPA SAB (2006) stated: "Because the available data for PFOA in rats and monkeys indicate similar responses in the livers of rodents and primates (increased liver weight and induction of hepatic peroxisomal enzyme activity), about three quarters of the Panel members shared the view that human relevance for liver effects induced by PFOA by a PPARα agonism mode of action cannot be discounted."




Figure 12. Relative liver weight and relative PCO activity (compared to controls) versus serum PFOA concentrations in male cynomolgus monkeys dosed with PFOA for 6 months (Butenhoff et al., 2002).

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 285 of 551


Data from a 90-day study of rhesus monkeys (Goldenthal, 1978) also suggest that PFOA caused increased liver weight, although this effect was not statistically significant likely due to the small number of animals.

Data from standard strains of laboratory rodents

In a standard strain of laboratory rats, PFOA activated PPAR-alpha, as indicated by increased PCO activity, and also activated other nuclear receptors, CAR and PXR, as indicated by induction of specific cytochrome P450 proteins associated with these receptors (Elcombe et al., 2010). Similarly, PFOA treatment increased gene expression for cytochrome P450 proteins associated with each of these three receptors in wild type mice (Cheng and Klaasen, 2008).

Loveless et al. (2006) evaluated the effects of three isomeric forms of PFOA (linear isomers, branched isomers, and mixed linear/branched isomers) on relative liver weight and hepatic PCO activity in standard strains of male rats and mice. As can be seen in Figure 13, increased relative liver weight did not correlate with hepatic peroxisome proliferation, as indicated by PCO activity. In mice, liver weight increased with administered dose and serum PFOA level, but PCO activity was lower at the highest administered doses and serum levels than at lower doses and serum levels. Additionally, in rats (Figure 14), branched isomers of PFOA were more potent in increasing relative liver weight than linear isomers, but were less potent in increasing PCO activity. These results illustrate the involvement of PPAR-alpha independent processes in the increased relative liver weight caused by PFOA even in standard strains of rodents with normal PPAR-alpha function.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 286 of 551







Figure 13. Relative liver weight and relative PCO activity (compared to controls) versus serum PFOA concentrations in male mice dosed with linear/branched, linear, or branched PFOA for 14 days (Loveless et al., 2006). * p < 0.05.



Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 287 of 551





Figure 14. Relative liver weight and relative PCO activity (compared to controls) versus serum PFOA concentrations in male rats dosed with linear/branched, linear, or branched PFOA for 14 days (Loveless et al., 2006). * p < 0.05.

Data from a standard strain of male rats exposed for 4, 7, or 13 weeks (Figure 15) also indicate that PCO activity does not necessarily correlate with the increased liver weight caused by PFOA (Perkins et al., 2004). Although relative PCO activity was much greater at 7 weeks than 4 weeks, and was lower at 13 weeks than at the two earlier time points, the dose-response curve for increased relative liver weight was similar at all three time points.



Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 288 of 551

Figure 15. Relative liver weight and relative PCO activity (compared to controls) versus serum PFOA concentrations in male rats and mice dosed with PFOA for 4, 7, or 13 weeks (Perkins et al., 2004).

A recent study of histopathological change in livers of female CD-1 mouse offspring with developmental exposure to PFOA does not support the involvement of peroxisome proliferation in the observed hepatic toxicity (Quist et al, 2015; described in the <u>Animal Toxicology</u> section). Transmission electron microscope studies of the livers found no evidence that PFOA caused peroxisome proliferation, but rather indicated that it caused mitochondrial proliferation and abnormal mitochondrial morphology.

Activation of PPAR-alpha inhibits accumulation of fat in the liver. In contrast, PFOA increased the accumulation of hepatic triglycerides, cholesterol, and phospholipids in a standard strain of laboratory rats, and the authors noted that these effect are not consistent with the actions of other peroxisome proliferators such as clofibric acid and di(2-ethylhexyl) phthalate (Kawashima et al., 1995). Additionally, PFOA caused a dose-dependent increase in hepatic triglycerides in mice exposed to perilla oil and soybean oil, although there was no effect in mice exposed to fish oil (Kudo and Kawashima, 1997). In more recent studies of standard strains of mice given either afregular or high fat diet, PFOA caused increased triglyceride levels in the liver and decreased relative adipose tissue weight in animals on both diets (Tan et al., 2013; Wang et al., 2013).

Data from wild type mice, PPAR-alpha null mice, and humanized PPAR-alpha mice

Studies comparing wild type and PPAR-alpha null mice clearly demonstrate that PFOA causes PPAR-alpha independent and PPAR-alpha dependent hepatic effects. Yang et al. (2002) reported that liver weight was

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 289 of 551

increased in both wild type and PPAR-alpha null mice treated with PFOA (0.02% in the diet) for 7 days, while peroxisomal acyl CoA oxidase (a marker of peroxisome proliferation) was increased only in wild type mice. In contrast, the model PPAR-alpha activator, WY, increased liver weight and peroxisome proliferating activity in wild type mice but had no effect in PPAR-alpha null mice. Based on this study, which was the only study of PFOA in wild type and PPAR- alpha null mice available at the time, the USEPA Science Advisory Board (2006) concluded that PPAR-alpha independent modes of action may be important in hepatic effects of PFOA in rodents. Numerous studies that have been published subsequent to the USEPA SAB (2006) review confirm this conclusion and provide additional relevant information.

Consistent with Yang et al. (2002), Wolf et al. (2008) also reported that PFOA (0, 1, 3, or 10 mg/kg/day for 7 days) increased liver weight similarly in both PPAR-alpha null mice and wild type mice, while WY increased liver weight only in wild type mice. Cell proliferation and hepatocyte hypertrophy were also increased by PFOA in a dose-related fashion in both wild type and PPAR-alpha null mice. However, the livers of wild type and PPAR-alpha null mice treated with PFOA differed histologically. Increased numbers of peroxisomes were seen in the livers of treated wild type mice, while the livers of PPAR-alpha null mice had no peroxisomes but had numerous vacuoles.

Gene profiling studies in wild type and PPAR-alpha null mice treated with PFOA and WY found that PFOA, but not WY, also activates CAR (constitutive activated/androstane receptor), a receptor that is activated by phenobarbital and other compounds, and possibly PXR (pregnane X receptor). Both compounds caused a similar profile of gene changes in wild type mice, including up-regulation of genes involved with PPAR-alpha activation. However, while there were few gene changes in WY treated PPAR-alpha null mice, gene expression was altered in PFOA-treated PPAR-alpha null mice, including some of the same genes affected by PFOA in the wild type mice (Rosen et al., 2008a). Further study (Rosen et al., 2008b) showed that 85% of the genes altered by PFOA were PPAR-alpha dependent. The PPAR-alpha independent genes included genes involved with lipid homeostasis and xenobiotic metabolism, and many were consistent with activation of CAR.

Additional studies suggest that PPAR-alpha may be protective against some types of hepatic toxicity caused by PFOA. Minata et al. (2010) showed that hepatic or biliary damage occurred in both wild type and PPAR-alpha null mice treated with PFOA, but the profile of toxicity differed greatly between the strains. They investigated the effects of PFOA in wild type and PPAR-alpha null mice given 4.4, 10.8, or 21.6 mg/kg/day for four weeks. Concentrations of PFOA in serum and liver were similar in wild type and PPAR-alpha null mice, but were much lower in bile of PPAR-alpha null mice than wild type mice, indicating a much lower capacity for transport of PFOA to bile in the null strain. Relative liver weights were similarly increased in both wild type and PPAR-alpha null mice at all doses of PFOA, to about three times the control value. Hepatocyte and bile duct injury was assessed by light and electron microscopy, by levels of serum enzymes, bile acids, and bilirubin, and by biochemical markers. Hepatocyte hypertrophy and elevated liver enzymes occurred in both wild type and PPAR-alpha null mice, but bile duct injury was much more severe in PPAR-alpha null mice. PFOA increased the levels of two inflammatory cytokines associated with liver injury in PPAR-alpha null, but not wild type, mice. The authors concluded that PPAR-alpha protects against cholestasis and bile duct injury caused by PFOA in mice.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 290 of 551

Finally, the hepatic effects of developmental PFOA exposure in 18-month old offspring of gestationally exposed dams were studied in CD-1, wild type, and PPAR-alpha null mice (Filgo et al., 2015). At this time point long after PFOA has been eliminated from the body, the incidence and/or severity of hepatocellular hypertrophy was increased by prenatal and early life exposure to PFOA in all three strains of mice, and this effect was more pronounced in PPAR-alpha null than wild type mice. Additionally, consistent with Minata et al. (2010), PFOA caused a dose-dependent increase in incidence and severity of bile duct toxicity in PPAR-alpha null, but not wild type, mice. Additional findings from this study related to carcinogenicity of PFOA are discussed below.

Three additional studies evaluated hepatic effects of PFOA in wild type, PPAR-alpha null, and humanized PPAR-alpha (having hepatic expression of human PPAR-alpha) mice of a Sv/129 genetic background (Nakamura et al., 2010; Nagakawa et al., 2011; Albrecht et al., 2013). PFOA caused hepatic toxicity in all three of these mouse strains, including in fetal liver. It should be noted that differences in response in humanized mice are not necessarily indicative of a different response of human PPAR-alpha to PFOA, for reasonse that may include species differences in binding of PFOA to recognition sites on mouse DNA (cognate DNA). PFOA concentrations in liver and serum were measured in only one of these three studies (Albrecht et al., 2013).

Hepatic effects were studied in male wild type, PPAR-alpha null, and humanized PPAR-alpha mice treated with 0, 0.1, or 0.3 mg/kg/day PFOA for two weeks (Nakamura et al., 2009). Relative liver weight was not affected at 0.1 mg/kg/day in any strain and was increased at 0.3 mg/kg/day only in wild type mice. Expression (mRNA and protein levels) of five genes that are targets of PPAR-alpha was measured in the three strains. Expression of four of these genes was significantly increased only in the wild type mice, while expression of the fifth gene was significantly increased only in the humanized PPAR-alpha mice. None of the PPAR-alpha target genes were affected by PFOA in the PPAR-alpha null mice. Histopathological examination showed mild hepatocellular hypertrophy in both wild type and humanized PPAR-alpha mice. Cytoplasmic vacuoles indicating lipid accumulation were observed in PPAR-alpha null mice, consistent with those described in this strain by Wolf et al. (2008).

Interpretation of these results is complicated by the fact that PFOA levels in serum and liver were not measured in this study and may vary between strains. Relative liver weight was increased at 0.3 mg/kg/day in wild type mice, but was not increased at this dose in the other two strains. However, there was no effect in wild type mice at 0.1 mg/kg/day, indicating that 0.3 mg/kg/day is relatively close to the NOAEL in this strain. In the absence of serum and liver PFOA data, it is not known whether the increased liver weight observed at 0.3 mg/kg/day in wild type, but not PPAR-alpha null or humanized PPAR-alpha, strains is due to an intrinsic difference in sensitivity or to toxicokinetic differences.

Hepatic effects were also evaluated in male wild type, PPAR-alpha null and humanized PPAR-alpha mice treated with 0, 1, or 5 mg/kg/day for six weeks (Nagakawa et al., 2011). The results of this study do not support the conclusion that rodent PPAR-alpha is required for the hepatic toxicity of PFOA. Hepatocyte hypertrophy occurred in both strains with PPAR-alpha activity (wild type and humanized), and activity of the liver enzyme ALT was increased in all three strains including PPAR-alpha null. Single cell hepatocyte necrosis occurred in all three strains, but hydropic degeneration of hepatocytes occurred only in PPAR-alpha null and humanized mice. Macrovesicular steatosis and inflammatory cells were found only in the PPAR-alpha null mice, while microvesicular steatosis occurred in the PPAR-alpha null and humanized strains but not the wild type strain.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 291 of 551

Liver triglyceride and cholesterol levels were increased several fold in the PPAR-alpha null mice, but not in the other strains, while plasma triglycerides were decreased only in the wild type mice. The authors concluded that PPAR-alpha may be important in <u>protecting</u> from hepatic damage caused by PFOA at the doses used in the study. They also concluded that, since hepatic PPAR-alpha may be weaker in its function and present in lower amounts in humans than in mice, humans may be susceptible to hepatic damage from similar doses of PFOA.

Finally, hepatic effects of PFOA were evaluated in pregnant wild type, PPAR-alpha null and humanized PPARalpha mice and their offspring after exposure to 3 mg/kg/day on GD 1-17 (Albrecht et al., 2013). Serum and liver PFOA levels were measured in dams and fetuses on GD 18, and in dams and offspring on PND 20. There were large differences in serum and/or liver PFOA concentrations among strains, and these differences were not consistent at the different life stages and time points. Therefore, differences in responses to PFOA among the strains may be due to toxicokinetic differences in addition to, or instead of, intrinsic strain differences in sensitivity to PFOA's effects.

In dams on GD 18, relative liver weight was significantly increased to a similar degree in all three strains. Expression of two target genes for PPAR-alpha was increased by PFOA in both wild type and humanized PPAR-alpha dams, but not PPAR-alpha null dams, although the increase in expression of one of the genes was not significant in the humanized mice. Expression of target genes for CAR and PXR was increased by PFOA in all three strains, with the biggest increase in the humanized PPAR-alpha dams. Minimal to mild hepatocellular hypertrophy was observed by histopathological examination in all three strains, although the morphological features differed among the strains.

On PND 20, relative liver weight remained increased in the wild type dams treated with PFOA, but not in PPAR-alpha null or humanized PPAR-alpha strains. Expression of a gene associated with PPAR-alpha was also increased by PFOA only in wild type dams. Expression of a gene associated with CAR was not affected in any strain, while expression of a gene associated with PXR remained significantly increased in all three strains. Histopathological changes were observed in livers from PFOA-treated dams of all three strains, but were decreased in incidence and severity compared to on GD 18 in wild type and humanized PPAR-alpha dams.

In fetuses on GD 18, relative liver weight was significantly increased in wild type and humanized PPAR-alpha, but not PPAR-alpha null, mice. Expression of two genes associated with PPAR-alpha was significantly increased in wild type and humanized fetal livers, but not in PPAR-null. The increased expression compared to controls was greater for both genes in the humanized PPAR-alpha fetuses than in the wild type fetuses, and the increase for one of them was about 5-fold greater in humanized than wild type (humanized PPAR-alpha significantly different from wild type). Fetal expression of a gene associated with CAR was not affected by PFOA in any of the three strains, and expression of a gene associated with PXR was increased only in the humanized PPAR-alpha fetal liver. Histopathological changes consistent with peroxisome proliferation were seen in some wild type mice, while no definitive changes were seen in the other strains.

In offspring on GD 20, relative liver weight and expression of genes associated with PPAR-alpha were increased only in wild type mice. Expression of a gene associated with CAR was increased in all three strains, with the largest increase in the PPAR-null offspring, while expression of a gene associated with PXR was increased in wild type and humanized, with the larger increase in wild type. At this time point,

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 292 of 551

histopathological changes in PFOA-treated wild type offspring were similar to those on GD 19, while changes were not clearly evident in livers from the other two strains.

These results indicate that hepatic effects of PFOA in adult, fetal, and neonatal mice are mediated by human PPAR-alpha and through PPAR-alpha independent pathways, as well as by mouse PPAR-alpha. As noted above, interpretation of these results is complicated by the fact that PFOA levels in serum and liver differed among the strains in dams, fetuses, and offspring. For example, serum and liver PFOA levels were lower in humanized dams and offspring than in wild type dams and offspring on PND 20. Therefore, it is unknown whether the greater hepatic effects in wild type than humanized PPAR-alpha mice at this time point are due to an intrinsic difference in sensitivity or to toxicokinetic factors.

Serum cholesterol and lipids

As discussed above, activation of PPAR-alpha causes decreased serum cholesterol and triglycerides in both humans and experimental animals, and this is the basis for the use of fibrates as cholesterol-reducing agents in humans. Consistent with other PPAR-alpha activators, PFOA decreased serum lipids levels in rodents in a number of studies (e.g. Loveless et al., 2006, and other studies summarized in Rebholz et al., 2016). In contrast, as discussed in the <u>Epidemiology</u> section, serum PFOA has been consistently associated with increased serum cholesterol, suggesting a human versus rodent difference in the effect of PFOA on this endpoint.

Two recent studies suggest the possibility that dietary factors, specifically differences in dietary fat content, may contribute to the observed differences in effects of PFOA on serum lipids in rodents versus humans. Male Balb/C mice on a regular diet or a high fat diet were dosed with 0, 5, 10, or 20 mg/kg/day PFOA for 14 days (Tan et al., 2013). Consistent with earlier mouse studies, both serum cholesterol and serum triglycerides decreased in a dose-related fashion in mice on the regular diet. In contrast, serum cholesterol and triglycerides were unaffected by PFOA in mice on the high fat diet. Additionally, hepatic toxicity from PFOA was more severe in mice on the high fat diet (discussed in <u>Animal Toxicity</u> section).

In another study, male and female C57BL/6 and BALB/c mice were fed a high fat diet containing 32% of calories from fat (similar to the mean of 33% calories from fat in the U.S. diet; CDC, 2016) and 0.25% cholesterol for 6 weeks (Rebholz et al., 2016). In both sexes of C57BL/6 mice and male Balb/c mice, plasma cholesterol was significantly increased by PFOA treatment (3.5 ppm in the diet, resulting in a dose of about 0.5 mg/kg/day), while PFOA had no effect on plasma cholesterol in female Balb/C mice. These results contrast with the decreased serum cholesterol and triglycerides caused by PFOA reported in other studies in which rodents were fed a standard laboratory diet (e.g. containing 13% of calories from fat and 0.02 % cholesterol; LabDiet, 2016). Interestingly, Minata et al. (2010) also observed that cholesterol was increased at the highest PFOA dose, and triglycerides were increased at all doses, in PPAR-alpha null mice.

Immune System Toxicity

Effects of PFOA on the immune system in humans and experimental animals are discussed in the <u>Epidemiology</u> and <u>Toxicology</u> sections above. Additionally, immunotoxicity of PFOA and other PFCs, including mode of action studies, was reviewed by DeWitt et al. (2012). PFOA suppressed the immune system in studies of both non-human primates and mice. Effects include decreased absolute and relative spleen and thymus weights, decreased thymocyte and splenocyte counts, decreased immunoglobulin response, and changes in total numbers and/or specific populations of lymphocytes in the spleen, thymus, peripheral blood, and bone marrow. Based

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 293 of 551

on the available data, rats are less sensitive than mice to immunotoxic effects of PFOA. Immune system effects were not observed in the two studies of rats; these studies included doses higher than those which generally caused immune effects in mice. In humans, exposures to PFOA within the general population range have been associated with decreased antibody levels in response to vaccination. Fletcher et al. (2009) also reported several statistically significant associations between several markers of immune function (decreased IgA, decreased IgE in females only, increased anti-nuclear antibody, decreased C-reactive protein) and serum PFOA levels in communities with drinking water exposure to PFOA in an unpublished C8 Science Panel report.

PPAR-alpha dependence of immune effects in rodents and humans

Two studies in wild type and PPAR-alpha null mice indicate that PFOA's effects on the immune system in mice occur through both PPAR-alpha dependent and PPAR-alpha independent mechanisms. Yang et al. (2002b) studied PFOA's effects on immune response in wild type and PPAR-alpha null mice given 0.02% PFOA in the diet (resulting in a dose of 30 mg/kg/day) for 7 days. Although food intake was similar in the treated wild type and PPAR-alpha null mice, but yee given 0.02% pFOA in the null mice, suggesting that weight loss is related to activation of PPAR-alpha, possibly through PFOA's effects on metabolism, rather than to non-specific toxicity. Consistent with studies discussed in the section on hepatic effects (above), liver weights were increased by PFOA similarly in wild type and null mice, but peroxisome proliferation (as measured by PCO oxidation) occurred only in wild type mice, indicating that increased liver weight was not PPAR-alpha dependent. PFOA caused some immune system effects (reduced splenocyte proliferation in response to mitogens. However, PFOA also caused other effects (reduced thymus weight and thymocyte numbers, and alterations in the distribution of thymocyte subpopulations) in the null mice, although to a lesser degree than in the wild type mice. These findings led the authors to conclude that PFOA's effects on the immune system are due to mechanisms both dependent and independent of PPAR-alpha.

DeWitt et al. (2009a) studied C57 and Sv/129 wild type and PPAR-alpha null mice exposed to 30 mg/kg/day PFOA in drinking water for 15 days to determine the involvement of PPAR-alpha in the immunotoxic effects of PFOA. Sensitivity to PFOA toxicity appeared to differ in the C57 and the Sv/129 mice, regardless of their PPAR-alpha status, as PFOA treatment decreased body weight, spleen weight, thymus weight, or antibody titer in the C57 wild type mice but did not have these effects in the Sv/129 wild type mice. IgM titer was decreased in both C57 and Sv/129 PPAR-alpha null mice, although this effect did not occur in the wild type Sv/129 mice, suggesting that this effect is not PPAR-alpha dependent. Relative liver weight was similarly increased in all four types of mice given 30 mg/kg/day PFOA in drinking water for 15 days, indicating that this response was not dependent on strain or PPAR-alpha status.

A more recent study suggests that the T-cell dependent antibody response (TDAR) in mice is independent of PPAR-alpha. DeWitt et al. (2016) evaluated the IgM response to immunization with a T-cell dependent antigen (sheep red blood cells: SRBC) in wild type and PPAR-alpha C57Bl/6 null mice exposed to 0, 7.5, or 30 mg/kg/day PFOA for 15 days. PFOA at 7.5 mg/kg/day did not affect TDAR, and production of sheep red blood cell-specific antigens was inhibited equally in wild type and PPAR-alpha null mice at 30 mg/kg/day.

In the C8 Health Study population, serum PFOA was significantly associated with a strong downward trend with C-reactive protein, a liver protein that is a marker for inflammation (Fletcher et al., 2009). Genser et al. (2015) found consistent and significant associations of serum PFOA with decreased C-reactive protein, both

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 294 of 551

within each of the six water districts included in the study and on an aggregated basis. They concluded that these within- and between-district associations strengthen the evidence of causality for this effect. Fibrate drugs act through activation of PPAR-alpha to decrease C-reactive protein in humans (Kleemann et al., 2003; Wagner et al., 2011). These drugs also cause decreases in other markers of inflammatory response *in vivo* in humans and animals, and *in vitro* through PPAR-alpha activation (Kleemann et al., 2003; Budd et al., 2007; Wagner et al., 2011). As it is well established that PFOA also activates PPAR-alpha, the decrease in C-reactive protein in populations exposed to PFOA through drinking water may have similarly occurred through PPAR-alpha activation.

Additionally, statins are a group of drugs that inhibit HMG-CoA reductase, a hepatic enzyme involved with cholesterol synthesis. Statins also activate PPARs including PPAR-alpha (Balakumar and Mahadevan, 2012). Two recent studies have reported that these drugs decrease the effectiveness of influenza vaccines in humans (Black et al., 2016; Omer et al., 2016). As above, it is well established that PFOA is an activator of PPAR-alpha, and HMG-CoA reductase activity was reduced by 50% in rats treated with 0.02% PFOA in the diet (22.7 mg/kg/day) for 7 days (Haughom and Spydevold, 1992). Taken together, these observations suggest that the decreased immune response associated with PFOA in humans may also be related to these effects.

Finally, an *in vitro* study in the human promyelocytic cell line THP-1 showed that PPAR-alpha plays a role in the immunotoxicity of PFOA in human cells (Corsini et al., 2011). Incubation of these cells with 100,000 ng/ml PFOA inhibited the lipopolysaccharide-stimulated release of two pro-inflammatory cytokines (TNF-alpha and IL-8) and matrix metallopeptidase-9, a molecule which plays a role in mobilization of inflammatory cells. This inhibition was reversed when PPAR-alpha was silenced by the addition of small interference RNA specific for PPAR-alpha.

Role of corticosterone production secondary to stress in immune effects in mice

Loveless et al. (2008) studied immune system and other effects in male CD rats and CD-1 mice given linear APFO by gavage at 0, 0.3, 1, 10, and 30 mg/kg/day for 29 days. This study evaluated the role of corticosterone in the immunotoxicity of PFOA. Hepatic effects from this study were described above.

Immunotoxicity caused by PFOA in the mice included decreased relative spleen weight at 1 mg/kg/day and above, and decreased numbers of spleen and thymus cells, decreased thymus weight, thymic depletion/atrophy, granulocytic bone marrow hyperplasia, and decreased anti-SRBC IgM titer at 10 and 30 mg/kg/day. The authors stated that the LOAEL for immunotoxic effects was 10 mg/kg/day, based on decreased IgM titers. However, the significant decrease in relative spleen weight at 1 mg/kg/day suggests that the LOAEL may actually have been 1 mg/kg/day.

Corticosterone levels were above the normal value of 400 ng/ml in 7 of 10 mice given 10 mg/kg/day PFOA and in 6 of 10 mice given 30 mg/kg/day PFOA, and decreased IgM correlated with increased corticosterone for individual mice (p<0.002). Based on this observation, the authors suggested that the IgM decreases from PFOA were secondary to stress-related increases in corticosterone.

In this study, rats were less sensitive to immunotoxic effects of PFOA than mice, and there were no effects of PFOA on spleen or thymus weight or on antibody production in the rats. Corticosterone levels were increased

above the level considered normal (300 ng/ml) in 2 of 10 rats in the 10 mg/kg/day group and 4 of 10 rats in the 30 mg/kg/day group.

DeWitt et al. (2009b) further investigated the hypothesis that immune effects of PFOA are secondary to corticosterone production in response to stress by studying adrenalectomized and sham-operated mice. Female C57BL/6N female mice (adrenalectomized or sham-operated) were dosed with 0, 7.5, or 15 mg/kg/day PFOA in drinking water for 10 days. Corticosterone levels were much higher in untreated sham-operated than adrenalectomized mice, and PFOA increased the levels of this hormone in sham-operated, but not adrenalectomized, animals. However, the immunotoxic effects of PFOA were not reduced by adrenalectomy, as SRBC-specific IgM levels were significantly reduced by 7.5 mg/kg/day PFOA in the adrenalectomized, but not sham-operated, mice, and in both groups of mice by 15 mg/kg/day PFOA. These authors concluded that the suppression of IgM synthesis by PFOA was not secondary to stress-related corticosterone production.

Developmental toxicity

As discussed in the <u>Epidemiology</u> section, a systematic review of relevant epidemiological evidence concluded that there is "sufficient" human evidence (the highest strength of evidence in the evaluation scheme) that developmental exposure to PFOA reduces fetal growth in humans (Johnson et al., 2014). The developmental effects of PFOA in mice have PPAR-alpha dependent and independent components (Dewitt et al., 2009; Abbott et al., 2007) and may involve toxicity to the placenta. Based on the information presented below, developmental effects of PFOA in laboratory animals are considered relevant to humans for the purposes of risk assessment.

The USEPA Science Advisory Board (2006) concluded that PPAR-alpha mediated effects of PFOA in human fetuses, neonates, and children are of potential concern because there was minimal information about human levels of PPAR-alpha during these life stages. Subsequent to the USEPA SAB (2006) review, additional relevant information on the role of PPARs in human development became available. It is now known that PPAR-alpha, -beta, and -gamma are expressed in many fetal and adult tissues in rodents and humans. Abbott et al. (2010, 2012) found that PPARs are present in nine human fetal tissues examined (liver, heart, lung, kidney, intestine, stomach, adrenal, spleen, and thymus) from embryonic days 54 to 125. They found that the levels may increase or decrease with age of the fetus, or between the fetus and the adult. In some fetal tissues, PPARs were expressed at levels equivalent to or higher than in adults. Although the role of PPAR-alpha and other PPARs in human and animal development is not well characterized, based on their physiological actions, they are expected to have important roles in reproduction and development (Abbott et al., 2010). For these reasons, it can be assumed that PPAR-alpha mediated effects on development are relevant to humans.

In 129S1/SvlmJ wild type and PPAR-alpha null mice dosed with PFOA on GD 1-17, full litter resorptions and increased pup liver weight caused by PFOA were independent of PPAR-alpha, while PFOA caused postnatal mortality, delayed eye opening, and decreased weight gain in wild type, but not PPAR-alpha null mice (Abbott et al., 2007). More recently, Albrecht et al. (2013) studied effects of gestational exposure of PFOA in wild-type, PPAR-alpha null, and humanized PPAR-alpha (expressing human PPAR-alpha) mice. They stated that PFOA decreased postnatal survival in wild type mice, but not PPAR-alpha null or humanized PPAR-alpha mice, suggesting that the humanized PPAR-alpha strain is less sensitive to this effect. However, a detailed review of this study, presented in the <u>Animal Toxicology</u> section, suggests that a firm conclusion on this point cannot be made from the data presented.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 296 of 551

In the lungs and the liver of fetal (GD 18) CD-1 mice exposed during gestation, PFOA primarily affected the expression of genes related to intermediary metabolism and inflammation, including genes both associated and not associated with PPAR-alpha activation (Rosen et al., 2007). The authors suggested that PFOA tends to shift metabolism in the direction of a fasted animal, consistent with the metabolic changes and obesity in adult mice exposed to PFOA during gestation (Hines et al., 2009).

Developmental exposure to PFOA was found to alter the expression pattern of PPAR-alpha, -beta, and –gamma in many tissues in fetal and neonatal CD-1 mice (Abbott et al., 2012). The expression of genes regulated by PPARs and other nuclear receptors (CAR and PXR), including genes involved with homeostatic control of lipid and glucose metabolism, was also altered as early as GD14. The authors suggested that these effects on metabolism could contribute to the neonatal mortality and decreased rate of growth caused by gestational exposure to PFOA.

Wolf et al. (2010) discussed the potential human relevance of developmental effects of PFNA that are mediated by PPAR-alpha in mice, and these comments are applicable to PFOA as well. They state: "Relevance of the PPAR-alpha mechanism to humans has been criticized primarily based on the lower number of these receptors in the liver of human versus mouse. However, PPAR-alpha is implicated here in the developmental effects of PFNA as well, and the etiology of PPAR-alpha in other tissues of the embryo, fetus and neonate of the human and the mouse that are involved in gross development has not been fully determined. Therefore, the possibility of relevance of PPAR-alpha to a human response to PFNA cannot be dismissed."

Although many of the developmental effects of PFOA appear to be PPAR-alpha dependent, PFOA's developmental effects are not shared by other potent PPAR-alpha activators. Palkar et al. (2010) evaluated the developmental effects of two well-studied PPAR-alpha activating compounds, WY and clofibrate, in wild type and PPAR-alpha null mice. Pregnant mice were given doses of WY and clofibrate known to cause the same increase in maternal liver weight that is produced by doses of PFOA that also cause developmental toxicity. As expected, both WY and clofibrate caused increased maternal relative liver weight on GD 18 in wild type, but not PPAR-alpha null, mice. However, WY did not increase fetal liver weight on GD 18, although PFOA caused this effect on GD 18 and/or at early postnatal time points (GD 1, GD 4) in other studies (Albrecht et al., 2013; Macon et al., 2011; White et al., 2009). Although WY did not increase fetal liver weight, both WY and clofibrate increased expression of two genes associated with PPAR-alpha in fetal and maternal liver of wild type mice on GD 18. Furthermore, unlike PFOA, which is considered a low affinity PPAR-alpha agonist, the two higher affinity PPAR-alpha activators, WY and clofibrate, had no effect on reproductive and developmental parameters such as litter loss, number of live pups, fetal growth, day of eye opening, or post-natal mortality in either wild type or PPAR-alpha null mice. Although the reasons for these differences between PFOA and the two higher affinity PPAR-alpha activators is not known, these results suggest that PFOA may cause increased fetal liver weight, and reproductive and developmental effects, through a mechanism unrelated to PPAR-alpha activation.

Toxicity to the placenta may play a role in developmental effects of PFOA such as fetal growth retardation (Suh et al., 2011). In pregnant CD-1 mice treated with PFOA (2, 10, or 25 mg/kg/day) on GD 11-16, fetal and placental weights were decreased in a dose-dependent manner. PFOA also increased resorptions and dead fetuses, and decreased the number of live fetuses, resulting in significant increases in post-implantation loss.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 297 of 551

Placental efficiency (ratio of fetal weight to placental weight) showed a dose-dependent decrease. Necrotic changes occurred in the placenta at the two higher doses, and decreases in several types of placental trophoblast cells occurred at all doses. These placental trophoblast cells produce prolactin family hormones that are vital to placental and fetal growth, adaptation to physiological stressors, and maintenance of pregnancy. Placental mRNA for these hormones was significantly decreased in all dose groups. Additionally, mRNA for the pituitary-specific transcription factor (Pit-1) that activates the prolactin family genes was also decreased. The authors concluded that reduced placental efficiency due to effects on placental trophoblast cells and placental hormones may play a role in PFOA's reproductive and developmental effects.

Male reproductive effects

As discussed above, PFOA caused toxicity to the male reproductive system in several mouse studies. Additionally, PFCs have also been associated with adverse effects on sperm parameters and/or effects on male reproductive hormones in humans, although these associations are not necessarily specific to PFOA (Joensen et al., 2009; Toft et al., 2012). Additionally, prenatal exposure to PFOA was associated with decreased sperm count and concentration and increased LH and FSH in young men (Vested et al., 2013).

Li et al. (2011) suggest that PPAR-alpha plays a role in male reproductive effects of PFOA and that these effects occur through activation of either mouse or humanized PPAR-alpha. Decreased serum testosterone and an increased percentage of abnormal sperm were statistically significant effects in wild type and humanized PPAR-alpha mice, but statistically significant changes in these parameters did not occur in PPAR-alpha null mice. Additionally, abnormal seminiferous tubules with vacuoles or lack of germ cells were observed in the wild type and humanized PPAR-alpha mice, while no obvious structural changes occurred in the PPAR-alpha null mice.

Other studies suggest that PFOA may decrease levels of enzymes involved with testosterone synthesis (Zhang et al., 2014), disrupt the blood-testis barrier (Lu et al., 2015), and/or affect cellular pathways in the testes leading to increased oxidative stress (Liu et al, 2015). In regard to the latter effect, it was noted by Liu et al. (2015) that the testes are very sensitive to oxidative damage produced by reactive oxygen species, and that oxidative stress is known to be an important cause of male infertility in humans.

Effects on mammary gland development

Because the developmental patterns of the mammary gland are similar in humans and rodents, rodents are considered to be a good model for studying the effects of environmental contaminants on human mammary gland development (Rudel and Fenton, 2009; Fenton et al. 2012; Rudel et al., 2011; Fenton and Birnbaum, 2015; Osborne et al., 2015).

PPAR-alpha null mice are viable, healthy, and fertile (Lee et al., 1995), suggesting that PPAR-alpha is not required for mammary gland development (Yang et al., 2006). However, activation of PPAR-alpha was shown to disrupt maternal mammary gland development in mice in two different mouse models (Yang et al., 2006). First, mammary gland development during pregnancy was impaired in transgenic mice with constitutively activated PPAR-alpha. Additionally, mammary gland development was suppressed in wild type mice administered the PPAR-alpha activator WY during pregnancy, and this effect was decreased when dosing with

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 298 of 551

WY was started later in pregnancy. In contrast, no significant effects on mammary gland development were observed in PPAR-alpha null mice similarly treated with WY during pregnancy.

The role of PPAR-alpha in PFOA's effects on mammary gland development in mice is not known. As discussed in detail above, prenatal and/or neonatal exposures to very low doses of PFOA cause persistent delays in mammary gland development in mice. However, the effects of gestational and/or lactational exposure to PFOA on mammary gland development have not been studied in wild type versus PPAR-alpha null mice. Limited data from two studies of effects of peripubertal exposure to PFOA on mammary gland in wild type and PPAR-alpha null mice (Zhang et al., 2010; Zhang et al., 2012) are insufficient to support a conclusion on this question.

In Zhao et al. (2010), PPAR-alpha null mice were treated with a single dose level of 5 mg/kg/day PFOA, 5 days per week for 4 weeks, starting at age 3 weeks. It was reported that PFOA caused stimulation of mammary gland development in the PPAR-alpha null mice, and, based on this single data point, the authors concluded that PFOA causes PPAR-alpha independent stimulation of mammary gland development. However, numerical data for this effect were not provided, and a similarly treated group of wild type mice was not included for comparison to the PPAR-alpha null mice in the study. A subsequent study (Zhao et al., 2012) reported no effect on mammary gland development in PPAR-alpha null mice from 7.5 mg/kg/day PFOA given 5 days per week for 4 weeks starting at age 3 weeks, while mammary gland development was inhibited in similarly treated wild type mice. However, the differences seen in the two strains may not have resulted from PPAR-alpha dependence of the effect, but rather from toxicokinetic differences, since the serum levels in the PPAR-alpha null mice (38,000 ng/ml) were much lower than in the wild type mice (93,000 ng/L). Additionally, the serum levels in PPAR-alpha null mice dosed with 5 mg/kg/day where stimulation was reported (28,000 ng/ml; Zhao et al., 2010) were close to the serum levels (38,000 ng/ml) in the same strain given 7.5 mg/kg/day at which no effects were reported. In summary, the stimulation of mammary gland development in PPAR-alpha null mice has not been clearly demonstrated. It was reported only in one study using a single dose level without a comparison group of wild type mice, and was not replicated in a second study of PPAR-alpha null mice with similar serum PFOA levels.

Estrogenic effects

Estrogenic activity and/or increased estrogen levels may be involved in the mode of action of PFOA. As discussed in the <u>Toxicology</u> section, serum estradiol was increased in male Sprague-Dawley rats exposed to 13.6 mg/kg/day APFO in the diet for 1 month to 12 months in a two-year dietary study (Biegel et al., 2001). PFOA was also shown to bind to and/or activate human estrogen receptor-alpha in several *in vitro* studies (Benninghoff et al., 2011; Kjeldsen and Bonefeld-Jorgensen, 2013; Buhrke et al., 2015).

Exposure to PFOA increased levels of the sensitive estrogen-dependent biomarker protein, vitellogenin, and the expression of estrogen receptor-beta in the livers of mature male and female rare minnows (Wei et al., 2007). Male fish exposed to PFOA developed oocytes in the testes, and the ovaries of exposed females underwent degeneration. PFOA (as well as PFNA and perfluorodecanoic acid [PFDA, C10]), induced vitellogenin in young rainbow trout, and these PFCs also activated rainbow trout estrogen receptor *in vitro* (Benninghoff et al, 2011).

Studies in rainbow trout, a species used as a model for human liver carcinogenesis because it is insensitive to peroxisome proliferation, suggest that PFOA promotes liver tumor development through an estrogenic

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 299 of 551

mechanism (Tilton et al., 2008; Benninghoff et al., 2012). PFOA and two other peroxisome proliferating compounds (clofibrate and dehydroepiandrosterone, DHEA) were tested for tumor promoting activity in rainbow trout which had been initiated with aflatoxin. PFOA and DHEA (Tilton et al., 2008), as well as PFNA and PFDA (Benninghoff et al., 2012), increased the incidence and number of liver tumors and also induced a genomic signature similar to that induced by 17-beta-estradiol, while clofibrate did not promote liver tumors and did not regulate genes in common with 17-beta-estradiol (Tilton et al., 2008).

Carcinogenicity

As discussed in the <u>Epidemiology</u> section, PFOA has been associated with testicular and kidney tumors in communities with drinking water exposure after adjustment for smoking and other relevant factors. As discussed in the <u>Toxicology</u> section, PFOA caused hepatic, testicular Leydig cell, and pancreatic acinar cell tumors in chronically exposed male rats (Biegel et al., 2001; Butenhoff et al., 2012). These tumor types are also caused by several other PPAR-alpha activating compounds in male rats (Klaunig et al., 2003).

Hepatic tumors

Many PPAR-alpha activators cause liver tumors in rodents through a mode of action involving PPAR-alpha activation. These chemicals are not directly genotoxic, and thus cause tumors through a non-genotoxic mechanism. Activation of PPAR-alpha causes a number of effects in the liver, but all of these effects are not necessarily causal for carcinogenesis. As summarized by USEPA (2009c), peroxisome proliferation and increases in biochemical markers for peroxisome proliferation such as PCO are considered indicative of PPAR-alpha activation, but they are not considered causal events for carcinogenicity since their correlation with carcinogenic potency is poor. As discussed by the USEPA SAB (2006), the key causal events for PPAR-alpha induced liver carcinogenesis are believed to be PPAR-alpha activation, followed by increased cell proliferation and decreased apoptosis mediated by gene expression changes, leading to clonal expansion of preneoplastic foci and tumor formation (Klaunig et al., 2003; NRC, 2006). However, aside from the initial event (PPAR-alpha activation), the other causal events are not specific to a PPAR-alpha mode of action but rather are also common to other modes of action for hepatic carcinogenesis (USEPA, 2006; Klaunig et al., 2012).

Much attention has been focused on the potential human relevance of rodent liver tumors induced by PPARalpha activators. There is wide variation among species in the ability of PPAR-alpha activators to cause hepatic peroxisome proliferation and liver tumors, with rats and mice the most sensitive, hamsters intermediate in sensitivity, and humans, monkeys, and guinea pigs least sensitive to these effects. These species differences may be due to lower levels of PPAR-alpha expression in humans than in rodents (NRC, 2006) or to differences in PPAR-alpha structure and function among species (Corton, 2010). Studies of humans exposed to peroxisome proliferating fibrate drugs have not shown increased risk of liver cancer (NRC, 2006), although these studies have limitations that are discussed by Guyton et al. (2009).

The majority of the USEPA SAB (2006) panel believed that the human relevance of the PPAR-alpah mode of action for liver tumors caused by PFOA could not be dismissed. This conclusion was based on data indicating similar responses to PFOA in the livers of rodents and primates (increased liver weight and induction of hepatic peroxisomal enzyme activity, discussed above). Although increased cell proliferation was not found in the monkeys (Butenhoff et al., 2002), the USEPA SAB (2006) noted that this endpoint was only measured after 6 months of exposure in the monkeys but not at an earlier time point during the first 1-2 weeks of exposure when it would have been more likely to occur, and apoptosis was not evaluated at any time point. The lack of data on

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 300 of 551

cell proliferation at an appropriate time point and apoptosis at any time point in the monkeys treated with PFOA precluded analysis of dose-response concordance between these key events and tumor induction for PFOA as compared to other PPAR-alpha agonists. Subsequent to the USEPA SAB (2006) evaluation, hepatic effects of PFOA were observed in three studies of mice with humanized PPAR-alpha, although chronic studies to evaluate tumor incidence in humanized PPAR-alpha mice have not been conducted (Nakamura et al., 2009; Nagakawa et al., 2011; Albrecht et al., 2013; discussed above).

The USEPA SAB (2006) also noted that the role of hepatic PPAR-alpha in human fetuses, neonates, and children is not known, and that a PPAR-alpha mode of action for hepatic effects could not be ruled out in these age groups. As discussed above, it was subsequently demonstrated that PPARs are present in many human fetal tissues, including liver, and that levels of PPARs increase and decrease with age of the fetus, and between the fetus and the adult (Abbott et al., 2010, 2012). Additionally, PFOA caused increased liver weight and expression of genes associated with PPAR-alpha in fetal livers from mice with humanized PPAR-alpha (Albrecht et al., 2013).

The USEPA SAB (2006) further concluded that PPAR-alpha activation may not be the sole mode of action for liver tumors caused by PFOA. This conclusion was based on the single study of PFOA in wild type and PPAR-alpha null mice that was available at the time (Yang et al., 2002b). In this study, PFOA increased liver weight in both wild type and PPAR-alpha null mice, while a model PPAR-alpha activator (WY) increased liver weight in wild type mice but had no effect in PPAR-alpha null mice. Numerous studies published subsequent to the USEPA SAB (2006) review confirm this conclusion and provide additional relevant information. These include several studies demonstrating PPAR-alpha independent hepatic effects of PFOA in standard strains of rodents and PPAR-alpha null mice, as well at the PPAR-alpha independent hepatic tumors, possibly related to estrogenic effects, in rainbow trout exposed to PFOA. The USEPA SAB (2006) also noted that some of the causal events in the PPAR-alpha mode of action for liver tumors had not been demonstrated for PFOA, including increased cell proliferation in the liver at early time points after dosing and/or decreased apoptosis in liver cells.

Newer information relevant to this issue shows that the hepatic effects of PFOA and WY differ, and that increased hepatic cell proliferation caused by PFOA is not totally dependent on PPAR-alpha activation. PFOA caused liver tumors in a two-year study of male rats (Biegel et al., 2001), but it did not increase hepatic cell proliferation at any of eight time points between one and 21 months after dosing began. In contrast, the PPAR-activating compound WY, which also caused liver tumors in this study, significantly increased hepatic cell proliferation at most of these time points.

Elcombe et al. (2010) suggested that the earliest time point evaluated by Biegel et al. (2001), one month after dosing began, may have been too late to observe hepatic cell proliferation in response to PFOA since cell proliferation occurs early in the sequence of events leading to liver tumors. They studied effects of PFOA and WY on hepatic endpoints including nuclear receptor activation, cell proliferation, and apoptosis in male rats at earlier time points (one day after the end of dosing for 1, 7, or 28 days). While PFOA acted as an activator of PPAR-alpha, CAR, and PXR, WY was a specific activator of PPAR-alpha only. WY increased hepatic cell proliferation and decreased apoptosis, and these effects were accompanied by increased hepatic DNA content. PFOA also increased hepatocellular proliferation, but, unlike WY, it did not cause decreased apoptosis or increased liver DNA content.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 301 of 551

Results from wild type and PPAR-alpha null mice demonstrate that PFOA causes hepatic cell proliferation, one of the key causal events for PPAR-alpha dependent liver carcinogenesis, through PPAR-alpha independent pathway(s). PFOA caused a similar or greater dose-dependent increase in hepatic cell proliferation in mice lacking PPAR-alpha as compared to wild type mice, and relative liver weight was also increased to a similar degree in both strains (Wolf et al., 2008). In contrast to PFOA, WY increased cell proliferation and relative liver weight only in the wild type mice in this study.

A carcinogenicity bioassay of PFOA has not been conducted in a standard strain of mice, or in wild type and PPAR-alpha null mice. However, the incidence of liver tumors at age 18 months was evaluated in female CD-1, 129/Sv wild type, and 129/Sv PPAR-alpha knockout offspring after developmental exposures to PFOA (Filgo et al., 2015). The authors emphasize that the study was not designed or intended to be a carcinogenicity bioassay, but that tumor incidence was assessed because of the unexpected finding of liver tumors in some animals that died before the scheduled end of the study.

In CD-1 mice, single or multiple hepatocellular adenomas occurred in one or more animals in each of the treated groups (n=21 to 37 per group; 0, 0.01, 0.1, 0.3, 1, and 5 mg/kg/day) except for at the lowest dose (0.01 mg/kg/day), but were not found in controls (n=29). In total, adenomas occurred in 4.9% (7 of 144) treated animals, compared to a historic control incidence of 0.4% in untreated female CD- mice. Additionally, hepatocellular carcinomas occurred in two treated mice (0.3 and 5 mg/kg/day) but not in controls.

In 129/Sv wild type mice, hepatocellular adenomas did not occur in control or treated groups (n=6 to 10 per group; 0, 0.1, 0.3, 1, and 3 mg/kg/day). In contrast, in PPAR-alpha null mice of this strain, there were no adenomas in the controls (n=6), one adenoma in each of the 0.1, 0.3, and 1 mg/kg/day PFOA-treated groups (n=9 or 10), and two adenomas in the 3 mg/kg/day group (n=9). These tumors occurred in 13.2% of all PFOA-treated PPAR-alpha null mice. The results of this study suggest the possibility that developmental exposure to low doses PFOA may cause hepatic tumors later in life through a PPAR-alpha independent mode of action, although more research is needed before any firm conclusions can be made.

Testicular Leydig cell and pancreatic acinar cell tumors

Modes of action that have been suggested for the non-hepatic tumors caused by PFOA are reviewed in USEPA (2005a) and Klaunig et al. (2012). Several other PPAR-alpha agonists have been found to induce the same three tumor types (hepatic adenomas, pancreatic acinar cell tumors, and testicular Leydig cell tumors) as PFOA in Sprague-Dawley rats. However, the modes of action for the latter two types of tumors have not been fully characterized, and it has not been shown that they occur through a PPAR-alpha mediated mode of action.

The mode of action for testicular Leydig cell tumor induction by PFOA is unknown. Proposed modes of action include 1) increased serum estradiol through PPAR-alpha mediated induction of hepatic aromatase activity, leading to estradiol-dependent increased production of growth factors inducing the tumors, and 2) inhibition of testosterone biosynthesis leading to an increase in luteinizing hormone (LH), which promotes Leydig cell tumor development (Klaunig et al., 2012). However, for each of these proposed modes of action, data from the chronic mechanistic rat study (Biegel et al., 2001) do not support one of the key events and the mode of action (Klaunig et al., 2012).

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 302 of 551

The key events in the first proposed mode of action above are:

Activation of PPAR-alpha in the liver \rightarrow increased hepatic aromatase \rightarrow increased serum and testicular interstitial fluid estradiol levels \rightarrow increased transforming growth factor-alpha \rightarrow increased testicular Leydig cell proliferation \rightarrow testicular Leydig cell tumors (Klaunig et al., 2012).

As discussed by Klaunig et al. (2012), testicular Leydig cell proliferation was not increased by PFOA at numerous time points during the chronic rat study of Biegel et al. (2001).

The key events in the second proposed mode of action above are:

Decreased testosterone levels \rightarrow increased LH levels \rightarrow testicular Leydig cell tumors.

As discussed by Klaunig et al. (2012), LH was not increased by PFOA at numerous time points during the chronic rat study (Biegel et al., 2001).

The mode of action for pancreatic acinar cell tumor induction by PFOA is also unknown. One possible hypothesis that has been suggested is that these tumors occur as a result of an increase in cholecystokinin secondary to hepatic effects of PFOA, but this has not been demonstrated experimentally (Klaunig et al., 2012).

The USEPA SAB (2006) concluded that insufficient data were available to determine the mode of action for the testicular Leydig cell tumors and the pancreatic acinar cell tumors found in PFOA treated male rats (Biegel et al., 2001). More recently, Klaunig et al. (2012) concluded that, based on information presented above, the available data do not definitively establish a mode of action for these tumors. In the absence of a defined mode of action for these tumor types, the USEPA SAB (2006) concluded that "they must be presumed to be relevant to humans, as suggested by EPA's Cancer Guidelines," and this conclusion remains valid at this time.

Other possible modes of action

A number of other modes of action for PFOA have been suggested. Although a complete review of this topic is beyond the scope of this document, information on several potential modes of action is summarized below.

PFOA and other perfluorinated carboxylates of carbon chain lengths C7-C10 inhibited intercellular gap junction communication *in vitro* in cultured rat liver cells, while non-fluorinated fatty acids and PFCs of chain length C2-C5 or C16 and C18 did not (Upham et al., 1998). In further *in vivo* studies, male F-344 rats fed diets containing 0.02% PFOA (resulting in a dose of 37.9 mg/kg/day) for 7 days had significantly increased liver weight and significantly decreased hepatic gap junction intercellular communication, as measured by the distribution of a fluorescent dye that travels through gap junction channels (Upham et al., 2009). Perfluoropentanoic acid (C5) did not cause either of these effects. The authors suggested that disruption of gap junction intercellular communication is a widespread phenomenon, and that these effects of PFOA and other PFCs have not been shown to be species or tissue specific.

The mode of action for PFOA may also involve effects on mitochondria. As discussed above, developmental exposure to PFOA in female mice caused hepatic mitochondrial proliferation and abnormal mitochondrial morphology later in life (Quist et al., 2015). Furthermore, hepatic activity of the mitochondrial enzyme, succinate dehydrogenase, was increased in cynomolgus monkeys treated with PFOA (Butenhoff et al., 2002).

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 303 of 551

Hepatic mitochondrial DNA copy number was also significantly increased in male rats 3 days after a single dose of 100 mg/kg PFOA and after 28 days of exposure to 30 mg/kg/day (Berthiaume and Wallace, 2002; Walters et al., 2009).

Starkov and Wallace (2002) investigated effects of PFOA and other PFCs in isolated mitochondria. The involvement of mitochondria in the mode of action of PFCs was suggested by earlier reports of proliferation of hepatic mitochondrial membranes after PFC exposure and uncoupling of mitochondrial respiration in isolated mitochondria exposed to high concentrations of PFCs (reviewed in Starkov and Wallace, 2002). They found that PFOA and PFOS caused slight effects only at high concentrations (e.g. 100 μ M for PFOA) which may have resulted from changes in membrane fluidity due to the surfactant properties of PFCs. In contrast, other PFCs were potent uncouplers of oxidative phosphorylation, such as perfluorooctane sulfonamide which had an IC₅₀ of 1 μ M for this effect.

MicroRNAs (miRNAs) are small non-coding RNAs which affect gene expression by binding to complementary mRNA to block translation or trigger degradation. Changes in miRNA may play a role in various diseases by affecting the expression of relevant genes (Wang et al., 2012; Yan et al., 2014). Recent studies suggest that PFOA may alter miRNA levels in both humans and rodents. Elevated levels of specific miRNAs in serum were associated with serum PFOA concentrations in a study of Chinese residents and workers with PFOA exposures from a fluoropolymer manufacturing facility (Wang et al., 2012). In this study, 63 of the 754 miRNAs that were evaluated were detected in all serum samples. Levels of 9 miRNAs were significantly higher in workers compared to less highly exposed residents. In a further analysis, levels of two of these (miR-26b and miR-199a-3p) were significantly increased in an exposure-related fashion within the worker group. A subsequent study found that levels of circulating miRNAs were increased in male BALB/cJ mice dosed with PFOA for 28 days, and that more miRNAs were affected as PFOA dose increased. Interestingly, the two miRNAs that were associated with PFOA in workers in a dose-related fashion were also increased by PFOA exposure in mice (Yan et al., 2014).

In addition, the mode of action of PFOA may involve effects related to organic anion transporters (OATs), organic anion transporting polypeptides (OATPs), and other multispecific transporter proteins such as multidrug resistance-associated proteins (MRPs/Mrps). These highly conserved transporters are present in the membranes of many tissues throughout the body in humans, other mammalian species, and lower vertebrates. They are responsible for the transport of numerous endogenous and xenobiotic compounds both into and out of cells. Substrates for transporter proteins include fatty acids, hormones, bile acids, drugs, environmental contaminants, and other exogenous and endogenous substances that are critical in homeostatic pathways (Roth et al., 2011).

It is well established that renal tubular secretion and reabsorption of PFOA occur through transport by various OATs and OATPs, and that the slow rate of excretion of PFOA in male (in contrast to female) rats and both genders of humans is due to reabsorption of PFOA by specific renal OATs and/or OATPs (Han et al., 2012). Recent studies have shown that effects of PFOA in organs other than the kidney may involve these transporter proteins as well. PFOA can act as an inhibitor of specific OATs and OATPs (Yang et al., 2009b; 2010), and it induced MRP in cultured human cells (Rusiecka and Skladanowski, 2008) and Mrp in mouse liver (Maher et al., 2008), potentially affecting transport of endogenous substances, drugs, and other transporter substrates. The role of OAT4 in placental transfer of PFOA in humans was recently studied (Kummu et al., 2015). OAT4 is found primarily in human kidney and placenta and has been identified as one of the specific transporters

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 304 of 551

responsible for renal reabsorption of PFOA in humans (Han et al., 2012). The level of placental OAT4 was inversely correlated with the rate of transfer of PFOA from the maternal circulation to fetal circulation in studies of perfused human placenta, suggesting that higher levels of placental OAT4 may protect the fetus from PFOA after maternal exposure (Kummu et al., 2015).

Summary of conclusions about human relevance of toxicological effects of PFOA

Based on the information presented above, the toxicological effects of PFOA are generally considered relevant to humans for the purposes of risk assessment.

Hepatic effects

Increased serum levels of liver enzymes are associated with exposure to PFOA in humans. Data from nonhuman primates, standard strains of rats and mice, PPAR-alpha null mice, and humanized PPAR-alpha mice support the conclusion that hepatic effects of PFOA in experimental animals are relevant to humans for the purposes of risk assessment.

PFOA caused increased relative liver weight in non-human primates, species for which the human relevance of hepatic effects is not in question. In a subchronic study in cynomolgus monkeys, several animals that did not complete the study due to overt toxicity exhibited notably increased liver weight, highly elevated serum liver enzymes and/or severe hepatic toxicity. In this study, hepatic peroxisome proliferating activity was increased in a dose-related fashion. As was noted by the USEPA SAB (2006), the effects of PFOA on both liver weight and peroxisome proliferation were similar in cynomolgus monkeys and rats. In contrast to rodents, the human relevance of hepatic effects mediated by PPAR-alpha in non-human primates is not subject to debate. Potential PPAR-alpha independent pathways for hepatic effects of PFOA have not been thoroughly investigated in non-human primates, although increased activity of a mitochondrial enzyme (succinate dehydrogenase) was reported in the subchronic cynomolgus monkey study.

Data from standard strains of mice and rats clearly show that PPAR-alpha independent mechanisms contribute to the hepatic effects of PFOA. Studies which evaluated both liver weight and hepatic peroxisome proliferating activity provide data relevant to this question. At the doses and time points evaluated in these studies, the dose-response curves for increased liver weight and hepatic peroxisome proliferating activity did not directly correspond. These data indicate that hepatic effects of PFOA involve PPAR-alpha independent mechanisms even in standard strains of rodents with normal PPAR-alpha status. Furthermore, PFOA caused fatty liver in standard strains of mice and rats, although PPAR-alpha activation causes decreased hepatic lipid accumulation. Additionally, recent studies suggest that the differences in the effects of PFOA on serum lipids in rodents (decreased cholesterol and triglycerides) versus humans (increased cholesterol and triglycerides) may be related to the low fat diet generally used in laboratory rodent studies versus the higher fat content of a typical Westernized human diet, rather than solely to interspecies differences. Finally, developmental exposure to PFOA caused abnormal mitochondria in livers of a standard strain of laboratory mice, with no evidence of peroxisome proliferation.

Data from studies comparing mice with normal PPAR-alpha status (wild type) and mice lacking PPAR-alpha (PPAR-alpha null) provide further evidence that hepatic effects occur through both PPAR-alpha dependent and PPAR-alpha independent pathways. PFOA causes similar increases in liver weight in wild type and PPAR-alpha null mice. PFOA also causes histopathological changes and increased liver enzymes in PPAR-alpha null

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 305 of 551

mice; the histopathological changes differ from those seen in wild type mice, particularly as related to damage to the bile duct. Additionally, developmental exposures to PPAR-alpha null mice caused persistent histopathological changes in the liver.

Data from mice expressing human PPAR-alpha in the liver indicate that activation of human PPAR-alpha by PFOA causes hepatic effects. PFOA caused similar increases in liver weight in humanized PPAR-alpha mice and wild type mice. Other hepatic effects of PFOA in humanized PPAR-alpha mice include activation of genes associated with PPAR-alpha, and histopathological changes including hepatocellular hypertrophy and single cell necrosis.

PPAR-alpha is known to be active in human fetal tissues, including liver. Fetal liver weight was increased similarly in wild type and PPAR-alpha humanized mice after *in utero* exposure. Additionally, PFOA increased the expression of genes associated with PPAR-alpha in fetal liver to a greater degree in PPAR-alpha humanized mice than in wild type mice.

Immune system effects

Data from epidemiological studies suggest that the immune system is a sensitive target for PFOA in humans. PFOA suppresses the immune system in both non-human primates and mice. Data from mouse studies indicate that these effects on the immune system occur through both PPAR-alpha dependent and PPAR-alpha independent modes of action. Both PPAR-alpha dependent and independent effects on the immune system are considered relevant to humans for the purposes of risk assessment. Potentially relevant to this conclusion, lipidlowering drugs that activate PPAR-alpha have recently been associated with decreased effectiveness of the influenza vaccine in humans, consistent with inhibition of human immune response by agents that activate PPAR-alpha such as PFOA.

Developmental and reproductive effects

PFOA is associated with decreased fetal growth in humans. PPAR-alpha and other PPARs are present in human fetal tissues and are expected to have important roles in reproduction and development. Therefore, PPAR-alpha mediated effects of PFOA on development are considered relevant to humans for the purposes of risk assessment. Developmental effects of PFOA in rodents appear to occur primarily through PPAR-alpha dependent mechanisms, while some reproductive effects such as full litter resorptions appear to be PPAR-alpha independent. However, high affinity "pure" PPAR-alpha activators (WY and clofibrate) do not cause the developmental effects in mice that were caused by PFOA.

Delayed mammary gland development after developmental exposure is a sensitive endpoint for PFOA toxicity in mice. The rodent is considered a good model for human mammary gland development, and there is no mode of action evidence suggesting that the effects of PFOA on this endpoint are not relevant to humans.

PFOA also causes reproductive toxicity in male mice, and there is no mode of action information to suggest that these effects are not relevant to humans.

Carcinogenicity

PFOA is associated with testicular and kidney cancer in communities with drinking water exposure after adjustment for smoking and other relevant factors. PFOA caused tumors of the liver, testicular Leydig cells,

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 306 of 551

and pancreatic acinar cells in male rats. USEPA (2006) SAB did not dismiss the potential human relevance of the liver tumors in rats, based on similarities in hepatic effects of PFOA in monkeys and rodents and the limited evidence available at the time for hepatic effects of PFOA in PPAR-alpha null mice. Subsequent studies have provided substantial additional information showing hepatic effects of PFOA in PPAR-alpha null mice. Importantly, hepatic cell proliferation, a causal event for tumor formation, is increased similarly by PFOA in wild type and PPAR-alpha null mice. Although a carcinogenicity bioassay for PFOA has not been conducted in PPAR-alpha null mice, a recent study suggests that developmental exposures to PFOA may cause hepatic tumors in adulthood in this strain. Finally, studies in rainbow trout, a species used as a model for human liver cancer because it lacks PPAR-alpha, suggest that PFOA causes liver tumors through an estrogenic mode of action.

Because the modes of action for the testicular and pancreatic tumors caused by PFOA have not been established, these tumors are considered relevant to humans for the purposes of risk assessment.

DEVELOPMENT OF RECOMMENDED HEALTH-BASED MCL

Health-based MCLs developed by the DWQI are intended to be protective for chronic (lifetime) exposure through drinking water. The 1984 Amendments to the New Jersey Safe Drinking Water Act (N.J.S.A. 58:12A-20) stipulate that Health-based MCLs are to be based on a one in one million lifetime cancer risk level for carcinogens and no adverse effects from lifetime ingestion for non-carcinogens.

Consideration of human epidemiological data

Both the human epidemiology data and the animal toxicology data were considered as part of the overall weight of evidence for the potential human health effects of PFOA. As reviewed in the <u>Epidemiology</u> section, associations of PFOA with numerous health endpoints have been found in human populations, with evidence supporting multiple criteria for causality for some effects. These health endpoints include non-carcinogenic effects in the general population, and both non-carcinogenic effects and cancer in communities with drinking water exposure. The epidemiologic data for PFOA are notable because of the consistency between results among human epidemiologic studies in different populations, the concordance with toxicological findings in experimental animals, the use of serum concentrations as a measure of internal exposure, the potential clinical importance of the endpoints for which associations are observed, and the observation of associations within the exposure range of the general population and communities with contaminated drinking water. These features of the epidemiologic data distinguish PFOA from most other organic drinking water contaminants and justify concerns about exposures to PFOA through drinking water.

Although the data for some endpoints support multiple criteria for causality, the human epidemiology data have limitations and are therefore not used as the quantitative basis for the Health-based MCL. Instead, the potential Health-based MCLs developed below are based on sensitive and well established animal toxicology endpoints that are considered relevant to humans based on mode of action data. Notwithstanding, continued exposure to even relatively low levels of PFOA in drinking water are known to cause substantial increases in PFOA in blood serum, to levels several fold higher than those found in the general population. The considerable evidence for increased risks of health effects from the low-level PFOA exposures prevalent in the general population (e.g. <10 ng/ml, NHANES 2007-2010; CDC 2015) and in communities with contaminated drinking water suggests a need for caution about drinking water exposures that will result in such elevations in serum PFOA level. Relevant to this point, it is noted that the German Human Biomonitoring Commission recently developed a

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 307 of 551

Human Biomonitoring Level I (the serum level below which adverse health effects are not expected) for PFOA of 2 ng/ml, close to the current median PFOA serum level in the U.S. general population. This HBM I is based on the serum PFOA levels associated with increased time to pregnancy, decreased fetal growth, increased serum cholesterol, and decreased immune response in humans, and with delayed mammary gland development in mice (Apel et al., 2016). The human epidemiological data thus support the use of a public health-protective approach in developing a Health-based MCL recommendation based on animal toxicology data.

Weight of Evidence for Carcinogenicity

PFOA caused tumors in male rats in two chronic studies (Sibinski et al., 1987, Butenhoff et al., 2012; and Biegel et al., 2001). It caused a statistically significant increase in testicular Leydig cell tumors in both studies, as well as a statistically significant increase in liver tumors and pancreatic tumors in Biegel et al. (2001). Human exposure to PFOA has also been associated with increased risk of cancer, including increased risk of kidney and testicular cancer in communities with contaminated drinking water after adjustment for smoking and other relevant factors (Barry et al, 2013; Vieira et al., 2013).

Based on the chronic animal data and mode of action studies available at the time, PFOA was described as "likely to be carcinogenic to humans" by the USEPA Science Advisory Board (USEPA, 2006). PFOA was classified as "possibly carcinogenic to humans" by IARC based on review of data from human epidemiology, animal toxicology, and mechanism of action studies (Benbrahim-Tallaa et al., 2014). More recently, PFOA was described by the USEPA Office of Water (2016a) as having "suggestive evidence of carcinogenic potential", a descriptor similar to the classification of "possibly carcinogenic to humans" used by IARC (2015).

The USEPA Guidelines for Carcinogen Risk Assessment (2005b) recommend dose-response modeling and low dose extrapolation for chemicals described as likely to be carcinogenic. For chemicals with suggestive evidence of carcinogenicity, dose-response modeling and low dose extrapolation may be performed when data to support it are available. The guidelines recommend that the risk-based estimates for suggestive carcinogens be used to obtain "a sense of the magnitude and uncertainty of potential risks, ranking potential hazards, or setting research priorities." Risk-based drinking water concentrations based on both non-carcinogenic and carcinogenic endpoints are presented below.

Potential Health-based MCLs based on non-carcinogenic endpoints

<u>Selection of toxicological endpoints for consideration as basis for potential Health-based MCLs</u> As reviewed in the <u>Toxicology</u> section above, PFOA causes numerous systemic effects in experimental animals. These include liver toxicity, immune system toxicity, adverse developmental effects, and other adverse effects. The Health Effects Subcommittee concluded that delayed mammary gland development and increased relative liver weight are the most sensitive systemic endpoints with data appropriate for dose-response modeling.

Delayed mammary gland development from perinatal exposure is the most sensitive systemic endpoint for PFOA with data appropriate for dose-response modeling. It is a well-established toxicological effect of PFOA that is considered to be adverse and relevant to humans for the purposes of risk assessment. An RfD based on this endpoint is presented below.

To the knowledge of the Health Effects Subcommittee, an RfD for delayed mammary gland development has not previously been used as the primary basis for health-based drinking water concentrations or other human

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 308 of 551

health criteria for environmental contaminants. Because the use of this endpoint as the basis for human health criteria is a currently developing topic, the Health Effects Subcommittee decided not to recommend a Healthbased MCL with the RfD for delayed mammary gland development as its primary basis. However, the occurrence of this and other effects at doses far below those that cause increased relative liver weight (the endpoint used as the primary basis for the recommended Health-based MCL) clearly requires application of an uncertainty factor to protect for these more sensitive effects.

Increased relative liver weight is a well-established effect of PFOA that is more sensitive than most other toxicological effects such as immune system toxicity and most reproductive/developmental effects (Table 12 of <u>Animal Toxicology</u> section). A recommended Health-based MCL with increased liver weight as its primary basis is presented below.

Selection of studies and data for dose-response modeling

Only those studies that provide serum PFOA data were considered for dose-response modeling of noncarcinogenic effects. A risk assessment approach based on measured serum PFOA levels is less uncertain than one based on pharmacokinetic modeling of estimated serum PFOA levels or an approach in which interspecies extrapolations is based on interspecies half-life differences. For example, as discussed above, serum PFOA concentrations from the same administered dose vary among strains and even between animals of the same strain obtained from different sources. Available approaches based on pharmacokinetic modeling or interspecies half-life conversions do not account for these intra-strain differences.

In some studies, serum PFOA was measured only at time points well after dosing had ended. Serum data from these later time points are not appropriate for dose-response modeling because PFOA body burdens would have decreased, and the serum levels thus do not represent the maximum exposures during the study. Therefore, only studies which provide serum PFOA levels close to the end of the dosing period were considered for dose-response modeling. Use of the maximum serum levels that occurred during the study is a non-conservative approach (i.e. would result in a less stringent, rather than more stringent, risk assessment than other potential approaches such as area under the curve modeling), since the observed toxicological effects could have resulted from the lower average exposures experienced over the entire dosing and post-dosing time periods.

Benchmark dose (BMD) modeling is a quantitative approach commonly used to estimate the lower 95% confidence limit (the BMDL) on the dose corresponding to a minimal response (the benchmark response, BMR) that is consistent with the observed data. The BMDL is considered to be an estimate of the NOAEL, but it is based on the entire dose-response curve for the endpoint of interest rather than just the fixed doses administered in the study. When the necessary data are available, BMD modeling can be performed using serum concentrations instead of administered doses. Serum concentrations are preferable to administered doses as the basis for BMD modeling because they are a better representation of the shape of the internal dose response curve. BMD modeling based on serum PFOA data was used to determine BMDLs for serum PFOA concentrations used as the points of departure (PODs) to develop RfDs for both increased relative liver weight and delayed mammary gland development.

Reference Dose based on delayed mammary gland development

Delayed mammary gland development in mice from developmental exposures is a sensitive endpoint for PFOA's toxicity. This effect has been reported in nine separate studies presented in five publications (Table 14

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 309 of 551

of <u>Toxicology</u> section). Only one study (Albrecht et al., 2013), which has several general problematic issues (discussed in <u>Toxicology</u> section) did not find this effect. Gestational and/or lactational exposures to PFOA caused delayed mammary gland development in pregnant dams and/or female offspring in two strains of mice. In one study, this effect was statistically significant in mouse pups exposed to concentrations of 5000 ng/L (5 μ g/L) in drinking water *in utero* and after birth. The serum PFOA levels (80 ng/ml in the dams and 20-70 ng/ml in the pups) that resulted in delayed mammary gland development in these mice are relevant to human serum PFOA levels from contaminated drinking water. Histological changes in the mammary gland development occurs in a dose-related fashion, and there is no information indicating it is not relevant to humans. For these reasons, delayed mammary gland development from developmental exposures to PFOA is considered a sensitive and relevant endpoint for dose-response modeling.

Selection of study and data for dose-response modeling of delayed mammary gland development

The late gestational exposure study conducted by Macon et al. (2011) is the only developmental exposure study of mammary gland development that provides serum PFOA data from the end of the dosing period (PND 1) that can be used for dose-response modeling. In this study, pregnant dams were dosed with PFOA (0.01 to 1 mg/kg/day) on GD 10-17. Mammary gland development was assessed on PND 1, 4, 7, 14, and 21, and delays in development were most evident on PND 21. Of the several endpoints related to mammary gland development reported by Macon et al. (2011), two endpoints (decreased mammary gland developmental score and decreased number of terminal end buds) showed a statistically significant dose-related decrease at PND 21 over the dose range studied. These endpoints were selected for dose-response modeling (Table 15).

Table 15. Mammary gland development parameters selected for dose-response modeling from PND 21 female offspring after exposure on GD 10-17 (Macon et al., 2011)							
Dose	Dose Pup Serum Developmental Number of						
(mg/kg/day)	PFOA, PND 1 score		Terminal End				
	(ng/ml)	(1-4)	Buds				
Control	22.6 ± 5.5	3.3 ± 0.3	40 ± 4				
0.01	284.5 ± 21.0	2.2 ± 0.2	33 ± 4				
0.1	2303.5 ± 114.1	1.8 ± 0.3	24 ± 4				
1.0	$16,305.5 \pm 873.5$	1.6 ± 0.1	15 ± 2				

Determination of Point of Departure for delayed mammary gland development

USEPA Benchmark Dose Modeling Software 2.1.2 was used to perform BMD modeling of the data for mammary gland developmental score and number of terminal endbuds at PND 21 from Macon et al. (2011), using serum PFOA data from PND 1 as the dose. Continuous response models were used to obtain the BMD and the BMDL for a 10% change from the mean (the percent change typically used as the BMR) for the two endpoints. Modeling was based on serum levels at PND 1, since they were higher at this time than at later time points. In this study, the serum level in the control group was 22.6 ng/ml, indicating that some PFOA exposure occurred in these non-dosed animals. The BMD and BMDL values presented in Table 16 were derived using this value from the control group (22.6 ng/ml) as the baseline. The serum level BMDs and BMDLs may have been lower if the baseline serum level had been lower (Post et al., 2012).

Compared to controls, the developmental score at PND 21 significantly decreased at all three doses; the number of terminal end buds also decreased at all three doses, with significance at the two higher doses. The BMDLs

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 310 of 551

for the two endpoints, 24.9 and 22.9 ng/ml (Table 16), are close to the NOAEL of 28.5 ng/ml that is estimated by applying a standard uncertainty factor of 10 for LOAEL-to-NOAEL extrapolation to the serum level of 285 ng/ml at the LOAEL, 0.01 mg/kg/day. Outputs of the BMD modeling are provided in Appendix 6.

Table 16. Benchmark	•			10	
Model	Chi-square p-value ^b			BMDL (Serum PFOA, ng/ml)	
	Decreased Mam	mary Gland Deve	Ionmental Score		
Hill	0.70	-4.28	57.4	28.1	
(non-logged concs.)	0.70	1.20	07.1	20.1	
Polynomial - 2 nd deg.	0.83	-4.39	25.9	24.0	
(logged concs.)					
Exponential -model 2	0.87	-36.86	25.7 ^d	24.7 ^d	
(logged concs.)					
Linear	0.83	-6.05	28.0	26.5	
(logged concs.)					
		umber of Termin			
Hill	0.47	88.43	235.1	78.5	
(non-logged concs.)	0.20		200.0	110.5	
Exponential - model 4	0.30	88.97	399.8	110.5	
(non-logged concs.)	0.62	00.15	(1.0	02.4	
Power	0.62	88.15	64.8	23.4	
(non-logged concs.)	0.81	97.06	87.2	20.0	
Power	0.81	87.96	81.2	29.0	
(logged concs.) Polynomial – 2 nd deg.	0.84	87.94	96.6	28.1	
(logged concs.)	0.04	0/.74	90.0	20.1	
Linear	0.12	89.47	27.0	25.7	
(logged concs.)	0.12	07.77	27.0	20.1	
Exponential – model 3	0.98	87.90	25.1 ^d	22.9 ^d	
(logged concs.)	0.20	01.00	-011		

^a Results are shown for all models that gave an acceptable visual fit.

^b A larger Chi-square p-value indicates a better fit to the data.

^c AIC: A measure of information loss from a dose-response model that can be used to compare a specified set of models. The AIC is defined as $-2 \times (LL - p)$, where LL is the log-likelihood of the model given the data, and p is the number of parameters estimated in the model. When comparing models, a lower AIC is preferable to a higher one (USEPA, 2012a).

^d BMDs and BMDLs from the models with the lowest AIC statistic for each endpoint.

Application of uncertainty factors for delayed mammary gland development

The choice of uncertainty factors is consistent with current USEPA IRIS guidance (USEPA, 2012c) and previous risk assessments developed by NJDEP and the DWQI.

The BMDL for decreased number of terminal endbuds of 22.9 ng/ml in serum (derived above) was used as the POD for RfD development. Uncertainty factors (UFs) were applied to the POD to obtain the Target Human Serum Level. The Target Human Serum Level (ng/ml in serum) is analogous to an RfD but is expressed in

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 311 of 551

terms of internal dose rather than administered dose.

The total of the uncertainty factors (UFs) applied to the POD serum level was 30, and included the following factors:

- 10 UF for <u>human variation</u>, to account for variation in susceptibility across the human population and the possibility that the available data may not be representative of individuals who are most sensitive to the effect.
- 3 UF for <u>animal-to-human extrapolation</u>, to account for toxicodynamic differences between humans and mice.

The typical uncertainty factor of 3 for toxicokinetic variability between species is not included because the risk assessment is based on comparison of internal dose (serum levels) rather than administered dose.

1 – UF for <u>LOAEL to NOAEL</u>.

The point of departure is a BMDL, not a LOAEL. Therefore, this uncertainty factor is not applied.

1 - UF for <u>duration of exposure</u>.

Delayed mammary gland development occurs from exposures during development. Therefore, an UF to account for effects from longer term exposures is not used.

1 – UF for more sensitive effects that are not considered (e.g. incomplete database).
 Because delayed mammary gland development is a sensitive endpoint for PFOA toxicity, the UF is not applied.

The target human serum level is: $\underline{22.9 \text{ ng/ml}} = 0.8 \text{ ng/ml} (800 \text{ ng/L}).$ 30

As discussed above, the most recent median and 95th percentile NHANES values for serum PFOA in the general population are 2.1 and 5.7 ng/ml (CDC, 2015). Therefore, the target human serum level for delayed mammary gland development, 0.8 ng/ml, is below the median serum PFOA level in the U.S. general population.

Development of Reference Dose based on delayed mammary gland development

USEPA (2016a) used a pharmacokinetic modeling approach to develop a species-independent clearance factor, $1.4 \times 10^{-4} \text{ L/kg/day}$ that relates serum PFOA level (µg/L) to human PFOA dose (µg/kg/day). As discussed in the <u>Toxicokinetics</u> section, this clearance factor predicts a serum:drinking water ratio of 114:1 with average drinking water consumption, consistent with the empirically observed average serum:drinking water ratio of greater than 100:1 in human populations exposed to PFOA through drinking water. The clearance factor can be used to calculate the RfD, as follows:

 $800 \text{ ng/L x } 1.4 \text{ x } 10^{-4} \text{ L/kg/day} = 0.11 \text{ ng/kg/day}$

Where: 800 ng/L = Target Human Serum Level $1.4 \ge 10^{-4} \text{ L/kg/day} = \text{Clearance}$ 0.11 ng/kg/day = RfD

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 312 of 551

Potential Health-based MCL based on increased relative liver weight

Increased relative liver weight is a well-established toxicological effect of PFOA in both non-human primates and rodents and is more sensitive than most other toxicological effects. Increased liver weight occurs in newborn animals after *in utero* exposure, during early life from lactational exposure, and from exposures during adulthood. As discussed in the <u>Mode of Action</u> section, PFOA may cause increased relative liver weight through multiple biochemical and cellular pathways. Increased relative liver weight can co-occur with and/or progress to other types of hepatic toxicity and is considered relevant to humans for the purposes of risk assessment.

According to USEPA IRIS guidance (USEPA, 2012c), endpoints that are "adverse, considered to be adverse, or a precursor to an adverse effect" are appropriate as the basis for non-cancer risk assessment. The increased relative liver weight caused by PFOA is usually accompanied by hepatocellular hypertrophy, and it can co-occur with and/or progress to more severe hepatic effects including hepatocellular necrosis, fatty liver, increased serum liver enzymes, and hyperplastic nodules. Additionally, PFOA caused hepatocellular adenomas in chronically exposed male rats in the study conducted by Biegel et al. (2001). Although these tumors were not reported to be increased in males rats in the earlier chronic study (Sibinski, 1987), Butenhoff et al. (2012) noted that these lesions represent a regenerative process and that diagnostic criteria for hepatic hyperplastic nodules have changed since the livers from the study were evaluated in 1986.

Increased relative liver weight in mice can result either from *in utero* exposure during the prenatal period or from lactational exposure during the neonatal period (Wolf et al., 2007; White et al., 2009). In other studies, ultrastructural and/or histopathological changes indicative of liver toxicity persisted until adulthood (age 3 months, Quist et al., 2015; age 18 months, Filgo et al., 2015) in offspring of dams dosed with PFOA during gestation. Hepatocellular hypertrophy and periportal inflammation occurred at doses below those that caused increased liver weight (Quist et al., 2015). It is not known whether these sensitive hepatic effects resulted from *in utero* exposure, lactational exposure, or both. Additionally, results from offspring at age 18 months suggest the possibility of an increased incidence of liver tumors from developmental exposures to PFOA, although the study was not designed as a carcinogenicity bioassay (Filgo et al., 2015). Although data from these studies are not amenable dose-response modeling, they support the conclusions that liver toxicity is a sensitive endpoint for PFOA, that the developmental period is a sensitive lifestage for PFOA's hepatic effects, and that increased relative liver weight is a relevant and appropriate endpoint for PFOA's toxicity.

Selection of study and data for dose-response modeling of increased liver weight

Increased relative liver weight has been observed in many studies of PFOA in both rodents and non-human primates. The five publications reporting studies of relative liver weight that were considered for dose-response modeling are summarized in the first part of Table 10 of the <u>Animal Toxicology</u> section. Studies were included if they provide serum PFOA data from the end of the dosing period, and, for rodent studies, include relatively low doses (1 mg/kg/day or less). Rodent studies that meet these criteria were reported in four publications. The 90-day cynomolgus monkey study in which the lowest dose was 3 mg/kg/day is also included in Table 10 of the <u>Animal Toxicology</u> section for comparison purposes, since it used a non-human primate species and has been the focus of risk assessments by other groups.

The 90 day cynomolgus monkey study (Thomford et al., 2001b; Butenhoff et al., 2002) was not considered appropriate for dose-response modeling for several reasons (discussed in detail in Appendix 3). The study does

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 313 of 551

not provide serum PFOA data that can be used for dose-response modeling because serum PFOA levels did not differ at the two lower doses (3 and 10 mg/kg/day); the high dose (30/20 mg/kg/day) group is excluded for use in dose-response modeling due to overt toxicity. Additionally, the death of one of four animals in the low dose group may have been due to PFOA toxicity. Aside from its lack of utility for dose-response modeling, this study provides no indication of the NOAEL for PFOA toxicity in this species because of the lack of a relationship between administered or internal dose and response, and because of the possibility of overt toxicity at the lowest dose.

Two of the four rodent studies (Loveless et al., 2006; Perkins et al., 2004) used adult male rats, and one of these (Loveless et al., 2006), also used adult male mice. Loveless et al. (2006) administered three different isomeric mixtures of PFOA (linear/branched, linear, and branched) to adult male mice and rats for 2 weeks, while Perkins et al. administered PFOA to adult male rats for 4, 7, or 13 weeks.

As discussed in the <u>Toxicology</u> section, increased relative liver weight associated with hepatocellular hypertrophy is an early manifestation of PFOA's hepatic toxicity. This effect does not appear to increase in magnitude over time, but rather it appears to progress over time to other more severe hepatic effects (Butenhoff et al., 2012). Relative liver weight data from male CD-1 mice after 14 day exposures (Loveless et al., 2006) and 29 day exposures (Loveless et al., 2008) were compared based on administered dose, as Loveless et al. (2008) does not provide serum PFOA levels. This comparison shows that the dose-response curves for increased relative liver weight are similar for the 14 day and 29 day exposure periods. Furthermore, dose-response curves for relative liver weight in male rats were similar after 4, 7, and 13 week exposures (Perkins et al., 2004).

Two additional developmental studies in mice (Lau et al., 2006; Macon et al., 2011) also met the criteria for inclusion in Table 10 of the <u>Toxicology</u> section. Lau et al. (2006) evaluated increased liver weight on GD 18 in pregnant mice dosed with PFOA on GD 1-18. The data for liver weight and serum PFOA levels in pregnant mice in this publication are not presented in a form that is appropriate for dose-response modeling of increased relative liver weight. Data on absolute liver weight and serum PFOA levels are presented in graphical form in the publication; numerical data for absolute liver weight, and liver weight relative to body weight minus weight of gravid uterus, were obtained from the investigator.

Macon et al. (2011) evaluated relative liver weight on PND 1 in female offspring exposed *in utero* on GD 10-17. Comparison of serum PFOA level LOAELs for increased relative liver weight in neonatal female mice in Macon et al. (2011) and in adult male mice (Loveless et al., 2006) suggest similar sensitivity to this effect at both life stages.

The relative liver weight data from male mice exposed to branched/linear PFOA for 14 days (Loveless et al., 2006) were selected for dose-response modeling. These data are shown in Table 17. The branched/linear isomeric mixture is relevant to environmental contamination and human exposure, and almost all toxicological studies of PFOA used the branched/linear isomeric mixture. An increasing response with dose was observed in mice for increased relative liver weight from branched/linear PFOA over the range of doses used in this study. Data from both the standard strain and PPAR-alpha null strains of mice demonstrate that increased liver weight and other types of hepatic toxicity occur through both PPAR-alpha dependent and independent modes of action in mice, and these effects are considered relevant to humans. As shown in Figure 13 in the <u>Mode of Action</u>

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 314 of 551

section, increased liver weight was not correlated with PPAR-alpha activity in mice in Loveless et al. (2006). As discussed above, relative liver weight does not appear to increase in magnitude with longer exposure durations. Therefore, 14 days is considered to be of sufficient duration, particularly since dose-response modeling is based on serum PFOA level, rather than administered dose, thus avoiding uncertainties about whether internal dose increases with exposures longer than 14 days.

Table 17: Serum PFOA and relative liver weight in Male						
CD-1 mice dosed with branched/linear PFOA for 14 days						
(Loveless et al., 2006)						
Dose Serum Relative Liver						
(mg/kg/day)	/day) PFOA Weigh					
	(µg/ml)	(g/100 g)				
0	0.04±0.02	5.14±0.27				
0.3	10±1.4	6.12±0.25				
1	27±5.0	7.92±0.49				
3	66±8.6	10.72±0.63				
10	190±29	16.27±1.05				
30	241±28	18.28±1.57				

Determination of Point of Departure (POD) for increased relative liver weight

USEPA Benchmark Dose Modeling Software 2.6.0.88 was used to perform BMD modeling of the data on increased relative liver weight in male mice exposed to linear/branched PFOA from Loveless et al. (2006). BMD and BMDL serum levels were determined for a BMR of a 10% increase in mean relative liver weight from the control values. All models for continuous data included in the software were run.

Results of the BMD modeling are shown in Table 18, and a more detailed explanation and the complete output of the BMDS software for each model are presented in Appendix 7. Both of the exponential models (models 4 and 5) gave identical fits. These exponential models and the 3rd

degree polynomial model gave acceptable fits to these data. The 3rd degree polynomial model over-fits the data at the high dose, forcing a fit and resulting in a biologically unlikely fit in this area of the dose-response curve. However, the fit of the 3rd degree polynomial model at the lower doses (i.e., in the range of the BMD) is regular and biologically appropriate. It is unlikely that the forced fit at the high dose has any significant influence on the fit of the model at the BMD. Although the 3rd degree polynomial model gave a slightly better fit than the exponential models and also yielded a slightly lower BMDL, the exponential models produced a highly comparable fit and a similar BMDL. As neither model appears to have a claim to greater biological significance, it was recommended that the point-of-departure be derived as the average of the BMDLs for both of these models. **This yielded an average BMDL of 4,351 ng/ml.**

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 315 of 551

Table 18. Benchmark Dose analysis for a 10% increase in relative liver weight from linear/branched PFOA in male mice (Loveless et al., 2006)^a

Model	Chi-square p-value ^b	AIC ^c	BMD (Serum PFOA, ng/ml)	BMDL (Serum PFOA, ng/ml)
Exponential (Models 4 and 5)	0.2636	2.12782	4,904 ^d	4,466 ^d
Hill	-	-	-	-
Linear	-	-	-	-
Polynomial (2 nd degree)	0.03245 °	6.92134	5,317	4,896
Polynomial (3 rd degree)	0.4678	1.66669	4,682 ^d	4,236 ^d
Average of Exponential (Models 4 and 5) and Polynomial (3rd degree)			4,793	4,351

^a Results are shown for all models that gave an acceptable visual fit.

^b A larger Chi-square p-value indicates a better fit to the data.

^c AIC: A measure of information loss from a dose-response model that can be used to compare a specified set of models. The AIC is defined as $-2 \times (LL - p)$, where LL is the log-likelihood of the model given the data, and p is the number of parameters estimated in the model. When comparing models, a lower AIC is preferable to a higher one (USEPA, 2012a).

^d BMDs and BMDLs from the models used to derive the point of departure, as discussed in text.

Application of uncertainty factors for increased relative liver weight

The choice of UFs is consistent with current USEPA IRIS guidance (USEPA, 2012c) and previous risk assessments developed by NJDEP and the DWQI.

The BMDL of 4,351 ng/ml was used as the POD for RfD development. UFs were applied to the POD serum level of 4,351 ng/ml to obtain the Target Human Serum Level. The Target Human Serum level (ng/ml serum) is analogous to the RfD but is expressed in terms of internal, rather than administered, dose.

The total of the UFs applied to the POD serum level was 300, and included the following factors:

- 10 UF for <u>human variation</u>, to account for variation in susceptibility across the human population and the possibility that the available data may not be representative of individuals who are most sensitive to the effect.
- 3 UF for <u>animal-to-human extrapolation</u>, to account for toxicodynamic differences between humans and mice.

The typical uncertainty factor of 3 for toxicokinetic variability between species is not included because the risk assessment is based on comparison of internal dose (serum levels) rather than administered dose.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 316 of 551

1 - UF for <u>LOAEL to NOAEL</u>.

The point of departure is a BMDL, not a LOAEL. Therefore, an adjustment for use of a LOAEL is not necessary.

1 - UF for <u>duration of exposure</u>.

The POD is based on increased liver weight resulting from exposure for 2 weeks, while the Healthbased MCL is intended to protect for chronic exposure. However, increased liver weight, usually associated with hepatocellular hypertrophy, is an early manifestation of PFOA's hepatic toxicity. Data from the relevant studies (reviewed above) indicate that the dose-response for this effect, on an internal dose (serum PFOA level) basis, is similar after 2 weeks of exposure and from longer exposures, and that this effect does not appear to occur at lower internal doses (serum PFOA levels) or increase in magnitude with chronic exposures. Rather, the initial effect (increased liver weight accompanied by hepatocellular hypertrophy) appears to progress over time to other more severe hepatic types of effects. Therefore, an adjustment based on duration of exposure is not necessary.

10 - UF for more sensitive effects that are not otherwise considered (e.g. incomplete database).

USEPA IRIS guidance (USEPA, 2012c) states that: "If an incomplete database raises concern that further studies might identify a more sensitive effect, organ system, or lifestage, the assessment may apply a database uncertainty factor." Adverse effects on mammary gland development occur at doses much more than 10-fold lower than those that cause increased relative liver weight. Additionally, hepatic toxicity not associated with increased liver weight occurs at similarly low doses after developmental exposures. Therefore, a UF of 10 to account for more sensitive effects was applied.

The target human serum level is: $\frac{4351 \text{ ng/ml}}{300} = 14.5 \text{ ng/ml} (14,500 \text{ ng/L})$

Development of Reference Dose for increased relative liver weight

As above, the clearance factor $(1.4 \times 10^{-4} \text{ L/kg/day}; \text{USEPA}, 2016a)$ was used to derive the RfD from the Target Human Serum Level. This factor was used to develop the RfD that is the basis for the recommended Health-based MCL. As discussed in the <u>Toxicokinetics</u> section, the clearance factor is consistent with empirical data on the serum:drinking water ratio from communities with contaminated drinking water. It should be noted that health-based drinking water values may also be developed from target human serum levels for PFOA and other PFCs using an approach based on this ratio.

14,500 ng/L x 1.4 x 10^{-4} L/kg/day = 2 ng/kg/day

Where: 14,500 ng/L = Target Human Serum Concentration 1.4 x 10^{-4} L/kg/day = Clearance Factor 2 ng/kg/day = RfD

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 317 of 551

Relative Source Contribution factor

A Relative Source Contribution (RSC) factor that accounts for non-drinking water sources including food, soil, air, water, and consumer products is used in the development of health-based drinking water concentrations based on non-carcinogenic effects. An RSC is used by the DWQI for Health-based MCLs, by USEPA for Maximum Contaminant Level Goals, and by other states in development of similar health-based drinking water values. The RSC is intended to prevent total exposure from all sources from exceeding the RfD (USEPA, 2000). When sufficient chemical-specific information on non-drinking water exposures is not available, a default RSC of 0.2 (20%) is used. This default value assumes that 20% of exposure comes from drinking water and 80% from other sources (USEPA, 2000). When sufficient chemical-specific RSC may be derived, with floor and ceiling RSC values of 20% and 80% (USEPA, 2000).

The Health Effects Subcommittee concluded that there are insufficient data to develop a chemical-specific RSC for PFOA. There are no New Jersey-specific biomonitoring data for PFOA, and its frequent occurrence in NJ PWS suggests that New Jersey residents may also have higher exposure from non-drinking sources than the U.S. general population (e.g. NHANES). Elevated levels of PFOA were detected in PWS located throughout NJ in USEPA UCMR3 and other monitoring studies; PFOA was detected much more frequently at > 20 ng/L in NJ PWS (10.5%) than nationwide (1.9%) in UCMR3 (discussed in the Drinking Water Occurrence section). Potential sources of this contamination have been identified in some instances, while sources are unknown in other locations. Environmental contamination with PFOA that results in its presence in drinking water can arise from a number of different types of sources (reviewed in Fate and Transport Relevant to Drinking Water Contamination). These include releases to air, soil, and water from fluoropolymer telomer manufacturing facilities, on-site and off-site disposal from smaller industrial facilities that make products from fluoropolymer dispersions containing PFOA, releases of aqueous firefighting foams, and land application of biosolids from wastewater treatment plants treating waste containing PFOA, among others. These various sources may potentially result in human exposures through contamination of nearby soils, house dust, or other environmental media. In communities with drinking water contamination, consumption of produce from home gardens or grown locally was associated with higher serum levels of PFOA (Emmett et al., 2006a; Holzer et al., 2008; Steenland et al., 2009a).

The exposure factors used to develop the Health-based MCL (below) are based on an adult drinking water consumption rate and body weight. The default RSC of 20%, while not explicitly intended for this purpose, also partially accounts for the higher PFOA exposures in infants. Exposures to infants, both breastfed and consuming formula prepared with contaminated drinking water, are much higher than in than older individuals. Infants consume much more fluid (breast milk or formula) than older individuals on a body weight basis; about 10-fold more from birth to 1 month of age, and 4 -6 fold more between ages 6-12 months. Additionally, PFOA concentrations in breast milk are similar or higher than in the mother's drinking water source (Post et al., 2012).

For these reasons, although serum levels in infants are similar to their mother's at birth (Post et al., 2012), they increase rapidly by several-fold shortly after birth for a period of at least several months. As shown in Figure 16, this increase was five-fold or greater in a considerable portion of infants evaluated in two studies (Fromme et al., 2010; Mogensen et al., 2015). Additionally, Monte Carlo simulations of results of a pharmacokinetic model predict median, 95th percentile, and maximum infant:mother plasma PFOA ratios of 4.5-fold, 7.8-fold,

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 318 of 551

and 15.3-fold, respectively, during the period of greatest infant exposure (Verner et al., 2016a; Figure 17).




Figure 16. Changes in PFOA levels in breast-fed infants from birth to later timepoints (Fromme et al., 2010; Mogensen et al., 2015)




Figure 17. Monte Carlo simulations of child/mother ratios of plasma PFOA levels (ng/ml) a breastfeeding period of 30 months. Black line - 50th percentile; blue line - 5th percentile; red line - 95th percentile; dotted lines - minimum and maximum values (Verner et al., 2016).

These higher infant exposures must be considered because the toxicological effects of concern (delayed mammary gland development and increased relative liver weight) occur from short term exposures relevant to elevated exposures in infancy. Cross-fostering studies (discussed in Toxicology section) show that lactational exposure causes increased relative liver weight and delayed mammary gland development (White et al., 2007; White et al., 2009) in animals with no *in utero* exposure. Additionally, hepatic toxicity that persists until adulthood occurs in offspring of dams exposed to low doses of PFOA during gestation (Quist et al., 2015). These effects could result from prenatal or lactational exposure, or both.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 319 of 551

For the reasons discussed above, the default RSC of 20% is used to develop the Health-based MCL.

Development of potential Health-based MCL based on hepatic effects

 $\frac{2 \text{ ng/kg/day x 70 kg x 0.2}}{2 \text{ L/day}} = 14 \text{ ng/L} (0.014 \text{ }\mu\text{g/L})$

Where:

2 ng/kg/day = Reference Dose 70 kg = assumed adult body weight 0.2 = Relative Source Contribution from drinking water 2 L/day = assumed adult daily drinking water intake

Potential Health-based MCL based on carcinogenicity

PFOA caused tumors in male rats in two chronic studies (Sibinski et al., 1987, Butenhoff et al., 2012; and Biegel et al., 2001). It caused a statistically significant increase in testicular Leydig cell tumors in both studies, as well as a statistically significant increase in liver tumors and pancreatic tumors in Biegel et al. (2001). The testicular tumor data from the chronic dietary exposure rat study reported by Sibinski et al. (1987) and Butenhoff et al. (2012) are appropriate for BMD modeling and can be used as the basis for development of a cancer potency factor. This study used two PFOA dose levels, and the incidence of testicular tumors increased in a dose-related fashion. Because Biegel et al. (2001) used only one dose, data from this study are not appropriate for dose-response modeling. As discussed above, the mode of action for rat testicular tumors has not been established and they are considered relevant to humans for the purposes of risk assessment. USEPA Guidelines for Carcinogen Risk Assessment (USEPA, 2005b) state that linear low-dose extrapolation should be used for dose-response modeling if the mode of action has not been established. Therefore, the linear low-dose extrapolation approach is appropriate for dose-response modeling of these testicular tumors. The linear low-dose extrapolation approach is based on the assumption that exposure to any dose of a carcinogen results in some risk of cancer.

The incidence of testicular tumors (Sibinski et al., 1987: Butenhoff et al., 2012) was 0/49, 2/50, and 7/50 in the control, 30 ppm (1.3 mg/kg/day), and 300 ppm (14.2 mg/kg/day) groups. Modeling was performed using EPA BMD software (version 2.6.0.86). Because serum PFOA levels were not measured in this study, the BMDL and slope factor were modeled in terms of dose administered to rats. The value based on administered dose to rats was then converted to the equivalent human dose, based on pharmacokinetic differences (ratio of half-lives) between rats and humans. A benchmark response (BMR) of 0.05 (5%) tumor incidence was selected for consistency with the recommendations for selection of the POD for cancer potency factor derivation in the USEPA (2005b) Guidance for Carcinogen Risk Assessment. This value is close to the 4% response at the lowest dose in this data set. Results of the modeling are shown in Table 21, and the complete output from the modeling is found in Appendix 8.

Table 19. BMD modeling (0.05 BMR; 5% response) of rat testicular tumor data (Butenhoff et al., 2012)^a

2012) ^a Model	Chi- square p-value ^b	AIC ^c	BMD (mg/kg/day)	BMDL (mg/kg/day)	Rat Cancer Potency Factor (mg/kg/day) ⁻¹	Rat Dose at 1 x 10 ⁻⁶ risk (mg/kg/day)
Gamma	0.2292	62.6851	4.42913 ^d	2.50664 ^d	0.020	5.0 x 10 ⁻⁵
(power restricted						
to ≥ 1)						
Multistage (betas ≥ 0)						
Weibull (power restricted to ≥ 1)						
Quantal linear						
Gamma	1.00	61.2908	4.42913	1.36483e-6		
(power unrestricted)						
Log-logistic	1.00	61.2908	1.95859	2.00091e-6		
(power unrestricted)						
Logisitic	0.1905	63.6843	8.85708	6.49805		
Log-logistic	0.2338	62.5526	4.02707 ^d	2.2101^d	0.023	4.3 x 10 ⁻⁵
(slope restricted to ≤ 1)						
Probit	0.1948	63.625	8.32341	5.95965		
Weibull	1.00	61.2908	1.97407	1.65976e-6		
(power unrestricted)						
Average of Gamma (and				2.36	0.021	4.8 x 10-5
other identical models)						
and Log-logistic						
(slope restricted to ≤ 1)						

^a Results are shown for all models that gave an acceptable visual fit.

^b A larger Chi-square p-value indicates a better fit to the data.

^c AIC: A measure of information loss from a dose-response model that can be used to compare a specified set of models. The AIC is defined as $-2 \times (LL - p)$, where LL is the log-likelihood of the model given the data, and p is the number of parameters estimated in the model. When comparing models, a lower AIC is preferable to a higher one (USEPA, 2012a).

^d BMDs and BMDLs from the models used to derive the potency factor, as discussed in the text.

The Gamma model with power restricted to ≥ 1 (and the other models shown in the same cell in Table 19) and the Log-logistic model with slope restricted to ≤ 1 fit the data very similarly and yielded very similar BMDLs. Because neither of these models has a form that is obviously more biologically accurate, it is appropriate to average their BMDLs. The average BMDL for these models is **2.36 mg/kg/day**. For a 5% BMR, the corresponding cancer potency factor in rats is **0.021 (mg/kg/day)**⁻¹, and the dose in rats corresponding to a 1 x 10^{-6} risk is estimated as **4.8 x 10**⁻⁵ mg/kg/day. These values are shown in the last row of Table 19.

As above, the dose-response modeling was based on administered PFOA dose to rats (mg/kg/day) instead of internal dose (serum PFOA level) since serum PFOA levels were not measured in the study. Thus, the rat doses derived through the modeling must be converted to equivalent human doses. As per USEPA (2005b) guidelines for carcinogen risk assessment, this adjustment is made based on pharmacokinetic differences between species instead of through the default adjustment based on body weight^{3/4}. To make the interspecies adjustment, the dose in male rats corresponding to a 1 x 10^{-6} cancer risk is converted to the human equivalent dose based on the

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 321 of 551

ratio of half-lives in the two species. This approach accounts for the much longer half-life of PFOA in humans than male rats, although it is associated with more uncertainty than an approach using measured serum PFOA levels.

The half-lives used for this adjustment were 7 days for male rats and 2.3 years (840 days) for humans. The half-life in male Sprague-Dawley rats after a single gavage dose of 0.1 to 25 mg/kg PFOA was about 7 days and was independent of dose (Kemper et al., 2003). Bartell et al. (2010a) estimated a human half-life of 2.3 years for a one-year period after exposure to contaminated drinking water ceased; elimination rate was not affected by age or gender. The ratio of these human and rat half-lives (840 days/7 days) is 120.

Therefore, the human dose corresponding to a 1×10^{-6} lifetime cancer risk is estimated as:

$(4.8 \times 10^{-5} \text{ mg/kg/day}) / 120 = 4 \times 10^{-7} \text{ mg/kg/day} (4 \times 10^{-4} \mu \text{g/kg/day}; 0.4 \text{ ng/kg/day})$

This corresponds to a human cancer potency factor of **2.52** $(mg/kg/day)^{-1}$ (i.e. rat cancer potency factor x ratio of human/rat half-lives; 0.021 $(mg/kg/day)^{-1}$ x 120).

Using default drinking water assumptions (2 L/day water consumption; 70 kg body weight), the potential Health-based MCL at the 1 x 10^{-6} lifetime cancer risk level is:

 $\frac{0.4 \text{ ng/kg/day x 70 kg}}{2 \text{ L}} = 14 \text{ ng/L} (0.014 \text{ }\mu\text{g/L})$

This value is identical to the Health-based MCL based on non-cancer endpoints developed above.

Recommended Health-based MCL

A potential Health-based MCL based on the RfD for delayed mammary gland development was not developed, for reasons discussed above. The potential Health-based MCL based on the RfD for increased relative liver weight is 14 ng/L (0.014 μ g/L). The potential Health-based MCL based on a lifetime carcinogenic risk one in one million (1 x 10⁻⁶), the cancer risk goal for New Jersey MCLs, is also 14 ng/L.

Therefore, the recommended Health-based MCL is 14 ng/L (0.014 μ g/L).

DISCUSSION OF UNCERTAINTIES

• PFOA is associated with multiple human health effects in epidemiology studies of the general population and communities with drinking water exposure. There is evidence to support multiple criteria for causality for some of these endpoints. Although causality cannot be definitively proven for these associations of PFOA with human health effects, these numerous findings indicate the need for caution about drinking water exposures that will increase serum PFOA to levels substantially higher than in the general population. This is particularly true because elevated serum PFOA levels persist for many years after exposure ends, due to its long human half-life (several years).

Ongoing exposure to the recommended Health-based MCL of 14 ng/L is expected to increase serum PFOA levels, on average, by about 1.6 ng/ml (ppb) with average daily water consumption and 2.8 ng/ml (ppb) with upper percentile daily water consumption in adults. Increases in serum PFOA levels are predicted to be several-

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 322 of 551

fold higher than in infants than in adults, including both breastfed infants whose mothers ingest PFOA in drinking water or from formula prepared with water contaminated with PFOA.

• The potential for prenatal and early life exposures to environmental contaminants to cause adverse health effects later in life is currently a focus of high interest in both epidemiology and toxicology (Boekelheide et al., 2012; Heindel and Vandenberg, 2015). Developmental exposures to PFOA caused effects in mice, with no threshold (NOAEL) identified, at doses far below those that caused effects in older animals. These effects include persistent changes in the mammary gland, persistent damage to hepatic cells, persistent neurobehavioral effects from a single relatively low dose to the pregnant dam, and obesity and metabolic changes in adulthood. Some of these effects were not evident until later in life and/or adulthood, long after the administered PFOA has been eliminated from the body. Some of these effects (obesity/overweight later in life after prenatal exposure; neurobehavioral effects) have been evaluated in humans, with both positive and negative findings among the studies. As discussed in the <u>Development of Health-Based MCL</u> section, the Target Human Serum Level based on delayed mammary gland development in mice is below the serum PFOA levels prevalent in the general population. The proposed Health-based MCL includes an uncertainty factor to protect for more sensitive developmental effects. However, there is still uncertainty about whether it is sufficiently protective for subtle effects later in life that may result from very low exposures during the developmental period.

• Chronic toxicity and carcinogenicity of PFOA have been studied only in the rat, a species in which PFOA is rapidly excreted by females. There is uncertainty about chronic effects including carcinogenicity in other species such as mice in which PFOA is persistent in both sexes. Furthermore, the chronic studies did not assess effects including carcinogenicity which might result from exposures during the critical developmental stages now known to be sensitive periods for PFOA toxicity.

• Uncertainties about the human relevance of effects seen in animals are inherent to all risk assessments based on animal data. As reviewed in detail in this document, the available information indicates that the effects of PFOA observed in experimental animals are relevant to humans for the purposes of risk assessment.

• Available information indicates that the target organs and modes of action are generally similar for PFOA and some other PFCs, including PFNA (DWQI, 2015c). Therefore, the toxicity of PFOA and other PFCs may be additive. Although PFOA and other PFCs, including PFNA, are known to co-occur in some NJ public water supplies, the potential for additive toxicity of PFOA and other PFCs was not considered in development of the Health-based MCL.

CITATIONS

Abbott, B. D., Wolf, C. J., Schmid, J. E., Das, K. P., Zehr, R. D., Helfant, L., Nakayama, S., Lindstrom, A. B., Strynar, M. J., Lau, C. (2007). Perfluorooctanoic acid induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-alpha. Toxicol. Sci. 98: 571–581.

Abbott, B.D. (2009). Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. Reprod. Toxicol. 27: 246-257.

Abbott, B.D., Wood, C.R., Watkins, A.M., Das, K.P., Lau, C.S. (2010). Peroxisome proliferator-activated receptors alpha, beta, and gamma mRNA and protein expression in human fetal tissues. PPAR Res. Volume 2010, Article ID 690907

Abbott, B.D., Wood, C.R., Watkins, A.M, Tatum-Gibbs, K., Das, K.P., Lau, C. (2012). Effects of perfluorooctanoic acid (PFOA) on expression of peroxisome proliferator-activated receptors (PPAR) and nuclear receptor-regulated genes in fetal and postnatal CD-1 mouse tissues. Reprod Toxicol. 33: 491-505

Abdellatif, A.G., Preat, V., Taper, H.S., Roberfroid, M. (1991). The modulation of rat liver carcinogenesis by perfluorooctanoic acid, a peroxisome proliferator. Toxicol. Appl. Pharmacol. 111: 530-537.

Abdelmegeed, M.A., Yoo, S.H., Henderson L.E., Gonzalez, F.J., Woodcroft, K.J., Song, B.J. (2011). PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J. Nutr. 141: 603-10.

Albrecht, P. P., Torsell, N. E., Krishnan, P., Ehresman, D. J., Frame, S. R., Chang, S. C., Butenhoff, J. L., Kennedy, G. L., Gonzalez, F. J., Peters, J. M. (2013). A species difference in the peroxisome proliferatoractivated receptor alpha-dependent response to the developmental effects of perfluorooctanoic acid. Toxicol. Sci. 131: 568-582.

Alexander, B.H., Olsen, G.W., Burris, J.M., Mandel, J.H., Mandel, J.S. (2003). Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility. Occup. Environ. Med. 60: 722-729.

Alexander, B.H., Olsen, G.W. (2007). Bladder cancer in perfluorooctanesulfonyl fluoride manufacturing workers. Ann. Epidemiol. 17: 471-478.

Andersen, M.E., Clewell, H.J., Tan, Y., Butenhoff, J. L., Olsen, G. W. (2006). Pharmacokinetic modeling of saturable, renal resorption of Perfluoroalkyl acids in monkeys—Probing the determinants of long plasma half-lives. Toxicology 227: 156–164.

Andersen, C.S., Fei, C., Gamborg, M., Nohr, E.A., Sørensen, T.I., Olsen, J. (2010). Prenatal exposures to perfluorinated chemicals and anthropometric measures in infancy. Am. J. Epidemiol. 172: 1230-1337.

Andersen, C. S., Fei, C., Gamborg, M., Nohr, E. A., Sorensen, T. I., Olsen, J. (2013). Prenatal exposures to perfluorinated chemicals and anthropometry at 7 years of age. Am. J. Epidemiol. 178: 921-927.

Anderson-Mahoney, P., Kotlerman, J., Takhar, H., Gray, D., Dahlgren, J.C. (2008). Self-reported health effects among community residents exposed to perfluorooctanoate. New Solut. 18: 129-143.

Apel, P., Angerer, J., Wilhelm, M., Kolossa-Gehring, M. (2016). New HBM values for emerging substances, inventory of reference and HBM values in force, and working principles of the German Human Biomonitoring Commission. Int. J. Hyg. Environ. Health (in press).

Apelberg, B.J., Witter, F.R., Herbstman, J.B., Calafat, A.M., Halden, R.U., Needham, L.L., Goldman, L.R. (2007). Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. Environ. Health Perspect. 115: 1670-1676.

Appleman, T.D., Higgins, C. P., Quinones, O., Vanderford, B.J, Kolstad, C., Zeigler-Holady, J.C., Dickenson, E.R. (2014). Treatment of poly- and perfluoroalkyl substances in U.S. full-scale water treatment systems. Water Res. 51: 246-255.

ATSDR (2013). Agency for Toxics Substances and Disease Registry. Health Consultation. Exposure Investigation Report. Perfluorochemical serum sampling in the vicinity of Decatur, Alabama. Morgan, Lawrence, and Limestone Counties. April 1, 2013. http://www.atsdr.cdc.gov/HAC/pha/Decatur/Perfluorochemical_Serum%20Sampling.pdf

ATSDR (2015). Agency for Toxics Substances and Disease Registry. Toxicological Profile for Perfluoroalkyls. Draft for Public Comment. August 2015.

Backe W.J., Day, T.C., Field, J.A. (2013). Zwitterionic, cationic, and anionic fluorinated chemicals in aqueous film forming foam formulations and groundwater from U.S. military bases by nonaqueous large-volume injection HPLC-MS/MS. Environ. Sci. Technol. 47: 5226-34.

Balakumar, P. and Mahadevan, N. (2015). Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? Br. J. Pharmacol. 165: 373-9.

Barouki, R., Gluckman, P.D., Grandjean, P., Hanson, M., Heindel, J.J. (2012). Developmental origins of non-communicable disease: implications for research and public health. Environ. Health. 11: 42.

Barry, V., Winquist, A., Steenland, K. (2013). Perfluorooctanoic acid (PFOA) exposures and incident cancers among adults living near a chemical plant. Environ. Health Perspect. 121: 1313-1318.

Barry, V., Darrow, L.A. Klein, M., Winquist, A. Steenland, K. (2014). Early life perfluorooctanoic acid (PFOA) exposure and overweight and obesity risk in adulthood in a community with elevated exposure. Environ. Res. 132: 62-69.

Bartell, S.M., Calafat, A.M., Lyu, C., Kato, K., Ryan, P.B., Steenland, K. (2010a). Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia. Environ. Health Perspect. 118: 222-8.

Bartell, S.M., Lyu, C., Ryan, P.B., Steenland, K. (2010b). Decline of perfluorooctanoic acid in human serum before and after granular activated carbon filtration in two public water supplies, and implications for half-life estimation. Presented at PFAA Days III, Research Triangle, Park, NC. June 2010. http://www.health.state.mn.us/divs/eh/hazardous/topics/pfcs/pfaadays3.pdf Accessed 1/17/12.

Beesoon, S., Webster G.M., Shoeib, M., Harner, T., Benskin, J.P., Martin, J.W. (2011). Isomer profiles of perfluorochemicals in matched maternal, cord and house dust samples: manufacturing sources and transplacental transfer. Environ. Health Perspect. 119: 1659-1664.

Beesoon, S., Martin, J.W. (2015). Isomer-specific binding affinity of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) to serum proteins. Environ. Sci. Technol. 49: 5722-31.

Benninghoff, A.D., Bisson, W.H., Koch, D.C., Ehresman, D.J., Kolluri, S.K., Williams, D.E. (2011). Estrogenlike activity of perfluoroalkyl acids in vivo and interaction with human and rainbow trout estrogen receptors in vitro. Toxicol. Sci. 120: 42-58.

Benninghoff A.D., Orner, G.A., Buchner, C.H., Hendricks, J.D., Duffy, A.M., Williams, D.E. (2012). Promotion of hepatocarcinogenesis by perfluoroalkyl acids in rainbow trout. Toxicol Sci. 125: 69-78.

Benskin, J.P., De Silva, A.O., Martin, L.J., Arsenault, G., McCrindle, R., Riddell, N., Mabury, S.A., Martin, J.W. (2009). Disposition of perfluorinated acid isomers in Sprague-Dawley rats; part 1: single dose. Environ. Toxicol. Chem. 28: 542-554.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 325 of 551

Berthiaume, J. and K. B. Wallace (2002). Perfluorooctanoate, perfluorooctanesulfonate, and N-ethyl perfluorooctanesulfonamido ethanol; peroxisome proliferation and mitochondrial biogenesis. Toxicol. Lett. 129: 23-32

Biegel, L.B, Hurtt, M.E., Frame, S.R., O'Connor, J.C., Cook, J.C. (2001). Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol. Sci. 60: 44-55.

Black, S., Nicolay, U., Del Giudice, G., Rappuoli, R. (2016). Influence of statins on influenza vaccine response in elderly individuals. J. Infect. Dis. 213: 1224-8.

Bloom, M. S., Kannan, K. Spliethoff, H. M., Tao, L. Aldous, K. M, Vena, J.E. (2010). Exploratory assessment of perfluorinated compounds and human thyroid function. Physiol. Behav. 99: 240-245.

Boekelheide K, Blumberg B, Chapin R.E., Cote I., Graziano J.H., Janesick, A., Lane, R., Lillycrop, K, Myatt, L., States J.C., Thayer, K.A., Waalkes, M.P., Rogers, J.M. (2012). Predicting later-life outcomes of early-life exposures. Environ. Health Perspect. 120: 1353-61.

Botelho S.C., Saghafian M, Pavlova S, Hassan M, DePierre J.W., Abedi-Valugerdi M. (2015). Complement activation is involved in the hepatic injury caused by high-dose exposure of mice to perfluorooctanoic acid. Chemosphere 129: 225-31.

Braun, J.M., Chen, A., Romano, M.E., Calafat, A.M., Webster, G.M., Yolton, K., Lanphear, B.P. (2016). Prenatal perfluoroalkyl substance exposure and child adiposity at 8 years of age: The HOME study. Obesity (Silver Spring) 24: 231-7.

Brede, E., Wilhelm, M., Göen, T., Müller, J., Rauchfuss, K., Kraft, M., Hölzer, J. (2010). Two-year follow-up biomonitoring pilot study of residents' and controls' PFC plasma levels after PFOA reduction in public water system in Arnsberg, Germany. Int. J. Hyg. Environ. Health 213: 217-223.

Buck, R.C., Franklin. J., Berger, U., Conder, J.M., Cousins, I.T., de Voogt, P., Jensen, A.A., Kannan, K., Mabury, S.A., van Leeuwen, S.P. (2011). Perfluoroalkyl and polyfluoroalkyl substances in the environment: terminology, classification, and origins. Integr. Environ. Assess. Manag. 7: 513-541.

Budd, A., Alleva, L., Alsharifi, M., Koskinen, A., Smythe, V., Müllbacher, A., Wood, J., Clark, I. (2007). Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob. Agents. Chemother. 51: 2965-8.

Buhrke, T., Krüger, E., Pevny, S., Rößler, M., Bitter, K., Lampen, A. (2015). Perfluorooctanoic acid (PFOA) affects distinct molecular signalling pathways in human primary hepatocytes. Toxicology 333: 53-62.

Butenhoff, J., Costa, G., Elcombe, C., Farrar, D., Hansen, K., Iwai, H., Jung, R., Kennedy, G., Lieder, P., Olsen, G., Thomford, P. (2002). Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. Toxicol. Sci. 69: 244-257.

Butenhoff, J.L., Kennedy, Jr, G.L., Hinderliter, P.M., Lieder, P.H., Jung, R., Hansen, K.J, Gorman, G.S., Noker, P.E., Thomford, P.J. (2004a). Pharmacokinetics of perfluorooctanoate in Cynomolgus monkeys. Toxicol. Sci. 82: 394-406.

Butenhoff, J.L., Kennedy, G.L., Frame, S.R., O'Conner, J.C., York, R.G. (2004b). The reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rat. Toxicology 196: 95-116.

Butenhoff, J. L., Gaylor, D. W., Moore, J. A., Olsen, G. W., Rodricks, J., Mandel, J. H., Zobel, L. R. (2004c). Characterization of risk for general population exposure to perfluorooctanoate. Regul. Tox. Pharmacol. 39: 363-380.

Butenhoff, J. L., Kennedy, G. L. Jr., Chang, S. C. Olsen, G. W. (2012). Chronic dietary toxicity and carcinogenicity study with ammonium perfluorooctanoate in Sprague-Dawley rats. Toxicology 298: 1-13.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 326 of 551

Butenhoff, J.L., Kennedy, G.L., Jung, R., Chang, S.C. (2014). Evaluation of perfluorooctanoate for potential genotoxicity. Toxicology Reports 1: 252-270.

Butt, C.M., Berger, U., Bossi, R., Tomy, G.T. (2010). Review: Levels and trends of poly- and perfluorinated compounds in the arctic environment. Sci. Total Environ. 408: 2936-2965.

Butt, C. M., Muir, D. C., Mabury, S. A. (2014). Biotransformation pathways of fluorotelomer-based polyfluoroalkyl substances: a review. Environ. Toxicol. Chem. 33: 243-267.

C8 Science Panel (undated, a). Background Informationo Lawsuit Settlement. http://www.c8sciencepanel.org/panel_background.html (accessed March 15, 2016).

C8 Science Panel (undated, b). The Science Panel Website. http://www.c8sciencepanel.org/ (Accessed March 15, 2016).

C8 Science Panel. (2011). Probable Link Evaluation of Preterm Birth and Low Birthweight. http://www.c8sciencepanel.org/pdfs/Probable_Link_C8_Preterm_and_LBW_birth_5Dec2011.pdf, (accessed March 18, 2016)

C8 Science Panel. (2012). "Probable Link Evaluation of Thyroid Disease." Retrieved February 12, 2016, http://www.c8sciencepanel.org/pdfs/Probable_Link_C8_Thyroid_30Jul2012.pdf (accessed February 12, 2016)

Calafat, A.M., Wong, L.Y., Kuklenyik, Z., Reidy, J.A., Needham, L.L. (2007). Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. Environ. Health Perspect. 115: 1596–1602.

CDC (2015). Centers for Disease Control and Prevention. Fourth National Report on Human Exposure to Environmental Chemicals. http://www.cdc.gov/biomonitoring/pdf/FourthReport_UpdatedTables_Feb2015.pdf.

CDC (2016). Centers for Disease Control and Prevention. National Center for Health Statistics. Diet/Nutrition. Last updated April 27, 2016. http://www.cdc.gov/nchs/fastats/diet.htm

Chan, E., Burstyn, I., Cherry, N. Bamforth, F., Martin, J. W. (2011). Perfluorinated acids and hypothyroxinemia in pregnant women. Environ. Res. 111: 559-564.

Cheng, X., Klaassen, C. D. (2008). Critical role of PPAR-alpha in perfluorooctanoic acid- and perfluorodecanoic acid-induced downregulation of Oatp uptake transporters in mouse livers. Toxicol. Sci. 106: 37-45.

Clarke, B.O., Smith, S.R. (2011). Review of 'emerging' organic contaminants in biosolids and assessment of international research priorities for the agricultural use of biosolids. Environ. Int. 37: 226-247.

Clewell, H.J. (2006). Application of pharmacokinetic modeling to estimate PFOA exposures associated with measured blood concentrations in human populations. Society for Risk Analysis 2006 Annual Meeting (PowerPoint Presentation).

Clewell, H. (2009). Pharmacokinetic modeling of PFOA and PFOS. PowerPoint presentation to USEPA, Washington DC, September 2009.

Conder, J.M., Hoke, R.A., De Wolf, W., Russell, M.H., Buck, R.C. (2008). Are PFCAs bioaccumulative? A critical review and comparison with regulatory criteria and persistent lipophilic compounds. Environ. Sci. Technol. 42: 995-1003.

Cornelis, C., D'Hollander, W., Roosens, L., Covac, A., Smolders, R., Van Den Heuvel, R., Govarts, E., Van Campenhout, K., Reynders, H., Bervoets, L. (2012). First assessment of population exposure to perfluorinated compounds in Flanders, Belgium. Chemosphere 86: 308-314.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 327 of 551

Corsini, E., Avogadro, A. Galbiati, V., dell'Agli, M. Marinovich, M., Galli, C. L., Germolec, D. R. (2011). In vitro evaluation of the immunotoxic potential of perfluorinated compounds (PFCs). Toxicol. Appl. Pharmacol. 250: 108-116.

Corton, J.C. (2010). Mode of action analysis and human relevance of liver tumors induced by PPAR-alpha activation. In: Hsu, C-H, Stedeford, T. (Eds.), Cancer Risk Assessment: Chemical Carcinogenesis from Biology to Standards Quantification, John Wiley & Sons, Inc., Hoboken, NJ.

Costa, G., Sartori, S., Consonni, D. (2009). Thirty years of medical surveillance in perfluooctanoic acid production workers. J. Occup. Environ. Med. 51: 364-372.

Cui, L., Zhou, Q. F. Liao, C. Y. Fu, J. J., Jiang, G. B. (2009). Studies on the toxicological effects of PFOA and PFOS on rats using histological observation and chemical analysis. Arch. Environ. Contam. Toxicol. 56: 338-349.

Cui, L., Liao, C. Y. Zhou, Q. F. Xia, T. M., Yun, Z. J., Jiang, G. B. (2010). Excretion of PFOA and PFOS in male rats during a subchronic exp osure. Arch. Environ. Contam. Toxicol. 58: 205-213.

Daniel, C.W., Silberstein, G.B. (1987). Chapter 1: Postnatal development of the rodent mammary gland. In: The Mammary Gland Development, Regulation and Function. Editors: Margaret C. Neville and Charles W. Daniel, Plenum Press, NY, London.

Darrow, L. A., Groth, A. C., Winquist, A. Shin, H. M., Bartell, S. M., Steenland, K. (2016). Modeled perfluorooctanoic acid (PFOA) exposure and liver function in a Mid-Ohio Valley community. Environ. Health. Perspect. (in press).

Das, K.P., Zehr, D., Strynar, M., Lindstrom, A., Wambaugh, J., Lau, C. (2010). Pharmacokinetic profiles of perfluorooctanoic acid in mice after chronic exposure. Toxicologist 114: 47.

Davis, K.L., Aucoin, M.D., Larsen, B.S., Kaiser, M.A., Hartten, A.S. (2007). Transport of ammonium perfluorooctanoate in environmental media near a fluoropolymer manufacturing facility. Chemosphere 67: 2011-2019.

de Cock, M., de Boer, M. R., Lamoree, M., Legler, J., van de Bor, M. (2014). Prenatal exposure to endocrine disrupting chemicals in relation to thyroid hormone levels in infants - a Dutch prospective cohort study. Environ. Health 13: 106

D'eon, J.C., Crozier, P.W., Furdui, V.I., Reiner, E.J., Libelo, E.L., Mabury, S.A. (2009). Observation of a commercial fluorinated material, the polyfluoroalkyl phosphoric acid diesters, in human sera, wastewater treatment plant sludge, and paper fibers. Environ. Sci. Technol. 43: 4589-4594.

D'eon, J.C., Mabury, S.A. (2011a). Exploring indirect sources of human exposure to perfluoroalkyl carboxylates (PFCAs): Evaluating uptake, elimination, and biotransformation of polyfluoroalkyl phosphate esters (PAPs) in the rat. Environ. Health Perspect. 119: 344-350.

D'eon, J.C., Mabury, S.A. (2011b). Is indirect exposure a significant contributor to the burden of perfluorinated acids observed in humans? Environ. Sci. Technol. 45: 7974-7984.

De Silva, A.O., Benskin, J.P., Martin, L.J., Arsenault, G., McCrindle, R., Riddell, N., Martin, J.W., Mabury, S.A. (2009b). Disposition of perfluorinated acid isomers in Sprague-Dawley rats; part 2: Subchronic dose. Environ. Toxicol. Chem. 28: 555-567.

Dewitt, J.C., Copeland, C.B., Strynar, M.J., Luebke, R.W. (2008). Perfluorooctanoic acid-induced immunomodulation in adult C57BL/6J or C57BL/6N female mice. Environ. Health Perspect. 116: 644-650.

Dewitt, J.C., Shnyra, A., Badr, M.Z., Loveless, SE., Hoban, D., Frame, S.R., Cunard, R., Anderson, S.E., Meade, B.J., Peden-Adams, M.M., Luebke, R.W., Luster M.I. (2009a). Immunotoxicity of perfluorooctanoic

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 328 of 551

acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. Crit. Rev. Toxicol. 39: 76-94.

DeWitt, J. C., Copeland, C. B., & Luebke, R. W. (2009b). Suppression of humoral immunity by perfluorooctanoic acid is independent of elevated serum cortisone concentration in mice. Toxicol. Sci., 109: 106-112.

Dewitt, J.C., Peden-Adams, M.M., Keller, J.M., Germolec, D.R. (2012). Immunotoxicity of perfluorinated compounds: recent developments. Toxicol. Pathol. 40: 300-11.

DeWitt, J.C., Williams, W.C., Creech, N.J., Luebke, R.W. (2016). Suppression of antigen-specific antibody responses in mice exposed to perfluorooctanoic acid: Role of PPARα and T- and B-cell targeting. J. Immunotoxicol. 13: 38-45.

D'Hollander, W., de Voogt, P., De Coen, W., Bervoets, L. (2010). Perfluorinated substances in human food and other sources of human exposure. Rev. Environ. Contam. Toxicol. 208: 179-215.

Dixon, D., Reed, C.E., Moore, A.B., Gibbs-Flournoy, E.A., Hines, E.P., Wallace, E.A., Stanko, J.P., Lu, Y., Jefferson, W.N., Newbold, R.R., Fenton, S.E. (2012). Histopathologic changes in the uterus, cervix and vagina of immature cd-1 mice exposed to low doses of perfluorooctanoic acid (PFOA) in a uterotrophic assay. Reproductive Toxicology 33:506-12

Domingo, J. L. (2012). Health risks of dietary exposure to perfluorinated compounds. Environ. Int. 40: 187-195.

DuPont and URS Diamond Corporate Remediation Group, 2008. Data Assessment Dupont Washington Works (OPPT-2004-0113 PFOA Site-Related Environmental Assessment Program). http://itp-pfoa.ce.cmu.edu/docs/Data%20Assessment/DA%20Report-1%20100208%20Text%20and%20Tables.pdf. Accessed 6/16/11.

DuPont (2009). Private Drinking Water Well Survey and Sampling Update. DuPont Chambers Works Facility, Deepwater, New Jersey (Table 1). Data submitted to NJDEP, May 12, 2009.

DWQI (1987). New Jersey Drinking Water Quality Institute. Maximum Contaminant Level Recommendations for Hazardous Contaminants in Drinking Water. March 26, 1987.

DWQI (1994). New Jersey Drinking Water Quality Institute. Maximum Contaminant Level Recommendations for Hazardous Contaminants in Drinking Water. March 26, 1987.

DWQI (2009). New Jersey Drinking Water Quality Institute. Maximum Contaminant Level Recommendations for Hazardous Contaminants in Drinking Water. March, 2009a.

DWQI (2009b). New Jersey Drinking Water Quality Institute. Minutes of January 27, 2009 meeting. http://www.nj.gov/dep/watersupply/pdf/minutes090127.pdf

(DWQI, 2010). New Jersey Drinking Water Quality Institute. Minutes of September 10, 2010meeting. http://www.nj.gov/dep/watersupply/pdf/minutes100910.pdf

DWQI (2015a). New Jersey Drinking Water Quality Institute. Maximum Contaminant Level Recommendations for Perfluorononanoic Acid in Drinking Water. July 1, 2015. http://www.nj.gov/dep/watersupply/pdf/pfna-recommend-final.pdf

DWQI (2015b). New Jersey Drinking Water Quality Institute. Recommendation on Perfluorinated Compound Treatment Options for Drinking Water. New Jersey Drinking Water Quality Institute Treatment Subcommittee. June 2015. http://www.nj.gov/dep/watersupply/pdf/pfna-pfc-treatment.pdf

DWQI (2015c). New Jersey Drinking Water Quality Institute. Health-Based Maximum Contaminant Level Support Document: Perfluorononanoic Acid (PFNA). New Jersey Drinking Water Quality Institute Health Effects Subcommittee. June 22, 2015. http://www.nj.gov/dep/watersupply/pdf/pfna-health-effects.pdf

ECHA (2013). European Chemical Agency. Member State Committee Support Document for Identification of Pentadecafluorooctanoic Acid (PFOA) as a Substance of Very High Concern Because of its CMR1 and PBT2 Properties. June 14, 2013. http://echa.europa.eu/documents/10162/8059e342-1092-410f-bd85-80118a5526f5

ECHA (2015). European Chemical Agency. RAC concludes on PFOA restriction. September 30, 2015. http://echa.europa.eu/view-article/-/journal_content/title/rac-concludes-on-pfoa-restriction

EFSA (2008) European Food Safety Authority. Opinion of the Scientific Panel on Contaminants in the Food Chain on Perfluorooctane sulfonate (PFOS) and Perfluorooctanoic acid (PFOA) and their Salts. EFSA Journal, 2008, Journal number 653: 1-131; available at http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1211902012410.htm.

Eggen, T., Moeder, M., Arukwe, A. (2010). Municipal landfill leachates: a significant source for new and emerging pollutants. Sci. Total. Environ. 408: 5147-5157.

Elcombe, C.R., Elcombe, B.M, Foster, J.R., Farrar, D.G., Jung, R., Chang, S.C., Kennedy, G.L., Butenhoff, J.L. (2010). Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats following dietary exposure to ammonium perfluorooctanoate occurs through increased activation of the xenosensor nuclear receptors PPARalpha and CAR/PXR. Arch. Toxicol. 84: 787-798.

Emmett, E.A., Shofer, F.S., Zhang, H., Freeman, D., Desai, C., Shaw, L.M. (2006a). Community exposure to perfluorooctanoate: Relationships between serum concentrations and exposure sources. J. Occ. Environ. Med. 48: 759-770.

Emmett, E. A., Zhang, H., Shofer, F. S., Freeman, D., Rodway, N. V., Desai, C., Shaw, L. M. (2006b). Community exposure to perfluorooctanoate: relationships between serum levels and certain health parameters. J. Occup. Environ. Med. 48: 771-779.

Eriksen, K. T., Raaschou-Nielsen, O., McLaughlin, K., Lipworth, L., Tjonneland, A., Overvad, K., Sorensen, M. (2013). Association between plasma PFOA and PFOS levels and total cholesterol in a middle-aged Danish population. PLoS One 8: e56969.

Eschauzier, C., Beerendonk, E., Scholte-Veenendaal, P., De Voogt, P. (2012). Impact of treatment processes on the removal of perfluoroalkyl acids from the drinking water production chain. Environ. Sci. Technol. 46: 1708-1715.

Fang, J., Alderman, M. H. (2000). Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283: 2404-2410.

Fairley, K.J., Purdy, R., Kearns, S., Anderson, S.E., Meade, B.J. (2007). Exposure to the immunosuppressant, perfluorooctanoic acid, enhances the murine IgE and airway hyperreactivity response to ovalbumin. Toxicol. Sci. 97: 375-383.

Fasano, W.J., Kennedy, G.L., Szostek, B., Farrar, D.G., Ward, R.J., Haroun, L., Hinderliter, P.M. (2005). Penetration of ammonium perfluorooctanoate through rat and human skin in vitro. Drug Chem. Toxicol. 28: 79-90.

Fei, C., McLaughlin, J.K., Tarone, R.E., Olsen, J. (2007). Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. Environ. Health Perspect. 115: 1677-1682.

Fei, C., McLaughlin, J. K., Lipworth, L., Olsen, J. (2010). Maternal concentrations of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) and duration of breastfeeding. Scand. J. Work Environ. Health 36: 413-421.

Fenton, S.E. (2006). Endocrine-disrupting compounds and mammary gland development: early exposure and later life consequences. Endocrinology 147: 518-524.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 330 of 551

Fenton, S.E., Reiner, J.L., Nakayama, S.F., Delinsky, A.D., Stanko, J.P., Hines, E.P., White, S.S., Lindstrom, A.B., Strynar, M.J., Petropoulou, S.S. (2009). Analysis of PFOA in dosed CD-1 mice. Part 2. Disposition of PFOA in tissues and fluids from pregnant and lactating mice and their pups. Reprod. Toxicol. 27: 365-732.

Fenton, S.E., Reed, C., Newbold, R.R. (2012). Perinatal environmental exposures affect mammary development, function, and cancer risk in adulthood. Annu. Rev. Pharmacol. Toxicol. 52: 455-79.

Fenton, S.E., Birnbaum, L.S. (2015). Timing of environmental exposures as a critical element in breast cancer risk. J. Clin. Endocrinol. Metab. 100: 3245-50.

Filgo, A.J., Quist, E.M., Hoenerhoff, M.J., Brix, A.E., Kissling, G.E., Fenton, S.E. (2015). Perfluorooctanoic acid (PFOA)-induced liver lesions in two strains of mice following developmental exposures: PPARα is not required. Toxicol. Pathol. 43:558-68.

Fisher, M., Arbuckle, T. E., Wade, M., Haines, D. A. (2013). Do perfluoroalkyl substances affect metabolic function and plasma lipids?--Analysis of the 2007-2009, Canadian Health Measures Survey (CHMS) Cycle 1. Environ. Res. 121: 95-103.

Fitz-Simon, N., Fletcher, T., Luster, M. I., Steenland, K. Calafat, A. M., Kato, K., Armstrong, B. (2013). Reductions in serum lipids with a 4-year decline in serum perfluorooctanoic acid and perfluorooctanesulfonic acid. Epidemiology 24: 569-576.

Fletcher, T., Steenland, K., Savitz, D. (2009). Status Report: PFOA and immune biomarkers in adults exposed to PFOA in drinking water in the Mid Ohio Valley. http://www.c8sciencepanel.org/pdfs/ Status_Report_C8_and_Immune_markers_March2009.pdf. Accessed April 12, 2016.

Fletcher, T., Galloway, T. S., Melzer, D., Holcroft, P., Cipelli, R. Pilling, L. C., Mondal, D., Luster, M., Harries, L. W. (2013). Associations between PFOA, PFOS and changes in the expression of genes involved in cholesterol metabolism in humans. Environ. Int. 57-58: 2-10.

Frame, S.R., McConnell, E.E. (2003). Review of proliferative lesions of the exocrine pancreas in two chronic studies in rats with ammonium perfluorooctanoate. DuPont-13788. Oct. 16, 2003. (Cited in USEPA, 2005a).

Franko J., Meade, B.J., Frasch, H.F., Barbero, A.M., Anderson, S.E. (2012). Dermal penetration potential of perfluorooctanoic acid (PFOA) in human and mouse skin. J. Toxicol. Environ. Health A 75: 50-62.

Fraser, A.J., Webster, T.F., Watkins, D.J., Nelson, J.W., Stapleton, H.M., Calafat, A.M., Kato, K., Shoeib, M., Vieira, V.M., McClean, M.D. (2012). Perfluorinated compounds in serum linked to indoor air in office environments. Environ. Sci. Technol. 46: 1209-1215.

Fraser, A. J., Webster, T. F., Watkins, D. J., Strynar, M. J. Kato, K., Calafat, A. M., Vieira, V. M. McClean, M. D. (2013). Polyfluorinated compounds in dust from homes, offices, and vehicles as predictors of concentrations in office workers' serum. Environ. Int. 60: 128-136.

Freberg, B.I., Haug, L.S., Olsen, R., Daae, H.L., Hersson, M., Thomsen, C., Thorud, S., Becher, G., Molander, P., Ellingsen, D.G. (2010). Occupational exposure to airborne perfluorinated compounds during professional ski waxing. Environ. Sci. Technol. 44: 7723-7728.

Freedman, D. S., Williamson, D. F., Gunter, E. W., Byers, T. (1995). Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am. J. Epidemiol. 141: 637-644.

Frisbee, S. J., Brooks, Jr., A. P., Maher, A., Flensborg, P., Arnold, S., Fletcher, T., Steenland, K., Shankar, A., Knox, S. S., Pollard, C., Halverson, J. A., Vieira, V. M., Jin, C., Leyden, K. M., Ducatman, A. M. (2009). The C8 health project: design, methods, and participants. Environ. Health Perspect. 117: 1873-1882.

Frisbee, S. J., Shankar, A., Knox, S. S., Steenland, K. D., Savitz, A., Fletcher, T., Ducatman, A. M. (2010). Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project. Arch. Pediatr. Adolesc. Med. 164: 860-869. Fromme, H., Tittlemier, S.A., Völkel, W., Wilhelm, M., Twardella, D. (2009). Perfluorinated compoundsexposure assessment for the general population in Western countries. Int. J. Hyg. Environ. Health. 212: 239-270.

Fromme, H., Mosch, C., Morovitz, M., Alba-Alejandre, I., Boehmer, S., Kiranoglu, M., Faber, F., Hannibal, I., Genzel-Boroviczény, O., Koletzko, B., Völkel, W. (2010). Pre- and postnatal exposure to perfluorinated compounds (PFCs). Environ. Sci. Technol. 44: 7123-7129.

Fujii, Y., Harada, K. H., Koizumi, A. (2013). Occurrence of perfluorinated carboxylic acids (PFCAs) in personal care products and compounding agents. Chemosphere 93: 538-544.

Fu, Y., Wang, T., Fu, Q., Wang, P., Lu, Y. (2014). Associations between serum concentrations of perfluoroalkyl acids and serum lipid levels in a Chinese population. Ecotoxicol. Environ. Saf. 106: 246-252.

Fujii, Y., Niisoe, T., Harada, K. H., Uemoto, S., Ogura, Y., Takenaka, K., A. Koizumi, K. (2015). Toxicokinetics of perfluoroalkyl carboxylic acids with different carbon chain lengths in mice and humans. J. Occup. Health 57: 1-12.

Gallo, V., Leonardi, G., Genser, B., Lopez-Espinosa, M. J., Frisbee, S. J., Karlsson, L., Ducatman, A. M., Fletcher, T. (2012). Serum perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) concentrations and liver function biomarkers in a population with elevated PFOA exposure. Environ. Health Perspec. 120: 655-660.

Gao, Y, Fu, J., Cao, H, Wang, Y, Zhang A, Liang Y, Wang, T., Zhao, C, Jiang, G. (2015). Differential accumulation and elimination behavior of perfluoroalkyl Acid isomers in occupational workers in a manufactory in China. Environ. Sci. Technol. 49: 6953-62.

Gebbink, W. A., Glynn, A, Darnerud, P. O., Berger, U. (2015a). Perfluoroalkyl acids and their precursors in Swedish food: The relative importance of direct and indirect dietary exposure. Environ. Pollut. 198: 108-115.

Gebbink, W. A., Berger, U., Cousins, I. T. (2015b). Estimating human exposure to PFOS isomers and PFCA homologues: the relative importance of direct and indirect (precursor) exposure. Environ. Int. 74: 160-169.

Geiger, S. D., Xiao, J., Ducatman, A., Frisbee, S., Innes, K., Shankar, A. (2014). The association between PFOA, PFOS and serum lipid levels in adolescents. Chemosphere 98: 78-83.

Geiger, S. D., Xiao, J., Shankar, A. (2013). Positive association between perfluoroalkyl chemicals and hyperuricemia in children. Am. J. Epidemiol. 177: 1255-1262.

Genser, B., Teles C.A., Barreto M.L., Fischer, J.E. (2015). Within- and between-group regression for improving the robustness of causal claims in cross-sectional analysis. Environ. Health 10: 14:60.

Gewurtz, S.B., Bhavsar, S.P., Crozier, P.W., Diamond, M.L., Helm, P.A., Marvin, C.H. Reiner, E.J. (2009). Perfluoroalkyl contaminants in window film: indoor/outdoor, urban/rural, and winter/summer contamination and assessment of carpet as a possible source. Environ. Sci. Technol. 43: 7317–7323.

Gibson, H. M. (1973) Plasma volume and glomerular filtration rate in pregnancy and their relation to differences in fetal growth. J. Obstet. Gynaecol. Br. Commonw. 80: 1067-1074.

Gibson, S.J., Johnson, J.D. (1983). Extent and route of excretion of total carbon-14 in pregnant rats after a single oral dose of ammonium 14C-PFOA. Riker Laboratories, St. Paul, MN. USEPA AR-226-0458. (Cited in Hinderliter et al., 2005).

Gilliland, F. D., Mandel, J. S. (1996). Serum perfluorooctanoic acid and hepatic enzymes, lipoproteins, and cholesterol: a study of occupationally exposed men. Am. J. Ind. Med. 29: 560-568.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 332 of 551

Gleason, J. A., Post, G. B., Fagliano, J. A. (2015). Associations of perfluorinated chemical serum concentrations and biomarkers of liver function and uric acid in the US population (NHANES), 2007-2010. Environ. Res. 136: 8-14.

Goldenthal, E.I. (1978). Final report. Ninety day subacute rhesus monkey toxicity study. International Research and Development Corporation. Study No. 137-090. November 10, 1978. USEPA AR226-0447 (Cited in USEPA, 2005a).

Gore, A.C., Chappell, V.A., Fenton, S.E., Flaws, J.A., Nadal, A., Prins, G.S., Toppari J., Zoeller, R.T. (2015). EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocr Rev. 36: E1-E150.

Gortner, E.G. (1981). Oral teratology study of T-2998CoC in rats. Safety Evaluation Laboratory and Riker Laboratories, Inc. Experiment Number: 0681TR0110, December 1981 (Cited in USEPA, 2005).

Gortner, E.G. (1982). Oral teratology study of T-3141CoC in rabbits. Safety Evaluation Laboratory and Riker Laboratories, Inc. Experiment Number: 0681TB0398, February 1982 (Cited in USEPA, 2005).

Goss, K.U. (2008). The pKa values of PFOA and other highly fluorinated carboxylic acids. Environ. Sci. Technol. 42: 456–458.

Grandjean, P., E. Andersen, W., Budtz-Jorgensen, E., Nielsen, F., Molbak, K., Weihe, P. Heilmann, C. (2012). Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. JAMA 307: 391-397.

Granum, B., L. Haug, S. Namork, E. Stolevik, S. B., Thomsen, C., Aaberge, I. S., H. van Loveren, I. S., Lovik, M., Nygaard , U. C. (2013). Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood. J. Immunotoxicol. 10: 373-379.

Griffith, F.D., Long, J.E. (1980). Animal toxicity studies with ammonium perfluorooctanoate. Am. Ind. Hyg. Assoc. J. 41: 576-583.

Guo, Z., Lin, X., Krebs, K.A., Roache, N. (2009). Perfluorocarboxylic acid content in 116 articles of commerce. ORD, USEPA, RTP, NC. EPA/600/R-09/033. March 2009. http://www.oecd.org/dataoecd/47/50/48125746.pdf Accessed 1/17/12.

Guruge, K.S., Taniyasu, S., Yamashita, N., Wijeratna, S., Mohotti, K.M., Seneviratne, H.R., Kannan, K., Yamanaka, N., Miyazaki, S. (2005). Perfluorinated organic compounds in human blood serum and seminal plasma: a study of urban and rural tea worker populations in Sri Lanka. J. Environ. Monit. 7: 371-7.

Gützkow, K.B., Haug, L.S., Thomsen, C., Sabaredzovic, A., Becher, G., Brunborg, G. (2012). Placental transfer of perfluorinated compounds is selective - A Norwegian Mother and Child sub-cohort study. Int. J. Hyg. Environ. Health 215: 216-19.

Guyton, K.Z., Chiu, W.A., Bateson, T. F., Jinot, J., Scott, C.S., Brown, R.C., Caldwell., J. C. (2009). A reexamination of the PPAR-α activation mode of action as a basis for assessing human cancer risks of environmental contaminants. Environ. Health Perspect. 117: 1664–1672.

Halldorsson, T.I., Rytter, D., Haug, L.S., Bech, B.H., Danielsen, I., Becher, G., Henriksen, T.B., Olsen, S.F. (2012). Prenatal exposure to perfluorooctanoate and risk of overweight at 20 years of age: a prospective cohort study. Env. Health Perspect. 120: 668-673.

Hamm, M.P., Cherry, N.M., Chan, E., Martin, J.W., Burstyn, I. (2010). Maternal exposure to perfluorinated acids and fetal growth. J. Expo. Sci. Environ. Epidemiol. 20: 589-597.

Han, H., Snow, T.A., Kemper, R.A., Jepson, G.W. (2003). Binding of perfluorooctanoic acid to rat and human plasma proteins. Chem. Res. Toxicol. 16: 775-781.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 333 of 551

Han, X, Kemper, R.A, Jepson, G.W. (2005). Subcellular distribution and protein binding of perfluorooctanoic acid in rat liver and kidney. Drug Chem. Toxicol. 28: 197-209.

Han, X., Nabb, D.L., Russell, M.H., Kennedy, G.L., Rickard, R.W. (2012). Renal elimination of perfluorocarboxylates (PFCAs). Chem. Res. Toxicol. 25: 35-46.

Hanhijarvi, H., Ylinen, M., Haaranen, T., Nevalainen, T. (1988). A proposed species difference in the renal excretion of perfluorooctanoic acid in the beagle dog and rat. In: Beynen, A.C. Solleveld, H.A. (Eds.), New Development in Biosciences: Their Implications for Laboratory Animal Sciences, Martinus Nijhoff Publishers, Dodrecht, The Netherlands, pp. 409–412. (Cited in Lau et al., 2007).

Hansen, K.J., Johnson, H.O., Eldridge, J.S., Butenhoff, J.L., Dick, L.A. (2002). Quantitative characterization of trace levels of PFOS and PFOA in the Tennessee River. Environ. Sci. Technol. 36: 1681-1685.

Hanssen, L., Röllin, H., Odland, J.O., Moe, M.K., Sandanger, T.M. (2010). Perfluorinated compounds in maternal serum and cord blood from selected areas of South Africa: results of a pilot study. J. Environ. Monit. 12: 1355 – 1361.

Harada, K.H., Koizumi, A. (2009). Environmental and biological monitoring of persistent fluorinated compounds in Japan and their toxicities. Environ Health Prev Med. 14, 7-19.

Hardisty, J.F., Willson, G.A., Brown, W.R., McConnell, E.E., Frame, S.R., Gaylor, D.W., Kennedy, G.L., Butenhoff, J.L. 2010. Pathology Working Group review and evaluation of proliferative lesions of mammary gland tissues in female rats fed ammonium perfluorooctanoate (APFO) in the diet for 2 years. Drug Chem. Toxicol. 33: 131-137.

Haug, L.S., Thomsen, C., Becher, G. (2009). Time trends and the influence of age and gender on serum concentrations of perfluorinated compounds in archived human samples. Environ. Sci. Technol. 43: 2131-2136.

Haug, L.S., Salihovic, S., Jogsten, I.E., Thomsen, C., van Bavel, B, Lindström, G., Becher, G., (2010a). Levels in food and beverages and daily intake of perfluorinated compounds in Norway. Chemosphere 80: 1137-1143.

Haug, L.S., Thomsen, C., Brantsaeter, A.L., Kvalem, H.E., Haugen, M., Becher, G., Alexander, J., Meltzer, H.M., Knutsen, H.K. (2010b). Diet and particularly seafood are major sources of perfluorinated compounds in humans. Environ. Int. 36: 772-778.

Haughom, B., Spydevold, O. (1992). The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. Biochim. Biophys. Acta 1128: 65-72.

Haug, L.S., Huber, S., Becher, G., Thomsen, C. (2011). Characterisation of human exposure pathways to perfluorinated compounds - comparing exposure estimates with biomarkers of exposure. Environ. Int. 37: 687-693.

Heindel , J.J., Vandenberg, L.N. (2015) Developmental origins of health and disease: a paradigm for understanding disease cause and prevention. Curr. Opin. Pediatr. 27: 248-53.

Hemat, H., Wilhelm, M., Völkel, W., Mosch, C., Fromme, H., Wittsiepe, J. (2010). Low serum levels of perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS) and perfluorohexane sulfonate (PFHxS) in children and adults from Afghanistan. Sci. Total Environ. 408: 3493-3495.

Hinderliter, P.M., Mylchreest, E., Gannon, S.A., Butenhoff, J.L., Kennedy, G.L. Jr. (2005). Perfluorooctanoate: Placental and lactational transport pharmacokinetics in rats. Toxicology. 211: 139-48.

Hinderliter, P.M., Han, X., Kennedy, G.L., Butenhoff, J.L. (2006). Age effect on perfluorooctanoate (PFOA) plasma concentration in post-weaning rats following oral gavage with ammonium perfluorooctanoate (APFO). Toxicology 225: 195-203.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 334 of 551

Hines, E.P., White, S.S., Stanko, J.P., Gibbs-Flournoy, E.A., Lau, C., Fenton, S.E. (2009). Phenotypic dichotomy following developmental exposure to perfluorooctanoic acid (PFOA) in female CD-1 mice: Low doses induce elevated serum leptin and insulin, and overweight in mid-life. Mol. Cell. Endocrinol. 304: 97-105.

Hoffman, K., Webster, T.F., Weisskopf, M.G., Weinberg, J., Vieira, V.M. (2010). Exposure to polyfluoroalkyl chemicals and attention deficit/hyperactivity disorder in U.S. children aged 12-15 years. Environ. Health Perspect. 118: 1762-1767.

Hoffman, K., Webster, T.F., Bartell, S.M., Weisskopf, M.G., Fletcher, T., Vieira, V.M. (2011). Private drinking water wells as a source of exposure to PFOA in communities surrounding a fluoropolymer production facility. Environ. Health Perspect. 119: 92-97.

Hölzer, J., Midasch, O., Rauchfuss, K., Kraft, M., Reupert, R., Angerer, J., Kleeschulte, P., Marschall, N., Wilhelm, M. (2008). Biomonitoring of perfluorinated compounds in children and adults exposed to perfluorooctanoate-contaminated drinking water. Environ. Health Perspect. 116: 651-657.

Hölzer, J., Göen T, Just, P., Reupert, R., Rauchfuss, K., Kraft, M., Müller, J., Wilhelm, M. (2011). Perfluorinated compounds in fish and blood of anglers at Lake Möhne, Sauerland area, Germany. Environ. Sci. Technol. 45: 8046-8052.

Howard, B.A., Gusterson, B.A. (2000). Human breast development. J Mammary Gland Biol Neoplasia. 5: 119-37.

Hu, Q., Strynar, M. J., DeWitt, J. C. (2010). Are developmentally exposed C57BL/6 mice insensitive to suppression of TDAR by PFOA? J. Immunotoxicol. 7: 344-349.

Hu, Q., Franklin, J. N., Bryan, I., Morris, E., Wood, A., DeWitt, J. C. (2012). Does developmental exposure to perflurooctanoic acid (PFOA) induce immunopathologies commonly observed in neurodevelopmental disorders? Neurotoxicology 33: 1491-1498.

Hundley, S.G., Sarrif, A.M., Kennedy, G.L. (2006). Absorption, distribution, and excretion of ammonium perfluorooctanoate (APFO) after oral administration to various species. Drug Chem. Toxicol. 29: 137-145.

Hurley, S., Houtz, E., Goldberg, D., Wang, M., Park, J-S., Nelson, D.O., Reynolds, P., Bernstein, L., Anton-Culver, H., Horn-Ross, P., Petreas, M. (2016). Preliminary associations between the detection of perfluoroalkyl acids (PFAAs) in drinking water and serum concentrations in a sample of California women. In press. DOI: 10.1021/acs.estlett.6b00154

IARC (2016). International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 110. Perfluorooctanoic acid. p. 37-110.

IOM (2011). Breast Cancer and the Environment: A Life Course Approach. Institute of Medicine of the National Academies. The National Academies Press, Washington, DC. Prepublication copy, December 7, 2011. https://download.nap.edu/catalog.php?record_id=13263. Accessed December 7, 2011.

Iwai, H., Yamashita, K. (2006). A fourteen-day repeated dose oral toxicity study of APFO in rats. Drug Chem. Toxicol. 29: 323-332.

Jain, R. B. (2013). Association between thyroid profile and perfluoroalkyl acids: data from NHNAES 2007-2008. Environ. Res. 126: 51-59.

Ji, K., Kim, S., Kho, Y., Paek, D., Sakong, J., Ha, J., Kim, S., Choi, K. (2012). Serum concentrations of major perfluorinated compounds among the general population in Korea: dietary sources and potential impact on thyroid hormones." Environ. Int. 45: 78-85.

Jiang, W., Zhang, Y., Zhu, L., Deng, J. (2014). Serum levels of perfluoroalkyl acids (PFAAs) with isomer analysis and their associations with medical parameters in Chinese pregnant women. Environ. Int. 64: 40-47.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 335 of 551

Joensen, U.N., Bossi, R., Leffers, H., Jensen, A.A., Skakkebaek, N.E., Jørgensen N. (2009). Do perfluoroalkyl compounds impair human semen quality? Environ. Health Perspect. 117: 923-927.

Johansson, N., Fredriksson, A., Eriksson, P. (2008). Neonatal exposure to perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) causes neurobehavioural defects in adult mice. Neurotoxicology 29: 160-169.

Johansson, N., Eriksson, P., Viberg, H. (2009). Neonatal exposure to PFOS and PFOA in mice results in changes in proteins which are important for neuronal growth and synaptogenesis in the developing brain. Toxicol. Sci. 108: 412-418.

Johnson, J. D., Gibson, S. J., Ober, R. E. (1979). Extent and route of excretion and tissue distribution of total carbon-14 in rats after a single i.v. dose of FC-95-14C. Riker Laboratories, Inc., St Paul, MN, US EPA Administrative Record, 8EHQ-1180-00374 (Cited in Lau et al., 2007).

Johnson, J.D., Gibson, S.J., Ober, R.E. (1984). Cholestyramine-enhanced fecal elimination of carbon-14 in rats after administration of ammonium [14C]perfluorooctanoate or potassium [14C]perfluorooctanesulfonate. Fundam. Appl. Toxicol. 4: 972-976.

Johnson, P.I., Sutton, P., Atchley, D.S., Koustas, E., Lam, J., Sen, S., Robinson, K.A., Axelrad, D.A., Woodruff, T.J. (2014). The Navigation Guide - evidence-based medicine meets environmental health: systematic review of human evidence for PFOA effects on fetal growth. Environ. Health Perspect. 122: 1028-39.

Kataria, A., Trachtman, H., Malaga-Dieguez, L., Trasande, L. (2015). Association between perfluoroalkyl acids and kidney function in a cross-sectional study of adolescents. Environ. Health 14: 89.

Kato, K., Calafat, A.M., Wong, L.Y., Wanigatunga, A.A., Caudill, S.P., Needham, L.L. (2009). Polyfluoroalkyl compounds in pooled sera from children participating in the National Health and Nutrition Examination Survey 2001-2002. Environ. Sci. Technol. 43: 2641-2647.

Kato, K., Wong, L.Y., Jia, L.T., Kuklenyik, Z., Calafat, A.M. (2011). Trends in exposure to polyfluoroalkyl chemicals in the U.S. population: 1999-2008. Environ. Sci. Technol. 45: 8037-8045.

Kato, K., Ye, X., Calafat, A.M. (2015). PFASs in the general population. In: Toxicological Effects of Perfluoroalkyl and Polyfluoroalkyl Substances. J.D. DeWitt, Editor. Humana Press. pp. 51-76.

Kawashima, Y., Kobayashi, H., Miura, H., Kozuka, H. (1995). Characterization of hepatic responses of rat to administration of perfluorooctanoic and perfluorodecanoic acids at low levels. Toxicology 99: 169-178.

Kemper, R.A. (2003). Perfluorooctanoic acid: Toxicokinetics in the rat. Association of Plastics Manufactures of Europe. Submitted to the U.S. Environmental Protection Agency's Administrative Record. AR226-1499. Cited in USEPA, 2005a.

Kemper, R.A., Jepson, G.W. (2003). Pharmacokinetics of PFOA in male and female rats. Toxicologist 72: 148.

Kennedy, G.L. (1985). Dermal toxicity of ammonium perfluorooctanoate. Toxicol. Appl. Pharmacol. 81: 348-355.

Kennedy, G.L. Jr., Hall, G.T., Brittelli, M.R., Barnes, J.R., Chen, H.C. (1986). Inhalation toxicity of ammonium perfluorooctanoate. Food Chem. Toxicol. 24: 1325-1329.

Kennedy, G.L., Butenhoff, J.L., Olsen, G.W., O'Connor, J.C., Seacat, A.M., Perkins, R.G., Biegel, L.B., Murphy, S.R., Farrar, D.G. (2004). The toxicology of perfluorooctanoate. Crit. Rev. Toxicol. 34: 351-384.

Kielsen, K., Shamim, Z., Ryder, L. P., Nielsen Z. F., Grandjean, P., Budtz-Jorgensen, E., Heilmann, C. (2015). Antibody response to booster vaccination with tetanus and diphtheria in adults exposed to perfluorinated alkylates. J. Immunotoxicol: 13: 270-273.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 336 of 551

Kim, S.K., Kannan, K. (2007). Perfluorinated acids in air, rain, snow, surface runoff, and lakes: relative importance of pathways to contamination of urban lakes. Env. Sci. Technol. 41: 8328–8334.

Kim, S.K., Lee, K.T., Kang, C.S., Tao, L., Kannan, K., Kim, K.R., Kim, C.K., Lee, J.S., Park, P.S., Yoo, Y.W., Ha, J.Y., Shin, Y.S., Lee, J.H. (2011). Distribution of perfluorochemicals between sera and milk from the same mothers and implications for prenatal and postnatal exposures. Environ. Pollut. 159: 169-174.

Kjeldsen L.S., Bonefeld-Jørgensen E.C. (2013). Perfluorinated compounds affect the function of sex hormone receptors. Environ. Sci. Pollut. Res. Int. 20: 8031-44.

Klaunig, J.E., Babich, M.A., Baetcke, K.P., Cook, J.C., Corton, J.C., David, R.M., DeLuca, J.G., Lai, D.Y., McKee, R.H., Peters, J.M., Roberts, R.A., Fenner-Crisp, P.A. (2003). PPAR alpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 33: 655-780.

Klaunig, J. E., Hocevar, B. A., Kamendulis, L. M. (2012). Mode of Action analysis of perfluorooctanoic acid (PFOA) tumorigenicity and human relevance. Reprod. Toxicol. 33: 410-418.

Kleemann, R., Gervois, P.P., Verschuren, L., Staels, B., Princen, H.M., Kooistra, T. (2003). Fibrates downregulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood. 101: 545-551.

Klein, R., Klein, B. E., Cornoni, J. C., Maready, J., Cassel, J. C., Tyroler, H. A. (1973). Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch. Intern. Med. 132: 401-410.

Knobeloch, L., Imm, P., Anderson, H. (2012). Perfluoroalkyl chemicals in vacuum cleaner dust from 39 Wisconsin homes. Chemosphere 88: 779-783.

Knox, S. S., Jackson, T., Frisbee, S. J. Javins, B., Ducatman, A. M. (2011). Perfluorocarbon exposure, gender and thyroid function in the C8 Health Project. J. Toxicol. Sci. 36: 403-410.

Konwick, B.J., Tomy, G.T., Ismail, N., Peterson, J.T., Fauver, R.J., Higginbotham, D., Fisk, A.T. (2008). Concentrations and patterns of perfluoroalkyl acids in Georgia, USA surface waters near and distant to a major use source. Environ. Toxicol. Chem. 27: 2011-2018.

Koskela, A., Finnilä, M.A., Korkalainen, M., Spulber, S., Koponen, J., Håkansson, H., Tuukkanen, J., Viluksela, M. (2016). Effects of developmental exposure to perfluorooctanoic acid (PFOA) on long bone morphology and bone cell differentiation. Toxicol. Appl. Pharmacol. 301:14-21.

Kotthoff, M., Müller, J, Jürling, H., Schlummer, M., Fiedler, D. (2015). Perfluoroalkyl and polyfluoroalkyl substances in consumer products. Environ. Sci. Pollut. Res. Int. 22: 14546-59.

Koustas E, Lam, J., Sutton, P., Johnson, P.I., Atchley, D.S., Sen, S., Robinson, K.A., Axelrad, D.A., Woodruff, T. J. (2014). The Navigation Guide - evidence-based medicine meets environmental health: systematic review of nonhuman evidence for PFOA effects on fetal growth. Environ. Health Perspect. 122: 1015-27.

Kudo, N., Kawashima, Y. (1997). Fish oil-feeding prevents perfluorooctanoic acid-induced fatty liver in mice. Toxicol. Appl. Pharmacol. 145: 285-293.

Kudo, N., Katakura, M., Sato, Y., Kawashima, Y. (2002). Sex hormone-regulated renal transport of perfluorooctanoic acid. Chem. Biol. Interact. 139: 301-316.

Kudo, N., Kawashima, Y. (2003). Toxicity and toxicokinetics of perfluorooctanoic acid in humans and animals. J. Toxicol, Sci. 28: 49-57.

Kudo, N., Sakai, A., Mitsumoto, A., Hibino, Y., Tsuda, T., Kawashima, Y. (2007). Tissue distribution and hepatic subcellular distribution of perfluorooctanoic acid at low dose are different from those at high dose in rats. Biol. Pharm. Bull. 30: 1535-40.

Kummu, M., Sieppi, E., Koponen, J., Laatio, L., Vähäkangas, K., Kiviranta, H., Rautio, A., Myllynen, P. (2015). Organic anion transporter 4 (OAT 4) modifies placental transfer of perfluorinated alkyl acids PFOS and PFOA in human placental ex vivo perfusion system. Placenta 36: 1185-91.

LabDiet. Laboratory Rodent Diet 5001. http://www.labdiet.com/cs/groups/lolweb/@labdiet/documents/web_content/mdrf/mdi4/~edisp/ducm04_02802 1.pdf Accessed April 10, 2016.

Lam, J., Koustas, E., Sutton, P., Johnson, P. I., Atchley, D. S., Sen, S., Robinson, K. A., Axelrad, D. A., Woodruff, T. J. (2014). The Navigation Guide - evidence-based medicine meets environmental health: integration of animal and human evidence for PFOA effects on fetal growth. Environ. Health Perspect. 122: 1040-1051.

Landsteiner, A., Huset, C., Johnson, J., Williams, A. (2014). Biomonitoring for perfluorochemicals in a Minnesota community with known drinking water contamination. J. Environ. Health 77: 14-19.

Lau, C., Strynar, M.J., Lindstrom, A.B., Hanson, R.G., Thibodeaux, J.R., Barton, H.A. (2005). Pharmacokinetic evaluation of perfluorooctanoic acid in the mouse. Toxicologist 84: 252.

Lau, C., Thibodeaux, J. R., Hanson, R. G., Narotsky, M. G., Rogers, J. M., Lindstrom, A. B., Strynar, M. J. (2006). Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. Toxicol. Sci. 90: 510–518.

Lau, C., Anitole, K., Hodes, C., Lai, D., Pfahles-Hutchens, A., Seed, J. (2007). Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol. Sci. 99: 366-394.

Lau, C. (2012). Perfluorinated compounds. EXS 101, 47-86

Lechner, M., Knapp, H. (2011). Carryover of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) from soil to plant and distribution to the different plant compartments studied in cultures of carrots (Daucus carota ssp. Sativus), potatoes (Solanum tuberosum), and cucumbers (Cucumis Sativus). J. Agric. Food Chem. 59: 11011-11018.

Lee, S.S., Pineau, T., Drago, J., Lee, E.J., Owens, J.W., Kroetz, D.L., Fernandez-Salguero, P.M., Westphal, H., Gonzalez, F.J. (1995). Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15: 3012-3022.

Lee, H., D'eon, J., Mabury, S.A., (2010). Biodegradation of polyfluoroalkyl phosphates as a source of perfluorinated acids to the environment. Env. Sci. Technol. 44: 3305-3310.

Lee, H., Mabury, S.A. (2011). A pilot survey of legacy and current commercial fluorinated chemicals in human sera from United States donors in 2009. Environ. Sci. Technol. 45: 8067-8074.

Leonard, R. C. (2003). Epidemiology Surveillance Program. Cancer Incidence Report 1959-2001 and All-Case Mortality Report 1957-2000 at the Washington Works, Parkersburg, WV. DuPont. USEPA. AR226-1307-6.

Leonard, R. C., Kreckmann, K. H., Sakr, C. J., Symons, J. M. (2008). Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers. Ann. Epidemiol. 18: 15-22.

Li, Y., Ramdhan, D. H., Naito, H., Yamagishi, N., Ito, Y., Hayashi, Y. Yanagiba, Y., Okamura, A., Tamada, H., Gonzalez, F. J., Nakajima, T. (2011). Ammonium perfluorooctanoate may cause testosterone reduction by adversely affecting testis in relation to PPARalpha. Toxicol. Lett. 205: 265-272.

Lien, G.W., Wen, T.W., Hsieh, W.S., Wu, K.Y., Chen, C.Y., Chen, P.C. (2011). Analysis of perfluorinated chemicals in umbilical cord blood by ultra-high performance liquid chromatography/tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879: 641-646.

Lin, C. Y., Lin, L. Y., Chiang, C. K., Wang, W. J., Su, Y. N., Hung, K. Y., Chen, P. C. (2010). Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults. Am. J. Gastroenterol. 105: 1354-1363.

Lin, C. Y., Lin, L. Y., Wen, T. W., Lien, G. W., Chien, K. L., Hsu, S. H., Liao, C. C., Sung, P., Chen, C., Su, C. (2013). Association between levels of serum perfluorooctane sulfate and carotid artery intima-media thickness in adolescents and young adults. Int. J. Cardiol. 168: 3309-3316.

Lin, C. Y., Wen, L. L., Lin, L. Y., Wen, T. W., Lien, G. W., Chen, C. Y., Hsu, S. H., Chien, K. L., Sung, F. C., Chen, P. C., Su, T. C. (2011). Associations between levels of serum perfluorinated chemicals and adiponectin in a young hypertension cohort in Taiwan. Environ. Sci. Technol. 45: 10691-10698.

Lin, C. Y., Wen, L. L., Lin, L. Y., Wen, T. W., Lien, G. W., Hsu, S. H., Chien, K. L., Liao, C.C., Sung, F.C., Chen, P. C. and Su, T. C. (2013). The associations between serum perfluorinated chemicals and thyroid function in adolescents and young adults. J. Hazard. Mater. 244-245: 637-644.

Lindstrom, A.B., Strynar, M.J., Libelo, E.L. (2011a). Polyfluorinated compounds: Past, present, and future. Environ. Sci. Technol. 45: 7954-7961.

Lindstrom, A.B., Strynar, M.J., Delinsky, A.D., Nakayama, S.F., McMillan, L., Libelo, E.L., Neill, M., Thomas, L. (2011b). Application of WWTP biosolids and resulting perfluorinated compound contamination of surface and well water in Decatur, Alabama, USA. Environ. Sci. Technol. 45: 8015-8021.

Liu, J., Li, J. Zhao, Y., Wang, X., Zhang, L., Wu, Y. (2010). The occurrence of perfluorinated alkyl compounds in human milk from different regions of China. Environ. Int. 36: 433-438.

Liu, J., Li, J., Liu, Y., Chan, H.M., Zhao, Y., Cai, Z., Wu, Y. (2011). Comparison on gestation and lactation exposure of perfluorinated compounds for newborns. Environ Int. 37: 1206-1212.

Liu, W, Yang, B, Wu, L, Zou, W, Pan, X, Zou, T, Liu, F, Xia, L, Wang, X, Zhang, D. (2015). Involvement of NRF2 in Perfluorooctanoic Acid-Induced Testicular Damage in Male Mice. Biol. Reprod. 93: 41.

Llorca, M., Farré, M., Picó, Y., Teijón, ML., Alvarez, J.G., Barceló, D. (2010). Infant exposure of perfluorinated compounds: levels in breast milk and commercial baby food. Environ. Int. 36: 584-592.

Looker, C., Luster, M. I., Calafat, A. M., Johnson, V. J., Burleson, G. R., Burleson, F. G., Fletcher, T. (2014). Influenza vaccine response in adults exposed to perfluorooctanoate and perfluorooctanesulfonate. Toxicol. Sci. 138: 76-88.

Lopez-Espinosa, M. J., Mondal, D., Armstrong, B., Bloom, M. S., Fletcher, T. (2012). Thyroid function and perfluoroalkyl acids in children living near a chemical plant. Environ Health Perspect 120: 1036-1041.

Lorber, M., Egeghy, P. P. (2011). Simple intake and pharmacokinetic modeling to characterize exposure of Americans to perfluoroctanoic acid, PFOA. Environ. Sci. Technol. 45: 8006-8014.

Lorber, M., Eaglesham, G.E., Hobson, P., Toms, L.M., Mueller, J.F., Thompson, J.S. (2015). The effect of ongoing blood loss on human serum concentrations of perfluorinated acids. Chemosphere 118: 170-177.

Lou, I., Wambaugh, J.F., Lau, C., Hanson, R.G., Lindstrom, A.B., Strynar, M.J., Zehr, R.D., Setzer, R.W., Barton, H.A. (2009). Modeling single and repeated dose pharmacokinetics of PFOA in mice. Toxicol. Sci. 107: 331-341.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 339 of 551

Loveless, S.E., Finlay, C., Everds, N.E., Frame, S.R., Gillies, P.J., O'Connor, J.C., Powley, C.R., Kennedy, G.L. (2006). Comparative responses of rats and mice exposed to linear/branched, linear, or branched ammonium perfluorooctanoate (APFO). Toxicology 220: 203–217.

Loveless, S.E., Hoban, D., Sykes, G., Frame, S.R., Everds, N.E. (2008). Evaluation of the immune system in rats and mice administered linear ammonium perfluorooctanoate. Toxicol. Sci. 105: 86-96.

Lu, Y., Luo, B., Li, J., Dai, J. (2015). Perfluorooctanoic acid disrupts the blood-testis barrier and activates the TNFalpha/p38 MAPK signaling pathway in vivo and in vitro. Arch. Toxicol. 90: 971-83.

Macon, M.B., Villanueva, L.R., Tatum-Gibbs, K., Zehr, R.D., Strynar, M.J., Stanko, J.P., White, S.S., Helfant, L., Fenton, S.E. (2011). Prenatal perfluorooctanoic acid exposure in CD-1 mice: low dose developmental effects and internal dosimetry. Toxicol. Sci. 122: 134-45.

Macon, M.B., Fenton, S.E. (2013). Endocrine disruptors and the breast: early life effects and later life disease. J. Mammary Gland Biol. Neoplasia. 18: 43-61.

Maher, J. M., Aleksunes, L. M., Dieter, M. Z. Tanaka, Y., Peters, J. M., Manautou, J. E., Klaassen, C. D. (2008). Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol. Sci. 106: 319-328.

Maine DHHS (2014). Maine Department of Health and Human Services. Maximum Exposure Guideline for Perfluorooctanoic Acid in Drinking Water. CAS Registry Number (Free Acid): 335-67-1. March 17th, 2014. http://www.bennington.edu/docs/default-source/docs-pfoa/me_pfoameg.pdf?sfvrsn=4

Maisonet, M., Terrell, M. L., McGeehin, M. A, Christensen, K. Y, Holmes, A., Calafat, A. M. Marcus, M. (2012). Maternal concentrations of polyfluoroalkyl compounds during pregnancy and fetal and postnatal growth in British girls. Environ. Health Perspect. 120: 1432-1437.

Mak, Y.L., Taniyasu, S., Yeung, L.W.Y., Lu, G., Jin, L., Yang, Y., Lam, P.K.S., Kannan, K., Yamashita, N. (2009). Perfluorinated compounds in tap water from China and several other countries. Environ. Sci. Technol. 43: 4824–4829.

Maloney, E. K., Waxman, D. J. (1999). trans-Activation of PPARalpha and PPARgamma by structurally diverse environmental chemicals. Toxicol. Appl. Pharmacol. 161: 209-218.

Mann, P., Frame, S.R. (2004). FC-143: Two year oral toxicity-oncongenicity study in rats. Peer review of ovaries. Submitted by E.I du Pont de Nemours and Company. USEPA Docket AR-226-1921.

Mann, P.C., Vahle, J., Keenan, C.M., Baker, J.F., Bradley, A.E., Goodman, D.G., Harada, T., Herbert, R., Kaufmann, W., Kellner, R., Nolte, T., Rittinghausen, S., Tanaka, T. (2012). International harmonization of toxicologic pathology nomenclature: an overview and review of basic principles. Toxicol. Pathol. 40: 7S-13S.

Martin, J.W., Mabury, S.A., Solomon, K.R., Muir, D.C. (2003). Bioconcentration and tissue distribution of perfluorinated acids in rainbow trout (Oncorhynchus mykiss). Environ. Toxicol. Chem. 22: 196-204.

Martin, M. T., Brennan, R. J., Hu, W., Ayanoglu, E., Lau, C., Ren, H., Wood, C. R., Corton, J. C., Kavlock, R. J., Dix, D. J. (2007). Toxicogenomic study of triazole fungicides and perfluoroalkyl acids in rat livers predicts toxicity and categorizes chemicals based on mechanisms of toxicity. Toxicol. Sci. 97: 595-613.

MDH (2008). Minnesota Department of Health. Health Risk Limits for Groundwater 2008 Rule Revision. Perfluorooctanoic Acid. http://www.health.state.mn.us/divs/eh/risk/guidance/gw/pfoa.pdf

MDH (2009). Minnesota Department of Health. East Metro Perfluorochemical Biomonitoring Pilot Project. July 21, 2009. http://www.health.state.mn.us/divs/eh/tracking/finalpfcrpt.pdf

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 340 of 551

Melzer, D., Rice, N., Depledge, M. H., Henley, W. E., Galloway, T. S. (2010). Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey. Environ. Health Perspect. 118: 686-692.

Michalik, L., Auwerx, J., Berger, J.P., Chatterjee, V.K., Glass, C.K., Gonzalez, F.J., Grimaldi, P.A., Kadowaki, T., Lazar, M.A., O'Rahilly, S., Palmer, C.N., Plutzky J., Reddy, J.K., Spiegelman, B.M., Staels, B., Wahli, W. (2006). International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 58: 726-41.

Midasch, O., Drexler, H., Hart, N., Beckmann, M.W., Angerer, J. (2007). Transplacental exposure of neonates to perfluorooctanesulfonate and perfluorooctanoate: a pilot study. Int. Arch. Occup. Environ. Health 80: 643-648.

Minata, M., Harada, K.H., Kärrman, A., Hitomi, T., Hirosawa, M., Murata, M., Gonzalez, F.J., Koizumi, A. (2010). Role of peroxisome proliferator-activated receptor-alpha in hepatobiliary injury induced by ammonium perfluorooctanoate in mouse liver. Ind. Health 48: 96-107.

Mogensen, U.B., Grandjean, P., Nielsen, F., Weihe, P., Budtz-Jørgensen, E. (2015). Breastfeeding as an exposure pathway for perfluorinated alkylates. Environ. Sci. Technol. 49: 10466-73.

Mondal, D., Lopez-Espinosa, M-J., Armstrong, B., Stein, C.R., Fletcher, T. (2012). Relationships of perfluorooctanoate and perfluorooctane sulfonate serum concentrations between child-mother pairs in a population with perfluorooctanoate exposure from drinking water. Environ. Health Perspect. 120: 752-757.

Mondal, D., Weldon, R. H., Armstrong, B. G., Gibson, L. J., Lopez-Espinosa, M. J., Shin, H. M., Fletcher, T. (2014). Breastfeeding: a potential excretion route for mothers and implications for infant exposure to perfluoroalkyl acids. Environ. Health Perspect. 122: 187-192.

Monroy, R., Morrison, K., Teo, K., Atkinson, S., Kubwabo, C., Stewart, B., Foster, W.G. (2008). Serum levels of perfluoroalkyl compounds in human maternal and umbilical cord blood samples. Environ. Res. 108: 56-62.

Moody, C.A., Hebert, G.N., Strauss, S.H., Field, J.A. (2003). Occurrence and persistence of perfluorooctanesulfonate and other perfluorinated surfactants in groundwater at a fire-training area at Wurtsmith Air Force Base, Michigan, USA. J. Environ. Monit. 5: 341-345.

Morel-Symons, J., Sakr, C.J., Kreckmann, K.H., Leonard, R.C. (2007). Addendum report on confirmed and potential carcinoid tumor cases in the DuPont Cancer Registry. D. E. Program. Newark, DE. DuPont-24117-Addendum. EPA Docket AR, 226.

Morken, N.-H., Travlos, G. S., Wilson, R. E., Eggesbø, M., Longnecker, M. P. (2014). Maternal glomerular filtration rate in pregnancy and fetal size. PLoS ONE 9: e101897.

Murakami, M., Shinohara, H., Takada, H. (2009). Evaluation of wastewater and street runoff as sources of perfluorinated surfactants (PFSs). Chemosphere 74: 487-493.

Mylchreest, E. (2003). PFOA: Lactational and placental transport pharmacokinetic study in mice. Laboratory Project ID: DuPont-13309. December 19, 2003. US EPA AR226-1551.

Nakagawa, T., Ramdhan, D.H., Tanaka, N., Naito, H., Tamada, H., Ito, Y., Li, Y., Hayashi, Y., Yamagishi, N., Yanagiba, Y., Aoyama, T., Gonzalez, F.J., Nakajima, T. (2011). Modulation of ammonium perfluorooctanoateinduced hepatic damage by genetically different PPARα in mice. Arch. Toxicol. 86: 63-74.

Nakayama, S., Strynar, M.J., Helfant, L., Egeghy, P., Ye, X., Lindstrom, A.B. (2007). Perfluorinated compounds in the Cape Fear drainage basin in North Carolina. Environ. Sci. Technol. 41: 5271-5276.

Nakayama, S.F., Strynar, M.J., Reiner, J.L., Delinsky, A.D., Lindstrom, A.B. (2010). Determination of perfluorinated compounds in the Upper Mississippi river basin. Environ. Sci. Technol. 44: 4103-4109.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 341 of 551

Needham, L.L., Grandjean, P., Heinzow, B., Jørgensen, P.J., Nielsen, F., Patterson, D.G. Jr., Sjödin, A., Turner, W.E., Weihe, P. (2011). Partition of environmental chemicals between maternal and fetal blood and tissues. Environ. Sci. Technol. 45: 1121-1126.

Nelson, J.W., Hatch, E.E., Webster, T.F. (2010). Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general US population. Environ. Health Perspect. 118: 197–202.

Ngo, H. T., Hetland, R. B., Sabaredzovic, A, Haug, L. S., Steffensen, I. L. (2014). In utero exposure to perfluorooctanoate (PFOA) or perfluorooctane sulfonate (PFOS) did not increase body weight or intestinal tumorigenesis in multiple intestinal neoplasia (Min/+) mice. Environ Res 132: 251-263.

NH (2017). New Hampshire Code of Administrative Rules. Chapter Env-Or 600. Contaminated Site Management.

NH DES (2016). New Hampshire Department of Environmental Services. Letter from John M. Regan. 11/22/16. http://www.des.nh.gov/organization/divisions/waste/hwrb/documents/pfc-stakeholder-notification-20161122.pdf

NH DHHS (2015). New Hampshire Department of Health & Human Services. Perfluorochemical (PFC) Testing Program: Summary of test results for children <12 y.o. September 9, 2015. http://www.dhhs.nh.gov/dphs/documents/pediatric-results-presentation.pdf

Nilsson, R., Beije, B., Préat, V., Erixon, K., Ramel, C. (1991). On the mechanism of the hepatocarcinogenicity of peroxisome proliferators. Chem. Biol. Interact. 78: 235-250.

Nilsson, H., Kärrman, A., Westberg, H., Rotander, A., van Bavel, B., Lindström, G. (2010). A time trend study of significantly elevated perfluorocarboxylate levels in humans after using fluorinated ski wax. Environ. Sci. Technol. 44: 2150-2155.

NJDEP (2007a). Guidance for PFOA in drinking water at Pennsgrove Water Supply Company. Division of Science, Research, and Technology. February 13, 2007. http://www.nj.gov/dep/watersupply/pdf/pfoa_dwguidance.pdf

NJDEP (2007b). Determination of Perfluorooctanoic Acid (PFOA) in Aqueous Samples, Final Report, January 2007. http://www.nj.gov/dep/watersupply/final_pfoa_report.pdf

NJDEP (2010). New Jersey Department of Environmental Protection. Letter to Reginald C. Jordan, Ph.D., CIH. NC Division of Air Quality. June 1, 2010.

NJDEP (2014). New Jersey Department of Environmental Protection. Occurrence of Perfluorinated Chemicals in Untreated New Jersey Drinking Water Sources Final Report. April 2014. http://www.nj.gov/dep/watersupply/pdf/pfc-study.pdf

NJDHSS (2010). New Jersey Department of Health and Senior Services. Letter to Reginald C. Jordan, Ph.D., CIH. NC Division of Air Quality. June 1, 2010.

NJDOH (2014). New Jersey Department of Health. ATSDR Technical Assistance Form. NJDOH response to NJDEP request for evaluation of showering/bathing exposure to PFNA.

Noorlander, C.W., van Leeuwen, S.P., Te Biesebeek, J.D., Mengelers, M.J., Zeilmaker, M.J. (2011). Levels of perfluorinated compounds in food and dietary intake of PFOS and PFOA in the Netherlands. J. Agric. Food Chem. 59: 7496-7505.

NRC (2006). National Research Council. Assessing the human health risk of trichloroethylene. Appendix E: Peroxisome proliferators and liver cancer. National Academies Press, Washington, DC.

NTP (1997). National Toxicology Program. NTP Toxicology and Carcinogenesis Studies of Tetrafluoroethylene (CAS No. 116-14-3) in F344/N Rats and B6C3F1 Mice (Inhalation Studies). Research Triangle Park, N.C., National Institute of Environmental Health Sciences.

NTP (2016). National Toxicology Program. Systematic review of immunotoxicity associated with exposure to perfluorooctanoic acid (PFOA) or perfluorooctane sulfonate (PFOS). September 2016. <u>https://ntp.niehs.nih.gov/ntp/ohat/pfoa_pfos/pfoa_pfosmonograph_508.pdf</u> Accessed January 24, 2017.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 342 of 551

NYS DOH (2016). New York State Department of Health. Information Sheet. PFOA Biomonitoring Group-Level Results. June 2, 2016. <u>https://www.health.ny.gov/environmental/investigations/hoosick/docs/infosheetshortgroupresults.pdf</u> Accessed June 9, 2016.

Ode, A., Kallen, K., Gustafsson, P., Rylander, L., Jonsson, B. A., Olofsson, P., Ivarsson, S. A., Lindh, C. H., Rignell-Hydbom, A. (2014). Fetal exposure to perfluorinated compounds and attention deficit hyperactivity disorder in childhood. PLoS One 9: e95891.

OECD (2015). Organisation for Economic Cooperation and Development. Working Towards a Global Emission Inventory of PFASs: Focus on PFCAs - Status Quo and the Way Forward. Paris, 2015. https://www.oecd.org/chemicalsafety/risk-management/Working%20Towards%20a%20Global%20Emission%20Inventory%20of%20PFASS.pdf

Olsen, G. W., Lange, C. C., Ellefson, M. E., Mair, D. C., Church, T. R., Goldberg, C. L., Herron, R. M., Medhdizadehkashi, Z. Nobiletti, J. B., Rios, J. A., Reagen, W. K., Zobel, L. R. (2012). Temporal trends of perfluoroalkyl concentrations in American Red Cross adult blood donors, 2000-2010. Environ. Sci. Technol. 46: 6330-6338.

Olsen, G. W., Ehresman, D. J., Buehrer, B. D., Gibson, B. A., Butenhoff, J. L., Zobel, L. R., (2012). Longitudinal assessment of lipid and hepatic clinical parameters in workers involved with the demolition of perfluoroalkyl manufacturing facilities. J. Occup. Environ. Med. 54: 974-983.

Olsen, G. W., Gilliland, F. D., Burlew, M. M., Burris, J. M., Mandel, J. S., Mandel, J. H. (1998). An epidemiologic investigation of reproductive hormones in men with occupational exposure to perfluorooctanoic acid. J. Occup. Environ. Med. 40: 614-622.

Olsen, G. W., Burris, J. M., Burlew, M. M., Mandel, J. H. (2000). Plasma cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers. Drug Chem. Toxicol. 23: 603-620.

Olsen, G. W., Burris, J. M., Burlew, M. M., Mandel, J. H. (2003). Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctaneate (PFOA) concentrations and medical surveillance examinations. J. Occup. Environ. Med. 45: 260-270.

Olsen, G. W., Zobel , L. R. (2007). Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int Arch. Occup. Environ. Health 81: 231-246.

Olsen, G.W. (2015). PFAS biomonitoring in higher exposed populations. In: Toxicological Effects of Perfluoroalkyl and Polyfluoroalkyl Substances. J.D. DeWitt, Editor. Humana Press. pp. 77-126.

Omer, S.B., Phadke, V.K., Bednarczyk, R.A., Chamberlain, A.T., Brosseau, J.L., Orenstein, W.A. (2016). Impact of statins on influenza vaccine effectiveness against medically attended acute respiratory illness. J. Infect. Dis. 213: 1216-23.

Onishchenko, N., Fischer, C., Wan Ibrahim, W.N., Negri, S., Spulber, S., Cottica, D., Ceccatelli, S. (2010). Prenatal exposure to PFOS or PFOA alters motor function in mice in a sex-related manner. Neurotox. Res. 19: 452-461.

Osborne, G, Rudel, R., Schwarzman, M. (2015). Evaluating chemical effects on mammary gland development: A critical need in disease prevention. Reprod. Toxicol. 54: 148-55.

Palkar, P.S., Anderson, C.R., Ferry, C.H., Gonzalez, F.J., Peters, J.M. (2010). Effect of prenatal peroxisome proliferator-activated receptor alpha (PPARalpha) agonism on postnatal development. Toxicology 276: 79-84.

Perkins, R.G., Butenhoff, J.L., Kennedy, G.L., Palazzolo, M.J. (2004). 13-Week dietary toxicity study of ammonium perfluorooctanoate (APFO) in male rats. Drug Chem. Toxicol. 27: 361-378.

Peters, J.M., Gonzalez, F.J. (2011). Why toxic equivalency factors are not suitable for perfluoroalkyl chemicals. Chem. Res. Toxicol. 24: 1601-1609.

Post, G.B., Louis, J.B., Cooper, K.R., Boros-Russo, B.J., Lippincott, R.L. (2009a). Occurrence and potential significance of perfluorooctanoic acid (PFOA) detected in New Jersey public drinking water systems. Environ. Sci. Technol. 43: 4547–4554.

Post, G.B., Louis, J.B., Cooper, K.R., Lippincott, R.L. (2009b). Response to Comment on Occurrence and potential significance of perfluorooctanoic acid (PFOA) detected in New Jersey public drinking water systems. Environ. Sci. Technol. 43: 8699–8700.

Post, G.B., Cohn, P.D., Atherholt, T.A. (2011). Health and aesthetic aspects of water quality. In: J. Edzwald (Ed.), Water Quality and Treatment: A Handbook of Community Water Supplies, American Water Works Association, 6th edition. McGraw-Hill, New York. pp. 2.1-2.100.

Post, G.B., Cohn, P.D., Cooper, K.R. (2012). Perfluorooctanoic acid (PFOA), an emerging drinking water contaminant: a critical review of recent literature. Env. Res. 116: 93-117.

Post, G.B., Louis, J.B., Lippincott, R.L., Procopio, N.A. (2013). Occurrence of perfluorinated chemicals in raw water from New Jersey public drinking water systems. Environ. Sci. Technol. 47: 13266-75.

Prevedouros, K., Cousins, I.T., Buck, R.C., Korzeniowski, S.H. (2006). Sources, fate and transport of perfluorocarboxylates. Environ. Sci. Technol. 40: 32–44.

PubChem (2016). Pefluorooctanoic acid. Accessed May 15, 2016.

Qazi, M. R., Bogdanska, J., Butenhoff, J. L., Nelson, B. D., DePierre, J. W., Abedi-Valugerdi, M. (2009a). High-dose, short-term exposure of mice to perfluorooctanesulfonate (PFOS) or perfluorooctanoate (PFOA) affects the number of circulating neutrophils differently, but enhances the inflammatory responses of macrophages to lipopolysaccharide (LPS) in a similar fashion. Toxicology 262: 207-214.

Qazi, M. R., Xia, Z., Bogdanska, J., Chang, S. C., Ehresman, D. J., Butenhoff, J. L., Nelson, B. D., DePierre, J. W., Abedi-Valugerdi, M. (2009b). The atrophy and changes in the cellular compositions of the thymus and spleen observed in mice subjected to short-term exposure to perfluorooctanesulfonate are high-dose phenomena mediated in part by peroxisome proliferator-activated receptor-alpha (PPARalpha). Toxicology 260: 68-76.

Qazi, M. R., Abedi, M. R., Nelson, B. D., DePierre, J. W., Abedi-Valugerdi, M. (2010). Dietary exposure to perfluorooctanoate or perfluorooctane sulfonate induces hypertrophy in centrilobular hepatocytes and alters the hepatic immune status in mice. Int. Immunopharmacol. 10: 1420-1427.

Qazi, M. R., Nelson, B. D., DePierre, J. W., Abedi-Valugerdi, M. (2012). High-dose dietary exposure of mice to perfluorooctanoate or perfluorooctane sulfonate exerts toxic effects on myeloid and B-lymphoid cells in the bone marrow and these effects are partially dependent on reduced food consumption. Food. Chem. Toxicol. 50: 2955-2963.

Qazi, M. R., Hassan, M., Nelson, B. D., Depierre, J. W., Abedi-Valugerdi, M. (2013). Sub-acute, moderatedose, but not short-term, low-dose dietary pre-exposure of mice to perfluorooctanoate aggravates concanavalin A-induced hepatitis. Toxicol. Lett. 219: 1-7.

Quist, E.M., Filgo, A.J., Cummings, C.A., Kissling, G.E., Hoenerhoff, M.J., Fenton, S.E. (2015). Hepatic mitochondrial alteration in CD-1 mice associated with prenatal exposures to low doses of perfluorooctanoic acid (PFOA). Toxicol. Pathol. 43: 546-57.

Rayne, S., Forest, K. (2010). Theoretical studies on the pKa values of perfluoroalkyl carboxylic acids. J. Mol. Struct. (Theochem) 949: 60–69.

Raleigh, K.K., Alexander, B.H., Olsen, G.W., Ramachandran, G., Morey, S.Z., Church, T.R., Logan, P.W., Scott, L.L.F., Allen. E.M. (2014). Mortality and cancer incidence in ammonium

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 344 of 551

perfluorooctanoate production workers. Occup. Environ. Med. 71:500-506

Rayne, S., Forest, K. (2010). Theoretical studies on the pKa values of perfluoroalkyl carboxylic acids. J. Mol. Struct. (Theochem) 949: 60–69.

Rebholz S.L., Jones, T., Herrick, R.L., Xie, C., Calafat, A.M., Pinney, S.M., Woollett, L.A. (2016). Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice. Toxicol. Rep. 3: 46-54.

Reiner, J.L., Nakayama, S.F., Delinsky, A.D., Stanko, J.P., Fenton, S.E., Lindstrom, A.B., Strynar, M.J. (2009). Analysis of PFOA in dosed CD1 mice. Part 1. Methods development for the analysis of tissues and fluids from pregnant and lactating mice and their pups. Reprod. Toxicol. 27: 360-4.

Romano, M.E., Xu, Y., Calafat, A.M..Yolton, K., Chen, A., Webster, G.M., Eliot, M.N., Howard, C.R., Lanphear, B.P., Braun, J.M. (2016). Maternal serum perfluoroalkyl substances during pregnancy and duration of breastfeeding. Env. Research 149: 239-46.

Roosens, L., D'Hollander, W., Bervoets, L., Reynders, H., Van Campenhout, K., Cornelis, C., Van Den Heuvel, R., Koppen, G., Covaci, A. (2010). Brominated flame retardants and perfluorinated chemicals, two groups of persistent contaminants in Belgian human blood and milk. Environ. Pollut. 158: 2546–2552.

Rosen, M.B., Thibodeaux, J.R., Wood, C.R., Zehr, R.D., Schmid, J.E., Lau, C. (2007). Gene expression profiling in the lung and liver of PFOA-exposed mouse fetuses. Toxicology 239: 15-33.

Rosen, M.B., Abbott, B.D., Wolf, D.C., Corton, J.C., Wood, C.R., Schmid, J.E., Das, K.P., Zehr, R.D., Blair, E.T., Lau, C. (2008a). Gene profiling in the livers of wild-type and PPAR alpha-null mice exposed to perfluorooctanoic acid. Toxicol. Pathol. 36: 592-607.

Rosen, M.B., Lee, J.S., Ren, H., Vallanat, B., Liu, J., Waalkes, M.P., Abbott, B.D., Lau, C., Corton, J.C. (2008b). Toxicogenomic dissection of the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of nuclear receptors PPAR alpha and CAR. Toxicol. Sci. 103: 46-56.

Roth, M., Obaidat, A, Hagenbuch, B. (2012). OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br. J. Pharmacol. 165: 1260-87.

Rudel, R.A., Fenton, S.E., Ackerman, J.M., Euling, S.Y., Makris, S.L. (2011). Environmental exposures and mammary gland development: state of the science, public health implications, and research recommendations. Environ. Health Perspect. 119: 1053-1061.

Rumsby, P.C., McLaughlin, C.L., Hall, T. (2009). Perfluorooctane sulphonate and perfluorooctanoic acid in drinking and environmental waters. Philos. Transact. A Math. Phys. Eng. Sci. 367: 4119-4136.

Rusiecka, I., Składanowski, A.C. (2008). Induction of the multixenobiotic/multidrug resistance system in various cell lines in response to perfluorinated carboxylic acids. Acta Biochim. Pol. 55: 329-37.

Russell, M.H., Berti, W.R., Szostek, B., Buck, R.C. (2008). Investigation of the biodegradation potential of a fluoroacrylate polymer product in aerobic soils. Environ. Sci. Technol. 42: 800-807.

Sakr, C. J., Kreckmann, K. H., Green, J. W., Gillies, P. J., Reynolds, J. L., Leonard, R. C. (2007). Crosssectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers. J. Occup. Environ. Med. 49: 1086-1096.

Sakr, C. J., Leonard, R. C., Kreckmann, K. H., Slade, M. D., Cullen, M. R. (2007). Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium perfluorooctanoate. J. Occup. Environ. Med. 49: 872-879.

Savitz, D. A., Stein, C. R., Elston, B., Wellenius, G. A., Bartell, S. M., Shin, H. M., Vieira, V. M. Fletcher, T. (2012). Relationship of perfluorooctanoic acid exposure to pregnancy outcome based on birth records in the mid-Ohio Valley. Environ. Health Perspect. 120: 1201-1207.

Schecter, A., Malik-Bass, N., Calafat, A.M., Kato, K., Colacino, J.A., Gent, T.L., Hynan, L.S., Harris, T.R., Malla, S., Birnbaum, L.S. (2011). Polyfluoroalkyl compounds in Texas children from birth through 12 years of age. Environ. Health Perspect. (in press).

Schlummer, M., Gruber, L. Fiedler, D. Kizlauskas, M., Muller, J. (2013). Detection of fluorotelomer alcohols in indoor environments and their relevance for human exposure. Environ. Int. 57-58: 42-49.

Seals, R., Bartell, S.M., Steenland, K. (2011). Accumulation and clearance of perfluorooctanoic acid (PFOA) in current and former residents of an exposed community. Environ. Health Perspect. 119: 119-124.

Sepulvado, J.G., Blaine, A.C., Hundal, L.S., Higgins, C.P. (2011). Occurrence and fate of perfluorochemicals in soil following the land application of municipal biosolids. Environ. Sci. Technol. 45: 8106-8112.

Shah, D. (2009). Healthy worker effect phenomenon. Indian J. Occup. Environ. Med. 13: 77-79.

Shankar, A., Xiao, J., Ducatman, A. (2011). Perfluoroalkyl chemicals and elevated serum uric acid in US adults. Clin. Epidemiol. 3: 251-258.

Shin, H.M., Vieira, V.M., Ryan, P.B., Steenland, K., Bartell, S.M. (2011). Retrospective exposure estimation and predicted versus observed serum perfluorooctanoic acid concentrations for participants in the C8 Health Project. Environ. Health Perspect. 119: 1760-1765.

Shrestha, S., Bloom, M. S., Yucel, R., Seegal, R. F., Wu, Q. Kannan, K., Rej, R., Fitzgerald, E. F. (2015). Perfluoroalkyl substances and thyroid function in older adults. Environ. Int. 75: 206-214.

Shoeib, M., Harner, T.M., Webster, G., Lee, S.C., (2011). Indoor sources of poly- and perfluorinated compounds (PFCS) in Vancouver, Canada: implications for human exposure. Environ. Sci. Technol. 45: 7999-8005.

Sibinski, L.J. (1987). Final report of a two year oral (diet) toxicity and carcinogenicity study of fluorochemical FC-143 (perfluorooctanoate ammonium carboxylate) in rats. Vol. 1-4, 3M Company/RIKER. No.0281CR0012; 8EHQ-1087-0394, October 16, 1987.

Sinclair, E., Kannan, K. (2006). Mass loading and fate of perfluoroalkyl surfactants in wastewater treatment plants. Env. Sci. Technol. 40: 1408-1414.

Skutlarek, D., Exner, M., Färber, H. (2006). Perfluorinated surfactants in surface and drinking waters. Environ. Sci. Pollut. Res. Int. 13: 299-307.

So, M.K., Yamashita, N., Taniyasu, S., Jiang, Q., Giesy, J.P., Chen, K., Lam, P.K. (2006). Health risks in infants associated with exposure to perfluorinated compounds in human breast milk from Zhoushan, China. Environ. Sci. Technol. 40: 2924-2929.

Sobolewski, M., Conrad, K., Allen, J. L., Weston, H., Martin, K., Lawrence, B. P., Cory-Slechta, D. A. (2014). Sex-specific enhanced behavioral toxicity induced by maternal exposure to a mixture of low dose endocrine-disrupting chemicals. Neurotoxicology 45: 121-130.

Son, H.Y., Kim, S.H., Shin, H.I., Bae, H.I., Yang, J.H. (2008). Perfluorooctanoic acid-induced hepatic toxicity following 21-day oral exposure in mice. Arch. Toxicol. 82: 239-246.

Son, H.Y., Lee, S., Tak, E.N., Cho, H.S., Shin H.I., Kim, S.H., Yang, J.H. (2009). Perfluorooctanoic acid alters T lymphocyte phenotypes and cytokine expression in mice. Environ. Toxicol. 24: 580-588.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 346 of 551

SRI. Southern Research Institute (2003). Protein binding of perfluorohexane sulfonate, perfluorooctane sulfonate and perfluorooctanoate to plasma (human, rat and monkey), and various human derived plasma protein fractions. Study ID: 9921.7. US EPA AR226-1354. Cited in USEPA (2005a).

Stahl, T., Heyn, J., Thiele, H., Hüther, J., Failing, K., Georgii, S., Brunn, H. (2009). Carryover of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) from soil to plants. Arch. Environ. Contam. Toxicol. 57: 289-298.

Starkov, A. A., Wallace, K. B. (2002). Structural determinants of fluorochemical-induced mitochondrial dysfunction. Toxicol Sci 66: 244-252.

Starling, A. P., Engel, S. M., Whitworth, K. W., Richardson, D. B., Stuebe, A. M., Daniels, J. L., Haug, L. S.,
Eggesbo, M., Becher, G., Sabaredzovic, A., Thomsen, C., Wilson, R. E., Travlos, G. S., Hoppin, J. A., Baird, D.
D., Longnecker, M. P. (2014). Perfluoroalkyl substances and lipid concentrations in plasma during pregnancy
among women in the Norwegian Mother and Child Cohort Study. Environ. Int. 62: 104-112.

Steenland, K., Jin, C., MacNeil, J., Lally, C., Ducatman, A., Vieira V., Fletcher, T. (2009a). Predictors of PFOA levels in a community surrounding a chemical plant. Environ. Health Perspect. 117: 1083-1088.

Steenland, K., Tinker, S., Frisbee, S., Ducatman, A., Vaccarino, V. (2009b). Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am. J. Epidemiol. 170: 1268-1278.

Steenland K., Fletcher T., Savitz D.A. (2010a). Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ. Health Perspect. 118: 1100-1108.

Steenland, K., Tinker, S., Shankar, A., Ducatman, A. (2010b). Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA. Environ. Health Perspect. 118: 229-233.

Steenland K., Savitz, D.A., Fletcher, T. (2014). Commentary: Class action lawsuits: can they advance epidemiologic research? Epidemiology 25: 167-9.

Steenland, K., Zhao, L., Winquist, A. (2015). A cohort incidence study of workers exposed to perfluorooctanoic acid (PFOA). Occup. Environ. Med. 72: 373-380.

Stein, C. R., Savitz, D. A., Dougan, M. (2009). Serum levels of perfluorooctanoic acid and perfluorooctane sulfonate and pregnancy outcome. Am. J. Epidemiol. 170: 837-846.

Stein, C. R., McGovern, K. J., Pajak, A. M., Maglione, P. J., Wolff, M. S. (2016). Perfluoroalkyl and polyfluoroalkyl substances and indicators of immune function in children aged 12-19 y: National Health and Nutrition Examination Survey. Pediatr. Res. 79: 348-357.

Stein, C.R., Savitz, D.A., (2011). Serum perfluorinated compound concentration and Attention Deficit/Hyperactivity Disorder in children 5–18 years of age. Environ. Health. Perspect. 119: 1466-1471.

Stein, C. R., Wolff, M. S., Calafat, A. M., Kato, K., Engel, S. M. (2012). Comparison of polyfluoroalkyl compound concentrations in maternal serum and amniotic fluid: a pilot study. Reprod. Toxicol. 34: 312-316.

Suh, C.H., Cho, N.K., Lee, C.K., Lee, C.H., Kim, D.H., Kim, J.H., Son, B.C., Lee, J.T. (2011). Perfluorooctanoic acid-induced inhibition of placental prolactin-family hormone and fetal growth retardation in mice. Mol. Cell. Endocrinol. 337: 7-15.

Sundström, M., Ehresman, D.J., Bignert, A., Butenhoff, J.L., Olsen, G.W., Chang, S.C., Bergman, A. (2011). A temporal trend study (1972-2008) of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in pooled human milk samples from Stockholm, Sweden. Environ. Int. 37: 178-183.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 347 of 551

Takagi, A., Sai, K., Umemura, T., Hasegawa, R., Kurokawa, Y. (1991). Short-term exposure to the peroxisome proliferators, perfluorooctanoic acid and perfluorodecanoic acid, causes significant increase of 8-hydroxydeoxyguanosine in liver DNA of rats. Cancer Lett. 57: 55-60.

Takagi, S., Adachi, F., Miyano, K., Koizumi, Y., Tanaka, H., Watanabe, I., Tanabe, S., Kannan, K. (2011). Fate of perfluorooctanesulfonate and perfluorooctanoate in drinking water treatment processes. Water Res. 45: 3925-3932

Tan, X., Xie, G., Sun, X., Li, Q., Zhong, W., et al. (2013). High Fat Diet Feeding Exaggerates Perfluorooctanoic acid-induced liver injury in mice via modulating multiple metabolic pathways. PLoS ONE 8: e61409.

Tao, L., Kannan, K., Wong, C.M., Arcaro, K.F., Butenhoff, J.L. (2008a). Perfluorinated compounds in human milk from Massachusetts, U.S.A. Environ. Sci. Technol. 42: 3096-3101.

Tao, L., Ma, J., Kunisue, T., Libelo, E.L., Tanabe, S., Kannan, K. (2008b). Perfluorinated compounds in human breast milk from several Asian countries, and in infant formula and dairy milk from the United States. Environ. Sci. Technol. 42: 8597-8602.

Tardiff, R.G., Carson, M.L., Sweeney, L.M., Kirman, C.R., Tan, Y.-M., Andersen, M., Bevan, C., Gargas, M.L. (2009). Derivation of a drinking water equivalent level (DWEL) related to the maximum contaminant level goal for perfluorooctanoic acid (PFOA), a persistent water soluble compound. Food Chem. Toxicol. 47: 2557-2589.

Taylor, K.W., Hoffman, K., Thayer, K.A., Daniels, J.L. (2014). Polyfluoroalkyl chemicals and menopause among women 20-65 years of age (NHANES). Environ. Health Perspect. 122: 145- 50.

Thomford, P.J. (2001a). 4-Week capsule capsule toxicity study with ammonium perfluorooctanoate (APFO) in cynomolgus monkeys. Covance Laboratories Inc., Madison, WI. Covance 6329-230. December 18, 2001.

Thomford, P.J. (2001b). 26-Week capsule toxicity study with ammonium perfluorooctanoate (APFO) in cynomolgus monkeys. Covance Laboratories Inc., Madison WI. Covance 6329-231. December 18, 2001.

Thompson, J., Lorber, M., Toms, L. M. L., Kato, K.; Calafat, A. M., Mueller, J. F. (2010). Use of simple pharmacokinetic modeling to characterize exposure of Australians to perfluorooctanoic acid and perfluorooctane sulfonic acid. Environ. Int. 36: 390–397.

Thompson, J., Eaglesham, G., Mueller, J., (2011). Concentrations of PFOS, PFOA and other perfluorinated alkyl acids in Australian drinking water. Chemosphere 83: 1320-1325.

Thomsen, C., Haug, L.S., Stigum, H., Frøshaug, M., Broadwell, S.L., Becher, G. (2010). Changes in concentrations of perfluorinated compounds, polybrominated diphenyl ethers, and polychlorinated biphenyls in Norwegian breast-milk during twelve months of lactation. Environ. Sci. Technol. 44: 9550-9556.

Tilton, S.C., Orner, G.A., Benninghoff, A.D., Carpenter, H.M., Hendricks, J.D., Pereira, C.B., Williams, D.E. (2008). Genomic profiling reveals an alternate mechanism for hepatic tumor promotion by perfluorooctanoic acid in rainbow trout. Environ. Health Perspect. 116: 1047-1055.

Timmermann, C.A., Budtz-Jørgensen, E., Petersen, M.S., Weihe, P., Steuerwald, U., Nielsen, F., Jensen, T.K., Grandjean, P. (2016). Shorter duration of breastfeeding at elevated exposures to perfluoroalkyl substances. Reprod Toxicol. (in press).

Tittlemier, S.A., Pepper, K., Seymour, C., Moisey, J., Bronson, R., Cao, X.L., Dabeka, R.W. (2007). Dietary exposure of Canadians to perfluorinated carboxylates and perfluorooctane sulfonate via consumption of meat, fish, fast foods, and food items prepared in their packaging. J. Agric. Food Chem. 18: 3203-3210.

Toms, L.M., Calafat, A.M, Kato, K., Thompson, J., Harden, F., Hobson, P., Sjödin, A., Mueller, J.F. (2009). Polyfluoroalkyl chemicals in pooled blood serum from infants, children, and adults in Australia. Environ. Sci. Technol. 43: 4194-4199. Trudel, D., Horowitz, L., Wormuth, M., Scheringer, M., Cousins, I.T., Hungerbuheler, K. (2008). Estimating consumer exposure to PFOS and PFOA. Risk Anal. 28: 251-269.

Tucker, D. K., Macon, M. B., Strynar, M. J., Dagnino, S., Andersen, E., Fenton, S. E. (2015). The mammary gland is a sensitive pubertal target in CD-1 and C57Bl/6 mice following perinatal perfluorooctanoic acid (PFOA) exposure. Reprod. Toxicol. 54: 26-36.

Upham, B.L., Deocampo, N.D., Wurl, B., et al. (1998). Inhibition of gap junctional intercellular communication by perfluorinated fatty acids is dependent on the chain length of the fluorinated tail. Int. J. Cancer 78: 491-495.

Upham, B.L., Park, J.S., Babica, P., Sovadinova, I., Rummel, A.M., Trosko, J.E., Hirose, A., Hasegawa, R., Kanno, J., Sai, K. (2009). Structure-activity-dependent regulation of cell communication by perfluorinated fatty acids using in vivo and in vitro model systems. Environ. Health Perspect. 117: 545-51.

USEPA (2000). Methodology for Deriving Ambient Water Quality Criteria for the Protection of Human Health. Office of Science and Technology. Office of Water. Washington, DC. EPA 822-B-00-004. October 2000. http://water.epa.gov/scitech/swguidance/standards/upload/2005_05_06_criteria_humanhealth_method_complet e.pdf

USEPA (2005a). United States Environmental Protection Agency. Draft Risk Assessment of the Potential Human Health Effects Associated with Exposure to Perfluorooctanoic Acid and Its Salts. Office of Pollution Prevention and Toxics, January 4, 2005. http://www.epa.gov/oppt/pfoa/pubs/pfoarisk.pdf. Accessed August 16, 2011.

USEPA (2005b). United States Environmental Protection Agency. Guidelines for Carcinogen Risk Assessment. Risk Assessment Forum, USEPA, Washington, DC. EPA/630.P-03/001F, March 2005.

USEPA (2006). United States Environmental Protection Agency. Science Advisory Board Review of EPA's Draft Risk Assessment of Potential Human Health Effects Associated with PFOA and Its Salts, May 30, 2006. http://www.epa.gov/sab/pdf/sab_06_006.pdf. Accessed August 16, 2011.

USEPA (2008a). United States Environmental Protection Agency. Child-Specific Exposure Factors Handbook. EPA/600/R-06/096F. National Center for Environmental Assessment, Washington, DC. September 2008. http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=199243 Accessed 1/17/12.

USEPA (2008b). Toxicological Review of 2,2',4,4',5-Pentabromodiphenyl Ether (BDE-99) (CAS No. 60348-60-9). June 2008. EPA/635/R-07/006F.

USEPA (2008c). Toxicological Review of 2,2',4,4'-Tetrabromodiphenyl Ether (BDE-47) (CAS No. 5436-43-1). June 2008. EPA/635/R-07/005F.

USEPA (2009a). United States Environmental Protection Agency. Long-Chain Perfluorinated Chemicals (PFCs) Action Plan. Office of Pollution Prevention and Toxics. December 30, 2009.

USEPA (2009b). Provisional Health Advisories for Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS). USEPA Office of Water, Jan. 8, 2009. http://www.epa.gov/waterscience/criteria/drinking/pha-PFOA_PFOS.pdf

USEPA (2009c). Toxicological Review of Trichloroethylene (CAS No. 79-01-6) In Support of Summary Information on the Integrated Risk Information System (IRIS), External Review Draft. October 2009. EPA/635/R-09/011A.

USEPA (2011a). United States Environmental Protection Agency. Integrated Risk Information System (IRIS) Glossary. Last updated August 21, 2011.

https://ofmpub.epa.gov/sor_internet/registry/termreg/searchandretrieve/glossariesandkeywordlists/search.do?det ails=&glossaryName=IRIS%20Glossary#formTop Accessed May 10, 2016.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 349 of 551

USEPA (2011b). Exposure Factors Handbook 2011 Edition (Final). U.S. Environmental Protection Agency, Washington, DC, EPA/600/R-09/052F.

USEPA (2012a). United States Environmental Protection Agency. Benchmark Dose Technical Guidance. Risk Assessment Forum. June 2012. EPA/100/R-12/001. https://www.epa.gov/sites/production/files/2015-01/documents/benchmark_dose_guidance.pdf

USEPA (2012b). United States Environmental Protection Agency. Revisions to the unregulated contaminant monitoring regulation (UCMR 3) for public water systems, final rule. Fed. Regist. 77, 26072–26101.

USEPA (2012c). United States Environmental Protection Agency. "Preamble to IRIS Toxicological Reviews" in: Toxicological Review of Ammonia (CAS No. 7664-41-7) in Support of Summary Information on the Integrated Risk Information System (IRIS). June 2012. EPA/635/R-11/013A.

USEPA (2014). United States Environmental Protection Agency. Draft Health Effects Document for Perfluoro.tanoic Acid (PFOA). Office of Water. EPA Document Number: 822R14001. February 2014

USEPA (2016a). United States Environmental Protection Agency. Drinking Water Health Advisory for Perfluorooctanoic Acid (PFOA). Office of Water. EPA 822-R-16-005. May 2016. https://www.epa.gov/sites/production/files/2016-05/documents/pfoa health advisory final-plain.pdf

USEPA (2016b). United States Environmental Protection Agency. Office of Pollution Prevention and Toxics. 2010/2015 PFOA Stewardship Program. https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/20102015-pfoa-stewardship-program Accessed May 15, 2016.

USEPA (2016c). United States Environmental Protection Agency. Drinking Water Health Advisory for Perfluorooctane Sulfonate (PFOS). Office of Water. EPA 822-R-16-005. May 2016. <u>https://www.epa.gov/sites/production/files/2016-05/documents/pfos_health_advisory_final_508.pdf</u>

USEPA (2016d). United States Environmental Protection Agency. Fact Sheet: PFOA & PFOS Drinking Water Health Advisories. Office of Water. May 2016.

USEPA (2016e). United States Environmental Protection Agency. Hoosick Falls, New York. Drinking Water and Groundwater Contamination. Frequently Asked Questions. https://www.epa.gov/sites/production/files/2016-01/documents/hoosickfalls_fags.pdf

USEPA (2016f). United States Environmental Protection Agency. Occurrence Data for the Unregulated Contaminant Monitoring Rule. Data posted through January 2016. <u>https://www.epa.gov/dwucmr/occurrence-data-unregulated-contaminant-monitoring-rule</u> Accessed March 3, 2016.

USEPA (2016f). United States Environmental Protection Agency. Health Effects Support Document for Perfluorooctanoic Acid (PFOA). Office of Water. EPA 822-R-16-003. May 2016. https://www.epa.gov/sites/production/files/2016-05/documents/pfoa_hesd_final_508.pdf

Vaalgamaa, S., Vähätalo, A.V., Perkola, N., Huhtala, S. (2011). Photochemical reactivity of perfluorooctanoic acid (PFOA) in conditions representing surface water. Sci. Total Environ. 409: 3043-3048.

van Esterik, J.C., Sales, L.B., Dollé, M.E., Håkansson, H., Herlin, M., Legler, J., van der Ven, L.T. (2016). Programming of metabolic effects in C57BL/6JxFVB mice by in utero and lactational exposure to perfluorooctanoic acid. Arch. Toxicol. 90: 701-15.

Vanden Heuvel, J.P., Kuslikis, B.I., Van Rafelghem, M.J., Peterson, RE. (1991). Tissue distribution, metabolism, and elimination of perfluorooctanoic acid in male and female rats. J. Biochem. Toxicol. 6: 83-92.

Vanden Heuvel, J. P., Thompson, J. T., Frame, S. R., Gillies, P. J. (2006). Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol. Sci. 92: 476-489.

Vermont DEC (2016a). Vermont Department of Environmental Conservation. Environmental Protection Rules. Chapter 12. Groundwater Protection Rule and Strategy. Adopted: December 16, 2016. http://dec.vermont.gov/sites/dec/files/documents/2016 12 16 GWPR%26Sadopted.pdf

Vermont DEC (2016b). Vermont Department of Environmental Conservation. Environmental Protection Rules. Chapter 21. Water Supply Rule. Original Effective Date: September 24, 1992. Revision Date: December 1, 2010

Vermont DOH (2016). Vermont Department of Health. Memorandum from Sarah Voseto Chuck Schwer, Vermont DEC. http://dec.vermont.gov/sites/dec/files/documents/2016.03.16.PFOA-interim-groundwater-enforcement-standard-1.pdf

Verner, M.-A., Loccisano, A. E., Morken, N.-H., Yoon, M., Wu, H., McDougall, R., Maisonet, M., Marcus, M., Kishi, R., Miyashita, C., Chen, M.-H., Hsieh, W.-S., Andersen, M. E., Clewell, H. J., Longnecker, M. P. (2015). Associations of perfluoroalkyl substances (PFAS) with lower birth weight: an evaluation of potential confounding by glomerular filtration rate using a physiologically based pharmacokinetic model (PBPK). Environ. Health Perspect. 123: 1317-1324.

Verner, M.A., Ngueta, G., Jensen, E.T., Fromme, H., Völkel, W., Nygaard, U.C., Granum, B., Longnecker, M.P. (2016a). A simple pharmacokinetic model of prenatal and postnatal exposure to perfluoroalkyl substances (PFASs). Environ. Sci. Technol. 50: 978-86.

Verner, M.A., Ngueta, G., Jensen, E.T., Fromme, H., Völkel, W., Nygaard, U.C., Granum, B., Longnecker, M.P. (2016b). Correction to A Simple Pharmacokinetic Model of Prenatal and Postnatal Exposure to Perfluoroalkyl Substances (PFASs). Environ. Sci. Technol. 50:5420-1.

Vestergren, R., Cousins, I.T. (2009). Tracking the pathways of human exposure to perfluorocarboxylates. Environ. Sci. Technol. 43: 5565-5575.

Vesterinen, H. M., Johnson, P. I., Atchley, D. S., Sutton, P., Lam, J., Zlatnik, M. G., Sen, S., Woodruff, T. J. (2015). Fetal growth and maternal glomerular filtration rate: a systematic review. J. Matern. Fetal Neonatal Med. 28: 2176-2181.

Vieira, V. M., Hoffman, K., Shin, H. M., Weinberg, J. M., Webster, T. F., Fletcher, T. (2013). Perfluorooctanoic acid exposure and cancer outcomes in a contaminated community: a geographic analysis. Environ. Health Perspect. 121: 318-323.

von Ehrenstein, O.S., Fenton, S.E., Kato, K., Kuklenyik, Z., Calafat, A.M., Hines, E.P. (2009). Polyfluoroalkyl chemicals in the serum and milk of breastfeeding women. Reprod. Toxicol. 27: 239-245.

Wägner, A.M., Sánchez-Quesada, J.L., Benítez, S., Bancells, C., Ordóñez-Llanos, J., Pérez (2011). Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study. Diabetes Res. Clin. Pract. 93: e25-8.

Walters, M. W., Bjork, J. A., Wallace, K. B. (2009). Perfluorooctanoic acid stimulated mitochondrial biogenesis and gene transcription in rats. Toxicology 264: 10-15.

Wang, M., Park, J.S., Petreas, M. (2011a). Temporal changes in the levels of perfluorinated compounds in California women serum over the past 50 years. Environ. Sci. Technol. 45: 7510-7516.

Wang, J., Zhang, Y., Zhang, W., Jin, Y., Dai, J. (2012). Association of perfluorooctanoic acid with HDL cholesterol and circulating miR-26b and miR-199-3p in workers of a fluorochemical plant and nearby residents. Environ. Sci. Technol. 46: 9274-9281.

Wang, L., Wang, Y., Liang, Y., Li, J., Liu, Y., Zhang, J., Zhang, A., Fu, J., Jiang, G. (2013). Specific accumulation of lipid droplets in hepatocyte nuclei of PFOA-exposed BALB/c mice. Sci. Rep. 3: 2174.

Wang, Y., Rogan, P. C. Chen, G. W. Lien, H. Y. Chen, Y. C. Tseng, M. P. Longnecker, Wang, S. L. (2014). Association between maternal serum perfluoroalkyl substances during pregnancy and maternal and cord thyroid hormones: Taiwan maternal and infant cohort study. Environ. Health Perspect. 122: 529-534.

Washburn, S.T., Bingman, T.S., Braithwaite, S.K., Buck, R.C., Buxton, L.W., Clewell, H.J., Haroun, L.A., Kester, J.E., Rickard, R.W., Shipp, A.M. (2005). Exposure assessment and risk characterization for perfluorooctanoate in selected consumer articles. Environ. Sci. Technol. 39: 3904-3910.

Washington, J.W., Ellington, J., Jenkins, T.M., Evans J.J., Yoo, H., Hafner, S.C. (2009). Degradability of an acrylate-linked, fluorotelomer polymer in soil. Environ. Sci. Technol. 43: 6617-6623.

Weaver, Y.M., Ehresman, D.J., Butenhoff, J.L., Hagenbuch, B. (2010). Roles of rat renal organic anion transporters in transporting perfluorinated carboxylates with different chain lengths. Toxicol. Sci. 113: 305-314.

Wang, Y., Rogan, W. J., Chen, P. C., Lien, G. W., Chen, H. Y. Tseng, Y. C., Longnecker, M. P., Wang, S. L. (2014). Association between maternal serum perfluoroalkyl substances during pregnancy and maternal and cord thyroid hormones: Taiwan maternal and infant cohort study. Environ. Health Perspect. 122: 529-534.

Wei, Y., Dai, J., Liu, M., Wang, J., Xu, M., Zha, J., Wang, Z. (2007). Estrogen-like properties of perfluorooctanoic acid as revealed by expressing hepatic estrogen-responsive genes in rare minnows (Gobiocypris rarus). Environ. Toxicol. Chem. 26: 2440-2447.

Wen, L. L., Lin, L. Y., Su, T. C., Chen, P. C., Lin, C. Y. (2013). Association between serum perfluorinated chemicals and thyroid function in U.S. adults: the National Health and Nutrition Examination Survey 2007-2010. J. Clin. Endocrinol. Metab. 98: E1456-1464.

White, S.S., Calafat, A.M., Kuklenyik, Z, Villanueva, L., Zehr, R.D., Helfant, L., Strynar, M.J., Lindstrom, A.B., Thibodeaux, J.R., Wood, C., Fenton, S.E. (2007). Gestational PFOA exposure of mice is associated with altered mammary gland development in dams and female offspring. Toxicol. Sci. 96: 133-144.

White, S.S., Kato, K., Jia, L.T., Basden, B.J., Calafat, A.M., Hines, E.P., Stanko, J.P., Wolf, C.J., Abbott, B.D., Fenton, S.E. (2009). Effects of perfluorooctanoic acid on mouse mammary gland development and differentiation resulting from cross-foster and restricted gestational exposures. Reprod. Toxicol. 27: 289-298.

White, S.S., Fenton, S.E., Hines, E.P. (2011a). Endocrine disrupting properties of perfluorooctanoic acid. J. Steroid Biochem. 127: 16-26.

White, S.S., Stanko, J.P., Kato, K., Calafat, A.M., Hines, E.P., Fenton, S.E. (2011b). Gestational and chronic low-dose PFOA exposures and mammary gland growth and differentiation in three generations of CD-1 Mice. Environ. Health Perspect. 119: 1070-1076.

Winquist, A., Steenland, K. (2014a). Modeled PFOA exposure and coronary artery disease, hypertension, and high cholesterol in community and worker cohorts. Environ. Health Perspect. 122: 1299-1305.

Winquist, A., Steenland, K. (2014b). Perfluorooctanoic acid exposure and thyroid disease in community and worker cohorts. Epidemiology 25: 255-264.

Wolf, C.J., Fenton, S.E., Schmid, J.E., Calafat, A.M., Kuklenyik, Z., Bryant, X.A., Thibodeaux, J., Das, K.P., White, S.S., Lau, C.S., Abbott, B.D. (2007). Developmental toxicity of perfluorooctanoic acid in the CD-1 mouse after cross-foster and restricted gestational exposures. Toxicol. Sci. 95: 462-473.

Wolf, C.J., Zehr, R.D., Schmid, J.E., Lau, C., Abbott, B.D. (2010). Developmental effects of perfluorononanoic acid in the mouse are dependent on peroxisome proliferator-activated receptor-alpha. PPAR Res. 2010, pii: 282896.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 352 of 551

Wolf, C.J., Schmid, J.E., Lau, C., Abbott, B.D. (2012). Activation of mouse and human peroxisome proliferator-activated receptor-alpha (PPARα) by perfluoroalkyl acids (PFAAs): Further investigation of C4-C12 compounds. Reprod Toxicol. 33: 546-551.

Wolf, D.C., Moore, T., Abbott, B.D., Rosen, M.B., Das, K.P., Zehr, R.D., Lindstrom, A.B., Strynar, M.J., Lau, C. (2008). Comparative hepatic effects of perfluorooctanoic acid and WY 14,643 in PPAR-alpha knockout and wild-type mice. Toxicol. Pathol. 36: 632-639.

Woodruff, T.J. and Sutton, P. (2014). The Navigation Guide systematic review methodology: a rigorous and transparent method for translating environmental health science into better health outcomes. Environ. Health Perspect. 122:1007–1014.

Yahia, D., El-Nasser, M. A., Abedel-Latif, M., Tsukuba, C., Yoshida, M., Sato, I., Tsuda, S., (2010). Effects of perfluorooctanoic acid (PFOA) exposure to pregnant mice on reproduction. J Toxicol. Sci. 35: 527-533.

Yamaguchi, M., Arisawa, K., Uemura, H., Katsuura-Kamano, S., Takami, H., Sawachika, F., Nakamoto, M., Juta, T., Toda, E., Mori, K., Hasegawa, M., Tanto, M., Shima, M., Sumiyoshi, Y., Morinaga, K., Kodama, K., Suzuki, T., Nagai, M., Satoh, H. (2013). Consumption of seafood, serum liver enzymes, and blood levels of PFOS and PFOA in the Japanese population. J. Occup. Health 55: 184-194.

Yan, S., Wang, J., Zhang, W., Dai, J. (2014). Circulating microRNA profiles altered in mice after 28 d exposure to perfluorooctanoic acid. Toxicol. Lett. 224: 24-31.

Yang, Q., Xie, Y. Depierre, W. (2000). Effects of peroxisome proliferators in the thymus and spleen of mice. Clin. Exp. Immunol. 122: 219-226.

Yang, Q., Abedi-Valugerdi, M., Xie, Y., Zhao, X., Moller, G., Nelson, B.D., DePierre, J.W. (2002a). Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. Internat. Immunopharmacol. 2: 389-397.

Yang, Q., Xie, Y., Alexson, S. E., Nelson, B. D. DePierre, J. W. (2002b). Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice. Biochem. Pharmacol. 63: 1893-1900.

Yang, Q., Kurotani, R., Yamada, A., Kimura, S., Gonzalez, F.J. (2006). Peroxisome proliferator-activated receptor alpha activation during pregnancy severely impairs mammary lobuloalveolar development in mice. Endocrinology 147: 4772-4780.

Yang, C., Tan, Y.S., Harkema, J.R., Haslam, S.Z. (2009a). Differential effects of peripubertal exposure to perfluorooctanoic acid on mammary gland development in C57Bl/6 and Balb/c mouse strains. Reprod. Toxicol. 27: 299-306.

Yang, C. H., Glover, K. P., Han, X. (2009b). Organic anion transporting polypeptide (Oatp) 1a1-mediated perfluorooctanoate transport and evidence for a renal reabsorption mechanism of Oatp1a1 in renal elimination of perfluorocarboxylates in rats. Toxicol. Lett. 190: 163-171.

Yang, C. H., Glover, K. P., Han, X. (2010). Characterization of cellular uptake of perfluorooctanoate via organic anion-transporting polypeptide 1A2, organic anion transporter 4, and urate transporter 1 for their potential roles in mediating human renal reabsorption of perfluorocarboxylates. Toxicol. Sci. 117: 294-302.

Yang, B., Zou, W., Hu, Z., Liu, F., Zhou, L., Yang, S., Kuang, H., Wu, L., Wei, J. Wang, J., Zou, T., Zhang, D. (2014). Involvement of oxidative stress and inflammation in liver injury caused by perfluorooctanoic acid exposure in mice. Biomed. Res. Int. 2014: 409837.

Yao, X., Zhong, L. (2005). Genotoxic risk and oxidative DNA damage in HepG2 cells exposed to perfluorooctanoic acid. Mutat. Res. 587: 38-44.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 353 of 551

Yao, P. L., Ehresman, D. J., Rae, J. M., Chang, S. C., Frame, S. R., Butenhoff, J. L., Kennedy, G. L., Peters, J. M. (2014). Comparative in vivo and in vitro analysis of possible estrogenic effects of perfluorooctanoic acid. Toxicology 326: 62-73.

Ylinen, M., Kojo, A. Hanhijdrvi, H., Peura, P. (1990). Disposition of perfluorooctanoic acid in the rat after single and subchronic administration. Bull. Environ. Contam. Toxicol. 44: 46-53.

Yoo, H., Washington, J.W., Jenkins, T.M., Ellington, J.J. (2011). Quantitative determination of perfluorochemicals and fluorotelomer alcohols in plants from biosolid-amended fields using LC/MS/MS and GC/MS. Environ. Sci. Technol. 45: 7985–7990.

York, R.G. (2002). Oral (gavage) two-generation (one litter per generation) reproduction study of ammonium perfluorooctanoic (APFO) in rats. Argus Research Laboratories, Inc. Protocol Number: 418-020, Sponsor Study Number: T-6889.6, March 26, 2002. USEPA AR226-1092.

Zeng, X. W., Qian, Z., Emo, B., Vaughn, M., Bao, J., Qin, X. D., Zhu, Y., Li, J., Lee, Y. L., Dong, G. H. (2015). Association of polyfluoroalkyl chemical exposure with serum lipids in children. Sci. Total Environ. 512-513: 364-370.

Zhang, T., Sun, H., Lin, Y., Wang, L., Zhang, X., Liu, Y., Geng, X., Zhao, L., Li, F., Kannan, K. (2011). Perfluorinated compounds in human blood, water, edible freshwater fish, and seafood in China: daily intake and regional differences in human exposures. J. Agric. Food Chem. 59: 11168-11176.

Zhang, Y., Beesoon, S., Zhu, L., Martin, J.W. (2013). Biomonitoring of perfluoroalkyl acids in human urine and estimates of biological half-life. Environ. Sci. Technol. 47: 10619-27.

Zhang, H., Lu, Y., Luo, B., Yan, S., Guo, X., Dai, J. (2014). Proteomic analysis of mouse testis reveals perfluorooctanoic acid-induced reproductive dysfunction via direct disturbance of testicular steroidogenic machinery. J. Proteome Res. 13: 3370-85.

Zhao, Y., Tan, Y.S., Haslam, S.Z., Yang, C. (2010). Perfluorooctanoic acid effects on steroid hormone and growth factor levels mediate stimulation of peripubertal mammary gland development in C57BL/6 mice. Toxicol. Sci. 115: 214-224.

Zhao, Y., Tan, Y. S., Strynar, M. J., Perez, G., Haslam, S. Z., Yang, C. (2012). Perfluorooctanoic acid effects on ovaries mediate its inhibition of peripubertal mammary gland development in Balb/c and C57Bl/6 mice. Reprod. Toxicol. 33: 563-576.

APPENDICES TO

HEALTH-BASED MAXIMUM CONTAMINANT LEVEL SUPPORT DOCUMENT: PERFLUOROOCTANOIC ACID (PFOA)

New Jersey Drinking Water Quality Institute Health Effects Subcommittee February 15, 2017

> Subcommittee Members: Jessie A. Gleason, M.S.P.H., Chair Keith R. Cooper, Ph.D. Judith B. Klotz, M.S., Dr.P.H. Gloria B. Post, Ph.D., DABT George Van Orden, Ph.D.


TABLE OF CONTENTS

Appendix 1 - Literature Search Criteria and Documentation – PFOA	3
Appendix 2 – Comparison of USEPA Office of Water Health Advisory and DWQI recommended Health- based MCL for PFOA	
Appendix 3 - Risk Assessment Considerations for Butenhoff et al. (2002) Subchronic Cynomolgus Monke	зy
Study	18
Appendix 4 - Individual Tables for Epidemiology Studies	21
Appendix 5 - Individual Tables for Toxicology Studies	78
Appendix 6- Outputs of Benchmark Dose Modeling for Mammary Gland Development Endpoints	.112
Appendix 7 - Benchmark Dose Analysis of Relative Liver Weight in Response to PFOA (Linear/Branched	ł)
using BMR of 10% Increase Relative to Controls	162
Appendix 8 - Benchmark dose analysis of testicular tumor data in response to PFOA using BMR of 5% turincidence	

APPENDIX 1. Literature Search Criteria and Documentation - PFOA

1159 citations (2010 to present) and 857 citations (pre-2010) from PubMed (April 13, 2015): search "(pfoa OR (PFO AND (perfluoroalk* OR perfluorocarb* OR perfluorinat* OR perfluorooc*)) OR (C8 AND (perfluoroalk* OR perfluorocarb* OR perfluorinat* OR perfluorooc*)) OR apfo OR (perfluorooctanoic AND acid) OR (pentadecafluorooctanoic AND acid) OR (perfluoroheptanecarboxylic AND acid) OR (ammonium AND perfluorooctanoate) OR (ammonium AND pentadecafluorooctanoic AND acid AND ammonium AND perfluorocaprilate) OR (pentadecafluorooctanoic AND acid AND ammonium AND salt) OR (sodium AND perfluorooctanoate) OR (sodium AND pentadecafluorooctanoate) OR (sodium AND perfluorocaprylate) OR (perfluorooctanoic AND acid AND sodium AND salt) OR (potassium AND perfluorooctanoate) OR (petfluorooctanoic AND acid AND sodium AND salt) OR (potassium AND petfluorooctanoate) OR (petfluorooctanoic AND acid AND sodium AND salt) OR (potassium AND petfluorooctanoate) OR (petfluorooctanoic AND acid AND sodium AND salt) OR (potassium AND petfluorooctanoate) OR (potassium AND petfluoroacrylate) OR (petfluorooctanoic AND acid AND solit) OR (potassium AND petfluoroacrylate) OR (petfluorooctanoic AND acid AND potassium AND salt) OR (PC-143 OR (335-67-1[EC/RN Number]) OR (3825-26-1[EC/RN Number]) OR (335-95-5[EC/RN Number]) OR (2395-00-8[EC/RN Number])"; Limits: none

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 357 of 551



¹Totals exceed number of imported files if articles are placed into more than one category. Additional studies were added via backward searching, relevant citations from earlier review by the Health Effects Subcommittee, and article title review of monthly PubMed key word searches.

²Title and/or abstract review

³Abstracts and/or text reviewed to be sorted into selected endpoints.

⁴Authors evaluated full text of each article to determine whether mammalian toxicology or human health effects were investigated in studies.

⁵This number does not represent unique studies.

⁶Some studies in this category are discussed in the text and others are not.

⁷Studies included in summary tables and/or individual study tables.

APPENDIX 2: Comparison of USEPA Office of Water Health Advisory and DWQI recommended Health-based MCL for PFOA

The basis for the USEPA (2016a) Health Advisory and the recommended DWQI Health-based MCL, and other relevant information about these two drinking water values, are compared in the table below. Additional information is provided in the text that follows the table.

Parameter	USEPA Office of Water	DWQI Recommended			
	Health Advisory	Health-based MCL			
Value	70 ng/L	14 ng/L			
General statement	"Protects the most sensitive	"Developed using a risk			
	populations, with a margin of	assessment approach intended to			
	protection from a lifetime of	be protective for chronic (lifetime)			
	exposure."	exposure."			
	As discussed in this document, PFOA is associated with several human				
	health effects, some with evidence supporting multiple criteria for				
	causality, within the general population exposure range even without				
	additional exposure from drinking water. Furthermore, the Reference				
	Dose (RfD) for mammary gland effects in mice is below the average				
	exposure level in the general population, and other toxicological effects				
	occurred at similarly low doses in animal studies. Therefore, the Health				
	Effects Subcommittee concluded that additional exposure from drinking				
	water may potentially pose some risk of health effects. For this reason, it				
	cannot be definitively concluded that lifetime exposure to these drinking				
	water concentrations is protective of sensitive subpopulations with a				
	margin of exposure.				
	USEPA recognizes that human studies provide evidence of associations of				
	several health effects with PFOA. However, USEPA concludes that the				
	human studies do not provide quantitative information on the exposure				
	levels or serum levels associated with these health effects. Therefore,				
	USEPA did not consider the possibility that health effects may result from				
	exposures within the general population range, even with no additional				
	exposure from drinking water. USEPA also dismissed the low dose				
	toxicological effects in animal studies from consideration in risk				
	assessment. See discussion of these po	ints below.			

Parameter (cont.)	USEPA (cont.)		DWQI (cont.)	
Reference Dose	20 ng/kg/day		2 ng/kg/day	
(RfD)	Based on delayed ossification of phalanges		Based on Benchmark	
	and accelerated male puberty after		Dose modeling of	
	developmental exposures to mice	e (Lau et	increased liver weight in	
	al., 2006).		mice, with additional	
	• Data do not follow typical dose-response of		uncertainty factor for	
	greater response as dose increases. (See		more sensitive	
	figures below.) An uncertainty factor of 10		developmental effects at	
	was applied for LOAEL-to-NOAEL		much lower doses	
	extrapolation. The basis and precedent for		(delayed mammary	
	this approach with dose-response curves of		gland development,	
	this type is uncertain and may be subject to		persistent liver toxicity,	
	debate.		and others).	
	Note: USEPA and DWQI RfDs are	identical nu	merically, with the	
	exception of application of an additional uncertainty factor of 10 in the			
	DWQI RfD to account for more sensitive developmental endpoints.			
	These more sensitive endpoints were not considered in development of			
	the USEPA RfD. Issues related to endpoints selected as the basis for			
	RfDs by DWQI and USEPA are further discussed below.			
Interspecies	Pharmacokinetic modeling was	1	K Dose modeling was	
conversion in RfD	used to predict average serum		on measured serum	
<i>development</i>	PFOA concentrations at the	-	centrations at each dose	
weverepittetti	NOAELs and/or LOAELs in		nd of the dosing period to	
	toxicological studies. A clearance		rum level Benchmark	
	factor that relates serum PFOA		D). This approach has less	
	level to human administered dose		than use of modeled	
	(applicable to serum PFOA data	-	A data. Uncertainty	
	from any species) was used to		re applied to the BMD	
	obtain the Human Equivalent		I to obtain the Target	
	Doses (HEDs) at the modeled		rum Level (i.e. the RfD in	
	average serum levels. Uncertainty		rum PFOA level). The	
	factors were applied to the HEDs		ance factor used by	
	to obtain potential RfDs.		5	
	to obtain potential KIDs.		as applied to the Target rum Level to obtain the	
			tum Level to obtain the	
		RfD.		

Parameter (cont.)	USEPA (cont.)	DWQI (cont.)			
Drinking water	500 ng/L.	14 ng/L			
concentration	Predicted risk at this concentration	(Identical to the value based on non-			
estimated to result in	based on the DWQI evaluation is	cancer effects)			
one in one million	about $4 \ge 10^{-5}$ (i.e. 40-fold				
(10^{-6}) lifetime cancer	higher than 1 in 1 million).				
risk	USEPA and DWQI cancer assessme	ents are both based on increased			
	incidence of testicular tumors in a chronic rat study (Butenhoff et al.,				
	2012), and the Benchmark Doses developed by USEPA and DWQI for				
	these tumors are almost identical. The two assessments differ in the				
	approach used for animal-to-human	conversion. DWQI used the ratio of			
	half-lives to account for interspecies				
	serum PFOA data are not provided i	-			
	considered interspecies pharmacokinetic differences in animal-to-human conversion for non-cancer effects, the default animal-to-human extrapolation (ratio of body weights to the ³ / ₄ power) was used by USEPA for cancer risk assessment. This default approach does not account for				
	interspecies pharmacokinetic differe				
	that does not account for pharmacokinetic differences for cancer risk assessment, although pharmacokinetic differences were considered for				
	non-cancer risk assessment, does not appear to be logical or consistent.				
Relative Source	20%. To account for non-drinking	20%. To account for non-			
Contribution Factor	water exposures.	drinking water exposures. Also			
	1	implicitly accounts for greater			
		exposures to breastfed and			
		formula fed infants than older			
		individuals.			
Assumed Drinking	0.054 L/kg/day.	0.029 L/kg/day.			
Water Consumption	Based on 90 th percentile for lactating				
1	woman.	percentile adult exposure			
		assumptions (2 L/day water			
	USEPA also developed an alternativ				
	Health Advisory of 100 ng/L that	weight).			
	applies to adults in the general				
	population based on standard adult				
	exposure assumptions (2.5 L/day				
	water consumption; 80 kg body				
	weight). More information is provid	ed			
	below under <u>Sensitive</u>				
	Subpopulations.				
	<u>F - F </u>				
		I			

Parameter (cont.)	USEPA (cont.)	DWQI (cont.)
Increase in serum	• With average water consumption:	• With average water
PFOA concentration	8.0 ng/ml; 4.8-fold increase from	consumption: 1.6 ng/ml; 1.8-
predicted from	U.S general population median of fold increase from U.S.	
ongoing exposure to	2.1 ng/ml (CDC, 2015).	general population median.
USEPA Health	• With upper percentile water	• With upper percentile water
Advisory and DWQI	consumption: 14 ng/ml; 7.7-fold	consumption: 2.8 ng/ml; 2.3-
recommended	increase from U.S. general	fold increase from U.S.
Health-based MCL	population median.	general population median.
(see <u>bar graph</u>	Note: A clearance factor that relates hu	0 1 1
below)	PFOA serum levels was developed by U	1
	Egeghy, 2011). This factor can be used	
	PFOA from drinking water exposures.	-
	another part of the USEPA (2016a) asse	
	from laboratory animals to human doses	
	not acknowledge that it is possible to pr	
	that will result from ongoing exposure t	-
~	in drinking water (ASDWA, 2016; USE	
Sensitive	Pregnant and lactating women; bottle for	ed infants. As is the case for all
Subpopulations	USEPA does not include women who plan	Health-based MCLs
	pregnant in its definition of sensitive subp	opulations developed by the
	but states that stated that states may choos	e to expand
	the sensitive subgroups to include women	f based MICT
	bearing age (ASDWA, 2016). This exclusion	recommended tor
	not appear to be supportable because the b	DEO A is intended to
	of PFOA remains elevated for many years	
	exposure ceases. Therefore, if body burde	· · · · 1
	elevated prior to pregnancy, it will remain	
	during pregnancy and lactation.	subpopulations.
		Sensitive
	USEPA (2016a) also calculated a lifetime	HA value
	for alternative exposure scenarios for the g	subpopulations for
	population (adults age 21 and older) of 10	health effects of
	based on standard adult exposure assumpt	ions. PFOA include
	USEPA states that the Lifetime Health Ad	
	ng/L is protective for effects other than de	velopmental become pregnant, cer. liver pregnant women,
	toxicity, such as testicular and kidney cancer, liver	
	damage, and immune effects.	lactating women,
	and breas	
	However, it has been reported in the news	
	some states have interpreted the USEPA designation of sensitive subgroups to mean that those not in these	
	sensitive subpopulations may continue to	
	exceeding the USEPA Health Advisory (e	.g.
	WAAYTV, 2016).	

Endpoints used as basis of DWQI recommended Health-based MCL

The primary basis for the recommended Health-based MCL is an RfD based on increased relative liver weight in mice (Loveless et al., 2006). As discussed elsewhere in this document, the Health Effects Subcommittee conducted an extensive and detailed review of the hepatic effects of PFOA. It was concluded that increased relative liver weight in animal studies is a sensitive and well established effect of PFOA which is accompanied by and/or can progress to more severe forms of liver toxicity, and that it should be considered relevant to humans. Additionally, human exposure to PFOA in the general population and in communities with contaminated drinking water is associated with increased serum levels of liver enzymes, strongly suggesting that low exposures to PFOA affect liver function in humans.

The Health Effects Subcommittee also conducted an extensive review of delayed mammary gland development in mice from developmental exposure to PFOA. This effect was observed in 9 separate studies from 5 publications and follows a typical (monotonic) dose-response curve, with greater effects at higher doses. The Health Effects Subcommittee concluded that this effect is adverse, results in persistent structural changes that are considered to be permanent, and should be considered relevant to humans. Additionally, recent human studies (Fei et al., 2010; Romano et al., 2016; Timmermann et al., 2016) suggest an association of PFOA exposure with decreased duration of breast feeding, an effect which may potentially be relevant to effects on mammary gland development.

The Health Effects Subcommittee developed an RfD for delayed mammary gland development (Macon et al., 2011) based on the Benchmark Dose presented in Post et al. (2012). A Healthbased MCL based on this RfD would be 1 ng/L or less. The Health Effects Subcommittee chose not to use this RfD as the basis for a recommended Health-based MCL, not because of uncertainty about the scientific validity of doing so, but rather because of lack of precedent for use of this endpoint as the primary basis for health-based criteria for environmental contaminants. However, the Health Effects Subcommittee concluded that an additional uncertainty factor to protect for developmental effects (delayed mammary gland development; persistent liver toxicity) at much lower doses than those that caused increased liver weight should be incorporated into the RfD.

USEPA (2016a) provides a detailed summary of studies of mammary gland development in mice but chose not to consider this effect in risk assessment. The reasons provided by USEPA for not considering this endpoint (mode of action not known, effects occurred only at higher doses in a second strain of mice, functional significance is unclear) do not appear to be scientifically valid and/or are also equally or more applicable to the endpoints selected by USEPA as the basis for its Health Advisory (discussed further below in the section on Endpoints used as basis of EPA Health Advisory).

In regard to the issue of strain difference in susceptibility, it should be noted that almost all of the studies of developmental exposures to PFOA and mammary gland development were conducted in CD-1 mice. A second strain of mice (C57/Bl6) was included in only one study in which a very small number of mice of this strain were used in each dose group (Tucker et al., 2015). USEPA (2016a) does not discuss that the higher LOAEL for effects on the mammary gland in C57Bl/6 mice as compared to CD-1 mice may potentially be explained by pharmacokinetic

differences (lower serum PFOA concentrations from the same dose of PFOA in the C57/Bl6 strain) and/or the very small number of C57/Bl6 mice per dose group, limiting the ability to achieve statistical significance (Tucker et al., 2015).

The Health Effects Subcommittee also considered persistent liver toxicity from developmental exposures to very low doses of PFOA (Quist et al., 2015). Although these effects cannot be used as the basis for an RfD because the serum PFOA data needed for dose-response modeling are not provided, they give further indication of effects at much lower doses than those that cause increased liver weight, the primary basis for the recommended RfD. The low doses at which these persistent hepatic effects from developmental exposures occurred were not considered by USEPA in developing its Health Advisory.

Endpoints used as basis of USEPA Health Advisory


The USEPA Health Advisory is based on an RfD for delayed ossification (conversion of cartilage to bone during development) of proximal phalanges and accelerated male puberty in offspring in a developmental study of CD-1 mice (Lau et al., 2006).

USEPA states that these effects have lifelong consequences. However, delayed ossification in Lau et al. (2006) represents a delay in timing of development rather than a permanent structural change, because the phalanges developed normally in mice treated with PFOA that were not sacrificed prior to delivery in this study (personal communication with C. Lau). Therefore, the long term consequences and functional significance of this effect are unclear. Similarly, the long term consequences and functional significance of accelerated puberty are unclear. This is particularly noteworthy because one of the reasons provided by USEPA for not considering delayed mammary gland development in risk assessment is that its functional significance is unclear, although developmental exposures to PFOA cause structural and/or histopathological changes that persist until adulthood in the mammary gland.

In regard to differences in strain sensitivity, there is a major difference in sensitivity to effects of gestational PFOA exposure on delayed ossification in ICR mice (Yahia et al., 2010) as compared to the CD-1 mice used by Lau et al. (2006). The LOAEL (10 mg/kg/day) and NOAEL (5 mg/kg/day) for delayed ossification in the ICR mice were much higher than the LOAEL (1 mg/kg/day) in CD-1 mice. In ICR mice, delayed ossification occurred only at a dose at or above the doses that caused maternal toxicity, decreased fetal weight, and decreased pup survival; no pups survived until 4 days of age at 10 mg/kg/day, the LOAEL for delayed ossification. This large difference in strain sensitivity is especially noteworthy because one of USEPA's reasons for dismissing effects on mammary gland development for consideration in risk assessment is the strain difference observed by Tucker et al. (2015), which may be explained by factors other than differences in intrinsic sensitivity (discussed above).

Accelerated puberty in male animals has not been reported in studies of PFOA other than Lau et al. (2006). To the knowledge of the Health Effects Subcommittee, this effect was not assessed in developmental studies of mice other than Lau et al. (2006). Timing of puberty in offspring was assessed in a two generation rat study (Butenhoff et al., 2004), and accelerated puberty was not observed in male offspring in this study.

The endpoints selected by USEPA (2016a) as the basis for the Health Advisory do not follow a typical (monotonic) dose-response in which greater effects occur with increasing dose (see graphs of data from Lau et al., 2006, below). In Lau et al. (2006), delayed ossification occurred at the lowest dose (1 mg/kg/day) but was not significantly increased at some of the higher doses. Acceleration of puberty in males in Lau et al. (2006) was greatest at the lowest dose (1 mg/kg/day), with a lesser effect with each increasing dose, and puberty was delayed rather than accelerated at the highest dose. USEPA (2016a) did not mention the shapes of these doseresponse curves in its discussions of these endpoints. They considered the lowest dose to be the LOAEL for both of these effects and applied an uncertainty factor of 10 for extrapolation from LOAEL-to-NOAEL. However, the Health Effects Subcommittee is not aware of any precedent for use of an uncertainty factor for extrapolation from LOAEL-to-NOAEL for these types of dose response curves. The basis for application of this uncertainty factor, based on the assumption that the NOAEL is 10-fold lower than the lowest dose, is uncertain and may be subject to debate for dose-response curves of this type. In contrast, effects considered by the Health Effects Subcommittee for dose-response modeling (increased relative liver weight and delayed mammary gland development) follow typical monotonic dose-response curves and provide data appropriate for Benchmark Dose modeling.



Finally, the modes of action for delayed ossification and accelerated puberty in males are not known. This is noteworthy because one of the reasons provided by USEPA for not considering effects on mammary gland development in risk assessment is that the mode of action is not known.

Consideration of data from human epidemiological studies

As discussed in detail in the <u>Epidemiology</u> section of this document, PFOA is associated with several human health effects, some with evidence supporting multiple criteria for causality, in the general population exposure and in communities with exposure from contaminated drinking water. USEPA (2016a) acknowledges that associations of PFOA and numerous health endpoints

are observed in these human populations and that associations with some effects have consistently been found in multiple human studies.

However, USEPA states that, while these human studies are useful for hazard identification, they cannot be used quantitatively because the PFOA exposures at which the associations were observed are unknown or highly uncertain. Although the Health Effects Subcommittee agrees that the human data have limitations that preclude their use as the primary basis for risk assessment, it does not agree with USEPA that the serum PFOA concentrations and PFOA exposures associated with human health effects are highly uncertain or unknown.

Relevant to this point, it is noted that the German Human Biomonitoring Commission recently developed a Human Biomonitoring Level I (the serum level below which adverse health effects are not expected) for PFOA of 2 ng/ml, close to the current median PFOA serum level in the U.S. general population. This HBM I is based on the serum PFOA levels associated with increased time to pregnancy, decreased fetal growth, increased serum cholesterol, and decreased immune response in humans, and with delayed mammary gland development in mice (Apel et al., 2016).

USEPA (2016a) provides the following reasons for its conclusions:

• Serum levels may have decreased (in both the general population and in communities with drinking water exposure) prior to when the blood sample was taken. Therefore, the effects may have been due to earlier exposures that were higher than indicated by the measured serum PFOA levels.

It is unlikely that this is a major source of uncertainty in evaluation of exposure since PFOA serum levels decrease slowly (half-life of several years) and are generally stable over time. In the C8 Health Study, blood samples were taken before or soon after the installation of treatment to remove PFOA from drinking water. Participants' blood was drawn between August 2005 and August 2006, with over 80% of samples taken in March 2006 or earlier, and treatment removal began between March 2006 and September 2008 (WVU School of Medicine, 2008; Frisbee et al., 2009; Fitz-Simons et al, 2013). Additionally, if effects were actually due to previous exposures that were higher than those at the time of blood sampling, it would mean that the detrimental effects of PFOA are persistent and do not resolve when exposures decrease, which would increase the level of concern about the effects.

• PFOA measured in serum may result from metabolism of precursors to PFOA rather than direct exposure to PFOA itself.

This does not appear to be a valid reason to dismiss consideration of serum PFOA levels as a measure of PFOA exposure. Effects of PFOA would be the same regardless of whether the source of exposure is PFOA itself or metabolism of precursors to PFOA.

• Co-exposure to other PFCs, even if accounted for as a potential confounding factor in the statistical analysis, increase uncertainty about observed associations of health endpoints with PFOA.


However, co-exposure to other chemicals is a general issue for all human studies of exposure to environmental contaminants and does not preclude evaluation of the levels of PFOA exposure associated with health endpoints.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 366 of 551

<u>Consideration of increases in serum PFOA levels from exposure to PFOA in drinking water</u> As noted in the table at the beginning of this Appendix, a clearance factor developed by USEPA scientists (Lorber and Egeghy, 2011) relates human PFOA exposures to human PFOA serum levels. This factor can be used to predict increases in serum PFOA from ongoing drinking water exposures. The bar graph below shows the predicted increases in serum PFOA levels from ongoing exposure in drinking water at the USEPA (2016a) Health Advisory (70 ng/L), the NJDEP (2007) guidance (40 ng/L), and the DWQI recommended Health-based MCL (14 ng/L). Predictions based on both average and upper percentile drinking water ingestion rates are shown.

USEPA (2016a) used the clearance factor to convert NOAEL and LOAEL serum levels from laboratory animals to human equivalent doses (p. 4-13 of USEPA, 2016a) and discusses that it relates human PFOA dose to human PFOA serum level, including from drinking water exposure (p. 2-51 of USEPA, 2016b). However, USEPA does not acknowledge that it is possible to predict increases in serum PFOA levels from exposures to PFOA at 70 ng/L, the Health Advisory concentration (ASDWA, 2016; USEPA, 2016c; USEPA, 2016d). The Health Effects Subcommittee has evaluated this question and concludes that the use of the clearance factor to predict increases in serum PFOA levels from drinking water exposures is technically sound and is not subject to debate.

Several health effects, some with evidence supporting multiple criteria for causality, are associated with PFOA exposures at serum levels well below those that would result from exposure to 70 ng/L in drinking water. The Health Effects Subcommittee therefore concludes that elevations in serum PFOA levels of the magnitude expected from ongoing exposure to 70 ng/L (the USEPA Health Advisory) in drinking water are not desirable and may not be protective of public health.




14 ng/L – Health-based MCL recommended by DWQI Health Effects Subcommittee 40 ng/L – NJDEP drinking water guidance (2007) based on older toxicology data 70 ng/L – USEPA Lifetime Health Advisory

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 367 of 551

Finally, as discussed elsewhere in this document, several studies have shown that serum PFOA concentrations in breastfed infants increase several fold from levels at birth (which are similar to maternal levels) within the first few months of life (see figure below). Exposures to infants who consume formula prepared with contaminated water are also highest during this time period, and serum PFOA levels remain elevated for the first several years of life (see figure below). Therefore, increases in blood serum levels in infants and children from exposure to PFOA in drinking water are expected to be several-fold higher than those shown in the bar graph above.

USEPA recognizes that lactating women and bottle-fed infants are sensitive subpopulations for exposure to PFOA in drinking water. The Health Effects Subcommittee also concludes that the elevated exposures during infancy and early childhood are of particular concern because early life effects are sensitive endpoints for the toxicity of PFOA. Additionally, the Health Effects Subcommittee concludes women who may become pregnant should also be included as sensitive subpopulations, because the body burden of PFOA remains elevated for many years after exposure ceases. Therefore, if serum PFOA levels are elevated when a woman becomes pregnant, they will remain elevated during pregnancy and lactation.



From Verner et al. (2016). Modeling simulation of the ratio of PFOA in blood plasma in breast fed infants/children to plasma concentration in mother. Black line - 50th percentile. Blue line - 5th percentile. Red line - 95th percentile. Dotted lines - minimum and

maximum values.

Citations

Apel, P., Angerer, J., Wilhelm, M., Kolossa-Gehring, M. (2016). New HBM values for emerging substances, inventory of reference and HBM values in force, and working principles of the German Human Biomonitoring Commission. Int. J. Hyg. Environ. Health (in press).

ASDWA (2016). Association of State Drinking Water Administrators. Information for States about the New Health Advisories for PFOA and PFOS. Presented by USEPA Office of Water. May 23, 2016. <u>https://www.youtube.com/watch?v=QoBBjLeOi s&feature=youtu.be</u>

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 368 of 551

Butenhoff, J.L., Kennedy, G.L., Frame, S.R., O'Conner, J.C., York, R.G., 2004b. The reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rat. Toxicology 196, 95-116.

Butenhoff, J. L., G. L. Kennedy, Jr., S. C. Chang and G. W. Olsen (2012). Chronic dietary toxicity and carcinogenicity study with ammonium perfluorooctanoate in Sprague-Dawley rats. Toxicology 298: 1-13.

CDC (2015). Centers for Disease Control and Prevention. Fourth National Report on Human Exposure to Environmental Chemicals. <u>http://www.cdc.gov/biomonitoring/pdf/FourthReport_UpdatedTables_Feb2015.pdf</u>

Fei, C., McLaughlin, J. K., Lipworth, L., Olsen, J. (2010). Maternal concentrations of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) and duration of breastfeeding. Scand. J. Work Environ. Health 36: 413-421.

Filgo AJ, Quist EM, Hoenerhoff MJ, Brix AE, Kissling GE, Fenton SE. 2015. Perfluorooctanoic Acid (PFOA)-induced Liver Lesions in Two Strains of Mice Following Developmental Exposures: PPARα Is Not Required. Toxicol Pathol. 43(4):558-68.

Fitz-Simon, N., T. Fletcher, M. I. Luster, K. Steenland, A. M. Calafat, K. Kato and B. Armstrong (2013). "Reductions in serum lipids with a 4-year decline in serum perfluorooctanoic acid and perfluorooctanesulfonic acid." Epidemiology 24(4): 569-576.

Frisbee, S. J., A. P. Brooks, Jr., A. Maher, P. Flensborg, S. Arnold, T. Fletcher, K. Steenland, A. Shankar, S. S. Knox, C. Pollard, J. A. Halverson, V. M. Vieira, C. Jin, K. M. Leyden and A. M. Ducatman (2009). "The C8 health project: design, methods, and participants." Environ Health Perspect 117(12): 1873-1882.

Lau, C.; Thibodeaux, J. R.; Hanson, R. G.; Narotsky, M. G.; Rogers, J. M.; Lindstrom, A. B.; Strynar, M. J., 2006. Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. Toxicol. Sci. 90: 510–518.

Lorber, M. and P. P. Egeghy (2011). "Simple intake and pharmacokinetic modeling to characterize exposure of Americans to perfluoroctanoic acid, PFOA." Environ Sci Technol 45(19): 8006-8014.

Loveless, S.E., Finlay, C., Everds, N.E., Frame, S.R., Gillies, P.J., O'Connor, J.C., Powley, C.R., Kennedy, G.L. (2006). Comparative responses of rats and mice exposed to linear/branched, linear, or branched ammonium perfluorooctanoate (APFO). Toxicology 220: 203–217.

Macon, M.B., Villanueva, L.R., Tatum-Gibbs, K., Zehr, R.D., Strynar, M.J., Stanko, J.P., White, S.S., Helfant, L., Fenton, S.E. (2011). Prenatal perfluorooctanoic acid exposure in CD-1 mice: low dose developmental effects and internal dosimetry. Toxicol. Sci. 122: 134-45.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 369 of 551

NJDEP. 2007a. Guidance for PFOA in drinking water at Pennsgrove Water Supply Company. Division of Science, Research, and Technology. February 13, 2007. http://www.nj.gov/dep/watersupply/pdf/pfoa_dwguidance.pdf

Post, G.B., Cohn, P.D., and Cooper, K.R. (2012). Perfluorooctanoic acid (PFOA), an emerging drinking water contaminant: a critical review of recent literature. Env. Res. 116, 93-117.

Quist, E.M., Filgo, A.J., Cummings, C.A., Kissling, G.E., Hoenerhoff, M.J., Fenton, S.E. (2015). Hepatic mitochondrial alteration in CD-1 mice associated with prenatal exposures to low doses of perfluorooctanoic acid (PFOA). Toxicol. Pathol. 43:546-57

Romano, M.E., Xu, Y., Calafat, A.M. Yolton, K., Chen, A., Webster, G.M., Eliot, M.N., Howard, C.R., Lanphear, B.P., Braun, J.M. (2016). Maternal serum perfluoroalkyl substances during pregnancy and duration of breastfeeding. Env. Research (in press).

Tucker, D. K., M. B. Macon, M. J. Strynar, S. Dagnino, E. Andersen and S. E. Fenton (2015). "The mammary gland is a sensitive pubertal target in CD-1 and C57Bl/6 mice following perinatal perfluorooctanoic acid (PFOA) exposure." Reprod Toxicol. 54:26-36.

USEPA (2016a). United States Environmental Protection Agency. Drinking Water Health Advisory for Perfluorooctanoic Acid (PFOA). Office of Water. May 2016.

USEPA (2016b). United States Environmental Protection Agency. Fact Sheet: PFOA & PFOS Drinking Water Health Advisories. Office of Water. May 2016.

USEPA (2016c). United States Environmental Protection Agency. Health Effects Support Document for Perfluorooctanoic Acid (PFOA). Office of Water. May 2016.

USEPA (2016d). Response to New Jersey Drinking Water Quality Institute (DWQI) Health Effects Subcommittee Draft Health-Based Maximum Contaminant Level Support Document: Perfluorooctanoic Acid (PFOA). Appendix 2 – Comparison of USEPA Office of Water Health Advisory and DWQI Recommended Health-Based MCL for PFOA. November 21, 2016. http://www.nj.gov/dep/watersupply/pdf/comment5.pdf

Verner MA, Ngueta G, Jensen ET, Fromme H, Völkel W, Nygaard UC, Granum B, Longnecker MP (2016). A Simple Pharmacokinetic Model of Prenatal and Postnatal Exposure to Perfluoroalkyl Substances (PFASs). Environ Sci Technol. 50:978-86.

WAAYTV (2016). ADPH Says Health Advisory Only Affects Pregnant and Breastfeeding Women. June 6, 2016. http://www.waaytv.com/appnews/adph-says-health-advisory-onlyaffectspregnant-and-breastfeeding-women/article_79f0e016-29dd-11e6-8842-57daea17923d.html Accessed June 6, 2016.

WVU School of Medicine (2008). West Virginia University School of Medicine. C8 Health Project. Demographic Characteristics. Number of Participants in the C8 Health Project. http://www.hsc.wvu.edu/media/4583/demographics-number-of-participants.pdf Accessed June 6, 2016. Yahia, D., M. A. El-Nasser, M. Abedel-Latif, C. Tsukuba, M. Yoshida, I. Sato and S. Tsuda (2010). "Effects of perfluorooctanoic acid (PFOA) exposure to pregnant mice on reproduction." J Toxicol Sci 35(4): 527-533.

APPENDIX 3: Risk Assessment Considerations for Butenhoff et al. (2002) Subchronic Cynomolgus Monkey Study

The Butenhoff et al. (2002) six month study in male cynomolgus monkeys is described in detail in the <u>Toxicology</u> section of this document. As discussed in the <u>Toxicology</u> section, only 3 of 4 of the low dose monkeys and 2 of 6 of the high dose monkeys tolerated the administered dose well enough to complete the study, while all 6 animals in the mid-dose group (10 mg/kg/day) completed the study. The LOAEL in this study was 3 mg/kg/day based on mortality (25%) possibly attributed to treatment and increased liver weight, and the NOAEL was not identified. Furthermore, it is important to note that 6 months represents less than 2% of the lifespan of this species of monkey, which is about 30 years. It is not known whether additional or more severe effects would have occurred with continued dosing of the monkeys that were able to tolerate dosing for the full 6 months of the study. Therefore, if this study were to be used as the basis for risk assessment, an uncertainty factor (UF) for less than chronic exposure duration should be included.

In the study, serum PFOA levels were analyzed every 2 weeks, and it appeared that steady state was reached after 2 to 4 weeks of dosing. Importantly, the serum levels were highly variable between animals and over time in the same animal, and they did not increase proportionally with dose. The average serum levels in the 0, 3, 10, 30/20 mg/kg/day groups, respectively, were: 134 \pm 113, 81,000 \pm 40,000, 99,000 \pm 50,000 ug/ml, and 156,000 \pm 103,000 ng/ml (Butenhoff et al., 2004a). The PFOA concentrations in liver also did not appear to increase with dose or time, and the highest concentration in the liver was in a high dose animal sacrificed at week 5.

Butenhoff et al. (2004b) reported benchmark dose modeling of the liver-to-brain weight data from this study. A BMIC₁₀ (maximum likelihood estimate of PFOA serum concentration at 10% effect level) of 40,000 ng/ml and a LBMIC₁₀ (lower bound estimate of serum concentration at 10% effect level) of 23,000 ng/ml were derived. The data on liver-to-brain weight ratio versus serum PFOA concentration are shown in Figure A-1 (below).

As can be seen from the graph in Figure A-1, Benchmark Dose (BMD) modeling of these data is not appropriate for the following reasons: The dose-response relationship needed to support BMD modeling does not exist, since (as stated by Butenhoff et al. (2002) the liver-to-brain weight ratio did not increase with dose. Additionally, there are an insufficient number of data points for BMD modeling. In the modeling conducted by Butenhoff et al. (2004b), the highest dose group was dropped, leaving only two data points for dosed groups plus the control group. It should be noted that the reported LBMIC₁₀ of 23,000 ng/L is within the same range as the serum PFOA concentration in the low dose monkey that was sacrificed in moribund condition during the weeks prior to its sacrifice. Based on the above considerations, this study does not appear to be appropriate as the basis for a health-based drinking water concentration. In addition to the lack of dose response, a very small number of animals completed the study, and there was a wide variation in the responses of the individual animals.

If a risk assessment were to be developed based on this study, in spite of its numerous limitations, the following point of departure (POD) and UFs appear to be appropriate:

- The serum level at the low dose, 3 mg/kg/day should be used as the POD. This dose was the LOAEL for both increased liver weight and increased mortality.
- In addition to the standard UFs for intraspecies (10) and interspecies toxicodynamic (3) variability used in risk assessments based on serum levels, a UF of 10 for extrapolation of a LOAEL to NOAEL and a UF of 10 for a study of less than chronic study duration, should be applied. These UFs combine to give a total UF of 3000.
- An additional UF for database limitations appears to be warranted due to the very small number of animals that completed the study, because mortality possibly related to treatment occurred in the low dose group, and because potentially more sensitive developmental endpoints were not evaluated.




Figure A-1: Cynomolgus Monkey PFOA Serum Levels vs. Liver/Brain Weight Ratio

Serum Level (µg/ml)

Citations:

Butenhoff, J., Costa, G., Elcomebe, C., Farrar, D., Hansen, K., Iwai, H., Jung, R., Kennedy, G., Lieder, P., Olsen, G., and Thomford, P. (2002). Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. Toxicol. Sci. 69: 244-257.

Butenhoff, J.L., Kennedy, G.L., Jr, Hinderliter, P.M., Lieder, P.H., Jung, R., Hansen, K.J., Gorman, G.S., Noker, P.E., and Thomford, P.J. (2004a). Pharmacokinetics of perfluorooctanoate in Cynomolgus monkeys. Toxicol. Sci. 82: 394-406

Butenhoff, J. L., Gaylor, D. W., Moore, J. A., Olsen, G. W., Rodricks, J., Mandel, J. H., & Zobel, L. R. (2004b). Characterization of risk for general population exposure to perfluorooctanoate. Regul. Tox. Pharmacol. 39: 363-380.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 374 of 551 APPENDIX 4. Individual tables for epidemiology studies

Reference and Study Design	Exposure Measures	Results	Comment
(Bloom, Kannan et al. 2010)	Exposure Assessment:	Stat Method:	Major Limitations:
	Serum concentrations	Linear regression, covariates and confounders	Power analyses = would require 408-fold
Study Design:		considered included age, gender, BMI, smoking,	increase in sample size to see statistically
Cross-sectional	Population-Level	goiter or thyroid condition, race/ethnicity, use of	significant associations with 80% power
	Exposure:	thyroid medication, and self-reported consumption	at observed effect sizes.
Location:	Geometric mean $= 1.33$	of sportfish caught from NY waters	
New York, USA	95% CI 1.15-1.53 ng/mL		Small sample size limited ability to
		PFCs and TSH log transformed.	control for potential covariates and
Population: Licensed anglers in			confounders simultaneously, or other
NYS, n=31. Participants are as		Outcome: In-TSH	potential environmental compounds of
subgroup of NYSACS participants		Major Findings: NS	interest or other PFCs.
(licensed anglers in New York state		$\beta = -0.06 \ (95\% \ \text{CI} - 0.78, \ 0.67)$	
and their partners)			Cross-sectional design prevents causal
		Outcome: FT4	inference.
Outcome Definition: Serum		Major Findings: NS	
samples		β = -0.01 (95% CI -0.16, 0.14)	High proportion of values measured
			below the LODs for these compounds.
			Funding Source: Agency for Toxic
			Substances and Disease Registry
			(ATSDR), Grant H75-ATH 298338,
			the Great Lakes Protection Fund, Grant
			RM 791-3021, and the
			Centers for Disease Control and
			Prevention (CDC) National Center
			for Environmental Health (NCEH), Grant
			U59CCU22339202

Case 1;16-cv-00917-LEK-DJS	Document 162	Eiled 04/06/20	Page 375 of 551

Reference and Study Design	Exposure Measures	Results	Comment
(Chan, Burstyn et al. 2011)	Exposure Assessment:	Stat Method:	Major Limitations:
Study Design:	Serum PFOA	Student's t-test and chi-square were used to calculate differences in means between cases	Small sample size.
Matched case-control	Population-Level Exposure: Geometric mean (SD)	and controls by maternal age, maternal weight, gestation age at blood draw, and maternal race.	There are no known confounders to be
Location:	nmol/mL		accounted for in the study design.
Edmonton, Alberta, Canada	Cases - 3.10 (3.10) Controls - 3.32 (2.72)	Conditional logistic regression, covariates and confounders considered include maternal age,	Possibility of confounding by
Population: Hypothyroxemic pregnant women	Median nmol/L	maternal weight, and gestational age at blood draw on mother.	socioeconomic or geographic factors
at 15-20 weeks gestation, N=96 +	Cases – 3.94		Potential outcome misclassification due to
175 nonhypothyroxemic pregnant controls, matched on age and referring physician	Controls – 3.62	Each PFA was modelled separately and with three in a model (PFOA, PFOS, PFHxS).	timing of the blood draw.
(Total N = 271), years 2005-2006		Adjusted analyses shown below.	
Outcome Definition: Hypothyroxinemic cases defined as (normal TSH, the lowest 10 th		Outcome: maternal hypothyroxemia Major Findings: PFOA only	
percentile of ft4 – measured in serum)		OR = 0.94 (95% CI 0.74, 1.18)	
		All PFCs in model OR=0.87 (95% CI 0.63,1.19)	Funding Source: University Hospital Foundation (U of Alberta) and Alberta Health and Wellness.

Reference and Study Design	Exposure Measures	Results	Comment
(Costa, Sartori et al. 2009)	Exposure Assessment:	Stat Method:	Major Limitations:
	Serum PFOA (monitoring 2000-	ANOVA, t test, multiple linear regression models,	Small sample size
Study Design: Case-control,	2007)	multivariate GEE models controlling form within-subject	
cross-sectional		correlations, covariates and confounders considered include	Healthy worker effect
	Population-Level Exposure:	age, years of exposure, year of PFOA sampling, BMI,	-
Location: Miteni, Trissino,	Year 2007:	smoking, and alcohol consumption.	Other environmental
Italy			contaminants were not
	Geometric mean (SD) µg/mL	People under treatment of primary hyperlidiemias and with	controlled for.
	Currently Exposed – 4.02 (14.43)	a history of chronic hepatitis were excluded.	
Population:	Formerly Exposed – 3.76 (6.06)	Natural log transformation was performed where	Cross-sectional design
Cases (exposed): Workers (all		appropriate.	prevents causal inference.
male aged 20-63 years) engaged	Median (SD) µg/mL		
in the PFOA production	Currently Exposed – 5.71 (14.43)	The following chemical chemistry was compared among	Funding Source: not
department ($n=53$). As of 2007,	Formerly Exposed – 4.43 (6.06)	exposed and non-exposed: BMI, glucose, urea nitrogen,	specified. Authors are

Case 1:16-cv-00917-LEK-DJS_Document 162_Filed 04/06/20_Page 376 of 551				
37 were active workers and 16		creatinine, uric acid, total cholesterol, HDL, triglycerides,	employed by Department	
unexposed.	Geometric Mean in	total bilirubin, AST, ALT, GGT, ALP, proteins, albumin,	of Occupational and	
	Production Workers	α 1 globulins (large proteins found in the blood), α 2	Environmental Health	
Controls (unexposed): Other	Year	globulins, β globulins, γ globulins, WBC, RBC,	(Costa, Sartori), University	
male workers never exposed to	2000 = 11.7	Haemoglobin, Haematocrit, platelets.	of Milano, Italy; Unit of	
PFOA ($n=107$) (12 executive	2001 = 10.2		Epidemiology (Consonni),	
clerks and 95 blue collar	2002 = 9.3	Outcome: Chemical chemistry	IRCCS Maggiore Hospital,	
workers from other	2003 = 6.9	Major Findings:	Mangiagalli and Regina	
departments)	2004 = 6.5	All the biochemical parameters turned out to be on average	Elena Foundation, Milano,	
	2006 = 5.8	within the laboratory reference ranges.	Italy; and Institute of	
Matched on age, time of shift,	2007 = 5.4		Medical Statistics (Sartori)	
area of residence and job		As compared with the control group some differences, both		
seniority	*renovation happened in the plant in	in terms of mean values and number of persons above the		
	2002 partially automating the process	upper reference limited, were noted for some parameters		
Outcome Definition:		such as uric acid, cholesterol, triglycerides, and liver		
Physical examination including		enzymes.		
blood chemical chemistry tests				
over 30 years (1978-2007)		Analysis#1: T-test (Nonexposed (34 controls) v. 34		
		exposed)		
		Uric acid – p-value= 0.039		
		Total cholesterol – p-value=0.003		
		All other findings are not significant.		
		Analysis#2: Multiple regression analysis (34 Exposed v.		
		<u>107 controls)</u>		
		Uric acid – p-value= 0.027		
		Total cholesterol – p-value=0.005		
		All other findings are not significant.		
		The other minings are not significant.		
		Analysis#3: GEE Model (subjects regardless of exposure		
		status with concurrent outcome and PFOA in the last 6		
		years)		
		Uric acid – p-value <0.05		
		Total cholesterol – p-value <0.05		
		Total bilirubin - p-value <0.01 (inversely)		
		ALT - p-value <0.01		
		GGT - p-value <0.01		
		ALP - p-value <0.05		
		α2 globulins – p-value <0.05		
		All other findings are not significant.		

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20, Page 377 of 551

Defenence and Stud-		Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20	Page 377 of 55
Reference and Study Design	Exposure Measures	Results	Comment
Darrow et al., 2016	Exposure Assessment:	Stat Method:	Major
	Historically modeled	In linear regression models, natural log-transformed liver function markers were	Limitations:
Study Design:	yearly PFOA exposure	analyzed in relation to estimated cumulative PFOA serum concentrations through	Cross-sectional
Cross-sectional; and a	estimated using	2005 or 2006 and estimated year-specific PFOA serum concentration in 2005 or	design prevents
subanalysis with	environmental fate and	2006. Logistic regression was used to model dichotomized measures of the liver	causal inference.
prospective analysis	transport models and	function measures. PFOA was analyzed continuously (log-transformed) and by	
among those reporting	participant residential	quintiles.	Other
liver disease in	histories, a measure of	4	environmental
2005/2006.	cumulative serum PFOA	Covariates and confounders considered include age, sex, BMI, alcohol consumption,	contaminants
2000/2000.	exposure was calculated	race, regular exercise, smoking status, education, household income, fasting status,	were not
Location:	by summing all previous	history of working at DuPont plant, and insulin resistance (HOMA-IR).	controlled for.
United States – West	yearly estimates	instory of working at Duront plant, and insumi resistance (mowin-mc).	controlled for.
Virginia and Ohio	yearry estimates	Stratified Cox proportional hazard models with age as the time scale, time-varying	
virginia and Onio	Dopulation Land	cumulative serum PFOA as a predictor and stratified by birth year to control for any	Funding
Dopulation	Population-Level		Funding
Population: Adults $(> 20 \text{ wears})$: liver	Exposure:	birth cohort trends used to analyzed liver disease. Covariates and confounders	Sources: C8 Class Action
Adults (> 20 years); liver	Median estimated PFOA	considered include sex, years of schooling, race, smoking, regular alcohol	
biomarkers (n=30,726,	serum concentration in	consumption, and BMI. A 10-year lag was also investigated. Stratified by history of	Settlement
including 1,892 workers)	2005-2006, 16.5 ng/mL	working in PFOA plant, gender, and age.	Agreement
and liver disease	(range 2.6 – 3559 ng/mL).		between DuPont
(n=32,254, including		Outcome: Liver biomarkers	and Plaintiffs
3,713 workers)		Major Findings:	
		<i>Cumulative PFOA (these findings are reflective of 2005/2006 PFOA results)</i>	
Outcome Definition:		<u>ALT:</u>	
Alanine aminotransferase		Contin.: β=0.012 (95% CI 0.008. 0.016)	
(ALT), γ-		Q2 v. Q1: β=0.023 (95% CI 0.006, 0.040)	
glutamyltransferase		Q3 v. Q1: β=0.035 (95% CI 0.018, 0.052)	
(GGT) and direct		Q4 v. Q1: β=0.039 (95% CI 0.022, 0.056)	
bilirubin, markers of liver		Q5 v. Q1: β=0.058 (95% CI 0.040, 0.076)	
toxicity (measures in			
2005-2006) and self-		Trend: p-value <0.001	
reported liver disease			
(from surveys		GGT:	
administered 2008 and		Contin.: β=0.003 (95% CI -0.003, 0.008)	
2011) which were		Q2 v. Q1: β=0.009 (95% CI -0.014, 0.031)	
medically reviewed. Liver		Q3 v. Q1: β=0.025 (95% CI 0.003, 0.047)	
disease was categorized		Q4 v. Q1: β=0.011 (95% CI -0.011, 0.033)	
as any medically-		Q5 v. Q1: β =0.020 (95% CI -0.004, 0.044)	
validated liver disease and			
liver disease restricted to		Trend: p-value 0.1021	
medically-validated		Trends b inne orrowr	
enlarged liver, fatty liver,		Direct Bilirubin:	
or cirrhosis.		Contin.: β =-0.005 (95% CI -0.008, -0.002)	
		Q2 v. Q1: β =0.012 (95% CI -0.002, 0.026)	
L	1	22 v. Q1. p=0.012 (95/0 C1-0.002, 0.020)	

	Q3 v. Q1: β= Q4 v. Q1: β=	: 16-cv-00917-LEK-DJS Document 1(-0.003 (95% Cl -0.017, 0.011) -0.007 (95% Cl -0.021, 0.007) =- 0.017 (95% CI -0.032, -0.001)	52 Filed 04/06/20	Page 378 of 55
	Contin.: HR= Q2 v. Q1: HI Q3 v. Q1: HI Q4 v. Q1: HI Q5 v. Q1: HI <u>Enlarged live</u> Contin.: HR= Q2 v. Q1: HI Q3 v. Q1: HI Q4 v. Q1: HI	iver disease		
Reference and Study Design	Exposure Measures	Results	Comm	ent
<pre>(de Cock, de Boer et al. 2014) Study Design: Cross-sectional Location: Six midwifery clinics in Netherlands Population: Mother-child cohort through neonatal screening programs, n=83 pairs Outcome Definition: Blood levels of thyroxine (T4) in cord plasma (immediately after birth) screening and heel prick blood spots (between day 4 and day 7 after birth)</pre>	Exposure Assessment: Cord plasma concentration Population-Level Exposure: Cord plasma: Median = 885 ng/L = 0.89 ng/mL Range 200-2700 ng/L = 0.2-2.7 ng/mL	Stat Method:Linear regression models (separate for each exposure). Models were stratified for gender.Covariates and confounders considered included health problems related to the thyroid gland, use of thyroid medication, birth weight, C-section, gestational weight gain, gestational age, parity, smoking, alcohol, maternal BMI, and maternal age at birth.Chemical compounds were analyzed as quartiles (after no linear associations were noted)Results reported for most adjusted modelOutcome: T4 Major Findings: $(2 v. Q1, \beta=7.9)(95\% CI - 18.0, 33.9)$ $(2 3 v. Q1, \beta=-2.1)(95\% CI - 20.9, 19.8)$ $(Q4 v. Q1, \beta=6.2)(95\% CI - 16.1, 28.5)$	Major Limitations: Homogenous w/r/t natieducation level No adjustment for time (between 4 and 7 days Small sample size Cross-sectional design inference. Power decreased by qu and stratifying, though justification for both pr Funding Sources: the European Commun Framework Programmounder grant agreement 227391.	e of heel prick after birth), prevents causal artile formation there was actices. ity's Seventh e [FP7/2007-2013]

Case 1;16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 379 of 55
$\frac{In \text{ girls:}}{\text{Q2 v. Q1, }\beta=-5.9 (95\% \text{ CI } -26.8, 14.9)}$ $\text{Q3 v. Q1, }\beta=11.8 (95\% \text{ CI } -19.1, 42.7)$ $\text{Q4 v. Q1, }\beta=38.6 (95\% \text{ CI } 13.3, 63.8)$
No linear associations found for any compound studied.

Reference and Study Design	Exposure Measures	Results	Comment
(Emmett, Zhang et al. 2006)	Exposure Assessment:	Stat Method: Simple regression (liver	Major Limitations:
	Serum concentrations	function/hematologic parameters), binary t-test (normal v.	Potential volunteer bias from volunteer
Study Design:		abnormal) blood chemistries or history of clinical diagnoses	group,
Cross-sectional	Population-Level	of interest	
	Exposure:		Cross sectional design precludes causal
Location: Little Hocking water	Median PFOA: 354	Outcome: Serum chemistry (BUN, creatinine, total	inference
district in SE Ohio	ng/mL, IQR 181 ng/mL	protein, albumin, total bilirubin, ASP, AST, ALT, GGR,	
	to 571 ng/mL	total cholesterol, TSH)	No confounders or covariates were
Population: Stratified random	_	Major Findings:	considered beyond stratified analyses
sample of residents (≥ 2 year		No significant positive linear relationships $(p > 0.05)$	by age.
residence) of district			
(N=371, 317 randomly selected,		Outcome: Hematologic parameters (WBC, RBC,	Other environmental or lifestyle
54 volunteer (18 occupationally		hemoglobin, hematocrit, MCV, MCH, MCHC, RDW,	confounder may be clouding true
exposed)), age range 2.5-89		Platelets, neutrophils, lymphocytes, monocytes,	relationship between exposure and
years		eosinophils, basophils, neutrophils, lymphocytes,	endpoints.
		monocytes, eos, basos	
Outcome Definition: Serum		Major Findings:	Funding Source: Grant ES12591 from
biomarkers and questionnaire of		Monocyte (linear) – r=0.13, p-value=0.01	the Environmental Justice Program and
previous clinical diagnoses of		AST (binary) – p-value=0.03 (inversely)	by grant number 1P30 ES013508-
liver or thyroid disease.		% neutrophils (binary) – p-value=0.02 (inversely)	01A1 from the National Institute of
		% lymphocytes (binary) – p-value=0.01 (inversely)	Environmental Health.
		No other significant positive relationships $(p > 0.05)$	
		Outcome: Liver disease	
		Major Findings: p-value=0.50	
		Disease (n=13), PFOA=527 ng/mL vs.	
		No disease, PFOA=441 ng/mL	
		No disease, i roa-441 lig/lile	
		Outcome: Thyroid disease	
		Major Findings: p-value=0.3	
		Disease (n=40), PFOA=387 ng/mL vs.	
		No disease, PFOA=451 ng/mL	
	ł	,, <u>0</u> ,	

Case 1;16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 380 of 551

Reference and Study Design	Exposure Measures	Results	Comment
(Eriksen, Raaschou-Nielsen et	Exposure Assessment:	Stat Method:	Major Limitations:
al. 2013)	Serum concentrations	Generalized linear models (crude adjusted for	Cross-sectional design precludes causal
		sex only and adjusted). Covariates and	inference.
Study Design:	Population-Level Exposure:	confounders considered included sex, age,	
Cross-sectional	Mean: 7.1 ng/mL	education, BMI, smoking status, alcohol	Other unidentified confounders may exist
		intake, egg intake, animal fat intake, physical	
Location: Denmark		activity.	Funding Sources : Danish Cancer Society and the International Epidemiology
Population: Middle aged (50-		Primary analyses treated PFCs continuously.	Institute (IEI), which received an
65 years of age),		Additionally, investigated as 8 exposure	unrestricted research grant from the 3M
N=753 (663 male, 90 female)		groups (100 per group), with lowest group as	Company.
Nested within a larger Danish		reference.	
Diet, Cancer, and Health cohort			
		Outcome: total cholesterol	
Outcome Definition:		Major Findings:	
Serum, questionnaires		$\beta_{\text{unadj}} = 4.1 \ (95\% \text{ CI } 0.8, 7.4)$	
		$\beta_{adj} = 4.4 \ (95\% \ CI \ 1.1, \ 7.8)$	
		Using the lowest exposure group as a referent	
		group, the level of total cholesterol appears to	
		be higher with higher PFOA plasma levels	
		with a borderline significant p value for trend.	

Reference and Study Design	Exposure Measures	Results	Comment
(Fisher, Arbuckle et al. 2013)	Exposure Assessment:	Stat Method: Multivariate linear and logistic	Major Limitations:
	Serum concentration	regression models, covariates and confounders	Cross sectional design precludes causal
Study Design:		considered include cholesterol lowering medications,	inference.
Cross-sectional	Population-Level	sampling weights, age, gender, marital status, income	
	Exposure:	adequacy, race, education, BMI, physical activity	Reverse causality or unexplored
Location:	Geometric mean $= 2.46$	index, smoking status and alcohol consumption.	confounder may exist
Canada	$\mu g/L (ng/mL)$		
		PFOA analyzed in quartiles, reference=1 ng/mL and	Excluded those on cholesterol-lowering
Population:		dichotomous	medication, removing some of diseased
CHMS (Canadian Health			population
Measures Survey, 2007-2009)		Outcomes and exposures were log transformed	
N=5604, 6-79 year olds			Other unidentified confounders may exist.
		Results shown for most adjusted models by	No adjustment for albumin (possible non-
Outcome Definition:		unweighted and weighted.	casual positive correlation between PFCs
Serum measures and			and cholesterol)
questionnaires			

For all clinical outcomes non-	Case 1:16-cy-00917-LEK-DJS Document 1 Outcome: Cholesterol outcomes	85% of participants were Caucasian, 60%
pregnant adults (\geq 18 years of	Major Findings:	with post-secondary education, and close
age)	Linear - unweighted	to half were in the highest income
	HDL $-\beta$ =0.007, p-value=0.45	adequacy category.
	TC/HDL – β =0.02, p-value=0.11	1
	$LDL - \beta = 0.008$, p-value=0.64	Funding Source: unspec, Authors are
	Non-HDL – β =0.03, p-value=0.003	employed by Health Canada.
	$TC - \beta = 0.02$, p-value=0.001	
	Triglycerides – β =0.02, p-value=0.49	
	Linear - weighted	
	HDL – β =0.009, p-value=0.96	
	TC/HDL – β =0.02, p-value=0.22	
	$LDL - \beta = 0.02$, p-value= 0.63	
	Non-HDL $-\beta$ =0.036, p-value=0.13	
	$TC - \beta = 0.03$, p-value=0.22	
	Triglycerides – β =-0.003, p-value=0.94	
	(High cholesterol)	
	Quartiles – unweighted	
	Q2 v. Q1, OR=1.26 (95% CI 0.98, 1.62)	
	Q3 v. Q1, OR=1.18 (95% CI 0.91, 1.52)	
	Q4 v. Q1, OR=1.46 (95% CI 1.13, 1.89)	
	P for Trend=0.01	
	Quartiles - weighted	
	Q2 v. Q1, OR=1.61 (95% CI 1.02, 2.53)	
	Q3 v. Q1, OR=1.26 (95% CI 0.76, 2.07)	
	Q4 v. Q1, OR=1.5 (95% CI 0.86, 2.62)	
	P for Trend=0.10	
	High cholesterol (dichotomous)	
	Unweighted OR=1.20 (95% CI 1.03, 1.40) Weighted	
	OR=1.22 (85% CI 0.89, 1.67)	
	Outcome: Metabolic outcomes	
	Major Findings:	
	Linear - unweighted	
	Insulin – β =-0.003, p-value=0.91	
	Glucose – β =-0.01, p-value=0.06	
	HOMA-IR – β =-0.01, p-value=0.63	

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20	Page 382 of 551
$\frac{\text{Linear - weighted}}{\text{Insulin} - \beta = -0.071, \text{ p-value} = 0.12}$	
Glucose – β =-0.04, p-value=0.17	
HOMA-IR $-\beta$ =-0.1, p-value=0.10	
Metabolic syndrome (dichotomous) Unweighted OR=1.26 (95% CI 0.92, 1.73) Weighted OR=1.13 (85% CI 0.46, 2.77)	

Reference and Study Design	Exposure Measures	Results	Comment
(Fitz-Simon, Fletcher et al.	Exposure Assessment:	Stat Method: adjusted linear regression	Major Limitations:
2013)	Serum concentration	models. Change-vs-change model, in which	Joint models should be assessed with
		the cross-sectional model as baseline is	caution because PFOA and PFOS are
Study Design: Cohort,	Population-Level Exposure:	subtracted from the cross-sectional model at	highly correlated.
Longitudinal, over a 4.4-year	(ng/mL)	follow-up. Covariates and confounders	
period		considered include age at baseline, time	Only two time points from which to
	Baseline (2005/06)	between measurements, sex, and fasting status	estimate relationship
Location: Ohio and West	Geometric Mean=74.8;	(from both baseline and follow-up). PFOS	
Virginia, USA	Arithmetic Mean=140.1	also controlled for in PFOA model.	Lag uncertainty
Population: n=560, living in	<u>Follow-up (2010)</u>	Sensitivity analysis adjusted for baseline BMI,	Cannot detect any possible irreversible
areas with PFOA	Geometric Mean=30.8	years of schooling, change in smoking, and	effects of PFOA on serum lipids
contaminated drinking water	Arithmetic Mean=68.2	baseline and changes in GFR. Additionally, a	Low power in LDL analysis – n=56
(sample derived from C8		ratio of baseline to follow-up and PFOA	
short term follow up study), 2005-2006 followed through		tertiles are ordered by decrease.	Exact mechanism unknown – limits causal explanation
2010 [C8 Short-Term		PFOA log transformed. Findings shown below	1
Follow-up Study], 20-60		are for most adjusted model and model	Caution when extrapolating to general
years		adjusting for PFOS. Effect estimates are	population – this is a highly exposed
		percentage decrease in serum lipid based on	population
Outcome Definition: Serum		halving of PFOA.	
concentration (LDL, HDL,			Funding Source: C8 Class Action
total cholesterol, triglycerides)		Estimates are shown as percent decrease.	Settlement Agreement between DuPont and Plaintiffs
		Outcome: LDL	
		Major Findings:	
		% ↓=3.58 (95% CI 1.47, 5.66)	
		% ↓ _(PFOS) =2.92 (95% CI 0.71, 5.09)	
		Outcome: Total cholesterol	
		Major Findings:	
		$\% \downarrow = 1.65 (95\% \text{ CI } 0.32, 2.97)$	
		$\% \downarrow_{(PFOS)} = 0.63(95\% \text{ CI} - 0.88, 2.12)$	

Case 1:16-cv-00917-LEK-DJS Docum	ent 162 Filed 04/06/20	Page 383 of 551
Outcome: HDL		. ago 000 0. 001
Major Findings:		
$\% \downarrow = 1.33 (95\% \text{ CI} - 0.21, 2.85)$		
% J _(PFOS) =1.24 (95% CI -0.34, 279)		
Outcome: Triglycerides		
Major Findings:		
$\% \downarrow = -0.78 (95\% \text{ CI} - 5.34, 3.58)$		
% ↓ _(PFOS) =-1.16 (95% CI -5.85, 3.33)		

Reference and Study Design	Exposure Measures			esults		Comment
(Fletcher, Galloway et al. 2013) Study Design: Cross-sectional	Exposure Assessment: Serum concentrations Population-Level Exposure:	Stat Method: Adjusted linear regression, some models stratify by gender and menopausal status. Covariates and confounders considered include age, sex, BMI, average			Major Limitations: Restriction on examining expression in whole blood only – may not correlate with expression in target organs.	
Location: Parkersburg, WV, USA Population: Residents for at least one year, 20-60 year olds, N=290	Median = 30.1 ng/mL	 bousehold income, and smoking status Expression value of each of the target genes and for PFOA/PFOS levels were log transformed. Outcome: Candidate gene transcript levels 			Limited size of population, power concerns. Cross sectional design precludes causal inference.	
N=290 Outcome definition: Changes in the expression of genes (13 target genes) involves in cholesterol metabolism in humans. Genes were selected on the basis of roles in cholesterol biogenesis (HMGCR), peroxisome proliferation (PPARA, PPARD,		Major Fine	dings: are statistic	gene transcri ally significa 95% CI -0.51, - 0.06 -0.63, - 0.04 -0.90, - 0.20		Funding Source: C8 Class Action Settlement Agreement between DuPont and Plaintiffs, funds administered by Garden City Group
PPARG, and PGC1A), cholesterol transport (ABCA1, ABCG1, and APOA1), downstream transcriptional activation of PPARA (NR1HA, NR1H2, and mobilization of cholesterol (NPC1, ACAT1, and NCEH1)		ABCA1, A NR1H3, PP	PARA, PPA	OA1, HMGC ARD, PPARC atistically sig	GC1A,	

	Case 1	:16-cv-00 Men:	917-LEK	-DJS De	ocument 10	62 Filed 04/06/20	Page 384 of 55
		Gene	Coeff	95%CI	Р		
		ABCG1	-0.34	-0.64,	0.024		
		NPC1	-0.53	0.047	0.025		
				0.06			
		PPARA	-0.38	-0.68, 0.07	0.012		
		NR1H2	-0.71	-1.29, - 0.12	0.019		
		Women:	-1		11		
		Gene	Coeff	95% CI	Р		
		NCEH1	0.44	0.03, 0.85	0.036		
				1			
				rse effects):			
		Gene NR1H2	Coeff -1.47	95%CI -2.63, -	P 0.013		
		INKIN2	-1.4/	0.32	0.013		
		PPARD	-1.06	-2.05, - 0.07	0.036		
		Postmenor	oausal (pos	itive effects):		
		Gene	Coeff	96% CI	Р		
		APOA1	0.051	0.11, 0.90	0.013		
				u			
				n a human p			
				ted with alte scripts invol			
				r mobilizatio			
		appear con	sistent with	PFOA pron	noting a		
		hyperchole	steroleamic	e environmer	nt.		
Reference and Study Design	Exposure Measures			esults		Comme	ent
(Frisbee, Shankar et al. 2010)	Exposure Assessment: Serum			e linear regr		Major Limitations:	1 1 1
Study Design:	concentration			sis to estima uintile. To a	ate predicted	Cross sectional design p inference.	orecludes causal
Cross-sectional	Population-Level Exposure:			of association			
		population	median for	20-group qu	antiles were	Self-reported survey dat	a not uniformly
Location: Mid-Ohio river	Mean = 69.2 ng/mL (SD = 111.9)	plotted aga	in the PFO.	A median. B	inary	reliable	

uniter (OIL on A WAY, LICA)	Case 1	16-cv-00917-LEK-DJS Document 16 logistic regression analysis with outcomes as	2 Filed 04/06/20 Page 385 of 551
valley (OH and WV, USA)		'high' or 'low' and PFCs as quintiles.	Limited availability of known covariates
Population: Children included		Covariates and confounders considered include	Linned availability of known covariates
in C8 Health Project		age, gender, BMI, time of fasting, and	Funding Source: C? Class Action
N=12,476, 1-17.9 years		exercise, and sensitivity analyses of fasting and	Funding Source: C8 Class Action Settlement Agreement between DuPont
IN-12,470, 1-17.9 years		socioeconomic status. Age and gender specific	and Plaintiffs, and contractual relationship
Outcome Definition: Serum		quantiles were created.	between Brookmar, INC. and West
		quantites were created.	
lipids (LDL, total cholesterol, HDL, fasting triglycerides)		DECA was log transformed Interaction	Virginia University. Authors are members of the separate C8 Science Panel.
HDL, lasting ungrycendes)		PFOA was log-transformed. Interaction between PFOA and PFOA was assessed.	of the separate Co Science Failer.
		between FFOA and FFOA was assessed.	
		Outcome: Total cholesterol	
		Major Findings:	
		*Results not shown but after adjustment	
		PFOA linearly/positively associated	
		(p<0.0001)	
		Q2 v. Q1, OR=1.1 (95% CI 1.0,1.3)	
		Q3 v. Q1, OR=1.2 (95% CI 1.0, 1.4)	
		Q4 v. Q1, OR=1.2 (95% CI 1.1, 1.4)	
		Q5 v. Q1, OR=1.2 (95% CI 1.1, 1.4)	
		Outcome: LDL	
		Major Findings:	
		*Results not shown but after adjustment	
		PFOA linearly/positively associated	
		(p<0.0001)	
		Q2 v. Q1, OR=1.2 (95% CI 1.0,1.5)	
		Q3 v. Q1, OR=1.2 (95% CI 1.0, 1.4)	
		Q4 v. Q1, OR=1.2 (95% CI 1.0, 1.4)	
		Q5 v. Q1, OR=1.4 (95% CI 1.1, 1.7)	
		Outcome: Triglycerides	
		Major Findings:	
		*Results not shown but after adjustment	
		PFOA linearly/positively associated	
		(p=0.019)	
		0.02 = 0.01 OD = 1.0 (0.50) (01.0.7.1.5)	
		Q2 v. Q1, $OR=1.0$ (95% CI 0.7,1.5)	
		Q3 v. Q1, OR=1.3 (95% CI 0.9, 1.9)	
		Q4 v. Q1, OR=1.6 (95% CI 1.1, 2.3)	
		Q5 v. Q1, OR=1.0 (95% CI 0.7, 1.6)	

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 386 of 551

Outcome: HDL Document 102 Fliet 04/00/20 Major Findings: *Results not shown but after adjustment PFOA not linearly associated	
Q2 v. Q1, OR=1.0 (95% CI 0.8,1.2) Q3 v. Q1, OR=1.0 (95% CI 0.8, 1.2) Q4 v. Q1, OR=1.0 (95% CI 0.9, 1.2) Q5 v. Q1, OR=0.9 (95% CI 0.8, 1.1)	

Reference and Study Design	Exposure Measures	Results	Comment
(Fu, Wang et al. 2014)	Exposure Assessment: Serum	Stat Method: Linear regression, exposure	Major Limitations:
	concentrations	modeled in quartiles with 1 st quartile serving as	Cross sectional design precludes causal
Study Design:		the referent group. Binary logistic regression	inference.
Cross-sectional	Population-Level Exposure:	of abnormal lipids by PFC quartile. Covariates	
	Median = 1.43 ng/mL	and confounders considered include age,	Did not take into account cholesterol-
Location:		gender, and BMI.	lowering medications or other
Henan, China	Quartile Mean		environmental factors and contaminants
	(ng/mL)	Outcomes are based on a change in values.	including other co-occurring PFCs.
Population: Random selection	1 0.71		
of people coming in for health	2 1.24	Outcome: Total cholesterol	Convenience sample – possible bias.
check-up at Yuanyang hospital,	3 1.97	Major Findings:	
N=133, aged 0-88 years	4 4.88	↑ (p-value for trend 0.015)	Small sample size.
Outcome Definition:		Outcome: Triglycerides	Funding Source: National Natural
Serum lipids		Major Findings:	Science Foundation of China (Grant nos.
		NS (p-value for trend 0.298)	41371488 and 41071355, the International Scientific Cooperation Program (Grant
		Outcome: HDLC	no. 2012DFA91150), and Key Project of
		Major Findings:	the Chinese Academy of Sciences (Grant
		NS (p-value for trend 0.260)	no. KZZD-EW-TZ-12).
		Outcome: LDLC	
		Major Findings:	
		↑ (p-value for trend 0.022)	
		*For each of these outcomes there were also	
		binary logistic regression results; however, no	
		results were statistically significant for any level of PFC or outcome.	

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 387 of 551

Reference and Study Design	Exposure Measures	Results	Comment
(Gallo, Leonardi et al. 2012)	Exposure Assessment: Serum	Stat Method: Linear regression of ln-	Major Limitations:
	concentrations	transformed values, logistic regression fitted	Cross sectional design precludes causal
Study Design:		(reference levels as cut-offs for outcomes)	inference.
Cross-sectional	Population-Level Exposure:	comparing deciles of exposure,	
	Median: 23.1 ng/mL, IQR 11.3-	multilevel analysis comparing individual-level	Self-reported data of lifestyle
Location:	58.2	associations to population-level associations.	characteristics strongly associated with
United States – West Virginia		Covariates and confounders considered include	exposures of interest – can hamper
and Ohio		age, physical activity, BMI, average household	confounder adjustment
		income, educational level, alcohol	
Population:		consumption, cigarette smoking, fasting status,	Possible confounding due to unmeasured
Adults (18 years or older).		SES, race, and month of blood sample	variables, and other environmental
Consumed water for at least 1		collection, and insulin resistance.	contaminants, including other PFCs.
year from a water district with			
known PFOA contamination,		Results for most adjusted models are	Funding Source: C8 Class Action
n=47,092		presented.	Settlement Agreement between DuPont
		Outcome: In-ALT	and Plaintiffs
Outcome Definition:		Major Findings:	
Serum biomarkers of liver			
function: ALT (alanine		$\beta = 0.022 \ (95\% \ \text{CI} \ 0.018, \ 0.025)$	
transaminase), GGT (gamma-		p-value for trend < 0.001	
glutamyltransferase), direct		In-Unit OR=1.10 (95% CI 1.01, 1.13)	
bilirubin		Deletionship consistent for both between	
		Relationship consistent for both between water districts and among individuals	
		within districts increases strength of	
		0	
		evidence for casual association.	
		Outcome: ln-GGT	
		Major Findings:	
		$\beta = 0.015 (95\% \text{ CI } 0.010, 0.019)$	
		p-value for trend = 0.213	
		In-Unit OR=1.01 (95% CI 0.99,1.04)	
		Alexandre of the set o	
		Absence of trend across districts might be	
		indicative of some confounding factor at the	
		individual level.	
		Outcome: In-Direct bilirubin	
		Major Findings:	
		$\beta = 0.001 \ (95\% \ \text{CI} - 0.002, \ 0.014)$	
		p-value for trend 0.496	
		In-Unit OR=0.97 (95% CI 0.90, 1.15)	
		m ont or 0.77 (7570 CI 0.90, 1.15)	
		Some evidence of geographic confounding.	

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 388 of 551

Reference and Study Design	Exposure Measures	Results	Comment
(Geiger, Xiao et al. 2013)	Exposure Assessment:	Stat Method: Linear regression models, and	Major Limitations:
	Serum concentrations	multivariable logistic regression.	Cross-sectional design precludes
Study Design:		Covariates and confounders considered include age, sex,	causal inference.
Cross-sectional	Population-Level Exposure:	race/ethnicity, BMI, annual household income, physical	
	Mean = 4.3 ng/mL (SE 0.1)	activity, total cholesterol, and serum cotinine levels.	Spot samples of urinalysis cannot
Location:			detect changes in response to recent
United States		PFCs were log-transformed in continuous analyses and categorized into quartiles for categorical analysis.	changes in exposure,
Population: NHANES 1999-			Possible confounding due to
2000 and 2003-2008, ≤18 years		Results shown for most adjusted models.	unmeasured variables, and other
of age, n=1,772			environmental contaminants,
		Outcome: Uric Acid	including other PFCs.
Outcome Definition:		Major Findings:	
Hyperuricemia (serum uric acid levels >6 mg/dL)		Ln-Unit, mean change=0.20 (0.11, 0.29)	
		Q2 v. Q1, mean change=0.02 (95% CI -0.10, 0.14)	
		Q3 v. Q1, mean change=0.03 (95% CI -0.11, 0.17)	
		Q4 v. Q1, mean change=0.30 (95% CI 0.17, 0.43)	
		P-value for trend=0.0001	
		Outcome: Hyperuricemia	
		Major Findings:	
		Ln-Unit, OR=1.59 (1.19, 2.13)	
		Q2 v. Q1, OR=0.94 (95% CI 0.58, 1.53)	
		Q3 v. Q1, OR=1.01 (95% CI 0.62, 1.63)	
		Q4 v. Q1, OR=1.62 (95% CI 1.10, 0.43)	
		P-value for trend=0.0071	

Reference and Study Design	Exposure Measures	Results	Comment
(Geiger, Xiao et al. 2014)	Exposure Assessment: Serum	Stat Method: Linear regression models, and	Major Limitations:
	concentrations	multivariable logistic regression.	Cross sectional design precludes causal
Study Design:		Covariates and confounders considered	inference.
Cross-sectional	Population-Level Exposure:	includes age, sex, race/ethnicity, BMI	
	Mean: $4.2 (SE = 0.2) \text{ ng/mL}$	categories, annual household incomes,	Possible confounding due to unmeasured
Location:		moderate activity, and serum cotinine.	variables, and other environmental
United States			contaminants, including other PFCs.

	Case 1;16-cv-00917-LEK-DJS Document 1	62. Filed_04/06/20 Page 389 of 551
Population: NHANES 1999-2000 and 2003-	PFCs were log-transformed in continuous analyses and categorized into tertiles for both	Funding Source : Grant numbers 5T32HL090610-04, 1R01ES021825-01
$2008, \le 18$ years of age, n=815	continuous and categorizal analysis.	and 5R03ES018888-02 from the
	continuous una categorieur anarysis.	National Institutes of Health.
Outcome Definition:	Results shown for most adjusted models.	
Dyslipidemia (TC > 170		
mg/dL, HDL < 40 mg/dL, LDL	Outcome: Total cholesterol	
>110 mg/dL, or triglycerides	Major Findings:	
>150 mg/dL)	Ln-Unit, OR=4.55 (95% CI 0.90, 8.20)	
	Q2 v. Q1, OR=4.72 (95% CI -1.23, 10.67)	
	Q3 v. Q1, OR=7.00 (95% CI 1.40, 12.60)	
	P-value for trend=0.017	
	Outcome: LDL	
	Major Findings:	
	Ln-Unit, OR=5.75 (95% CI 2.16, 9.33)	
	Q2 v. Q1, OR=3.61 (95% CI -1.13, 8.36)	
	Q3 v. Q1, OR=8.18 (95% CI 3.04, 13.32)	
	P-value for trend=0.0027	
	Outcome: HDL	
	Major Findings:	
	Ln-Unit, OR=-1.52 (95% CI -3.02, -0.03)	
	Q2 v. Q1, OR=0.53 (95% CI -1.23, 2.30) Q3 v. Q1, OR=-1.19 (95% CI -2.94, 0.56)	
	Q3 V. Q1, OK1.19 (95% CI -2.94, 0.50)	
	P-value for trend=0.1769	
	Outcome: Triglycerides	
	Major Findings: Ln-Unit, OR=1.74 (95% CI -2.88, 11.68)	
	Lii-Oint, OK=1./4 (7570 CI -2.00, 11.08)	
	Q2 v. Q1, OR=3.00 (95% CI -5.68, 11.68)	
	Q3 v. Q1, OR=0.09 (95% CI -6.11, 6.30)	
	P-value for trend=0.9943	
I		

Case 1;16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 390 of 551
Outcome: Dyslipidemia
Major Findings:
Findings consistent with findings from linear
regression analyses. Positive association
between PFOA exposures and high total
cholesterol and high LDL, but not with low
HDL or high triglycerides.

Reference and Study Design	Exposure Measures	Results	Comment
(Gilliland and Mandel 1996)	Exposure Assessment:	Stat Method: Stratified analysis using	Major Limitations:
	Workers with jobs involving direct	ANOVA procedures to assess differences in	Healthy worker effect
Study Design:	contact with PFOA = highly	mean values. Total fluorine divided into 5	
Cross-sectional	exposed. Workers without direct	groups. Pearson correlation coefficient	Cross sectional design precludes causal
	contact with PFOA for at least 5	(univariate), linear multivariate regression.	inference.
Location: 3M Chemolite plant	years = low exposure. Job metrics	Covariates and confounders considered include	
(PFOA production plant),	were not used once determine	age, BMI, alcohol use, and tobacco use.	Self-reported smoking and drinking status
Cottage Grove, MN	'unexposed' groups had levels 20-		 not uniformly reliable
	50 times higher than levels	Outcome: Serum lipids	
Population: Occupationally	reported for general population.	Major Findings:	Duration of exposure information not
exposed men (currently		Cholesterol, r=0.07 (NS)	available
employed), 1985-1989, n=115	Total serum fluorine used as a	LDL, r=0.02 (NS)	
	surrogate.	HDL, r=-0.01 (NS)	Concerns with using serum fluorine rather
Outcome Definition:			than direct PFOA,
Hepatic enzyme and serum	Population-Level Exposure:	HDL, β=-1.61, p-value=0.04	
lipids:		Cholesterol and LDL (NS), results not shown	
Serum glutamyl oxa.oacetic	Mean= 3.3ppm (mg/L)=3300		Funding Source: NIOSH grant
transaminase (SGOT), serum	ng/mL	Outcome: Hepatic enzymes	T150H07098-16 and the 3M Medical
glutamyl pyruvic transaminase	Range $0 - 26$ ppm	Major Findings: NS	Department
(SGPT), gamma glutamyl		SGOT (AST), r=0.01 (NS)	
transferase (GGT), cholesterol,		SGPT (ALT), r=0.01 (NS)	
low-density lipoproteins (LDL),		GGT, r=-0.04 (NS)	
high-density lipoproteins			
(HDL)		SGOT (AST), β=-3.23, p-value=0.02	
		SGPT (ALT), β=-15.8, p-value=0.0008	
Related Studies:		GGT, β =-1.93, p-value=0.36	
Gilliland and Mandel, 1993			
		Note: subclinical hepatic toxic effects in obese	
		workers, drinkers and smokers. PFOA may be	
		modulating these effects, i.e. "endocrine	
		disruptor"	

	Case 1	;16-cv-00917-LĘK-DJS Document 1	
Reference and Study Design	Exposure Measures	Results	Comment
(Gleason, Post et al. 2015)	Exposure Assessment: Serum	Stat Method: Linear regression, covariates	Major Limitations:
	concentrations	and confounders considered include age,	Modeling techniques may result in model-
Study Design:		gender, race/ethnicity, BMI group, poverty,	dependent estimates.
Cross-sectional	Population-Level Exposure:	smoking, serum creatinine, and/or alcohol	
	Geometric mean=3.5 ng/mL	consumption. PFCs were natural log	PFCs appear to be correlated with each
Location:	Median=3.7	transformed. Logistic regression in exposure	other, making it difficult to clearly
United States		quartiles.	distinguish the effects of individual PFCs.
Population:		Results are presented for models with most	Cross sectional design precludes causal
NHANES 2007-2010,		adjustment.	inference.
individuals > 12 years of age,			
n=4,333		Outcome: Uric acid (mg/dL)	
<i>`</i>		Major Findings:	Funding Source: None, authors
Outcome Definition: Clinical		LinR: β = .303 (95% CI .238, .367)	employed by NJDEP and NJDOH.
biomarkers of liver function and		LogR: p-value for trend <.001	
uric acid			
		Outcome: alanine transferase (ALT) (ppb)	
		Major Findings:	
		LinR: : β = .038 (95% CI .014, .062)	
		LogR: p-value for trend =.007	
		Logic. p-value for trend	
		Outcome: gamma-glutamyl transferase	
		(GGT) (ppb)	
		Major Findings:	
		LinR: β = .058 (95% CI .021, .096)	
		Link. p = .038 (95% C1 .021, .090) LogR: p-value for trend =.042	
		Logk. p-value for trend042	
		Outcome: Total bilirubin (mg/dL)	
		Major Findings:	
		LinR: β = .048 (95% CI .016, .081)	
		LogR: p-value for trend <.001	
		Logra P and for a char tool	
		Outcome: asparate aminotransferase (AST)	
		(ppb)	
		Major Findings:	
		$LinR: : \beta = .025 (95\% \text{ CI } .007, .043)$	
		LogR: p-value for trend=.058	
		Outcome: alkaline phosphate (ALP) (ppb)	
		Major Findings: Lim B_{12} , $\theta = -0.02$, (0.5%) , $CL = 0.022$, 0.16)	
		LinR: : β =003 (95% CI023, .016)	
		LogR: p-value for trend=.528	

Exposure Measures	Results	Comment
Exposure	Stat Method:	Major Limitations:
Assessment:		Possible confounding due
Prenatal		to unmeasured variables,
		and other environmental
		contaminants, including
		other PFCs.
^		
	models.	
U		
years.		
	estimated.	
	PFCs and antibodies were log-transformed.	
	Ortonau	
$\Gamma\Gamma OA = 4.00$		
	$(1 \text{ cal } / \text{ auj. 101 } 5)$. 12.5 $(55/0 \text{ c1}^{-0.0}, 50.1)$	
	Structural Fa	
	Child (age 5) PFC	
	<u>Structural Eq.</u>	
	(Year 5 Pre):-20.5 (95% CI -44.4, 13.6)	
	(Age 7): -55.2 (95% CI -73.3, 25.0)	
1	(Vear 7): -58 8 (95% CL -76 0 29 3)	
	Measures Exposure Assessment:	MeasuresIterationExposure Assessment:Stat Method:Assessment: Prenatal exposures to PFCs at weekStat Method: Correlations were determined by pairwise Pearson correlation coefficients. Linear regression, covariates and confounders considered include sex and age. For 5-year pre-booster data models adjusted for time since vaccination, possible PCB exposures to pregnancy, determine the joint association of PFCs with the overall antibody concentrations. Also controlled for PFCs in maternal pregnancy, and duration of determine the joint association of PFCs with the overall antibody concentrations.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 392 of 551

ГГ	Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06	/20 Page 393 of 551
	Diphtheria % difference (2-fold) Maternal PFC	
	(Year 5 Pre): -16.2 (95% CI -34.2, 6.7)	
	(Year 5 Post): -6.2 (95% CI -22.4, 13.3)	
	(Year 7): -22.8 (95% CI -39.4, -1.7)	
	(Year 7 adj. for 5): -16.8 (95% CI -32.9, 3.8	
	<u>Structural Eq.</u>	
	(Year 5 Pre): -47.9 (95% CI -67.7, -15.9) (Age 7): -42.0 (95% CI -66.1, -0.8)	
	(Age 7)42.0 (7570 CI -00.1, -0.8)	
	Child (age 5) PFC	
	(Year 5 Pre): -6.8 (95% CI -28.3, 21.0)	
	(Year 5 Post): -6.1 (95% CI -23.6, 15.5)	
	(Year 7): -25.2 (95% CI -42.9, -2.0); OR=4.20 (95% CI 1.54, 11.44)	
	(Year 7 adj for 5): -23.4 (95% CI -39.3, -3.4)	
	Structural Eq.	
	(Year 5 Pre): -7.9 (95% CI -88.0, 37.0)	
	(Age 7): -44.4 (95% CI -65.5, -10.5)	
	Child (age 5 adj.) PFC:	
	<u>Structural Eq.</u>	
	(Year 5 Pre): -1.2 (95% CI -33.6, 46.8)	
	(Year 7): -45.5 (95% CI -66.9, 10.3)	
	For the structural equation model the joint change in antibody showed	
	statistical significance with PFCs at age 5 and at age 5 with adjustment for	
	PFC in maternal pregnancy serum.	
	· · ·	

Case 1;16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 394 of 551 Results Comment **Reference and Study Design Exposure Measures** (Granum, Haug et al. 2013) **Exposure Assessment:** Stat Method: **Major Limitations:** Maternal serum concentrations Poisson regression used for health outcomes with count data, otherwise logistic or linear No direct measures of fetal exposure **Study Design:** collected at time of delivery. Prospective birth cohort regression analyses were applied. Confounders without cord blood PFCs. Also can not and covariates considered include maternal differentiate from prenatal v. postnatal **Population-Level Exposure:** allergy, paternal allergy, maternal education, Location: exposure. Oslo and Akershus, Norway child's gender, and/or age at 3-year follow-up. Median 1.1 ng/mL Possible selection bias due to the low PFCs categorized into quartiles. recruitment rate in the original cohort **Population:** Sub-cohort from Norwegian (authors suggest selection bias between participants and non-participants due to Mother and Child Cohort Study **Outcome:** Anti-vaccine antibody levels recruited 2007-2008, n=49-99. self-selection has been evaluated and not **Major Findings:** Rubella: (Bivariate) β=-0.40 (95% CI -0.64, likely to be a problem). **Outcome Definition:** -0.17); Three annual questionnaire-Measles: β =-0.13 (95% CI -0.35, 0.09) Small study size. based follow-ups (infectious Hib: β=-0.05 (95% CI -3.85, 3.74) diseases, allergies, and asthma) Tetanus: β =0.01 (95% CI -0.09, 0.10) Possible confounding due to unmeasured and blood samples collect from variables, and other environmental the mothers at the time of contaminants, including other PFCs. (Multivariate) β =-0.40 (-0.64, -0.17) delivery and from the children at the age of 3 years. **Outcome:** Health outcomes **Major Findings:** Serological outcomes: antibody Common Cold levels specific for four vaccines (No. of episodes) 3rd vear: β=0.42 (95% CI 0.16, 0.72) (measles, rubella, tetanus, and All 3 years: β=0.17 (95% CI 0.01, 0.33) HiB) (Dichotomous) 3rd year: OR=1.24 (95% CI 0.32, 4.83) Gastroenteritis (No. of episodes) 3^{rd} vear: β =0.21 (95% CI -0.21, 0.64) All 3 years: β=0.31 (95% CI 0.002, 0.61) (Dichotomous) 3rd year: OR=1.16 (95% CI 0.37, 3.65) All 3 years: OR=3.13 (95% CI 0.37, 3.65)

Reference and Study Design	Exposure Measures	1:16-cv-00917-LEK-DJS Document 1 Results	62 Filed 04/06/20 Page 395 of Comment
(Jain 2013)	Exposure Assessment: Serum	Stat Method: Linear regression, covariates	Major Limitations:
	concentrations	and confounders considered included age,	88 participants were on thyroid
Study Design:		gender, race/ethnicity, smoking, iodine status,	medication or reported a current thyroid
Cross-sectional	Population-Level Exposure:	C-reactive proteins, BMI, fasting time, and	problem (small compared to overall N),
	4.1 ng/mL	caloric intake. Only select PFCs and outcomes	
Location:		are analyzed following some modeling	Combined effect of persistent organic
United States	1^{st} tertile $\leq 3.3 \text{ ng/mL}$	selection criteria.	pollutants not known,
D	3^{rd} tertile ≥ 5.1 ng/mL		
Population:		PFCs and thyroid parameters were log	Cross sectional design precludes causal
NHANES 2007-08, >12 years of age. n=1,540		transformed.	inference.
		Outcome: TSH	
Outcome Definition: Six		Major Findings: positively associated	Funding Source: unspec - Author was
thyroid function variables		β=0.053, p-value=0.098	publishing regularly for CDC until 2011,
(TSH, FT4, TT4, FT3, TT3,		↑(tertile) p-value <0.01	then seemed to be researching
thyroglobulin)			independently. Address on paper is a
, , ,		Outcome: TT3	residential property in GA. Author
		Major Findings: positively associated	subsequently worked for Fort Bragg in
		$R^2 = 17.3\%$	NC in 2014 before moving to an
		β=0.032, p-value=0.013	independent biostatistics consulting firm, empiristat, in January 2015.
		Outcome: FT3, FT4, TT4, TGN	empiristat, in sandary 2015.
		Major Findings:	
		FT3: β=0.012, p-value=0.09	
		FT4: β=0.003, p-value=0.83	
		TT4: β=0.012, p-value=0.43	
		TGN: β =0.057, p-value=0.17	

Reference and Study Design	Exposure Measures	Results	Comment
(Ji, Kim et al. 2012)	Exposure Assessment:	Stat Method:	Major Limitations:
	Serum concentrations	Linear regression, covariates and confounders	One city not representative of all of Korea
Study Design:		considered include age and BMI.	 very homogenous.
Cross-sectional	Population-Level Exposure:		
	2.74 ng/mL	Outcome: T4	Cross sectional design precludes causal
Location:	IQR=2.04-3.64	Major Findings:	inference. Unknown
Sigeung, Korea		β =-0.007 (95% CI -0.029,0.015)	
			Did not control other environmental
Population:		Outcome: TSH	pollutants, including other PFCs.
Recruited from cohort, aged		Major Findings:	-
greater than 12 years, $n = 633$		β=-0.066 (95% CI -0.220,0.089)	Funding Sources: This research was
			supported by Korea Food & Drug
Outcome Definition: Thyroid			Administration (08182KFDA499).
hormones			

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 396 of 551

Reference and Study Design	Exposure Measures	Results	Comment
(Jiang, Zhang et al. 2014)	Exposure Assessment:	Stat Method: Pearson rank-order correlations, PFCs and	Major Limitations:
	Serum concentrations	outcomes were log transformed.	Cross sectional design precludes
Study Design:			causal inference.
Cross-sectional	Population-Level Exposure:	Results shown here for total PFOA.	
	Geo Mean		Third party confounders may
Location: Tianjin, China	n-PFOA = 4.18 ng/mL	Outcome:	exist
	iso-PFOA = 0.04 ng/mL	Major Findings:	
Population: Pregnant	5m-PFOA = 0.002 ng/mL		Funding Source: Natural
women, n=141		WBC, r=-0.042 (NS)	Science Foundation of
	Total=4.22	RBC, r=0.061 (NS)	China (NSFC 21077060,
Outcome Definition:		Hemo, r=0.192, p<0.05	21325730, 21050110427),
White blood cells, red		Platelet, r=-0.004 (NS)	Ministry of Education
blood cells, hemoglobin,		Glucose, r=0.103 (NS)	(20130031130005), and the
and platelet, total bilirubin,		Total protein, r=0.092 (NS)	Ministry of Environmental
total protein, albumin,		Albumin, r=0.251, p<0.01	Protection
glucose, AST, and ALT.		Total bilirubin, r=0.135 (NS)	(201009026).
		AST, r=0.041 (NS)	
		ALT, r=-0.071 (NS)	

Reference and Study Design	Exposure Measures	Results	Comment
(Kielsen et al., 2015)	Exposure Assessment:	Stat Method:	Major Limitations:
	Serum PFOA measured	Modeling which assumed a constant	Small sample size
Study Design:	prospectively for 30 days after	concentration level until Day 4 followed by a	
Prospective cohort	booster vaccination (days	linear increase between days 4-10 after which	Possible confounding due to unmeasured
	2,4,7,10,14 and 30).	the concentration was assumed to be constant,	variables, including other environmental
Location:		allowing the PFOA concentration to especially	contaminant as well as other PFCs.
Denmark	Population-Level Exposure:	affect the intercept of the curve on those days.	
	Median 1.69 ng/mL,	The analyses estimate how much this factor	
Population:	range 1.30-2.79	change, in percent, when the PFOA	
Healthy adults (n=12) without a		concentration doubled.	
history of tetanus-diphtheria			
booster vaccination in the past		Effects were adjusted for sex and age.	
5, recruited among staff at a			
hospital, 23 to 66 years of age		PFOA and antibody concentrations were log	
		transformed.	
Outcome Definition:			
Antibody responses followed		Outcome: Diphtheria Antibody Concentration	
for 30 days after a booster		Major Findings:	
vaccination (days 2,4,7,10,14		% Change (Day 4-10)=-8.22 (95% CI 6.44, -	
and 30) with diphtheria and		20.85)	

	<u>— Case 1;16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 397 (</u>	xt 5 51
tetanus.		/ 001
	Effects were stronger for diphtheria in general	
Median antibody concentration	than compared with tetanus, and affects were	
pre-vaccination:	statistically significant for PFOS, PFNA, and	
Diphtheria 1.00 IU/ml	PFDA	
Tetanus 4.03 IU/ml		
	Outcome: Tetanus Antibody Concentration	
	Major Findings:	
	% Change (Day 4-10)=0.23 (95% CI 12.1, -	
	10.40)	

Reference and Study Design	Exposure Measures	Results	Comment
(Kim, Choi et al. 2011)	Exposure Assessment:	Stat Method: Correlations between exposure	Major Limitations:
	Maternal blood serum (n=44),	and outcomes using Pearson correlation testes	Possible confounding due to unmeasured
Study Design:	fetal cord blood serum (n=43), and	performed using the log of thyroid hormones	variables, including other PFCs.
Prospective birth cohort	breast milk (n=35)	and PFCs with and with-out adjustment for	_
(matching prepartum blood –		influential covariates. The following covariates	Plausible competing mechanism involved
cord blood- postpartum breast	Population-Level Exposure:	and confounders were considered maternal	in transplacental transfer.
milk)		age, gestational age, and maternal BMI.	-
,	Median (maternal prepartum blood		Cross-sectional design prevents causal
Location:	serum) = 1.46 ng/mL^{1}	Results shown for adjusted correlations.	inference.
Seoul, Cheongju, and Gumi,	, ,		
South Korea	Median (cord serum) = 1.15	Outcome: fetal cord blood total T3	Small sample size.
	ng/mL	Major Findings:	1
Population:		Fetal, $r=-0.210$ (NS)	Funding Source: This research was
Pregnant women recruited from	Median (breast milk) = 0.05	Maternal, $r=-0.238$ (NS)	supported by Korea Food & Drug
three hospitals (n=44), age > 25	ng/mL		Administration
years. Paired samples available		Outcome: fetal cord blood total T4	(08182KFDA499). The research was also
for n=26 mother-infant pairs.		Major Findings:	supported by
		Fetal, r=-0.157 (NS)	a Discovery Grant from the National
Outcome Definition:		Maternal, r=-0.071 (NS)	Science and Engineering
Serum concentrations mostly			Research Council of Canada (Project #
sampled in third trimester but		Outcome: fetal cord blood TSH	326415-07) and a grant
some earlier (n=7, week 20-25),		Major Findings:	from the Western Economic
cord blood at delivery, and		Fetal, r=0.089 (NS)	Diversification Canada (Project #
breast milk during mother		Maternal, r=0.443 p<0.05	6578 and 6807). The authors wish to
checkup visit.			acknowledge the support of
*		No significant association with birth weight	an instrumentation grant from the Canada
		and length for any measures of PFOA.	Foundation for
			Infrastructure.

Reference and Study Design	Exposure Measures	1;16-cv-00917-LEK-DJS Document 1 Results	62 Filed 04/06/20 Page 398 of 5 Comment
(Knox, Jackson et al. 2011)	Exposure Assessment:	Stat Method: Linear regression and ANOVA	Major Limitations:
	Serum concentrations	to estimate gender differences, covariates and	Thyroxin-Binding Globulin production
Study Design:		confounders considered include age, serum	not measured, albumin used instead,
Cross-sectional	Population-Level Exposure:	estradiol, and alcohol.	
			Cross sectional design precludes causal
Location:	PFOA (ng/mL) Means by age	Outcome: TSH	inference.
United States – West Virginia	group	Major Findings:	
and Ohio	Women 20-50=52.6	No significant associations, results not shown	Possible confounding due to unmeasured
	Men 20-50=91.0		variables, including other PFCs.
Population: Adults (20 years or	Women > 50=98.6	Outcome: Thyroxine (T4)	
older) without thyroid disease,	Men > 50=124.3	Major Findings:	
consumed water for at least 1		Women 20-50, β=0.05, p<0.0001	Quality of study: previously unreported
year from a water district with	Total Mean = 86.57 ng/mL	Men 20-50, (NS) results not provided	gender differences in thyroxine and T3
known PFOA contamination,		Women > 50, β=0.08, p<0.0001	uptake
n=50,113 members of the class		Men > 50, β=0.06, p=0.0001	
of those affected by C8 spill			Funding Source: unspec, All authors
		Outcome: T3	employed by WVU School of Medicine.
Outcome Definition:		Major Findings:	
thyroxine, T3 uptake, TSH,		Women 20-50, β=-0.08, p=0.0001	
		Men 20-50, (NS) results not provided	
		Women > 50, β=-0.07, p<0.005	
		Men > 50, β=-0.04, p=0.037	
		Outcome: albumin	
		Major Findings:	
		Women 20-50, β=0.02, p<0.0001	
		Men 20-50, β =0.02, p<0.0001	
		Women > 50, β =0.02, p<0.0001 Women > 50, β =0.02, p<0.0001	
		Men > 50, β =0.02, p<0.0001 Men > 50, β =0.02, p<0.0001	

Reference and Study Design	Exposu	ire Measures	Results	Comment
(Lin, Lin et al. 2010)	Exposure Assessment: Serum		Stat Method: Linear regression, covariates	Major Limitations:
	concentrations	5	and confounders considered include age,	Cross sectional design precludes causal
Study Design:			gender, race/ethnicity, smoking, alcohol	inference.
Cross-sectional	Population-Level Exposure:		consumption, education level, BMI, HOMA-	
			IR, metabolic syndrome, and iron saturation.	No other environmental chemicals were
Location:	Gender	Mean PFOA	PFCs assessed as quartiles and natural log	included, may be important covariates
United States		(ng/mL)	transformed. Model estimates are shown for	
	Male	5.05	most adjusted.	Did not take into account any medications
Population:	Female	4.06		that may cause elevated ALT or GGT
NHANES 1999-2000 & 2003-		1	PFCs modeled separately and included in a	
2004, n=2,216, 18 years of age	Population Me	ean: 4.54 ng/mL	composite analysis with PFOS, PFNA, and	Common physiology could influence both
or older	1	e	PFHxS.	serum PFCs and liver enzymes

	Case 1:16-cv-00917-LEK-DJS Document 10	62 Filed 04/06/20 Page 399 of 551
Outcome Definition:	Outcome: ALT	
Serum liver enzymes: ALT	Major Findings:	determine hepatic steatosis, inflammation,
(alanine transaminase), GGT	Quartiles of PFOA (unadj.), increasing	or fibrosis.
(gamma-glutamyltransferase),	trend (p<0.001)	
total bilirubin	Separate, $\beta = 1.86$, p=0.005.	Funding Source: This was an
	Composite, $\beta = 2.19$, p=0.009.	investigator-initiated unfunded study. All
		authors had access to the data and the
	Outcome: GGT	statistical analysis report. Pau-Chung
	Major Findings:	Chen was the guarantor of the article,
	Quartiles of PFOA (unadj.), increasing	from the institute of Occupational
	trend (p<0.001)	Medicine and Industrial Hygiene,
	Separate, $\beta = 0.08$, p=0.019.	National Taiwan University College of
	Composite, $\beta = 0.15$, p=0.001.	Public Health.
	Outcome: Total bilirubin	
	Major Findings:	
	Quartiles of PFOA (Unadj), no trend (p=0.638)	
	Separate, $\beta = -0.09$, p=0.645.	
	Composite, $\beta = -0.20$, p=0.378.	

Reference and Study Design	Exposure Measures	Results	Comment
(Lin, Wen et al. 2011)	Exposure Assessment: Screening	Stat Method:	Major Limitations:
Study Design: Cross-sectional	of school-age children via urine with subsequent blood serum tests,	The relation of PFC variables to categorical variables was tested using the Mann-Whitney U test or Kruskal-Wallis test.	Cross sectional design precludes causal inference.
Location: Taipei, Taiwan	Population-Level Exposure: Median: 2.39 ng/mL	Linear regression with adiponectin, glucose homeostasis, lipid profile, inflammatory	No inclusion of other environmental chemicals which may be important covariates
Population: 287 adolescents and young adults, aged 12-30 years of age recruited from a hypertension cohort. Outcome Definition: Serum measures	$\begin{array}{ c c c c }\hline Percentile & Median \\ (ng/mL) \\\hline <50^{th} & 0.75 \\\hline 50-74^{th} & 3.86 \\\hline 75^{th}\text{-}89^{th} & 7.89 \\\hline \geq 90^{th} & 11.54 \\\hline \end{array}$	markers Covariates and confounders: Model 1 (age and gender), Model 2 (age, gender, lifestyle factors), Model 3 (Model 2 + measurement data). Significant only if significant in all models.	The study population is made up of adolescents and young adults with abnormal urinalysis results. Study population only adolescents and young adults – not generalizable to larger population
Adiponectin is a protein hormone that modulates a number of metabolic processes, including glucose regulation and fatty acid catabolism.		Outcome: Serum adiponectin, glucose, insulin, triglycerides, CRP, HDL Major Findings: PFOA levels were significantly lower in subjects with metabolic syndrome (p=0.009)	Common physiology could influence both serum PFCs and outcome measures Funding Source: This study was supported by grants from the National Health Research Institute of Taiwan (NHRI-EX97-9721PC, EX97-9821P C,

Case 1:16-cy-00917-LEK-DIS Document	162 Eiled 04/06/20 Page 400 of 551
Results in Supporting Information Tables – reported as all non-significant for all 3 model types.	and X97 -9921PC) and (NHRI-EX95-953 I PI, EX95 - 9631PI, and EX95-973IPI) and from the National Science Council of Taiwan (99-2314-B-385 001- MY3).

Reference and Study Design	Exposure Measures	Results	Comment
(Lin, Wen et al. 2013)	Exposure Assessment: Serum	Stat Method:	Major Limitations:
	concentrations	Linear and logistic regression for categories of	Cross sectional design precludes causal
Study Design:		PFCs ($\leq 50^{\text{th}}$, $\leq 50^{\text{th}}$ -75 th , $\leq 75^{\text{th}}$ -90 th , >90 th),	inference.
Cross sectional	Population-Level Exposure:	covariates and confounders considered include	
		age, gender, smoking, and alcohol	Population is not generalizable – very
Location:	Geometric mean = 2.67 ng/mL	consumption.	specific,
Taipei, Taiwan			-
	Quartile Levels	TSH was natural log transformed.	Did not take into account all medications
Population:	ng/mL		that may have impact on thyroid
Young adults with abnormal	< 50 th < 3.64	Outcome: Free T4 (ng/dL)	functioning,
urinalysis in childhood, 12-30	$50^{\text{th}}-75^{\text{th}} \leq 6.66$	Major Findings:	_
years old, N=551 (510 with	$75^{\text{th}} - 90^{\text{th}} \leq 9.71$	Means=1.07, 1.08, 1.10, 1.06 (P for Trend NS)	Unmeasured confounders possible,
normal blood pressure and 41	$> 90^{\text{th}}$ > 9.71		
hypertensive)		Outcome: log TSH (m IU/l)	Status of thyroid tissue unavailable to
		Major Findings:	determine thyroid pathology.
		Means=0.48, 0.45, 0.36, 0.41 (P for Trend	
Outcome Definition:		NS)	Funding Source: This study was
Laboratory, examination, and			supported by grants from National Health
survey information.			Research Institute of Taiwan (EX97-
			9721PC, EX97-9821PC, X97-
			9921PC, EX95-9531PI, EX95-9631PI and
			EX95-9731PI) and from National Science
			Council of Taiwan (99-2314-B-385-001-
			MY3).

Reference and Study Design	Exposure Measures	1:16-cv-00917-LEK-DJS Document 1 Results	Comment
(Lin, Lin et al. 2013)	Exposure Assessment:	Stat Method:	Major Limitations:
	Serum concentrations	Linear regression and logistic regression for	Cross sectional design precludes causal
Study Design:		categories of PFCs ($\leq 50^{\text{th}}$, $\leq 50^{\text{th}}$ -75 th , $\leq 75^{\text{th}}$ -	inference.
Cross-sectional	Population-Level Exposure:	90^{th} , >90 th) covariates and confounders	
	Median: 3.49 ng/mL	considered include age, gender, smoking	Did not include other environmental
Location: Taipei area, Taiwan	Range: 0.75-52.2	status, alcohol consumption, and BMI to	factors (ie particulate matter air pollution)
		estimate association with cardiovascular risk	
Population: Taiwanese young		factors, and additionally sBP, BMI, LDL,	Tenuous generalizability due to sample
adults with abnormal urinalysis		CRP, TG, and HOMA-IR for CIMT.	
in childhood, 12-30 years old,			Did not take into account medicines
N=664 (246 with elevated		Logistic regression analysis was conducted to	which may affect CIMT
blood pressure and 398 with		examine the odds ratios of thicker CIMT for	
normal blood pressure)		PFOS only. Investigators performed a	Common physiology could influence both
		composite analysis with four PFCs modeled	things.
Outcome Definition:		together.	
Serum samples,			
sociodemographic data		Outcome: Cardiovascular risk factors	Funding Source: This study was
collected during interview.		Major Findings:	supported by grants from the National
Clinical outcomes were		$SBP - \downarrow (P \text{ for trend}=0.177)$	Health Research Institute of Taiwan
determined from clinical serum		BMI - \downarrow (P for trend=0.130)	(NHRI EX97-9721PC, EX98-9721PC,
measures.		LDL-C - \downarrow (P for trend=0.117)	EX99-9721PC, and EX100-9721PC;
		Log-TG - \downarrow (P for trend=0.015)	EX95-9531PI, EX96-9531PI and EX95-
Carotid intima-media thickness		UA - \uparrow (P for trend=0.983)	9731PI) and from the National Science
(CIMT) is a marker of		Log-HOMA-IR - \uparrow/\downarrow (P for trend=0.694)	Council of Taiwan (NSC 99-2314-B-385-
subclinical atherosclerosis.			001-MY3 and NSC 101-2314-B-002-184-
		Outcome: CIMT	MY3).
		Major Findings: NS	
		(findings in paper are only PFOS-relevant)	

Reference and Study Design	Exposure Measures	Results	Comment
(Looker, Luster et al. 2014)	Exposure Assessment:	Stat Method:	Major Limitations:
	Serum concentrations at	Linear regression for PFC (log transformed and quartiles), covariates	Reporting of previous –
Study Design:	time of vaccination.	and confounders considered include age and gender, smoking status,	potential of recall bias
Prospective cohort		any previous influenza vaccination, specific H1N1 vaccination in	
	Population-Level	previous year, day of serum sample collection, coexisting medical	Given the high background
Location:	Exposure:	conditions, and common anti-inflammatory, and pain relief	rate of respiratory infection,
U.S., mid-Ohio region of Ohio	Median, 31.5 ng/mL	medications, as well as mobility. Logistic regression also utilized for	there is not much scope to
and West Virginia		dichotomized outcomes.	detect an increase in
			infections.
Population: Adults who		Differences and ratios of antibody titers were log transformed. Titers	
consumed water (for at least 1		also dichotomized into seroconversions (4-fold or greater increase in	Not a longitudinal analysis.
year) from a water district with		antibody titer following vaccination) and seroprotection (HI titer >	No vaccination information

	Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/	0 <u>6/20Page 402 of 5</u> 51
known PFOA contamination, n=411. Initial recruitment was		ersons could have been
2005-06 and were followed-up		blowed as the PFC levels
1		ecreased.
in 2010.	quartiles. de	creased.
Outcome Definition:	Outcome: Geometric Mean antibody titer (GMT) Rise Following	
Hemagglutionation inhibition	Vaccination	
tests were conducted on serum	Major Findings:	
samples collected preinfluenza	Influenza Type B	
vaccination and 21 ± 3	Q1: 49.46 (95% CI 38.14, 64.12)	
postvaccination in $\overline{2010}$.	Q2: 46.00 (95% CI 35.28, 59.97)	
1	Q3: 43.55 (95% CI 33.08, 57.33)	
Questionnaires were conducted	Q4: 20.90 (95% CI 16.58, 28.24)	
regarding the occurrence and		
frequency of recent (last 12	Titer Rise:	
months) of respiratory	Linear - $\beta(adj.)$ =-0.2 (95% CI -0.13, 0.09)	
infections.	Q2 v. Q1 - β(adj.)=-0.3 (95% CI -0.19, 0.13)	
	$Q3 v. Q1 - \beta(adj.) = -0.2 (95\% CI - 0.19, 0.15)$	
	$Q4 v. Q1 - \beta(adj.) = -0.7 (95\% CI - 0.24, 0.10)$	
	Titer Ratio:	
	Linear - $\beta(adj.)$ =-0.2 (95% CI -0.11, 0.08)	
	$Q2 v. Q1 - \beta(adj.)=0.5 (95\% CI -0.09, 0.19)$	
	Q3 v. Q1 - β (adj.)=0.7 (95% CI -0.07, 0.22)	
	Q4 v. Q1 - β (adj.)=-0.3 (95% CI -0.17, 0.12)	
	No statistically significant ORs for seroconversions or	
	seroprotection.	
	Influenza Type A H1N1	
	476.23 (360.77, 628.65)	
	352.22 (255.33, 485.88)	
	306.32 (232.58, 403.44)	
	274.79 (202.85, 372.23)	
	Titer Rise:	
	Linear - $\beta(adj.)$ =-0.3 (95% CI -0.14, 0.09)	
	$Q_2 v. Q_1 - \beta(adj.) = -0.9 (95\% CI - 0.27, 0.08)$	
	Q3 v. Q1 - $\beta(adj.)$ =-0.10 (95% CI -0.28, 0.09)	
	$Q_{4} v. Q_{1} - \beta(adj.) = -0.12 (95\% \text{ CI} - 0.28, 0.06)$	
	Titer Ratio:	
	Linear - β(adj.)=-0.7 (95% CI -0.06, 0.21)	
	Q2 v. Q1 - β(adj.)=-0.8 (95% CI -0.29, 0.12)	
	Q3 v. Q1 - β(adj.)=-0.04 (95% CI -0.25, 0.18)	
	Q4 v. Q1 - β(adj.)=0.7 (95% CI -0.14, 0.29)	

Case 1:16-cy-00917-LEK-DJS Document 162 Filed 04/06	20 Page 403 of 551
Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06 No statistically significant ORs for seroconversions or	
seroprotection.	
Influenza A H3N2	
228.86 (161.53, 324.27)	
125.36 (86.01, 182.73)	
104.13 (72.47, 149.64)	
183.73 (127.28, 265.23)	
Titer Rise:	
Linear - $\beta(adj.)=-0.1$ (95% CI -0.17, 0.14)	
$Q2 v. Q1 - \beta(adj.) = -0.28 (95\% CI - 0.51, -0.06)$	
Q3 v. Q1 - $\beta(adj.)$ =-0.37 (95% CI -0.60, -0.13)	
$Q4 v. Q1 - \beta(adj.) = -0.12 (95\% CI - 0.36, 0.13)$	
Q + +. Q = p(udj.) 0.12 (7570 C1 0.50, 0.15)	
Titer Ratio:	
Linear - β (adj.)=-0.127 (95% CI -0.25, 0.02)	
$Q2 v. Q1 - \beta(adj.) = -0.10 (95\% CI - 0.30, 0.10)$	
Q3 v. Q1 - $\beta(adj.)$ =-0.07 (95% CI -0.28, 0.14)	
$Q4 v. Q1 - \beta(adj.) = -0.22 (95\% CI -0.43, -0.01)$	
$Q = v \cdot Q = p(a u j \cdot j)^{-0.22} (j \cdot j \cdot v \cdot C = 0.45, -0.01)$	
No statistically significant seroconversions.	
ivo statistically significant scroconversions.	
Seroprotection	
Q2 v. Q1 - OR=0.34 (95% CI 0.14, 0.83)	
Q3 v. Q1 - OR=0.28 (95% CI 0.11, 0.70)	
Q4 v. Q1 - OR=0.39 (95% CI 0.15, 0.99)	
(75 / 0.07)	
*No statistically significant associations between self-reported colds	
or influenza and PFOA levels.	
or influenza and FFOA levels.	

Reference and Study Design	Exposure Measures	Results	Comment
(Lopez-Espinosa, Mondal et al.	Exposure Assessment:	Stat Method:	Major Limitations:
2012)	Serum PFOA and modeled in	Linear and logistic regression, covariates and	Mostly cross-sectional design precludes
	utero PFOA (information on	confounders considered include age, sex,	much causal inference,
Study Design:	historical releases, environmental	race/ethnicity, BMI, month of sampling,	
Cross-sectional and birth cohort	distribution, pharmacokinetic	average household family income, smoking,	Absence of measurements of child
	modeling, residential histories)	and alcohol consumption.	triiodothyronine,
Location: mid-Ohio valley,			
USA	Population-Level Exposure:		Reliance on recall for thyroid diagnosis
	Median in utero: 12 ng/mL	Outcome: In-TSH	(though a more stringent case definition
	Median serum PFOA: 29 ng/mL	Major Findings:	produced similar results).
		Modeled (% change 1-17 years old, IQR):	
		%=-0.5 (95% CI -2.4, 1.5)	

	37	N 6 1 1	Case	1;16-cv-00917-LEK-DJS Document	162 Filed 04/06/20 Page 404 of 551 No control for other environmental
Population: Children (age 1-17) who	Years	Model		%=1.0 (95% CI -0.5, 2.7)	chemicals including other PFCs.
consumed water (for at least 1	1-5	23.8	33.8	^{70-1.0} (95% C1-0.5, 2.7)	chemicals including other PPCs.
	6-10	14.5	32.2	Outcome: TT4	Reliant of modeled in utero PFOA
year) from a water district with	> 10	9.32	26.9		
known PFOA contamination,	1-17	11.5	29.3	Major Findings:	exposure for birth cohort.
n=10,725 were included in the				Modeled (% change 1-17 years old, IQR): N = 0.1 (05% CL 0.8, 0.6)	Quality of studen first lance cools not out
analysis. Subsample of				%=-0.1 (95% CI -0.8, 0.6)	Quality of study: first large scale report
children matched to mothers for				Maaron (0/shares 1, 17 second ald IOD).	in children suggesting associations of
model in utero PFOA exposure,				Measure (%change 1-17 years old, IQR):	serum PFOA and hypothyroidism
n=4,713 (pregnancies from				%=0.1 (95% CI -0.5, 0.6)	
1987-2005)					Funding Source: C8 class action
Ostanov Definition Sa				Outcome: Thyroid disease	settlement agreement between DuPont
Outcome Definition: Serum				Major Findings:	and plaintiffs
samples of TSH, TT4,				Modeled, Reported	
categorized into subclinical				OR=1.47 (95% CI 0.95, 2.27)	
hypothyroidism and				Measured, Reported	
hyperthyroidism. Also parent				OR=1.44 (95% 1.02, 2.03)	
self-reported thyroid disease					
and thyroid disease related				Outcome: Hypothyroidism	
medication use.				Major Findings:	
				Modeled, Reported	
				OR=1.61 (95% CI 0.96, 2.63)	
				Measured, Reported	
				OR=1.54 (95% 1.00, 2.37)	
				Modeled (in utero), Subclinical	
				OR=0.94 (95% CI 0.76, 1.16)	
				Measure, Subclinical	
				OR=0.98 (95% CI 0.86, 1.15)	
				Outcome: Hyperthyroidism	
				Major Findings:	
				Modeled, Subclinical	
				OR=1.10 (95% CI 0.69, 1.74)	
				Measure, Subclinical	
				· · · · · · · · · · · · · · · · · · ·	
				OR=0.81 (95% CI 0.58, 1.15)	

Reference and Study Design	Exposure Measures	Results	Comment
(Melzer, Rice et al. 2010)	Exposure Assessment:	Stat Method: Multivariate logistic regression	Major Limitations:
	Serum PFOA	of thyroid disease by PFC quartile. Sex	Investigators based PFOA on a single
Study Design:		specific models were used.	serum sample, likely to represent
Cross-sectional	Population-Level Exposure:	Covariates and confounders considered include	medium-term internal dose, samples taken
	Geo mean men = 4.91 ng/mL	year of NHANES cycle, age, sex,	at several time points might be more
Location:		race/ethnicity, education, smoking status, BMI,	accurate in classifying exposure. Any
United States	Geo mean women = 3.77 ng/mL	and alcohol intake.	misclassification from single measures

Population:	Case 1:16-cv-00917-LEK-DJS Document Results shown for most adjusted models.	
NĤANES 1999-2000, 2003-		underestimate the real strengths of
2004, and 2005-2006	Outcome: Thyroid disease	association.
N=3974; \geq 20 years of age	Major Findings:	
	EVER:	Cross sectional design precludes causal
Outcome Definition: Thyroid	Women,	inference.
disease= ever self-reported	Q2 v. Q1, OR=0.95 (95% CI 0.62,1.47)	
health professional diagnosis	Q3 v. Q1, OR=1.11 (95% CI 0.67, 1.83)	Confounding is also possible but unlikely.
and current diagnosis and	Q4 v. Q1, OR= 1.64 (95% CI 1.09, 2.46)	
currently taking medication for		Since associations reported were in people
the disease (CURRENT).	Men,	on thyroid medications, which mimic
	Q2 v. Q1, OR=1.11 (95% CI 0.62,1.99)	normal thyroid function, reverse causation
Also examined other self-	Q3 v. Q1, OR=0.57 (95% CI 0.19, 1.66)	implausible.
reported diseases.	Q4 v. Q1, QR = 1.58 (95% CI 0.74, 3.39)	1
r		Funding Source: Peninsula Medical
	CURRENT:	School and University of Exeter
	Women	
	Q2 v. Q1, OR=0.89 (95% CI 0.49,1.59)	
	Q3 v. Q1, OR=1.86 (95% CI 1.12, 3.09)	
	Q4 v. Q1, OR=2.24 (95% CI 1.38, 3.65)	
	Men,	
	Q2 v. Q1, OR=1.12 (95% CI 0.52, 2.39)	
	Q3 v. Q1, OR=0.49 (95% CI 0.18, 1.38)	
	Q4 v. Q1, OR=1.89 (95% CI 0.60, 5.90)	
	Outcome: Arthritis ever, asthma ever, COPD	
	ever, Diabetes ever, Heart disease ever, Liver	
	disease current	
	Major Findings:	
	Some evidence of positive association with	
	arthritis (Q2 v. Q1 and Q3 v. Q1 P <0.05, but	
	not Q4). For asthma ever Q2 v. Q1 is	
	statistically significant (p<0.05) but not for	
	other quartile. For other disease in which the	
	percentage of 'disease' become increasingly	
	minimal: COPD (11.2-11.9%), Diabetes (7.0-	
	10.9%), Heart disease (5.4-5.7%), and Liver	
	disease $(0.8-1.4\%)$ there are no significant	
	disease (0.8-1.4%) there are no significant findings.	

	Case 1	;16-cv-00917-LEK-DJS Document 16	
Reference and Study Design	Exposure Measures	Results	Comment
(Nelson, Hatch et al. 2010)	Exposure Assessment:	Stat Method: Linear regression, covariates	Major Limitations:
	Serum concentrations	and confounders considered include age, sex,	Cross sectional design precludes causal
Study Design:		race/ethnicity, socioeconomic status, saturated	inference.
Cross-sectional	Population-Level Exposure:	fat intake, exercise, TV time, alcohol	
	Median = $3.8 \mu g/L (ng/mL)$	consumption, smoking, and parity in women.	Differing physiology might affect PFOA
Location:		Also examined PFCs as quartile and performed	behavior (PFCs may bind to beta-
United States		test for trend.	lipoproteins and albumin in the blood)
Population:		Effect estimates of each quartile to the lowest	Only one measurement of PFCs and
NHANES 2003-2004, 12-80		quartile, Test for trend performed.	cholesterol concentrations
year olds, N=416-860			
depending on parameter		Outcome: Total & non-HDL cholesterol (70-	Unable to consider other environmental
1 0 1		80% of TC)	contaminants
		Major Findings:	
Outcome Definition:		TC, β=1.22 (95% CI 0.04, 2.40)	
Serum samples and		P for Trend=0.07	Quality of study: large sample size,
anthropometric measurements:		Non-HDL, β=1.38 (95% 0.12, 2.65)	ability to account for key covariates like
cholesterol, body weight,		P for Trend=0.05	alcohol and cholesterol lowering
insulin resistance			medications, and consideration of
		Outcome: HDL	modification by age and/or gender.
		Major Findings:	
		$\beta = -0.12 (95\% - 0.41, 0.16)$	Funding Source: This work was
		P for Trend=0.34	supported in part by grant
			R21ES013724 from the National Institute
		Outcome: LDL	of Environmental Health Sciences
		Major Findings:	(NIEHS). J.W.N.
		β =-0.21 (95% -1.91, 1.49)	was supported in part by award
		P for Trend=0.84	T32ES014562 from NIEHS.
			152E0017502 HOIII TALLIIS.
		Outcome: Anthropometric measures	
		Major Findings:	
		BMI, P for Trend=096	
		Waist Circumference, P for Trend=0.84	
		Log-HOMA, P for Trend=0.31	

		;16-cv-00917-LEK-DJS Document 10	
Reference and Study Design	Exposure Measures	Results	Comment
	Exposure Assessment:	Stat Method:	Major Limitations:
(Olsen, Gillilan et al. 1998)	PFOA serum concentrations	Simple and stratified analyses, analysis of	Cross sectional design precludes causal
~		variance (ANOVA), Pearson correlation	inference.
Study Design:	Population-Level Exposure:	coefficients, and ordinary multivariable	
Two cross-sectional studies	Mean by PFOA category	regression were used to evaluate associations	Healthy worker effect
(1993 & 1995)		between PFOA and each hormone, with	
	1993 (ppm):	adjustment for potential confounding variables.	Few subjects exposed at highest and
Location: U.S. – 3M Plant	0-1: 0.48	Covariates and confounders considered include	lowest levels
	1-<10: 3.34	age, BMI, alcohol use, and cigarette use.	
Population:	10-<30: 16.26		No females included.
111 and 80 male production	>=30: 60.13	PFOA serum concentrations were divided into	
workers (68 workers		four categories (0-1, 1-<10, 10-<30, and >=30	Funding Source:
participated in both years)	1995 (ppm):	ppm).	Not explicitly stated but 3M –
	0-1: 0.31		corresponding (lead) author is employee
Outcome Definition:	1-<10: 3.03	Outcome: Hormones (reproductive mainly)	of 3M Company
Eleven hormones were assayed:	10-<30: 17.11	Major Findings: (Description is limited since	
cortisol,	>=30: 55.96	endpoints are not being comprehensively	
dehydroepiandrosterone sulfate		reviewed).	
(CHEAS), estradiol, FSH, 17α-			
hydroxyprogesterone (17-HP),		"Simple linear regression of the natural log of	
free testosterone, LH, prolactin,		each hormone with PFOA, treated as a	
thyroid-stimulating hormone		continuous variable, resulted in no statistically	
(TSH), and sex hormone-		significant coefficients in 1993 for any	
binding globulin (SHBG)		hormone and only one in 1995 (17-HP). "	
		These findings were the same for the	
		multivariable regression also.	
		Univariate analysis (1995) - Statistically	
		increased mean for TSH between 1-<10 and	
		10-30 ppm groups (p=0.002), but not for	
		highest PFOA category. Findings were not	
		statistically significant for 1993 but mean TSH	
		increased for the 10-<30 category compared to	
		the lower two categories.	
	1	the former two eurogonies.	

Reference and Study Design	Exposure Measures			res	L6-CV-00917-LEK-DJS Document 16: Results	Comment	
(Olsen, Burris et al. 2000)	Exposur concentr		sment: se	rum	Stat Method: Simple and stratified analyses, ANOVA, multivariable regression (linear and	Major Limitations: Cross sectional design precludes causal	
Study Design:	concentrations				nonlinear). Covariates and confounders	inference.	
Cross-sectional	Populat	ion-Leve	el Exposu	re:	considered include age, BMI, alcohol use,		
	(ppm)		-		and cigarette use.	Healthy worker effect	
Location: U.S. – 3M Plant	Year	Mean	Median	Range			
	1993	5.0	1.1	0.0-	Participants were stratified into 3 categories	Only 17 subjects were common in all 3	
Population:				80.0	of PFOA (0-<1ppm), (1-<10ppm), (≥10ppm).	study years.	
Male workers involved in	1995	6.8	1.2	0.0-			
ammonium perfluorooctanate				114.1	Outcome: Hepatic enzymes	Voluntary participation, 50-70%	
production in 1993 (n=111),	1997	6.4	1.3	0-	Major Findings:	participation	
1995 (n=80), and 1997 (n=74);				81.3	Simple analysis (p-values)	T	
N total=265					1993 1995 1997	Turnover of employees prevented	
Outcome Definition: serum		PFOA: 1			ALP 0.52 0.25 0.28	longitudinal assessment	
hepatic enzymes, cholesterol,	Mean Pl	FOA: 5.9	3 ppm		GGT 0.24 0.41 0.78	Changes in laboratory procedures	
lipoproteins, serum					AST 0.33 0.45 0.83	between 1995 and 1997 may have	
cholecystokinin (CCK, a					ALT 0.82 0.30 0.73	disguised lower exposure doses in earlier	
peptide hormone of the					T. Bilir 0.48 0.11 0.58	years.	
gastrointestinal system					D. Bilir 0.82 0.05 0.74	years.	
responsible for stimulating the						Male only	
digestion of fat and protein) -					Multivariate (β / p-value)	while only	
1997 only					1990 1993 1995 1997	Unable to consider other environmental	
1997 Only					ALT -15.8/ 0.89/ 0.81/ 2.77/	contaminants	
					0.0008 0.76 0.75 0.03	containments	
					Outcome: Serum lipids	Funding Sources 2M	
					Major Findings:	Funding Source: 3M	
					Simple analysis (p-values)		
					1993 1995 1997		
					Choles 0.45 0.48 0.08		
					HDL 0.32 0.70 0.40		
					LDL 0.84 0.96 0.11		
					Trigly 0.77 0.07 0.13		
					Multivariate (β / p-value)		
					1990 1993 1995 1997		
					HDL -1.61/ -0.14/ -0.10/ -0.19/		
					0.04 0.67 0.08 0.16		
					Outcome: CCK (1997 only)		
					Major Findings:		

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 409 of 551

Reference and Study Desi		posure M			Results	Comment
(Olsen, Burris et al. 2003)	Exposure				Stat Method: ANOVA, multivariable for	Major Limitations:
	Serum con	centration	S		cross-sectional analyses. Logistic regression	Voluntary participation, volunteer bias
Study Design:					for PFOS quartile distribution for those with	
Cross sectional and longitud	inal Population	n-Level Ex	xposure:		elevated liver function tests. And linear	Potential environmental confounders
					regression with parameters as continuous.	Only 41 employees completed all 3
Location: Antwerp, Belgium						testing dates (subgroup C)
and Decatur, AL, USA	Site	Mean	GeoMe		For longitudinal assessment, repeated	
		(range)	(95%C)	I)	measures incorporating the random subject's	Healthy worker effect
Population:	Antwerp	0.84	0.33 (0.	.27-	effect fitted to a mixed model. Covariates and	
Cross Sectional: male and	_	(0.01-	0.40)		confounders considered include years of	Cross sectional design of one section
female workers at PFC		7.04)			observation, the interaction term of PFOS and	precludes causal inference for that
manufacturing locations	Decatur	1.78	1.13 (0.	.99-	years of observation, age, BMI, cigarettes	section.
N=263 in Decatur		(0.04-	1.30)		smoked per day, alcohol drinks per day,	
N= 255 in Antwerp		12.70)	,		location, year at first entry, and baseline years	Low participation rate in first years of
Total $N = 421$ male, 97 fema	lle		1		worked.	study, participation rates in earlier years
Year: 2000	Longitudir	al (ppm):	means			were lower, participation rate and date
	Subgroup			2000	Outcome: Serum lipids	could be related to QC procedures
Longitudinal: male workers,		95			Major Findings:	
both locations n=174	А	1.36	-	1.72	Longitudinal (n=174 male employees):	Unclear mechanisms for
6 year time period	В	-		1.49	Cholesterol	PFOA/triglycerides
	C	1.41		1.77	β=0.032 (95% CI 0.013, 0.051)	
		1.11	1.70	1.//	Triglycerides	Unable to consider other environmental
Worker % involved in	Range: 1,2	20_1 900 r	ng/mI		β=0.094 (95% CI 0.045, 0.144)	contaminants
Cohort production	Kange. 1,2	20-1,9001	ig/iiiL			
activities					"There were no significant [PFOA]	
Total 73					coefficients associated with changes in HDL"	Funding Source: DuPont/3M
Antwerp						
Female 12					Outcome: Liver function	
Antwerp					Major Findings:	
Total 75					"There were no significant [PFOA]	
Decatur					coefficients associated with changes in	
Female 63					various liver function tests (data not shown)	
Decatur					adjusted for potential confounders".	
					Outcome: Thyroid hormones	
Outcome Definition:					Major Findings:	
hematological, lipid, hepatic					Results not provided, following description in	
thyroid, urinary parameters:	,				report: "Multivariate regression analyses of	
Cholesterol, HDL,					the thyroid hormones resulted in no	
Triglycerides, ALP, GGT,					significant associations with [PFOS or] PFOA	
AST, ALT, total bilirubin,					except for a positive association with the	
					natural log of T3 (β =0.016, p-value=0.01)	
TSH, T4, Free T4, T3					(F 1010) F (mile 0.01)	

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 410 of 551

Reference and Study Design	Exposure Measures	Results	Comment
(Olsen and Zobel 2007)	Exposure Assessment: Serum concentrations	Stat Method: Multiple and logistic regression and analysis of covariance. Covariates and confounders considered are age,	Major Limitations: Voluntary participation,
Study Design: Cross-sectional	Population-Level Exposure:	BMI, and alcohol usage, and serum triglycerides for analysis of hepatic enzymes.	50-65% participation,
 Location: Antwerp, Belgium; Decatur, AL; Cottage Grove,, MN Population: Voluntary participation of male employees (PFOA production), n=506, from three locations. Exclusion of those taking lipid-lowering medications Outcome Definition: lipid, hepatic, thyroid parameters: Cholesterol, HDL, Triglycerides, ALP, GGT, AST, ALT, total bilirubin, TSH, T4, Free T4, T3 	Population-Level Exposure:	Results shown for most adjusted models (age, BMI, alcohol), and all locations combined. Outcome: Serum lipids Major Findings: <u>All locations</u> Cholesterol: β=0.0076, p-value=0.20 LDL: β=0.0021, p-value=0.81 HDL: β=-0.0183, p-value=0.01 Triglycerides: β=0.0711, p-value=0.001 Findings from cholesterol and LDL were similar for the three locations. HDL associations were not found in any of the other locations. Triglycerides associations only for Antwerp location and Decatur (borderline nonsignificant). Decile analyses suggest decreasing HDL and increasing triglycerides with increasing PFOA. Outcome: Hepatic enzymes Major Findings: All locations ALP: $β=0.0093$, p-value=0.25 AST: $β=-0.0249$, p-value=0.06 GGT: $β=0.0326$, p-value=0.05 Total Bili: $β=-0.0325$, p-value=0.001 Direct Bili: not shown ALP significant in Decatur, AST borderline insignificant in Cottage Grove, ALT highly significant for unadjusted models for all locations and significant in Decatur, bilirubin significance appears to be driven by Decatur. Decile analyses suggest some	 S0-65% participation, Demographics of nonparticipants unknown. They talk about lots of residual confounding when putting locations together – use to explain away HDL effect Healthy worker effect Unable to consider other environmental contaminants Funding Source: unspec, authors employed by 3M Medical Department

C	ase 1.16-cv-00917-LEK-D.1S Document 162 Filed 04/06/20 Page 411 of 551
	ase 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 411 of 551 increase in ALT levels with increasing PFOA deciles. There is an inverse association (NS) for GGT in Cottage Grove while other findings suggest a positive association. Model results are not shown for direct bilirubin but decile analyses don't suggest a trend.
	Outcome: Thyroid hormones Major Findings: TSH: β=0.0360, p-value=0.08 T4: β=-0.0057, p-value=0.29 Free T4: β=-0.0117, p-value=0.01 T3: β=0.0105, p-value=0.05
	No significant findings for any of three locations for TSH, TT4 has no significance, FT4 association only overall but Antwerp and Decatur almost reaches significance, and T3 significant except for Cottage Grove. TT4 appears to decrease with increasing deciles of PFOA; no other consistent differences seem to be meaningful for the other thyroid hormones.

Reference and Study Design	Expo	sure Measu	ires	Results	Comment
(Olsen, Ehresman et al. 2012)	Exposure Assessment:			Stat Method: Matched-pair and linear	Major Limitations:
	Serum conce	entrations		regression analyses. Covariates and	Healthy worker effect,
Study Design:				confounders considered include sex, baseline	
Longitudinal	Population-	Level Expo	sure:	age, BMI, and alcohol consumption, and time	Exclusion of persons on lipid-lowering
	(ng/mL)			interval between assessments.	medications,
Location: Cottage Grove MN,		Baseline	Mean		
Decatur AL			Change	Stratified by magnitude of change	Time period of study,
	Mean 3M	881	-218.3		
Population: n=204, analyses	employee			Linear regression results shown for entire	Inclusion of largely managerial 3M
restricted to 98 to 179 workers	Mean	28.9	32.1	database, and adjusted models.	workers in sample
not on lipid lowering	contract				
medication	worker			Outcome: Serum lipids	Unable to consider other environmental
				Major Findings:	contaminants
In 2008-2010, 3M employees –	Mean time ir	nterval betw	veen	Cholesterol: β =-0.003, p-value=0.79	
general management tasks and	baseline and endpoint			Non-HDL: β =-0.006, p-value=0.54	
Non-3M employees (Contract	assessments:	1		HDL: β=0.004, p-value=0.35	Funding Source: unspec, authors
workers) – specific demolition	3M workers	= 306 days		Choles/HDL ratio: β=-0.00097, p-value=0.03	employed by 3M Medical Department
tasks, demolished a building	Contract wor	kers = 152	days		
where 3M produced PFOA.			5	Outcome: Liver enzymes	
				Major Findings:	
Outcome Definition: lipids and				ALP: β =-0.002, p-value=0.67	
hepatic clinical chemistries at				AST: β=-0.003, p-value=0.29	
baseline and end-of-project				ALT: β=-0.0097, p-value=0.05	
				T. Bilirubin: β =-0.000, p-value=0.60	

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 412 of 551

Reference and Study Design	Exposure Measures	Results	Comment
(Sakr, Kreckmann et al. 2007)	Exposure Assessment:	Stat Method: Linear regression. Covariates	Major Limitations:
	Serum concentrations	and confounders considered include age, BMI,	Cross sectional design precludes causal
Study Design:		gender, and alcohol consumption, parental	inference.
Cross-sectional	Population-Level Exposure:	history of heart attack, and use of lipid-	
	Mean = 0.428 ppm = 428 ppb	lowering medication.	55% voluntary participation rate
Location:	(µg/L)		
Washington Works production		Log transformation of outcomes as required.	Healthy worker effect
site, WV, U.S.A	Median = 0.189 ppm (IQR =		
	0.099-0.381)	Outcome: Serum lipids	Biological factors not taken into account
Population:		Major Findings:	
Active workers with potential	Range= 0.005-9.55 ppm	Cholesterol: β=4.04, p-value=0.002	Unable to consider other environmental
exposure to APFO, N=1025-		LDL: β=2.834, p-value=0.005	contaminants
excluding those on lipid-		HDL: β =-0.178, p-value=0.680	
lowering medications = 840		VLDL: β=0.045, p-value=0.031	
		Triglycerides: β=0.018, p-value=0.384	Funding Source: DuPont
Outcome Definition:			
Serum lipids and liver enzymes		*findings remained similar with exclusion for	
and other outcomes:		lipid-lowering medication use.	
Cholesterol, HDL, LDL,		Outcome: Liver enzymes	
triglyceride VLDL, AST, ALT<		Major Findings:	
GGT, CBC (complete blood		AST: β =0.012, p-value=0.317	
count), glucose, blood urea		ALT: β =0.023, p-value=0.124	
nitrogen, creatinine, iron, uric		GGT: β=0.048,p-value=0.016	
acid, electrolytes, creatinine		Bilirubin: β =0.008, p=value=0.590	
kinase, lactate dehydrogenase,			
ALP, protein, albumin, and c-		*findings remained similar with exclusion for	
reactive protein, serum PSA in		lipid-lowering medication use.	
men, and serum hormonal			
levels TSH, T4, T3 uptake,		Outcome: others	
estradiol, and testosterone.		Major Findings:	
		"Uric acid, iron, lactate dehydrogenase,	
		calcium, and potassium showed statistically	
		significant associations with serum PFOA in	
		linear regression models. In men estradiol	
		and testosterone were significantly	
		associated with serum PFOA: DuPont –	
		22458, 2007, internal report.	
		, ,	

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 413 of 551

Reference and Study Design	Exposure Measures	:16-CV-00917-LEK-DJS Document 10 Results	Comment
(Sakr, Leonard et al. 2007)	Exposure Assessment:	Stat Method: Linear mixed effect model	Major Limitations:
	Serum concentrations	including a random effect for subject and	Healthy worker effect
Study Design:		fixed effects for age, and other potential	
Longitudinal	Population-Level Exposure:	confounders. An interaction term gender X	Sample is only 16% of all workers who
	Overall mean: 1.13 ppm	age was included. Used a spatial Gaussian	had ever worked at plant, 10% of workers
Location:	Mean first measurement: 1.04 ppm	covariance structure. Covariates and	for over one year.
Washington Works site,	Mean last measurement: 1.16 ppm	confounders considered include age, age-	
WV, USA		squared, gender, BMI, and decade of hire	No info on lipid lowering medications or
		along with all interactions.	alcohol intake.
Population: n=454			
workers with two or more		Number of observations differed for each	Exposure and outcome were not measured
measures of PFOA unless		outcome analyzed.	on same date.
outcomes measures were			
taken in the same year		Outcome: Serum lipids	LDL calculated based on outdated
		Major Findings:	Friedewald formula (except for 2004
Outcome Definition:		Choles: β=1.06, (95% CI 0.24, 1.88)	data).
Serum lipids and liver		Trigly: β=0.79, (95% CI -5.99, 7.57)	
enzymes, calculation of		HDL: β=0.16, (95% CI -0.39, 0.71)	Other environmental contaminants,
LDL based on Friedewald		LDL: β=0.46, (95% Ci -0.87, 1.79)	including other PFCs, were not
formula			considered.
		Outcome: Liver enzymes	
		Major Findings:	Funding Source: DuPont
		T. Bilir: β=-0.008, (95% CI -0.0138, -	
		0.0021)	
		GGT: β=1.24, (95% CI -1.09, 3.57)	
		ALP: β=-0.21, (95% CI -0.60, 0.18)	
		AST: β=0.35, (95% CI 0.10, 0.60)	
		ALT: β=0.54, (95% CI -0.46, 1.54)	

Reference and Study Design	Exposure Measures	:16-CV-00917- 	Results	S Document 1(2 Filed 04/06/20 Page 414 of 551 Comment
(Shankar, Xiao et al. 2011)	Exposure Assessment:	Stat Method: Lin	near regres	ssion models with	Major Limitations:
	Plasma concentrations	continuous log-tra	ansformed	PFOA and quartile	Cross sectional design precludes causal
Study Design:				ic regression with	inference.
Cross-sectional	Population-Level Exposure:			and confounders	
	Median = 3.5 ppb (women), 4.6			der, race/ethnicity,	Unclear biological mechanism,
Location: USA	ppb (men)	education, smoking	ng, alcoho	l consumption,	
					Over-adjustment for mediators may have
Population:		Results presented	for most	adjusted models.	underestimated true association between
NHANES 1999-2000 & 2003-					PFOA and hyperuricemia
2006, > 20 years of age, n=3883		Outcome: Uric A			
		Major Findings:			Other environmental contaminants,
Outcome Definition:		Mean Change-			including other PFCs, were not
Hyperuricemia (serum uric acid		Q2 v. Q1: 0.14 (9			considered.
levels >6.8mg/dL in men and		Q3 v. Q1: 0.37 (9			
>6.0 mg/dL in women)		Q4 v. Q1: 0.44 (9		.32, 0.56)	Funding Source: American Heart
		P for Trend < 0.	0001		Association National Clinical Research
					Program award and a National Institutes
		0	formed: 0	.22 (95% CI 0.15,	of Health/National Institute of
		0.30)			Environmental Health Sciences grant
					(NIH/NIEHS 5R03ES018888–02)
		Outcome: Hyper			
		Major Findings:	1		
		Quartile	OR	95% CI	
		1	1	referent	
		2	1.14	0.78, 1.67	
		3	1.90	1.35, 2.69	
		4	1.97	1.44, 2.70	
		P for Trend <0.0	0001		
		PFOA log transf	formed O	R=1.43 (95% CI	
		1.16, 1.76)		× ×	

Reference and Study Design	Exposure Measures	;16-cv-00917-LEK-DJS Document 1 Results	$\begin{array}{c c} \hline & & \\ \hline & \\ \hline & \\ & \\ & \\ & \\ & \\ & \\$
(Shrestha, Bloom et al. 2015)	Exposure Assessment:	Stat Method: Multivariable linear regression	Major Limitations:
	Serum concentrations	analyses. Covariates and confounders	Cross sectional design precludes causal
Study Design:		considered include age, sex, years of	inference.
Cross sectional	Population-Level Exposure:	education, and serum PCBs	
			No information on serum albumin and
Location:	Median = 9.32 ng/mL	PFOA was log transformed. Effects were	TBG
Upper Hudson River		reported as the changed in thyroid hormone	
communities, NY		level per interquartile range increase in In-	Multiple statistical analyses increase
D L (* 011 11; 55.74		PFOA.	probability of chance findings,
Population: Older adults 55-74		T 1 1 4 1 4 1	C 11
years of age who lived in three		Looked at interactions with other	Small n
communities adjacent to the		environmental contaminants.	
Hudson River for 25 years or			Unable to analyze joint effects of age and
more, without clinically		Outcome: Thyroid hormones	sex,
diagnosed thyroid disease and		Major Findings:	
did not work in PCB related job		TSH: β=0.102 (95% -0.023, 0.281)	Used archived sera to estimate thyroid
for a year or more, and other		FT4: β=0.016 (95% CI -0.036, 0.069)	biomarkers and PFOA, raising possibility
health conditions, n=87		T4: β=0.380 (95% CI -0.070, 0.830)	for sample degradation over time (not
		T3: β=3.032 (95% CI -1.725, 7.789)	likely a concern).
Outcome Definition: Thyroid			
function as measured by serum		Statistical interactions between age and PFOA	Funding Source: grants provided by the
thyrotropin, free thyroxine, total		for effect of FT4 and T4 ($p < 0.05$).	National Institute on Aging (Grant #
thyroxine, and total			R15/AG0333700A1) and the Agency for
triiodothyronine		The joint effect of age and $PFOA = 7\%$	Toxic Substances and Disease Registry
		increase in T4 and 3% for FT4.	(Grant # H75/ATH298312)

Reference and Study Design	Exposure Measures	Results	Comment
(Starling, Engel et al. 2014)	Exposure Assessment:	Stat Method: Weighted linear regression + multiple	Major Limitations:
	Plasma concentrations	PFAS model, spearman rank-order correlations.	Cross sectional design precludes causal
Study Design:	taken at mid-pregnancy	Covariates and confounders considered include	inference.
Cross-sectional		maternal age, pre=pregnancy BMI, nulliparious or most	Use of nonfasting plasma lipid
	Population-Level	recent inter-pregnancy interval, duration of	measurements,
Location: Norway	Exposure:	breastfeeding most recent child, maternal years of	
		education, current smoking at mid-pregnancy,	No measurement of other environmental
Population:	Median: 2.25 ng/mL	gestational weeks at blood draw, and amount of oily	contaminants,
Pregnant women enrolled in the		fish consumed daily, and weight gain, and albumin.	
Norwegian Mother and Child			Funding Source: in part by the
Cohort Study 2003-04 (n= 891)		PFOA natural log transformed and categorized into	Intramural Research Program of the NIH,
		quartiles. Results reported for IQR change increase.	National Institute of Environmental
		Outcome log transformed as needed.	Health Sciences. A.P. Starling was

Outcome Definition:	Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 416 of 55 Outcome: Serum lipids supported by an extramural award (1-F30-
Serum measurements of lipids –	Outcome: Serum nputsSupported by an extramular award (1-F30-Major Findings:ES022126-01) from the National Institute
measured from same exposure	of Environmental Health Sciences.
assessment sample.	Total cholesterol
•	$\overline{\text{Q2 v. Q1 }\beta}$ =1.49 (95% CI -6.49, 9.48)
	Q3 v. Q1 β=3.54 (95% CI -4.51, 11.59)
	Q4 v. Q1 β=3.90 (95% CI -5.00, 12.80)
	Ln-unit β =2.58 (95% CI -4.32, 9.47)
	IQR β=1.55 (95% CI -2.60, 5.69)
	Multi-pollutant model brought the already non- significant relationship even closer to the null.
	HDL
	Q2 v. Q1 β=0.22 (95% CI -2.38, 2.83)
	Q3 v. Q1 β =2.31 (95% CI -0.59, 5.20)
	Q4 v. Q1 β =3.42 (95% CI 0.56, 6.28)
	Ln-unit β =2.13 (95% CI -0.26, 4.51) IQR β =1.28 (95% CI -0.15, 2.71)
	IQK p=1.28 (95% CI -0.15, 2.71)
	LDL
	$\overline{\text{Q2 v}}$. Q1 β =0.94 (95% CI -6.08, 7.96)
	Q3 v. Q1 β=4.16 (95% CI -3.19, 11.50)
	Q4 v. Q1 β=3.35 (95% CI -4.35, 11.06)
	Ln-unit β =2.25 (95% CI -3.97, 8.48)
	IQR β=1.36 (95% CI -2.38. 5.10)
	Ln-triglycerides
	$\overline{\text{Q2 v. Q1 }\beta=0.03}$ (95% CI -0.04, 0.11)
	Q3 v. Q1 β=0.01 (95% CI -0.08, 0.09)
	Q4 v. Q1 β=-0.04 (95% CI -0.12, 0.04)
	Ln-unit β =0.00 (95% CI -0.07, 0.06)
	IQR β=0.00 (95% CI -0.04, 0.04)

Reference and Study Design	Exposure Measures	Case 1:16-cv-00917-LEK-D Resu	ts	Filed 04/06/20 Page 417 of Comment Major Limitations
(Steenland, Tinker et al. 2009)	Exposure Assessment:		Stat Method: Linear regression (continuous and	
	Serum PFOA			Cross-sectional design precludes
Study Design:		cholesterol" with PFOA in quar		causal inference.
Cross-sectional	Population-Level	confounders considered include		
	Exposure:	education, smoking, regular exe		Lack of a measure of cumulative
Location:	Mean: 80 ng/mL	consumption, and fasting and P	FOS.	exposure
OH and WV, USA	Median: 27 ng/mL			
		Outcomes were natural log tran	sformed.	Did not control for other
Population:				environmental contaminants (did
Residents 18 years of age and		Outcome: Serum lipids		control for PFOS).
older who drank water		Major Findings:		
contaminated by nearby plant,		A largely monotonic increase	in log cholesterol with	Funding Source: C8 Class Action
for at least one year, $n = 46,294$		each decile of PFOA (p<0.000	1). Tests for linear trend	Settlement between DuPont and
		were highly significant.		Plaintiffs
Outcome Definition:				
Serum lipids; High cholesterol		Trends for LDL cholesterol, n	on-HDL cholesterol, and	
(>240 mg/dL), serum lipids		the ratio of total cholesterol to	HDL were similar to the	
		nearly monotonic trends for t	otal cholesterol. Therefore	
		was a positive trend with trig	ycerides but little	
		association with HDL.	·	
		The results for unlogged PFO	A are test for linear trend	
		for the categorical models; all		
		positive (total cholesterol, LD		
		ratio, non-HDL-C) and signifi		
		HDL.		
		Outcome: "High cholesterol"		
		Major Findings:		
		Quartile OR	95% CI	
			Referent	·
		2 1.21	1.12,1.31	
		3 1.33	1.12,1.31	
		4 1.4	1.23,1.43	
		P for trend <0.0001	1.20,1.30	

Reference and Study Design	Exposure Measures	<u>;16-cv-00917-LEK-DJS Document 16</u> Results	52 Filed 04/06/20 Page 418 of 55 Comment
(Steenland, Tinker et al. 2010)	Exposure Assessment:	Stat Method: Linear regression, some	Major Limitations:
	Serum concentrations	analyses log transformed PFOA, others treated	Cross sectional design precludes causal
			inference.
Cross-sectional	Population-Level Exposure:	hyperuricemia, PFOA in quintiles.	
Study Design: Cross-sectional Location: OH and WV, USA Population: Residents 20 years of age and older who drank water contaminated by nearby plant, for at least one year, n= 54,591 Outcome Definition: Uric acid; hyperuricemia (serum uric acid > 6 mg/dL for women and >6.8 mg/dL for men.	Population-Level Exposure: (ng/mL) Mean: 86.4 SD: 261.3 IQR: 13.5 – 71.4 Median: 27.9	 as categorical. Logistic regression for hyperuricemia, PFOA in quintiles. Covariates and confounders considered include age, sex, BMI, education, smoking, alcohol consumption, serum creatinine (log), and control for PFOS. Sensitivity analysis – restricting elevated serum creantinine (indicator of kidney disease) Outcome: Uric acid Major findings: Test for linear trend was highly significant (p<0.001). A close to monotonic increase in uric acid with an increase in PFOA. There is an increase in uric acid of 0.2-0.3 from the lowest to the heist decile for PFOA. Outcome: Hyperuricemia 	inference. Mechanism unknown – may have unknown confounder, No data on blood pressure for population, Funding Source: C8 Class Action Settlement between DuPont and Plaintiffs
		Major Findings:	
		Quintile OR 95% CI	
		1 1 Referent	
		2 1.33 1.24-1.43	
		3 1.35 1.26-1.45	
		4 1.47 1.37-1.58	
		5 1.47 1.37-1.58	
		P for Trend <0.0001 More consistent linear relationship for women than for men.	

Reference and Study Design	Exposure Measures	-16-cv-00917-LEK-DJS Document 16	Comment
(Steenland, Zhao et al. 2015)	Exposure Assessment:	Stat Method: Cox regression models with age	Major Limitations:
	Historical estimates of serum	as the time scale and time-varying exposure	Small n compared to whole C8 cohort
Study Design:	PFOA levels based on job history	and covariates. Additionally performed	under representation of hard to trace
Retrospective occupational	+ nonoccupational exposures \rightarrow	parametric tests for trend, categorical trend	decedents.
cohort	lifetime serum cumulative dose.	tests.	
			Few low-exposed referents.
Location: Washington Works	Investigators used a job exposure	Looked at lag and 10-year lag.	-
plant, DuPont – WV, USA	matrix validated using worker		Largely confined to men.
, ,	serum samples from 1979-2004.	Coronary heart disease, stroke, chronic	
Population:	The second secon	obstructive pulmonary disease, autoimmune	Healthy worker effect.
Workers or next of kin in 2008-	Population-Level Exposure:	disease, type 2 diabetes, liver disease (hepatitis	
20011, n=3713.	In 2005, median measured serum	and non-hepatitis), Parkinson's disease,	Limited sample size for some outcomes.
20011, 11 3713.	level was 113 ng/mL (n=1881)	Alzheimer's disease, thyroid disease, asthma	Entitled sumple size for some outcomes.
Original DuPont Cohort		with reported current medication, and cancer.	62% of target population.
included 6026 workers with at		And three self-reported outcomes:	
			Failure to obtain medical records for 17%
least 1 day of work between		osteoarthritis, hypertension, and high	
1948 and 2002.		cholesterol.	of those self-reporting disease.
			0 111
Outcome Definition:		All statistically significantly results are listed	Survival bias
Self-reported disease –		below (p < 0.05). Those not listed mean that	
validated by medical record		outcomes were not significant.	Truncated residential histories at 1970 -
abstraction: all but three.			underestimated exposures for some
		Outcome:	participants.
		Major Findings:	
		Ulcerative colitis – positive trend using the	Funding Source: C8 Class Action
		log cumulative exposure for no lag and a 10-	Settlement between DuPont and Plaintiffs
		year lag. For 10-year the highest exposure	
		category for had a RR relative to the first	
		quartile of 6.57 ((%CI 1.47, 29.40).	
		No other disease showed a statistically	
		significant positive trend using the log	
		transform trend test.	
		Rheumatoid arthritis showed a significant	
		positive trend using the trend test based on	
		the quartile midpoints (p=0.04). The highest	
		exposure category (no lag) had a RR	
		relative to the first quartile of 4.45 (95% CI	
		0.99, 19.9) – p=0.05.	
		Type II disheter (10 year las) had a	
		Type II diabetes (10 year lag) had a	
		significant trend using the categorical trend	
		test.	

Case 1;16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 420 of 551

		Bladder cancer showed a negative trend using log cumulative dose (for the analysis with no lag) and the categorical trend test (for the analysis with a 10-year lag). Negative trend for asthma with medication (no lag) in the categorical trend test		
--	--	---	--	--

Reference and Study Design	Exposure Measures	Results	Comment
(Stein et al., 2016)	Exposure Assessment: PFOA	Stat Method:	Major Limitations:
	serum concentrations	Adjusted, survey-weighted regression models.	
Study Design:		Covariates and confounders considered include	Cross-sectional design limits causality
Cross-sectional	Population-Level Exposure:	age, sex, and race/ethnicity, serum cotinine, BMI, and others.	interpretation.
Location:	Geometric Mean= 4.13 ng/mL		Receipt and/or timing of measles-mumps-
U.S. general population	(cycles 1999-2000 and 2003-2005)	Linear regression was used for the vaccine study with PFC treated continuously and as	rubella vaccination are not available.
Population:	Geometric Mean=3.59 ng/mL	quartiles. Exposures and outcomes were	Other environmental contaminants,
NHANES (1999-2000 and	(cycles 2005-2006)	natural log transformed. All models were run	including other PFCs not controlled for.
2003-2005), n=1,191 and		for full population and run again restricted to	
(2005-2006), n=640;		the seropositive population. Logistic regression	
adolescents aged 12 to 19 years.		for estimates for the allergy study. Odds ratios	
		based on an IQR shift and for quartiles of	
Outcome Definition:		PFOA and linear regression used to estimates	
Measles, mumps, and rubella		allergen specific IgE antibodies and IgE	
antibody concentrations (1999-		antibody level by quartiles.	
2000 and 2003-2004 cycles) and allergic conditions and		Effect estimates shown for doubling of PFC	
allergic sensitization (2005-		concentration.	
2006 cycles).		concentration.	
		Outcome: Antibody titers	
Allergic sensitization defined as		Major Findings:	
sIgE ≥0.35 kU/L		% Change	
		All	
		Measles=-0.1 (95% CI -13.8, 15.6)	
		Mumps=-6.0 (95% CI -12.4, 0.9)	
		Rubella=-2.5 (95% CI -9.1, 5.3)	
		Seropositive	
		Measles=-3.4 (95% CI - 16.7, 11.9)	
		Mumps= -6.6 (95% CI -11.7, -1.5)	
		Rubella=-8.9 (95% CI -14.6, -2.9)	

Case 1;16-cv-00917-LEK-DJS	Document 162	Eiled 04/06/20	Page /21 of 551

Ouse I.		1 uge 421 01 301
	Outcome: Allergic conditions	
	Major Findings:	
	Asthma OR=1.28 (95% CI 0.81, 2.04)	
	Wheeze OR=0.94 (95% CI 0.51, 1.73)	
	Allergy OR=1.12 (95% CI 0.85, 1.47)	
	Rhinitis OR=1.35 (95% CI 1.10, 1.66)	
	Outcomer Allengie geneitization	
	Outcome: Allergic sensitization	
	Major Findings:	
	Any, Plants, Dust mites, Pets,	
	Cockroach/shrimp, Rodents, Mold, Food:	
	No findings were statistically significant,	
	confidence intervals appeared wide and	
	findings were both positive or negative	
	depending on the type of allergen.	
	-	
	Outcome: Serum IgE Antibody Titer	
	Major Findings:	
	%Change=10.5 (95% CI 0.17, 22)	

-

Reference and Study Design	Exposure Measures	Results	Comment
(Wang, Rogan et al. 2014)	Exposure Assessment:	Stat Method: Linear regression, covariates	Major Limitations:
	Maternal serum concentrations.	and confounders considered included maternal	Only one sample from mother and
Study Design:		age, maternal education, previous live births,	neonate was obtained, calls causal
Cross-sectional and prospective		family income, maternal pregnancy BMI, and	inference into question,
birth cohort.	Population-Level Exposure:	maternal fish consumption during pregnancy.	
			Measurement of cord blood rather than
Location:	Maternal Median = 2.39 ng/mL	Estimates calculated with and without log-	infant blood may have been more
Central Taiwan		transformation of thyroid hormones.	informative, less affected by perturbations
			of birth,
Population: Recruited from			
Taiwan Maternal and Infant		Outcome: Thyroid hormones	Sample size not sufficient for evaluation
Cohort Study (longitudinal birth		Major Findings:	of clinical outcomes,
cohort study of pregnant		Maternal PFOA and maternal:	
women and children); n=285		FT4: β=-0.003 (95% -0.012, 0.005)	Did not have measures of all possible
pregnant women in 3 rd		TT4: β=0.011 (95% CI -0.108, 0.130)	factors that affect thyroid hormones (i.e.,
trimester, n=116 neonates.		TT3: β=-0.000 (95% CI -0.002, 0.009)	iodine)
		TSH: β=0.011 (95% CI -0.057, 0.078)	
Outcome Definition: Maternal			Some aspects of the study were cross
(@ 3^{rd} trimester) and cord			sectional, therefore precluding causal
serum neonatal thyroid			inference.

	Case 1:16-cv-00917-LEK-DJS Document 2	62 Filed 04/06/20 Page 422 of 551
hormone status (TSH, FT4,	Maternal PFOA and cord:	
TT4, T3)	FT4: β=-0.029 (95% -0.062, 0.004)	Funding Source: National Health
	TT4: β=0.128 (95% CI -0.094, 0.350)	Research Institutes, Taiwan (grants EO-
	TT3: β =-0.001 (95% CI -0.004, 0.001)	101-PP-05,EH-102-SP-02, EO-102-PP-
	TSH: β=-0.498 (95% CI -1.464, 0.468)	05), the National Science Council, Taiwan
		(grant NSC101-
		2325-B-400-008), and in part by the
		National Institute of Environmental
		Health Sciences, National Institutes of
		Health (USA).

Reference and Study Design	Exposure Measures	Results	Comment
(Wang, Zhang et al. 2012)	Exposure Assessment:	Stat Method: Described correlations using Spearman non-	Major Limitations:
	Serum PFOA	parametric correlation coefficients. Also linear regression	Cross sectional design precludes
Study Design:		with control for age and BMI, smoking and drinking status.	causal inference.
Cross-sectional	Population-Level Exposure:		
		Also did a sensitivity analysis excluding older individuals	Healthy worker effect
Location: Jiangsu High-Tech	Median: 284 ng/mL	(residents only) and combined younger (resident and	
Fluorine Chemical Industrial	(residents)	workers). All outcomes and PFOA were natural log	Small n.
Zone, Changshu City, Jiangsu	1636 ng/mL (occupational	transformed.	
Province, CN	cohort)		Volunteer bias.
	,	Outcome: Serum lipids and liver enzymes	
Population: Employees at		Major findings:	Age discrepancy in miRNA
plant for greater than 2 years,		Residents	cohort.
n=55 (male) and nearby		Cholesterol: β =-0.00, p-value=0.85	
residents for at least 5 years,		HDL: β=0.02, p-value=0.39	Self-reported weight and height,
n=132.		LDL: β=-0.00, p-value=0.97	
		HDL/LDL: $\beta = 0.02$, p-value=0.57	No info on socioeconomic data.
Outcome Definition: serum		TG: β =0.02, p-value=0.73	
lipid biomarkers and nine		ALT: β =-0.10, p-value=0.05	No known covariates for miRNA
circulating miRNAs		AST: β =-0.04, p-value=0.22	
(endogenous, small			No known exact pathological
noncoding RNAs. They play		Workers	meanings of altered serum
an important role in		Cholesterol: β=0.02, p-value=0.36	miRNAs
regulating gene expression by		HDL: β=-0.07, p-value=0.01	
base-pairing to		LDL: β=0.03, p-value=0.43	Funding Source: National
complementary sites on target		HDL/LDL: β =-0.09, p-value=0.01	Natural Science Foundation of
mRNAs to block translation		TG: β =0.02, p-value=0.73	China
or trigger the degradation of		ALT: β=0.04, p-value=0.38	
target mRNAs.		AST: β =-0.12, p-value=0.02	
6			

Case 1:16-cy-00917-LEK-DJS_ Document 162 Filed 04/06/20 Page 423 of 551

Outcome: Cir Major Findir		26b and miR	-199a-3p		neu 04/00/20	- uge -
miRNA	Residents	Workers	Fold change	Р		
miR-26b	4.05	3.11	1.9	0.03		
miR-199a- 3p	8.98	6.9	3.47	0.02		
Other miRs w	ere not statisti	cally signific	ant.			

Reference and Study Design	Exposure Measures	Results	Comment
(Webster, Venners et al. 2014)	Exposure Assessment:	Stat Method:	Major Limitations:
	Serum concentrations	Mixed effects linear regression models with random	Small n, especially in high TPOAb group,
		intercept for individual, Confounders and covariates	
Study Design:	Population-Level	considered include maternal age, ethnicity,	Sample unrepresentative of background
Prospective cohort study	Exposure:	education, household income, current stress levels,	population of Vancouver,
		smoking, environmental tobacco smoke exposure,	
Location:	Median = 1.7 ng/mL	drug use, alcohol use, and use of iodized salt and	Use of questionnaires to determine iodine
Vancouver, Canada		prenatal vitamins containing iodine.	sufficiency and exposure to environmental
			tobacco smoke,
Population:		PFCs and hormones not log transformed.	
Euthyroid pregnant women in			No control for serum binding protein
early 2 nd trimester, enrolled in		Sensitivity analysis stratified by high v. normal	levels or urinary/blood selenium,
the Chemicals, Health, and		TPOAb (thyroid peroxidase antibody levels, as	
Pregnancy study, ≥ 19 years of		marker of autoimmune hypothyroidism).	Sightly outdated radioimmunoassay
age, n=152			method,
		Estimates presented for most adjusted models and an	
Outcome Definition:		IQR increase.	Reverse causation may be a factor
Repeated measures of			
maternal thyroid hormones at		Outcome: FT4	Note:
15 and 18 weeks gestation.		Major Findings:	Associations found early in critical
		Normal TPOAb: β=-0.03 (95% CI -0.3, 0.2)	gestational period
		High TPOAb: β=-0.4 (95% CI -1, 0.5)	
			Funding Source: Health Canada, BC
		Outcome: TSH	Medical Services Foundation, BC
		Major Findings:	Environmental and Occupational Health
		Normal TPOAb: β=0.07 (95% CI -0.1, 0.2)	Research Network, UBC Centre for
		High TPOAb: β=0.7 (95% CI 0.09, 1)	Health and Environment Research,
			Natural Sciences and Engineering
		Outcome: TT4	Research Council, Michael Smith
		Major Findings:	Foundation for Health Research, UBC
		No associations found, estimates presented in	Bridge Program, Interdisciplinary
		supplemental material.	Women's Reproductive Health Program

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 424 of 551

Reference and Study Design	Exposure Measures	Results	Comment		
(Wen, Lin et al. 2013)	Exposure Assessment:	Stat Method: Linear and logistic regression,	Major Limitations:		
	Serum concentrations	covariates and confounders considered	Cross sectional design precludes causal		
Study Design:		included age, gender, race, alcohol	inference,		
Cross-sectional	Population-Level Exposure:	consumption, smoking, and urinary iodine.			
	Geometric mean = 4.15 ng/mL	Modeled separately for men and women.	Common physiology could confound,		
Location:	_				
General U.S. population		Outcomes were log transformed if improved model fit, PFOA was log transformed.	No accounting for thyroid medications,		
Population:			Data set limited to single time point		
NHANES 2007-2008, and		PFCS were modeled separately and in	measures (thyroid hormone levels vary in		
2009-2010, adults > 20 years of		composite model. Most adjusted (weighted)	an individual).		
age, n=1.180		results shown below.	East 1 and Commence and the set		
		O (T1 11	Funding Source: unspec, authors		
Outcome Definition:		Outcome: Thyroid hormones	employed by En Chu Kong Hospital (Wer		
Serum concentrations of thyroid		Major Findings:	LL, Lin CY), National Taiwan University		
measures (TT3, TT4, FT4,		$\frac{TT4}{M} = 0.000 (050) (CL = 0.200) (0.200)$	Hospital (Lin LY, Su TC), National		
thyroglobulin), subclinical		Men: β =0.000 (95% CI -0.280, 0.280)	Taiwan University of Public Health (Cher		
hyperthyroidism was defined as		Women: β=0.82 (95 % CI -0.369, 0.532)	PC) and Fu Jen Catholic University (Lin		
TSH < 0.24 mIU/L and			CY).		
subclinical hypothyroidism		Ln-FT4			
defined as TSH > 5.43 mIU/L		Men: β=-0.010 (95% CI -0.041, 0.022)			
		Women: β=-0.004 (95 % CI -0.047, 0.039)			
		<u>TT3</u>			
		Men: β=0.775 (95% CI -3.048, 4.598)			
		Women: β=6.628 (95 % CI 0.545, 12.712)			
		ln-FT3			
		$\frac{\text{M} + 15}{\text{Men}; \beta = 0.013 (95\% \text{ CI} - 0.004, 0.031)}$			
		Women: β =0.016 (95 % CI -0.018, 0.051)			
		women: p 0.010 (55 % C1 0.010, 0.051)			
		Ln-TSH			
		Men: β =0.004 (95% CI -0.081, 0.090)			
		Women: β=-0.030 (95 % CI -0.215, 0.154)			
		<u>Ln-thyroglobulin</u>			
		Men: $β$ =-0.096 (95% CI -0.258, 0.066)			
		Women: β=0.095 (95 % CI -0.111, 0.302)			
		· · · · · · · · · · · · · · · · · · ·			

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 425 of Outcome: Subclinical thyroid diseases	5 51
Major Findings:	
<u>Hypothyroidism</u> Men: OR=1.29 (95% CI 0.40, 4.10)	
Women: OR=7.42 (95% CI 1.14, 48.12)	
Hyperthyroidism	
Men: OR=0.38 (95% CI 0.16, 0.95)	
Women: OR=0.99 (95% CI 0.13, 7.59)	

Reference and Study Design	Exposure Measures	Results	Comment
(Winquist and Steenland 2014)	Exposure Assessment:	Stat Method: Cox proportional hazard	Major Limitations:
	Yearly estimated serum PFOA	models (survival analysis), stratified by birth	Healthy worker effect for worker cohort
Study Design:	concentrations starting at birth of	year. Covariates and confounders considered	
Retrospective cohort,	1952, whichever came later.	include sex, race, education, smoking and	Population in study area changed over time,
prospective analyses in 2005-	Estimates of yearly air and	alcohol use.	no way to identify and include all residents
2006.	drinking water PFOA exposure		over exposure period.
	using an environmental fate and	Primary models considered patterns of	
Location:	transport model were developed.	hazard ratios across quintiles of each	Potential bias if exposure and thyroid
WV and OH, USA	Additional information for	exposure metric. In tests for trend, natural	conditions were correlated with migration
	community estimates includes	log-transformed PFOA concentration	or participation in original C8 study,
Population:	residential history and drinking	estimates were used.	
Community member cohort	water consumption rates and		Possible changes in population
(recruited from C8 Health	sources. For workers an	Retrospective analyses used deciles to	susceptibility over time,
Project participants (>20 years	occupational exposure model was	explore dose-response curve shape.	
of age)), $n = 28,541$ and plant	used, after work, they were		Potential error in exposure estimates (would
workers in mid-Ohio River	decayed until they met the	Outcome: Functional thyroid disease	bias towards null),
Valleys (recruited from a	community exposure models.	(n=2,323)	
previous occupational mortality		Major Findings:	Exclusion of people who reported thyroid
study cohort of people who	Population-Level Exposure:	Primary retrospective analysis:	disease with no type specified,
worked at the chemical plant			
during 1948-2002), n = 3,713,	Median $2005-06 = 26.1 \text{ ng/mL}$	Quintile HR	Potential impact of differential access to
n=32,254 total	Median concentrations highest in	1 1	care (w/r/t thyroid diagnoses)
	late 1990s-early 2000s	2 1.21	
Outcome Definition:		3 1.12	Funding Source: C8 Class Action
Self-reported health		4 1.27	Settlement between DuPont and Plaintiffs
professional diagnosis-		5 1.28	
Questionnaire of demographics,		HR log μ g/ml*yr = 1.03, p-value=0.09	
health-related behaviors, and			
lifetime personal medical		The trend was more pronounced among	
history, completed 2008-2010		women (HR per log µg/ml*yr = 1.04, p-	
and 2010-2011.		value=0.03), but was absent among men (HR	
		per log μ g/ml*yr = 1.01, p-value=0.85).	

Case 1;16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 426 of 551

	Case 1;16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 426 of 551
Medical records were reviewed to confirm diagnosis.	Yearly exposure metric:
to confirm diagnosis. Functional thyroid disease defined as a report of goiter, Graves' disease, hyperthyroidism, Hashimoto's disease, hypothyroidism, thyroiditis not otherwise specified, or a thyroid function problem of unknown type. Hyperthyroidism defined as report of hyperthyroidism or Graves' disease. Hypothyroidism defined as report of hypothyroidism or Hashimoto's disease.	Yearly exposure metric: $Quintile HR 1 1 2 1.23 3 1.24 4 1.10 5 1.28 1$
	function thyroid disease with increasing cumulative exposure among men (p- value=0.09). Outcome: Hypothyroidism (n=1,655) Major Findings: A trend for increasing hazards with increasing exposure was suggested for both hypothyroidism in relation to cumulative exposure (although log-linear trend p-values
	were > 0.05). For men considering the cumulative and yearly exposure metrics, and measured PFOA - HR per log μ g/ml*yr = 1.24 P=0.021. And for prospective analyses.
	Outcome: Hyperthyroidism (n=456) Major Findings: A trend for increasing hazards with increasing exposure was suggested for both. Log-linear trend p-value < 0.05, overall and for women.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 427 of 551

Reference and Study Design	Exposure Measures	Results	Comment
(Winquist and Steenland 2014)	Exposure Assessment:	Stat Method: Cox proportional hazard models	Major Limitations:
	Yearly estimated serum	(survival analysis), stratified by birth year.	Survivor bias,
Study Design:	PFOA concentrations	Covariates and confounders considered include	
Longitudinal	starting at birth of 1952,	sex, race, education, smoking and alcohol use,	Hard to find decedents proxies (workers),
	whichever came later.	BMI, self-reported diabetes type 2, family	
Location:	Estimates of yearly air and	history of coronary disease.	Healthy worker effect (workers)
WV and OH, USA	drinking water PFOA		
	exposure using an	Retrospective analyses started at the late of age	Self-report bias (towards null)
Population:	environmental fate and	20 years or the age in 1952. Prospective	
Community member cohort (recruited	transport model were	analyses started at the participant's age 1 year	Funding Source: C8 Class Action
from C8 Health Project participants	developed. Additional	after enrollment in the C8 Health Project	Settlement between DuPont and Plaintiffs
(>20 years of age)), n = 28,541and	information for	(2005-2006).	
plant workers in mid-Ohio River	community estimates		
Valleys (recruited from a previous	includes residential history	Primary exposure metric was a measure of	
occupational mortality study cohort of	and drinking water	cumulative PFOA (sum of all yearly serum	
people who worked at the chemical	consumption rates and	concentration estimates). To look at short term	
plant during 1948-2002), n = 3,713,	sources. For workers an	effects, secondary analyses looked at yearly	
n=32,254 total	occupational exposure	concentrations of PFOA estimates. Primary	
	model was used, after	analyses considered the exposure by quintiles.	
Outcome Definition:	work, they were decayed	Log of cumulative or yearly concentrations	
Self-reported health professional	until they met the	was used for a test of trend.	
diagnosis- 2008-2011 Questionnaire	community exposure		
completion for high blood pressure,	models.	All analyses performed overall and by age	
high cholesterol, or heart disease.		strata. Sensitivity analysis examining only	
		community cohort.	
Questions include diagnosis of	Population-Level		
hypertension (not during pregnancy),	Exposure:	Outcome: Hypertension	
hypercholesterolemia, coronary artery	Median measured in 2005-	Major Findings:	
disease	06: 26.1 ng/mL (24.2	Retrospective analyses of both cumulative and	
	community, 112.7 worker)	yearly exposure metrics were similar and did	
		no show clear evidence of association.	
		Cumulative-	
		Quintile HR 95% CI	
		2 1.10 1.02, 1.19	
		3 1.10 1.02, 1.18	
		4 1.05 0.97, 1.12	
		5 0.98 0.91, 1.06	
		Age- and sex- stratified analyses found some	
		evidence of hypertension with increasing	
		exposure among females, 20 to 39 years and	

Case 1	;16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 428 of 551
	:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 428 of 551 males 40 to 59 but trends were not monotonic or statistically significant. Prospective analysis also did not show clear evidence.
	Outcome: Incident hypercholesterolemia with medication
	Major Findings: Retrospective analyses showed elevated hazard.
	Cumulative- Quintile HR 95% CI 2 1.24 1.15, 1.33 3 1.17 1.09, 1.26 4 1.19 1.11, 1.27 5 1.19 1.11, 1.28 Test for trend p=0.005
	Yearly exposure showed the same effect as cumulative (Test for trend p<0.001).
	The increased hazard was most pronounced among men 40-59 years of age (Test for trend p<0.001).
	Prospective analyses showed no evidence of a positive association.
	Outcome: Coronary artery disease Major Findings: Retrospective analyses showed no clear association.
	Quintile HR 95% CI 2 1.26 1.10, 1.45 3 1.17 1.02, 1.35 4 0.99 0.86, 1.14 5 1.07 0.93, 1.23
	Among males 20 to 39 years of age, there appeared to be higher hazards, but log linear test for trend not significant (P for trend = 0.64)
	Prospective analyses also showed no evidence of association.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 429 of 551

Reference and Study Design	Exposure Measures	Results			Comment	
(Yamaguchi, Arisawa et al. 2013)	Exposure Assessment: Serum concentrations	Stat Method: Spearman rank correlations, covariates and			Major Limitations: Cross sectional design precludes causal	
Study Design:	Serum concentrations	confounders				inference.
Cross-sectional	Population-Level	age, sex, BM				
	Exposure:	and intake of				Subjects engaged in fishing and farming
Location:	Median: 2.1 ng/mL	und mund of	urconon	e eeveruge.		may have been oversampled compared
Japan (15 prefectures)	IQR: 1.5-3.3 ng/mL	Most adjusted results presented when available.			with gen pop	
Population:						
Participants in larger "Survey on the		Outcome: Liver enzymes and fatty acids			Funding Source: National Natural	
Accumulations of Dioxins and Other		Major Findi	ings:		-	Science Foundation of China
Chemical Compounds in Humans"			_			
project, ages 16-76, resided in area for		Outcome	r	Р		
at least 10 years with little relocation,		DHA	0.12	0.003		
n=608		EPA	0.20	<0.0001		
		γ-GTP	0.06	0.12		
Outcome Definition:		(GGT)				
Serum fatty acids and hepatic enzymes:		GOT 0.13 0.002				
γ -GTP (glutamyl transpeptidase), GOT		(AST)				
(glutamic-oxaloacetic transaminase),		GPT	0.09	0.04		
GPT (glutamic-pyruvic transaminase),		(ALT)				
EPA (eicosapentaenoic acid), DHA						
(docosahexaenoic acid)						

	Case	1:16-cv-00917	<u>z-fék-</u>	DJS-	Docun	nent 16	2 Filed 04/06/20 Page 430 of 55 Comment
Reference and Study Design	•						
(Zeng, Qian et al. 2015)	Exposure Assessment:	Stat Method: Linear regression models with continuous log transformed PFOA and as				Major Limitations:	
	Serum concentrations				A and as	Cross sectional design precludes causal	
Study Design:		quartiles. Covariates and confounders considered				inference,	
Cross-sectional	Population-Level Exposure:	include age, gender, BMI, regular exercise,					
	ng/mL	parental education, and environmental tobacco			ental tob	May be unmeasured confounders	
Location:	Mean (boys,) = $1.1 (+/- 1.4)$	smoke.				(dietary sources, etc) or pharmokinetics.	
Taipei, Taiwan	Mean (girls)=0.92 (+/- 0.79)						
-		Ordinal variable used to assess trends.				Funding Source: National Natural	
Population:							Science Foundation of China
Taiwanese children ages 12-15		Outcome: Serum lipids					
years, n=225		Major Findings:					
From control group of Genetic							
and Biomarkers Study for		Outcome	β	95% CI P for			
Childhood Asthma				trend		trend	
		Total	6.57	2.72	10.42	0.004	
Outcome Definition: Serum		Cholesterol					
lipids.		HDL	-1.56	-3.20	0.08	0.36	
		LDL	4.66	1.67	7.65	0.002	
LDL was calculated using the		Triglycerides		14.82		0.01	
Friedewald formula for							
participants when TGs were							
lower than 400 mg/dl.							
-							

Co umant 162 Filed 04/06/20 De 10 420 of FE1

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 431 of 551 APPENDIX 5: Individual Tables for Toxicology Studies

Appendix 5A. Studies that evaluated increased liver weight and provide serum PFOA data from end of dosing period

Note: An additional study (Macon et al, 2011) that includes this information is presented in Appendix 5B

Reference and Study Design		Comment						
Lau et al. (2006).	Maternal body weight gain (GD							
Effects of perfluorooctanoic acid	Data shown graphically.							
exposure during pregnancy in the	• n = 9-57 dams per dose							
mouse.	 Dams were weighted dai 							
NOTE: A separate study of	Weight gain dramatically							
pharmacokinetics of PFOA in male								
and non-pregnant female mice and	Maternal liver weight (GD 18)	• Weight loss instead of gain during latter part of gestation at 40 mg/kg/day (weight effects stated significant on GD 5-18).						
rats reported in this paper is not		eiaht sho	wn graphically. Nume	erical data for liver weight (abs	olute, and relative to body weight with			
included in this table.	gravid uterus removed) p							
Species and strain:	 n = 9-45 dams per dose 							
Timed pregnant CD-1 mice	Absolute liver weight incr							
Timed pregnant CD-T mice	uterus not provided by in							
Test article and vehicle:		•		n 10 mg/kg/day, but body wei	ght also decreased at these doses.			
PFOA (>98% pure; 98.9% linear,	Dose Absolut			ve liver weight				
1.1% branched isomers)	(mg/kg/day) weigh							
	0 2.4±0		7.3±0.14	1				
Vehicle was NANOpure water.	<u>1 3.4±0</u>		10.9±0.16	1.49				
Route of exposure:	3 4.2±0		12.9±0.41	1.77				
Oral gavage	5 4.4±0		13.8±0.40	1.89				
	10 5.1±0 20 4.2±0		15.9±0.52 16.9±0.51	2.18 2.32				
Exposure levels: 0, 1, 3, 5, 10, 20,	40 4.0±0		18.9±0.63	2.59				
40	*p<0.05		10.0±0.00	2.00				
Exposure regimen:	Maternal PFOA serum levels (C	GD 18 <u>)</u> .						
GD 1-17	Dose (mg/kg/day) n	n Ser	rum level (µg/ml)					
	0 58	8	0.51±0.12					
Group size:	1 6		21.93±1.71					
Not explicitly stated. Group numbers	3 7		40.5±1.89					
are reported with data in Results	5 33		71.91±8.33					
section.	10 30		116.12±16.18					
	20 54 40 14		180.55±19.05 271.14±19.15					
	Shown graphically; nume			ator				
			a provided by investig	Jaloi.				
	• n = 6-58 per dose level.							

Reference and Study Design	Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 432 of 551 Results									
au et al. (2006).	Increased in a									
(continued)	Reproductive outcom									
	Data presented in tabu									
	 Parameters ex 									
	fetuses per litte									
	• n = 9-45 dams									
	Data in table b									
	parameters no									
	Dose	# of	% full litter	# live	% prenatal loss	Fetal body				
	(mg/kg/day)	dams	resorptions	fetuses	per live litter	weight (g)				
	0	45	6.7	per litter 12.5±0.4	4.1±1.4	1.05±0.02				
	1	17	11.8	13.0±0.4	1.0±0.7	0.98±0.03				
	3	17	5.9	10.8±0.9	7.4±2.5	1.03±0.04				
	5	27	25.9*	11.1±0.4	2.4±0.8	1.03±0.04*				
	10	26	46.1*	11.7±0.8	7.7±3.3	0.98±0.05				
	20	42	88.1*	7.2±2.0*	25.9±11.7*	0.86±0.11*				
	40	9	100*							
	*p<0.05	Ũ	100							
	 Full litter resorptions increased at 5 mg/kg/day and above. NOAEL – 3 mg/kg/day. Number of live fetuses and fetal body weight decreased, % prenatal loss increased at 20 mg/kg/day. NOAEL – 10 mg/kg/day. Fetal teratology Data shown in tabular form. Extent of ossification assessed in sternebrae, caudal vertebrae, metacarpals, metatarsals, proximal phalanges of forelimb and hindlimb, calvari, supraoccipital, and hyoid. Statistically significant (p<0.05) reduction in ossification at one or more sites at all doses (1 mg/kg/day or above). No NOAEL identified. Reduced ossification effects at some sites. Do not increase in a dose-dependent fashion. 									
	 Tail defects significantly (p<0.05) increased at 5, 10, and 20 mg/kg/day and limb defects at 5 and 20 mg/kg/day. NOAEL – 3 mg/kg/day. 									
	 Microcardia significantly increased at 10 and 20 mg/kg/day. NOAEL – 5 mg/kg/day. 									

Reference and Study Design	Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 433 of 551 Results	Comment
Lau et al. (2006).		
(continued)	Neonatal survival	
	Data shown graphically for birth - PND 23.	
	n = 8-22 litters per dose group.	
	Stillbirth and neonatal mortality increased (p<0.05) at 5 mg/kg/day and above. Effect most severe (>50% stillbirth; >70% neonatal	
	mortality at 10 and 20 mg/kg/day.	
	Offspring body weight	
	Birth – PND 23: Data shown graphically.	
	\circ n = 7-30 litters per dose group.	
	 Body weight decreased (p<0.05) at 3 mg/kg/day and higher. At PND 23, body weight 25-30% lower than controls at 3 mg/kg/day and higher. NOAEL – 1 mg/kg/day 	
	 6.5 – 60 weeks: Data shown in tabular form (male and female separately). 	
	\circ n = 4-11 litters per dose group.	
	 Significant (p<0.05) dose-related effect at 6.5 weeks in males. 	
	 Trend to higher body weights in treated than control at later time points. 	
	Developmental landmarks	
	Data shown in tabular form. n=4-56 pups from 2-22 litters.	
	• Day of eye opening – Dose-related delay at all doses 1 mg/kg/day and higher. Significant (p<0.05) at 3 mg/kg/day and	
	higher. Delayed by 3.1 days at 20 mg/kg/day.	
	Day of vaginal opening – Significant delay (p<0.05) of 2.9 days at 20 mg/kg/day.	
	Day of first estrus – Significantly delayed at 5 and 20 mg/kg/day, but not 10 mg/kg/day	
	• Day of preputial separation – Significantly accelerated compared to controls at 1 – 10 mg/kg/day, with greatest effect at 1	
	mg/kg/day (3.8 days). Significantly delayed at 20 mg/kg/day.	

Reference and Study Design	Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 434 of 551 Results	Comment
Loveless et al. (2006). Comparative responses of rats		Data for parameters for hepatic effects and dosimetry are presented
Loveless et al. (2006). Comparative responses of rats and mice exposed to linear/branched, linear, or branched ammonium perfluorooctanoate (APFO) Species and strain: Male rats and mice, approximately 8 weeks old, strain not stated. Test article and vehicle: Linear/branched APFO, 77.6% linear. 97.99% pure. Linear APFO, purity not stated. Branched APFO, purity not stated. Vehicle was NANOpure water. Route of exposure: Oral gavage Exposure levels: 0, 0.3, 1, 3 or 1 mg/kg/day Exposure regimen: 14 days Group size: 10 per species per dose group.	Hepatic endpoints Linear/Branched Linear Branched Dose PFOA Liver Peroxisomal Serum Relative Peroxisomal Dose PFOA Liver beta- PFOA Liver beta- PFOA Liver beta- peroxisomal Calimitavit (µg/ml) Weight oxidation (µg/ml) Weight oxidation (µg/ml) Weight oxidation (µg/ml) (ratimitavit) (ratimitavit) (ratimitavit) (ratimitavit) (ratimitavit) (ratimitavit)	
	<u>Body weight/body weight gain</u> : Data for body weight on day 0, 7, and 13, and for body weight gain on day 13; shown in tabular form. Body weight decreased (p<0.05) compared to control on days 7 and 13 in linear/branched and linear 30 mg/kg/day groups. Body weight gain on days 0-13 decreased (p<0.05) compared to control at 3 mg/kg/day in linear, 10 mg/kg/day in branched/linear, and 30 mg/kg/day in all treated groups.	

Case 1.16-0V-00017-	Document 162	Eiled 04/06/20	Page /35 of 551

Reference and Study		Case 1:16 -	- cv-00917-L E	K-DJS Do			06/20 Page	435 of 551			0
Design	Results									Comment	
Loveless et al. (2006). (continued)	Hematology: Data not shown. Treatment related increases in acanthocytes in linear/branched and linear at 3, 10, and 30 mg/kg/day. Treatment related poililocytes and schistocytes in linear/branched at 30 mg/kg/day, and linear at 3,10, and 30 mg/kg/day. Dose-related increases, but not present at high numbers. Serum lipids: Data shown in tabular form. Cholesterol, HDL, Non-HDL, and triglycerides decreased by all 3 forms at multiple doses. Linear caused statistically significant (p<0.05_decreases on cholesterol, non-HDL, and triglycerides at lowest dose (0.3 mg/kg/day and above). All 3 forms caused statistically significant effects on one or more parameter at 1 mg/kg/day and above.										
	MOUSE STUDY										
			Linear/Branch	ed		Linear			Branched		
	Dose (mg/kg/day)	Serum PFOA (µg/ml)	Relative Liver Weight	Peroxisomal beta- oxidation	Serum PFOA (µg/ml)	Relative Liver Weight	Peroxisomal beta- oxidation	Serum PFOA (µg/ml)	Relative Liver Weight	Peroxisomal beta- oxidation	
			(g/100g)	(nM/min/mg protein)		(g/100g)	(nM/min/mg protein))		(g/100g)	(nM/min/mg protein))	
	0	0.04±0.02	5.14±0.27	17.9±5.7	0.07±0.06	5.52±0.24	17.3±4.1	0.02±0.03	5.14±0.31	18.2±4.3	
	0.3	10±1.4 27±5.0	6.12±0.25 7.92±0.49	34.4±7.4* 48.8±8.9*	13±2.4 32±5.2	6.45±0.23* 8.33±0.31*	42.0±10.8* 49.6±11.4*	14±3.5 34±10	6.12±0.34* 7.85±0.85*	24.2±3.7 36.9±10.2*	
	3	66±8.6	10.72±0.63*	47.1±7.1*	69±10	11.67±1.06*	48.5±10.0*	82±10	11.94±0.83*	44.5±8.5*	
	10	190±29	16.27±1.05*	31.6±7.4*	225±68	17.18±1.13*	37.2±9.0*	172±29	17.71±1.81*	42.5±4.4*	
	30	241±28	18.28±1.57*	30.7±8.2*	259±34	17.96±1.06*	31.9±4.5*	244±50	21.01±1.40*	35.4±9.7*	
	*p<0.05. LOAEL for incl No NOAEL ide Beta-oxidation Maximum beta	entified. similar in all	3 forms. Did n	ot continue to					inued to increa	ase with dose.	

Reference and Study Design	Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 436 of 551 Results	Comment
Loveless et al. (2006). (continued)	Other Endpoints Mortality/clinical signs: One mouse in 30 mg/kg/day linear group died suddenly of unknown cause. The incidence of enophthalmos and lethargy was significantly increased in 30 mg/kg/day linear group.	
	<u>Body weight/body weight gain</u> : Data for body weight on day 0, 7, and 13, and for body weight gain on day 13; shown in tabular form. Data were also analyzed on the basis of subtraction of liver weight, to account for liver weight gain. In summary, there was a dose-related decrease in body weight gain and/or loss of body weight (adjusted for liver weight) in all 3 forms. Linear/branched and linear affected body weight gain more than branched.	
	<u>Hematology</u> : Data not shown. Treatment related increases in acanthocytes in linear/branched and linear at 3, 10, and 30 mg/kg/day. Treatment related poiliocytes and schistocytes in linear/branched at 30 mg/kg/day, and linear at 3,10, and 30 mg/kg/day. Dose-related increases, but not present at high numbers.	
	<u>Serum lipids:</u> Data shown in tabular form. Cholesterol and HDL decreased at all doses in all treatment groups. Cholesterol significant (p<0.05) at 3 and 30 mg/kg/day (except branched) for cholesterol. HDL significant at 3, 10, and 30 mg/kg/day for all treatment groups. Non-HDL generally not affected. Triglycerides significantly increased in linear /branched at 0.3, 1, 3, and 10 mg/kg/day.	

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 437 of 551

Reference and Study			Cas	e 1:10-C/	/-0091/- L	EK-DJS I				6/20 Pag	e 437 of :	551			
Design		Results								Comment					
Perkins et al. (2004). 13-week dietary toxicity study of ammonium	LIVER Liver weight relative to body weight (g/100 g) and brain weight (g/g) and PFOA dose (mg/kg/day) & serum levels at weeks 4, 7, and 13											NOAEL for increased relative liver			
perfluorooctanoate (APFO) in male rats.	Week 4 Week 7 Week 13										weight – 1 ppm (0.07 mg/kg/day;				
Species and strain: Males CR:CD BR rats, approximately 41 days old.	Diet Conc. (ppm)	Mean Dose (mg/kg/day)	Dose (mg/kg/day)	PFOA serum level (µg/ml)	Relative to body weight (g/100 g)	Relative to brain weight (g/g)	Dose (mg/kg/day)	PFOA serum level (µg/ml)	Relative to body weight (g/100 g)	Relative to brain weight (g/g)	Dose (mg/kg/day)	PFOA serum level (µg/ml)	Relative to body weight (g/100 g)	Relative to brain weight (g/g)	6.51 μg/ml in serum; Week 4).
	0	-		ND	3.97 <u>+</u> 0.37	7.88 <u>+</u> 0.94		ND	3.75 <u>+</u> 0.29	8.50 <u>+</u> 1.07		ND	3.53 <u>+</u> 0.28	9.03 <u>+</u> 1.20	increased relativ
Test article and vehicle: Ammonium	0-pair fed**			ND	4.07 <u>+</u> 0.27	7.87 <u>+</u> 0.70		ND	3.76 <u>+</u> 0.37	8.12 <u>+</u> 1.14		ND	3.24 <u>+</u> 0.23	7.64 <u>+</u> 0.77	liver weight – 10 ppm (0.71
perfluorooctanoate (98%	1	0.06	0.07	6.51 <u>+</u> 1.0	3.73 <u>+</u> 0.23	7.63 <u>+</u> 0.92	0.06	7.5 <u>+</u> 1.3	3.64 <u>+</u> 0.33	8.53 <u>+</u> 1.29	0.05	7.1 <u>+</u> 1.2	3.24 <u>+</u> 0.30	8.19 <u>+</u> 1.56	mg/kg/day; 55
pure) in feed	10 30	0.64	0.71	55 <u>+</u> 8.1 104 <u>+</u> 14	4.49 <u>+</u> 0.32* 5.77 <u>+</u> 0.60*	8.77 <u>+</u> 1.13 11.3 <u>+</u> 1.35*	0.60	46 <u>+</u> 16 87 <u>+</u> 28	4.12 <u>+</u> 0.37 5.14+0.53*	9.33 <u>+</u> 1.10 11.4+1.58*	0.47	41 <u>+</u> 13 70+16	3.69 <u>+</u> 0.32 4.21+0.56*	9.41 <u>+</u> 1.33 10.8+1.96	µg/ml in serum; Week 4).
Route of exposure:	100	6.50	2.14 7.39	159+30	6.73 <u>+</u> 0.49*	12.5+1.10*	6.21			13.3+1.52*	4.97	138+34	5.50+0.84*	12.6+2.88*	Serum levels
 Exposure levels: 0, 0 (pair fed with 100 ppm), 1, 10, 30, 100 ppm. Mean doses: 0, 0.06, 0.64, 1.94, 6.50 mg/kg/day. (Doses in mg/kg/day are provided for each time point). Exposure regimen: 4, 7, and 13 weeks exposure, and 8 weeks post-exposure. Group size: For each dose group; 15 per group for 4, 7, and 13 week exposure; 10 per group for 8 week recovery (week 22) sacrifice. 	**Pair fee • M • M • L • S • F <u>Liver his</u> Data sho dose, bu It is state are not s <u>Palimitoy</u> Discuss <u>MORTAI</u> Only mo No clinic Body we	d based of No effect NOAEL fo OAEL fo Serum lev Relative li stopatholo wm in tab t not with ed that the hown. <u>I CoA ox</u> ed in det LITY, CLI rtality was al signs o ight data	on 100 ppr on relative or increase r increase vels increase vels increa ver weight oular form. duration of histopath idase active ail in Moo NICAL OI s one 100 bserved. shown in f	n group. e liver weig d liver rela d relative li sed with di increases Minimal to of exposure iology of th <u>vity</u> le of Action <u>BSERVAT</u> ppm rat sa rabular forr	ht in recover tive liver we iver weight - ose, but did were simila slight hepate be livers in the on section.	ight – 1 ppm - 10 ppm (0. not increase r at all 3 time tocellular hyp ne recovery g <u>Y WEIGHT</u> ng week 4 du ght affected	rificed at V n (0.07 mg 71 mg/kg/ e over time e points. pertrophy group (sac ue to seve only at 10	Veek 21. /kg/day; 6 day; 55 µ; e. Steady in 10, 30, in 10, 30, rrificed at	PFOA serui 5.51 µg/ml in g/ml in serur state serum and 100 pp week 21 afte ores. gh dose). A	n level was re m groups at er 8 weeks o	ek 4)). eached by \ 4, 7, and 1 f recovery) ody weight	Veek 4. 3 weeks. was simil decrease	Severity incr ar to control ed (p<0.05) c	reased with s. The data	dose, but did no increase over time. Steady- state was apparently reached by Wee 4.

Reference and Study Design	Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 438 of 551 Results	Comment
Perkins et al. (2004). continued)	Results OTHER ORGANS Organ weight and histopathology It is stated that organ weight, organ to body weight, organ to brain weight were assessed for brain, lungs, testes, and accessory sex organs, and that these organs were examined microscopically. Data for organ weights is not shown or discussed. It is stated that there was an increase in testis to body weight ratio in the 100 ppm recovery group that was not statistically significant. It is assumed that no effects were seen on these parameters for other organs or other treatment groups, although this is not stated. It is stated that histopathology of tissues from treated groups (other than liver) did not differ from controls. SERUM HORMONE LEVELS (ESTRADIOL, LUTEINIZING HORMONE, TESTOSTERONE) Assessed at weeks, 4, 7, 13, and 21 (recovery). Data shown in tabular form. No statistically significant effects. For estradiol, most results were below detection level. More detectable levels in treated groups (and elevated levels at some timepoints) suggest that PFOA increased estradiol.	Comment

Reference and Study Design				0917-LEK-DJS	Resi	ults				Comment
Six month oral capsule study in	<u>Note:</u> Re	esults presente	d here	focus primarily	on hepatic effect	ts, since this er	ndpoint has b	een the focus of ot	her	The results of this study are of
Cynomolgus monkeys.	evaluati	ons and risk as	sessm	ents based on th	nis study. A sun	nmary of the en	tire study is	presented in the tex	t.	limited use in risk assessment
Citational Themford (2004):										because of the small number of
<i>Citations</i> : Thomford (2001); Butenhoff et al. (2002); Butenhoff et	Animals	sacrificed or r	emove	d from study bef	ore end of dosin	ig period				animals per group, the
al. (2004)	• L	• Low dose (3 mg/kg/day) group: In this group, 3 monkeys were dosed for the full 26 week study period. A monkey in this								heterogeneity of the monkeys
	c c	group (which en	(e.g. widely different ages,							
Species and strain:	0	condition on day	potential for having been expos							
Male Cynomolgus monkeys, estimated	v	was possibly tre	atment	-related. The relat	tive liver weight o	f this monkey (2.	.37%) was mu	ich higher than for the	e others in this	to other chemicals in previous
age 3 – 9 years, mean 6 years.	0	dosing group, ar	nd was	comparable to the	se in the high do	se (30/20 mg/kg	/day) group.	-		studies, etc.), possible treatme
	• /	High dose group	(30/20	mg/kg/day): In th	is group, 2 monke	eys were dosed	for the full 26	week study period. C	ne monkey in	related mortality in the low dos
Test article and vehicle:		• • •	•		•	•		weight and showing	•	group, and because internal do
Ammonium perfluorooctanoate (95.2%		• •			•	-		ed for 3 other monke	-	of PFOA (levels in serum and
pure; impurities included		•		atic weight loss, a	•		• • • •		, , , ,	liver) did not differ in the low ar
perfluorhexanoate, 0.73%;		,		;;;;;						mid-dose groups.
perfluoroheptanoate, 3.76%).	Body we	eiaht								
Vehicle was gelatin capsule.			ntrol 3	and 10 mg/kg/da	v aroups (19-20%	during 26 wk st	udy period)			Only two high dose monkeys
venicie was gelatin capsule.					· ·	-		eight gain similar to	controls (18%)	completed the study, while 4 w
Route of exposure:		and the other los	•	0 , 0 1				Cigin gain Sinnar to		sacrificed and/or removed due
Oral in capsule.			51 0 /0 0	i body weight.						toxicity. The 2 high dose anim
	Relative	liver weight P	FOA s	erum concentrati	ons and henatio	c nalmitovl CoA				that completed the study
Exposure levels: 0, 3, 10, and 30/20	Itelative	inver weight, i		erum concentrati	ions, and nepation		<u>`</u>			appeared to react very differen
mg/kg/day (30 mg/kg/day suspended on		[]			Relative Liv	(or Woight	Pal	mitoyl Co-A		to PFOA. One monkey gained
Day 12, resumed at 20 mg/kg/day on Day 22 due to toxicity at higher level).		Dose		Serum PFOA	% of body		µmol/min/			weight similarly to those in the
Day 22 due to toxicity at higher level).		(mg/kg/day)	n	(µg/ml) ^a	weight ^c	Comparison to control	g liver ^e	Comparison to control		control and lower dose groups,
Exposure regimen:			4		-		_			and its liver PFOA concentratio
Daily for at least 26 weeks.		03	4 3 (4) ^d	0.16±0.15 72±47 ^b	1.53±0.08 1.82±0.05*	1.19	0.53±0.12 0.47±0.13	0.89		was also similar to the low dose
Recovery animals observed for 13		3	3 (4)	12±41	$(1.96)^{d}$	(1.28) ^d	0.47±0.13	0.09		groups. The other monkey los
weeks following 26 weeks dosing		10	4	85±20	1.87±0.06*	1.23	0.90±0.29	1.70		weight during the study and its
		20/30	2	155±102	2.41±0.05*	1.58	1.36±1.36	2.60*		PFOA liver concentration was
Group size:	*p<0.05			ata comes from ta						about 4-fold higher than that of
Control – 4 plus 2 recovery. 3 mg/kg/day – 4		•		Data from weeks 2						any other high dose monkey
10 mg/kg/day – 4 plus 2 recovery		`	,				moribund cor	ndition on Day 137.		completing the study.
30/20 mg/kg/day - 6		•			•			cant in Butenhoff et a	l. (2002).	completing the study.
Note: some animals did not complete		· · /						of this monkey was 2.	. ,	Because of the potential morta
the study.)		From Butenhoff								at the low dose, and the fact th
	noight.		5t al. (/							the serum and liver PFOA leve
										did not differ the low and mid
										doses, the results of this study

Reference and Study Design	Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 440 of 551 Results		Comment
Six month oral capsule study in Cynomolgus monkeys. (continued). <i>Citations</i> : Thomford (2001); Butenhoff et al. (2002); Butenhoff et al. (2004)	 Pathological observations Discussed in text. In the 30/20 mg/kg/day monkey sacrificed in moribund condition, had liver lesions including hepatocellular degeneration and necrosis and other changes indicative of liver regeneration. The liver of the 3 mg/kg/day monkey sacrificed in moribund condition appeared normal, although this monkey had a highly elevated liver to body weight ratio. No other notable pathological findings were reported. Hepatic and non-hepatic clinical endpoints Data for liver enzymes, serum lipid, bilirubin, glucose, thyroid hormones, and other hormones is shown in tabular form for before dosing began and weeks 5, 10, 14, and 27. Comparisons are made with baseline values and with controls at same timepoint. For comparisons with baseline values, data from monkeys remaining in the study are compared with data from all monkeys who began the study. 3 and 10 mg/kg/day. No effects on clinical parameters including hematology, clinical chemistry, and urinalysis except in 3 mg/kg/day monkey sacrificed moribund on Day 137. This monkey had increased plasma fibrinogen, and decreased lymphocytes, albumin, and cholesterol. 30/20 mg/kg/day: The 2 monkeys removed from the study due to toxicity also had decreased neutrophils, total protein, and albumin. The 3 monkeys removed from the study due to toxicity also had decreased neutrophils and albumin. Liver enzymes were extremely elevated (10-30 fold) in the monkey sacrificed moribund on Day 29 and the monkey removed from the study due to toxicity on Day 66. Levels of several thyroid hormones appeared to be decreased in a dose dependent manner (shown in table above0. Activity of succinate dehydrogenase, a mitochondrial enzyme, was increased in treated groups. Biochemical markers for subcellular fractions in liver Peroxisomal oxidation (palmitoyl CoA oxidation) w	NOAEL for of monkey. An additior	ormative as to the r PFOA in this spec , nal major uncertain ormation from fema
	Liver PFOA concentrations Shown in table and discussed in text. Concentrations were within a similar range (6.3 -18.8 ug/g) and did not increase with dose in the monkeys that completed the study and the 3 mg/kg/day monkey sacrificed in moribund condition, with the exception of one monkey in the 30/20 mg/kg/group (83.3 ug/g). The monkey in this group sacrificed in moribund condition in the high dose group had a very high concentration (154 ug/g).		

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 441 of 551

Appendix 5B. Studies that evaluated mammary gland development in mice

Notes:

- Tables include 9 publications on this endpoint. The tables are arranged in two groups:
 - Appendix 5B-1: Studies of exposure to PFOA during the perinatal period (pregnant dams, and offspring during gestation and/or nursing) 6 publications. Appendix 5B-2: Studies of exposure to PFOA during the peripubertal period – 3 publications.
- Some of the publications include several separate studies.
- Many of the studies evaluated endpoints in addition to mammary gland development. Data on all endpoints are summarized in the tables.

Reference and Study Design	Results	Comment
Albrecht et al. (2013). A species difference in the peroxisome proliferator-activated receptor α - dependent response to the developmental effects of perfluorooctanoic acid.	MAMMARY GLAND DEVELOPMENT Whole mounts of MG from female pups on PND 20 were assessed. There were no significant differences in number of terminal end buds (TEB) or ductal length in control versus PFOA treated mice in any of the 3 strains. Effect of Prenatal PFOA Exposure on Mammary Gland Development in PND20 Female Offspring	• The authors conclude that the study confirms the PPAR alpha dependent postnatal lethality of PFOA previously reported by Abbott et al. (2007). They conclude that this effect occurs only in WT mice, but not in PPAR alpha null (KO) or humanized PPAR alpha (H) mice, and that this suggests a strain difference in developmental toxicity of PFOA.
Species and strain: Sv/129 (obtained from NIH) wild type (WT), PPAR-alpha null (KO), and PPAR-alpha humanized (H) pregnant female mice and their offspring. Test article and vehicle:	GenotypeTreatmentTEB/glandDuctal length (mm) N Wild-typeControl 2.1 ± 0.1 2.4 ± 0.3 3 (WT)PFOA 2.2 ± 0.2 2.4 ± 0.4 4 Ppara-nullControl 2.1 ± 0.2 2.5 ± 0.1 9 (KO)PFOA 2.6 ± 0.6 1.7 ± 0.4 3 hPPARaControl 2.1 ± 0.3 2.7 ± 0.3 4 (H)PFOA 1.5 ± 0.3 2.6 ± 0.2 5 Note. Values represent the litter mean \pm SEM.	 They also conclude that PFOA did not affect MG development in WT, KO, or H mice at the single dose tested. However, there are several issues with the data and presentation of this study that are problematic and that limit the consideration of its results. The study used only one dose of PFOA, and it is unclear whether that dose was sufficient to cause developmental toxicity in the WT strain. For this reason, the basis for the conclusion that WT, but
PFOA (provided by DuPont Haskell Laboratories, purity not specified)	OTHER ENDPOINTS	not H, mice are sensitive to developmental effects of PFOA is uncertain.
Route of exposure: Oral gavage	 Effect of PFOA on maternal and fetal reproductive outcomes on GD 18 Tabular data. N = 5-8 dams or litters per group. Significance evaluated at p<0.05 level No effect on maternal weight gain, gravid uterus weight, # of implantations per dam, # of 	 It is stated in the text that elevated PFOA levels (up to > 1000 ng/ml) were found in liver and serum from some control fetuses, pups, and dams. However, no further information as to which
Exposure levels: 0 or 3 mg/kg/day. Preliminary studies reported in methods section used 0.6 and 1.0 mg/kg/day.	 No effect on number of fetuses per litter, fetus length or body weight, or number of live or dead fetuses per litter in any strain. 	groups of animals these samples came from, how many samples were elevated, or statistics for serum levels in the control samples is provided. Data from control animals with elevated PFOA exposures were not excluded from the comparisons of endpoints
Exposure regimen: GD 1-17.	 Effect of PFOA on maternal liver on GD18 Tabular data. Absolute and relative maternal liver weight increased significantly and to a similar degree in all 3 strains. (photomicrographs and discussion in text; N = 5-8 dams per group. 	of toxicity in control and treated groups. Including the data from these control animals could have affected the results of the study, especially since serum levels in some of the treated groups were
Group size: 5-8 per strain per dose group	 Significance evaluated at p<0.05 level) Hepatocellular hypertrophy in all 3 strains, with some differences in morphological features 	only a few fold higher than those in some of the controls.The serum PFOA data for WT dams on PND 20 appear to be
Timepoint for mammary gland (MG) evaluation: Offspring on PND 20.	 among the 3 strains. (n not provided) Gene expression in maternal liver (Data presented in bar graphs. n not provided; significance at p<0.05): 	inconsistent within the paper. Maternal serum levels in WT dams on PND 20 are stated to range from 2066 – 6812 ng/ml. No statistical parameters (e.g. median, mean, S.D.) are provided
Related studies: Comparisons with Abbott et al. (2007)	Acox1 (PPAR alpha target gene) increased in WT, not KO or H Cyp4a10 (PPAR alpha target gene) increased in WT and H, but not KO Cyp2b10 (CAR target gene) and Cyp3a11 (PXR target gene) increased in all 3 strains.	numerically. However, the estimated serum level from the bar graph of maternal serum levels is 6700 ± 3600 in WT (higher than what would be expected from the range provided in the text).

Appendix 5B-1: Publications/studies of mammary gland development after perinatal (gestational and/or lactational) exposure to PFOA in mice

Reference and Study Design	Results	Comment
Albrecht et al. (2013).	Effect of PFOA on fetal liver on GD18	The post-natal lethality in WT mice on PND 20 reported as
(continued)	• Relative liver weight increased in WT and H fetuses, but not KO (Data presented in bar graph. n	statistically significant (p<0.05) appears to be based on an
	not provided; p<0.05).	inappropriate statistical comparison. Number of pups per litter on
	 Microscopic changes consistent with peroxisome proliferation in 2/5 of livers from WT fetuses. 	PND 20 in the control and PFOA-treated groups of WT mice were
	 No effects in other strains (n not provided). 	compared. However, this comparison does not appear to be valid
	Gene expression in fetal liver (Data presented in bar graphs; n not provided; significance at	because the control and PFOA treated litters had different
	p<0.05):	numbers of pups on PND 0. This parameter should be evaluated
	 Acox1 and Cyp4a10 (PPAR alpha target genes) increased in WT and H but not KO. 	by comparing number of pups in the same litter on PND 0 and
	 Cyp2b10 (CAR target gene) not changed in all 3 strains. 	PND 20 (i.e. percent mortality within the litter between PND 0 and
	 Cyp3a11 (PXR target gene) increased in H, but no effect in WT and KO. 	PND 20). In WT pups, 96% of controls and 70% of PFOA-treated
	Effect of PFOA on reproductive and developmental parameters in offspring of dams	survived from PND 0 to PND 20. From the analysis presented, it
	allowed to deliver their litters	is unclear whether post-natal lethality was actually significantly
	• N = 8-14 dams and litters per group. Significance at $p<0.05$	increased by PFOA in WT pups.
	 Day of parturition slightly but significantly increased by PFOA in H (numerical data). 	The outhors note that DECA corrupt lough in this study are lough
	 No effect on number of pups per litter at birth (numerical data). 	• The authors note that PFOA serum levels in this study are lower
	 Percentage of male pups significantly increased by PFOA in H (numerical data). 	than in the same strain of WT mice given comparable PFOA doses in Abbott et al. (2007). For example, the WT maternal
	• Day of eye opening not affected by PFOA in any strain (bar graph).	serum PFOA levels on PND 20 are comparable to those in WT
	• Pup wt. gain through PND 20 not affected by PFOA in any strain (numerical data & bar graph).	dams similarly dosed with lower levels of PFOA $(0.3 - 1)$
	• At 3 mg/kg/day, post-natal lethality at PND 20 reported significantly increased in WT, but	mg/kg/day) in Abbott et al (2007). Although both studies used
	not KO or H (numerical data). This conclusion appears to be based on an invalid statistical	SV/129 mice, this study obtained them from NIH and Abbott et al.
	comparison. See comments.	(2007) obtained them from Jackson Laboratories.
	 Text states that no post-natal lethality was seen in WT dosed with 0.6 or 1 mg/kg/day PFOA, 	
	but numerical data for this effect and serum levels at these doses are not provided.	The authors suggest that pharmacokinetic differences in the mice
	Effect of PFOA on pup liver on PND20	used may explain the differences in effects of PFOA in WT mice in
	 Pup liver weight on PND 20 increased in WT, but not KO or H (n not provided; bar graph). 	the two studies. However, a close review of the data from the two
	 Microscopic changes consistent with peroxisome proliferation in WT livers on PND 20 (n not 	studies indicates that Albrecht et al. (2013) did not observe
	stated). Equivocal evidence of centrilobular hypertrophy in 1/5 KO pup livers on PND 20. No	developmental effects of PFOA in WT pups that were seen at
	definitive liver changes in H (n not stated).	similar or lower PFOA levels in WT mice by Abbott et al. (2007).
	• Gene expression in fetal liver (Data presented in bar graphs. n not provided; significance at	
	p<0.05):	Abbott et al. (2007) reported significantly increased post-natal
	Acox1 (PPAR alpha target gene) increased in WT, not KO or H	lethality in WT pups exposed gestationally to 0.6 and 1 mg/kg/day
	• Cyp4a10 (PPAR alpha target gene) increased in WT and to a lesser degree in KO, but not	PFOA. In both of these dose groups, pup survival to PND 22 was
	H S S /	43%. WT pup serum levels on PND 22 in the 0.6 and 1 mg/kg/day
	Cyp2b10 (CAR target gene) increaaed in all 3 strains.	dose groups in Abbott et al. (2007) were 3810 and 9860 ng/ml
	Cyp3a11 (PXR target gene) increased in WT and H, but no effect in KO.	(respectively). PFOA serum level in treated WT pups on PND 22
	• Cypsair (FAR largel gene) incleased in wir and H, but no enecl in KO.	(·····································

(continued)• Dams – n=5 per strain on GD18 and PND 20. Fetuses and pups – n= 7-25 fetuses or pups from 3 – 7 litters on GD 18 and PND 20. It is not clear if this represents 7-25 fetuses/pups altogether at each time point or 7-25 pups per strain at each time point. • Text states that PFOA levels from control dams, fetuses, and pups ranged from <5 to 1060 ng/ml in liver and from <5 to 1370 ng/ml in serum. This is described as a "small cohort" of samples, and it is stated that concentrations in control samples "typically" were ND (<5 ng/ml). However, the number/percentage of control samples with elevated levels (including how many from fetuses, pups, and dams), and data or statistics on the levels found in controls, are not provided numerically or in bar graphs. Additionally, the data on endpoints of toxicity from control animals with elevated PFOA levels were not excluded from the analysis (see comments).• In summary, this study of data from controls with the comparisons of effect	(2013; this study) are estimated as 10,000 ng/ml
from 3 – 7 litters on GD 18 and PND 20. It is not clear if this represents 7-25 fetuses/pups altogether at each time point or 7-25 pups per strain at each time point. • Text states that PFOA levels from <u>control</u> dams, fetuses, and pups ranged from <5 to 1060 ng/ml in liver and from <5 to 1370 ng/ml in serum. This is described as a "small cohort" of samples, and it is stated that concentrations in control samples "typically" were ND (<5 ng/ml). However, the number/percentage of control samples with elevated levels (including how many from fetuses, pups, and dams), and data or statistics on the levels found in controls, are not provided numerically or in bar graphs. Additionally, the data on endpoints of toxicity from control animals with elevated PFOA levels were not excluded from the analysis (see comments).	
 statistics (median, mean, S.D., etc.) are provided numerically. However, the estimated serum level from the bar graph of maternal serum level s is 6700±3600 in WT (higher than what would be expected from the range provided in the text). The WT maternal serum PFOA levels on PND 20 are comparable to those in WT dams similarly dosed with lower levels of PFOA (0.3 – 1 mg/kg/day) in Abbott et al (2007). See comments. In dams, serum PFOA levels were lower in WT than in KO or H on PND 22 (shown in bar graph).). In pups and fetuses, PFOA serum levels were higher in H than in KO or WT on GD 18, and were higher in H than in KO or WT on PND 22. Liver PFOA levels in dams, pups, and fetuses did not necessarily follow the same relative pattern among strains as serum PFOA. In this study, no effect or pups from the 3 strains or gland development in SV studies. It is possible th effect than the other statistics (median, mean, S.D., etc.) are provided in the text is the statistics (median, mean, S.D., etc.) are provided in the text is possible the effect than the other statistics (median, mean, S.D., etc.) are provided in the text. 	r graph), yet post-natal mortality (70% survival to ach lower than in Abbott et al. (2007) and may not gnificant (see above). Similarly, eye opening was yed in the 0.6 and 1 mg/kg/day WT pups in Abbott not in the treated pups with similar and higher els in Albrecht et al. (2013). is problematic for several reasons. The inclusion n elevated PFOA exposures may have influenced ts in control and treated groups. Important data on inted or is presented inconsistently. It is unclear dity actually was significantly increased in WT ve opening seen in WT pups in Abbott et al. . The differences in developmental effects in WT 013) versus Abbott et al. (2007) cannot be f pharmacokinetic differences in the two studies, at pup serum levels in Abbott et al. (2007) that are n levels in Albrecht et al. (2013). For these that developmental toxicity occurs in WT mice but oha mice, indicating that humans may be less tal toxicity of PFOA, is not clearly supported by mammary gland development was reported in n PND 20. The effects of PFOA on mammary (/129 mice have not been evaluated in other at this strain may be less sensitive to this rains in which it has been reported. However, this study discussed above create

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 445 of 551

Reference and Study Design				Res	sults					Comment
Macon et al (2011). Prenatal perfluorooctanoic acid exposure in CD-1 mice: low-dose developmental effects and internal dosimetry.	assessed at a give	General note: The litter was the unit used for statistical analysis in this study. Thus, when multiple pups from the same litter were assessed at a given time point, the individual pup data were averaged to give a single data point for that litter. Full-gestation exposure study (GD 1-17) MG developmental scores in whole mounts (1-4 scale) from female offspring after exposure on GD 1-17								In the <u>full gestation exposure study</u> (exposure on GD 1-7 to 0.3, 1.0, and 3 mg/kg/day), delayed MG development, as assessed by developmental score, occurred in female offspring the absence of
Species and strain: Timed pregnant CD-1 mice and their offspringTest article and vehicle: PFOA (ammonium salt, >98% pure) in deionized waterRoute of exposure: Oral gavage <i>Full-gestation exposure study</i>	0.3 (mg/kg Cont 0.3 1.0 3.0	$\begin{array}{c c} \hline v/day) & \hline (n) \\ \hline trol & 3.3 \pm 0.2 \\ \hline (5) \\ \hline 3 & 2.4 \pm 0.4 \\ \hline (4) \\ \hline 0 & 2.2 \pm 0.3^* \\ \hline (5) \\ \hline 0 & 1.6 \pm 0.2^{**} \\ \hline (4) \\ \hline \end{array}$	$\begin{array}{c} \underline{PND \ 14}\\(n)\\3.2 \pm 0.3\\(4)\\1.5 \pm 0.2^{***}\\(6)\\1.5 \pm 0.1^{***}\\(6)\\1.7 \pm 0.3^{**}\\(4)\end{array}$	$\begin{array}{c} \underline{PND \ 21}\\(n)\\3.4 \pm 0.3\\(3)\\1.9 \pm 0.2^{**}\\(5)\\1.3 \pm 0.1^{***}\\(5)\\1.6 \pm 0.4^{**}\\(3)\end{array}$	$\begin{array}{r} \underline{PND \ 28} \\ (n) \\ 3.4 \pm 0.3 \\ (4) \\ 2.8 \pm 0.2 \\ (6) \\ 2.3 \pm 0.3^{**} \\ (4) \\ 1.8 \pm .2^{***} \\ (6) \end{array}$	$\frac{PND \ 42}{(n)}$ 3.8 ± 0.1 (4) 2.8 ± 0.3* (5) 2.0 ± 0.3*** (6) 2.8 ± 0.2 (4)	$ \frac{PND \ 63}{(n)} $ 2.4 ± 0.6 (3) 2.9 ± 0.4 (5) 1.8 ± 0.5 (2)	$ \frac{PND 84}{(n)} 4.0 \pm 0.0 (2) 2.4 \pm 0.3^{*} (3) 2.2 \pm 0.2^{**} (4) 2.9 \pm 0.4 (2) contained a number of the number $		effects on body weight. The LOAEL was 0.3 mg/kg/day and no NOAEL was identified. Delays were evident, and were statistically significant (with the exception of the 3 mg/kg/day dose group with n of only 2), at the end of the study on PND 84. In the <u>late gestation exposure study</u> (exposure on GD 10-17 to 0.01, 0.1, and 1 mg/kg/day), individual parameters of MG development were evaluated in addition to the overall
MG Assessment: Female offspring Exposure levels: 0, 0.3, 1.0, or 3.0 mg/kg/day Exposure regimen: Gestational. GD 1-17. Group size: 13 dams per treatment group. Litters equalized to 10 pups, with equal M & F when possible.	 control group). * p≤0.05, ** p≤0.0 MG developme MG developme The authors sta and that histologic to controls could r differentiate into to as completely as in PND 28, at 0.3 and significant, possib 	³ Significance at PND 63 could not be determined due to absence of controls at this time point (because of low # of female pups in developmental energy used in the f								
Timepoint(s) for mammary gland (MG) evaluation: PND 7, PND 14, PND 28, PND 42, PND 63, and PND 84	 Body weight - N Relative liver weight 14, and in 3 mg/kg 	<u>(full gestation exp</u> lo effect in M or F p e <i>ight</i> – Increased (p g/day M & F pups o No effect on relative	ups (with or with o< 0.05, p < 0.0 ⁻ n PND 14, PND	1, or p < 0.001) 21, and PND 2	at all doses in 8.	M & F pups on	PND 7, in 1 m			 while data from other time points are not shown. On PND 21, the overall developmental score was significantly decreased in all dose groups compared to controls in a dose-related fashion. Other MG parameters were also decreased on

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 446 of 551

Reference and Study Design	Results	Сог	nment					
Macon et al. (2011) (cont.)	Late-gestation exposure (GD 10-17) study		PND 21 in all treated groups in a					
Late-gestation exposure study	MG development parameters in whole mounts from female offspring at PND 21 after exposure on		dose-related fashion, but were significant only for change in longitudinal growth and number of					
MG Assessment: Female offspring	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	end buds(n) ends (n)	terminal end buds in the highest dose group (possibly due to the small n (3- 5) at each dose.					
Exposure levels: 0, 0.01, 0.1, or 1.0 mg/kg/day		$24 \pm 4^{*}(3)$ $58 \pm 4(3)$	There were no effects on body weight, and liver weight was not					
Exposure regimen: Gestational.	^a Change in lateral or longitudinal epithelial growth based on comparison to mean values on PND Significant effects compared with controls, $*p < 0.05$, $**p < 0.01$, $***p < 0.001$.	1.	affected at 0.01 or 0.1 mg/kg/day.					
GD 10-17. Group size: <i>Block 1</i> : 5 dams per treatment group. <i>Block 2</i> : 8 dams per treatment	 At PND 14, longitudinal epithelial growth in the 0.1 and 1.0 mg/kg/day groups reduced compared with c 37.3% (p = 0.01), respectively, and the change in longitudinal growth from PNDs 1 to 14 was reduced by 2 (p = 0.002), respectively. Other PND 14 data not shown. Developmental delays were most evident at PND 21. Numerical data presented in table. MG developm were significantly lower than in controls (p < 0.02; Table 1). Effects for developmental score and other end change in lateral growth) occurred in a dose-related fashion. 	27.4% (p = 0.005) and 56.5% lent scores in all treated groups	treated pups on PND 1 and had decreased to 6-12% of the PND 1 levels by PND 21. The serum level on PND 1 in the 0.01 mg/kg/day group was 285 ng/ml.					
group. Pups pooled on PND 1 and redistributed to dams within treatment group. n=7-9 pups per dam, including 4-7 female pups per dam.	 LOAEL for delayed MG development was 0.01 mg/kg/day. No NOAEL was identified. <u>Other endpoints (only female pups assessed) (late gestation exposure study)</u> <u>Body weight</u> - No effect (with or without liver weight subtracted) at any time point. <u>Liver weight</u> - Absolute liver weight Increased (p<0.001) in 1 mg/mg/day group on PND 4 and PND 7. (p< 0.05, p < 0.01, or p < 0.001) in 1 mg/kg/day group on PND 4 - PND 14. No effect in 0.01 or 0.1 mg/kg/day 		Serum levels in the dams were not measured but are expected to be similar to those in the pups. Serum levels in non-pregnant adult CD-1 mice exposed to 0.1 and 1 mg/kg/day for 8 days were 3200, and 31,000					
Timepoint(s) for mammary gland (MG) evaluation: Offspring – PND 1, PND 4, PND 7, PND 14, PND 21.	• <u>NOAEL for increased relative liver weight based on PFOA serum level</u> - In the 1 mg/kg/day group durin was increased, serum PFOA levels were 16,305 ng/ml on PND 1 and had decreased to 6084 ng/ml on PN increased relative liver weight was 2303 ng/ml, the highest serum level in the 0.1 mg/kg/day group, which consistent with the serum level in the 1 mg/kg/day group on PND 21 (when liver weight was no longer increased processing).	ND 14. The NOAEL for occurred on PND 1. This is	ng/ml, from preliminary data of Das et al. (2010), and the serum level after dosing with 0.01 mg/kg/day for 8 days can be estimated at 320 ng/ml from these data. Earlier studies showed					
Related studies: Post et al. (2012)	PFOA levels in serum, liver, and brain Numerical data are presented for serum, liver, and brain in M & F pups in the full gestational (GD 1-17) study. Data from PND 7 (earliest time point assessed) shows that serum levels were similar in M&F pups, with slightly higher values at all doses in males. Serum levels in the dams at the late gestational (GD 10-17) study are for combined M&F pups on PND 1, and for F pups at other times. Serum data for late gestational study (exposure on PND 10-17) shown below.							
			<u>Summary</u> : Gestational exposure to ≥ 0.01 mg/kg/day PFOA caused dose- related delays in MG development in female offspring. MG development was delayed by doses that did not					

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 447 of 551

Reference and Study Design			Comment				
Macon et al. (2011) (cont.)	PFOA serum leve	els on PND 1-21 in off	spring exposed or	n GD 10-17 (late gestatio	n exposure study)		affect body weight or liver weight.
	Serum (ng/ml)	<u>PND 1 (</u> n)	<u>PND 4 (</u> n)	<u>PND 7 (</u> n)	<u>PND 14 (n)</u>	<u>PND 21 (n)</u>	The LOAEL for delayed MG development in the pups is a serum
	Control	22.6 ± 5.5 (4)	8.6 ± 0.5 (2)	7.8 ± 2.1 (5)	7.8 ± 1.5 (8)	4.1 ± 0.6 (7)	level of 285 ng/ml (measured) and is
	0.01 mg/kg	284.5 ± 21.0 (3)	184.1 ± 12.1 (2)	150.7 ± 20.9 (7)	80.2 ± 13.9 (8)	16.5 ± 2.1 (10)	also estimated as about 300 ng/ml or
	0.1 mg/kg	2303.5 ± 114.1 (2)	-	1277.8 ± 122.6 (8)	645.4 ± 114.2 (7)	131.7 ± 24.5 (7)	lower in the dams, and no NOAEL
	1.0 mg/kg 16305.5 ± 873.5 (7) - 11880.3 ± 1447.6 (11) 6083.7 ± 662.6 (11) 2025.1 ± 281.9 (11)					2025.1 ± 281.9 (11)	was identified. This LOAEL is based on the serum level on PND 1, and the
	• Serum levels inc	creased with dose and g	generally decreased	d over time.			actual LOAEL may be lower, since effects occurred at later time points when serum levels had decreased. These findings indicate that delayed mammary gland development is a more sensitive endpoint for PFOA's effects in female mouse pups than decreased body weight or increased liver weight.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 448 of 551

		R	esults			Comment
B DEVELOPMENT	MG development was delayed on PNE 21 until PND 56 or 61 in CD-1 and C57BI/6 mice exposed to 0.01- 1 mg/kg/day PFOA on GD 1-17. No					
CD-1 PND 21 PND 35 PND 56 C57BI/6 PND 21 PND 61 20.05; **p≤0.01, ***p Authors report that of AG development sca ack of significance Specific observation Delayed MG develop HER ENDPOINTS dy weight: Assessed obtracted decreased of er weight: Assessed 0.05) on PND 21 or bertal events: PFOA her strain. rum estradiol and pr	Control (n) 2.9 \pm 0.1 (19) 3.1 \pm 0.1 (16) 3.3 \pm 0.1 (9) 2.9 \pm 0.2 (7) 2.8 \pm 0.2 (10) $p \le 0.001$, **** $p \le 0.00$ delayed MG develor ores were lower th in C57Bl/6 at lowe is indicating delayer oment persisted th d at same time point (p<0.05) only in 1 n d at same time point hy in 1 mg/kg/day A treatment had no	0.01 mg/kg (n) $2.4 \pm 0.1 (22)$ $2.3 \pm 0.2 (17)^{-}$ $2.3 \pm 0.2 (13)^{-}$ $2.5 \pm 0.4 (5)$ $2.2 \pm 0.2 (5)$ 001. Means represent at an controls at all doses r doses may be due to d MG development at of rough early adulthood (ints as MG development mg/kg/day CD-1 on PNI ints as MG development CD-1. effect on day of vagina	$0.1 \text{ mg/kg } (n)$ $2.3 \pm 0.1 (22)^{-}$ $2.2 \pm 0.2 (14)^{-}$ $2.5 \pm 0.2 (8)^{-}$ $2.1 \pm 0.7 (2)$ $2.6 \pm 0.1 (3)^{-}$ averages of individual p t lowest dose (0.01 mg/k , including lowest (0.01 lower PFOA serum level different time points in e end of study) in both str t. No effect on absolute D 21 and PND 35, but r t. No effects on absolute I opening, body weight	$0.3 \text{ mg/kg}(n)$ $2.0 \pm 0.1 (21)^{11}$ $2.3 \pm 0.1 (16)^{12}$ $2.2 \pm 0.1 (10)^{11}$ $1.8 \pm 0.3 (6)^{12}$ $2.1 \pm 0.1 (10)^{11}$ The product of the strains. mg/kg/day) in both strains. mg/kg/day) and timepoint of the strain are described of the strain	1.0 mg/kg (n) $1.7 \pm 0.1 (21)^{\text{min}}$ $1.9 \pm 0.2 (14)^{\text{min}}$ $1.9 \pm 0.2 (9)^{\text{min}}$ $1.8 \pm 0.2 (5)^{\text{min}}$ $1.7 \pm 0.1 (8)^{\text{min}}$ Ints in both strains. npared to CD-1. I in the text. I in the text. ght with liver weight iver weight increased y of first estrus in	
	D-1 PND 21 PND 35 PND 56 257BI/6 PND 21 PND 61 D.05; **p≤0.01, ***p uthors report that of G development sc ack of significance pecific observation elayed MG develop HER ENDPOINTS y weight: Assessed racted decreased r weight: Assessed r weight: Assessed o.05) on PND 21 or ertal events: PFOA er strain. um estradiol and pr	Control (n)Control (n)PND 21 $2.9 \pm 0.1 (19)$ PND 35 $3.1 \pm 0.1 (16)$ PND 56 $3.3 \pm 0.1 (9)$ C57BI/6PND 61 $2.9 \pm 0.2 (7)$ PND 61 $2.8 \pm 0.2 (10)$ 0.05; **p≤0.01, ***p≤0.001, ****p≤0.00outhors report that delayed MG develoG development scores were lower that ack of significance in C57BI/6 at lowerpecific observations indicating delayeelayed MG development persisted theHER ENDPOINTSy weight: Assessed at same time poirracted decreased (p<0.05) only in 1 r	Control (n)0.01 mg/kg (n)CD-1 PND 21 $2.9 \pm 0.1 (19)$ $2.4 \pm 0.1 (22)$ $2.3 \pm 0.2 (17)^-$ PND 56PND 35 PND 56 $3.1 \pm 0.1 (16)$ $2.3 \pm 0.2 (17)^-$ $2.3 \pm 0.2 (13)^-$ C57BI/6 PND 21 PND 61 $2.9 \pm 0.2 (7)$ $2.5 \pm 0.4 (5)$ $2.2 \pm 0.2 (5)$ 0.05; **p<0.01, ***p<0.001, ****p<0.0001. Means represent at G development scores were lower than controls at all doses ack of significance in C57BI/6 at lower doses may be due to pecific observations indicating delayed MG development at delayed MG development persisted through early adulthood (HER ENDPOINTS y weight: Assessed at same time points as MG development racted decreased (p<0.05) only in 1 mg/kg/day CD-1 on PN r weight: Assessed at same time points as MG development 0.05) on PND 21 only in 1 mg/kg/day CD-1.ertal events: PFOA treatment had no effect on day of vagina er strain.um estradiol and progesterone: Content Assessed at same time points	Control (n)0.01 mg/kg (n)0.1 mg/kg (n)CD-1 PND 21 $2.9 \pm 0.1 (19)$ $2.4 \pm 0.1 (22)$ $2.3 \pm 0.1 (22)^{-1}$ PND 35 3.1 \pm 0.1 (16) $2.3 \pm 0.2 (17)^{-1}$ $2.2 \pm 0.2 (14)^{-1}$ PND 56 $3.3 \pm 0.1 (9)$ $2.3 \pm 0.2 (13)^{-1}$ $2.5 \pm 0.2 (8)^{-1}$ 257Bl/6 PND 21 $2.9 \pm 0.2 (7)$ $2.5 \pm 0.4 (5)$ $2.1 \pm 0.7 (2)$ PND 61 $2.8 \pm 0.2 (10)$ $2.2 \pm 0.2 (5)$ $2.6 \pm 0.1 (3)^{-1}$ 0.05; **p ≤ 0.01 , ***p ≤ 0.001 . Means represent averages of individual puthors report that delayed MG development was apparent at lowest dose (0.01 mg/lG development scores were lower than controls at all doses, including lowest (0.01 ack of significance in C57Bl/6 at lower doses may be due to lower PFOA serum level pecific observations indicating delayed MG development at different time points in e elayed MG development persisted through early adulthood (end of study) in both str IER ENDPOINTS y weight:Assessed at same time points as MG development. No effect on absolute racted decreased (p<0.05) only in 1 mg/kg/day CD-1 on PND 21 and PND 35, but r r weight:Assessed at same time points as MG development. No effects on absolute 0.05) on PND 21 only in 1 mg/kg/day CD-1.ertal events:PFOA treatment had no effect on day of vaginal opening, body weight er strain.um estradiol and progesterone:Assessed at same time points as MG development.	Control (n)0.01 mg/kg (n)0.1 mg/kg (n)0.3 mg/kg (n)CD-1 PND 21 $2.9 \pm 0.1 (19)$ $2.4 \pm 0.1 (22)$ $2.3 \pm 0.1 (22)^{}$ $2.0 \pm 0.1 (21)^{}$ PND 55 $3.1 \pm 0.1 (16)$ $2.3 \pm 0.2 (17)^{}$ $2.2 \pm 0.2 (14)^{}$ $2.3 \pm 0.1 (21)^{}$ PND 56 $3.3 \pm 0.1 (9)$ $2.3 \pm 0.2 (13)^{}$ $2.5 \pm 0.2 (8)^{}$ $2.2 \pm 0.1 (10)^{}$ S78H/6 PND 21 $2.9 \pm 0.2 (7)$ $2.5 \pm 0.4 (5)$ $2.1 \pm 0.7 (2)$ $1.8 \pm 0.3 (6)^{}$ PND 51 $2.9 \pm 0.2 (7)$ $2.5 \pm 0.4 (5)$ $2.1 \pm 0.7 (2)$ $1.8 \pm 0.3 (6)^{}$ PND 61 $2.8 \pm 0.2 (10)$ $2.2 \pm 0.2 (5)$ $2.6 \pm 0.1 (3)$ $2.1 \pm 0.1 (10)^{}$ 0.05; **p ≤ 0.01 , ***p ≤ 0.001 . Means represent averages of individual pup scores.uthors report that delayed MG development was apparent at lowest dose (0.01 mg/kg/day) in both strains.G development scores were lower than controls at all doses, including lowest (0.01 mg/kg/day) and timepoiack of significance in C57BI/6 at lower doses may be due to lower PFOA serum levels and smaller n, as conpecific observations indicating delayed MG development at different time points in each strain are describedelayed MG development persisted through early adulthood (end of study) in both strains. tER ENDPOINTS y weight: Assessed at same time points as MG development. No effect on absolute body weight. Body weightracted decreased (p<0.05) only in 1 mg/kg/day CD-1 on PND 21 and PND 35, but not PND 56.	$\frac{1}{PND 21} = \frac{2.9 \pm 0.1 (19)}{2.3 \pm 0.2 (17)} = \frac{2.4 \pm 0.1 (22)}{2.2 \pm 0.2 (17)} = \frac{2.3 \pm 0.1 (22)''}{2.2 \pm 0.2 (14)'} = \frac{2.3 \pm 0.1 (21)'''}{2.3 \pm 0.1 (16)'} = \frac{1.7 \pm 0.1 (21)'''}{1.5 \pm 0.2 (14)''} = \frac{1.5 \pm 0.2 (15)}{2.5 \pm 0.2 (10)} = \frac{2.5 \pm 0.4 (5)}{2.2 \pm 0.2 (5)} = \frac{2.1 \pm 0.7 (2)}{2.6 \pm 0.1 (3)} = \frac{1.8 \pm 0.3 (6)'}{2.1 \pm 0.1 (10)'} = \frac{1.8 \pm 0.2 (5)'}{1.7 \pm 0.1 (8)''} = \frac{1.7 \pm 0.1 (8)''}{1.7 \pm 0.1 (8)''} = \frac{1.7 \pm 0.1 (8)''}{1.7 \pm 0.1 (8)''} = \frac{1.5 \pm 0.2 (10)}{2.2 \pm 0.2 (10)} = \frac{1.5 \pm 0.4 (5)}{2.2 \pm 0.2 (5)} = \frac{1.5 \pm 0.4 (5)}{2.6 \pm 0.1 (3)} = \frac{1.8 \pm 0.3 (6)'}{2.1 \pm 0.1 (10)'} = \frac{1.8 \pm 0.2 (5)'}{1.7 \pm 0.1 (8)''} = \frac{1.5 \pm 0.2 (10)}{1.7 \pm 0.1 (8)''} = 1.$

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 449 of 551

Reference and Study Design	1			Results			Comment		
Tucker et al. (2015) (cont.)	PFOA SERUM	LEVELS (ng/ml)	,						
		Control (n)	0.01 mg/kg (n)	0.1 mg/kg (n)	0.3 mg/kg (n)	1.0 mg/kg (n)			
	CD-1 PND 21 PND 35 PND 56	<loq (6)<br=""><loq (11)<br=""><loq (5)<="" td=""><td>$74.8 \pm 16.9 (10)$ $14.3 \pm 2.3 (12)$ < LOQ (5)</td><td>$\begin{array}{c} 457.3 \pm 91.0 (9) \\ 61.7 \pm 6.5 (9) \\ 15.0 \pm 5.0 (4) \end{array}$</td><td>$\begin{array}{c} 904.8 \pm 131.5 \ (10)^{'} \\ 200.9 \pm 32.2 \ (11)^{'} \\ 46.2 \pm 7.5 \ (6) \end{array}$</td><td>$3119.0 \pm 396.4 (5)^{**}$ $889.8 \pm 117.5 (11)^{**}$ $200.2 \pm 21.1 (7)^{**}$</td><td></td></loq></loq></loq>	$74.8 \pm 16.9 (10)$ $14.3 \pm 2.3 (12)$ < LOQ (5)	$\begin{array}{c} 457.3 \pm 91.0 (9) \\ 61.7 \pm 6.5 (9) \\ 15.0 \pm 5.0 (4) \end{array}$	$\begin{array}{c} 904.8 \pm 131.5 \ (10)^{'} \\ 200.9 \pm 32.2 \ (11)^{'} \\ 46.2 \pm 7.5 \ (6) \end{array}$	$3119.0 \pm 396.4 (5)^{**}$ $889.8 \pm 117.5 (11)^{**}$ $200.2 \pm 21.1 (7)^{**}$			
	C57BI/6 PND 21 PND 61	<loq (2)<br=""><loq (6)<="" td=""><td>$\begin{array}{c} 26.1 \pm 19.0(2) \\ < LOQ(2) \end{array}$</td><td>$\begin{array}{c} 247.1 \pm 11.4 (2) \\ 27.7 \pm 10.4 (3) \end{array}$</td><td>$\begin{array}{c} 891.3 \pm 528.7 (3) \\ 9.3 \pm 2.2 (5) \end{array}$</td><td>2141.67 ± 666.8 (2) 22.0 ± 7.6 (5)</td><td></td></loq></loq>	$\begin{array}{c} 26.1 \pm 19.0(2) \\ < LOQ(2) \end{array}$	$\begin{array}{c} 247.1 \pm 11.4 (2) \\ 27.7 \pm 10.4 (3) \end{array}$	$\begin{array}{c} 891.3 \pm 528.7 (3) \\ 9.3 \pm 2.2 (5) \end{array}$	2141.67 ± 666.8 (2) 22.0 ± 7.6 (5)			
	 Serum PFOA delayed. 	 Serum PFOA levels in both strains increased with dose and decreased over time. Serum PFOA was below LOQ or very low (9-27 ng/L) at some doses and time points when MG development was significantly delayed. Serum PFOA levels were lower in C57BI/6 than CD-1 mice on PND 21, and generally lower at later time points (PND 56 in CD-1 							
		versus PND 61 in C57Bl/6).							

Reference and Study Design	Results	Comments
White et al. (2007). Gestational PFOA exposure of mice is associated with altered mammary gland development in dams and female offspring. Species and strain: Timed pregnant CD-1 mice and their offspring	Study 1 MG development in dams on GD 18 after treatment on GD 1-17 Whole mounts were examined microscopically and scored on a scale of 1-4. Delay in 5 mg/kg/day group. MG Development Score (mean ± SE) Control (n=4) 5 mg/kg/day (n=3) 3.9±0.1 2.0±0.6* *p<0.015	Study 1 The authors interpreted the delayed MG development in treated dams on PND 18 (prior to parturition) as indicating that the delayed MG development in dams at later time points in Study 2 was not due to a deficiency in stimulation of lactation due to decreased suckling ability of pups. Study 2 Lactating dams on PND 10 and 20
Test article and vehicle: PFOA (ammonium salt, >98% pure) in deionized water Route of exposure: Oral gavage	<u>Study 2</u> MG DEVELOPMENT (Study 2) Lactating dams on PND 10 or PND 20 after treatment during gestation (Study 2)	<u>MG development in lactating dams</u> Delayed MG development in dams occurred in the absence of decreased maternal weight gain. Exposure during the second half of pregnancy was sufficient to cause this effect. MG development in non-pregnant females was not affected by similar exposures.
Exposure levels: 0 or 5 mg/kg/day Study 1 MG assessment: Dams	 <u>MG development scores</u> All treated groups were dosed with 5 mg/kg/day on stated gestational days (GD). Whole mounts/H&E slides were scored on a scale of 1-4. Numerical data shown only for whole mount scores. Representative H&E slides from control and treated mice are shown. PND 10: MG development was delayed in all exposure groups (significant for GD 8-17 and 1-17). PND 20: MG in all PFOA-exposed groups resembled MG from PND 10 controls, indicating delayed development. 	On PND 10, normally the peak of lactation in rodents, MG from treated mice on PND 10 resembled those normally seen earlier in lactation. On PND 20, immediately prior to weaning, MG are normally involuted, but MG from PFOA-treated mice resembled PND 10 (peak of lactation) MG from controls. This suggests a delay of up to 10 days in MG differentiation due to PFOA exposure.
Exposure regimen: Gestational. GD 1-17 Group size:	MG Development Score in Whole Mounts (mean ± SE) Control GD 12-17 GD 8-17 GD 1-17 PND 10 (n=4-6) 4.0±0.0 3.7±0.1 3.2±0.2* 1.8±0.5** PND 20 (n=3-6) 2.7±0.2 2.8±0.2 3.2±0.1 3.3±0.2	<u>Expression of milk proteins in lactating dams</u> The authors stated that the decrease in LactoF at PND 20, when a peak normally occurs, is consistent with the observed structural delays in mammary gland development seen at PND 20.
5 Timepoint(s) for mammary gland (MG) evaluation:	 *p<0.05; **p<0.001 Non-pregnant adult females dosed with PFOA for up to 17 days have no effects on MG (data not shown) 	<u>Decreased pup body weight at birth</u> The authors state that this effect was not due to general maternal toxicity, since maternal body weight and reproductive parameters were not affected.
GD 18	<u>Expression of milk proteins</u> Gene expression profiles of four milk protein genes (beta-casein, EGF, alpha-Lac, and LactoF) in maternal mammary gland tissue on PND 10 and 20 showed that expression of genes for all 4 proteins was significantly (p<0.05 or p<0.001) \uparrow or \downarrow in at least one exposure group (GD 12-17, 8-17, and 1-17) on PND 10 and/or PND 20. Some of the changes did not follow a consistent pattern.	<u>MG development in female offspring</u> Delayed MG development occurred after exposure during the final 6 days of gestation. MG development was arrested between PND 10 and 20, although pups grew isometrically during this time period.

Reference and Study Design	Results	Comments
White et al. (2007) continued <u>Study 2</u> MG assessment: Dams and female offspring	LactoF expression was significantly (about 50%-80%) ↓ compared to controls in all 3 exposure duration groups on PND 20, the time point when a peak in this protein normally occurs. LactoF levels in the treated groups on PND 20 were similar to the controls on PND 10. Female Offspring on PND 10 or PND 20 (Study 2)	
Exposure regimen: Gestational. GD 1-17; GD 8-17; or 12-17. Controls dosed with water GD 1-17. White et al. (2007) (continued).	 Whole mounts were examined microscopically and scored on a scale of 1-4. All treated groups were prenatally exposed to 5 mg/kg/day on stated gestational days (GD). MG development was delayed (p<0.001) in all groups at both time points. MG development was not correlated with body weight. Virtually no MG development occurred in treated pups between PND 10 and 20, although relative body weight gain was not decreased in treated pups during this period. PFOA serum levels in serum and liver decreased from PND 10 to PND 20, but MG development remained arrested. 	
Group size: 14-16 dams 10 offspring per litter (litters equalized on PND 1) Timepoint(s) for mammary	$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	
gland evaluation: PND 10 - Half of dams and litters PND 20 - Half of dams and litters	P<0.001 OTHER REPRODUCTIVE AND DEVELOPMENTAL PARAMETERS (Study 2) Maternal body weight gain – No effect.	
	<u>Reproductive parameters</u> – No effect on number of implants, live fetuses, or % prenatal loss per live litter. <u>Offspring body weight</u> – Significantly ↓ (p<0.05; p<0.01, or p<0.001) in all treated exposure duration groups at all timepoints assessed (At birth [PND 1], PND 5, PND 10, and PND 20).	
	 PFOA LEVELS IN DAMS (BLOOD) AND OFFSPRING (BLOOD, LIVER) PFOA was determined semiquantitatively in blood and quantitatively in liver (n=3-6 for each treatment duration group at each time point). Dam blood - PND 10 and 20: ↑ with exposure duration; similar levels on PND 10 and 20; differences may have been masked by semiquantitative determination. Offspring blood – PND 10 and 20: ↑ with exposure duration; ↓ between PND 10 and 20. Offspring liver – PND 1, 10, and 20: ↑ with exposure duration; similar on PND 1 and 10, ↓ on PND 20. Offspring liver:blood ratio: Levels in liver approximately 2 – 3 times higher than in blood in all treated groups at all time points. 	

White et al. (2009). Effects of	EARLY-LIFE EF	Offspring					
perfluorooctanoic acid on mouse mammary							MG development was delayed in
gland development and differentiation	MG developmen	nt (Early effects cross	foster study)				female offspring after gestational
resulting from cross-foster and restricted							and/or lactational exposure.
gestational exposure		ounts assessed micros					
					ered differentiation on F		MG development delay in female
Species and strain:	appeared	d immature, resembling	g normal late pregnar	ncy MG. Deficits pers	sisted until end of study	(PND 10).	offspring occurred at timepoints at
Timed pregnant CD-1 mice and their					IG morphology on PND		which body weight was not decreased
offspring,					exposure through mater	rnal behavior such as	and/or relative liver weight was not
	grooming	g of pups and ingestion	of waste excreted by	y pups.			increased, suggesting that MG
Test article and vehicle:							development may be a more sensitive
PFOA (ammonium salt, >98% pure; 98.9%	Female offspring	:					endpoint in offspring than decreased
straight chain, 1.1.% branched isomers) in							growth or increased relative liver
deionized water	MG de	velopment scores of w	hole mounts from fen	nale offspring expose	ed on GD 1-17		weight.
	Treatment grou	p PND 1	PND 3	PND 5	PND 10	-	
Route of exposure:	Control	3.3 + 0.2	3.5 + 0.2	3.0 + 0.1	2.8 + 0.2		MG development delay occurred as
Oral gavage	5L	1.7 + 0.4*	1.8 + 0.2*	1.5 + 0.1*	2.3 + 0.2*		early as PND 1, including in PND 1
	5U	1.9 + 0.2*	1.9 + 0.3*	2.0 + 0.2*	1.4 + 0.1*	-	female offspring exposed only
Early-life effects cross-foster study	5U/5L	1.5 + 0.2*	1.7 + 0.3*	1.1 + 0.1*	1.5 + 0.2*	-	lactationally with less than 1 day of
MG assessment: Dams and female	*p<0.05. n=4 litte	ers, 3 pups per litter, pe	er treatment group pe	r timepoint.			exposure and serum levels of ~2000
offspring	Scored on a 1-4	scale adjusted for stag	e of development and	d age.			ng/ml.
Exposure levels: 0 and 5 mg/kg/day		ant was delayed on PN	D 1 (after less than 1	day of exposure in	5L group), and in the ab	sence of effects on	MG development delay in female
		ver weight. See Comm		day of exposure in	or group), and in the ac		offspring persisted until PND 63 (9
Exposure regimen:							weeks) after gestational and/or
Gestational.	Other Effects (B	ody Weight and Rela	tive I iver Weight) (I	arly effects cross	foster study)		lactational exposure. At this time
GD 8-17.		iouy moight and noia					point, serum levels were <1000 ng/ml
Pups were cross-fostered at birth. Four	Dams:						in treated groups, and as low as 350
groups of pups, with exposures to 0 or 5		ody weight at any time	point (PND 1-10)				ng/ml.
mg/kg/day in utero (U), during lactation (L),		weight (p<0.05) at all ti		5 10) in treated day	ms (5U: 5U/5L)		
or both (U, L), designated as follows:		worgine (p. 10.00) at an a					MG developmental deficits after
0U/0L, 5U/5L, 5U/0L, and 0U/5L.	Offspring:						gestational and/or lactational
00/0E, 50/5E, 50/0E, and 00/5E.		odv weight on PND 1	body weight (p<0.0	5) in 5U/5L on PND (3, and in all treated grou	ins (5U_5I_5U/5I_) on	exposure persisted until age 18
Group size:	PND 5 and PND		,	,	,	.po (00; 01; 00;01) 0	months, a time point when PFOA had
56 per dose level on GD 8-17.			and PND 3 in pups	exposed in utero (5U	l, 5U/5L) and in all treat	ed groups (5U. 5L.	essentially been completed eliminated
10 pups per foster litters (M and F equal					ly exposure (5L group).		from the body.
when possible).					,		
							Exposure on GD 15-17, or longer
Timepoint(s) for mammary gland (MG)							portions of gestation, caused MG
evaluation:							development delay in female offspring
PND 1, PND 3, PND 5, and PND 10							on PND 29 and 32, and persistent
							changes in MG morphology at age 18
							months.

White et al. (2009) (continued).

Late-life effects cross-foster study

Note: This study is an additional component of Wolf et al. (2007).

MG Assessment: Female offspring only.

Exposure levels: 0, 3, 5 mg/kg/day

Exposure regimen:

Gestational.

GD 1-17.

Pups were cross-fostered at birth. Seven groups of pups, with exposures to 0, 3, or 5 mg/kg/day in utero (U), during lactation (L), or both (U, L), designated as follows: Control (0U/0L), 3U/3L, 5U/5L, 3U, 5U, 3L, and 5L.

Group size:

28-48 dams per dose level on GD 1-17. 10 pups per foster litter (M and F equal when possible).

Timepoint(s) for mammary gland (MG) evaluation:

Offspring - PND 22, PND 43, PND 63, and 18 months

LATE-LIFE EFFECTS CROSS-FOSTER STUDY

MG development (Late-life effects cross foster study)

MG development scores of whole mounts from female offspring exposed on GD 1-17									
Treatment group	PND 22 (weaning)	PND 42	PND 63						
Control (0U/0L)	3.7 <u>+</u> 0.1	3.2 <u>+</u> 0.2	3.1 <u>+</u> 0.2						
3L	3.0 <u>+</u> 0.2*	2.5 <u>+</u> 0.2*	2.6 <u>+</u> 0.2*						
5L	2.1 <u>+</u> 0.2*	2.5 <u>+</u> 0.1*	2.4 <u>+</u> 0.2*						
3U	1.8 <u>+</u> 0.2*	2.2 <u>+</u> 0.1*	2.6 <u>+</u> 0.2*						
5U	2.1 <u>+</u> 0.3*	2.2 <u>+</u> 0.1*	1.9 <u>+</u> 0.2*						
3U/3L	1.8 <u>+</u> 0.2*	2.7 <u>+</u> 0.1	2.6 <u>+</u> 0.3*						
5U/5L	1.2 <u>+</u> 0.2*	1.9 <u>+</u> 0.2*	1.9 <u>+</u> 0.2*						

*p<0.05. n=9-18 per treatment group at each time point.

5 Scored on a 1-4 scale adjusted for stage of development and age.

• MG development delayed until PND 63 (9 weeks of age) in all treatment groups. See Comments.

MG development at 18 months:

- MG examined both as whole mounts and as histological sections stained with H & E; n= 5-12 per group. (Could not be assessed with scoring criteria used at earlier timepoints.)

- Epithelial density appeared reduced in treated animals.
- Higher densities of darkly staining foci in glands of treated animals. Mean # foci/gland: Control, 6.9; 3 mg/kg/day groups, 34.3; 5 mg/kg/day groups, 38.6. No statistical parameters presented.

- Foci appear due to hyperplasia of ductal epithelium, infiltration of inflammatory cells into ductal regions, increased stromal density surrounding the ducts, and/or inappropriate differentiation of ductal epithelium. Some ductal inflammation observed in controls.

Other endpoints in female offspring (Late-life effects cross foster study; from Wolf et al., 2007)

● ↓ body weight and/or body weight gain on PND 22 (weaning) in all groups except 3L (not significant at p<0.05 in 3U). p<0.05 or 0.001 in other groups.

- \downarrow body weight persisted to PND 85 in 5U and 5U/5L (p<0.05).
- J survival until PND 22 (weaning) (65%) in 5U/5L (p<0.001).
- Delayed eye opening in 3U/3L, 5U, and 5U/5L (p<0.05).
- ↑ relative liver weight on PND 22 in all exposed groups (p<0.001).

Dams MG development was profoundly delayed in treated dams on PND 1, and delays persisted until PND 10.

MG development was also delayed beginning on PND 3 in untreated dams with exposure through nursing of treated pups. The exposure presumably was through maternal behavior and ingestion of excreted PFOA in pups' waste.


Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 454 of 551

White et al. (2009) (continued).	RESTRICTED-EXPOSURE STUDY
Restricted exposure study	MG development (restricted exposure study)
Note: This study is an additional	MG development scores of whole mounts from female
component of Wolf et al. (2007).	offspring exposed to 0 or 5 mg/kg/day during gestation
	Treatment group PND 29 PND 32
MG Assessment: Female offspring	Control 3.6 ± 0.1 3.6 ± 0.1
	GD $7-17$ $2.1 \pm 0.1^*$ $2.2 \pm 0.2^*$
Exposure levels: 0, and 5 mg/kg/day	GD 10-17 $2.0 \pm 0.2^*$ $2.2 \pm 0.2^*$
	GD 13-17 $2.2 \pm 0.1^*$ $2.5 \pm 0.1^*$
Exposure regimen:	GD 15-17 $2.0 \pm 0.2^*$ $2.3 \pm 0.3^*$
Gestational.	*p<0.05. n=10-21 per treatment group at each time point.
GD 7-17, GD 10-17, GD 13-17, or GD 15-	Scored on a 1-4 scale adjusted for stage of development and age.
17.	
	- At 18 months, MG examined both as whole mounts and as histological sections stained with H & E; n= 4-11 per group.
Group size:	(Could not be assessed with scoring criteria used at earlier time points.)
12-14 dams per group.	- Higher densities of darkly staining foci in glands of treated animals. Mean # foci/gland: Control, 1.5; GD 15-17, 29.8; GD 13-
10 pups per litter (M and F equal when	17, 17.9; GD 10-17, 32.8; GD 7-17, 25.5. No statistical parameters presented.
possible).	- Foci appear due to hyperplasia of ductal epithelium, infiltration of inflammatory cells into ductal regions, increased stromal
	density surrounding the ducts, and/or inappropriate differentiation of ductal epithelium. Some ductal inflammation in controls.
Timepoint(s) for mammary gland (MG)	-Peripheral localized increases in epithelial density in whole mounts from many treated animals.
evaluation:	
PND 29, PND 32, and 18 months	Other endpoints in female offspring (restricted exposure study; from Wolf et al., 2007)
	 No effect on pup survival to weaning.
Related studies:	• No effect on body weight at birth.
Wolf et al. (2007)	● ↓ body weight starting on PND 2 in longest exposed groups (GD 7-17, GD 10-17) and in all groups on PND 7-22 (p<0.05 or
	lower).
	 No ↓ body weight after PND 29. Deleved every exercise in all groups circuificant (n <0.01) in langest every every of (CD 7.47, CD 10.47).
	 Delayed eye opening in all groups, significant (p<0.01) in longest exposed (GD 7-17, GD 10-17 A relative liver weight on DND 22 in all exposed groups (p <0.001)
	● ↑ relative liver weight on PND 22 in all exposed groups (p<0.001).
	PFOA SERUM LEVELS
	 Data for 5 mg/kg/day dams from early-life exposure study, and 5 mg/kg/day offspring from early-life exposure and late-life
	exposure studies presented graphically together for comparison. (3 mg/kg/day data not shown).
	 Levels in treated dams decreased from LD (lactation day) 1-10.
	 Levels in control dams nursing treated pups increased from LD 1-5.
	 Levels in control dans notsing iteated pups increased non LD 1-5. Levels in gestationally exposed pups were higher than in dams on PND 1.
	 Levels in gestationally exposed (5U and 5U/5L) pups decreased from PND 1-63, with 5U (no lactational exposure)
	decreasing more quickly.
	 Levels in lactation-only group (5L) offspring stated to be ~2000 ng/ml on PND 1 in text. Levels in 5L increased from PND 1-
	10, and then decreased from PND 22-42. Levels in 5L were similar to 5U on PND 10-22.
	 Levels in all offspring groups had decreased to <1000 ng/ml at PND 63.
	 Levels in all offspring groups had decreased to < 1000 fig/ml at PND 63. Data from restricted exposure study from Wolf et al. (2007) discussed in text, not shown.

Reference and Study Design			Comments					
White et al. (2011).	MG DEVELOPMEI	NT and LACTATIONAL E	Results FFECTS (P0 and F1 dai	ms: F1 and F2 fe	male offspring)	- In P0 dams , MG development was delayed in the		
Gestational and chronic low-dose			absence of overt maternal toxicity (decreased body					
PFOA exposures and mammary	MG Devel	opment Scores of Whole	weight or effects on reproductive parameters),					
gland growth and differentiation in	Treatment group		PND 22	PND 42	PND 63	suggesting that MG development is a more sensitive		
three generations of CD-1 mice.		mg/kg/day, P0 GD 1-17 ai			F1 PND 22)	endpoint.		
Species and strain:	Control		2.4 + 0.2					
Timed pregnant CD-1 mice and	5 ppb in dw		3.4 + 0.1*			Higher MG development scores of whole mounts in all		
their offspring	1 mg/kg/day		3.0 + 0.2*			treated P0 dams and 5 mg/kg/day F1 dams on PND 22		
	1 mg/kg/day +		3.2 + 0.2*			is indicative of delayed MG development. In these		
MG assessment:	5 ppb in dw		_			treated dams, MG at PND 22, when MG involution is		
Dams and female offspring	5 mg/kg/day		3.9 + 0.1*			normally seen at weaning, resembled normal MG on		
Test article and vehicle:		d with control; n=7-11 per	group.	•		PND 10, the peak of lactation. This is consistent with		
PFOA (ammonium salt, >98%	Stated to be cons	istent with observations fro	om <u>H&E stained slides</u> (d	lata not shown)		observations in MG from these animals in H&E stained		
pure) in deionized water or drinking	F1 female offspr	ing (1 or 5 mg/kg/day, P0	GD 1-17 and/or 5 ppb	in drinking water	r, P0 GD 7- F1 PND 63)	slides. Results are also consistent with White et al.		
water	Control		3.8 <u>+</u> 0.1	3.8 + 0.1	<u>3.8 + 0.2</u>	(2007), but also occurred in this study after 34 days of		
	5 ppb in dw		2.5 + 0.2*	3.3 + 0.2*	2.6 <u>+</u> 0.4*	exposure to 5 ppb in drinking water.		
Route of exposure:	1 mg/kg/day		2.3 <u>+</u> 0.2*	2.6 + 0.4*	2.9 <u>+</u> 0.2*	- In the F1 female pups , MG development was		
Oral gavage and/or drinking water	1 mg/kg/day +		2.2 <u>+</u> 0.1*	2.2 + 0.3*	2.0 <u>+</u> 0.3* [#]	significantly delayed in all dosed groups including 5 ug/L		
	5 ppb in dw			_	_	in drinking water at PND 22, 42, and 63. MG		
Exposure levels:	5 mg/kg/day		1.6 <u>+</u> 0.1*	2.0 + 0.3*	2.2 <u>+</u> 0.2*	development was delayed in 5 ppb drinking water group		
0, 1, or 5 mg/kg/day and/or 5 ppb	*p<0.05 compared	d with control; [#] p<0.05 corr	pared with 1 mg/kg/day.	n=4-10 per grou	ip.	in the absence of effects on body weight or relative liver		
in drinking water	F1 dams (1 or 5 ı	ng/kg/day, P0 GD 1-17 aı	nd/or 5 ppb in drinking	water, P0 GD 7-	F2 PND 22)	weight at any timepoint, indicating that it is a more		
	Control	4.0 <u>+</u> 0.1	2.1 <u>+</u> 0.3			sensitive endpoint.		
Exposure regimen (see study	5 ppb in dw	2.8 <u>+</u> 0.5*	2.2 <u>+</u> 0.2					
design figure in 2 nd column,	1 mg/kg/day	2.5 <u>+</u> 0.2*	1.9 <u>+</u> 0.4			The PFOA serum levels in the F1 pups exposed to 5 ppb		
below):	1 mg/kg/day +	2.0 <u>+</u> 0.2*	1.5 <u>+</u> 0.2*			in drinking water ranged from 21.3 ng/ml on PND 22 to		
Gestational through PND 63.	5 ppb in dw					66.2 ng/ml on PND 63 (compared to 0.6 and 3.1 ng/ml,		
5 groups as follows: - Control	5 mg/kg/day	2.5 <u>+</u> 0.2*	3.2 <u>+</u> 0.3*			respectively, at these times in the controls). Thus the		
		d with control; n=4-10 per g				LOAEL for delayed mammary gland development in the		
- GD 1-17: 1 mg/kg/day (P0 dams) - GD 1-17: 5 mg/kg/day (P0 dams)		<u>E stained slides</u> showed co				F1 pups is 21.3 ng/ml (the level on PND 22), and no		
- 5 ppb in drinking water (P0 dams)		only 5 mg/kg/day group difi				NOAEL was identified.		
on GD 7-17 and continuing for P0		ing (1 or 5 mg/kg/day, P0						
dams, F1, and F2 until end of	Control	2.8 <u>+</u> 0.1	3.1 <u>+</u> 0.4	3.5 <u>+</u> 0.2	3.4 <u>+</u> 0.2	- In the F1 dams that were bred at 7-8 weeks of age, MG		
study on F2 PND 63).	5 ppb in dw	3.0 <u>+</u> 0.2	1.9 <u>+</u> 0.3	2.5 <u>+</u> 0.4*	3.5 <u>+</u> 0.2	development was significantly delayed in all treated		
- 1 mg/kg/day (P0 dams, GD 1-17)	1 mg/kg/day	1.9 <u>+</u> 0.3	2.3 <u>+</u> 0.1	3.4 <u>+</u> 0.2	2.4 <u>+</u> 0.2*	groups on PND 10 and in the 1 mg/kg/day + 5 ppb		
+ 5 ppb in drinking water (P0 dams	1 mg/kg/day +	2.6 <u>+</u> 0.2	2.3 <u>+</u> 0.2	2.4 <u>+</u> 0.2* [#]	2.6 <u>+</u> 0.5	drinking water group on PND 22. Maternal toxicity		
on GD 7-17 and continuing for P0	5 ppb in dw					(effects on reproductive parameters) occurred only in the		
dams, F1, and F2 until end of	5 mg/kg/day	2.0 <u>+</u> 0.2	2.0 <u>+</u> 0.2	3.3 <u>+</u> 0.4	2.6 <u>+</u> 0.4	5 mg/kg/day group. These MG development delays are		
study on F2 PND 63).	*p<0.05 compared	d with control; [#] p<0.05 corr	pared with 1 mg/kg/day.	. n=4-8 per group).	consistent with the delayed MG development in the		
,	**PFOA exposure t	hrough drinking water was	50-100 ng/day in pregn	ant P0 dams and	lower in F1 offspring.	virgin F1 siblings up to PND 63, the latest time point assessed (see above).		

	Lactational challenge in F1	dams and F2 litters on PND	10		- In the lactational challenge experiment with F1 dams
White et al. (2011) (cont.)		Ailly and the odd in 20 min (a)	Time to initiate (as a)	7	and F2 litters on PND 10, milk produced in 30 minutes
Group size:	<u>Treatment group</u> Control	<u>Milk produced in 30 min (g)</u> 2.10 + 0.20	<u>Time to initiate (sec)</u>	-	was decreased, and time to initiate nursing behavior was increased, in all treated groups compared to controls.
P0 dams: 7-12 per treatment group			<u>267 + 38</u> 284 + 55	-	However, none of the changes were statistically
F1 offspring: 12-13 per litter	5 ppb in dw	1.80 <u>+</u> 0.35	384 <u>+</u> 55	-	significant, possibly due to high variability and the small
F1 dams: 7-10 per treatment group	1 mg/kg/day	2.08 <u>+</u> 0.25	<u>307 + 114</u>	-	number of animals assessed. Additionally, postnatal
F2 offspring: 10 per litter	1 mg/kg/day + 5 ppb in dw		<u>351 + 86</u>	-	survival and body weight were not affected in the treated
1 2 onspring. To per litter	5 mg/kg/day	<u>1.73 + 0.51</u>	279 <u>+</u> 30		F2 offspring, suggesting that the ability of the F1 dams to
Timepoint(s) for mammary gland	n=7-10 litters per group; n=1	0 offspring per litter.			provide nutritional support was not decreased. However,
(MG) evaluation:	Dams were separated from	n offspring for three hours, the	n returned to their litters	and allowed to nurse for 30	it is not known if there were deficits in lactational function
(mo) evaluation.				-pup litter were recorded before	that were compensated for by increased frequency or
F0 dams: PND 22		es of nursing, in order to estima			longer duration of nursing events, since these
F1 offspring: PND 22, PND 42,	period.	, , , , , , , , , , , , , , , , , , ,		g	parameters were not assessed.
PND 63	 Although not statistically stat	ignificant, milk volume was \downarrow a	nd time to initiate nursin	g was ↑ in all treated groups	
F1 dams: PND 10, PND 22		variability limited power to dete			- The F2 pups showed a trend toward delayed mammary
F2 offspring: PND 10, PND 22,	, 3	у I	, ,		gland development, with decreased scores in all treated
PND 42, PND 63	OTHER ENDPOINTS (n=4-1	10 per treatment group)			groups compared to controls at all time points (PND 10,
1 110 42,1 110 00		No significant effect in P0 dam	ns (data not shown for F	1 dams)	22, 42, and 63) except for the 5 ug/L drinking water group
	matoma body worght gam	rto olgimouni onoot in r o dan		r damoj.	on PND 63. However, decreases were statistically
	Reproductive parameters (P	() and F1 dams)			significant only on PND 42 in the 5 ppb drinking water
		of implants or live fetuses, or 1	nrenatal loss or postna	atal survival except in 5	group and the 1 mg/kg/day + 5 ppb drinking water
	mg/kg/day group.				groups, and on PND 63 in the 1 mg/kg/day group. Serum
		number of implants (F1) and li	ive fetuses (P0_E1)_and	d ↑ prenatal loss (P0) and	levels in F2 pups exposed to 5 ppb in drinking water were
	postnatal survival (F1).				26.6 to 68.5 ng/ml, similar to the F1 pups with the same
					exposure (see above). In the F2 pups which were the
	Female offspring (F1 and F2) - body weight, body weight e	xcluding liver weight an	d relative liver weight	offspring of dams exposed during development to 1
		assessed on PND 22, PND 42		a rolativo inter trolgitt.	mg/kg/day or 5 mg/kg/day, but not exposed later through
				to control) on PND 42 (p<0.05).	drinking water, serum levels at the various time points
		/day + 5 ppb in drinking water of			(PND 22, 42, and 63) ranged from 0.4 ng/ml (below
		ng/kg/day on PND 22, and 5 n			controls) to 7.8 ng/ml.
	42 (p<0.05).				Summary: Chronic exposure to 5 ppb PFOA in drinking
	, ,				water caused delayed MG development in both P0 and
		sessed on PND 1, PND 3, PNI			F1 dams and F1 and F2 offspring. MG development was
		, and relative liver weight asse			delayed by exposure to 5 ppb in drinking water at all
		ody weight. \downarrow Body weight only			timepoints in F1 offspring and on PND 42 in F2 offspring.
			t a few timepoints in 1 n	ng/kg/day (with or without 5 ppb	Delayed MG development was a more sensitive endpoint
	in drinking water) groups (p<				than decreased body weight in dams and offspring,
	• Relative liver weight was r	not affected.			reproductive effects in dams, and increased liver weight
	PFOA SERUM LEVELS				in offspring. The LOAEL based on serum PFOA levels for
		P0 and F1 dams on PND 22; i			delayed MG development in the F1 pups is 21.3 ng/ml
		osed only to 5 ppb in drinking v	vater were 75-87 ng/mL	. Serum levels in F1 and F2	(the level on PND 22). No NOAEL was identified in this
	offspring were 21–69 ng/ml.				study.
	1				

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 457 of 551



Reference & Study Design		Comment				
Yang et al. (2009). Differential effects of peripubertal exposure to perfluorooctanoic acid on mammary gland development in	MAMMARY GLAND DE MG development in wh ALSO SUMMARY TAB	After peripubertal exposure to PFOA, MG development was delayed at 1-10 mg/kg/day in Balb/C mice. In C57BL/6 mice, MG development was stimulated				
C57BI/6 and Balb/c mouse strains.	<u>Treatment</u> (mg/kg/day)	PFOA serum level (ug/ml) ^a	Ductal Length (relative units)	<u># Terminal End Buds</u> (TEBs)	<u># Stimulated Terminal Ducts</u> (TDs)	at 1 and 5 mg/kg/day and delayed at 10 mg/kg/day. The range of serum PFOA
 Species and strain: Female Balb/C and C57Bl/6 mice Test article and vehicle: PFOA (ammonium salt, >98% pure) in deionized water Route of exposure: Oral gavage Exposure levels: 0, 1, 5 or 10 mg/kg/day Exposure regimen: Peripubertal. Starting at age 3 weeks for 4 weeks (5 days per week). 	 * p<0.05 compared to compared to	ontrol. n=5 per strain delayed at 1, 5, and /kg/day, had no effec development was s feration in TEBs/sti	per dose group. 10 mg/kg/day, in a o t on MG developmen timulated at 5 mg/kg mulated TDs and d	dose-related fashion in Balb/C nt in Balb/C mice (data not sho g/day and totally arrested at 10 lucts in 7 week old Balb/C ar	mg/kg/day. nd C57BL/6 mice treated with PFOA	 levels was similar in the two strains of mice within the dose ranges mentioned above. The dose-response curve for MG development in the C57BI/6 mice was non-monotonic, and the change from a large stimulatory effect to a large inhibitory effect occurred within a relatively small range of serum PFOA levels (68 µg/ml to 96 µg/ml). <u>Uterine development</u> followed a similar pattern of delay/simulation as MG development in the two strains. However, in C57BL/6, stimulation of uterine development occurred at 1 mg/kg/day but not 5 mg/kg/day. <u>Vaginal opening</u> was delayed at all
Group size: 5 per strain per dose group Timepoint for mammary gland (MG) evaluation: Age 7 weeks Related studies: Zhao et al. (2010). Zhao et al. (2012).	 Assessed in 1 and 5 mg/kg/day groups as % Brdu positive cells after treatment with Brdu 2 hours before sacrifice. Data shown graphically and discussed in text. In Balb/C, ↓ % proliferating cells in TEBs/stimulated TDs at 1 and 5 mg/kg/day (dose-related) and ducts at 5 mg/kg/day. In C57BL/6, % proliferating cells in TEBs/stimulated TDs and ducts at both doses. Since # of TEBs/stimulated TDs was ↑ at 5 mg/kg/day, results indicate overall ↑ in MG epithelial cell proliferation at this dose. 					 doses in both strains. <u>Liver weight</u> was increased at all doses in both strains. In this study, PFOA exposure was during the peripubertal period, while exposure was prenatal and/or neonatal in White et al., 2007, 2009, 2011; Macon et al., 2011; and Tucker et al., 2015. PFOA serum levels from this study are not reported in this publication, but are reported in Zhao et al. (2012).

Appendix 5B-2: Publications/studies of mammary gland development after peribubertal exposure to PFOA in mice

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 459 of 551

Reference & Study Design	Results	Comment
Reference & Study Design Yang et al. (2009). (continued)	OTHER ENDPOINTS Body weight: • Numerical data provided. • Body weight was unaffected except for decreased body weight at 10 mg/kg/day of both strains on the final 2 days of dosing (Day 19 and 20). Liver weight and histology: • Numerical data provided for liver weight. • In both strains, dose-related increase in absolute and relative weight. Significant (p<0.05) compared to control at all doses. Principal change seen in histological examination was dose-related increase in hepatocellular hypertrophy. Uterine weight and histology: • Numerical data provided for uterine weight. • In Balb/C, dose-related decrease in absolute and relative weight. Significant (p<0.05) compared to control at all doses. Histological	Comment
	 In Balb/C, dose-related decrease in absolute and relative weight. Significant (p<0.05) compared to control at all doses. Histological evaluation also showed decreased uterine development. In C57BL/6, absolute and relative uterine weight (p<0.05) and histological development were increased at 1 mg/kg/day, no effect at 5 mg/kg/day, and delayed at 10 mg/kg/day. Effects were not due to differences between groups in stage of estrus cycle at sacrifice. Day of vaginal opening Numerical data provided. Delayed in a dose-related manner at all doses in both strains. In Balb/C, delayed (p<0.05) compared to control at 1 mg/kg/day and did not occur by Day 50 (end of study) in 5 and 10 mg/kg/day. In C57BL/6, delayed (p<0.05) compared to control at 1 and 5 mg/kg/day and did not occur by Day 50 (end of study) in 10 mg/kg/day. 	

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 460 of 551

Reference & Study Design				Results				Со	mment
Zhao et al. (2012). Perfluorooctanoic acid effects on ovaries mediate its inhibition of peripubertal mammary gland development in Balb/c and	MG developm	MG development in whole mounts from female / week old Balb/C, C5/BL/6 WT, and C5/BL/6 PPAR-hull (KO) mice treated with						The purpose of this study was to evaluate effects on MG development from peripubertal exposure to	
C57BI/6 mice Species and strain: Female Balb/C, C57BI/6 Wild Type	<u>Treatment</u> (mg/kg/day)	PFOA serum level (ng/ml) ^a	<u>Ductal</u> <u>Length</u> (relative units)	<u># Terminal</u> <u>End Buds</u> <u>(TEBs)</u>	<u># Stimulated</u> <u>Terminal Ducts</u> <u>(TDs)</u>	<u>Absolute MG</u> <u>Weight (g)</u>	<u>Relative MG</u> <u>Weight (%)</u>		doses lower than those that caused delayed MG development in Balb/C and C57BI/6 WT mice in an earlier
(WT), and C57Bl/6 PPAR-alpha null (KO) mice	Balb/c 0 2.5	 51,000± 8000	8.17 ± 1.08 4.99 ± 0.67*	7.40 ± 1.14 3.25 ± 0.95*	6.11 ± 2.52 2.63 ± 1.41*	0.09±0.004 0.11±0.024	0.51±0.04 0.63±0.13		study (Yang et al., 2009). Effects in PPAR-alpha null mice were also studied.
Test article and vehicle: PFOA (ammonium salt, >98% pure) in deionized water	C57BL/6 WT 0 7.5	 93,000±11,000	6.30 ± 0.96 2.10 ± 1.98*	6.25 ± 2.06 1.00 ± 1.41*	6.50 ± 2.89 0.80 ± 1.31*	0.15±0.035 0.11±0.026	0.77±0.18 0.66±0.13		In Balb/C mice, inhibition of MG development occurred at 2.5 mg/kg/day, lower than the LOAEL of 5 mg/kg/day
Route of exposure: Oral gavage	C57BL/6 PPAR-null (KO) 0		8.90 ± 1.04	10.00 ± 4.36	6.20 ± 1.64	0.17±0.035	0.88±0.21		identified in Yang et al.(2009). In C57BL/6 WT mice, inhibition of MG development
Exposure levels: 0 or 2.5 mg/kg/day (Balb/C)	7.5	,	8.43 ± 1.08	9.43 ± 1.90	7.02 ± 2.16 rels estimated from ba	0.14±0.026	0.78±0.11		occurred at 7.5 mg/kg/day, lower than the LOAEL of 10
0 or 7.5 mg/kg/day(C57BL/6 WT & KO) PFOA exposure regimen: Peripubertal. Starting at age 3 weeks for 4 weeks (5 days per week)	 Doses of PFOA (2.5 mg/kg/day in Balb/C mice and 7.5 mg/kg/day in WT and KO mice) were chosen because they were lower than the LOAELs for delayed MG development in Balb/C (5 mg/kg/day) and WT (10 mg/kg/day) strains in the previous study (Yang et al., 2009). The goal was to further study the delayed MG development caused by PFOA in these strains. 							et al. (2009). In Yang et al. (2009), 5 mg/kg/day was reported to stimulate MG development in this strain.	
days per week)). In study of effect of estradiol and progesterone, starting at age 3 weeks for 2 weeks. Estradiol and progesterone treatment during 2 nd week of PFOA treatment.	In <u>Balb/C mice</u> , the PFOA serum level and the MG development delay at 2.5 mg/kg/day were intermediate to the serum PFOA levels and MG development delays at 1 mg/kg/day and 5 mg/kg/day in this strain in Yang et al. (2009). In <u>WT mice</u> , the PFOA serum level (93,000±11,000 ng/ml) at 7.5 mg/kg/day in this study is very close to the PFOA serum level at 10 mg/kg/day (96,000±10,000 ng/ml) in the earlier study (Yang et al., 2009). MG development was delayed at both of these doses in these two studies. The serum level (68,000±10,000 ng/ml) at which MG development was reported to be greatly stimulated in Yang et al. (2000) is relatively close to the serum level to the serum level of the serum level of the serum level to the serum level of the serum lev						In C57BL/6 PPAR alpha null (KO) mice, 7.5 mg/kg/day PFOA had no effect on MG development. Lack of inhibition of MG development in C57Bl/6 KO, as compared to the other two strains, in this		
Group size: 5-10 Timepoint for MG evaluation: 50 days (7 weeks). 356 days (5 weeks) for studies of effect of estradiol and progesterone.	were much low serum levels w levels in KO m	ver than the serum vere similar to thos	level where M e at 7.5 mg/kg n those in WT	G was inhibited in /day and there was mice where MG d	nt. However, serum P WT mice. It is stated s no effect on MG development was dela e data.	that in KO mice trea velopment (data not	ated with 10 mg/kg shown). Because	g/day, the the serum	study, may be due to kinetic factors unrelated to PPAR status. PFOA serum levels in KO mice were below the serum levels at which MG development was delayed in the other two strains of mice.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 461 of 551

Reference & Study Design
Reference & Study Design Zhao et al. (2012). (continued) Related studies: (ang et al. (2009). Zhao et al. (2010). Zhao et al. (2010).

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 462 of 551

Reference & Study Design	Results	Comment		
Zhao et al. (2012). (continued)	Day of vaginal opening, presence of corpus lutea in ovary, and uterine histology:	Additionally, it is difficult to		
	 Vaginal opening data presented numerically, other information presented in text. n=5 per group. 	interpret the effects seen in		
	 PFOA treatment delayed vaginal opening in Balb/C and WT (p<0.05), but not KO. 	Yang et al. (2009) and in this		
	• PFOA prevented development of corpus lutea present in Balb/C and WT, but had no effect in KO.	study in C57BL/6 WT mice because the dose-response		
	PFOA caused thinning of uterine myometrium and endometrium thinned Balb/C and WT; no change	s in KO. between 5 and 7.5 mg/kg/day		
	Absence of corpus lutea and uterine changes in Balb/C and WT stated to be indicative of absence of			
		same study. The 5 and 10		
	Levels of ovarian enzymes related to steroid hormone synthesis and PPAR alpha	mg/kg/day doses were not		
	PFOA treatment in both Balb/C and WT mice <u>decreased (p<0.05)</u> levels of 4 ovarian enzymes related to s	vnthesis of steroid included along with 7.5		
	hormones (StAR, CYP11A1, HSD3beta1, HSD17beta1) and had no effect on aromatase. PFOA did not affect	Ing/kg/day dose in this study.		
	mice (n=3 per group).	The two doses and serum levels are close together (68		
	 PFOA treatment did not affect ovarian PPAR alpha levels. Ovarian PPAR alpha was higher (p<0.05) in Ba 			
	(0.43 + 0.19), and was not measured in KO mice. Units not stated.	opposite effects on MG		
		development (stimulation		
	MG levels of ovarian growth factors, receptors, and cell proliferation marker in Balb/C, WT, and KO m			
	• Levels of 3 growth factors (Areg, IGF-I, HGF), 2 receptors (ERalpha, EGFR), and the cell proliferation mar			
	in ovaries. (Data shown in bar graphs. n = 3 per group).	Ralpha, EGFR), and higher dose. This implies that a very steep dose-		
	In Balb/C and WT mice, PFOA decreased 2 growth factors (Areg and HGF), decreased both receptors (EF	response curve exists for		
	decreased PCNA (p<0.05) in Balb/C and WT mice. PFOA had no effect on IGF-I.	stimulation versus inhibition.		
	PFOA had <u>no effect</u> on any parameter in KO mice.	and that there is a dose		
	These results are not consistent with the results in WT and KO mice dosed with 5 mg/kg/day PFOA	between 5 and 7.5 mg/kg/da		
	al. (2010). Ovarian levels of 3 growth factors (Areg, IGF-I, HGF), 2 receptors (ERalpha, EGFR), and			
	(cyclin D1, PCNA) were assessed (see above).	68 and 93 μg/ml where no		
	 5 mg/kg/day PFOA increased all 3 growth factors in KO mice and 2 growth factors in WT mice (1.5-2 			
	both receptors in WT and KO mice , and increased both markers of cell proliferation) in both WT and	in the absence of data at both		
	Estrogen and progesterone levels	doses from the same study.		
	• It is not known if estrogen and progesterone levels were affected by PFOA treatment. The authors state the	nat this could not be		
	assessed due to insufficient numbers of animals in each stage of estrous. However, delayed vaginal openin	a absence of corpus lutea Similarly, it is difficult to		
	and abnormal uterine histology suggest abnormal ovarian function and decreased hormone levels.	interpret the opposite effects of PFOA at 5 versus 7.5		
	Kidney organic anion transporters (OATs):	mg/kg/day on ovarian		
	• Expression of 7 OATs was measured in kidneys from the three strains of mice (control and PFOA-treated)	enzymes related to hormone		
	• In control & PFOA-treated mice, levels of 3 OATs were higher in KO than Balb/C, & 2 of these OATs were	higher in WT than Balb/C. synthesis, and MG growth		
	 PFOA treatment did not affect levels of OATs expression. 	factors, receptors, and markers of proliferation, since		
	• This endpoint is of interest in evaluation of strain differences in serum PFOA levels from same administered	ed dose, but is not directly the data at each dose comes		
	relevant to the evaluation of effects of PFOA on MG development.	from a different study.		

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 463 of 551

Reference & Study Design	Results	Comment
	SERUM PFOA LEVELS	
	• Serum PFOA levels from 3 studies (this study; Yang et al., 2009; and Zhao et al., 2010) are presented in t	his study.
	Numerical data are not shown and were estimated from the bar graph. n = 5 per group. These estimated numerical bar the table on MG developmental effects above, and in the tables presenting the other two studies.	merical data are shown in
	 Serum PFOA levels were not measured in the component of this study in which the effects of estradiol an with PFOA were studied. 	d progesterone given along

SUPPLEMENTAL TABLE: Mammary gland development parameters and serum PFOA levels from female 7 week old Balb/C and C57BL/6 mice treated with PFOA for 4 weeks

<u>Treatment</u> (mg/kg/day) <i>Balb/c</i>	<u>Citation</u> ^a	Serum <u>PFOA^b</u> (µg/ml)	<u>Ductal</u> <u>Length</u> (relative units)	% <u>Control</u>	# Terminal <u>End Buds</u> (TEBs)	<u>% Control</u>	<u># Stimulated Terminal</u> <u>Ducts</u> (TDs)	% <u>Control</u>
Balg/C								
0	1		7.60 ± 0.94		8.20 ± 1.92		6.20 ± 2.39	
0	3		8.17 ± 1.08		7.40 ± 1.14		6.11 ± 2.52	
1	1	29 ± 4	7.28 ± 0.73	96%	6.00 ± 3.74	73	3.80 ± 1.64	61
2.5	3	51 ± 8	4.99 ± 0.67*	61	3.25 ± 0.95*	44	2.63 ± 1.41*	43
5	1	109 ± 12	3.99 ± 0.36*	53%	3.99 ± 0.36*	49	1.20 ± 1.30*	19
10	1		3.40 ± 4.77*	45	0.00 ± 0.00*	0	0.00 ± 0.00*	0
C57BL/6 Wild Type								
0	1		4.76 ± 1.19		7.80 ± 2.39		6.60 ± 2.88	
0	3		6.30 ± 0.96		6.25 ± 2.06		6.50 ± 2.89	
1	1	26 ± 6	4.06 ± 0.85	85	10.40 ± 3.36	133	9.80 ± 2.77	148
5	1	68 ± 10	4.01 ± 0.71	84	11.20 ± 1.30*	144	16.60 ± 5.90*	252
7.5	3	93 ±11	2.10 ± 1.98*	33	1.00 ± 1.41*	16	0.80 ± 1.31*	12
10	1	96 ±10	0.30 ± 0.67*	6	$0.00 \pm 0.00^*$	0	0.00 ± 0.00*	0
C57BL/6 PPAR-null (KO)								
0	3		8.90 ± 1.04		10.00 ± 4.36		6.20 ± 1.64	
5	2	28 ± 2	Terminal end bu	uds and stim	ulated terminal du	ucts stated to b	e INCREASED. Numerica	l data not shown.
7.5	3	38 ± 7	8.43 ± 1.08	95	9.43 ± 1.90	94	7.02 ± 2.16	113


^a Citations are: 1. Yang et al. (2009); 2. Zhao et al. (2010); 3. Zhao et al. (2012).

^b PFOA serum data from all 3 studies are presented in a bar graph in Zhao et al. (2012). Numerical values were extrapolated from the bar graph.

*P<0.05 compared to control. n=5 per strain per dose group.

Appendix 6: Outputs of Benchmark Dose Modeling for Mammary Gland Development Endpoints (Macon et al., 2011)

Appendix 6A: Benchmark Dose Modeling of Mammary Gland Developmental Score in Response to PFOA Using BMR of 10% Decrease Relative to Controls (Macon et al., 2011)



+

11

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 467 of 551

Default Initia	11	Parameter Valu	18.0
alpha		0.231538	
zho	-	Q.	Specified
istercept	-	3.3	
· · · · · · · · · · · · · · · · · · ·	-	-1.7	
	-	1.59127	
2	-	202.223	

Asymptotic Correlation Matrix of Parameter Estimates

(*** The model parameter(s) -rho -n
have been estimated at a boundary point, or have been
specified by the user,

hardeness of the se

and do not appear in the correlation matrix)

	alpha	intercopt.	v	х.
alpha	1	-2,2e-011	-9.98-008	6.46-008
intercept	-2.2e-011	3	-0.74	-0.27
×	-9.9e-008	-0.74	1	-9.17
k.	6.10-008	-0.27	-0.17	1

Parameter Estimates

95.05 Wald Coeffdense

				bbras serve restricted
	able	Estimate	Std. Ker.	hower Conf. Limit Opper
	lpha	0.178604	0.0612607	0.0505353
0.238673 inter	cept	3.29993	0.199163	2,92010
3.66968	¥	-1.67528	0.250648	-2.16654
-1.18402	n	4	84	
332.058	k	141.000	97.0679	-48.4413

38329. b. . . .

NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error.

Tuble of Date and Estimated Values of Interest

Dose	н	Obs Hean	Est Nean	Obs Std Dev	Est Std Dev	Scaled Res.
0 261.7 2281 1.628#+0 0.202		3.3 2.2 1.8 1.6	3.3 2.21 1.72 1.64	0.67 0.4 0.52 0.22	0.423 0.423 0.423 0.423	0.00565 -0.0597 0.321 -

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 468 of 551

Model Descriptions for likelihoods calculated

Model Al: Yij = Ma(i) + e(i) Var(e(i)) = Sigma*2

Model A2: Yij = Mu(i) + m(ij) Var(e(ij)) = Sigma(i)*2

Model A3: Yij = Hu(i) + e(ij) Var(e(ij)) = Sigma'2 Model A3 uses any fixed variance parameters that were specified by the user

Model B: Yi = Mu + e(1) $Var(e(1)) = Sigma^{2}$

£

Likelihoods of Taterest

Medal	Log(likelihood)	# Param's	AIC
AI	6.215023	5	-2,431646
8.2	0.999240		-1.998497
6.8	6.215023	5	-2-431616
litted	6.141961	4	(-4.283923)
R	-4.983792	2	13,967403

Explanation of Tests

Test 1: Do responses and/or variances differ among Dose levels? (A2 vs. R) Test 2: Are Variances Homogeneous? (A1 vs A2) Test 3: Are variances adequately modeled? (A2 vs. A3) Test 4: Does the Model for the Mean Fit? (A3 vs. fitted) (Note: Nhon rho=0 the results of Test 3 and Test 2 will be the same.)

Tests of Interest

Test	-2*log(Likelihood Ratio)	Test df	p-value
Tent 1	27,9659	6	<.0001
Test 2	5.56685	3	D.1347
Test 3	5.56685	3	D.1347
Test 4	0.147723	1	0,7007

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the done levels. It assess appropriate to model the data

The p-walos for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here


The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here

The p-value for Test 4 is greater than .1. The model chosen seems to adequately doscribe the data

Benchmark Done Computation

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 469 of 551

Specified effect	-	0.1
Risk Type	-	Relative risk
Confidence level	-	0.95
BND	-	34.7717
IOID.	-	5.51541



Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 471 of 551

Default Init	141	Parameter, Valv	- 669
alph	14. 14	0,231538	
c'h	e =	0	Specified
beta	0.+	3.30302	
beta	1	-0.544614	
beta_	2.+	0.032366	

Anymptotic Correlation Matrix of Faramater Estimates

	alpha	bots_0	bets_1	bets_2
alpha	1	3.76-008	8.94-009	-10-007
bsts_0	3.7e-008	1	-0.51	0.32
beta_1	8.9e-008	-0.51	1	-0.96
beta_2	-1e-007	0.32	-0,96	1

Parameter Estimatos

			95.0% Wald Conf.	dence
Interval Variable	Estimate	Std. Err.	Lower Conf. Limit	Upper
Conf. Limit alpha	0.177536	0.0608942	0.0581851	
C.296986 beta_0	3.33294	0.188191	2.93319	
3.67089 beta_1 -0.0906905	-0.541825	0.230176	-0,992962	
beta_2 0.139975	0.0320545	0.0550625	-0.075866	

Table of Data and Estimated Values of Interest

Dose		Obe Mean	Est Hean	Obs Std Dev	Eat Std Dev	Scaled Res.
0 2.42 3.36 4.21	5 4 3 5	3.3 2.2 1.8 1.6	3.3 2.18 1.04 1.59	0.67 0.4 0.52 0.22	0.421 0.421 0.423 0.423 0.421	-0.0100 0.102 -0.178 0.0579

Model Descriptions for likelihoods calculated

Model Al: Yij = Ha(i) + e(ij) Var(e(ij)) = Sigma^2

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 472 of 551

```
Hodel A2: Y_{1j} = H_{0}(1) + \sigma(1j)
Var(e(1j)) = Signa(1)*2
```

Nodel A3: Yij = Mn(i) + e(ij) Var(e(ij)) = Sigma^2 Nodel A3 uses any fixed variance parameters that were specified by the user

Model B: Yi = Mu + w(1) Var(a(1)) = Sigma*2

Likelihoods of Interest

Mode1	Log(likelihood)	# Faras's	ATC
A1	6.215823	5	-2.431646
A2	8.599248	8	-1.990497
A3	6,215823	5	-2.431646
fitted	6,192967		/-4.385934 >
8	-4.903702	2	13.307403

Explanation of Tests

Test 1: Do responses and/or variances differ among Dose levels? (A2 vs. 8) Test 2: Are Variances Nomogeneous? (A1 vs A2)

Test 3: Are variances adequately modeled? (A2 vs. A3)

Test 4: Does the Model for the Mean Fit? (Al vs. fitted)

(Note: When showd the results of Test 3 and Test 2 will be the same.)

Tests of Isterest

Test	-2*log(Likelihood Ratio)	Test df	p-walue
Test 1	27,9659	6	<.0001
Test 2	5.56685	3	0.1347
Test 3		3	0.1347
Test 4	0.0457138	1	0.8307

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dows levels it seems appropriate to model the data

The p-value for Test 2 is greater than .). A homogeneous variance model appears to be appropriate here

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here

The p-value for Test 4 is greater than .1. The model chosen seems to adequately describe the data

Benchmark Dose Computation

Specified effect	÷.,	0.1
Risk Type	-	Relative risk
Confidence level	-	0.95

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 473 of 551

BHD = 0.633144 BHDL = 0.307553

IMDL computation failed for one or more point on the BNDL curve. The BBDL curve will not be plotted

```
Exponential Model 2 with 0.95 Confidence Level
                         Exponential
         4
        3.5
         3
Response
        2.5
Mean
         2
        1.5
         1
                  FILAC
                                                                   3.5
               0
                     0.5
                                     1.5
                                             2
                                                    2.5
                                                            3
                                                                           4
                            1
                                             dose
 11:16 05/04 2011
        Exponential Model. (Version: 1.7; Date: 12/10/2005)
        Input Data File: C:/USEFA/SHDS212/Data/exp_pfca mammary_Setting.(d)
        dauplet Plotting File:
                                                  Wed May D4 11:16:37 2011
BMD5 Model Non
  ter en invest en terrar la startis de tier de se
  The form of the response function by Model:
     Model 2: Y(dose) = a * exp(sign * b * dose)
                   Y[dose] = s * exp[sign * (b * dose)*d)
     Model 31
                   Y[dose] = a * [0-[0-1] * exp[-b * dose]]
     Hodel 4:
                   Y[dose] = a * [c-[c-1] * exp[-(b * dose)*d)]
     Model 5:
  Note: T(dose) is the median response for exposure = dose;
         sign = +1 for increasing trend in data;
         sign = -1 for decreasing trend.
     Model 2 is nested within Models 3 and 4.
     Hodel 3 is nested within Model 5.
     Model 4 is nested within Model 5.
  Dependent variable = Calculated Median
```

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 475 of 551

Independent variable = reroed_log_serum Data are assumed to be distributed: lognoreally Variance Model: Log-acale variance = exp(lnalphs) sho is set to 0. A constant log-scale variance model is fit.

Total number of dose groups = 4 Total number of records with missing values = 0 Maximum number of iterations = 250 Relative Function Convergence has been set to: 1s-008 Parameter Convergence has been set to: 1s-008

Hig solution provided: Approximate

Initial Parameter Values

Vari	able .	Model 2	Nodel 3	Model 4	
Nodel 5			10.000		157
ins]	pha	-3.53767	-3.53767	-3.53767	
	zho (S)	0	0	0	
0	83	1.41095	1,56697	3,39572	
3.39512	to .	0.172782	-0.0106424	0.296517	
0.206517	0	**		0.233395	
0.233395	d.	0752	2		
1					

(8) = Specified

Parameter Estimates by Model

Variable Model 2 Model 3 Model 4 Model 5
lnalpha -3.52095 -3.52095 -3.52146
1.53767
a 3.23432 3.23432 3.2415
3.23402 b 0.172782 0.172782 0.19561
0.414661 0.090262
d 1
2.43417

Table of Stats From Input Data

Dose	ж	Calc'd Median	Calc'd GSD
	-	and an an an an an an an an	
0	5	3.234	1.223

2.42	4	2.165	3.298
3.36	3	1.729	1.327
4,21	5	1.585	1.343

Estimated Values of Interest

aled Repiduel
0.0005776
0.05960
-0.1176
0.04216
0.0005775
0.05568
-0.1176
0.04216
-0.01413
0.07956
-0.1109
0.03103
4.18e-008
,7710-008
1.37e-008
.044e-009

Other models for which likelihoods are calculated:

Model Al: Yij = Ma(i) + e(ij) Var(e(ij)) = Sigma^2

Model A2: Tij = Mc(1) * c(ij) Var(c(ij)) = Sigma(i)*2

Model A3: Tij = Mu(i) + e(ij) Var(e(ij)) = esp(lalphs + log(mean(i)) + she) Model R: Tij = Mu + e(1) Var(e(ij)) = Sigma*3

Likelihoods of Interest

Model	Log(Likelihood)	DF	AIC
. 3.1	21.57016	5	-33.14031
3.2	22.40331		-28.80662
.8.3	21.57016	5	-33,14031
R	9.975396	2	-15.95079
2	21.42831	3	<3E.88823>
3	21.42811	3	-36.05623
400	21.43241	4	=34.86481
5	21.57016	5	-33.14031

Additive constant for all log-likelihoods = to the

-15.62. This constant added

showe values gives the log-likelihood including the term that does not depend on the model parameters.

Explanation of Tesis

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 477 of 551

Test 1: Does response and/or variances differ among Dose levels? (A2 vs. R) Test 2: Are Variances Homogeneous? (A2 vs. A1) Test 3: Are variances adequately modeled? (A2 vs. A3)

Test 4: Does Model 2 fit the data? (A3 vs. 2)

Test Sa: Soes Model 3 fit the data? (A3 vs 3) Test Sb: Is Model 3 better than Model 2? (3 vs. 2)

Test 6a: Does Hodel 4 fit the data? (A3 vz 4) Test 6b: Is Model 6 better than Model 2? (4 vs. 2)

Test Te: Does Model 5 fit the data? (A3 vs 51 Test Te: Is Model 5 better than Model 3? (5 vs. 3) Test Te: Is Model 5 better than Model 4? (5 vs. 4)

Tests of Interest

Test	-2*log(Likelihood Batio)	D. F.	p-value
Test 1	24.86	6	0.0003631
Test 2	1.666	3.	0.6445
Test 3	2,666	3	0,6445
Tost 4	0.2841	2	0.8676
Test 5a	0.2841	2	0.8676
Test 5b	7,105e-014		N/A
Tent 6a	0.2755	1	0.5997
Test fb	0.008586	1	0.9262
Test 7s	1.421e-014	0	H/A
Test 7b	0,2841	2	0.0676
Test 7d	0.2755	1	0.5997

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the done levels, it seems appropriate to model the data.

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-walue for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is greater than .1. Hodel 2 seems to adequately describe the data.

The p-value for Test 5a is greater than .1. Model 3 seems to adequately describe the data.

Degrees of freedom for Test 5b are less than or equal to 0. The Chi-Square test for fit is not valid.

The p-value for Yest 6s is greater than .1. Model 4 seems to adequately describe the data.

The p-value for Test 6b is greater than .05. Model 4 does not seem to fit the data better than Model 2.

Degrees of freedom for Test 7a are less than or equal to D. The Chi-Dquare test for fit is not valid.

The p-value for Test 7b is greater than .05. Hodel 5 does

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 478 of 551

not seem to fit the data botter than Model 3.

The p-value for Test 7c is greater than .05. Hodel 5 does not seem to fit the data better then Nodel 4.

Beachmark Dose Computations:


Specified Effect = 0.100000

Risk Type - Relative deviation

Confidence Level = 0.950000

2MD and 2MDL by Model

Model	IND .	BNDL
and the second second		second and do a second
2	0.60979	0.489341
3	0.60919	0.489341
4	0.588417	0.286515
5	1.27833	0.259859
5	1.27833	0.259059



Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 480 of 551

cho	10	0	Specified
beta 0	+	3.2622	
beta 1	-	-0.415294	

Asymptotic Correlation Natrix of Paramoter Estimates

(*** The model parameter(s) -sho

have been estimated at a boundary point, or have been specified by the user,

and do not appear is the correlation matrix 1

	alphs	bets_0	beta_1
alpha	1	4.6e-010	T.7e-010
beta_0	4.60-010	1	-0.82
bets_1	7.7e-010	-0.82	

Parameter Estimates

55.0% Wald Confidence Interval Lower Conf. Limit Opper Std. Ser. Veriable Estimato Conf. limit 0.0593451 0.0621081 0.181075 alpha 0.302804 2,91407 3,26695 0.180042 bots_0 3.61982 -0.533045 0.0614538 -0.412597bets 1 -0.29215

Table of Date and Estimated Values of Interest

Dose	8	Obs Mean	Est Mean	Obe Std Dev	Est Std Dev	Scaled Res.
0	5435	3.3	3.27	0.67	0.426	0.174
2.42		2.2	2.27	0.4	0.426	-5.322
3.36		1.6	1.68	0.52	0.426	-5.328
4.21		1.6	1.53	0.22	0.426	0.368

Model Descriptions for likelihoods calculated

Model Al: Yij = Mu(i) + e(ij) Var(e(ij)) = Sigma*2

Model A2: Yij = Mu(i) + e(ij) Var(e(ij)) = Sigma(i)*2

Model A3: Yij = Mu(i) + e(ij) Var(e(ij)) = Sigma*2 Model A3 uses any fixed variance parameters that were specified by the user Model h) $Y_1 = Mu + e(1)$ $Var(n(1)) = Sigma^22$

Likelihoods of Interest

Hode1	Log(likelihood)	# Paran's	ATC
A1.	6,215823	5	-2.431646
8.2	0.999248	8	-1.998497
64	6.215623	5	-2.431646
fitted	6.025186	3	-6.050372
	-4.983702	2	13.967403

Explanation of Tests

Test 1: Do responses and/or variances differ among Dose levels? (A2 vs. R)

Test 2: Are Variances Homogeneous? (Al vs A2) Test 3: Are variances adequately modeled? (A2 vs. A3) Test 4: Does the Nodel for the Mean Fit? (A3 vs. fitted) (Note: When rho-0 the results of Test 3 and Test 2 will be the same.)

Tests of Interest

Test	-2*log(Likelihood Hatio)	Test df	p-walos
Test 1	27,9659	6	<.0001
Test 2	5.56685	3	0.1347
Test 3	5.56685	3	0.1347
Test 4	0.381274	2	0,8264

The p-walue for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels It seems appropriate to model the data

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate hero


The p-value for 7eet 3 is greater than .1. The modeled variance appears to be appropriate here

The p-value for Test 4 is greater than .1. The model chosen seems to adequately describe the data

Benchmark Dose Computation

Specified e	ffect	-	0.1		
Risk Type		Ξ.	Relative risk		
Confidence		-	0.95		
	IND	-	0.7918		
	REDL		0.673285		

SMDL computation failed for one or more point on the BMDL curve. The BMDL curve will not be plotted **Appendix 6B:** Benchmark Dose Modeling of Number of Terminal Endbud in Response to PFOA Using BMR of 10% Decrease Relative to Controls (Macon et al., 2011)



alpha	+	52.0975	
rho		0	Specified
Intercept.	*	40	1.202407.002404
	*	-25	1.12
÷	-	0.952636	
*	**	1495.53	

Asymptotic Correlation Hatrix of Parameter Setimates

{ *** The model parameter(s) -: ho -: have been estimated at a boundary point, or have been
specified by the user,

and do not appear in the correlation matrix |

*		۷	intercept	alpha	10
80	4.8e-00	-4.54-008	-3.20-008	1	alpha
57	-0.1	=0.37	1	-3.2e-009	intercept
35	-0.3	1	-0.37	-4.5e-009	۷
10		~0.35	-0.57	4.8e-008	k

Parameter Estimates

			95.0% Wald Confldence
Interval Variable	Estimite	Std. Ker.	Lower Cosf. Limit Upper
Conf. Limit alpha	41.7264	14.312	13.6753
69.7774 Intercept	39.2599	2.85240	33.6692
44.8507	-25.532	4.27964	-33.9199
-17.144 6	1	SA.	
3364.03 k	1169.31	1119.77	-1025.41

SA - Indicatos that this parameter has hit a bound implied by some inequality constraint and thus has no standard error.

Table of Data and Estimated Values of Interest

Dose		Obe Hean	Est Maan	Obs Std Dev	Est Std Dev	Scaled Res.
0 261.7 2281 1.629e+0 0.152	5 4 3 104	40 33 24 15	39.3 34.6 22.4 15.4	8.94 8 6.33 4.47	6.46 6.46 6.46 6.46	0.256 -0.493 0.434 -

Nodel Descriptions for likelihoods calculated

```
Hodel Al: Y11 = Mu(1) + #(1)
Var(e(1)1) = Sigma^2
```

Model A2: Y1j = Nu(1) = e(1) Var(e(1)) = Sigma(1)^2

Model A3: Yij = Na(i) + e(i)) Var(e(ij)) = Sigma^2 Nodel A3 uses any fixed variance parameters that ware specified by the user

```
Model R: YI = Ma + e(i)
Var(e(i)) = Sigma^2
```

Likelihoods of Interest

Node1	Log(likelihood)	Pacan's.	ADC
A1	-39.950786	5	89,901573
3.2	-38,765686		93.531372
6.6	-39.950786	- 5	89, 901573
fitted	-40,214633	4	(10.429266)
R	-50.575583	2	405.191102

Explanation of Tests

Test 1: Bo responses and/or variances differ among Dose levels? (A2 ws. 8) Test 2: Are Variances Homogeneous? (A1 vs A2) Test 3: Are variances edequately modeled? (A2 vs. A3) Test 4: Boos the Hodel for the Maan Fit? (A3 vs. fitted) (Note: When rho-0 the results of Test 3 and Test 2 will be the same.)

Tests of Interest

Test	-2*log(likelihood Ratio)	Test df	p-value	
Test 1	23.6198	6	0.0006134	
Test 2	2.3702	3	0.4992	
Test 3	2.3702	3	0.4992	
Test 4	0,527693	1	0.4676	

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels. It seems appropriate to model the data

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here

The p-walue for Test 4 is greater than .1. The model chosen seems to adequately describe the data

Benchmark Dose Computation

Specified effect = 0.1

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 486 of 551

Risk Type = Relative risk Confidence level = 0.95 BMD = 212.474 BMDL = 55.9134

```
Exponential Model 4 with 0.95 Coeffidence Level
                                                                       Exponential
                     50
                     40
                     30
                    20
                     10
                             RIMOU)
                                             EMD
                                                                                                                                                                                                         14000
                                                                                                                                                                                                                                 16000
                                                                                                                                                                                  12000
                                                                                                                                   8008
                                                                                                                                                          10000
                                        ø
                                                  2000
                                                                                   4000
                                                                                                           6000
                                                                                                                                    dose
 5641 05/04 2011
                         Exponential Model. (Version: 1.7; Date: 12/10/2009)
                         Input Data File: C:/USRPA/BMD0212/Data/exp_pfoa mammary Setting.(d)
                         dauplot Plotting File:
                                                                                                                                                     Med May 04 14:41:27 2011
DHDS Model New
     the local distance is the first of the local distance of the local
      The focm of the response function by Model:
               Model 2: Yideeel + a * exp[sign * b * dose]
                                                         Y[doss] = a * exp(sign * (b * doss)*d)
                Model 31
                                                         Y(dose) = a * (c-(c-1) * exp[-b * dose)]
                Model 4:
                                                         Y[doss] = a * [c-(c-1) * exp[-(b * dose]*d]]
               Model 51
         Note: Y[dose] is the median response for exposure = dose;
                             sign = +1 for increasing trend in data;
                             sign = -1 for decreasing trend.
                Model 2 is nested within Models 3 and 4.
                Model 3 is mested within Model 5.
                Model 4 is mosted within Model 5.
      Dependent variable = bods
       Independent variable = perced_serum
      Data are assumed to be distributed: normally
```

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 488 of 551

Variance Model: exp(imalphs +rho *in(V(dose)))
rho is set to 0.
A constant variance model is fit.

```
Total number of dose groups = 4
Total number of records with missing values = 0
Maximum number of iterations = 250
Relative Function Convergence has been set to: in-008
Farameter Convergence has been set to: in-008
```

```
MLE solution provided: Exact
```

Initial Parameter Values

10.11

	risble	Hodel 2	Hodel 3	Model 4
Hodel 5				
	alpha	3.70009	3,70009	3,70009
. 70005	1			
6	rho(8)	0		0
12		19,8825	19.0825	42
1.	- E	5.23786e-005	5.23786e-005	0.000229525
.00022	19525 C		1.11	0.340136
0.34013	-CC		1	-
1				

(5) - Specified

Ferameter Estimates by Model

Variable Model 5	Model 2	Model 3	Model 4
HOGET D			
Inalpha	4.03627	4.03627	3.76287
3.76287 sho	D	0	0
	35,4078	35,4078	30.36
38.36 b	5.87408#-005	5.07408e-005	0.000419266
0.000479266			0.395353
0.395353 d	**	13	

13.

Table of Stats From Input Data

Dose	н	Obs Nean	Obs Std Dev
0	5	40	8.94
261.7 2281	3	33 24	6.93

1.628e+D06

4243

Estimated Values of Interest

1.5

Model.	Dose.	Est Mean	Est Std	Scaled Residual
2		35.41	7.524	1.365
	265.7	34.07	7.524	-0.4964
	2201	30.97	7,524	-1.604
1.4	28e+004	13.61	7.524	0.4144
3		35.41	7.524	1.365
	263.7	34.07	7.524	-0.4964
	2291	30,97	3,524	-1.604
1.6	28e+004	13.61	7.524	0.4144
4		38.36	6,563	0.5508
	261.7	35,63	6.563	-0.8002
	2201	22.94	6.563	0,2797
	28e+004	55.38	6.563	-0.05969
5	0	38.36	6,563	0.5500
	261.7	35.63	6.563	-0.0002
	2281	22.94	6.563	0.2797
1.4	28e+004	15.18	6.563	-0.05969

Other models for which likelihoods are calculated:

Nodel Al: Tij = Mu(i) + e(ij) Var(e(ij)) = Sigma*2 Nodel A2: Tij = Mu(i) + e(ij) Var(e(ij)) = Sigma(i)*2

Model A3: T15 = Mu(1) + e(55) Var(e(15)) = exp(lalphs + log(mean(1)) * cho)

Model R: Tij = Mu + e(i) Var(e(ij)) = 81gma*2

Likelihoods of Interest

Model	log(likslihood)	DP	AIC
A1	-39,95079	.5	89.90157
AZ	-38.76569	8	93.53137
A3	-39.95079	5	89,90157
B.	~50.57558	2.	105,1512
œ	-42.80832	3	(31/61664)
ò	-42.00032 -40.48439	4	10.96877
5	-40.48439	4	(Yee-b6833

Additive constant for all log-likelihoods = -15.62. This constant added to the

above values gives the log-likelihood including the term that does not depend on the model parameters.

Explanation of Tests

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 490 of 551

Test 1: Does response and/or variances differ among Dose levels? (A2 vs. B)
Test 2: Are Variances Homogeneous? (A2 vs. A1)
Test 3: Are variances adequately modeled? (A2 vs. A3)
Test 4: Does Model 2 fit the data? (A3 vs. 2)
Test 5a: Does Model 3 fit the data? (A3 vs. 3)
Test 5b: Is Model 3 better than Model 2? (3 vs. 2)

Test 6a: Does Nodel 4 fit the data? (A3 vs 4) Test 6b: Is Model 4 better than Model 27 (4 vs. 2)

Test Te: Does Model 5 fit the data? (A3 vs 5) Test Tb: Is Model 5 better than Model 3? (5 vs. 3) Test Tc: Is Model 5 better than Model 4? (5 vs. 4)

Tests of Interest

Test	-2*log(Likelihood Natio)	D. F.	p-value
Tost 1	23.62	- 6	0.0006134
Tost 2	2.37	3	0.4592
Test 3	2.37	3	0.4992
Tost 4	5.715	2	0.05741
Test 5a	5.715	2	0.05741
Test 5b	-1.077e-011	0	S/A
Tept 6a	1.067		0.3016
Tent 6b	4,648		0.03109 0.3016
Test 7a	4,648	1	0.03109
Test 75 Test 7c	1.4210-914	ô	S/A

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels, it seems appropriate to model the data.

The p-value for Yest 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled wariance appears to be appropriate here.

The p-value for Test 4 is less than .1. Model 2 may not adequately describe the data; you may want to consider another model.

The p-walue for Test 5a is less than .1. Model 3 may not adequately describe the data; you may want to consider another model.

Degrees of freedom for Yest 5b are less than or equal to 9-The Chi-Square test for fit is not valid.

The p-value for Test 6s is greater than .1. Model 4 seems to adequately describe the date.

The p-value for Test 6b is less than .05. Model 4 appears to fit the data better than Model 2.

The p-value for Test 7a is greater than .1. Model 5 seems to adoptately describe the data.

The p-value for Test 7b is less than .05. Model 5 appears to fit the data better than Model 3.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 491 of 551

Degrees of freedom for Test 7c are less than or equal to 0. The Chi-degree test for fit is not valid.

Benchmark Done Computations:

Specified Effect = 0.100000


Risk Type - Relative deviation

Confidence Level = 0.950000

IND and IMDS by Model

Node1	BMD	Resolu-
		10-11-12 (2010) (2010) (2010) (2010)
2	1793.65	1101-42
3	1793.65	1101.42
4	377.213	87.861
5	377,213	87.861

Power Model with 0.95 Confidence Level



Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 493 of 551

Default Initia	ù.	Parameter Val-	0.02
alpha	-	52,8975	
rbo		0	Specified
control	-	40	
slope	÷	-1.24383	
power	*	0.309416	

Anymptotic Correlation Matrix of Parameter Estimates

	alpha	control	slope	power
alpha	1	1.10-009	-1.2e-009	-1.40-009
control	1.1e-009	1	-0.61	-0.51
slope	-1.2e-009	-0.61	3	0.99
power	-1.4e-009	-0.51	0.99	1

Parameter Entimates

AL AS Muld Ganfidane

			32.08 Wald Contradence
Interval Variable	Estinate	Std. Mar.	Lower Conf. Limit Upper
Conf. Limit alpha	41.0366	14,0754	13.4492
69.6239 control	40.1466	2.02403	34.61
45.6831 slope 1.56067	-1.72177	1.67474	-5.0042
0.468367	0.277549	0.0973577	0.0867315

Table of Data and Estimated Values of Interest

Done	8	Obs Nean	Est Hean	Obs Std Dev	Sat Std Dev	Scaled Bes.
0 261.7 2281	5 4 3	40 33 24	40.1 32.1 25.4	8.94 8 6.93	6.41 6.41 6.41	-0.0512 0.209 -0.385
1.628e+0	004	5 15	14,7	4.47	6.43	

0.0905

Model Descriptions for likelihoods calculated

```
Model Al: Tij = Ma(1) * e(ij)
Var(e(ij)) = Sigma^2
```

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 494 of 551

AT2 + MU(1) + +(T3) Model A2: Var(e(ij)) = Signa(i)"2

Y15 = Ma(1) = a(1)) Model A3: $Varia(ij) = 5igma^2$ Hodel A3 uses any fixed variance parameters that were specified by the user

 $T_{1} = H_{0} + n\{1\}$ Hodel Rr Var(e(1)) = 35gma^2

likelihoods of Interest

Model -	Log(likelihood)	# Param's	AIC
24	-35.950786	5	89.901573
A2	-38.765686		93.531372
A3	-39.950786	5	09,901573
fitted	-40.072946	4	(12,145893)
ж	-50.575501	2	105.151162

Explanation of Tests

Test 1: Do responses and/or variances differ among Dose levels? IA2 vs. 81

Test 2: Are Variances Homogeneous? (Al vs A2)

Test 3: Are variances adoquately modeled? (A2 vs. A3)

Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)

(Note: When rho-0 the recults of Test 3 and Test 2 will be the same.)

Tests of Interest

Test	-2*log(Likelihood Ratio)	Test df	p-value
Test 1	23.6198	6	0.0006134
Test 2	2.3702	3	0.4992
Test 3	2.3702	3	0.4992
Test 4	0.24432	1	0.6211

The p-walue for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels It seems appropriate to model the data

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here

The p-walue for Test 4 is greater than .1. The model chosen seems to adequately describe the data


Benchmark Dose Computation

Specified effect =		0-1
Risk Type	-	Belative risk
Confidence level	-	0.95

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 495 of 551

BHD = 21.1211

BHDL = 0.0759616



Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 497 of 551

Default Initio	11	Parameter Valu	2400
alpha	-	52.8975	
rho	-		Specified
control	-	40	
slope	\sim		
power	*	-2,11214	

Asymptotic Correlation Matrix of Parameter Estimates

	alpha	costrol	alope	power
alpha	4	4e-000	3.10-000	4e-000
control	44-008	1	-0.6	-0.52
alope	3.1e-008	-0.6	1	0.99
ромет	40-008	-0.52	0.99	1

Parameter Estimates

35.0% Maid Confidence

				ARTER HERE CONTRACTOR	
	ziable	Estimate	Std. Rer.	Lower Conf. Limit Opp	per
Conf. Lim	alpha	40.5843	13,9203	13.301	
	ontrol	40.0006	2.81393	34.5654	
45.5958	alope	-1.09474	1.27305	-3.57987	
3,75202	power	2.18902	0.797466	0.626014	

Table of Date and Natimated Values of Interest

Dose	8	Obe Mean	Eat Mean	Obs Std Dev	Est Std Dov	Scaled Res.
0	5	40	40.1	8.94	6.37 6.37	-0.0283
2.42 3.36	3	33 24	32.6 24.7	6.93	6.37	-0.185
4.21	5.0	15	14.9	4.47	6.37	0.0519

Model Descriptions for likelihoods calculated

Model Al: Yij = Mu(1) = e(ij) Var[e(ij)] = Sigma^2

Model A2: Tij = Mu(1) + e(1)

1.4

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 498 of 551

Var(eliji) ~ Signs(i)^2

Hodel A3: Yij = Mu(i) + e(ij) Var(e(ij)) = Sigma*2 Nodel A3 uses any fixed variance parameters that were specified by the user

Hodel N: Y1 = 301 + #(1) Var(e(1)) = 51gma*2

Likelihoods of Interest

Mode1	Log(likelShood)	# Param's	AIC
743	-39,950706	5	89.901573
A2	-38,765686		93.531372
A3	-39,950706	5	89,961533
fitted	-39,978739	4	(37.957477)
	-50,575501	2	105.151142

Explanation of Tests

Test 1: Do responses and/or variances differ among Dose levels? (A2 vs. R) Test 2: Are Variances Homogeneous? (A1 vs A2) Test 3: Are variances adequately modeled? (A2 vs. A3) Test 4: Does the Model for the Nean Fit? (A3 vs. fitted) (Note: When rho=0 the results of Test 3 and Test 2 will be the same.)

Tests of Interest

Test	-2*log(Likelihood Ratio)	Test df	p-value
Test 1	23.6150	6	0.0006134
Test 2	2.3702	3	0.4992
Test 3	2.3702	3	0.4992
Test 6	0.0559044	1	0.0131

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels. It seems appropriate to model the data

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here

The p-value for Test 4 is greater than .1. The model chosen seems to adequately describe the data


Benchmark Dose Computation


#pecified affect = 0.1
#isk Type = Relative risk
Confidence level = 0.95

3MD = 1.81676

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 499 of 551

BMDL = 0.870604





į

Default Initial Parameter Values

alpha =	52.8975	
xho =	0	Specified
bets 0 =	40.044	
beta 1 =	0.912419	
bota_2 =	-1.64299	

Asymptotic Correlation Matrix of Parameter Estimates

and do not appear in the correlation matrix)

	alpha	beta_0	bets_l	beta_2
alpha	4	-1.50-007	3.6e-007	-3.7e-007
bets_0	-1.50-007	1	-0.51	0.32
bets_1	3,60-007	-0.51	1	-0.96
bets_2	-3,7e-007	0.32	-0.96	λ

Paramoter Estimates

95.0% Wald Confidence

Interval Variable	Estimate	Std. Err.	Lower Conf. Limit Upper
Conf. Limit alpha	40.5522	13.9093	13.2505
67.8139 beta_0 45.6043	40.0297	2.84422	34.4552
bota_1	0.953024	3,47875	-5.06521
7,77126 Beta_2 -0.0164714	-1,64752	0.832185	-3.27858

Table of Cata and Estimated Values of Interest

Dose	я	Obs Hean	Est Noan	Obe Std Dev	Est Std Dev	Scaled Bss.
0 2.42 3.36 4.21	5435	40 33 24 15	40 32.7 24.6 14.8	8.94 8 6.93 4.47	6.37 6.37 6.37 6.37 8.37	-0.0104 0.0981 -0.172 0.0559

Model Descriptions for likelihoods calculated

Hodel Al: Y15 = Hu(1) + e(1) Var(e(1)) = Eigea*2 Model A2: Y15 = Nu(1) + e(1)

Var(e(ij1) = Sigma(i)*2

Model A3: Tij = Bi(i) + u(i)) Var(u(i)) = Sigma^2 Model A3 uses any fixed variance parameters that were specified by the user

Model 9: Y1 = Nu + e(1) Var(e(1)) = Sigma*2

Likelihoods of Interest

Model.	Log(likelihood)	# Paxan's	AIC
A3.	-39,950706	5	89.901573
A2	-38.765686		93.531372
A3	-39.950786	5	89,801573
fitted	-39.972016		(87.944031)
8	-50.575581	2	105.151182

Explanation of Tests

Test 1: Do responses and/or variances differ among Dose levels? (A2 vs. R) Test 2: Are Variances Homogeneous? (A1 vs A2) Test 3: Are variances adequately modeled? (A2 vs. A3) Test 4: Does the Model for the Hean Fit? (A3 vs. fitted) (Note: When rho=D the results of Test 3 and Test 2 will be the same.)

Tests of Interest

7645	-2*log(Likelihood Ratio)	Test df	p-value
Test 1	23.6190	6	0.0006134
Test 2	2.3702	3	0.4992
Tost 3	2.3702	3	0.4552
Test 4	0.0424585	1	0.0367

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels it seems appropriate to model the data

The p-value for Tost 2 is greater than .1. A homogeneous variance model appears to be appropriate have

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate hero


The p-value for Test 4 is greater than .1. The model chosen serms to adequately describe the data

Benchmark Dose Computation

Specified effect		0.1
Risk Type	*	Relative risk
Confidence Level	•	0.95
3M0	-	1.87459

BNDL -- 0.811908

EMDL computation failed for one or more point on the EMDL curve. The EMDL curve will not be plotted



alpha -	52.8975	
sho -	0	Specified
bots 0 -	42.1163	- 18
lets 1 -	-5.65218	

Asymptotic Correlation Matrix of Parameter Estimates

bets_1	bets_0	alpha	
-5.5e-010	-3.6e-008	1	alpha
-0.82	1	-3.6e-008	bets_0
1	-0.02	-5,5e-010	bets 1

.

Parameter Estimates

95.08 Hald Confidence

Interval Variable	Katimate	Std. Err.	Lower Conf. Limit Upper
Conf. Limit alpha	49.9017	17,1161	16.3547
83.4487 bets_0 47.6315	41.8335	2,98884	35.9755
-3.60952 beta_1	-5.68904	1.02018	-7,68056

Table of Data and Estimated Values of Interest

Dose		Obs Hean	Lot Mean	Obs Std Dev	Est Std Dev	Scaled Res.
0	5	40	41.8	8.94	7.06	-0.58
2.42	4	33	20.1	8	7,06	1.4
3.36	3	24	22.7	6.93	7.06	0.314
4.21	5	35	17.9	4.47	7.06	-0.912

Model Descriptions for likelihoods calculated

Model Al: Yij = Mu(1) + +(ij) Var[e(ij)] = Sigma^2

Nodel A2: Y1j = Ma(1) + a(1j) Var(e(1j)) = Sigma(1)*2

Model A3: Yij = Mu(1) + e(1j) Var(e(1j)) = Sigma^2 Model A3 uses any fixed variance parameters that were specified by the user

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 507 of 551

Hodel R: Y1 = Hu + e(1) Var(e(1)) = Signa^2

Likelihoods of Interest

Mode1	Log(likelihood)	# Paren's	AIC
A1	-39.950786	5	89.901573
A.2	-30.765686		93.531372
83	-39,950786	5	19:901573
fitted	-41.735470	3	(.89.470940)
R	-50.575501	2	105,751102

Explanation of Tests

Test 1: Do responses and/or variances differ among Dose levels? (A2 vs. R) Test 2: Are Variances Homogeneous? (A1 vs A2) Test 3: Are variances adequately modeled? (A2 vs. A3) Test 4: Does the Model for the Hean Fit? (A3 vs. fitted) (Note: When sho-D the results of Test 3 and Test 2 will be the same.)

Tests of Interest

2601	-2*log(Likelihood Ratio)	Test df	p-value
Test 1	23.6190	6	0.0006134
Teat 2	2.3702	3	0.4992
Test 3	2,3702	3	0.4992
Test 4	3,56937	2	0.1679

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose lovels It seems appropriate to model the data

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here

The p-value for Test 3 is greater than .1. The modelod variance appears to be appropriate here

The p-value for Test 4 is greater than .1. The model chosen seems to adequately describe the data

Benchmark Dose Computation

Specified effect	*	0.1
Risk Type	-	Relative risk
Confidence level	-	0.95
BHD	-	0.735335
BMDG		0.610445

BMDD, computation failed for one or more point on the BMDG curve.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 508 of 551

The BHDL curve will not be plotted

```
Exponential Model. (Version: 1.7; Date: 12/10/2009)
        Input Data File: C:/USEPA/EMDS212/Data/exp pfos mammary detting.(d)
        Emuplot Flotting File:
                                              Med May 04 15:16:09 2011
EMDS Nodel Ron
a babara da babara a se se
  The form of the response function by Nodel:
     Model 2: Y(done) = a * exp(sign * h * dose)
                  Y(dose) = a * exp(sign * (b * dose)*d)
     Model 3:
                  Y[dose] = a * [c-(c-1) * exp[-b * dose])
     Model 41
                  Y(dose) = a * (c-(c-1) * exp(-(b * dose)*d))
     Model 5:
   Note: Y[done] is the median response for exposure = dose;
         sign = +1 for increasing trend in data;
         sign - -1 for decreasing trend.
     Model 2 is nested within Models 3 and 4.
     Model 3 is nested within Model 5.
     Model 4 is nested within Model 5.
  Dependent variable - buds
  Independent variable = seroed log serum
  Data are assumed to be distributed: normally
  Variance Model: exp(lnslphs +rho +ln(Y[dose]))
  rho is set to 0.
  A constant variance model is fit.
```

Total number of dese groups = 4 Yotal number of records with missing values = 0 Maximum number of iterations = 250 Relative Function Convergence has been set to: 1e-000 Parameter Convergence has been set to: 1e-000

MLE solution provided: Exact

	In	itial Parameter Va.	Later	
riable	Hodel 2	Model 3	Model 4	
	40.0000000		0-1-1-1-10-10-10	
alpha	3,70009	3.70009	3.10005	
xho(8)	0	0	0	
	15.5056	15.5856	42	
b	0.216048	0.216048	0.19508	1
	100		0.000357343	
d				
	nlpha xho(5) n b 7143	riable Hodel 2 alpha 3.70009 who(8) 0 a 15.5056 b 0.216049 0 0	riable Hodel 2 Hodel 3 alpha 3.70009 3.70009 who(8) 0 0 a 15.5056 15.5056 b 0.216040 0.216048 0	alpha 3,70009 3,70009 3,70009 sho(8) 0 0 0 0 a 15,5056 15,5856 42 b 0,216048 0,216048 0,19508 c 0,000357143

(8) = Specified

Parameter Xatimates by Model

- -

	sidble.	Model 2	Model 3	Hodel 4
Nodel 5				
1na 3,70009	lpha	4.02818	3.70014	4.02818
	rho	0	2	
0.		41.4292	40.0112	41.4292
40	ь	0.178366	0.236123	0.178366
D.245098 D.062818	-0			0
3.01825	4	55	2.92913	

Table of Stats From Input Data

Dose	1	Obs Nean	Obs Std Dev
0	5	40	8.54
2.42	4	33	8
3.36	3	24	6.93
4.21	5	15	4.47

Estimated Values of Interest

Mode1	Dase	Est Nean	Est Std	Scaled Residual
	0	41.43	7.494	-0.4265
2.2.1	2.42	26.93	7.494	1.626
	3,34	22.75	7.494	0.2803
	4.21	19,55	7.494	-1,358
3	0	40.01	6.36	-0.003927
	2.42	32.95	6.36	0.01529
	3.36	24.00	6.36	-0.02269
	4.21	14.98	6.36	0.000652
4	0	43.43	7.494	-0.4265
	2.42	26.91	7.494	3.626
	3.36	22,75	7.484	0.2863
	4.21	19.55	7.494	-1,35#
	0	40	6.36	-1.534e-DOB
	2.42	33	6.36	8.575e-009
	3.36	24	6.36	3.1740-008
	4.21	15	6.36	-4,441e-008

Other models for which likelihoods are calculated:

Hodel AL: Yij = Mi(i) + e(ij) Var(e(ij)) = Sigma*2

Hodel A2: Y15 = Hu(1) + n(1) Var(n(1)) = Signa(1)*2

Nodel A3: Yij = Ni(i) + e(ij) Var(e(ij)) = exp(lalphs + log(mean(i)) * rho)

Nodel R: Yij = Ma + e(1) Var(e(1)) = Sigma*2

Likelihoods of Interest

Model	Log(likelihood)	DF	ATC
Al	-39.95079	5	89.90157
A2	-38.76569		93.53137
A3	-39.95079	5	89.90157
8	-50.57558	2	105.1512
2	-42.73957	3	92.47914
3	-39.95121	-4	UET: 90241
4	-42.73957	3	92.47914
5	-39,95075	5	89,90157
			C21 (10 (10 (10 (10 (10 (10 (10 (10 (10 (1

Additive constant for all log-likelihoods = -15.62. This constant added to the

above values gives the log-likelihood including the term that does not depend on the model parameters.

Explanation of Tests

Test 1: Does response and/or variances differ among Dose levels? (A2 vs. R) Test 2: Are Variances Homogeneous? (A2 vs. A1) Test 3: Are variances adoquately modeled? (A2 vs. A3) Test 4: Does Nodel 2 fit the data? (A3 vs. 2) Test Sa: Does Hodel 3 fit the data? (A3 vs 3) Test Sb: Is Hodel 3 better than Nodel 27 (3 vs. 2)

Test 6a: Does Hodel 4 fit the data? (A3 vz 4) Test 6b: Is Hodel 4 better than Model 2? (4 vs. 2)

Test Ta: Does Model 5 fit the data? (A3 vs 5) Test Tb: Is Model 5 better than Model 3? (5 vs. 3) Test Tc: Is Model 5 better than Model 4? (5 vs. 4)

Tests of Interest

Test.	-2*log(Likelihood Ratio)	D. F.	p-value
Tost 1	23.62	6	0.0006134
Test 2	2,37	3	0.4992
Test 3	2,37	3	0.4992
Test 4	5.578	2	0.0615
Test Sa	0.0000309	1	0.9769
Test Sb	5,577	- X	0.0182
Test 6a	5.578	2	0.0615
Test 6b	0	0	8./A
Tost 7a	0	0	N/A
Test 7b	0.0008389	1.1	0.9765
Test Jo	5,578	2	0.0615

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels, it seems appropriate to model the data.

The p-walos for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is less than .1. Model 2 may not adequately describe the data; you may want to consider another model.

The p-walue for Tept 5a is greater than .1. Model 3 seems to adequately describe the data.

The p-walue for Test 5b is ldss than .05. Model 3 appears to fit the data better than Model 2.

The p-value for Test 6a is less than .1. Model 4 may not adequately describe the data; you may wast to consider another model.

Degrees of freedom for Test 6b are less than or equal to 0. The Chi-Square test for fit is not valid.

Degrees of freedom for Test 7s are less than or equal to 0. The Chi-Square test for fit is not valid.

The p-value for Test 7b is greater than .05. Model 5 does not seem to fit the data better than Model 3.

The p-value for Yest 7c is greater than .05. Model 5 does not seem to fit the data better than Model 4.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 513 of 551

Benchmark Dose Computations:

Specified Sffect - 0.100000

Hisk Type = Absolute deviation


Confidence Level = 0.950000

1.1

BND and BMDL by Model

IMD	INCO.
and a distance in the second second	the second second second
0.0135489	0.00916547
0.547859	0.0955696
0.0135489	0.00827023
0.572901	0.095613
	0.547959 0.0135489

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 514 of 551



APPENDIX 7: Benchmark dose analysis of relative liver weight in response to PFOA (linear/branched) using BMR of 10% increase relative to controls (Loveless et al., 2006).

Model	Chi-sq p- value	AIC	BMD (μg/ml in serum)	BMDL (µg/ml in serum)
Exponential (Models 4 and 5)	0.2636	2.12782	4.90419	4.46612
Hill ^a	-	-	-	-
Linear ^b	-	-	-	-
Polynomial (2 nd deg)	0.03245 °	6.92134	5.31705	4.89558
Polynomial (3 rd deg) ^d	0.4678	1.66669	4.68238	4.23604

^a The individual observations in these data have unequal variance in response. When modeled to account for the unequal variance, the Hill model fails (with or without restriction of the exponential function to > 1)

^b Scaled residuals for one or more doses/serum concentrations for each of the four exponential models were > |2|. The fit of these models is considered inadequate for benchmark dose modeling. ^c Note that the p-value is less than the value of 0.1 used by the BMDS software as a cut-off for determining goodness of fit by this test. However, the AIC value indicates a reasonable fit. ^d The 3rd degree polynomial model over fits the data at the high doses (see graphic description). However, the fit at the lower doses (including the doses contributing most to the BMD and BMDL) appears appropriate

<u>Summary</u>

Both the exponential models (models 4 and 5 give identical fits) and the 3^{rd} degree polynomial model give acceptable fits to these data. The 3^{rd} degree polynomial model over fits the data at the high dose, forcing a fit and resulting in a biologically unlikely fit in this area of the dose-response. However, the fit of the model at the lower doses (i.e., in the range of the BMD) is regular and biologically appropriate. It is unlikely that the forced fit at the high dose has any significant influence on the fit of the model at the BMD. Although this model gives a slightly better fit than the exponential models and also yields a slightly lower BMDL, the exponential models give a highly comparable fit and a similar BMDL. As neither model appears to have a claim to greater biological significance, it is recommended that the point-of-departure be derived as the average of the BMDLs for both of these models. This yields an average BMDL of 4.35 $\mu g/ml$.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 516 of 551

_____ Exponential Model. (Version: 1.10; Date: 01/12/2015) Input Data File: C:/BMDS2601_20150629/BMDS2601/Data/exp_Loveless 2006 - Mouose- rel liver wt - linear-branched Opt.(d) Gnuplot Plotting File: Thu Mar 24 11:27:03 2016 BMDS Model Run The form of the response function by Model: Model 2: Y[dose] = a * exp{sign * b * dose}
Model 3: Y[dose] = a * exp{sign * (b * dose)^d}

 Model 3:
 $Y[dose] = a + [c-(c-1) + exp{-b + dose]$

 Model 4:
 $Y[dose] = a + [c-(c-1) + exp{-b + dose]$

 Model 5:
 $Y[dose] = a + [c-(c-1) + exp{-(b + dose)^d}]$
Note: Y[dose] is the median response for exposure = dose; sign = +1 for increasing trend in data; sign = -1 for decreasing trend. Model 2 is nested within Models 3 and 4. Model 3 is nested within Model 5. Model 4 is nested within Model 5. Dependent variable = Mean Independent variable = Dose Data are assumed to be distributed: normally Variance Model: exp(lnalpha +rho *ln(Y[dose])) The variance is to be modeled as Var(i) = exp(lalpha + log(mean(i)) * rho) Total number of dose groups = 6Total number of records with missing values = 0Maximum number of iterations = 500 Relative Function Convergence has been set to: 1e-008 Parameter Convergence has been set to: 1e-008 MLE solution provided: Exact

Initial Parameter Values

Variable	Model 2	Model 3	Model 4	Model 5
lnalpha	-7.4076	-7.4076	-7.4076	-7.4076
rho	2.77531	2.77531	2.77531	2.77531
a	6.24624	6.24624	4.883	4.883
b	0.00485613	0.00485613	0.0101307	0.0101307
С	0 *	0 *	3.93078	3.93078
d	1 *	1	1 *	1

* Indicates that this parameter has been specified

Parameter Estimates by Model

Variable	Model 2	Model 3	Model 4	Model 5
lnalpha	-0.912445	-0.912444	-7.45681	-7.45681
rho	0.694024	0.694024	2.79344	2.79344
a	6.58236	6.58236	5.13807	5.13807
b	0.00447289	0.00447289	0.00664742	0.00664742
С			4.11774	4.11774
d		1		1

-- Indicates that this parameter does not appear in model

Std. Err. Estimates by Model

Variable	Model 2	Model 3	Model 4	Model 5
lnalpha	0.192224	1.23391	0.893622	0.893622
rho	0.536418	0.536418	0.386543	0.386543
a	0.227146	0.227146	0.0668152	0.0668152
b	0.000208654	0.000208654	0.00066635	0.00066635
С	NA	NA	0.180148	0.180147
d	NA	NA	NA	NA

NA - Indicates that this parameter was specified (by the user or because of the model form) or has hit a bound implied by some inequality constraint and thus has no standard error.

Table of Stats From Input Data

Dose	Ν	Obs Mean	Obs Std Dev
0.04	10	5.14	0.27
10	10	6.12	0.25
27	10	7.92	0.49
66	10	10.72	0.63
190	10	16.27	1.05
241	10	18.28	1.57

Estimated Values of Interest

Model	Dose	Est Mean	Est Std	Scaled Residual
2	0.04	6.584	1.219	-3.746
	10	6.883	1.238	-1.951
	27	7.427	1.271	1.226
	66	8.843	1.35	4.397
	190	15.4	1.637	1.685
	241	19.34	1.771	-1.899
3	0.04	6.584	1.219	-3.746
	10	6.883	1.238	-1.951
	27	7.427	1.271	1.226
	66	8.843	1.35	4.397
	190	15.4	1.637	1.685
	241	19.34	1.771	-1.899
4	0.04	5.142	0.2366	-0.03107
	10	6.168	0.3051	-0.5007
	27	7.77	0.4211	1.127
	66	10.83	0.6694	-0.5063
	190	16.63	1.219	-0.9262
	241	17.93	1.354	0.8184
5	0.04	5.142	0.2366	-0.03107
	10	6.168	0.3051	-0.5007
	27	7.77	0.4211	1.127
	66	10.83	0.6694	-0.5063
	190	16.63	1.219	-0.9262
	241	17.93	1.354	0.8184

Other models for which likelihoods are calculated:

Model A1:	Yij = Var{e(ij)} =	= Mu(i) + e(ij) = Sigma^2
Model A2:	Yij = Var{e(ij)} =	= Mu(i) + e(ij) = Sigma(i)^2
Model A3:	2	• Mu(i) + e(ij) • exp(lalpha + log(mean(i)) * rho)
Model R:	Yij =	Mu + e(i)

Var{e(ij)} = Sigma^2

Likelihoods of Interest

Model	Log(likelihood)	DF	AIC
Al	-17.12125	7	48.2425
A2	6.872288	12	10.25542
A3	5.926418	8	4.147163
R	-126.9627	2	257.9255
2	-50.15017	4	108.3003
3	-50.15017	4	108.3003
4	3.936092	5	2.127815
5	3.936092	5	2.127815

Additive constant for all log-likelihoods = -55.14. This constant added to the above values gives the log-likelihood including the term that does not depend on the model parameters.

Explanation of Tests

Test 1: Does response and/or variances differ among Dose levels? (A2 vs. R) Test 2: Are Variances Homogeneous? (A2 vs. A1) Test 3: Are variances adequately modeled? (A2 vs. A3) Test 4: Does Model 2 fit the data? (A3 vs. 2) Test 5a: Does Model 3 fit the data? (A3 vs. 3) Test 5b: Is Model 3 better than Model 2? (3 vs. 2) Test 6a: Does Model 4 fit the data? (A3 vs 4) Test 6b: Is Model 4 better than Model 2? (4 vs. 2) Test 7a: Does Model 5 fit the data? (A3 vs 5) Test 7b: Is Model 5 better than Model 3? (5 vs. 3) Test 7c: Is Model 5 better than Model 4? (5 vs. 4)

Tests of Interest

Test	-2*log(Likelihood Ratio)	D. F.	p-value
Test 1	267.7	10	< 0.0001
Test 2	47.99	5	< 0.0001
Test 3	1.892	4	0.7557
Test 4	112.2	4	< 0.0001
Test 5a	112.2	4	< 0.0001
Test 5b	-6.736e-012	0	N/A
Test 6a	3.981	3	0.2636
Test 6b	108.2	1	< 0.0001
Test 7a	3.981	3	0.2636
Test 7b	108.2	1	< 0.0001
Test 7c	-3.023e-012	0	N/A

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels, it seems appropriate to model the data.

The p-value for Test 2 is less than .1. A non-homogeneous variance model appears to be appropriate.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is less than .1. Model 2 may not adequately describe the data; you may want to consider another model.

The p-value for Test 5a is less than .1. Model 3 may not adequately

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 519 of 551

describe the data; you may want to consider another model.

Degrees of freedom for Test 5b are less than or equal to 0. The Chi-Square test for fit is not valid.

The p-value for Test 6a is greater than .1. Model 4 seems to adequately describe the data.

The p-value for Test 6b is less than .05. Model 4 appears to fit the data better than Model 2.

The p-value for Test 7a is greater than .1. Model 5 seems to adequately describe the data.

The p-value for Test 7b is less than .05. Model 5 appears to fit the data better than Model 3.

Degrees of freedom for Test 7c are less than or equal to 0. The Chi-Square test for fit is not valid.

Benchmark Dose Computations:

Specified Effect = 0.100000


Risk Type = Relative deviation

Confidence Level = 0.950000

BMD and BMDL by Model

Model	BMD	BMDL
2	21.3084	19.7104
3	21.3084	19.7104
4	4.90419	4.46612
5	4.90419	4.46612


Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 520 of 551



Exponential 4 Model, with BMR of 0.1 Rel. Dev. for the BMD and 0.95 Lower Confidence Limit for the BMDL

11:27 03/24 2016

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 521 of 551



Exponential 5 Model, with BMR of 0.1 Rel. Dev. for the BMD and 0.95 Lower Confidence Limit for the BMDL

11:26 03/24 2016

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 522 of 551

_____ Polynomial Model. (Version: 2.20; Date: 10/22/2014) Input Data File: C:/BMDS2601 20150629/BMDS2601/Data/ply Loveless 2006 - Mouose- rel liver wt - linear-branched Opt.(d) Gnuplot Plotting File: C:/BMDS2601 20150629/BMDS2601/Data/ply Loveless 2006 - Mouoserel liver wt - linear-branched Opt.plt Thu Mar 24 11:40:48 2016 BMDS Model Run The form of the response function is: $Y[dose] = beta_0 + beta_1*dose + beta_2*dose^2 + ...$ Dependent variable = Mean Independent variable = Dose Signs of the polynomial coefficients are not restricted The variance is to be modeled as Var(i) = exp(lalpha + log(mean(i)) * rho) Total number of dose groups = 6Total number of records with missing values = 0Maximum number of iterations = 500 Relative Function Convergence has been set to: 1e-008 Parameter Convergence has been set to: 1e-008 Default Initial Parameter Values lalpha = -0.323931 rho = 0 5.38261 beta_0 = 5.38261 beta_1 = 0.0864747 beta 2 = -0.000141161Asymptotic Correlation Matrix of Parameter Estimates

	lalpha	rho	beta_0	beta_1	beta_2
lalpha	1	-0.98	0.17	-0.25	0.24
rho	-0.98	1	-0.17	0.25	-0.24
beta_0	0.17	-0.17	1	-0.59	0.5
beta_1	-0.25	0.25	-0.59	1	-0.94
beta_2	0.24	-0.24	0.5	-0.94	1

Parameter Estimates

			95.0% Wald Conf.	idence Interval
Variable	Estimate	Std. Err.	Lower Conf. Limit	Upper Conf. Limit
lalpha	-7.55129	0.915261	-9.34516	-5.75741
rho	2.86927	0.39557	2.09396	3.64457
beta O	5.175	0.0667518	5.04417	5.30584
beta_1	0.0983433	0.0042131	0.0900857	0.106601
beta_2	-0.000190851	1.99132e-005	-0.00022988	-0.000151822

Table of Data and Estimated Values of Interest

Dose	N	Obs Mean	Est Mean	Obs Std Dev	Est Std Dev	Scaled Res.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 523 of 551

0.04	10	5.14	5.18	0.27	0.243	-0.508
10	10	6.12	6.14	0.25	0.31	-0.198
27	10	7.92	7.69	0.49	0.428	1.69
66	10	10.7	10.8	0.63	0.7	-0.517
190	10	16.3	17	1.05	1.33	-1.66
241	10	18.3	17.8	1.57	1.43	1.09

Model Descriptions for likelihoods calculated

```
Model A1: Yij = Mu(i) + e(ij)
Var{e(ij)} = Sigma^2
```

Model A2: Yij = Mu(i) + e(ij) Var{e(ij)} = Sigma(i)^2

Model A3: Yij = Mu(i) + e(ij)
Var{e(ij)} = exp(lalpha + rho*ln(Mu(i)))
Model A3 uses any fixed variance parameters that
were specified by the user

Model R: Yi = Mu + e(i) Var{e(i)} = Sigma^2

Likelihoods of Interest

Model	Log(likelihood)	# Param's	AIC
A1	-17.121248	7	48.242497
A2	6.872288	12	10.255424
A3	5.926418	8	4.147163
fitted	1.539332	5	6.921336
R	-126.962744	2	257.925488

Explanation of Tests

Test 1:	Do responses and/or variances differ among Dose levels? (A2 vs. R)
Test 2:	Are Variances Homogeneous? (A1 vs A2)
Test 3:	Are variances adequately modeled? (A2 vs. A3)
Test 4:	Does the Model for the Mean Fit? (A3 vs. fitted)
(Note:	When rho=0 the results of Test 3 and Test 2 will be the same.)

Tests of Interest

Test	-2*log(Likelihood Ratio)	Test df	p-value
Test 1	267.67	10	<.0001
Test 2	47.9871	5	<.0001
Test 3	1.89174	4	0.7557
Test 4	8.77417	3	0.03245

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels It seems appropriate to model the data


The p-value for Test 2 is less than .1. A non-homogeneous variance model appears to be appropriate

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here

The p-value for Test 4 is less than .1. You may want to try a different model $% \left[{{\left[{{{\rm{Test}}} \right]}_{\rm{Test}}} \right]$

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 524 of 551

Specified effect	=	0.1
Risk Type	=]	Relative deviation
Confidence level	=	0.95
BMD	=	5.31705
BMDL	=	4.89558



Polynomial Model, with BMR of 0.1 Rel. Dev. for the BMD and 0.95 Lower Confidence Limit for the BMDL

11:48 03/24 2016

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 525 of 551

_____ Polynomial Model. (Version: 2.20; Date: 10/22/2014) Input Data File: C:/BMDS2601 20150629/BMDS2601/Data/ply Loveless 2006 -Mouose- rel liver wt - linear-branched Opt.(d) Gnuplot Plotting File: C:/BMDS2601_20150629/BMDS2601/Data/ply Loveless 2006 - Mouose- rel liver wt - linear-branched_Opt.plt Thu Mar 24 11:45:36 2016 _____ BMDS Model Run The form of the response function is: $Y[dose] = beta 0 + beta 1*dose + beta 2*dose^2 + ...$ Dependent variable = Mean Independent variable = Dose Signs of the polynomial coefficients are not restricted The variance is to be modeled as Var(i) = exp(lalpha + log(mean(i)) * rho) Total number of dose groups = 6Total number of records with missing values = 0Maximum number of iterations = 500 Relative Function Convergence has been set to: 1e-008 Parameter Convergence has been set to: 1e-008

```
Default Initial Parameter Values
    lalpha = -0.323931
        rho = 0
        beta_0 = 5.13303
        beta_1 = 0.109803
        beta_2 = -0.000421158
        beta_3 = 7.96683e-007
```

Asymptotic Correlation Matrix of Parameter Estimates

beta_3	lalpha	rho	beta_0	beta_1	beta_2	
lalpha 0.048	1	-0.98	0.012	-0.028	0.043	-
rho 0.056	-0.98	1	-0.012	0.031	-0.05	
beta_0 0.32	0.012	-0.012	1	-0.59	0.4	-
beta_1 0.78	-0.028	0.031	-0.59	1	-0.88	
beta_2 0.98	0.043	-0.05	0.4	-0.88	1	-
beta_3 1	-0.048	0.056	-0.32	0.78	-0.98	

Parameter Estimates

95.0% Wal					Idence				
Interva	Interval								
	Variable	Estimate	Std. Err.	Lower Conf. Limit	Upper Conf.				
Limit		= 00000	0.05000	0.05000					
5.6139	lalpha	-7.33636	0.87882	-9.05882	-				
J.0139	rho	2,72236	0.379829	1.97791					
3.46681	1110	2.72200	0.079029	±• <i>3</i> ,,,,,,					
	beta_0	5.11878	0.0674735	4.98653					
5.25102	_								
	beta_1	0.111381	0.00620885	0.0992116					
0.12355	1	0 000 4 4 4 1 0 0	0 0 6 5 1 0 0 0 5	0.000005700					
0.000262	beta_2	-0.000444193	9.26512e-005	-0.000625786	-				
0.000202	beta 3	8.69446e-007	3.09892e-007	2.62068e-007	1.47682e-				
006	2000_3	0.031100 007	0.000020 007	2.0200000000	1.170020				

Table of Data and Estimated Values of Interest

Dose	Ν	Obs Mean	Est Mean	Obs Std Dev	Est Std Dev	Scaled Res.
0.04	10	5.14	5.12	0.27	0.236	0.225
10	10	6.12	6.19	0.25	0.305	-0.715
27	10	7.92	7.82	0.49	0.419	0.759
66	10	10.7	10.8	0.63	0.65	-0.316
190	10	16.3	16.2	1.05	1.13	0.17
241	10	18.3	18.3	1.57	1.34	-0.124

Model Descriptions for likelihoods calculated

- Model A1: Yij = Mu(i) + e(ij)
 Var{e(ij)} = Sigma^2
- Model A2: Yij = Mu(i) + e(ij) Var{e(ij)} = Sigma(i)^2
- Model A3: Yij = Mu(i) + e(ij)
 Var{e(ij)} = exp(lalpha + rho*ln(Mu(i)))
 Model A3 uses any fixed variance parameters that
 were specified by the user

Model R: Yi = Mu + e(i) Var{e(i)} = Sigma^2

Likelihoods of Interest

Model	Log(likelihood)	# Param's	AIC
Al	-17.121248	7	48.242497
A2	6.872288	12	10.255424
A3	5.926418	8	4.147163
fitted	5.166654	6	1.666693
R	-126.962744	2	257.925488

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 527 of 551

Explanation of Tests

Test 1: Do responses and/or variances differ among Dose levels? (A2 vs. R)						
Test 2: Are Variar	2					
Test 3: Are variar						
Test 4: Does the M		,	z 2 will be the same.)			
(Note: When tho-o	CHE LESUICS OF 10	est 5 and lest	2 WIII DE CHE Same.)			
	Tests of Interes	st				
Test -2*log(Li	kelihood Ratio)	Test df	p-value			
Test 1	267.67	10	<.0001			
	47.9871		<.0001			
Test 3	1.89174	4	0.7557			
Test 4	1.51953	2	0.4678			
The p-value for Test difference between r It seems appropriate	esponse and/or va	ariances among	-			
The p-value for Test 2 is less than .1. A non-homogeneous variance model appears to be appropriate						
The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here						
The p-value for Test to adequately descri		an .1. The mo	odel chosen seems			

Benchmark Dose Computation


Specified effect =	0.1
Risk Type =	Relative deviation
Confidence level =	0.95

BMD = 4.68238

BMDL = 4.23604

BMDL computation failed for one or more point on the BMDL curve. The BMDL curve will not be plotted

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 528 of 551



Polynomial Model, with BMR of 0.1 Rel. Dev. for the BMD and 0.95 Lower Confidence Limit for the BMDL

11:45 03/24 2016

APPENDIX 8: Benchmark dose analysis of testicular tumor data in response to PFOA using BMR of 5% tumor incidence (Butenhoff et al., 2012)

Model	Chi- sq stat	Chi-sq p- value	AIC	BMD (mg/kg/ d)	BMDL (mg/kg/d)	Cancer Potency Slope (mg/kg/d) ⁻¹	Dose at 1 x 10 ⁻⁶ risk (mg/kg/d)
Gamma (power restricted to ≥ 1)	1.45	0.2292	62.6851	4.42913	2.50664	0.020	5.0 x 10 ⁻⁵
Multistage (betas ≥ 0)							
Weibull (power restricted to ≥ 1)							
Quantal linear							
Gamma (power unrestricted)	0.00	1.00	61.2908	4.42913	1.36483e-6		
Log-logistic (power unrestricted)	0.00	1.00	61.2908	1.95859	2.00091e-6		
Logisitic	1.71	0.1905	63.6843	8.85708	6.49805		
Log-logistic (slope restricted to ≤ 1)	1.42	0.2338	62.5526	4.02707	2.2101	0.023	4.3 x 10 ⁻⁵
Probit	1.68	0.1948	63.625	8.32341	5.95965		
Weibull (power unrestricted)	0.00	1.00	61.2908	1.97407	1.65976e-6		

<u>Summary</u>

The BMR of 0.05 (5%) was selected for consistency with the recommendations for selection of point-of-departure (POD) for cancer potency slope derivation in the USEPA (2005) Guidance for Carcinogen Risk Assessment. This value is close to the 4% response at the lowest dose in this data set. The Gamma model (power restricted to ≥ 1); Multistage model (betas ≥ 0); Weibull

model (power restricted to ≥ 1); and Quantal linear model all give good and essentially identical fits to this dataset and consequently yield identical BMDLs and cancer potency slopes. The Loglogistic model (slope restricted to ≤ 1) gives a closely comparable fit to these data and a similar BMDLs and cancer potency estimate. These models were selected as most appropriate for deriving a cancer potency slope from these data.

The Gamma model with power unrestricted; the Log-logistic model with power unrestricted; and the Weibull model with power unrestricted all fit the data exactly and yield very small BMDLs. However, despite their better fit of the data than the selected models, these models are not considered appropriate for derivation of a cancer potency slope from these data. This is because these models all assume a steep dose-response relationship at low doses which becomes much less steep at higher doses. The steepness of the dose-response at low doses (i.e., doses associated with a less than 5% response) leads to the very small BMDL values associated with these models. The steepness of the dose-response at low doses is a highly specific assumption which is not necessary and which is not dictated by any empirical or theoretical consideration. These models are therefore rejected.

The Gamma, power restricted to ≥ 1 , (and the other models giving essentially identical results) and the Log-logistic model (with slope restricted to ≤ 1) fit the data with very similar fits and yield very similar BMDLs. Additionally, none of these models has a form that is obviously more biologically accurate. For these reasons, it is appropriate to average their BMDLs. The average BMDL for these models is 2.36 mg/kg/day. For a 5% BMR, the corresponding linear (no threshold) cancer potency slope is 0.021 (mg/kg/day)⁻, and the dose corresponding to a 1 x 10⁻⁶ risk is 4.8 x 10⁻⁵ mg/kg/day.

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 531 of 551

Gamma Model. (Version: 2.16; Date: 2/28/2013) Input Data File: C:/BMDS2601 20150629/BMDS2601/Data/gam butenhoff testicular tumors_Opt.(d) Gnuplot Plotting File: C:/BMDS2601_20150629/BMDS2601/Data/gam butenhoff testicular tumors_Opt.plt Tue Mar 01 13:55:34 2016 _____ BMDS Model Run The form of the probability function is: P[response] = background+(1-background)*CumGamma[slope*dose,power], where CumGamma(.) is the cummulative Gamma distribution function Dependent variable = Incidence Independent variable = Dose Power parameter is restricted as power >=1 Total number of observations = 3 Total number of records with missing values = 0Maximum number of iterations = 500 Relative Function Convergence has been set to: 1e-008 Parameter Convergence has been set to: 1e-008 Default Initial (and Specified) Parameter Values Background = 0.0196078 Slope = 0.0294212 Stope = 0.0294212 Power = Asymptotic Correlation Matrix of Parameter Estimates (*** The model parameter(s) -Power have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix) Background Slope 1 -0.58 Background Slope -0.58 1 Parameter Estimates 95.0% Wald Confidence Interval
 Variable
 Estimate
 Std. Err.
 Lower Conf. Limit
 Upper Conf. Limit

 Background
 0.00436511
 0.0163662
 -0.027712
 0.0364423

 Slope
 0.0115809
 0.00506549
 0.0016527
 0.0215091
 Power 1 NA NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error. Analysis of Deviance Table Log(likelihood) # Param's Deviance Test d.f. P-value Model

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 532 of 551

		Goodi	ness of E	Fit	Scaled
Dose	EstProb.	Expected	Observed	Size	Residual
0.0000 1.3000 14.2000	0.0044 0.0192 0.1553	0.214 0.962 7.767	0.000 2.000 7.000	49.000 50.000 50.000	-0.463 1.068 -0.299
Chi^2 = 1.45	d.f. = 1	P-va	alue = 0.22	292	


62.6851

Benchmark Dose Computation

AIC:

Specified effect	=	0.05
Risk Type	=	Extra risk
Confidence level	=	0.95
BMD	=	4.42913
BMDL	=	2.50664

Gamma Multi-Hit Model, with BMR of 5% Extra Risk for the BMD and 0.95 Lower Confidence Limit for the BMDL



13:55 03/01 2016

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 533 of 551

Multistage Model. (Version: 3.4; Date: 05/02/2014) Input Data File: C:/BMDS2601 20150629/BMDS2601/Data/mst butenhoff testicular tumors_Opt.(d) Gnuplot Plotting File: C:/BMDS2601 20150629/BMDS2601/Data/mst butenhoff testicular tumors_Opt.plt Tue Mar 01 14:29:06 2016 _____ BMDS Model Run _____ The form of the probability function is: P[response] = background + (1-background) * [1-EXP(-beta1*dose^1-beta2*dose^2)] The parameter betas are restricted to be positive Dependent variable = Incidence Independent variable = Dose Total number of observations = 3 Total number of records with missing values = 0Total number of parameters in model = 3 Total number of specified parameters = 0 Degree of polynomial = 2 Maximum number of iterations = 500 Relative Function Convergence has been set to: 1e-008 Parameter Convergence has been set to: 1e-008 Default Initial Parameter Values Background = 0.0132945 Beta(1) = 0.0097738 0.0097738 Beta(2) = 0 Asymptotic Correlation Matrix of Parameter Estimates (*** The model parameter(s) -Beta(2) have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix) Background Beta(1) 1 Background -0.58 Beta(1) -0.58 1 Parameter Estimates 95.0% Wald Confidence Interval
 Variable
 Estimate
 Std. Err.
 Lower Conf. Limit
 Upper Conf. Limit

 Background
 0.00436512
 0.0163652
 -0.0277101
 0.0364403

 Beta(1)
 0.0115808
 0.00506553
 0.00165257
 0.0215091
 Beta(2) 0 NA NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error. Analysis of Deviance Table Model Log(likelihood) # Param's Deviance Test d.f. P-value

Full model	-28.6454	3			
Fitted model	-29.3426	2	1.39438	1	0.2377
Reduced model	-33.983	1	10.6753	2	0.004807

AIC: 62.6851

		Good	ness of F	it	Scaled
Dose	EstProb.	Expected	Observed	Size	Residual
0.0000 1.3000 14.2000	0.0044 0.0192 0.1553	0.214 0.962 7.767	0.000 2.000 7.000	49.000 50.000 50.000	-0.463 1.068 -0.299


Chi^2 = 1.45 d.f. = 1 P-value = 0.2292

Benchmark Dose Computation

Specified effect	=	0.05
Risk Type	=	Extra risk
Confidence level	=	0.95
BMD	=	4.42916
BMDL	=	2.50664
BMDU	=	12.158

Taken together, (2.50664, 12.158) is a 90 % two-sided confidence interval for the BMD

Multistage Model, with BMR of 5% Extra Risk for the BMD and 0.95 Lower Confidence Limit for the BMDL



14:29 03/01 2016

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 535 of 551

_____ Weibull Model using Weibull Model (Version: 2.16; Date: 2/28/2013) Input Data File: C:/BMDS2601 20150629/BMDS2601/Data/wei butenhoff testicular tumors Opt.(d) Gnuplot Plotting File: C:/BMDS2601 20150629/BMDS2601/Data/wei butenhoff testicular tumors_Opt.plt Tue Mar 01 14:38:20 2016 _____ BMDS Model Run _____ The form of the probability function is: P[response] = background + (1-background)*[1-EXP(-slope*dose^power)] Dependent variable = Incidence Independent variable = Dose Power parameter is restricted as power >= 1.000000 Total number of observations = 3 Total number of records with missing values = 0Maximum number of iterations = 500 Relative Function Convergence has been set to: 1e-008 Parameter Convergence has been set to: 1e-008 Default Initial (and Specified) Parameter Values Background = 0.0196078 Slope = 0.0103698 Power = 1 Asymptotic Correlation Matrix of Parameter Estimates (*** The model parameter(s) -Power have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix $\ensuremath{)}$ Background Slope Background 1 -0.58 Slope -0.58 1 Parameter Estimates 95.0% Wald Confidence Interval
 Variable
 Estimate
 Std. Err.
 Lower Conf. Limit
 Upper Conf. Limit

 Background
 0.00436513
 0.0163652
 -0.0277102
 0.0364404

 Slope
 0.0115809
 0.00506554
 0.00165257
 0.0215091

 Power
 1
 NA
 NA
 NA
 NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error. Analysis of Deviance Table Model Log(likelihood) # Param's Deviance Test d.f. P-value Full model -28.6454 3 -29.3426 2 1.39438 1 0.2377 Fitted model


Reduced mo	del -:	33.983	1	10.6753	2	0.004807
A	IC: 62	2.6851				
Dose	EstProb.	Goodn Expected	ess of Observed		I	Scaled Residual
0.0000 1.3000 14.2000	0.0044 0.0192 0.1553	0.214 0.962 7.767	0.000 2.000 7.000	49.000 50.000 50.000		-0.463 1.068 -0.299

Chi^2 = 1.45 d.f. = 1 P-value = 0.2292

Benchmark Dose Computation

Specified effect	=	0.05
Risk Type	=	Extra risk
Confidence level	=	0.95
BMD	=	4.42915
BMDL	=	2.50664





14:38 03/01 2016

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 537 of 551

_____ Weibull Model using Weibull Model (Version: 2.16; Date: 2/28/2013) Input Data File: C:/BMDS2601 20150629/BMDS2601/Data/wei butenhoff testicular tumors Opt.(d) Gnuplot Plotting File: C:/BMDS2601 20150629/BMDS2601/Data/wei butenhoff testicular tumors_Opt.plt Tue Mar 01 14:44:17 2016 _____ BMDS Model Run _____ The form of the probability function is: P[response] = background + (1-background)*[1-EXP(-slope*dose^power)] Dependent variable = Incidence Independent variable = Dose Power parameter is not restricted Total number of observations = 3 Total number of records with missing values = 0Maximum number of iterations = 500 Relative Function Convergence has been set to: 1e-008 Parameter Convergence has been set to: 1e-008 Default Initial (and Specified) Parameter Values Background = 0.0196078 Slope = 0.0214176 Power = 0.726632Asymptotic Correlation Matrix of Parameter Estimates (*** The model parameter(s) -Background have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix) Power Slope 1 Slope -0.91 -0.91 Power 1 Parameter Estimates 95.0% Wald Confidence Interval
 Variable
 Estimate
 Std. Err.

 Background
 0
 NA

 Slope
 0.0353681
 0.0277941

 Power
 0.546613
 0.33544
 Std. Err. Lower Conf. Limit Upper Conf. Limit NA 0.0277841 -0.0191074 0.0898435 -0.0191074 0.0898435 -0.110837 1.20406 NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error. Warning: Likelihood for the fitted model larger than the Likelihood for the full model. Analysis of Deviance Table Log(likelihood) # Param's Deviance Test d.f. P-value Model


Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 538 of 551

		Good	lness of F	it	
Dose	EstProb.	Expected	Observed	Size	Scaled Residual
1.3000 14.2000	0.0400 0.1400		2.000 7.000	50.000	0.000
	Dose Comput	= 1 P-v	7alue = 1.00	00	
Specified ef	fect =	0.05			
Risk Type	=	Extra risk			
Confidence l	evel =	0.95			
	BMD =	1.97407			

BMDL = 1.65976e-006

61.2908

AIC:



Weibull Model, with BMR of 5% Extra Risk for the BMD and 0.95 Lower Confidence Limit for the BMDL

14:44 03/01 2016

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 539 of 551

_____ Gamma Model. (Version: 2.16; Date: 2/28/2013) Input Data File: C:/BMDS2601 20150629/BMDS2601/Data/gam butenhoff testicular tumors Opt.(d) Gnuplot Plotting File: C:/BMDS2601 20150629/BMDS2601/Data/gam butenhoff testicular tumors_Opt.plt Tue Mar 01 14:56:54 2016 _____ BMDS Model Run _____ The form of the probability function is: P[response] = background+(1-background)*CumGamma[slope*dose,power], where CumGamma(.) is the cummulative Gamma distribution function Dependent variable = Incidence Independent variable = Dose Power parameter is not restricted Total number of observations = 3 Total number of records with missing values = 0Maximum number of iterations = 500 Relative Function Convergence has been set to: 1e-008 Parameter Convergence has been set to: 1e-008 Default Initial (and Specified) Parameter Values Background = 0.0196078 Slope = 0.0294212 Power = 1.3 Asymptotic Correlation Matrix of Parameter Estimates (*** The model parameter(s) -Background have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix) Slope Power 1 Slope 0.98 Power 0.98 1 Parameter Estimates 95.0% Wald Confidence Interval Variable Estimate Std. Err. Lower Conf. Limit Upper Conf. Limit 0 0.00135774 0.526497 Background Slope Power -0.00647598 0.00919146 -0.126424 1.17942 0.333129 NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error. Analysis of Deviance Table Log(likelihood) # Param's Deviance Test d.f. P-value Model
 Full model
 -28.6454
 3

 itted model
 -28.6454
 2

 duced model
 -33.983
 1

 10.6753
 Full model 1 1 2 0.004807 Reduced model

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 540 of 551


AIC: 61.2908

Goodness of Fit

Do	se	EstProb.	Expected	Observed	Size	Scaled Residual	
0.00		0.0000	0.000	0.000	49.000	0.000 0.000	
14.2	000	0.1400	7.000	7.000	50.000	0.000	

Chi^2 = 0.00 d.f. = 1 P-value = 1.0000

Specified effect	=	0.05
Risk Type	=	Extra risk
Confidence level	=	0.95
BMD	=	1.98737
BMDL	=	1.36483e-006



Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 542 of 551

User has chosen the log transformed model

Default Initial	Parameter Values
background =	0
intercept =	-4.17047
slope =	1

Asymptotic Correlation Matrix of Parameter Estimates

(*** The model parameter(s) -slope have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix)

intercept

background	1	-0.63
intercept	-0.63	1

Parameter Estimates

			95.0% Wald Confi	dence Interval
Variable	Estimate	Std. Err.	Lower Conf. Limit	Upper Conf. Limit
background	0.00240787	0.0171729	-0.0312504	0.0360661
intercept	-4.33748	0.484279	-5.28665	-3.38831
slope	1	NA		

NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error.

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value
Full model	-28.6454	3			
Fitted model	-29.2763	2	1.26188	1	0.2613
Reduced model	-33.983	1	10.6753	2	0.004807


AIC: 62.5526

		Good	ness of F	it	
Dose	EstProb.	Expected	Observed	Size	Scaled Residual
0.0000 1.3000 14.2000	0.0024 0.0191 0.1586	0.118 0.954 7.928	0.000 2.000 7.000	49.000 50.000 50.000	-0.344 1.082 -0.359

Chi^2 = 1.42 d.f. = 1 P-value = 0.2338

Specified effect	=	0.05
Risk Type	=	Extra risk
Confidence level	=	0.95
BMD	=	4.02707
BMDL	=	2.2101

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 543 of 551



Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 544 of 551

```
Default Initial Parameter Values
background = 0
intercept = -3.3276
slope = 0.569985
```

Asymptotic Correlation Matrix of Parameter Estimates

(**	* The model	parameter(s) -	-background
	have been	estimated at a	boundary point, or have been specified by the user,
	and do not	: appear in the	correlation matrix)

	intercept	slope
intercept	1	-0.9
slope	-0.9	1

Parameter Estimates

			95.0% Wald Conf:	idence Interval
Variable	Estimate	Std. Err.	Lower Conf. Limit	Upper Conf. Limit
background	0	NA		
intercept	-3.3276	0.802128	-4.89974	-1.75546
slope	0.569985	0.346658	-0.109453	1.24942

NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error.

Warning: Likelihood for the fitted model larger than the Likelihood for the full model.

Analysis of Deviance Table


Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value	
Full model	-28.6454	3				
Fitted model	-28.6454	2 -7	.10543e-015	1		-1
Reduced model	-33.983	1	10.6753	2	0.004807	

AIC: 61.2908

		Good	ness of F	it	
Dose	EstProb.	Expected	Observed	Size	Scaled Residual
0.0000 1.3000 14.2000	0.0000 0.0400 0.1400	0.000 2.000 7.000	0.000 2.000 7.000	49.000 50.000 50.000	0.000 -0.000 -0.000

Chi^2 = 0.00 d.f. = 1 P-value = 1.0000

Specified effect	=	0.05
Risk Type	=	Extra risk
Confidence level	=	0.95
BMD	=	1.95859
BMDL	=	2.00091e-006





Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 546 of 551

slope = 0.156823

Asymptotic Correlation Matrix of Parameter Estimates

(*** The model parameter(s) -background have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix)

	intercept	slope
intercept	1	-0.89

slope -0.89 1

Parameter Estimates

			95.0% Wald Confi	dence Interval
Variable	Estimate	Std. Err.	Lower Conf. Limit	Upper Conf. Limit
intercept	-4.0346	0.768353	-5.54055	-2.52866
slope	0.157289	0.0618536	0.0360579	0.27852

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value
Full model	-28.6454	3			
Fitted model	-29.8421	2	2.3935	1	0.1218
Reduced model	-33.983	1	10.6753	2	0.004807


AIC: 63.6843

Goodness of Fit

Dose	EstProb.	Expected	Observed	Size	Scaled Residual
0.0000	0.0174	0.852	0.000	49.000	-0.931
1.3000	0.0212	1.062	2.000	50.000	0.920
14.2000	0.1417	7.086	7.000	50.000	-0.035

Chi^2 = 1.71 d.f. = 1 P-value = 0.1905

Specified effect	=	0.05
Risk Type	=	Extra risk
Confidence level	=	0.95
BMD	=	8.85708
BMDL	=	6.49805



Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 548 of 551

Default Initial (and Specified) Parameter Values background = 0 Specified intercept = -2.30551 slope = 0.089861

Asymptotic Correlation Matrix of Parameter Estimates

(*** The model parameter(s) -background have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix)

	intercept	slope
intercept	1	-0.83

slope -0.83 1

Parameter Estimates

			95.0% Wald Confi	idence Interval
Variable	Estimate	Std. Err.	Lower Conf. Limit	Upper Conf. Limit
intercept	-2.12433	0.312226	-2.73628	-1.51238
slope	0.0742381	0.0273837	0.020567	0.127909

Analysis of Deviance Table


Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value
Full model	-28.6454	3			
Fitted model	-29.8125	2	2.33427	1	0.1266
Reduced model	-33.983	1	10.6753	2	0.004807
AIC:	63.625				

Goodness of Fit

Dose	EstProb.	Expected	Observed	Size	Scaled Residual
0.0000	0.0168	0.824	0.000	49.000	-0.916
1.3000	0.0213	1.064	2.000	50.000	0.917
14.2000	0.1423	7.114	7.000	50.000	-0.046

Chi^2 = 1.68 d.f. = 1 P-value = 0.1948

Specified effect	=	0.05
Risk Type	=	Extra risk
Confidence level	=	0.95
BMD	=	8.32341
BMDL	=	5.95965



Probit Model, with BMR of 5% Extra Risk for the BMD and 0.95 Lower Confidence Limit for the BMDL

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 550 of 551

Power = 1 Specified

Asymptotic Correlation Matrix of Parameter Estimates

(*** The model parameter(s) -Power have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix)

	Background	Slope
Background	1	-0.58
Slope	-0.58	1

Parameter Estimates

			95.0% Wald Confidence Interval		
Variable	Estimate	Std. Err.	Lower Conf. Limit	Upper Conf. Limit	
Background	0.00436513	0.0163652	-0.0277102	0.0364404	
Slope	0.0115809	0.00506554	0.00165257	0.0215091	

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value
Full model	-28.6454	3			
Fitted model	-29.3426	2	1.39438	1	0.2377
Reduced model	-33.983	1	10.6753	2	0.004807

AIC: 62.6851


Goodness of Fit

Dose	EstProb.	Expected	Observed	Size	Scaled Residual
0.0000	0.0044	0.214	0.000	49.000	-0.463
1.3000	0.0192	0.962	2.000	50.000	1.068
14.2000	0.1553	7.767	7.000	50.000	-0.299

Chi^2 = 1.45 d.f. = 1 P-value = 0.2292

Specified effect	=	0.05
Risk Type	=	Extra risk
Confidence level	=	0.95
BMD	=	4.42915
BMDL	=	2.50664

Case 1:16-cv-00917-LEK-DJS Document 162 Filed 04/06/20 Page 551 of 551



Quantal Linear Model, with BMR of 5% Extra Risk for the BMD and 0.95 Lower Confidence Limit for the BMDL

15:30 03/01 2016